(lp0
(dp1
S'line'
p2
S'Some biomarkers play important roles in the endothelial dysfunction of patients with pulmonary arterial hypertension (PAH), including nitric oxide (NO), endothelin-1 (ET-1), asymmetric dimethylarginine (ADMA), galectin-3 (Gal-3), B-type natriuretic peptide (BNP), and uric acid (UA).\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I222
sS'uniprot'
p8
VP16278
p9
sS'lengthInChars'
p10
I5
sS'name'
p11
VGal-3
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I230
sg8
VP16860
p15
sg10
I26
sg11
VB-type natriuretic peptide
p16
sg13
I3
sa(dp17
g7
I210
sg8
VP17931
p18
sg10
I10
sg11
Vgalectin-3
p19
sg13
I1
sa(dp20
g7
I258
sg8
VP16860
p21
sg10
I3
sg11
VBNP
p22
sg13
I1
sa(dp23
g7
I167
sg8
VP05305
p24
sg10
I4
sg11
VET-1
p25
sg13
I1
sa(dp26
g7
I153
sg8
VP20800
p27
sg10
I12
sg11
Vendothelin-1
p28
sg13
I1
sasS'diseases'
p29
(lp30
(dp31
g7
I85
sS'cui'
p32
VC0152171
p33
sg10
I31
sg11
Vpulmonary arterial hypertension
p34
sg13
I3
sa(dp35
g7
I44
sg32
VC0856169
p36
sg10
I23
sg11
Vendothelial dysfunction
p37
sg13
I2
sa(dp38
g7
I118
sg32
VC0152171
p39
sg10
I3
sg11
VPAH
p40
sg13
I1
sasa(dp41
g2
S'Subgroup analyses revealed that AMOT P130 protein expression was increased in OSA patients with excessive daytime sleepiness, BIRC3 protein expression was decreased in OSA patients with hypertension, and LGALS3 protein expression was increased in OSA patients with chronic kidney disease.\n'
p42
sg4
(lp43
(dp44
g7
I204
sg8
VP17931
p45
sg10
I14
sg11
VLGALS3 protein
p46
sg13
I2
sa(dp47
g7
I126
sg8
S''
p48
sg10
I13
sg11
VBIRC3 protein
p49
sg13
I2
sa(dp50
g7
I32
sg8
g48
sg10
I17
sg11
VAMOT P130 protein
p51
sg13
I3
sasg29
(lp52
(dp53
g7
I96
sg32
VC0694563
p54
sg10
I28
sg11
Vexcessive daytime sleepiness
p55
sg13
I3
sa(dp56
g7
I78
sg32
VC0520679
p57
sg10
I3
sg11
VOSA
p58
sg13
I1
sa(dp59
g7
I265
sg32
VC1561643
p60
sg10
I22
sg11
Vchronic kidney disease
p61
sg13
I3
sa(dp62
g7
I78
sg32
VC0520679
p63
sg10
I3
sg11
VOSA
p64
sg13
I1
sa(dp65
g7
I78
sg32
VC0520679
p66
sg10
I3
sg11
VOSA
p67
sg13
I1
sa(dp68
g7
I186
sg32
VC0020538
p69
sg10
I12
sg11
Vhypertension
p70
sg13
I1
sasa(dp71
g2
S'AMOT and GALIG may constitute an important determinant for the development of hypersomnia and kidney injury, respectively, while BIRC3 may play a protective role in the development of hypertension.\n'
p72
sg4
(lp73
(dp74
g7
I0
sg8
g48
sg10
I4
sg11
VAMOT
p75
sg13
I1
sa(dp76
g7
I129
sg8
g48
sg10
I5
sg11
VBIRC3
p77
sg13
I1
sa(dp78
g7
I9
sg8
VP17931
p79
sg10
I5
sg11
VGALIG
p80
sg13
I1
sasg29
(lp81
(dp82
g7
I184
sg32
VC0020538
p83
sg10
I12
sg11
Vhypertension
p84
sg13
I1
sa(dp85
g7
I78
sg32
VC0917799
p86
sg10
I11
sg11
Vhypersomnia
p87
sg13
I1
sasa(dp88
g2
S"Kaposi's sarcoma-associated herpesvirus (KSHV) in vitro infection of dermal endothelial cell begins with its binding to host cell surface receptor molecules such as heparan sulfate (HS), integrins (Alfa3Beta1, AlfaVBeta3 and AlfaVBeta5), xCT and EphA2 receptor tyrosine kinase (EphA2R).\n"
p89
sg4
(lp90
(dp91
g7
I246
sg8
g48
sg10
I30
sg11
VEphA2 receptor tyrosine kinase
p92
sg13
I4
sa(dp93
g7
I238
sg8
g48
sg10
I3
sg11
VxCT
p94
sg13
I1
sa(dp95
g7
I278
sg8
g48
sg10
I6
sg11
VEphA2R
p96
sg13
I1
sasg29
(lp97
(dp98
g7
I56
sg32
VC0009450
p99
sg10
I9
sg11
Vinfection
p100
sg13
I1
sa(dp101
g7
I0
sg32
VC0036220
p102
sg10
I16
sg11
VKaposi's sarcoma
p103
sg13
I2
sasa(dp104
g2
S'Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) is overexpressed in more than 90% of non-small cell lung cancer (NSCLC) but not significantly in normal lung tissue.\n'
p105
sg4
(lp106
(dp107
g7
I25
sg8
g48
sg10
I35
sg11
Vhepatocellular carcinoma A2 (EphA2)
p108
sg13
I4
sa(dp109
g7
I0
sg8
VP01588
p110
sg10
I14
sg11
VErythropoietin
p111
sg13
I1
sasg29
(lp112
(dp113
g7
I25
sg32
VC1512411
p114
sg10
I24
sg11
Vhepatocellular carcinoma
p115
sg13
I2
sa(dp116
g7
I98
sg32
VC0007131
p117
sg10
I26
sg11
Vnon-small cell lung cancer
p118
sg13
I4
sa(dp119
g7
I126
sg32
VC0007131
p120
sg10
I5
sg11
VNSCLC
p121
sg13
I1
sasa(dp122
g2
S'The effect in vivo was evaluated in xenograft SCID Beige mouse model of EphA2 positive NSCLC.\n'
p123
sg4
(lp124
(dp125
g7
I72
sg8
g48
sg10
I5
sg11
VEphA2
p126
sg13
I1
sasg29
(lp127
(dp128
g7
I46
sg32
VC0085110
p129
sg10
I4
sg11
VSCID
p130
sg13
I1
sa(dp131
g7
I87
sg32
VC0007131
p132
sg10
I5
sg11
VNSCLC
p133
sg13
I1
sasa(dp134
g2
S'Thus, EphA2-specific T-cell immunotherapy may be a promising approach for the treatment of EphA2-positive NSCLC.\n'
p135
sg4
(lp136
(dp137
g7
I6
sg8
g48
sg10
I5
sg11
VEphA2
p138
sg13
I1
sa(dp139
g7
I6
sg8
g48
sg10
I5
sg11
VEphA2
p140
sg13
I1
sasg29
(lp141
(dp142
g7
I106
sg32
VC0007131
p143
sg10
I5
sg11
VNSCLC
p144
sg13
I1
sasa(dp145
g2
S'Ligand-independent activation of EphA2 receptor kinase promotes cancer metastasis and invasion.\n'
p146
sg4
(lp147
(dp148
g7
I33
sg8
g48
sg10
I21
sg11
VEphA2 receptor kinase
p149
sg13
I3
sasg29
(lp150
(dp151
g7
I71
sg32
VC0027627
p152
sg10
I10
sg11
Vmetastasis
p153
sg13
I1
sa(dp154
g7
I86
sg32
VC2699153
p155
sg10
I8
sg11
Vinvasion
p156
sg13
I1
sa(dp157
g7
I64
sg32
VC0006826
p158
sg10
I6
sg11
Vcancer
p159
sg13
I1
sasa(dp160
g2
S'Activating EphA2 receptor tyrosine kinase with small molecule agonist is a novel strategy to treat EphA2 overexpressing cancer.\n'
p161
sg4
(lp162
(dp163
g7
I11
sg8
g48
sg10
I30
sg11
VEphA2 receptor tyrosine kinase
p164
sg13
I4
sa(dp165
g7
I11
sg8
g48
sg10
I5
sg11
VEphA2
p166
sg13
I1
sasg29
(lp167
(dp168
g7
I120
sg32
VC0006826
p169
sg10
I6
sg11
Vcancer
p170
sg13
I1
sasa(dp171
g2
S'Soluble EphA2 fragment levels in cancer-patient sera were higher than those in healthy donors (n=50).\n'
p172
sg4
(lp173
(dp174
g7
I8
sg8
g48
sg10
I5
sg11
VEphA2
p175
sg13
I1
sasg29
(lp176
(dp177
g7
I33
sg32
VC0006826
p178
sg10
I6
sg11
Vcancer
p179
sg13
I1
sasa(dp180
g2
S'These results indicated that specific detection of soluble EphA2 fragment levels in serum could be potentially useful as a biomarker to diagnose pancreatic cancer.\n'
p181
sg4
(lp182
(dp183
g7
I59
sg8
g48
sg10
I14
sg11
VEphA2 fragment
p184
sg13
I2
sasg29
(lp185
(dp186
g7
I145
sg32
VC0235974
p187
sg10
I17
sg11
Vpancreatic cancer
p188
sg13
I2
sasa(dp189
g2
S'Targeting CD13/ANPEP by a blocking antibody induced apoptosis in both parental A375- and BRAFi-resistant daughter cells as well as in melanoma cells with intrinsic BRAFi resistance and led to dephosphorylation of EPHA2 on S897, previously demonstrated to cause inhibition of the migratory capacity.\n'
p190
sg4
(lp191
(dp192
g7
I15
sg8
VP15144
p193
sg10
I5
sg11
VANPEP
p194
sg13
I1
sa(dp195
g7
I10
sg8
VP15144
p196
sg10
I4
sg11
VCD13
p197
sg13
I1
sa(dp198
g7
I213
sg8
g48
sg10
I5
sg11
VEPHA2
p199
sg13
I1
sasg29
(lp200
(dp201
g7
I134
sg32
VC0025202
p202
sg10
I8
sg11
Vmelanoma
p203
sg13
I1
sa(dp204
g7
I26
sg32
VC0233660
p205
sg10
I8
sg11
Vblocking
p206
sg13
I1
sasa(dp207
g2
S'We analyzed the surface expression of 3 targetable glioma antigens (HER2, IL13RAlfa2 and EphA2) in 15 primary GBM samples.\n'
p208
sg4
(lp209
(dp210
g7
I68
sg8
VP04626
p211
sg10
I4
sg11
VHER2
p212
sg13
I1
sa(dp213
g7
I38
sg8
g48
sg10
I28
sg11
V3 targetable glioma antigens
p214
sg13
I4
sa(dp215
g7
I89
sg8
g48
sg10
I5
sg11
VEphA2
p216
sg13
I1
sasg29
(lp217
(dp218
g7
I110
sg32
VC0017636
p219
sg10
I3
sg11
VGBM
p220
sg13
I1
sa(dp221
g7
I51
sg32
VC0017638
p222
sg10
I6
sg11
Vglioma
p223
sg13
I1
sasa(dp224
g2
S'PAK6, which is overexpressed in prostate cancer, was recently reported to localize to cell-cell adhesions and to drive epithelial cell colony escape.\n'
p225
sg4
(lp226
(dp227
g7
I119
sg8
VP12830
p228
sg10
I29
sg11
Vepithelial cell colony escape
p229
sg13
I4
sa(dp230
g7
I0
sg8
g48
sg10
I4
sg11
VPAK6
p231
sg13
I1
sasg29
(lp232
(dp233
g7
I32
sg32
VC0600139
p234
sg10
I15
sg11
Vprostate cancer
p235
sg13
I2
sa(dp236
g7
I96
sg32
VC0001511
p237
sg10
I9
sg11
Vadhesions
p238
sg13
I1
sasa(dp239
g2
S'In summary, we have identified the miR-23a-PAK6-LIMK1 pathway of prostate cancer metastasis.\n'
p240
sg4
(lp241
(dp242
g7
I35
sg8
g48
sg10
I7
sg11
VmiR-23a
p243
sg13
I1
sa(dp244
g7
I48
sg8
VP53667
p245
sg10
I5
sg11
VLIMK1
p246
sg13
I1
sa(dp247
g7
I43
sg8
g48
sg10
I4
sg11
VPAK6
p248
sg13
I1
sasg29
(lp249
(dp250
g7
I81
sg32
VC0027627
p251
sg10
I10
sg11
Vmetastasis
p252
sg13
I1
sa(dp253
g7
I65
sg32
VC0600139
p254
sg10
I15
sg11
Vprostate cancer
p255
sg13
I2
sasa(dp256
g2
S'The present study analyzed the expression by immunochemistry of the novel markers P21-activated protein kinase 6 (PAK6) and proteasome beta-4 subunit (PSMB4) in men with localized prostate cancer (PC) who were treated with dose-escalation radiotherapy (RT) and androgen deprivation therapy.\n'
p257
sg4
(lp258
(dp259
g7
I82
sg8
g48
sg10
I30
sg11
VP21-activated protein kinase 6
p260
sg13
I4
sa(dp261
g7
I124
sg8
VP28070
p262
sg10
I25
sg11
Vproteasome beta-4 subunit
p263
sg13
I3
sa(dp264
g7
I114
sg8
g48
sg10
I4
sg11
VPAK6
p265
sg13
I1
sa(dp266
g7
I151
sg8
VP28070
p267
sg10
I5
sg11
VPSMB4
p268
sg13
I1
sasg29
(lp269
(dp270
g7
I197
sg32
VC0600139
p271
sg10
I2
sg11
VPC
p272
sg13
I1
sa(dp273
g7
I180
sg32
VC0600139
p274
sg10
I15
sg11
Vprostate cancer
p275
sg13
I2
sasa(dp276
g2
S'p-21 activated 6 (PAK6), first identified as interacting with the androgen receptor (AR), is over-expressed in multiple cancer tissues and has been linked to the progression of prostate cancer, however little is known about PAK6 function in the absence of AR signaling.\n'
p277
sg4
(lp278
(dp279
g7
I66
sg8
VP10275
p280
sg10
I17
sg11
Vandrogen receptor
p281
sg13
I2
sa(dp282
g7
I18
sg8
g48
sg10
I4
sg11
VPAK6
p283
sg13
I1
sa(dp284
g7
I18
sg8
g48
sg10
I4
sg11
VPAK6
p285
sg13
I1
sasg29
(lp286
(dp287
g7
I111
sg32
VC0346429
p288
sg10
I15
sg11
Vmultiple cancer
p289
sg13
I2
sa(dp290
g7
I162
sg32
VC1739135
p291
sg10
I30
sg11
Vprogression of prostate cancer
p292
sg13
I4
sasa(dp293
g2
S'We report here that PAK6 is specifically required for carcinoma cell-cell dissociation downstream of hepatocyte growth factor (HGF) for both DU145 prostate cancer and HT29 colon cancer cells.\n'
p294
sg4
(lp295
(dp296
g7
I127
sg8
VP05231
p297
sg10
I3
sg11
VHGF
p298
sg13
I1
sa(dp299
g7
I101
sg8
VP05231
p300
sg10
I24
sg11
Vhepatocyte growth factor
p301
sg13
I3
sa(dp302
g7
I20
sg8
g48
sg10
I4
sg11
VPAK6
p303
sg13
I1
sasg29
(lp304
(dp305
g7
I127
sg32
VC0399440
p306
sg10
I3
sg11
VHGF
p307
sg13
I1
sa(dp308
g7
I101
sg32
VC0399440
p309
sg10
I24
sg11
Vhepatocyte growth factor
p310
sg13
I3
sa(dp311
g7
I172
sg32
VC0699790
p312
sg10
I12
sg11
Vcolon cancer
p313
sg13
I2
sa(dp314
g7
I147
sg32
VC0600139
p315
sg10
I15
sg11
Vprostate cancer
p316
sg13
I2
sa(dp317
g7
I54
sg32
VC0007097
p318
sg10
I9
sg11
Vcarcinoma
p319
sg13
I1
sa(dp320
g7
I74
sg32
VC0086168
p321
sg10
I12
sg11
Vdissociation
p322
sg13
I1
sasa(dp323
g2
S'We used hormone responsive prostate cancer LAPC4 and LNCap cell lines as models to study the signaling events associated with androgen stimulation and PAK6.\n'
p324
sg4
(lp325
(dp326
g7
I27
sg8
g48
sg10
I21
sg11
Vprostate cancer LAPC4
p327
sg13
I3
sa(dp328
g7
I151
sg8
g48
sg10
I4
sg11
VPAK6
p329
sg13
I1
sasg29
(lp330
(dp331
g7
I27
sg32
VC0600139
p332
sg10
I15
sg11
Vprostate cancer
p333
sg13
I2
sasa(dp334
g2
S'Furthermore, androgen-stimulation promoted prostate cancer cell motility and invasion were demonstrated in LNCap cells ectopically expressing PAK6-WT.\n'
p335
sg4
(lp336
(dp337
g7
I142
sg8
g48
sg10
I4
sg11
VPAK6
p338
sg13
I1
sasg29
(lp339
(dp340
g7
I77
sg32
VC2699153
p341
sg10
I8
sg11
Vinvasion
p342
sg13
I1
sa(dp343
g7
I43
sg32
VC0600139
p344
sg10
I15
sg11
Vprostate cancer
p345
sg13
I2
sasa(dp346
g2
S'Our results demonstrate that androgen-stimulated PAK6 activation is mediated through a direct interaction between AR and PAK6 and PAK6 activation promotes prostate cancer cells motility and invasion.\n'
p347
sg4
(lp348
(dp349
g7
I49
sg8
g48
sg10
I4
sg11
VPAK6
p350
sg13
I1
sa(dp351
g7
I49
sg8
g48
sg10
I4
sg11
VPAK6
p352
sg13
I1
sa(dp353
g7
I49
sg8
g48
sg10
I4
sg11
VPAK6
p354
sg13
I1
sasg29
(lp355
(dp356
g7
I190
sg32
VC2699153
p357
sg10
I8
sg11
Vinvasion
p358
sg13
I1
sa(dp359
g7
I155
sg32
VC0600139
p360
sg10
I15
sg11
Vprostate cancer
p361
sg13
I2
sasa(dp362
g2
S'Our observations suggest that although some level of functional redundancy exists between Pak1 and Pak6 in prostate cancer cells, targeting Pak1 is a potential option for the management of prostate tumor growth, microinvasion, and metastasis.\n'
p363
sg4
(lp364
(dp365
g7
I90
sg8
g48
sg10
I4
sg11
VPak1
p366
sg13
I1
sa(dp367
g7
I90
sg8
g48
sg10
I4
sg11
VPak1
p368
sg13
I1
sa(dp369
g7
I99
sg8
g48
sg10
I4
sg11
VPak6
p370
sg13
I1
sasg29
(lp371
(dp372
g7
I107
sg32
VC0600139
p373
sg10
I15
sg11
Vprostate cancer
p374
sg13
I2
sa(dp375
g7
I231
sg32
VC0027627
p376
sg10
I10
sg11
Vmetastasis
p377
sg13
I1
sa(dp378
g7
I189
sg32
VC0033578
p379
sg10
I14
sg11
Vprostate tumor
p380
sg13
I2
sasa(dp381
g2
S'Interestingly, we found a strong inverse correlation between PAK6 and AR expression in the cytoplasm of prostate cancer cells.\n'
p382
sg4
(lp383
(dp384
g7
I61
sg8
g48
sg10
I4
sg11
VPAK6
p385
sg13
I1
sasg29
(lp386
(dp387
g7
I104
sg32
VC0600139
p388
sg10
I15
sg11
Vprostate cancer
p389
sg13
I2
sasa(dp390
g2
S'These observations indicate that PAK6 may be important for the maintenance of androgen-induced AR signaling homeostasis and in prostate malignancy, as well as being a possible new therapeutic target for AR-positive and hormone-sensitive prostate cancer.\n'
p391
sg4
(lp392
(dp393
g7
I33
sg8
g48
sg10
I4
sg11
VPAK6
p394
sg13
I1
sasg29
(lp395
(dp396
g7
I237
sg32
VC0600139
p397
sg10
I15
sg11
Vprostate cancer
p398
sg13
I2
sa(dp399
g7
I136
sg32
VC0006826
p400
sg10
I10
sg11
Vmalignancy
p401
sg13
I1
sasa(dp402
g2
S'Our work identifies a key role of the type I interferon/IL-7 axis in the regulation of intratumoral GammaDeltaT17 cell functions and in the development of primary breast tumor growth and metastasis.\n'
p403
sg4
(lp404
(dp405
g7
I38
sg8
VP13232
p406
sg10
I22
sg11
Vtype I interferon/IL-7
p407
sg13
I3
sasg29
(lp408
(dp409
g7
I187
sg32
VC0027627
p410
sg10
I10
sg11
Vmetastasis
p411
sg13
I1
sa(dp412
g7
I170
sg32
VC0598934
p413
sg10
I12
sg11
Vtumor growth
p414
sg13
I2
sasa(dp415
g2
S'In breast cancer (BC), IL-7 promotes growth of tumor cells in culture through the activation of JAK1/3-STAT5 and PI3K/AKT pathways, and expression of IL-7 signaling components was associated with worst prognosis.\n'
p416
sg4
(lp417
(dp418
g7
I23
sg8
VP13232
p419
sg10
I4
sg11
VIL-7
p420
sg13
I1
sa(dp421
g7
I96
sg8
VP23458
p422
sg10
I6
sg11
VJAK1/3
p423
sg13
I1
sa(dp424
g7
I113
sg8
VP42336
p425
sg10
I4
sg11
VPI3K
p426
sg13
I1
sa(dp427
g7
I103
sg8
VP42229
p428
sg10
I5
sg11
VSTAT5
p429
sg13
I1
sa(dp430
g7
I118
sg8
g48
sg10
I3
sg11
VAKT
p431
sg13
I1
sa(dp432
g7
I23
sg8
VP13232
p433
sg10
I4
sg11
VIL-7
p434
sg13
I1
sasg29
(lp435
(dp436
g7
I47
sg32
VC0027651
p437
sg10
I5
sg11
Vtumor
p438
sg13
I1
sa(dp439
g7
I3
sg32
VC0678222
p440
sg10
I13
sg11
Vbreast cancer
p441
sg13
I2
sa(dp442
g7
I18
sg32
VC0678222
p443
sg10
I2
sg11
VBC
p444
sg13
I1
sasa(dp445
g2
S'Additionally, IL-7 is the primary driver of T and B cell differentiation, maturation, and response (Corfe and Paige, 2012 [4]) and its elevated levels have been associated with poor prognosis in breast cancer.\n'
p446
sg4
(lp447
(dp448
g7
I14
sg8
VP13232
p449
sg10
I4
sg11
VIL-7
p450
sg13
I1
sasg29
(lp451
(dp452
g7
I195
sg32
VC0678222
p453
sg10
I13
sg11
Vbreast cancer
p454
sg13
I2
sasa(dp455
g2
S'The data presented here shows the relationship between pre-existing use of insulin secretagogues in women diagnosed with breast cancer and type 2 diabetes mellitus, the GM-CSF, G-CSF and IL-7 cytokine profiles at the time of breast cancer diagnosis, and subsequent cancer outcomes.\n'
p456
sg4
(lp457
(dp458
g7
I75
sg8
VP01308
p459
sg10
I7
sg11
Vinsulin
p460
sg13
I1
sa(dp461
g7
I187
sg8
VP13232
p462
sg10
I22
sg11
VIL-7 cytokine profiles
p463
sg13
I3
sa(dp464
g7
I177
sg8
VP09919
p465
sg10
I5
sg11
VG-CSF
p466
sg13
I1
sa(dp467
g7
I169
sg8
VP04141
p468
sg10
I6
sg11
VGM-CSF
p469
sg13
I1
sasg29
(lp470
(dp471
g7
I225
sg32
VC0678222
p472
sg10
I23
sg11
Vbreast cancer diagnosis
p473
sg13
I3
sa(dp474
g7
I121
sg32
VC0678222
p475
sg10
I13
sg11
Vbreast cancer
p476
sg13
I2
sa(dp477
g7
I139
sg32
VC0011860
p478
sg10
I24
sg11
Vtype 2 diabetes mellitus
p479
sg13
I4
sa(dp480
g7
I128
sg32
VC0006826
p481
sg10
I6
sg11
Vcancer
p482
sg13
I1
sasa(dp483
g2
S'DLN lymphocytes were antigen-sensitized with 4T1 mammary carcinoma 10 days prior to harvest, activated with B/I, and expanded in culture for 7 days with either IL-2, IL-21, IL-2/21, IL-7/15, or IL-7/15/21.\n'
p484
sg4
(lp485
(dp486
g7
I182
sg8
VP13232
p487
sg10
I4
sg11
VIL-7
p488
sg13
I1
sa(dp489
g7
I160
sg8
VP60568
p490
sg10
I4
sg11
VIL-2
p491
sg13
I1
sa(dp492
g7
I182
sg8
VP13232
p493
sg10
I7
sg11
VIL-7/15
p494
sg13
I1
sa(dp495
g7
I173
sg8
VP60568
p496
sg10
I7
sg11
VIL-2/21
p497
sg13
I1
sa(dp498
g7
I166
sg8
g48
sg10
I5
sg11
VIL-21
p499
sg13
I1
sasg29
(lp500
(dp501
g7
I49
sg32
VC0678222
p502
sg10
I17
sg11
Vmammary carcinoma
p503
sg13
I2
sasa(dp504
g2
S'Our previous study has confirmed that IL-7Delta5 (an IL-7 variant lacking exon 5) promotes breast cancer growth.\n'
p505
sg4
(lp506
(dp507
g7
I53
sg8
VP13232
p508
sg10
I27
sg11
VIL-7 variant lacking exon 5
p509
sg13
I5
sasg29
(lp510
(dp511
g7
I91
sg32
VC0678222
p512
sg10
I13
sg11
Vbreast cancer
p513
sg13
I2
sasa(dp514
g2
S'In this study, we investigated the preclinical effects and molecular mechanisms of IL-7Delta5 on EMT and metastasis in human MCF-7 and BT-20 breast cancer cells in vitro and in vivo.\n'
p515
sg4
(lp516
(dp517
g7
I97
sg8
g48
sg10
I3
sg11
VEMT
p518
sg13
I1
sasg29
(lp519
(dp520
g7
I105
sg32
VC0027627
p521
sg10
I10
sg11
Vmetastasis
p522
sg13
I1
sa(dp523
g7
I141
sg32
VC0678222
p524
sg10
I13
sg11
Vbreast cancer
p525
sg13
I2
sasa(dp526
g2
S'Inhibition of PI3K/Akt pathway by LY294002 reversed the EMT transition in breast cancer cell lines MCF-7 and BT-20 induced by IL-7Delta5.\n'
p527
sg4
(lp528
(dp529
g7
I14
sg8
VP42336
p530
sg10
I4
sg11
VPI3K
p531
sg13
I1
sa(dp532
g7
I19
sg8
g48
sg10
I3
sg11
VAkt
p533
sg13
I1
sasg29
(lp534
(dp535
g7
I74
sg32
VC0678222
p536
sg10
I13
sg11
Vbreast cancer
p537
sg13
I2
sa(dp538
g7
I60
sg32
VC0599156
p539
sg10
I10
sg11
Vtransition
p540
sg13
I1
sasa(dp541
g2
S'In addition, IL-7Delta5 enhanced cancer metastasis and shortened survival time, with increased level changes of activated Akt in nude mice with breast cancer.\n'
p542
sg4
(lp543
(dp544
g7
I122
sg8
g48
sg10
I3
sg11
VAkt
p545
sg13
I1
sasg29
(lp546
(dp547
g7
I40
sg32
VC0027627
p548
sg10
I10
sg11
Vmetastasis
p549
sg13
I1
sa(dp550
g7
I144
sg32
VC0678222
p551
sg10
I13
sg11
Vbreast cancer
p552
sg13
I2
sa(dp553
g7
I33
sg32
VC0006826
p554
sg10
I6
sg11
Vcancer
p555
sg13
I1
sasa(dp556
g2
S'In conclusion, our findings demonstrate that IL-7Delta5 induces human breast cancer cell lines EMT and metastasis via activation of PI3K/Akt pathway.\n'
p557
sg4
(lp558
(dp559
g7
I137
sg8
g48
sg10
I3
sg11
VAkt
p560
sg13
I1
sa(dp561
g7
I132
sg8
VP42336
p562
sg10
I4
sg11
VPI3K
p563
sg13
I1
sasg29
(lp564
(dp565
g7
I103
sg32
VC0027627
p566
sg10
I10
sg11
Vmetastasis
p567
sg13
I1
sa(dp568
g7
I70
sg32
VC0678222
p569
sg10
I13
sg11
Vbreast cancer
p570
sg13
I2
sasa(dp571
g2
S'Thus, IL-7Delta5 may be a potential target against human breast cancer.\n'
p572
sg4
(lp573
sg29
(lp574
(dp575
g7
I57
sg32
VC0678222
p576
sg10
I13
sg11
Vbreast cancer
p577
sg13
I2
sasa(dp578
g2
S'Imaging studies, either CT temporal bones or MRI of the internal auditory canals without gadolinium, and genetic testing, in particular for connexin 26, connexin 30, and Pendred syndrome, are the most useful diagnostic tests.\n'
p579
sg4
(lp580
(dp581
g7
I140
sg8
g48
sg10
I11
sg11
Vconnexin 26
p582
sg13
I2
sa(dp583
g7
I153
sg8
g48
sg10
I11
sg11
Vconnexin 30
p584
sg13
I2
sasg29
(lp585
(dp586
g7
I170
sg32
VC0271829
p587
sg10
I16
sg11
VPendred syndrome
p588
sg13
I2
sasa(dp589
g2
S'A heterozygous missense mutation, 31G-&gt;A, in GJB6 gene was detected in all patients in this family, but this mutation was not detected in family members without the clinical manifestations of HED.\n'
p590
sg4
(lp591
(dp592
g7
I48
sg8
g48
sg10
I9
sg11
VGJB6 gene
p593
sg13
I2
sasg29
(lp594
(dp595
g7
I195
sg32
VC1720965
p596
sg10
I3
sg11
VHED
p597
sg13
I1
sasa(dp598
g2
S'The missense mutation 31G-&gt;A in the GJB6 gene may be one of the molecular mechanisms for HED.\n'
p599
sg4
(lp600
(dp601
g7
I92
sg8
VP61296
p602
sg10
I3
sg11
VHED
p603
sg13
I1
sa(dp604
g7
I39
sg8
g48
sg10
I9
sg11
VGJB6 gene
p605
sg13
I2
sasg29
(lp606
(dp607
g7
I92
sg32
VC1720965
p608
sg10
I3
sg11
VHED
p609
sg13
I1
sasa(dp610
g2
S'Mutations in GJB6, GJB2 and GJA1 are related to HED.\n'
p611
sg4
(lp612
(dp613
g7
I28
sg8
VP17302
p614
sg10
I4
sg11
VGJA1
p615
sg13
I1
sa(dp616
g7
I13
sg8
g48
sg10
I4
sg11
VGJB6
p617
sg13
I1
sa(dp618
g7
I48
sg8
VP61296
p619
sg10
I3
sg11
VHED
p620
sg13
I1
sasg29
(lp621
(dp622
g7
I48
sg32
VC1720965
p623
sg10
I3
sg11
VHED
p624
sg13
I1
sasa(dp625
g2
S'Summarize the clinical feature and analyse the mutation of the GJB6 gene in a large Chinese family with HED.\n'
p626
sg4
(lp627
(dp628
g7
I104
sg8
VP61296
p629
sg10
I3
sg11
VHED
p630
sg13
I1
sa(dp631
g7
I63
sg8
g48
sg10
I9
sg11
VGJB6 gene
p632
sg13
I2
sasg29
(lp633
(dp634
g7
I104
sg32
VC1720965
p635
sg10
I3
sg11
VHED
p636
sg13
I1
sasa(dp637
g2
S'There are significant differences in the clinical picture of two rare autosomal dominant syndromes: keratitis-ichthyosis-deafness (KID) syndrome and hidrotic ectodermal dysplasia (Clouston syndrome), which are caused by GJB2 and GJB6 mutations, respectively.\n'
p638
sg4
(lp639
(dp640
g7
I229
sg8
g48
sg10
I4
sg11
VGJB6
p641
sg13
I1
sasg29
(lp642
(dp643
g7
I89
sg32
VC0039082
p644
sg10
I8
sg11
Vsyndrome
p645
sg13
I1
sa(dp646
g7
I149
sg32
VC0162361
p647
sg10
I29
sg11
Vhidrotic ectodermal dysplasia
p648
sg13
I3
sa(dp649
g7
I110
sg32
VC0020758
p650
sg10
I10
sg11
Vichthyosis
p651
sg13
I1
sa(dp652
g7
I180
sg32
VC0162361
p653
sg10
I17
sg11
VClouston syndrome
p654
sg13
I2
sa(dp655
g7
I100
sg32
VC0022568
p656
sg10
I9
sg11
Vkeratitis
p657
sg13
I1
sa(dp658
g7
I89
sg32
VC0039082
p659
sg10
I9
sg11
Vsyndromes
p660
sg13
I1
sa(dp661
g7
I121
sg32
VC0011053
p662
sg10
I8
sg11
Vdeafness
p663
sg13
I1
sasa(dp664
g2
S'KID syndrome is characterized by progressive vascularizing keratitis, ichthyosiform erythrokeratoderma, and neurosensory hearing loss, whereas Clouston syndrome is characterized by nail dystrophy, hypotrichosis, and palmoplantar keratoderma.\n'
p665
sg4
(lp666
sg29
(lp667
(dp668
g7
I197
sg32
VC0020678
p669
sg10
I13
sg11
Vhypotrichosis
p670
sg13
I1
sa(dp671
g7
I59
sg32
VC0022568
p672
sg10
I9
sg11
Vkeratitis
p673
sg13
I1
sa(dp674
g7
I143
sg32
VC0162361
p675
sg10
I17
sg11
VClouston syndrome
p676
sg13
I2
sa(dp677
g7
I121
sg32
VC0011053
p678
sg10
I12
sg11
Vhearing loss
p679
sg13
I2
sa(dp680
g7
I0
sg32
VC0265336
p681
sg10
I12
sg11
VKID syndrome
p682
sg13
I2
sa(dp683
g7
I216
sg32
VC0022596
p684
sg10
I24
sg11
Vpalmoplantar keratoderma
p685
sg13
I2
sa(dp686
g7
I181
sg32
VC0221260
p687
sg10
I14
sg11
Vnail dystrophy
p688
sg13
I2
sa(dp689
g7
I84
sg32
VC0432330
p690
sg10
I18
sg11
Verythrokeratoderma
p691
sg13
I1
sasa(dp692
g2
S'The other case presented is that of a family with Clouston syndrome (caused by p.Gly11Arg mutation in GJB6), who are the first reported patients of Polish origin suffering from this disorder.\n'
p693
sg4
(lp694
(dp695
g7
I102
sg8
g48
sg10
I4
sg11
VGJB6
p696
sg13
I1
sasg29
(lp697
(dp698
g7
I162
sg32
VC0683278
p699
sg10
I9
sg11
Vsuffering
p700
sg13
I1
sa(dp701
g7
I50
sg32
VC0162361
p702
sg10
I17
sg11
VClouston syndrome
p703
sg13
I2
sasa(dp704
g2
S'Distinct mutations in the gap junction protein connexin30 (Cx30) can cause the ectodermal dysplasia Clouston syndrome in humans.\n'
p705
sg4
(lp706
(dp707
g7
I26
sg8
VP52757
p708
sg10
I31
sg11
Vgap junction protein connexin30
p709
sg13
I4
sa(dp710
g7
I59
sg8
g48
sg10
I4
sg11
VCx30
p711
sg13
I1
sasg29
(lp712
(dp713
g7
I100
sg32
VC0162361
p714
sg10
I17
sg11
VClouston syndrome
p715
sg13
I2
sa(dp716
g7
I79
sg32
VC0013575
p717
sg10
I20
sg11
Vectodermal dysplasia
p718
sg13
I2
sasa(dp719
g2
S'We have generated a new mouse line expressing the Clouston syndrome mutation Cx30A88V under the control of the endogenous Cx30 promoter.\n'
p720
sg4
(lp721
(dp722
g7
I122
sg8
g48
sg10
I13
sg11
VCx30 promoter
p723
sg13
I2
sasg29
(lp724
(dp725
g7
I50
sg32
VC0162361
p726
sg10
I17
sg11
VClouston syndrome
p727
sg13
I2
sasa(dp728
g2
S'Therefore, we wanted to elucidate if the main cardiac gap junction protein connexin43 (GJA1) is altered in patients with Tetralogy of Fallot or double-outlet right ventricle of Fallot-type (62 patients referred to as Fallot) compared to other cardiac anomalies (21 patients referred to as non-Fallot).\n'
p729
sg4
(lp730
(dp731
g7
I87
sg8
VP17302
p732
sg10
I4
sg11
VGJA1
p733
sg13
I1
sa(dp734
g7
I67
sg8
VP17302
p735
sg10
I18
sg11
Vprotein connexin43
p736
sg13
I2
sa(dp737
g7
I54
sg8
VP52757
p738
sg10
I3
sg11
Vgap
p739
sg13
I1
sasg29
(lp740
(dp741
g7
I243
sg32
VC0018798
p742
sg10
I17
sg11
Vcardiac anomalies
p743
sg13
I2
sa(dp744
g7
I121
sg32
VC0039685
p745
sg10
I19
sg11
VTetralogy of Fallot
p746
sg13
I3
sa(dp747
g7
I144
sg32
VC0013069
p748
sg10
I29
sg11
Vdouble-outlet right ventricle
p749
sg13
I3
sasa(dp750
g2
S'Furthermore, the changes in cell morphology and GJA1-distribution were not due to the heart defect itself but were significantly dependent on age.\n'
p751
sg4
(lp752
(dp753
g7
I48
sg8
VP17302
p754
sg10
I4
sg11
VGJA1
p755
sg13
I1
sasg29
(lp756
(dp757
g7
I86
sg32
VC0018798
p758
sg10
I12
sg11
Vheart defect
p759
sg13
I2
sasa(dp760
g2
S'This study aimed to investigate the expression of Cx43 and its related miRNAs in patients with tetralogy of Fallot (TOF), and illustrate the potential role of abnormal miRNAs regulation to Cx43 expression in the pathology of TOF.\n'
p761
sg4
(lp762
(dp763
g7
I50
sg8
VP17302
p764
sg10
I4
sg11
VCx43
p765
sg13
I1
sa(dp766
g7
I50
sg8
VP17302
p767
sg10
I4
sg11
VCx43
p768
sg13
I1
sasg29
(lp769
(dp770
g7
I116
sg32
VC0039685
p771
sg10
I3
sg11
VTOF
p772
sg13
I1
sa(dp773
g7
I95
sg32
VC0039685
p774
sg10
I19
sg11
Vtetralogy of Fallot
p775
sg13
I3
sa(dp776
g7
I212
sg32
VC0677042
p777
sg10
I9
sg11
Vpathology
p778
sg13
I1
sa(dp779
g7
I116
sg32
VC0039685
p780
sg10
I3
sg11
VTOF
p781
sg13
I1
sasa(dp782
g2
S'Although recent findings implicate the major role of GJA1 during cardiac organogenesis, congenital heart defects are infrequently reported in oculodentodigital dysplasia.\n'
p783
sg4
(lp784
(dp785
g7
I53
sg8
VP17302
p786
sg10
I4
sg11
VGJA1
p787
sg13
I1
sasg29
(lp788
(dp789
g7
I142
sg32
VC0812437
p790
sg10
I27
sg11
Voculodentodigital dysplasia
p791
sg13
I2
sa(dp792
g7
I88
sg32
VC0018798
p793
sg10
I24
sg11
Vcongenital heart defects
p794
sg13
I3
sasa(dp795
g2
S'Conversely, those patients with type III syndactyly and congenital heart defect should be screened for GJA1 mutations.\n'
p796
sg4
(lp797
(dp798
g7
I103
sg8
VP17302
p799
sg10
I4
sg11
VGJA1
p800
sg13
I1
sasg29
(lp801
(dp802
g7
I41
sg32
VC0039075
p803
sg10
I10
sg11
Vsyndactyly
p804
sg13
I1
sa(dp805
g7
I56
sg32
VC0018798
p806
sg10
I23
sg11
Vcongenital heart defect
p807
sg13
I3
sasa(dp808
g2
S'The use of proton pump inhibitors (PPIs) to control the syndrome is a cornerstone in the ZES therapy.\n'
p809
sg4
(lp810
sg29
(lp811
(dp812
g7
I56
sg32
VC0039082
p813
sg10
I8
sg11
Vsyndrome
p814
sg13
I1
sasa(dp815
g2
S'Omeprazole is a proton pump inhibition and ranitidine is an H2 histamine receptor antagonist widely used in the treatment of gastroesophageal reflex disease, peptic ulcer disease, Zollinger-Ellison syndrome and as a protector of the gastric mucosae.\n'
p816
sg4
(lp817
(dp818
g7
I60
sg8
g48
sg10
I21
sg11
VH2 histamine receptor
p819
sg13
I3
sasg29
(lp820
(dp821
g7
I158
sg32
VC0030920
p822
sg10
I20
sg11
Vpeptic ulcer disease
p823
sg13
I3
sa(dp824
g7
I180
sg32
VC0043515
p825
sg10
I26
sg11
VZollinger-Ellison syndrome
p826
sg13
I2
sasa(dp827
g2
S'Omeprazole is a proton pump inhibition and ranitidine is an H2 histamine receptor antagonist widely used in the treatment of gastroesophageal reflex disease, peptic ulcer disease, Zollinger-Ellison syndrome and as a protector of the gastric mucosae.\n'
p828
sg4
(lp829
(dp830
g7
I60
sg8
g48
sg10
I21
sg11
VH2 histamine receptor
p831
sg13
I3
sasg29
(lp832
(dp833
g7
I158
sg32
VC0030920
p834
sg10
I20
sg11
Vpeptic ulcer disease
p835
sg13
I3
sa(dp836
g7
I180
sg32
VC0043515
p837
sg10
I26
sg11
VZollinger-Ellison syndrome
p838
sg13
I2
sasa(dp839
g2
S'Abrupt discontinuation of proton pump therapy can lead to adverse outcomes in patients with Zollinger-Ellison syndrome.\n'
p840
sg4
(lp841
sg29
(lp842
(dp843
g7
I92
sg32
VC0043515
p844
sg10
I26
sg11
VZollinger-Ellison syndrome
p845
sg13
I2
sasa(dp846
g2
S'Proton pump inhibitors are widely used in upper gastrointestinal diseases, including gastric and duodenal ulcers, eradication of Helicobacter pylori in combination with antibiotics, gastroesophageal reflux disease, Zollinger-Ellison syndrome, eosinophilic esophagitis, and prevention of non-steroidal anti-inflammatory drug-induced peptic ulceration.\n'
p847
sg4
(lp848
(dp849
g7
I0
sg8
g48
sg10
I6
sg11
VProton
p850
sg13
I1
sasg29
(lp851
(dp852
g7
I48
sg32
VC0017178
p853
sg10
I25
sg11
Vgastrointestinal diseases
p854
sg13
I2
sa(dp855
g7
I332
sg32
VC0030920
p856
sg10
I17
sg11
Vpeptic ulceration
p857
sg13
I2
sa(dp858
g7
I182
sg32
VC0017168
p859
sg10
I31
sg11
Vgastroesophageal reflux disease
p860
sg13
I3
sa(dp861
g7
I97
sg32
VC0013295
p862
sg10
I15
sg11
Vduodenal ulcers
p863
sg13
I2
sa(dp864
g7
I243
sg32
VC0341106
p865
sg10
I24
sg11
Veosinophilic esophagitis
p866
sg13
I2
sa(dp867
g7
I215
sg32
VC0043515
p868
sg10
I26
sg11
VZollinger-Ellison syndrome
p869
sg13
I2
sasa(dp870
g2
S'At the Outpatient Department for Infertility, University of Rome La Sapienza, we investigated the effect of high-activity ACP1 genotype on spermatic parameters in 105 subjects referred to for varicocele.\n'
p871
sg4
(lp872
(dp873
g7
I122
sg8
VP24666
p874
sg10
I4
sg11
VACP1
p875
sg13
I1
sasg29
(lp876
(dp877
g7
I192
sg32
VC0042341
p878
sg10
I10
sg11
Vvaricocele
p879
sg13
I1
sa(dp880
g7
I33
sg32
VC0021359
p881
sg10
I11
sg11
VInfertility
p882
sg13
I1
sasa(dp883
g2
S'Gene expression analysis for EPHA2 (EPH receptor A2), EPHB2 (EPH receptor B2), S100A9 (S100 calcium binding protein A9), PBEF(nicotinamide phosphoribosyltransferase), LILRB2 (leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2), PLAUR (plasminogen activator, urokinase receptor), LTB (lymphotoxin beta (TNF superfamily, member 3)), WNT5A (wingless-type MMTV integration site family, member 5A) has been conducted using real-time polymerase chain reaction in specimens affected by psoriasis versus visually intact skin in 18 patients.\n'
p884
sg4
(lp885
(dp886
g7
I369
sg8
VP41221
p887
sg10
I5
sg11
VWNT5A
p888
sg13
I1
sa(dp889
g7
I79
sg8
VP06702
p890
sg10
I6
sg11
VS100A9
p891
sg13
I1
sa(dp892
g7
I175
sg8
g48
sg10
I51
sg11
Vleukocyte immunoglobulin-like receptor, subfamily B
p893
sg13
I5
sa(dp894
g7
I61
sg8
VP52799
p895
sg10
I15
sg11
VEPH receptor B2
p896
sg13
I3
sa(dp897
g7
I167
sg8
g48
sg10
I6
sg11
VLILRB2
p898
sg13
I1
sa(dp899
g7
I29
sg8
g48
sg10
I5
sg11
VEPHA2
p900
sg13
I1
sa(dp901
g7
I296
sg8
VP00749
p902
sg10
I18
sg11
Vurokinase receptor
p903
sg13
I2
sa(dp904
g7
I322
sg8
g48
sg10
I33
sg11
Vlymphotoxin beta (TNF superfamily
p905
sg13
I4
sa(dp906
g7
I126
sg8
VP43490
p907
sg10
I38
sg11
Vnicotinamide phosphoribosyltransferase
p908
sg13
I2
sa(dp909
g7
I273
sg8
VP00747
p910
sg10
I21
sg11
Vplasminogen activator
p911
sg13
I2
sa(dp912
g7
I36
sg8
g48
sg10
I15
sg11
VEPH receptor A2
p913
sg13
I3
sa(dp914
g7
I317
sg8
g48
sg10
I3
sg11
VLTB
p915
sg13
I1
sa(dp916
g7
I87
sg8
VP06702
p917
sg10
I31
sg11
VS100 calcium binding protein A9
p918
sg13
I5
sa(dp919
g7
I121
sg8
VP43490
p920
sg10
I4
sg11
VPBEF
p921
sg13
I1
sa(dp922
g7
I54
sg8
VP52799
p923
sg10
I5
sg11
VEPHB2
p924
sg13
I1
sasg29
(lp925
(dp926
g7
I517
sg32
VC0033860
p927
sg10
I9
sg11
Vpsoriasis
p928
sg13
I1
sasa(dp929
g2
S'Gene expression analysis for EPHA2 (EPH receptor A2), EPHB2 (EPH receptor B2), S100A9 (S100 calcium binding protein A9), PBEF(nicotinamide phosphoribosyltransferase), LILRB2 (leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2), PLAUR (plasminogen activator, urokinase receptor), LTB (lymphotoxin beta (TNF superfamily, member 3)), WNT5A (wingless-type MMTV integration site family, member 5A) has been conducted using real-time polymerase chain reaction in specimens affected by psoriasis versus visually intact skin in 18 patients.\n'
p930
sg4
(lp931
(dp932
g7
I369
sg8
VP41221
p933
sg10
I5
sg11
VWNT5A
p934
sg13
I1
sa(dp935
g7
I79
sg8
VP06702
p936
sg10
I6
sg11
VS100A9
p937
sg13
I1
sa(dp938
g7
I175
sg8
g48
sg10
I51
sg11
Vleukocyte immunoglobulin-like receptor, subfamily B
p939
sg13
I5
sa(dp940
g7
I61
sg8
VP52799
p941
sg10
I15
sg11
VEPH receptor B2
p942
sg13
I3
sa(dp943
g7
I167
sg8
g48
sg10
I6
sg11
VLILRB2
p944
sg13
I1
sa(dp945
g7
I29
sg8
g48
sg10
I5
sg11
VEPHA2
p946
sg13
I1
sa(dp947
g7
I296
sg8
VP00749
p948
sg10
I18
sg11
Vurokinase receptor
p949
sg13
I2
sa(dp950
g7
I322
sg8
g48
sg10
I33
sg11
Vlymphotoxin beta (TNF superfamily
p951
sg13
I4
sa(dp952
g7
I126
sg8
VP43490
p953
sg10
I38
sg11
Vnicotinamide phosphoribosyltransferase
p954
sg13
I2
sa(dp955
g7
I273
sg8
VP00747
p956
sg10
I21
sg11
Vplasminogen activator
p957
sg13
I2
sa(dp958
g7
I36
sg8
g48
sg10
I15
sg11
VEPH receptor A2
p959
sg13
I3
sa(dp960
g7
I317
sg8
g48
sg10
I3
sg11
VLTB
p961
sg13
I1
sa(dp962
g7
I87
sg8
VP06702
p963
sg10
I31
sg11
VS100 calcium binding protein A9
p964
sg13
I5
sa(dp965
g7
I121
sg8
VP43490
p966
sg10
I4
sg11
VPBEF
p967
sg13
I1
sa(dp968
g7
I54
sg8
VP52799
p969
sg10
I5
sg11
VEPHB2
p970
sg13
I1
sasg29
(lp971
(dp972
g7
I517
sg32
VC0033860
p973
sg10
I9
sg11
Vpsoriasis
p974
sg13
I1
sasa(dp975
g2
S'Statistically significant advantage in cognitive response (but not with global impression of change or non-cognitive measures) was seen with rivastigmine treatment at 24 weeks (MMSE change from baseline MD 0.6, 95% CI 0.11 to 1.09, P value 0.02; Vascular Dementia Assessment Scale (VaDAS) change from baseline MD -1.3, 95% CI-2.62 to 0.02, P value 0.05 ).\n'
p976
sg4
(lp977
sg29
(lp978
(dp979
g7
I246
sg32
VC0011269
p980
sg10
I17
sg11
VVascular Dementia
p981
sg13
I2
sasa(dp982
g2
S'The genes encode cytoskeletal tropomyosin TM30nm (TPM3), HS1-binding protein Hax-1 (HAX1), RNA-specific adenosine deaminase (ADAR1), the 34/67-kD laminin receptor (LAMRL6), and the 26S proteasome subunit p31 (PSMD8L), as well as five hitherto uncharacterized proteins (NICE-1, NICE-2, NICE-3, NICE-4, and NICE-5).\n'
p983
sg4
(lp984
(dp985
g7
I277
sg8
g48
sg10
I6
sg11
VNICE-2
p986
sg13
I1
sa(dp987
g7
I181
sg8
VP48556
p988
sg10
I26
sg11
V26S proteasome subunit p31
p989
sg13
I4
sa(dp990
g7
I146
sg8
g48
sg10
I16
sg11
Vlaminin receptor
p991
sg13
I2
sa(dp992
g7
I57
sg8
VP27348
p993
sg10
I25
sg11
VHS1-binding protein Hax-1
p994
sg13
I3
sa(dp995
g7
I125
sg8
VP55265
p996
sg10
I5
sg11
VADAR1
p997
sg13
I1
sa(dp998
g7
I84
sg8
g48
sg10
I4
sg11
VHAX1
p999
sg13
I1
sa(dp1000
g7
I269
sg8
g48
sg10
I6
sg11
VNICE-1
p1001
sg13
I1
sa(dp1002
g7
I104
sg8
VP00813
p1003
sg10
I19
sg11
Vadenosine deaminase
p1004
sg13
I2
sa(dp1005
g7
I293
sg8
g48
sg10
I6
sg11
VNICE-4
p1006
sg13
I1
sa(dp1007
g7
I17
sg8
VP07951
p1008
sg10
I31
sg11
Vcytoskeletal tropomyosin TM30nm
p1009
sg13
I3
sa(dp1010
g7
I50
sg8
VP06753
p1011
sg10
I4
sg11
VTPM3
p1012
sg13
I1
sasg29
(lp1013
(dp1014
g7
I57
sg32
VC2674218
p1015
sg10
I3
sg11
VHS1
p1016
sg13
I1
sasa(dp1017
g2
S'To explore the role of mitochondrial DNA 5178 C/A (Mt5178) polymorphism of NADH-dehydrogenase subunit 2 (ND2) gene in type-2 diabetes mellitus (T2DM) among ethnic Han Chinese through a case-control study.\n'
p1018
sg4
(lp1019
(dp1020
g7
I75
sg8
VP49366
p1021
sg10
I28
sg11
VNADH-dehydrogenase subunit 2
p1022
sg13
I3
sa(dp1023
g7
I105
sg8
VP03891
p1024
sg10
I3
sg11
VND2
p1025
sg13
I1
sasg29
(lp1026
(dp1027
g7
I125
sg32
VC0011849
p1028
sg10
I17
sg11
Vdiabetes mellitus
p1029
sg13
I2
sasa(dp1030
g2
S'To investigate whether a single nucleotide polymorphism (SNP) in the mitochondrial gene for NADH dehydrogenase 2 (mt-Nd2) can modulate susceptibility to type 1 diabetes in NOD mice.\n'
p1031
sg4
(lp1032
(dp1033
g7
I114
sg8
VP03891
p1034
sg10
I6
sg11
Vmt-Nd2
p1035
sg13
I1
sa(dp1036
g7
I69
sg8
VP03891
p1037
sg10
I43
sg11
Vmitochondrial gene for NADH dehydrogenase 2
p1038
sg13
I6
sasg29
(lp1039
(dp1040
g7
I153
sg32
VC0011854
p1041
sg10
I15
sg11
Vtype 1 diabetes
p1042
sg13
I3
sa(dp1043
g7
I172
sg32
VC0751781
p1044
sg10
I3
sg11
VNOD
p1045
sg13
I1
sasa(dp1046
g2
S'NOD/ShiLtJ mice conplastic for the alloxan resistant (ALR)/Lt-derived mt-Nd2(a) allele (NOD.mt(ALR)) were created and compared with standard NOD (carrying the mt-Nd2(c) allele) for susceptibility to spontaneous autoimmune diabetes, or to diabetes elicited by reciprocal adoptive splenic leukocyte transfers, as well as by adoptive transfer of diabetogenic T-cell clones.\n'
p1047
sg4
(lp1048
(dp1049
g7
I159
sg8
VP03891
p1050
sg10
I16
sg11
Vmt-Nd2(c) allele
p1051
sg13
I2
sa(dp1052
g7
I0
sg8
VP54259
p1053
sg10
I3
sg11
VNOD
p1054
sg13
I1
sa(dp1055
g7
I70
sg8
VP03891
p1056
sg10
I6
sg11
Vmt-Nd2
p1057
sg13
I1
sasg29
(lp1058
(dp1059
g7
I222
sg32
VC0011849
p1060
sg10
I8
sg11
Vdiabetes
p1061
sg13
I1
sa(dp1062
g7
I0
sg32
VC0751781
p1063
sg10
I3
sg11
VNOD
p1064
sg13
I1
sa(dp1065
g7
I0
sg32
VC0751781
p1066
sg10
I3
sg11
VNOD
p1067
sg13
I1
sa(dp1068
g7
I0
sg32
VC0751781
p1069
sg10
I3
sg11
VNOD
p1070
sg13
I1
sa(dp1071
g7
I211
sg32
VC0205734
p1072
sg10
I19
sg11
Vautoimmune diabetes
p1073
sg13
I2
sasa(dp1074
g2
S'However, conplastic mice with the mt-Nd2(a) allele exhibited resistance to transfer of diabetes by the CD4(+) T-cell clone BDC 2.5 as well as the CD8(+) AI4 T-cell clones from T-cell receptor transgenic animals.\n'
p1075
sg4
(lp1076
(dp1077
g7
I103
sg8
VP01730
p1078
sg10
I25
sg11
VCD4(+) T-cell clone BDC 2
p1079
sg13
I5
sa(dp1080
g7
I146
sg8
VP01732
p1081
sg10
I10
sg11
VCD8(+) AI4
p1082
sg13
I2
sa(dp1083
g7
I34
sg8
VP03891
p1084
sg10
I6
sg11
Vmt-Nd2
p1085
sg13
I1
sasg29
(lp1086
(dp1087
g7
I123
sg32
VC1266044
p1088
sg10
I3
sg11
VBDC
p1089
sg13
I1
sa(dp1090
g7
I153
sg32
VC1863012
p1091
sg10
I3
sg11
VAI4
p1092
sg13
I1
sa(dp1093
g7
I87
sg32
VC0011849
p1094
sg10
I8
sg11
Vdiabetes
p1095
sg13
I1
sasa(dp1096
g2
S'Conplastic introduction into NOD mice of a variant mt-Nd2 allele alone was not sufficient to prevent spontaneous autoimmune diabetes.\n'
p1097
sg4
(lp1098
(dp1099
g7
I51
sg8
VP03891
p1100
sg10
I13
sg11
Vmt-Nd2 allele
p1101
sg13
I2
sasg29
(lp1102
(dp1103
g7
I29
sg32
VC0751781
p1104
sg10
I3
sg11
VNOD
p1105
sg13
I1
sa(dp1106
g7
I113
sg32
VC0205734
p1107
sg10
I19
sg11
Vautoimmune diabetes
p1108
sg13
I2
sasa(dp1109
g2
S'To investigate the association between serum concentrations of placental leucine aminopeptidase (P-LAP) and hypertensive disorders in pregnancy (HDP), gestational diabetes mellitus (GDM), and perinatal mortality.\n'
p1110
sg4
(lp1111
(dp1112
g7
I63
sg8
VP11117
p1113
sg10
I32
sg11
Vplacental leucine aminopeptidase
p1114
sg13
I3
sa(dp1115
g7
I97
sg8
VP11117
p1116
sg10
I5
sg11
VP-LAP
p1117
sg13
I1
sasg29
(lp1118
(dp1119
g7
I99
sg32
VC0396060
p1120
sg10
I3
sg11
VLAP
p1121
sg13
I1
sa(dp1122
g7
I151
sg32
VC0085207
p1123
sg10
I29
sg11
Vgestational diabetes mellitus
p1124
sg13
I3
sa(dp1125
g7
I182
sg32
VC0085207
p1126
sg10
I3
sg11
VGDM
p1127
sg13
I1
sasa(dp1128
g2
S'Few of the substrates of Tankyrases are Telomeric Repeat binding Factor protein (TRF1), Axis Inhibitory protein (AXIN 1&amp;amp;2), Insulin Responsive Amino Peptidase (IRAP), Nuclear Mitotic Apparatus protein (NuMa), that become aberrantly active due to the apparent overexpression of the enzyme during hyper proliferative disease conditions like cancer, fibrosis and metabolic disorders like diabetes.\n'
p1129
sg4
(lp1130
(dp1131
g7
I168
sg8
g48
sg10
I4
sg11
VIRAP
p1132
sg13
I1
sa(dp1133
g7
I25
sg8
g48
sg10
I10
sg11
VTankyrases
p1134
sg13
I1
sa(dp1135
g7
I132
sg8
g48
sg10
I34
sg11
VInsulin Responsive Amino Peptidase
p1136
sg13
I4
sa(dp1137
g7
I40
sg8
VP54274
p1138
sg10
I39
sg11
VTelomeric Repeat binding Factor protein
p1139
sg13
I5
sa(dp1140
g7
I-1
sg8
g48
sg10
I8
sg11
VAXIN 1&2
p1141
sg13
I2
sa(dp1142
g7
I81
sg8
VP54274
p1143
sg10
I4
sg11
VTRF1
p1144
sg13
I1
sasg29
(lp1145
(dp1146
g7
I309
sg32
VC0334094
p1147
sg10
I13
sg11
Vproliferative
p1148
sg13
I1
sa(dp1149
g7
I368
sg32
VC0025517
p1150
sg10
I19
sg11
Vmetabolic disorders
p1151
sg13
I2
sa(dp1152
g7
I355
sg32
VC0016059
p1153
sg10
I8
sg11
Vfibrosis
p1154
sg13
I1
sa(dp1155
g7
I393
sg32
VC0011849
p1156
sg10
I8
sg11
Vdiabetes
p1157
sg13
I1
sa(dp1158
g7
I347
sg32
VC0006826
p1159
sg10
I6
sg11
Vcancer
p1160
sg13
I1
sasa(dp1161
g2
S'Pathway analysis indicated that LNPEP was involved in the renin-angiotensin system, which also has a key role in cardiovascular disease and diabetes.\n'
p1162
sg4
(lp1163
(dp1164
g7
I58
sg8
VP00797
p1165
sg10
I5
sg11
Vrenin
p1166
sg13
I1
sa(dp1167
g7
I64
sg8
VP21549
p1168
sg10
I18
sg11
Vangiotensin system
p1169
sg13
I2
sa(dp1170
g7
I32
sg8
g48
sg10
I5
sg11
VLNPEP
p1171
sg13
I1
sasg29
(lp1172
(dp1173
g7
I113
sg32
VC0007222
p1174
sg10
I22
sg11
Vcardiovascular disease
p1175
sg13
I2
sa(dp1176
g7
I140
sg32
VC0011849
p1177
sg10
I8
sg11
Vdiabetes
p1178
sg13
I1
sasa(dp1179
g2
S'In this study we measured the cell surface IRAP activity and 3-O-[methyl-14C]-D-Glucose uptake in adipocytes isolated from Otsuka Long Evans Tokushima Fatty rats (OLETF), developed as a model of type 2 diabetes mellitus, to evaluate whether the translocation of GLUT4/IRAP vesicles is affected.\n'
p1180
sg4
(lp1181
(dp1182
g7
I262
sg8
VP14672
p1183
sg10
I5
sg11
VGLUT4
p1184
sg13
I1
sa(dp1185
g7
I43
sg8
g48
sg10
I4
sg11
VIRAP
p1186
sg13
I1
sa(dp1187
g7
I43
sg8
g48
sg10
I4
sg11
VIRAP
p1188
sg13
I1
sasg29
(lp1189
(dp1190
g7
I195
sg32
VC0011860
p1191
sg10
I24
sg11
Vtype 2 diabetes mellitus
p1192
sg13
I4
sa(dp1193
g7
I245
sg32
VC0040715
p1194
sg10
I13
sg11
Vtranslocation
p1195
sg13
I1
sa(dp1196
g7
I273
sg32
VC0333262
p1197
sg10
I8
sg11
Vvesicles
p1198
sg13
I1
sasa(dp1199
g2
S'In individuals with type 2 diabetes the insulin-stimulated translocation of IRAP to the cell surface of muscle and fat cells is impaired.\n'
p1200
sg4
(lp1201
(dp1202
g7
I40
sg8
VP01308
p1203
sg10
I7
sg11
Vinsulin
p1204
sg13
I1
sa(dp1205
g7
I76
sg8
g48
sg10
I4
sg11
VIRAP
p1206
sg13
I1
sasg29
(lp1207
(dp1208
g7
I20
sg32
VC0011860
p1209
sg10
I15
sg11
Vtype 2 diabetes
p1210
sg13
I3
sa(dp1211
g7
I128
sg32
VC0684336
p1212
sg10
I8
sg11
Vimpaired
p1213
sg13
I1
sa(dp1214
g7
I59
sg32
VC0040715
p1215
sg10
I13
sg11
Vtranslocation
p1216
sg13
I1
sasa(dp1217
g2
S'Impaired IRAP action may thus play a role in the development of complications in type 2 diabetes.\n'
p1218
sg4
(lp1219
(dp1220
g7
I9
sg8
g48
sg10
I4
sg11
VIRAP
p1221
sg13
I1
sasg29
(lp1222
(dp1223
g7
I81
sg32
VC0011860
p1224
sg10
I15
sg11
Vtype 2 diabetes
p1225
sg13
I3
sa(dp1226
g7
I0
sg32
VC0684336
p1227
sg10
I8
sg11
VImpaired
p1228
sg13
I1
sasa(dp1229
g2
S'In complications of diabetes mellitus, the urinary estriol assays were sensitive and reliable indicators of the pregnancy state, whereas in preeclampsia complications, both the serum oxytocinase and urinary estriol assays were of prognostic value.\n'
p1230
sg4
(lp1231
(dp1232
g7
I177
sg8
g48
sg10
I17
sg11
Vserum oxytocinase
p1233
sg13
I2
sasg29
(lp1234
(dp1235
g7
I140
sg32
VC0032914
p1236
sg10
I12
sg11
Vpreeclampsia
p1237
sg13
I1
sa(dp1238
g7
I3
sg32
VC0342257
p1239
sg10
I34
sg11
Vcomplications of diabetes mellitus
p1240
sg13
I4
sasa(dp1241
g2
S'In primary CFs, isoproterenol increased the phosphorylation of ERK1/2 and the expression levels of both 11Beta-HSD1 and collagen-I; these isoproterenol-attributable effects were inhibited by co-treatment with eplerenone and PD98059, a specific inhibitor of mitogen-activated protein kinase/ERK kinase activity.\n'
p1242
sg4
(lp1243
(dp1244
g7
I104
sg8
g48
sg10
I11
sg11
V11Beta-HSD1
p1245
sg13
I1
sa(dp1246
g7
I63
sg8
VP27361
p1247
sg10
I6
sg11
VERK1/2
p1248
sg13
I1
sa(dp1249
g7
I257
sg8
VP53779
p1250
sg10
I32
sg11
Vmitogen-activated protein kinase
p1251
sg13
I3
sa(dp1252
g7
I63
sg8
VP29323
p1253
sg10
I3
sg11
VERK
p1254
sg13
I1
sasg29
(lp1255
(dp1256
g7
I11
sg32
VC0015674
p1257
sg10
I3
sg11
VCFs
p1258
sg13
I1
sasa(dp1259
g2
S'Eplerenone inhibited isoproterenol-induced ERK1/2 phosphorylation and expression of 11Beta-HSD1 and collagen-I in primary CFs, as well as the progression of cardiac fibrosis in the left ventricle.\n'
p1260
sg4
(lp1261
(dp1262
g7
I84
sg8
g48
sg10
I11
sg11
V11Beta-HSD1
p1263
sg13
I1
sa(dp1264
g7
I43
sg8
VP27361
p1265
sg10
I6
sg11
VERK1/2
p1266
sg13
I1
sasg29
(lp1267
(dp1268
g7
I157
sg32
VC1397307
p1269
sg10
I16
sg11
Vcardiac fibrosis
p1270
sg13
I2
sa(dp1271
g7
I122
sg32
VC0015674
p1272
sg10
I3
sg11
VCFs
p1273
sg13
I1
sasa(dp1274
g2
S'The number of CD68+ Mo/M phi infiltrating in one glomerulus was significantly higher in Henoch-Schoenlein purpura nephritis(HSPN) (p &lt; 0.01) in comparison with that in minimal change nephrotic syndrome(MCNS) (p &lt; 0.01), and a high tendency was found in IgA nephropathy (IgAN), proliferative glomerulonephritis (non-IgAN), focal segmental glomerulosclerosis(FSGS) and membranoproliferative glomerulonephritis (MPGN), respectively.\n'
p1275
sg4
(lp1276
(dp1277
g7
I259
sg8
VP11912
p1278
sg10
I15
sg11
VIgA nephropathy
p1279
sg13
I2
sa(dp1280
g7
I14
sg8
VP34810
p1281
sg10
I14
sg11
VCD68+ Mo/M phi
p1282
sg13
I3
sa(dp1283
g7
I276
sg8
VP11912
p1284
sg10
I4
sg11
VIgAN
p1285
sg13
I1
sa(dp1286
g7
I276
sg8
VP11912
p1287
sg10
I4
sg11
VIgAN
p1288
sg13
I1
sasg29
(lp1289
(dp1290
g7
I276
sg32
VC0017661
p1291
sg10
I4
sg11
VIgAN
p1292
sg13
I1
sa(dp1293
g7
I88
sg32
VC0034152
p1294
sg10
I25
sg11
VHenoch-Schoenlein purpura
p1295
sg13
I2
sa(dp1296
g7
I29
sg32
VC0332448
p1297
sg10
I12
sg11
Vinfiltrating
p1298
sg13
I1
sa(dp1299
g7
I283
sg32
VC0235618
p1300
sg10
I32
sg11
Vproliferative glomerulonephritis
p1301
sg13
I2
sa(dp1302
g7
I114
sg32
VC0027697
p1303
sg10
I9
sg11
Vnephritis
p1304
sg13
I1
sa(dp1305
g7
I171
sg32
VC1704321
p1306
sg10
I33
sg11
Vminimal change nephrotic syndrome
p1307
sg13
I4
sa(dp1308
g7
I328
sg32
VC0017668
p1309
sg10
I34
sg11
Vfocal segmental glomerulosclerosis
p1310
sg13
I3
sa(dp1311
g7
I259
sg32
VC0017661
p1312
sg10
I15
sg11
VIgA nephropathy
p1313
sg13
I2
sa(dp1314
g7
I415
sg32
VC0017662
p1315
sg10
I4
sg11
VMPGN
p1316
sg13
I1
sa(dp1317
g7
I276
sg32
VC0017661
p1318
sg10
I4
sg11
VIgAN
p1319
sg13
I1
sa(dp1320
g7
I373
sg32
VC0017662
p1321
sg10
I40
sg11
Vmembranoproliferative glomerulonephritis
p1322
sg13
I2
sasa(dp1323
g2
S"Renal biopsy specimens from 13 patients with glomerular disease (6 with Alport's syndrome, 5 with focal glomerulosclerosis, 2 with membranoproliferative glomerulonephritis, Type 1) showing interstitial FCs were investigated by histochemical means for neutral lipid (oil red O stain); immunohistochemical means for monocytes/macrophages (CD68), apolipoproteins (Apo) A-I, B, and E, and oxidized low-density lipoprotein (LDL); and by electron microscopic examination.\n"
p1324
sg4
(lp1325
(dp1326
g7
I419
sg8
VP02652
p1327
sg10
I3
sg11
VLDL
p1328
sg13
I1
sa(dp1329
g7
I337
sg8
VP34810
p1330
sg10
I4
sg11
VCD68
p1331
sg13
I1
sa(dp1332
g7
I344
sg8
g48
sg10
I25
sg11
Vapolipoproteins (Apo) A-I
p1333
sg13
I3
sa(dp1334
g7
I394
sg8
VP02652
p1335
sg10
I23
sg11
Vlow-density lipoprotein
p1336
sg13
I2
sasg29
(lp1337
(dp1338
g7
I131
sg32
VC0017662
p1339
sg10
I40
sg11
Vmembranoproliferative glomerulonephritis
p1340
sg13
I2
sa(dp1341
g7
I72
sg32
VC1567741
p1342
sg10
I17
sg11
VAlport's syndrome
p1343
sg13
I2
sa(dp1344
g7
I98
sg32
VC0017668
p1345
sg10
I24
sg11
Vfocal glomerulosclerosis
p1346
sg13
I2
sa(dp1347
g7
I45
sg32
VC0268731
p1348
sg10
I18
sg11
Vglomerular disease
p1349
sg13
I2
sasa(dp1350
g2
S"1-Cys-peroxiredoxin, glutathione transferase and dehydrin were mainly recognized by patients with baker's asthma but not wheat-induced food allergy.\n"
p1351
sg4
(lp1352
(dp1353
g7
I21
sg8
VP78417
p1354
sg10
I36
sg11
Vglutathione transferase and dehydrin
p1355
sg13
I4
sa(dp1356
g7
I0
sg8
VP30041
p1357
sg10
I19
sg11
V1-Cys-peroxiredoxin
p1358
sg13
I1
sasg29
(lp1359
(dp1360
g7
I98
sg32
VC0264480
p1361
sg10
I14
sg11
Vbaker's asthma
p1362
sg13
I2
sa(dp1363
g7
I135
sg32
VC0016470
p1364
sg10
I12
sg11
Vfood allergy
p1365
sg13
I2
sasa(dp1366
g2
S'In addition to confirming mutations in known cancer-associated genes (TP53, KRAS, PIK3CA, MET, NOTCH, STK11, and RB1), several novel mutations in additional genes, including RASA1, CDH4, CDH7, LAMB4, SCAF1, and LMTK2, were identified and validated.\n'
p1367
sg4
(lp1368
(dp1369
g7
I102
sg8
g48
sg10
I5
sg11
VSTK11
p1370
sg13
I1
sa(dp1371
g7
I76
sg8
VP01116
p1372
sg10
I4
sg11
VKRAS
p1373
sg13
I1
sa(dp1374
g7
I113
sg8
VP27986
p1375
sg10
I3
sg11
VRB1
p1376
sg13
I1
sa(dp1377
g7
I174
sg8
VP20936
p1378
sg10
I5
sg11
VRASA1
p1379
sg13
I1
sa(dp1380
g7
I200
sg8
g48
sg10
I5
sg11
VSCAF1
p1381
sg13
I1
sa(dp1382
g7
I211
sg8
g48
sg10
I5
sg11
VLMTK2
p1383
sg13
I1
sa(dp1384
g7
I181
sg8
VP55283
p1385
sg10
I4
sg11
VCDH4
p1386
sg13
I1
sa(dp1387
g7
I193
sg8
g48
sg10
I5
sg11
VLAMB4
p1388
sg13
I1
sa(dp1389
g7
I187
sg8
g48
sg10
I4
sg11
VCDH7
p1390
sg13
I1
sa(dp1391
g7
I82
sg8
VP42336
p1392
sg10
I6
sg11
VPIK3CA
p1393
sg13
I1
sasg29
(lp1394
(dp1395
g7
I45
sg32
VC0006826
p1396
sg10
I6
sg11
Vcancer
p1397
sg13
I1
sasa(dp1398
g2
S'However, differential transcription levels were observed for CDH19 and Hs.96900 in head and neck cancer cell lines supporting their putative involvement through down regulation mechanisms in head and neck cancer progression.\n'
p1399
sg4
(lp1400
(dp1401
g7
I61
sg8
g48
sg10
I5
sg11
VCDH19
p1402
sg13
I1
sasg29
(lp1403
(dp1404
g7
I83
sg32
VC0278996
p1405
sg10
I20
sg11
Vhead and neck cancer
p1406
sg13
I4
sa(dp1407
g7
I83
sg32
VC0278996
p1408
sg10
I20
sg11
Vhead and neck cancer
p1409
sg13
I4
sasa(dp1410
g2
S'Nested PCR (nPCR) with EBV-1 or EBV-2 specific primers was used to detect EBV-1 and EBV-2 in the subgingival samples from 65 chronic periodontitis patients, 65 gingivitis patients and 24 periodontal healthy individuals.\n'
p1411
sg4
(lp1412
sg29
(lp1413
(dp1414
g7
I160
sg32
VC0017574
p1415
sg10
I10
sg11
Vgingivitis
p1416
sg13
I1
sa(dp1417
g7
I125
sg32
VC0266929
p1418
sg10
I21
sg11
Vchronic periodontitis
p1419
sg13
I2
sasa(dp1420
g2
S'The vitronectin receptor alpha(v)beta(3) has been identified as a promising potential target for the treatment of osteoporosis, diabetic retinopathy and cancer.\n'
p1421
sg4
(lp1422
(dp1423
g7
I4
sg8
VP04004
p1424
sg10
I36
sg11
Vvitronectin receptor alpha(v)beta(3)
p1425
sg13
I3
sasg29
(lp1426
(dp1427
g7
I128
sg32
VC0011884
p1428
sg10
I20
sg11
Vdiabetic retinopathy
p1429
sg13
I2
sa(dp1430
g7
I114
sg32
VC0029456
p1431
sg10
I12
sg11
Vosteoporosis
p1432
sg13
I1
sa(dp1433
g7
I153
sg32
VC0006826
p1434
sg10
I6
sg11
Vcancer
p1435
sg13
I1
sasa(dp1436
g2
S"Several presentations focused on the role of calreticulin and other ER chaperones in a variety of disease states, including haemophilia, obesity, diabetes, Sjogren's syndrome, Chagas diseases, multiple sclerosis, amyotrophic lateral sclerosis, neurological malignancies (especially glioblastoma), haematological malignancies (especially essential thrombocythemia and myelofibrosis), lung adenocarcinoma, renal pathology with emphasis in fibrosis and drug toxicity.\n"
p1437
sg4
(lp1438
(dp1439
g7
I45
sg8
VP27797
p1440
sg10
I12
sg11
Vcalreticulin
p1441
sg13
I1
sasg29
(lp1442
(dp1443
g7
I367
sg32
VC0001815
p1444
sg10
I13
sg11
Vmyelofibrosis
p1445
sg13
I1
sa(dp1446
g7
I257
sg32
VC0006826
p1447
sg10
I12
sg11
Vmalignancies
p1448
sg13
I1
sa(dp1449
g7
I282
sg32
VC0017636
p1450
sg10
I12
sg11
Vglioblastoma
p1451
sg13
I1
sa(dp1452
g7
I202
sg32
VC0002736
p1453
sg10
I30
sg11
Vsclerosis, amyotrophic lateral
p1454
sg13
I3
sa(dp1455
g7
I202
sg32
VC0036429
p1456
sg10
I9
sg11
Vsclerosis
p1457
sg13
I1
sa(dp1458
g7
I156
sg32
VC1527336
p1459
sg10
I18
sg11
VSjogren's syndrome
p1460
sg13
I2
sa(dp1461
g7
I124
sg32
VC0684275
p1462
sg10
I11
sg11
Vhaemophilia
p1463
sg13
I1
sa(dp1464
g7
I176
sg32
VC0041234
p1465
sg10
I15
sg11
VChagas diseases
p1466
sg13
I2
sa(dp1467
g7
I146
sg32
VC0011849
p1468
sg10
I8
sg11
Vdiabetes
p1469
sg13
I1
sa(dp1470
g7
I137
sg32
VC0028754
p1471
sg10
I7
sg11
Vobesity
p1472
sg13
I1
sa(dp1473
g7
I372
sg32
VC0016059
p1474
sg10
I8
sg11
Vfibrosis
p1475
sg13
I1
sa(dp1476
g7
I388
sg32
VC0007134
p1477
sg10
I21
sg11
Vadenocarcinoma, renal
p1478
sg13
I2
sa(dp1479
g7
I337
sg32
VC0040028
p1480
sg10
I25
sg11
Vessential thrombocythemia
p1481
sg13
I2
sa(dp1482
g7
I410
sg32
VC0677042
p1483
sg10
I9
sg11
Vpathology
p1484
sg13
I1
sa(dp1485
g7
I257
sg32
VC0006826
p1486
sg10
I12
sg11
Vmalignancies
p1487
sg13
I1
sasa(dp1488
g2
S'The current study aimed to determine whether stimulation of aromatase by obesity-associated adipokine leptin involves the regulation of the p53-HIF1Alfa/PKM2 axis.\n'
p1489
sg4
(lp1490
(dp1491
g7
I140
sg8
VP42771
p1492
sg10
I3
sg11
Vp53
p1493
sg13
I1
sa(dp1494
g7
I60
sg8
VP11511
p1495
sg10
I9
sg11
Varomatase
p1496
sg13
I1
sa(dp1497
g7
I92
sg8
VP41159
p1498
sg10
I16
sg11
Vadipokine leptin
p1499
sg13
I2
sasg29
(lp1500
(dp1501
g7
I73
sg32
VC0028754
p1502
sg10
I7
sg11
Vobesity
p1503
sg13
I1
sasa(dp1504
g2
S'Our previous findings in obesity-resistant BALB/c mice showed that a diet high in saturated animal fat (HFD) promotes mammary tumorigenesis in both DMBA carcinogenesis and Trp53-null transplant models.\n'
p1505
sg4
(lp1506
(dp1507
g7
I172
sg8
VP42771
p1508
sg10
I5
sg11
VTrp53
p1509
sg13
I1
sasg29
(lp1510
(dp1511
g7
I153
sg32
VC0596263
p1512
sg10
I14
sg11
Vcarcinogenesis
p1513
sg13
I1
sa(dp1514
g7
I118
sg32
VC1512981
p1515
sg10
I21
sg11
Vmammary tumorigenesis
p1516
sg13
I2
sa(dp1517
g7
I25
sg32
VC0028754
p1518
sg10
I7
sg11
Vobesity
p1519
sg13
I1
sasa(dp1520
g2
S'Wiedemann-Steiner syndrome (WDSTS) is an autosomal dominant disorder characterized by hypertrichosis, intellectual disability, and dysmorphic facial appearances (down-slanted vertically narrow palpebral fissures, wide nasal bridge, broad nasal tip, and thick eyebrows).\n'
p1521
sg4
(lp1522
(dp1523
g7
I244
sg8
g48
sg10
I3
sg11
Vtip
p1524
sg13
I1
sasg29
(lp1525
(dp1526
g7
I102
sg32
VC0025362
p1527
sg10
I23
sg11
Vintellectual disability
p1528
sg13
I2
sa(dp1529
g7
I28
sg32
VC1854630
p1530
sg10
I5
sg11
VWDSTS
p1531
sg13
I1
sa(dp1532
g7
I0
sg32
VC1854630
p1533
sg10
I26
sg11
VWiedemann-Steiner syndrome
p1534
sg13
I2
sa(dp1535
g7
I86
sg32
VC0020555
p1536
sg10
I14
sg11
Vhypertrichosis
p1537
sg13
I1
sasa(dp1538
g2
S'Wiedemann-Steiner syndrome (WDSTS) is a very rare genetic disorder characterized by short stature, intellectual disability and distinctive facial appearance.\n'
p1539
sg4
(lp1540
sg29
(lp1541
(dp1542
g7
I99
sg32
VC0025362
p1543
sg10
I23
sg11
Vintellectual disability
p1544
sg13
I2
sa(dp1545
g7
I84
sg32
VC0013336
p1546
sg10
I13
sg11
Vshort stature
p1547
sg13
I2
sa(dp1548
g7
I28
sg32
VC1854630
p1549
sg10
I5
sg11
VWDSTS
p1550
sg13
I1
sa(dp1551
g7
I0
sg32
VC1854630
p1552
sg10
I26
sg11
VWiedemann-Steiner syndrome
p1553
sg13
I2
sa(dp1554
g7
I50
sg32
VC0019247
p1555
sg10
I16
sg11
Vgenetic disorder
p1556
sg13
I2
sasa(dp1557
g2
S'Here, we showed that in clinically obtained colorectal carcinoma (CRC) specimens, Flt-1, the type 1 receptor for vascular endothelial growth factor A, was significantly upregulated.\n'
p1558
sg4
(lp1559
(dp1560
g7
I82
sg8
VP17948
p1561
sg10
I5
sg11
VFlt-1
p1562
sg13
I1
sa(dp1563
g7
I93
sg8
g48
sg10
I15
sg11
Vtype 1 receptor
p1564
sg13
I3
sa(dp1565
g7
I113
sg8
g48
sg10
I36
sg11
Vvascular endothelial growth factor A
p1566
sg13
I5
sasg29
(lp1567
(dp1568
g7
I44
sg32
VC0009402
p1569
sg10
I20
sg11
Vcolorectal carcinoma
p1570
sg13
I2
sa(dp1571
g7
I66
sg32
VC1527249
p1572
sg10
I3
sg11
VCRC
p1573
sg13
I1
sasa(dp1574
g2
S'Nintedanib is a triple angiokinase inhibitor approved with docetaxel for adenocarcinoma non-small cell lung cancer after first-line chemotherapy (FLT).\n'
p1575
sg4
(lp1576
sg29
(lp1577
(dp1578
g7
I73
sg32
VC0001418
p1579
sg10
I14
sg11
Vadenocarcinoma
p1580
sg13
I1
sa(dp1581
g7
I88
sg32
VC0007131
p1582
sg10
I26
sg11
Vnon-small cell lung cancer
p1583
sg13
I4
sasa(dp1584
g2
S'In the phase III LUME-Lung 1 study, overall survival (OS) was significantly longer with nintedanib/docetaxel than with placebo/docetaxel in all adenocarcinoma patients and those with time from start of FLT (TSFLT) &lt;9 months.\n'
p1585
sg4
(lp1586
sg29
(lp1587
(dp1588
g7
I144
sg32
VC0001418
p1589
sg10
I14
sg11
Vadenocarcinoma
p1590
sg13
I1
sasa(dp1591
g2
S'This study sought to extend analyses from the LUME-Lung 1 study, specifically for adenocarcinoma patients, to explore the impact of clinically relevant characteristics on outcomes such as time to progression after FLT.\n'
p1592
sg4
(lp1593
sg29
(lp1594
(dp1595
g7
I82
sg32
VC0001418
p1596
sg10
I14
sg11
Vadenocarcinoma
p1597
sg13
I1
sasa(dp1598
g2
S'Nintedanib/docetaxel demonstrated significant OS benefits in adenocarcinoma patients, which were more pronounced in patients with shorter TSFLT or TEFLT, or with PD as best response to FLT.\n'
p1599
sg4
(lp1600
(dp1601
g7
I140
sg8
VP17948
p1602
sg10
I3
sg11
VFLT
p1603
sg13
I1
sasg29
(lp1604
(dp1605
g7
I61
sg32
VC0001418
p1606
sg10
I14
sg11
Vadenocarcinoma
p1607
sg13
I1
sasa(dp1608
g2
S'The present study aimed to investigate the alteration of MMP-9 and VEGFR-1 expression patterns following treatment with these tyrosine kinase inhibitors in p16-positive and -negative squamous carcinoma cells.\n'
p1609
sg4
(lp1610
(dp1611
g7
I57
sg8
VP14780
p1612
sg10
I5
sg11
VMMP-9
p1613
sg13
I1
sa(dp1614
g7
I126
sg8
VP29401
p1615
sg10
I15
sg11
Vtyrosine kinase
p1616
sg13
I2
sa(dp1617
g7
I67
sg8
VP17948
p1618
sg10
I7
sg11
VVEGFR-1
p1619
sg13
I1
sa(dp1620
g7
I156
sg8
VP42771
p1621
sg10
I3
sg11
Vp16
p1622
sg13
I1
sasg29
(lp1623
(dp1624
g7
I183
sg32
VC0007137
p1625
sg10
I18
sg11
Vsquamous carcinoma
p1626
sg13
I2
sasa(dp1627
g2
S"Carcinoma proliferative activity was assessed using accumulation of [methyl-3H]-3'-deoxy-3'-fluorothymidine ([3H]FLT).\n"
p1628
sg4
(lp1629
sg29
(lp1630
(dp1631
g7
I10
sg32
VC0334094
p1632
sg10
I13
sg11
Vproliferative
p1633
sg13
I1
sa(dp1634
g7
I0
sg32
VC0007097
p1635
sg10
I9
sg11
VCarcinoma
p1636
sg13
I1
sasa(dp1637
g2
S'We report on a 4-year-old girl with autosomal recessive cutis laxa, type IA, or pulmonary emphysema type (ARCL1A; OMIM #219100), with loose and wrinkled skin, mitral and tricuspid valve prolapse, conjunctivochalasis, obstructed nasolacrimal ducts, hypoplastic maxilla, and early childhood-onset pulmonary emphysema.\n'
p1638
sg4
(lp1639
sg29
(lp1640
(dp1641
g7
I80
sg32
VC0034067
p1642
sg10
I19
sg11
Vpulmonary emphysema
p1643
sg13
I2
sa(dp1644
g7
I106
sg32
VC0268351
p1645
sg10
I6
sg11
VARCL1A
p1646
sg13
I1
sa(dp1647
g7
I196
sg32
VC0878693
p1648
sg10
I19
sg11
Vconjunctivochalasis
p1649
sg13
I1
sa(dp1650
g7
I80
sg32
VC0034067
p1651
sg10
I19
sg11
Vpulmonary emphysema
p1652
sg13
I2
sa(dp1653
g7
I170
sg32
VC0040962
p1654
sg10
I24
sg11
Vtricuspid valve prolapse
p1655
sg13
I3
sa(dp1656
g7
I56
sg32
VC0010495
p1657
sg10
I10
sg11
Vcutis laxa
p1658
sg13
I2
sasa(dp1659
g2
S'FBLN5 and LTBP4 mutations cause a very similar phenotype associated with severe pulmonary emphysema, in the absence of vascular tortuosity or aneurysms.\n'
p1660
sg4
(lp1661
(dp1662
g7
I0
sg8
g48
sg10
I5
sg11
VFBLN5
p1663
sg13
I1
sa(dp1664
g7
I10
sg8
g48
sg10
I15
sg11
VLTBP4 mutations
p1665
sg13
I2
sasg29
(lp1666
(dp1667
g7
I80
sg32
VC0034067
p1668
sg10
I19
sg11
Vpulmonary emphysema
p1669
sg13
I2
sa(dp1670
g7
I142
sg32
VC0002940
p1671
sg10
I9
sg11
Vaneurysms
p1672
sg13
I1
sasa(dp1673
g2
S'Preeclampsia was defined by blood pressure &gt;=140/90 mmHg and proteinuria &gt;=3 g/24 h. Serum immune biomarkers included interleukin (IL)-6, IL-6 receptor, IL-4, IL-4 receptor, IL-5, IL-12, IL-2, TNF-Alfa, TNF-Beta, TNF-receptor, IL-1Beta, IL-1Alfa, IL-8, IL-10, IFN-Gamma, IL-18, macrophage migration inhibitory factor, macrophage inflammatory protein, transforming growth factor-beta (TGF-Beta), and RANTES.\n'
p1674
sg4
(lp1675
(dp1676
g7
I159
sg8
VP05112
p1677
sg10
I4
sg11
VIL-4
p1678
sg13
I1
sa(dp1679
g7
I357
sg8
VP18075
p1680
sg10
I31
sg11
Vtransforming growth factor-beta
p1681
sg13
I3
sa(dp1682
g7
I266
sg8
VP01579
p1683
sg10
I9
sg11
VIFN-Gamma
p1684
sg13
I1
sa(dp1685
g7
I209
sg8
VP01375
p1686
sg10
I8
sg11
VTNF-Beta
p1687
sg13
I1
sa(dp1688
g7
I124
sg8
VP60568
p1689
sg10
I18
sg11
Vinterleukin (IL)-6
p1690
sg13
I2
sa(dp1691
g7
I193
sg8
VP60568
p1692
sg10
I4
sg11
VIL-2
p1693
sg13
I1
sa(dp1694
g7
I233
sg8
VP01584
p1695
sg10
I8
sg11
VIL-1Beta
p1696
sg13
I1
sa(dp1697
g7
I219
sg8
VP01375
p1698
sg10
I12
sg11
VTNF-receptor
p1699
sg13
I1
sa(dp1700
g7
I165
sg8
VP05112
p1701
sg10
I13
sg11
VIL-4 receptor
p1702
sg13
I2
sa(dp1703
g7
I144
sg8
VP05231
p1704
sg10
I13
sg11
VIL-6 receptor
p1705
sg13
I2
sa(dp1706
g7
I180
sg8
VP05113
p1707
sg10
I4
sg11
VIL-5
p1708
sg13
I1
sa(dp1709
g7
I390
sg8
VP18075
p1710
sg10
I8
sg11
VTGF-Beta
p1711
sg13
I1
sa(dp1712
g7
I199
sg8
VP01375
p1713
sg10
I8
sg11
VTNF-Alfa
p1714
sg13
I1
sa(dp1715
g7
I405
sg8
VP13501
p1716
sg10
I6
sg11
VRANTES
p1717
sg13
I1
sasg29
(lp1718
(dp1719
g7
I0
sg32
VC0032914
p1720
sg10
I12
sg11
VPreeclampsia
p1721
sg13
I1
sasa(dp1722
g2
S'Differential MIF concentrations have been correlated with pathological events during pregnancy, such as recurrent miscarriages and severe pre-eclampsia (PE).\n'
p1723
sg4
(lp1724
sg29
(lp1725
(dp1726
g7
I131
sg32
VC0341950
p1727
sg10
I20
sg11
Vsevere pre-eclampsia
p1728
sg13
I2
sa(dp1729
g7
I104
sg32
VC0000809
p1730
sg10
I22
sg11
Vrecurrent miscarriages
p1731
sg13
I2
sasa(dp1732
g2
S'To investigate whether single nucleotide polymorphism (SNP) of macrophage migration inhibitory factor (MIF) gene -173G/C is associated with severe preeclampsia.\n'
p1733
sg4
(lp1734
(dp1735
g7
I63
sg8
VP14174
p1736
sg10
I57
sg11
Vmacrophage migration inhibitory factor (MIF) gene -173G/C
p1737
sg13
I7
sasg29
(lp1738
(dp1739
g7
I140
sg32
VC0341950
p1740
sg10
I19
sg11
Vsevere preeclampsia
p1741
sg13
I2
sasa(dp1742
g2
S'(1) The MIF -173G/C SNP genotype frequencies of GG, CG, and CC were 62.1% (77/124), 30.6% (38/124), 7.3% (9/124), the allelic frequencies of G and C were 77.4% (192/248) and 22.6% (56/248), respectively, in severe preeclampsia patients; the MIF -173G/C SNP genotype frequencies of GG, CG, and CC were 64.4% (103/160), 30.6% (49/160), 5.0% (8/160), the allelic frequencies of G and C were 79.7% (255/320) and 20.3% (65/320), respectively, in the control group.\n'
p1743
sg4
(lp1744
sg29
(lp1745
(dp1746
g7
I207
sg32
VC0341950
p1747
sg10
I19
sg11
Vsevere preeclampsia
p1748
sg13
I2
sasa(dp1749
g2
S'No significant differences were observed in the genotypes and allele distributions of MIF -173G/C SNP between the severe preeclampsia patients and control group (all P &gt; 0.05).\n'
p1750
sg4
(lp1751
sg29
(lp1752
(dp1753
g7
I114
sg32
VC0341950
p1754
sg10
I19
sg11
Vsevere preeclampsia
p1755
sg13
I2
sasa(dp1756
g2
S'The present study suggests that the MIF -173G/C SNP is associated with insulin resistance in severe preeclampsia patients.\n'
p1757
sg4
(lp1758
(dp1759
g7
I71
sg8
VP01308
p1760
sg10
I7
sg11
Vinsulin
p1761
sg13
I1
sa(dp1762
g7
I36
sg8
g48
sg10
I15
sg11
VMIF -173G/C SNP
p1763
sg13
I3
sasg29
(lp1764
(dp1765
g7
I71
sg32
VC0021655
p1766
sg10
I18
sg11
Vinsulin resistance
p1767
sg13
I2
sa(dp1768
g7
I93
sg32
VC0341950
p1769
sg10
I19
sg11
Vsevere preeclampsia
p1770
sg13
I2
sasa(dp1771
g2
S'MIF maternal serum levels are increased in preeclampsia (PE).\n'
p1772
sg4
(lp1773
sg29
(lp1774
(dp1775
g7
I43
sg32
VC0032914
p1776
sg10
I12
sg11
Vpreeclampsia
p1777
sg13
I1
sa(dp1778
g7
I57
sg32
VC0032914
p1779
sg10
I2
sg11
VPE
p1780
sg13
I1
sasa(dp1781
g2
S'To investigate the expression of macrophage migration inhibitory factor (MIF) and CD74, the receptor of MIF, in preeclamptic placenta and its correlation with the pathogenesis of preeclampsia.\n'
p1782
sg4
(lp1783
(dp1784
g7
I73
sg8
VP05109
p1785
sg10
I3
sg11
VMIF
p1786
sg13
I1
sa(dp1787
g7
I82
sg8
VP04233
p1788
sg10
I4
sg11
VCD74
p1789
sg13
I1
sa(dp1790
g7
I44
sg8
VP05109
p1791
sg10
I27
sg11
Vmigration inhibitory factor
p1792
sg13
I3
sasg29
(lp1793
(dp1794
g7
I163
sg32
VC0699748
p1795
sg10
I12
sg11
Vpathogenesis
p1796
sg13
I1
sa(dp1797
g7
I179
sg32
VC0032914
p1798
sg10
I12
sg11
Vpreeclampsia
p1799
sg13
I1
sasa(dp1800
g2
S'Overexpression of MIF and CD74 in the placenta may up-regulate the CRP level in maternal blood, resulting in systemic inflammatory reaction and vascular endothelium damage which may be involved in the pathogenesis of preeclampsia.\n'
p1801
sg4
(lp1802
(dp1803
g7
I67
sg8
VP02741
p1804
sg10
I3
sg11
VCRP
p1805
sg13
I1
sa(dp1806
g7
I18
sg8
VP05109
p1807
sg10
I3
sg11
VMIF
p1808
sg13
I1
sa(dp1809
g7
I26
sg8
VP04233
p1810
sg10
I4
sg11
VCD74
p1811
sg13
I1
sasg29
(lp1812
(dp1813
g7
I217
sg32
VC0032914
p1814
sg10
I12
sg11
Vpreeclampsia
p1815
sg13
I1
sa(dp1816
g7
I201
sg32
VC0699748
p1817
sg10
I12
sg11
Vpathogenesis
p1818
sg13
I1
sa(dp1819
g7
I118
sg32
VC0021368
p1820
sg10
I21
sg11
Vinflammatory reaction
p1821
sg13
I2
sasa(dp1822
g2
S'Maternal serum concentrations of macrophage migration inhibitory factor (MIF) have recently been reported to be elevated in cases with preeclampsia.\n'
p1823
sg4
(lp1824
sg29
(lp1825
(dp1826
g7
I135
sg32
VC0032914
p1827
sg10
I12
sg11
Vpreeclampsia
p1828
sg13
I1
sasa(dp1829
g2
S'In addition, MIF levels were examined from cases with mild and severe preeclampsia (n=20 per study cohort) and matched normotensive pregnancies (n=20).\n'
p1830
sg4
(lp1831
sg29
(lp1832
(dp1833
g7
I63
sg32
VC0341950
p1834
sg10
I19
sg11
Vsevere preeclampsia
p1835
sg13
I2
sasa(dp1836
g2
S'Our data suggest that circulatory MIF concentrations are elevated throughout pregnancy, but are not further increased in preeclampsia.\n'
p1837
sg4
(lp1838
sg29
(lp1839
(dp1840
g7
I121
sg32
VC0032914
p1841
sg10
I12
sg11
Vpreeclampsia
p1842
sg13
I1
sasa(dp1843
g2
S'The isozymes hPAD2 and hPAD4 have been implicated in the development and progression of several autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.\n'
p1844
sg4
(lp1845
sg29
(lp1846
(dp1847
g7
I96
sg32
VC0004364
p1848
sg10
I19
sg11
Vautoimmune diseases
p1849
sg13
I2
sa(dp1850
g7
I127
sg32
VC0003873
p1851
sg10
I20
sg11
Vrheumatoid arthritis
p1852
sg13
I2
sa(dp1853
g7
I152
sg32
VC0026769
p1854
sg10
I18
sg11
Vmultiple sclerosis
p1855
sg13
I2
sasa(dp1856
g2
S'Protein arginine deiminase 2 (PAD2) plays a key role in the onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer.\n'
p1857
sg4
(lp1858
(dp1859
g7
I0
sg8
g48
sg10
I28
sg11
VProtein arginine deiminase 2
p1860
sg13
I4
sa(dp1861
g7
I30
sg8
g48
sg10
I4
sg11
VPAD2
p1862
sg13
I1
sasg29
(lp1863
(dp1864
g7
I105
sg32
VC0003873
p1865
sg10
I20
sg11
Vrheumatoid arthritis
p1866
sg13
I2
sa(dp1867
g7
I131
sg32
VC0678222
p1868
sg10
I13
sg11
Vbreast cancer
p1869
sg13
I2
sa(dp1870
g7
I85
sg32
VC0026769
p1871
sg10
I18
sg11
Vmultiple sclerosis
p1872
sg13
I2
sasa(dp1873
g2
S"Previously, we reported the abnormal accumulation of citrullinated proteins and the increase in the amount of PAD2 in hippocampi from Alzheimer's disease (AD) patients.\n"
p1874
sg4
(lp1875
(dp1876
g7
I110
sg8
g48
sg10
I4
sg11
VPAD2
p1877
sg13
I1
sasg29
(lp1878
(dp1879
g7
I134
sg32
VC1521724
p1880
sg10
I19
sg11
VAlzheimer's disease
p1881
sg13
I2
sa(dp1882
g7
I111
sg32
VC1521724
p1883
sg10
I2
sg11
VAD
p1884
sg13
I1
sasa(dp1885
g2
S'The enzyme peptidylarginine deiminase 2 (PAD2) has been associated with inflammatory diseases, such as rheumatoid arthritis and neurodegenerative diseases including multiple sclerosis.\n'
p1886
sg4
(lp1887
(dp1888
g7
I11
sg8
g48
sg10
I28
sg11
Vpeptidylarginine deiminase 2
p1889
sg13
I3
sa(dp1890
g7
I41
sg8
g48
sg10
I4
sg11
VPAD2
p1891
sg13
I1
sasg29
(lp1892
(dp1893
g7
I103
sg32
VC0003873
p1894
sg10
I20
sg11
Vrheumatoid arthritis
p1895
sg13
I2
sa(dp1896
g7
I128
sg32
VC0524851
p1897
sg10
I26
sg11
Vneurodegenerative diseases
p1898
sg13
I2
sa(dp1899
g7
I165
sg32
VC0026769
p1900
sg10
I18
sg11
Vmultiple sclerosis
p1901
sg13
I2
sasa(dp1902
g2
S'To define the association of deimination with the pathogenesis of age-related macular degeneration (AMD), we studied protein deimination and PAD2 levels in retinas of AMD donor eyes compared to age-matched non-AMD retinas.\n'
p1903
sg4
(lp1904
(dp1905
g7
I141
sg8
g48
sg10
I4
sg11
VPAD2
p1906
sg13
I1
sasg29
(lp1907
(dp1908
g7
I100
sg32
VC0242383
p1909
sg10
I3
sg11
VAMD
p1910
sg13
I1
sa(dp1911
g7
I66
sg32
VC0242383
p1912
sg10
I32
sg11
Vage-related macular degeneration
p1913
sg13
I3
sa(dp1914
g7
I100
sg32
VC0242383
p1915
sg10
I3
sg11
VAMD
p1916
sg13
I1
sa(dp1917
g7
I100
sg32
VC0242383
p1918
sg10
I3
sg11
VAMD
p1919
sg13
I1
sa(dp1920
g7
I50
sg32
VC0699748
p1921
sg10
I12
sg11
Vpathogenesis
p1922
sg13
I1
sasa(dp1923
g2
S'We therefore examined whether SNPs associated with the steroid-responsive expression of GLCCI1 might predict steroid-responsiveness in nephrotic syndrome.\n'
p1924
sg4
(lp1925
(dp1926
g7
I88
sg8
g48
sg10
I6
sg11
VGLCCI1
p1927
sg13
I1
sasg29
(lp1928
(dp1929
g7
I135
sg32
VC0027726
p1930
sg10
I18
sg11
Vnephrotic syndrome
p1931
sg13
I2
sasa(dp1932
g2
S'While larger cohorts are needed to ascertain the possibility of a small effect of GLCCI1 SNPs on the steroid-responsiveness of nephrotic syndrome, the GLCCI1 SNPs associated with steroid-responsiveness in asthmatic patients are unlikely to have a clinically actionable impact in pediatric nephrotic syndrome.\n'
p1933
sg4
(lp1934
(dp1935
g7
I82
sg8
g48
sg10
I11
sg11
VGLCCI1 SNPs
p1936
sg13
I2
sa(dp1937
g7
I82
sg8
g48
sg10
I11
sg11
VGLCCI1 SNPs
p1938
sg13
I2
sasg29
(lp1939
(dp1940
g7
I205
sg32
VC0004096
p1941
sg10
I9
sg11
Vasthmatic
p1942
sg13
I1
sa(dp1943
g7
I127
sg32
VC0027726
p1944
sg10
I18
sg11
Vnephrotic syndrome
p1945
sg13
I2
sa(dp1946
g7
I127
sg32
VC0027726
p1947
sg10
I18
sg11
Vnephrotic syndrome
p1948
sg13
I2
sasa(dp1949
g2
S'In the previous study, we had showed the expression of CD133+ CD54+ CD44+ cellular subpopulation of circulating tumor cells (CTCs) was significantly associated with liver metastasis of colorectal cancer (CRC).\n'
p1950
sg4
(lp1951
(dp1952
g7
I55
sg8
g48
sg10
I12
sg11
VCD133+ CD54+
p1953
sg13
I2
sasg29
(lp1954
(dp1955
g7
I112
sg32
VC0027651
p1956
sg10
I5
sg11
Vtumor
p1957
sg13
I1
sa(dp1958
g7
I185
sg32
VC1527249
p1959
sg10
I17
sg11
Vcolorectal cancer
p1960
sg13
I2
sa(dp1961
g7
I165
sg32
VC0494165
p1962
sg10
I16
sg11
Vliver metastasis
p1963
sg13
I2
sa(dp1964
g7
I204
sg32
VC1527249
p1965
sg10
I3
sg11
VCRC
p1966
sg13
I1
sasa(dp1967
g2
S'Liver cancer stem cells are a small subset of undifferentiated liver tumor cells, responsible for cancer initiation, metastasis, relapse and chemoresistance, enriched and isolated according to immunophenotypic and functional properties: cell surface proteins (CD133, CD90, CD44, EpCAM, OV-6, CD13, CD24, DLK1, Alfa2Delta1, ICAM-1 and CD47); the functional markers corresponding to side population, high aldehyde dehydrogenase (ALDH) activity and autofluorescence.\n'
p1968
sg4
(lp1969
(dp1970
g7
I323
sg8
VP05362
p1971
sg10
I6
sg11
VICAM-1
p1972
sg13
I1
sa(dp1973
g7
I267
sg8
VP04216
p1974
sg10
I4
sg11
VCD90
p1975
sg13
I1
sa(dp1976
g7
I304
sg8
VP80370
p1977
sg10
I4
sg11
VDLK1
p1978
sg13
I1
sa(dp1979
g7
I427
sg8
VP00352
p1980
sg10
I4
sg11
VALDH
p1981
sg13
I1
sa(dp1982
g7
I279
sg8
VP16422
p1983
sg10
I5
sg11
VEpCAM
p1984
sg13
I1
sa(dp1985
g7
I298
sg8
VP25063
p1986
sg10
I4
sg11
VCD24
p1987
sg13
I1
sa(dp1988
g7
I260
sg8
g48
sg10
I5
sg11
VCD133
p1989
sg13
I1
sa(dp1990
g7
I260
sg8
VP15144
p1991
sg10
I4
sg11
VCD13
p1992
sg13
I1
sa(dp1993
g7
I398
sg8
VP49366
p1994
sg10
I27
sg11
Vhigh aldehyde dehydrogenase
p1995
sg13
I3
sa(dp1996
g7
I334
sg8
g48
sg10
I4
sg11
VCD47
p1997
sg13
I1
sasg29
(lp1998
(dp1999
g7
I63
sg32
VC0023903
p2000
sg10
I11
sg11
Vliver tumor
p2001
sg13
I2
sa(dp2002
g7
I117
sg32
VC0027627
p2003
sg10
I10
sg11
Vmetastasis
p2004
sg13
I1
sa(dp2005
g7
I0
sg32
VC0345904
p2006
sg10
I12
sg11
VLiver cancer
p2007
sg13
I2
sa(dp2008
g7
I6
sg32
VC0006826
p2009
sg10
I6
sg11
Vcancer
p2010
sg13
I1
sa(dp2011
g7
I129
sg32
VC0277556
p2012
sg10
I7
sg11
Vrelapse
p2013
sg13
I1
sasa(dp2014
g2
S'In order to provide clinical guidance for the treatment of CRC, this study is conducted to investigate the correlations of intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms with susceptibility and multidrug resistance (MDR) of colorectal cancer (CRC).\n'
p2015
sg4
(lp2016
(dp2017
g7
I158
sg8
VP05362
p2018
sg10
I6
sg11
VICAM-1
p2019
sg13
I1
sa(dp2020
g7
I209
sg8
VP31749
p2021
sg10
I53
sg11
Vmultidrug resistance (MDR) of colorectal cancer (CRC)
p2022
sg13
I7
sa(dp2023
g7
I123
sg8
VP05362
p2024
sg10
I33
sg11
Vintercellular adhesion molecule 1
p2025
sg13
I4
sasg29
(lp2026
(dp2027
g7
I239
sg32
VC1527249
p2028
sg10
I17
sg11
Vcolorectal cancer
p2029
sg13
I2
sa(dp2030
g7
I59
sg32
VC1527249
p2031
sg10
I3
sg11
VCRC
p2032
sg13
I1
sa(dp2033
g7
I137
sg32
VC0001511
p2034
sg10
I8
sg11
Vadhesion
p2035
sg13
I1
sa(dp2036
g7
I59
sg32
VC1527249
p2037
sg10
I3
sg11
VCRC
p2038
sg13
I1
sasa(dp2039
g2
S'The objective of the present study was to investigate the effects of remifentanil on hemodynamics, liver function, and expression of intercellular adhesion molecule-1 (ICAM-1) in patients with liver cancer undergoing surgery.\n'
p2040
sg4
(lp2041
(dp2042
g7
I133
sg8
VP05362
p2043
sg10
I33
sg11
Vintercellular adhesion molecule-1
p2044
sg13
I3
sa(dp2045
g7
I168
sg8
VP05362
p2046
sg10
I6
sg11
VICAM-1
p2047
sg13
I1
sasg29
(lp2048
(dp2049
g7
I193
sg32
VC0345904
p2050
sg10
I12
sg11
Vliver cancer
p2051
sg13
I2
sa(dp2052
g7
I147
sg32
VC0001511
p2053
sg10
I8
sg11
Vadhesion
p2054
sg13
I1
sasa(dp2055
g2
S'To evaluate the estrogen receptor coactivator amplified in breast cancer 1 (AIB1) as a prognostic marker, as well as a predictive marker for response to adjuvant tamoxifen and/or aromatase inhibitors, in early estrogen receptor-positive breast cancer.\n'
p2056
sg4
(lp2057
(dp2058
g7
I46
sg8
g48
sg10
I28
sg11
Vamplified in breast cancer 1
p2059
sg13
I5
sa(dp2060
g7
I76
sg8
g48
sg10
I4
sg11
VAIB1
p2061
sg13
I1
sa(dp2062
g7
I204
sg8
VP03372
p2063
sg10
I23
sg11
Vearly estrogen receptor
p2064
sg13
I3
sa(dp2065
g7
I179
sg8
VP11511
p2066
sg10
I9
sg11
Varomatase
p2067
sg13
I1
sasg29
(lp2068
(dp2069
g7
I59
sg32
VC0678222
p2070
sg10
I13
sg11
Vbreast cancer
p2071
sg13
I2
sa(dp2072
g7
I59
sg32
VC0678222
p2073
sg10
I13
sg11
Vbreast cancer
p2074
sg13
I2
sasa(dp2075
g2
S'The oncogene nuclear receptor coactivator amplified in breast cancer 1 (AIB1) is a transcriptional coactivator, which is overexpressed in various types of human cancers, including breast cancer.\n'
p2076
sg4
(lp2077
(dp2078
g7
I42
sg8
g48
sg10
I28
sg11
Vamplified in breast cancer 1
p2079
sg13
I5
sa(dp2080
g7
I72
sg8
g48
sg10
I4
sg11
VAIB1
p2081
sg13
I1
sasg29
(lp2082
(dp2083
g7
I55
sg32
VC0678222
p2084
sg10
I13
sg11
Vbreast cancer
p2085
sg13
I2
sa(dp2086
g7
I161
sg32
VC0006826
p2087
sg10
I7
sg11
Vcancers
p2088
sg13
I1
sa(dp2089
g7
I55
sg32
VC0678222
p2090
sg10
I13
sg11
Vbreast cancer
p2091
sg13
I2
sasa(dp2092
g2
S'GCN5 knockdown decreased the protein levels of the proliferation marker proliferating cell nuclear antigen (PCNA) and amplified in breast cancer 1 (AIB1), but increased the protein levels of cell cycle inhibitor p21(Cip1/Waf1) in HepG2 cells.\n'
p2093
sg4
(lp2094
(dp2095
g7
I118
sg8
g48
sg10
I28
sg11
Vamplified in breast cancer 1
p2096
sg13
I5
sa(dp2097
g7
I212
sg8
VP42857
p2098
sg10
I3
sg11
Vp21
p2099
sg13
I1
sa(dp2100
g7
I108
sg8
VP12004
p2101
sg10
I4
sg11
VPCNA
p2102
sg13
I1
sa(dp2103
g7
I216
sg8
VP38936
p2104
sg10
I4
sg11
VCip1
p2105
sg13
I1
sa(dp2106
g7
I72
sg8
VP12004
p2107
sg10
I34
sg11
Vproliferating cell nuclear antigen
p2108
sg13
I4
sa(dp2109
g7
I148
sg8
g48
sg10
I4
sg11
VAIB1
p2110
sg13
I1
sa(dp2111
g7
I0
sg8
g48
sg10
I4
sg11
VGCN5
p2112
sg13
I1
sa(dp2113
g7
I221
sg8
VP38936
p2114
sg10
I4
sg11
VWaf1
p2115
sg13
I1
sasg29
(lp2116
(dp2117
g7
I51
sg32
VC0334094
p2118
sg10
I13
sg11
Vproliferation
p2119
sg13
I1
sa(dp2120
g7
I131
sg32
VC0678222
p2121
sg10
I13
sg11
Vbreast cancer
p2122
sg13
I2
sasa(dp2123
g2
S'We previously demonstrated that amplified in breast cancer 1 (AIB1) and eukaryotic initiation factor 2 (EIF5A2) overexpression was an independent predictor of poor clinical outcomes for patients with bladder cancer (BCa).\n'
p2124
sg4
(lp2125
(dp2126
g7
I32
sg8
g48
sg10
I28
sg11
Vamplified in breast cancer 1
p2127
sg13
I5
sa(dp2128
g7
I62
sg8
g48
sg10
I4
sg11
VAIB1
p2129
sg13
I1
sa(dp2130
g7
I72
sg8
VP46199
p2131
sg10
I30
sg11
Veukaryotic initiation factor 2
p2132
sg13
I4
sa(dp2133
g7
I104
sg8
g48
sg10
I6
sg11
VEIF5A2
p2134
sg13
I1
sasg29
(lp2135
(dp2136
g7
I200
sg32
VC0699885
p2137
sg10
I14
sg11
Vbladder cancer
p2138
sg13
I2
sa(dp2139
g7
I216
sg32
VC0699885
p2140
sg10
I3
sg11
VBCa
p2141
sg13
I1
sa(dp2142
g7
I45
sg32
VC0678222
p2143
sg10
I13
sg11
Vbreast cancer
p2144
sg13
I2
sasa(dp2145
g2
S'Amplified in breast cancer 1 (AIB1) is frequently overexpressed in human HCC tissues and promotes HCC progression.\n'
p2146
sg4
(lp2147
(dp2148
g7
I13
sg8
VP38398
p2149
sg10
I15
sg11
Vbreast cancer 1
p2150
sg13
I3
sasg29
(lp2151
(dp2152
g7
I73
sg32
VC2239176
p2153
sg10
I3
sg11
VHCC
p2154
sg13
I1
sa(dp2155
g7
I73
sg32
VC2239176
p2156
sg10
I3
sg11
VHCC
p2157
sg13
I1
sa(dp2158
g7
I13
sg32
VC0678222
p2159
sg10
I13
sg11
Vbreast cancer
p2160
sg13
I2
sasa(dp2161
g2
S'The estrogen receptor coactivator Amplified in Breast Cancer 1 (AIB1) has been associated with an improved response to adjuvant tamoxifen in breast cancer, but also with endocrine treatment resistance.\n'
p2162
sg4
(lp2163
(dp2164
g7
I4
sg8
VP03372
p2165
sg10
I58
sg11
Vestrogen receptor coactivator Amplified in Breast Cancer 1
p2166
sg13
I8
sasg29
(lp2167
(dp2168
g7
I141
sg32
VC0678222
p2169
sg10
I13
sg11
Vbreast cancer
p2170
sg13
I2
sa(dp2171
g7
I47
sg32
VC0678222
p2172
sg10
I13
sg11
VBreast Cancer
p2173
sg13
I2
sasa(dp2174
g2
S'Amplified in breast cancer 1 (AIB1), also known as steroid receptor coactivator 3 (SRC-3), is a transcriptional coactivator that interacts with nuclear receptors and other transcription factors to enhance their effects on target gene transcription.\n'
p2175
sg4
(lp2176
(dp2177
g7
I83
sg8
VP12931
p2178
sg10
I5
sg11
VSRC-3
p2179
sg13
I1
sa(dp2180
g7
I51
sg8
g48
sg10
I30
sg11
Vsteroid receptor coactivator 3
p2181
sg13
I4
sa(dp2182
g7
I13
sg8
VP38398
p2183
sg10
I15
sg11
Vbreast cancer 1
p2184
sg13
I3
sasg29
(lp2185
(dp2186
g7
I13
sg32
VC0678222
p2187
sg10
I13
sg11
Vbreast cancer
p2188
sg13
I2
sasa(dp2189
g2
S'Apelin-13 also markedly increased the expression of cyclin D1, extracellular matrix metalloproteinase-1 and amplified in breast cancer 1 (AIB1) in a dose-dependent manner by polymerase chain reaction assays.\n'
p2190
sg4
(lp2191
(dp2192
g7
I0
sg8
g48
sg10
I9
sg11
VApelin-13
p2193
sg13
I1
sa(dp2194
g7
I138
sg8
g48
sg10
I4
sg11
VAIB1
p2195
sg13
I1
sa(dp2196
g7
I108
sg8
g48
sg10
I28
sg11
Vamplified in breast cancer 1
p2197
sg13
I5
sa(dp2198
g7
I52
sg8
VP24385
p2199
sg10
I9
sg11
Vcyclin D1
p2200
sg13
I2
sa(dp2201
g7
I63
sg8
VP03956
p2202
sg10
I40
sg11
Vextracellular matrix metalloproteinase-1
p2203
sg13
I3
sasg29
(lp2204
(dp2205
g7
I121
sg32
VC0678222
p2206
sg10
I13
sg11
Vbreast cancer
p2207
sg13
I2
sasa(dp2208
g2
S'Amplified in breast cancer 1 (AIB1) is a member of p160 steroid receptor coactivator (SRC) family that mediates the transcriptional activities of nuclear receptors and other transcription factors.\n'
p2209
sg4
(lp2210
(dp2211
g7
I51
sg8
VP52701
p2212
sg10
I33
sg11
Vp160 steroid receptor coactivator
p2213
sg13
I4
sa(dp2214
g7
I86
sg8
VP12931
p2215
sg10
I3
sg11
VSRC
p2216
sg13
I1
sa(dp2217
g7
I13
sg8
VP38398
p2218
sg10
I15
sg11
Vbreast cancer 1
p2219
sg13
I3
sasg29
(lp2220
(dp2221
g7
I13
sg32
VC0678222
p2222
sg10
I13
sg11
Vbreast cancer
p2223
sg13
I2
sasa(dp2224
g2
S'Previous genetic studies revealed that mutations in protocadherin-19 (Pcdh19) lead to an epilepsy syndrome with a variable degree of cognitive disability.\n'
p2225
sg4
(lp2226
(dp2227
g7
I70
sg8
g48
sg10
I6
sg11
VPcdh19
p2228
sg13
I1
sa(dp2229
g7
I52
sg8
g48
sg10
I16
sg11
Vprotocadherin-19
p2230
sg13
I1
sasg29
(lp2231
(dp2232
g7
I98
sg32
VC0039082
p2233
sg10
I8
sg11
Vsyndrome
p2234
sg13
I1
sa(dp2235
g7
I89
sg32
VC0014544
p2236
sg10
I8
sg11
Vepilepsy
p2237
sg13
I1
sasa(dp2238
g2
S'The presence of endothelial markers, cluster of differentiation (CD)31 and vascular endothelial (VE)-cadherin, and mesenchymal markers, Alfa smooth muscle actin (SMA) and fibroblast-specific protein 1 (FSP1) was performed using immunohistochemistry.\n'
p2239
sg4
(lp2240
(dp2241
g7
I202
sg8
VP26447
p2242
sg10
I4
sg11
VFSP1
p2243
sg13
I1
sa(dp2244
g7
I136
sg8
VP68032
p2245
sg10
I24
sg11
VAlfa smooth muscle actin
p2246
sg13
I4
sa(dp2247
g7
I75
sg8
g48
sg10
I34
sg11
Vvascular endothelial (VE)-cadherin
p2248
sg13
I3
sa(dp2249
g7
I171
sg8
VP14222
p2250
sg10
I29
sg11
Vfibroblast-specific protein 1
p2251
sg13
I3
sa(dp2252
g7
I162
sg8
g48
sg10
I3
sg11
VSMA
p2253
sg13
I1
sasg29
(lp2254
(dp2255
g7
I141
sg32
VC0026847
p2256
sg10
I19
sg11
Vsmooth muscle actin
p2257
sg13
I3
sa(dp2258
g7
I202
sg32
VC2931355
p2259
sg10
I4
sg11
VFSP1
p2260
sg13
I1
sa(dp2261
g7
I171
sg32
VC2931355
p2262
sg10
I29
sg11
Vfibroblast-specific protein 1
p2263
sg13
I3
sa(dp2264
g7
I162
sg32
VC0026847
p2265
sg10
I3
sg11
VSMA
p2266
sg13
I1
sasa(dp2267
g2
S'Immunohistochemistry and double-immunofluorescence staining demonstrated that the expression of CD31 and VE-cadherin were significantly decreased in DCM samples, whereas the FSP-1, and AlfaSMA were significantly increased.\n'
p2268
sg4
(lp2269
(dp2270
g7
I174
sg8
VP09341
p2271
sg10
I5
sg11
VFSP-1
p2272
sg13
I1
sa(dp2273
g7
I96
sg8
VP69905
p2274
sg10
I4
sg11
VCD31
p2275
sg13
I1
sa(dp2276
g7
I105
sg8
VP33151
p2277
sg10
I11
sg11
VVE-cadherin
p2278
sg13
I1
sasg29
(lp2279
sa(dp2280
g2
S'CD31 and VE-cadherin labeling indexes were respectively negatively correlated with left ventricular end-diastolic diameter (LVEDD) (CD31 r=-0.82, P&lt;0.01; VE-cadherin r=-0.73, P&lt;0.01), while FSP-1 and AlfaSMA were positively associated with LVEDD (AlfaSMA r=0.65, P&lt;0.01, FSP1 r=0.53, P&lt;0.01) and left ventricular ejection fraction (AlfaSMA r=-0.18, P&lt;0.05; FSP1 r=-0.21, P&lt;0.05).\n'
p2281
sg4
(lp2282
(dp2283
g7
I132
sg8
VP69905
p2284
sg10
I9
sg11
VCD31 r=-0
p2285
sg13
I2
sa(dp2286
g7
I280
sg8
VP26447
p2287
sg10
I4
sg11
VFSP1
p2288
sg13
I1
sa(dp2289
g7
I9
sg8
VP33151
p2290
sg10
I11
sg11
VVE-cadherin
p2291
sg13
I1
sa(dp2292
g7
I0
sg8
VP69905
p2293
sg10
I4
sg11
VCD31
p2294
sg13
I1
sa(dp2295
g7
I196
sg8
VP09341
p2296
sg10
I5
sg11
VFSP-1
p2297
sg13
I1
sa(dp2298
g7
I280
sg8
VP26447
p2299
sg10
I8
sg11
VFSP1 r=0
p2300
sg13
I2
sasg29
(lp2301
(dp2302
g7
I280
sg32
VC2931355
p2303
sg10
I4
sg11
VFSP1
p2304
sg13
I1
sa(dp2305
g7
I280
sg32
VC2931355
p2306
sg10
I4
sg11
VFSP1
p2307
sg13
I1
sasa(dp2308
g2
S'Furthermore, PICP and PIIINP levels were positively associated with the co-expression labeling indexes (CD31/SMA co-labeling index and PICP r=0.727, P&lt;0.01; CD31/SMA co-labeling index and PIIINP r=0.741, P&lt;0.01; VE-Cadherin/FSP-1 co-labeling index and PICP r=0.716, P&lt;0.01; VE-cadherin/FSP-1 co-labeling index and PIIINP r=0.648, P&lt;0.05).\n'
p2309
sg4
(lp2310
(dp2311
g7
I104
sg8
VP69905
p2312
sg10
I4
sg11
VCD31
p2313
sg13
I1
sa(dp2314
g7
I221
sg8
g48
sg10
I8
sg11
VCadherin
p2315
sg13
I1
sa(dp2316
g7
I230
sg8
VP09341
p2317
sg10
I5
sg11
VFSP-1
p2318
sg13
I1
sa(dp2319
g7
I109
sg8
g48
sg10
I3
sg11
VSMA
p2320
sg13
I1
sa(dp2321
g7
I230
sg8
VP09341
p2322
sg10
I5
sg11
VFSP-1
p2323
sg13
I1
sa(dp2324
g7
I283
sg8
VP33151
p2325
sg10
I11
sg11
VVE-cadherin
p2326
sg13
I1
sa(dp2327
g7
I104
sg8
VP69905
p2328
sg10
I4
sg11
VCD31
p2329
sg13
I1
sa(dp2330
g7
I109
sg8
g48
sg10
I3
sg11
VSMA
p2331
sg13
I1
sasg29
(lp2332
(dp2333
g7
I109
sg32
VC0026847
p2334
sg10
I3
sg11
VSMA
p2335
sg13
I1
sa(dp2336
g7
I109
sg32
VC0026847
p2337
sg10
I3
sg11
VSMA
p2338
sg13
I1
sasa(dp2339
g2
S'TRPV4 was co-localised with vascular endothelial (VE)-cadherin, and VE-cadherin expression was decreased by repeated intravenous administration of GSK1016790A during colitis.\n'
p2340
sg4
(lp2341
(dp2342
g7
I68
sg8
VP33151
p2343
sg10
I11
sg11
VVE-cadherin
p2344
sg13
I1
sa(dp2345
g7
I28
sg8
g48
sg10
I34
sg11
Vvascular endothelial (VE)-cadherin
p2346
sg13
I3
sasg29
(lp2347
(dp2348
g7
I166
sg32
VC0009319
p2349
sg10
I7
sg11
Vcolitis
p2350
sg13
I1
sasa(dp2351
g2
S'In premenopausal women, two environmental factors (history of breastfeeding, and history of benign breast disease) and four genetic variants (TOX3-rs3803662, ESR1-rs2046210, 8q24-rs13281615, and SLC4A7-rs4973768) were considered to be risk predictors, whereas three environmental factors (body mass index, history of breastfeeding, and hyperlipidemia), serum levels of testosterone and 25-hydroxyvitamin D, and two genetic variants (TOX3-rs3803662 and ESR1-rs2046210) were identified as risk predictors.\n'
p2352
sg4
(lp2353
(dp2354
g7
I142
sg8
g48
sg10
I4
sg11
VTOX3
p2355
sg13
I1
sa(dp2356
g7
I142
sg8
g48
sg10
I4
sg11
VTOX3
p2357
sg13
I1
sa(dp2358
g7
I158
sg8
VP03372
p2359
sg10
I4
sg11
VESR1
p2360
sg13
I1
sa(dp2361
g7
I158
sg8
VP03372
p2362
sg10
I14
sg11
VESR1-rs2046210
p2363
sg13
I1
sa(dp2364
g7
I195
sg8
g48
sg10
I16
sg11
VSLC4A7-rs4973768
p2365
sg13
I1
sasg29
(lp2366
(dp2367
g7
I336
sg32
VC0020473
p2368
sg10
I14
sg11
Vhyperlipidemia
p2369
sg13
I1
sa(dp2370
g7
I92
sg32
VC0016034
p2371
sg10
I21
sg11
Vbenign breast disease
p2372
sg13
I3
sasa(dp2373
g2
S'Objective: To investigate the MRI characteristics of posterior reversible encephalopathy syndrome (PRES) in patients with pre-eclampsia(PE) and its correlation with serum placental growth factor (PlGF), soluble endoglin (sEng) and sEng/PlGF ratio.\n'
p2374
sg4
(lp2375
(dp2376
g7
I196
sg8
VP49763
p2377
sg10
I4
sg11
VPlGF
p2378
sg13
I1
sa(dp2379
g7
I165
sg8
VP17813
p2380
sg10
I54
sg11
Vserum placental growth factor (PlGF), soluble endoglin
p2381
sg13
I7
sasg29
(lp2382
(dp2383
g7
I99
sg32
VC3160858
p2384
sg10
I4
sg11
VPRES
p2385
sg13
I1
sa(dp2386
g7
I53
sg32
VC3160858
p2387
sg10
I44
sg11
Vposterior reversible encephalopathy syndrome
p2388
sg13
I4
sa(dp2389
g7
I122
sg32
VC0032914
p2390
sg10
I13
sg11
Vpre-eclampsia
p2391
sg13
I1
sasa(dp2392
g2
S'Conclusion: The value of sEng/PlGF ratio was correlated with brain edema score in PE.\n'
p2393
sg4
(lp2394
(dp2395
g7
I30
sg8
VP49763
p2396
sg10
I4
sg11
VPlGF
p2397
sg13
I1
sasg29
(lp2398
(dp2399
g7
I61
sg32
VC1527311
p2400
sg10
I11
sg11
Vbrain edema
p2401
sg13
I2
sasa(dp2402
g2
S'However, relatively little data are available linking placenta growth factor (PIGF) with epilepsy.\n'
p2403
sg4
(lp2404
(dp2405
g7
I78
sg8
VP49763
p2406
sg10
I4
sg11
VPIGF
p2407
sg13
I1
sa(dp2408
g7
I54
sg8
VP49763
p2409
sg10
I22
sg11
Vplacenta growth factor
p2410
sg13
I3
sasg29
(lp2411
(dp2412
g7
I89
sg32
VC0014544
p2413
sg10
I8
sg11
Vepilepsy
p2414
sg13
I1
sasa(dp2415
g2
S'Besides, SC-560 treatment improved hepatic encephalopathy and decrease plasma levels of PGF(1Alfa), but did not change TNF-Alfa levels.\n'
p2416
sg4
(lp2417
(dp2418
g7
I88
sg8
VP49763
p2419
sg10
I10
sg11
VPGF(1Alfa)
p2420
sg13
I1
sa(dp2421
g7
I119
sg8
VP01375
p2422
sg10
I8
sg11
VTNF-Alfa
p2423
sg13
I1
sasg29
(lp2424
(dp2425
g7
I35
sg32
VC0019151
p2426
sg10
I22
sg11
Vhepatic encephalopathy
p2427
sg13
I2
sasa(dp2428
g2
S'Immunohistochemical reactivity with anti-human IL-38 monoclonal antibody (clone H127C) was evaluated semi-quantitatively in lung tissue samples from 12 patients with idiopathic pulmonary fibrosis/usual interstitial pneumonia (IPF/UIP), 5 with acute exacerbation of IPF, and 10 with anticancer drug-induced ILD (bleomycin in 5 and epidermal growth factor receptor-tyrosine kinase inhibitor in 5).\n'
p2429
sg4
(lp2430
(dp2431
g7
I330
sg8
VP29401
p2432
sg10
I48
sg11
Vepidermal growth factor receptor-tyrosine kinase
p2433
sg13
I5
sasg29
(lp2434
(dp2435
g7
I196
sg32
VC0085786
p2436
sg10
I28
sg11
Vusual interstitial pneumonia
p2437
sg13
I3
sa(dp2438
g7
I230
sg32
VC0085786
p2439
sg10
I3
sg11
VUIP
p2440
sg13
I1
sa(dp2441
g7
I166
sg32
VC3161101
p2442
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p2443
sg13
I3
sasa(dp2444
g2
S'In this study, we used genetic approaches that revealed that endophilin B2 is not required for embryonic development in vivo but that endophilin B2 deficiency impairs endosomal trafficking in vitro, as evidenced by suppressed endosome acidification, EGFR degradation, autophagic flux, and influenza A viral RNA nuclear entry and replication.\n'
p2445
sg4
(lp2446
(dp2447
g7
I61
sg8
g48
sg10
I13
sg11
Vendophilin B2
p2448
sg13
I2
sa(dp2449
g7
I61
sg8
g48
sg10
I13
sg11
Vendophilin B2
p2450
sg13
I2
sasg29
(lp2451
(dp2452
g7
I289
sg32
VC0021400
p2453
sg10
I9
sg11
Vinfluenza
p2454
sg13
I1
sasa(dp2455
g2
S'Here we show that suppressor of cytokine signaling (SOCS) five has a pivotal role in restricting influenza A virus in the airway epithelium, through the regulation of epidermal growth factor receptor (EGFR).\n'
p2456
sg4
(lp2457
(dp2458
g7
I167
sg8
VP01133
p2459
sg10
I32
sg11
Vepidermal growth factor receptor
p2460
sg13
I4
sa(dp2461
g7
I201
sg8
VP01133
p2462
sg10
I4
sg11
VEGFR
p2463
sg13
I1
sasg29
(lp2464
(dp2465
g7
I97
sg32
VC0021400
p2466
sg10
I9
sg11
Vinfluenza
p2467
sg13
I1
sasa(dp2468
g2
S'The frequency of EGFR mutations was significantly lower in adenocarcinomas in the H-IIP group, although the frequencies of KRAS and ALK mutations did not differ among the three groups.\n'
p2469
sg4
(lp2470
(dp2471
g7
I123
sg8
VP01116
p2472
sg10
I4
sg11
VKRAS
p2473
sg13
I1
sa(dp2474
g7
I132
sg8
g48
sg10
I3
sg11
VALK
p2475
sg13
I1
sasg29
(lp2476
(dp2477
g7
I59
sg32
VC0001418
p2478
sg10
I15
sg11
Vadenocarcinomas
p2479
sg13
I1
sasa(dp2480
g2
S'Finally, we demonstrated that downregulation of A2bR inhibited the proliferation, migration and invasion of BUC in part via the MAPK signaling pathway, increasing the levels of P21 but decreasing the levels of cyclin B1, D, E1, MMP-2 and MMP-9.\n'
p2481
sg4
(lp2482
(dp2483
g7
I228
sg8
VP08253
p2484
sg10
I5
sg11
VMMP-2
p2485
sg13
I1
sa(dp2486
g7
I238
sg8
VP14780
p2487
sg10
I5
sg11
VMMP-9
p2488
sg13
I1
sa(dp2489
g7
I128
sg8
VP53779
p2490
sg10
I4
sg11
VMAPK
p2491
sg13
I1
sa(dp2492
g7
I210
sg8
VP14635
p2493
sg10
I9
sg11
Vcyclin B1
p2494
sg13
I2
sasg29
(lp2495
(dp2496
g7
I96
sg32
VC2699153
p2497
sg10
I8
sg11
Vinvasion
p2498
sg13
I1
sa(dp2499
g7
I67
sg32
VC0334094
p2500
sg10
I13
sg11
Vproliferation
p2501
sg13
I1
sasa(dp2502
g2
S'Overexpression of MMP-2 could rescue BUC cells migration and invasion.\n'
p2503
sg4
(lp2504
(dp2505
g7
I18
sg8
VP08253
p2506
sg10
I5
sg11
VMMP-2
p2507
sg13
I1
sasg29
(lp2508
(dp2509
g7
I61
sg32
VC2699153
p2510
sg10
I8
sg11
Vinvasion
p2511
sg13
I1
sasa(dp2512
g2
S'To determine the levels of MMP-2 and COX-2 mRNA in bladder transitional cell carcinoma tissues and explore their relationship.\n'
p2513
sg4
(lp2514
(dp2515
g7
I27
sg8
VP08253
p2516
sg10
I5
sg11
VMMP-2
p2517
sg13
I1
sa(dp2518
g7
I37
sg8
VP35354
p2519
sg10
I10
sg11
VCOX-2 mRNA
p2520
sg13
I2
sasg29
(lp2521
(dp2522
g7
I51
sg32
VC0279680
p2523
sg10
I35
sg11
Vbladder transitional cell carcinoma
p2524
sg13
I4
sasa(dp2525
g2
S'MMP-2 and COX-2 mRNA are highly expressed in bladder transitional cell carcinoma tissues and their expressions are positively correlated with the degree of malignancy.\n'
p2526
sg4
(lp2527
(dp2528
g7
I0
sg8
VP08253
p2529
sg10
I5
sg11
VMMP-2
p2530
sg13
I1
sa(dp2531
g7
I10
sg8
VP35354
p2532
sg10
I10
sg11
VCOX-2 mRNA
p2533
sg13
I2
sasg29
(lp2534
(dp2535
g7
I156
sg32
VC0006826
p2536
sg10
I10
sg11
Vmalignancy
p2537
sg13
I1
sa(dp2538
g7
I45
sg32
VC0279680
p2539
sg10
I35
sg11
Vbladder transitional cell carcinoma
p2540
sg13
I4
sasa(dp2541
g2
S'MMP-2 and COX-2 might play a synergetic role in the pathogenesis and progression of bladder transitional cell carcinoma.\n'
p2542
sg4
(lp2543
(dp2544
g7
I10
sg8
VP35354
p2545
sg10
I5
sg11
VCOX-2
p2546
sg13
I1
sa(dp2547
g7
I0
sg8
VP08253
p2548
sg10
I5
sg11
VMMP-2
p2549
sg13
I1
sasg29
(lp2550
(dp2551
g7
I84
sg32
VC0279680
p2552
sg10
I35
sg11
Vbladder transitional cell carcinoma
p2553
sg13
I4
sa(dp2554
g7
I52
sg32
VC0699748
p2555
sg10
I12
sg11
Vpathogenesis
p2556
sg13
I1
sasa(dp2557
g2
S'However, the relationship between MMP2 activity in tumor tissue and tumor progression is still unclear in bladder transitional cell carcinoma (BTCC).\n'
p2558
sg4
(lp2559
(dp2560
g7
I34
sg8
VP08253
p2561
sg10
I4
sg11
VMMP2
p2562
sg13
I1
sasg29
(lp2563
(dp2564
g7
I106
sg32
VC0279680
p2565
sg10
I35
sg11
Vbladder transitional cell carcinoma
p2566
sg13
I4
sa(dp2567
g7
I68
sg32
VC0178874
p2568
sg10
I17
sg11
Vtumor progression
p2569
sg13
I2
sa(dp2570
g7
I51
sg32
VC0027651
p2571
sg10
I5
sg11
Vtumor
p2572
sg13
I1
sa(dp2573
g7
I143
sg32
VC0279680
p2574
sg10
I4
sg11
VBTCC
p2575
sg13
I1
sasa(dp2576
g2
S'The aim of this study was to evaluate the significance of MMP2 in the progression of BTCC.\n'
p2577
sg4
(lp2578
(dp2579
g7
I58
sg8
VP08253
p2580
sg10
I4
sg11
VMMP2
p2581
sg13
I1
sasg29
(lp2582
sa(dp2583
g2
S'Of 20 BTCC tissues, activated MMP2 were detected in 19 cases and the activity was increased with the tumor grade and invasiveness.\n'
p2584
sg4
(lp2585
(dp2586
g7
I30
sg8
VP08253
p2587
sg10
I4
sg11
VMMP2
p2588
sg13
I1
sasg29
(lp2589
(dp2590
g7
I101
sg32
VC0027651
p2591
sg10
I5
sg11
Vtumor
p2592
sg13
I1
sasa(dp2593
g2
S'The activities of the MMP2 was 8896.5+/-1655.6(mg x ml(-1))(-1) in grade I BTCC(n=11),18 355.6+/-5 307.1(mg x ml(-1))(-1) in grade II BTCC(n=5), and 26,467.1+/-4 705.6 (mg x ml(-1))(-1) in gradeIII BTCC (n=3).\n'
p2594
sg4
(lp2595
sg29
(lp2596
sa(dp2597
g2
S'Activated MMP2 might play a key role in the progression of BTCC and the gelatine zymography is a useful method for the detection of activated type IV collagenase.\n'
p2598
sg4
(lp2599
(dp2600
g7
I10
sg8
VP08253
p2601
sg10
I4
sg11
VMMP2
p2602
sg13
I1
sa(dp2603
g7
I132
sg8
VP08253
p2604
sg10
I29
sg11
Vactivated type IV collagenase
p2605
sg13
I4
sasg29
(lp2606
sa(dp2607
g2
S'To detect the level of matrix metalloproteinase-2 (MMP-2) mRNA and the tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA in bladder transitional cell carcinoma (BTCC), and to estimate the prognosis for bladder tumor based on the quality and quantity of MMP-2 and TIMP-2 mRNA.\n'
p2608
sg4
(lp2609
(dp2610
g7
I23
sg8
VP08253
p2611
sg10
I26
sg11
Vmatrix metalloproteinase-2
p2612
sg13
I2
sa(dp2613
g7
I51
sg8
VP08253
p2614
sg10
I5
sg11
VMMP-2
p2615
sg13
I1
sa(dp2616
g7
I51
sg8
VP08253
p2617
sg10
I5
sg11
VMMP-2
p2618
sg13
I1
sa(dp2619
g7
I267
sg8
VP16035
p2620
sg10
I11
sg11
VTIMP-2 mRNA
p2621
sg13
I2
sa(dp2622
g7
I112
sg8
VP16035
p2623
sg10
I6
sg11
VTIMP-2
p2624
sg13
I1
sa(dp2625
g7
I71
sg8
VP52888
p2626
sg10
I39
sg11
Vtissue inhibitor of metalloproteinase-2
p2627
sg13
I4
sasg29
(lp2628
(dp2629
g7
I128
sg32
VC0279680
p2630
sg10
I35
sg11
Vbladder transitional cell carcinoma
p2631
sg13
I4
sa(dp2632
g7
I165
sg32
VC0279680
p2633
sg10
I4
sg11
VBTCC
p2634
sg13
I1
sa(dp2635
g7
I206
sg32
VC0005695
p2636
sg10
I13
sg11
Vbladder tumor
p2637
sg13
I2
sasa(dp2638
g2
S'The level of the MMP-2 mRNA in BTCC was significantly increased compared with that in normal bladder epithelium.\n'
p2639
sg4
(lp2640
(dp2641
g7
I17
sg8
VP08253
p2642
sg10
I10
sg11
VMMP-2 mRNA
p2643
sg13
I2
sasg29
(lp2644
sa(dp2645
g2
S'The positive rates of MMP-2 and TIMP-2 mRNA were 71.4% and 65.7% in BTCC, and 66.7% and 60.0% in the normal bladder wall.\n'
p2646
sg4
(lp2647
(dp2648
g7
I22
sg8
VP08253
p2649
sg10
I5
sg11
VMMP-2
p2650
sg13
I1
sa(dp2651
g7
I32
sg8
VP16035
p2652
sg10
I11
sg11
VTIMP-2 mRNA
p2653
sg13
I2
sasg29
(lp2654
sa(dp2655
g2
S'A high level of the MMP-2 mRNA exists in BTCC, which may function to damage collagen IV inside the basement membrane and the extracellular basement of the bladder.\n'
p2656
sg4
(lp2657
(dp2658
g7
I69
sg8
g48
sg10
I18
sg11
Vdamage collagen IV
p2659
sg13
I3
sa(dp2660
g7
I20
sg8
VP08253
p2661
sg10
I10
sg11
VMMP-2 mRNA
p2662
sg13
I2
sasg29
(lp2663
sa(dp2664
g2
S'The level of the MMP-2 mRNA is proportional to BTCC grading and staging, which may have prognostic value.\n'
p2665
sg4
(lp2666
(dp2667
g7
I17
sg8
VP08253
p2668
sg10
I10
sg11
VMMP-2 mRNA
p2669
sg13
I2
sasg29
(lp2670
sa(dp2671
g2
S'In human breast cancers, SLC2A1 was higher in ductal carcinoma in situ compared to the normal breast, but lower in invasive versus in situ lesions, suggesting the requirement for GLUT1 decreases as tumors progress.\n'
p2672
sg4
(lp2673
(dp2674
g7
I25
sg8
VP11166
p2675
sg10
I6
sg11
VSLC2A1
p2676
sg13
I1
sa(dp2677
g7
I179
sg8
VP11166
p2678
sg10
I5
sg11
VGLUT1
p2679
sg13
I1
sasg29
(lp2680
(dp2681
g7
I198
sg32
VC0027651
p2682
sg10
I6
sg11
Vtumors
p2683
sg13
I1
sa(dp2684
g7
I9
sg32
VC0006142
p2685
sg10
I14
sg11
Vbreast cancers
p2686
sg13
I2
sa(dp2687
g7
I46
sg32
VC0007124
p2688
sg10
I24
sg11
Vductal carcinoma in situ
p2689
sg13
I4
sasa(dp2690
g2
S'The p16(INK4A) showed statistically significant odds ratios in CIN II, CIN III, and cancer; GLUT1, in CIN II and CIN III; hPygopus2, in CIN III; and beta-catenin, in CIN III and cancer.\n'
p2691
sg4
(lp2692
(dp2693
g7
I63
sg8
g48
sg10
I6
sg11
VCIN II
p2694
sg13
I2
sa(dp2695
g7
I71
sg8
g48
sg10
I7
sg11
VCIN III
p2696
sg13
I2
sa(dp2697
g7
I63
sg8
g48
sg10
I6
sg11
VCIN II
p2698
sg13
I2
sa(dp2699
g7
I71
sg8
g48
sg10
I7
sg11
VCIN III
p2700
sg13
I2
sa(dp2701
g7
I71
sg8
g48
sg10
I7
sg11
VCIN III
p2702
sg13
I2
sa(dp2703
g7
I4
sg8
VP42771
p2704
sg10
I3
sg11
Vp16
p2705
sg13
I1
sa(dp2706
g7
I8
sg8
VP42771
p2707
sg10
I5
sg11
VINK4A
p2708
sg13
I1
sa(dp2709
g7
I149
sg8
VP35222
p2710
sg10
I12
sg11
Vbeta-catenin
p2711
sg13
I1
sa(dp2712
g7
I71
sg8
g48
sg10
I7
sg11
VCIN III
p2713
sg13
I2
sasg29
(lp2714
(dp2715
g7
I63
sg32
VC0349459
p2716
sg10
I6
sg11
VCIN II
p2717
sg13
I2
sa(dp2718
g7
I71
sg32
VC0851140
p2719
sg10
I7
sg11
VCIN III
p2720
sg13
I2
sa(dp2721
g7
I71
sg32
VC0851140
p2722
sg10
I7
sg11
VCIN III
p2723
sg13
I2
sa(dp2724
g7
I71
sg32
VC0851140
p2725
sg10
I7
sg11
VCIN III
p2726
sg13
I2
sa(dp2727
g7
I63
sg32
VC0349459
p2728
sg10
I6
sg11
VCIN II
p2729
sg13
I2
sa(dp2730
g7
I84
sg32
VC0006826
p2731
sg10
I6
sg11
Vcancer
p2732
sg13
I1
sa(dp2733
g7
I84
sg32
VC0006826
p2734
sg10
I6
sg11
Vcancer
p2735
sg13
I1
sa(dp2736
g7
I71
sg32
VC0851140
p2737
sg10
I7
sg11
VCIN III
p2738
sg13
I2
sasa(dp2739
g2
S'We therefore studied HIF-1Alfa overexpression in ductal carcinoma in situ (DCIS), an established precursor of invasive breast cancer.We used immunohistochemistry to examine the expression of the hypoxia markers HIF-1Alfa, CAIX and Glut-1 in DCIS and available invasive carcinoma lesions of 32 BRCA1, 16 BRCA2 and 77 non-BRCA mutation-related cases.\n'
p2740
sg4
(lp2741
(dp2742
g7
I231
sg8
VP11166
p2743
sg10
I6
sg11
VGlut-1
p2744
sg13
I1
sa(dp2745
g7
I222
sg8
g48
sg10
I4
sg11
VCAIX
p2746
sg13
I1
sa(dp2747
g7
I290
sg8
VP38398
p2748
sg10
I18
sg11
V32 BRCA1, 16 BRCA2
p2749
sg13
I4
sasg29
(lp2750
(dp2751
g7
I110
sg32
VC0853879
p2752
sg10
I22
sg11
Vinvasive breast cancer
p2753
sg13
I3
sa(dp2754
g7
I195
sg32
VC0242184
p2755
sg10
I7
sg11
Vhypoxia
p2756
sg13
I1
sa(dp2757
g7
I260
sg32
VC1334274
p2758
sg10
I18
sg11
Vinvasive carcinoma
p2759
sg13
I2
sa(dp2760
g7
I75
sg32
VC0007124
p2761
sg10
I4
sg11
VDCIS
p2762
sg13
I1
sa(dp2763
g7
I75
sg32
VC0007124
p2764
sg10
I4
sg11
VDCIS
p2765
sg13
I1
sa(dp2766
g7
I49
sg32
VC0007124
p2767
sg10
I24
sg11
Vductal carcinoma in situ
p2768
sg13
I4
sasa(dp2769
g2
S'GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002).\n'
p2770
sg4
(lp2771
(dp2772
g7
I0
sg8
VP11166
p2773
sg10
I5
sg11
VGLUT1
p2774
sg13
I1
sasg29
(lp2775
(dp2776
g7
I57
sg32
VC1134719
p2777
sg10
I25
sg11
Vinvasive ductal carcinoma
p2778
sg13
I3
sa(dp2779
g7
I88
sg32
VC0686619
p2780
sg10
I21
sg11
Vlymph node metastasis
p2781
sg13
I3
sa(dp2782
g7
I136
sg32
VC0333994
p2783
sg10
I18
sg11
Vductal hyperplasia
p2784
sg13
I2
sa(dp2785
g7
I31
sg32
VC0007124
p2786
sg10
I24
sg11
Vductal carcinoma in situ
p2787
sg13
I4
sasa(dp2788
g2
S'In contrast, the total positive rate of Glut1 in breast carcinoma was 58.8% (47/80); that in the ductal carcinoma in situ (DCIS) was 45.0% (9/20), that in the well-differentiated invasive carcinoma was 50.0% (15/30) and that in the poorly differentiated was 76.7% (23/30).\n'
p2789
sg4
(lp2790
sg29
(lp2791
(dp2792
g7
I49
sg32
VC0678222
p2793
sg10
I16
sg11
Vbreast carcinoma
p2794
sg13
I2
sa(dp2795
g7
I97
sg32
VC0007124
p2796
sg10
I24
sg11
Vductal carcinoma in situ
p2797
sg13
I4
sa(dp2798
g7
I179
sg32
VC1334274
p2799
sg10
I18
sg11
Vinvasive carcinoma
p2800
sg13
I2
sa(dp2801
g7
I123
sg32
VC0007124
p2802
sg10
I4
sg11
VDCIS
p2803
sg13
I1
sasa(dp2804
g2
S'GLUT1 was expressed in nearly all cases of CIN and ISCC, however, CAIX was expressed only in CIN III and ISCC.\n'
p2805
sg4
(lp2806
(dp2807
g7
I0
sg8
VP11166
p2808
sg10
I5
sg11
VGLUT1
p2809
sg13
I1
sa(dp2810
g7
I93
sg8
g48
sg10
I7
sg11
VCIN III
p2811
sg13
I2
sa(dp2812
g7
I66
sg8
g48
sg10
I4
sg11
VCAIX
p2813
sg13
I1
sasg29
(lp2814
(dp2815
g7
I93
sg32
VC0851140
p2816
sg10
I7
sg11
VCIN III
p2817
sg13
I2
sa(dp2818
g7
I43
sg32
VC0206708
p2819
sg10
I3
sg11
VCIN
p2820
sg13
I1
sasa(dp2821
g2
S'Multicellular spheroids recapitulating ductal carcinoma in situ (DCIS) microenvironmental conditions demonstrate upregulated glucose transporter 1 (GLUT1) as adaptation to hypoxia followed by growth into normoxic regions in qualitative agreement with model predictions.\n'
p2822
sg4
(lp2823
(dp2824
g7
I148
sg8
VP11166
p2825
sg10
I5
sg11
VGLUT1
p2826
sg13
I1
sa(dp2827
g7
I125
sg8
VP11166
p2828
sg10
I21
sg11
Vglucose transporter 1
p2829
sg13
I3
sasg29
(lp2830
(dp2831
g7
I172
sg32
VC0242184
p2832
sg10
I7
sg11
Vhypoxia
p2833
sg13
I1
sa(dp2834
g7
I65
sg32
VC0007124
p2835
sg10
I4
sg11
VDCIS
p2836
sg13
I1
sa(dp2837
g7
I39
sg32
VC0007124
p2838
sg10
I24
sg11
Vductal carcinoma in situ
p2839
sg13
I4
sasa(dp2840
g2
S'We have overexpressed OTX2 in retinal pigmented epithelial cells before their transplantation in the eye of a model of retinitis pigmentosa carrying a mutation in Mertk, a gene specifically expressed by retinal pigmented epithelial cells.\n'
p2841
sg4
(lp2842
(dp2843
g7
I22
sg8
VP32243
p2844
sg10
I4
sg11
VOTX2
p2845
sg13
I1
sa(dp2846
g7
I163
sg8
g48
sg10
I5
sg11
VMertk
p2847
sg13
I1
sasg29
(lp2848
(dp2849
g7
I119
sg32
VC0035334
p2850
sg10
I20
sg11
Vretinitis pigmentosa
p2851
sg13
I2
sasa(dp2852
g2
S'Transplantation of OTX2-genetically modified cells may be medically effective for other retinal diseases involving the retinal pigmented epithelium as age-related macular degeneration.\n'
p2853
sg4
(lp2854
(dp2855
g7
I19
sg8
VP32243
p2856
sg10
I4
sg11
VOTX2
p2857
sg13
I1
sasg29
(lp2858
(dp2859
g7
I88
sg32
VC0035309
p2860
sg10
I16
sg11
Vretinal diseases
p2861
sg13
I2
sa(dp2862
g7
I151
sg32
VC0242383
p2863
sg10
I32
sg11
Vage-related macular degeneration
p2864
sg13
I3
sasa(dp2865
g2
S'Syndromic microphthalmia due to mutations in OTX2 can present with significant intrafamilial phenotypic variability.\n'
p2866
sg4
(lp2867
(dp2868
g7
I45
sg8
VP32243
p2869
sg10
I4
sg11
VOTX2
p2870
sg13
I1
sasg29
(lp2871
(dp2872
g7
I10
sg32
VC0026010
p2873
sg10
I14
sg11
Vmicrophthalmia
p2874
sg13
I1
sasa(dp2875
g2
S'Mutations in OTX2 are mostly identified in patients with anophthalmia/microphthalmia with variable severity.\n'
p2876
sg4
(lp2877
(dp2878
g7
I13
sg8
VP32243
p2879
sg10
I4
sg11
VOTX2
p2880
sg13
I1
sasg29
(lp2881
(dp2882
g7
I70
sg32
VC0026010
p2883
sg10
I14
sg11
Vmicrophthalmia
p2884
sg13
I1
sa(dp2885
g7
I57
sg32
VC0003119
p2886
sg10
I12
sg11
Vanophthalmia
p2887
sg13
I1
sasa(dp2888
g2
S'Mutations in OTX2 cause hypopituitarism, ranging from isolated growth hormone deficiency to combined pituitary hormone deficiency (CPHD), which are commonly detected in association with severe eye abnormalities, including anophthalmia or microphthalmia.\n'
p2889
sg4
(lp2890
(dp2891
g7
I63
sg8
VP01242
p2892
sg10
I14
sg11
Vgrowth hormone
p2893
sg13
I2
sa(dp2894
g7
I92
sg8
VP18509
p2895
sg10
I26
sg11
Vcombined pituitary hormone
p2896
sg13
I3
sa(dp2897
g7
I13
sg8
VP32243
p2898
sg10
I4
sg11
VOTX2
p2899
sg13
I1
sasg29
(lp2900
(dp2901
g7
I70
sg32
VC0599750
p2902
sg10
I18
sg11
Vhormone deficiency
p2903
sg13
I2
sa(dp2904
g7
I54
sg32
VC0271563
p2905
sg10
I34
sg11
Visolated growth hormone deficiency
p2906
sg13
I4
sa(dp2907
g7
I24
sg32
VC0020635
p2908
sg10
I15
sg11
Vhypopituitarism
p2909
sg13
I1
sa(dp2910
g7
I222
sg32
VC0003119
p2911
sg10
I12
sg11
Vanophthalmia
p2912
sg13
I1
sa(dp2913
g7
I238
sg32
VC0026010
p2914
sg10
I14
sg11
Vmicrophthalmia
p2915
sg13
I1
sa(dp2916
g7
I193
sg32
VC0015393
p2917
sg10
I17
sg11
Veye abnormalities
p2918
sg13
I2
sasa(dp2919
g2
S'We report a novel missense OTX2 (R89P) mutation in a CPHD patient with severe hypoglycemia in the neonatal period due to ACTH deficiency, bilateral microphthalmia, and agenesis of the left internal carotid artery (ICA).\n'
p2920
sg4
(lp2921
(dp2922
g7
I121
sg8
VP01189
p2923
sg10
I4
sg11
VACTH
p2924
sg13
I1
sa(dp2925
g7
I27
sg8
VP32243
p2926
sg10
I4
sg11
VOTX2
p2927
sg13
I1
sasg29
(lp2928
(dp2929
g7
I148
sg32
VC0026010
p2930
sg10
I14
sg11
Vmicrophthalmia
p2931
sg13
I1
sa(dp2932
g7
I168
sg32
VC0332907
p2933
sg10
I8
sg11
Vagenesis
p2934
sg13
I1
sa(dp2935
g7
I78
sg32
VC0020615
p2936
sg10
I12
sg11
Vhypoglycemia
p2937
sg13
I1
sa(dp2938
g7
I121
sg32
VC0342388
p2939
sg10
I15
sg11
VACTH deficiency
p2940
sg13
I2
sasa(dp2941
g2
S'Interestingly, C3 treatment resulted in decreased AR binding to target genes accompanied by decreased recruitment of an AR and Beta-catenin cofactor, coactivator-associated arginine methyltransferase 1 (CARM1), providing insight into the unrecognized function of Beta-catenin in prostate cancer.\n'
p2942
sg4
(lp2943
(dp2944
g7
I127
sg8
VP35222
p2945
sg10
I74
sg11
VBeta-catenin cofactor, coactivator-associated arginine methyltransferase 1
p2946
sg13
I6
sa(dp2947
g7
I203
sg8
g48
sg10
I5
sg11
VCARM1
p2948
sg13
I1
sa(dp2949
g7
I127
sg8
VP35222
p2950
sg10
I12
sg11
VBeta-catenin
p2951
sg13
I1
sasg29
(lp2952
(dp2953
g7
I279
sg32
VC0600139
p2954
sg10
I15
sg11
Vprostate cancer
p2955
sg13
I2
sa(dp2956
g7
I102
sg32
VC0271510
p2957
sg10
I11
sg11
Vrecruitment
p2958
sg13
I1
sasa(dp2959
g2
S'Correspondingly, overexpression of CARM1 has been associated with the development of prostate cancer (PCa) and its progression to androgen-independent PCa.\n'
p2960
sg4
(lp2961
(dp2962
g7
I35
sg8
g48
sg10
I5
sg11
VCARM1
p2963
sg13
I1
sasg29
(lp2964
(dp2965
g7
I102
sg32
VC0376358
p2966
sg10
I3
sg11
VPCa
p2967
sg13
I1
sa(dp2968
g7
I102
sg32
VC0376358
p2969
sg10
I3
sg11
VPCa
p2970
sg13
I1
sa(dp2971
g7
I85
sg32
VC0600139
p2972
sg10
I15
sg11
Vprostate cancer
p2973
sg13
I2
sasa(dp2974
g2
S'Immunohistochemistry of CARM1 was performed on primary prostate cancer specimens.\n'
p2975
sg4
(lp2976
(dp2977
g7
I24
sg8
g48
sg10
I5
sg11
VCARM1
p2978
sg13
I1
sasg29
(lp2979
(dp2980
g7
I55
sg32
VC0600139
p2981
sg10
I15
sg11
Vprostate cancer
p2982
sg13
I2
sasa(dp2983
g2
S'CARM1 expression was increased in the nucleus of castration-resistant, but not androgen-stimulated prostate cancer.\n'
p2984
sg4
(lp2985
(dp2986
g7
I0
sg8
g48
sg10
I5
sg11
VCARM1
p2987
sg13
I1
sasg29
(lp2988
(dp2989
g7
I99
sg32
VC0600139
p2990
sg10
I15
sg11
Vprostate cancer
p2991
sg13
I2
sasa(dp2992
g2
S'CARM1 is essential for AR function and may play a role in prostate cancer progression.\n'
p2993
sg4
(lp2994
(dp2995
g7
I0
sg8
g48
sg10
I5
sg11
VCARM1
p2996
sg13
I1
sasg29
(lp2997
(dp2998
g7
I67
sg32
VC0178874
p2999
sg10
I18
sg11
Vcancer progression
p3000
sg13
I2
sasa(dp3001
g2
S'CARM1 may represent a novel therapeutic target in prostate cancer.\n'
p3002
sg4
(lp3003
(dp3004
g7
I0
sg8
g48
sg10
I5
sg11
VCARM1
p3005
sg13
I1
sasg29
(lp3006
(dp3007
g7
I50
sg32
VC0600139
p3008
sg10
I15
sg11
Vprostate cancer
p3009
sg13
I2
sasa(dp3010
g2
S'The expression of CARM1 in normal prostate epithelium, high-grade prostatic intraepithelial neoplasia (PIN), and prostate carcinoma tissue was examined in 66 previously untreated patients with prostate carcinomas, as well as 12 patients with hormone-independent prostate carcinoma, using immunohistochemical methods.\n'
p3011
sg4
(lp3012
(dp3013
g7
I18
sg8
g48
sg10
I5
sg11
VCARM1
p3014
sg13
I1
sasg29
(lp3015
(dp3016
g7
I55
sg32
VC1168327
p3017
sg10
I46
sg11
Vhigh-grade prostatic intraepithelial neoplasia
p3018
sg13
I4
sa(dp3019
g7
I113
sg32
VC0600139
p3020
sg10
I18
sg11
Vprostate carcinoma
p3021
sg13
I2
sa(dp3022
g7
I103
sg32
VC0282612
p3023
sg10
I3
sg11
VPIN
p3024
sg13
I1
sa(dp3025
g7
I113
sg32
VC0600139
p3026
sg10
I18
sg11
Vprostate carcinoma
p3027
sg13
I2
sa(dp3028
g7
I202
sg32
VC0007097
p3029
sg10
I10
sg11
Vcarcinomas
p3030
sg13
I1
sasa(dp3031
g2
S'The authors found that overexpression of CARM1 was involved in the development of prostate carcinoma as well as androgen-independent prostate carcinoma.\n'
p3032
sg4
(lp3033
(dp3034
g7
I41
sg8
g48
sg10
I5
sg11
VCARM1
p3035
sg13
I1
sasg29
(lp3036
(dp3037
g7
I82
sg32
VC0600139
p3038
sg10
I18
sg11
Vprostate carcinoma
p3039
sg13
I2
sa(dp3040
g7
I82
sg32
VC0600139
p3041
sg10
I18
sg11
Vprostate carcinoma
p3042
sg13
I2
sasa(dp3043
g2
S'Since CARM1 is functionally different from most other transcriptional coactivators of the AR, it may serve as a new target for the treatment of hormone-independent prostate carcinoma.\n'
p3044
sg4
(lp3045
(dp3046
g7
I6
sg8
g48
sg10
I5
sg11
VCARM1
p3047
sg13
I1
sasg29
(lp3048
(dp3049
g7
I164
sg32
VC0600139
p3050
sg10
I18
sg11
Vprostate carcinoma
p3051
sg13
I2
sasa(dp3052
g2
S'Moreover, knocking down of p21Waf1/Cip1 blocks the ability of Foxp1 to protect neurons from mut-Htt-induced neurotoxicity.\n'
p3053
sg4
(lp3054
(dp3055
g7
I35
sg8
VP38936
p3056
sg10
I4
sg11
VCip1
p3057
sg13
I1
sa(dp3058
g7
I92
sg8
VP22033
p3059
sg10
I7
sg11
Vmut-Htt
p3060
sg13
I1
sa(dp3061
g7
I62
sg8
g48
sg10
I5
sg11
VFoxp1
p3062
sg13
I1
sasg29
(lp3063
sa(dp3064
g2
S"We propose that the selective vulnerability of neurons of the striatum and cortex in HD is related to the loss of expression of Foxp1, a protein that is highly expressed in these neurons and required for their survival.SIGNIFICANCE STATEMENT Although the mutant huntingtin gene is expressed widely, neurons of the striatum and cortex are selectively affected in Huntington's disease (HD).\n"
p3065
sg4
(lp3066
(dp3067
g7
I128
sg8
g48
sg10
I5
sg11
VFoxp1
p3068
sg13
I1
sa(dp3069
g7
I255
sg8
VP42858
p3070
sg10
I22
sg11
Vmutant huntingtin gene
p3071
sg13
I3
sasg29
(lp3072
(dp3073
g7
I85
sg32
VC0020179
p3074
sg10
I2
sg11
VHD
p3075
sg13
I1
sa(dp3076
g7
I85
sg32
VC0020179
p3077
sg10
I2
sg11
VHD
p3078
sg13
I1
sa(dp3079
g7
I362
sg32
VC0020179
p3080
sg10
I20
sg11
VHuntington's disease
p3081
sg13
I2
sa(dp3082
g7
I255
sg32
VC0596988
p3083
sg10
I6
sg11
Vmutant
p3084
sg13
I1
sasa(dp3085
g2
S"Here, we report that the SINE compounds (KPT-350 or KPT-335) sequestered TBI-induced neuroinflammation-related proteins (NF-(k)B, AKT, FOXP1) within the nucleus of cultured primary rat cortical neurons, which coincided with protection against TNF-Alfa (20 ng/mL)-induced neurotoxicity as shown by at least 50% and 100% increments in preservation of cell viability and cellular enzymatic activity, respectively, compared to non-treated neuronal cells (P's &lt; 0.05).\n"
p3086
sg4
(lp3087
(dp3088
g7
I243
sg8
VP01375
p3089
sg10
I8
sg11
VTNF-Alfa
p3090
sg13
I1
sa(dp3091
g7
I135
sg8
g48
sg10
I5
sg11
VFOXP1
p3092
sg13
I1
sa(dp3093
g7
I130
sg8
g48
sg10
I3
sg11
VAKT
p3094
sg13
I1
sasg29
(lp3095
sa(dp3096
g2
S"We found that mouse Foxp1 overexpression in striatal cells elicited expression changes of genes related to immune signaling, transcriptional regulation and a manually curated Huntington's disease (HD)-signaling pathway.\n"
p3097
sg4
(lp3098
(dp3099
g7
I14
sg8
g48
sg10
I11
sg11
Vmouse Foxp1
p3100
sg13
I2
sasg29
(lp3101
(dp3102
g7
I175
sg32
VC0020179
p3103
sg10
I20
sg11
VHuntington's disease
p3104
sg13
I2
sa(dp3105
g7
I197
sg32
VC0020179
p3106
sg10
I2
sg11
VHD
p3107
sg13
I1
sasa(dp3108
g2
S'Knowledge of SjS has progressed substantially, but this disease is still characterized by sicca symptoms, the systemic involvement of disease, lymphocytic infiltration to exocrine glands, the presence of anti-Ro/SSA and anti-La/SSB autoantibodies and the increased risk of lymphoma in patients with SjS.\n'
p3109
sg4
(lp3110
(dp3111
g7
I212
sg8
VP19474
p3112
sg10
I3
sg11
VSSA
p3113
sg13
I1
sa(dp3114
g7
I228
sg8
VP05455
p3115
sg10
I18
sg11
VSSB autoantibodies
p3116
sg13
I2
sasg29
(lp3117
(dp3118
g7
I13
sg32
VC0036391
p3119
sg10
I3
sg11
VSjS
p3120
sg13
I1
sa(dp3121
g7
I13
sg32
VC0036391
p3122
sg10
I3
sg11
VSjS
p3123
sg13
I1
sa(dp3124
g7
I143
sg32
VC1262091
p3125
sg10
I24
sg11
Vlymphocytic infiltration
p3126
sg13
I2
sa(dp3127
g7
I273
sg32
VC0024299
p3128
sg10
I8
sg11
Vlymphoma
p3129
sg13
I1
sasa(dp3130
g2
S'Primary SS negative for anti-Ro/SSA and anti-La/SSB antibodies appears to be characterized by a lower risk of lymphoma and by a lower level of B-cell expansion.\n'
p3131
sg4
(lp3132
(dp3133
g7
I40
sg8
VP05455
p3134
sg10
I22
sg11
Vanti-La/SSB antibodies
p3135
sg13
I2
sa(dp3136
g7
I32
sg8
VP19474
p3137
sg10
I3
sg11
VSSA
p3138
sg13
I1
sasg29
(lp3139
(dp3140
g7
I110
sg32
VC0024299
p3141
sg10
I8
sg11
Vlymphoma
p3142
sg13
I1
sasa(dp3143
g2
S'Ubiquitous ASIP expression in mice gives rise to a pleiotropic phenotype characterized by a uniform yellow coat color, obesity, overgrowth, and metabolic derangements similar to type II diabetes in humans.\n'
p3144
sg4
(lp3145
sg29
(lp3146
(dp3147
g7
I119
sg32
VC0028754
p3148
sg10
I7
sg11
Vobesity
p3149
sg13
I1
sa(dp3150
g7
I178
sg32
VC0011860
p3151
sg10
I16
sg11
Vtype II diabetes
p3152
sg13
I3
sasa(dp3153
g2
S'Proximity ligation assay quantified the expression levels of 36 pancreatic cancer-specific candidate seromarkers: Axl, BMP2, CA 125, CA 19-9, CEA, CXCL-1/6/9/10, EGFR, Gas6, Her2, IGF-2, IGFBP-2/3/7, IL-6/6Ra/7/8/12, mesothelin, MMP-1/2/3/7, osteopontin, PDGFRa, PDK1, PF4, RegIV, SPARC, TGF-Beta, VEGF-A/D, and YKL40.\n'
p3154
sg4
(lp3155
(dp3156
g7
I229
sg8
VP03956
p3157
sg10
I11
sg11
VMMP-1/2/3/7
p3158
sg13
I1
sa(dp3159
g7
I288
sg8
VP18075
p3160
sg10
I8
sg11
VTGF-Beta
p3161
sg13
I1
sa(dp3162
g7
I255
sg8
VP16234
p3163
sg10
I6
sg11
VPDGFRa
p3164
sg13
I1
sa(dp3165
g7
I281
sg8
VP09486
p3166
sg10
I5
sg11
VSPARC
p3167
sg13
I1
sa(dp3168
g7
I174
sg8
VP04626
p3169
sg10
I4
sg11
VHer2
p3170
sg13
I1
sa(dp3171
g7
I168
sg8
g48
sg10
I4
sg11
VGas6
p3172
sg13
I1
sa(dp3173
g7
I125
sg8
g48
sg10
I6
sg11
VCA 125
p3174
sg13
I2
sa(dp3175
g7
I180
sg8
VP01344
p3176
sg10
I5
sg11
VIGF-2
p3177
sg13
I1
sa(dp3178
g7
I114
sg8
VP30530
p3179
sg10
I3
sg11
VAxl
p3180
sg13
I1
sa(dp3181
g7
I142
sg8
VP40198
p3182
sg10
I3
sg11
VCEA
p3183
sg13
I1
sa(dp3184
g7
I269
sg8
VP02776
p3185
sg10
I3
sg11
VPF4
p3186
sg13
I1
sa(dp3187
g7
I119
sg8
VP12643
p3188
sg10
I4
sg11
VBMP2
p3189
sg13
I1
sa(dp3190
g7
I312
sg8
VP36222
p3191
sg10
I5
sg11
VYKL40
p3192
sg13
I1
sa(dp3193
g7
I200
sg8
VP05231
p3194
sg10
I15
sg11
VIL-6/6Ra/7/8/12
p3195
sg13
I1
sa(dp3196
g7
I263
sg8
g48
sg10
I4
sg11
VPDK1
p3197
sg13
I1
sa(dp3198
g7
I187
sg8
VP18065
p3199
sg10
I11
sg11
VIGFBP-2/3/7
p3200
sg13
I1
sa(dp3201
g7
I242
sg8
VP10451
p3202
sg10
I11
sg11
Vosteopontin
p3203
sg13
I1
sasg29
(lp3204
(dp3205
g7
I64
sg32
VC0235974
p3206
sg10
I17
sg11
Vpancreatic cancer
p3207
sg13
I2
sasa(dp3208
g2
S"Insulin-like growth factor binding protein 2 (IGFBP-2) is a member of the IGFBP family of proteins, and it is highly expressed in pancreatic cancer patients' serum and tumor tissues.\n"
p3209
sg4
(lp3210
(dp3211
g7
I0
sg8
VP01308
p3212
sg10
I44
sg11
VInsulin-like growth factor binding protein 2
p3213
sg13
I6
sa(dp3214
g7
I46
sg8
VP18065
p3215
sg10
I7
sg11
VIGFBP-2
p3216
sg13
I1
sasg29
(lp3217
(dp3218
g7
I130
sg32
VC0235974
p3219
sg10
I17
sg11
Vpancreatic cancer
p3220
sg13
I2
sa(dp3221
g7
I168
sg32
VC0027651
p3222
sg10
I5
sg11
Vtumor
p3223
sg13
I1
sasa(dp3224
g2
S'In this study, we sought to determine the impact of IGFBP-2 expression on pancreatic cancer tumorigenesis and metastasis in vitro and in vivo.\n'
p3225
sg4
(lp3226
(dp3227
g7
I52
sg8
VP18065
p3228
sg10
I7
sg11
VIGFBP-2
p3229
sg13
I1
sasg29
(lp3230
(dp3231
g7
I74
sg32
VC0235974
p3232
sg10
I17
sg11
Vpancreatic cancer
p3233
sg13
I2
sa(dp3234
g7
I110
sg32
VC0027627
p3235
sg10
I10
sg11
Vmetastasis
p3236
sg13
I1
sa(dp3237
g7
I92
sg32
VC0007621
p3238
sg10
I13
sg11
Vtumorigenesis
p3239
sg13
I1
sasa(dp3240
g2
S'PTCH-1 is found contribute to the function of IGFBP-2 in suppressing metastasis and EMT of pancreatic cancer.\n'
p3241
sg4
(lp3242
(dp3243
g7
I0
sg8
g48
sg10
I6
sg11
VPTCH-1
p3244
sg13
I1
sa(dp3245
g7
I46
sg8
VP18065
p3246
sg10
I7
sg11
VIGFBP-2
p3247
sg13
I1
sasg29
(lp3248
(dp3249
g7
I69
sg32
VC0027627
p3250
sg10
I10
sg11
Vmetastasis
p3251
sg13
I1
sa(dp3252
g7
I91
sg32
VC0235974
p3253
sg10
I17
sg11
Vpancreatic cancer
p3254
sg13
I2
sasa(dp3255
g2
S'Silencing IGFBP-2 inhibited invasion and metastatic properties, partially through inhibiting PTCH1 in pancreatic cancer.\n'
p3256
sg4
(lp3257
(dp3258
g7
I93
sg8
g48
sg10
I5
sg11
VPTCH1
p3259
sg13
I1
sa(dp3260
g7
I10
sg8
VP18065
p3261
sg10
I7
sg11
VIGFBP-2
p3262
sg13
I1
sasg29
(lp3263
(dp3264
g7
I102
sg32
VC0235974
p3265
sg10
I17
sg11
Vpancreatic cancer
p3266
sg13
I2
sa(dp3267
g7
I28
sg32
VC2699153
p3268
sg10
I8
sg11
Vinvasion
p3269
sg13
I1
sasa(dp3270
g2
S'Additionally, inhibition of IGFBP-2 enhanced the sensitivity of pancreatic cancer cells to gemcitabine, suppressed tumor growth and potentiated the anti-tumor effect of gemcitabine in the orthotopic tumor model.\n'
p3271
sg4
(lp3272
(dp3273
g7
I28
sg8
VP18065
p3274
sg10
I7
sg11
VIGFBP-2
p3275
sg13
I1
sasg29
(lp3276
(dp3277
g7
I115
sg32
VC0598934
p3278
sg10
I12
sg11
Vtumor growth
p3279
sg13
I2
sa(dp3280
g7
I115
sg32
VC0027651
p3281
sg10
I5
sg11
Vtumor
p3282
sg13
I1
sa(dp3283
g7
I115
sg32
VC0027651
p3284
sg10
I5
sg11
Vtumor
p3285
sg13
I1
sa(dp3286
g7
I64
sg32
VC0235974
p3287
sg10
I17
sg11
Vpancreatic cancer
p3288
sg13
I2
sasa(dp3289
g2
S'Our results provide novel insight of IGFBP-2 as a promising target to inhibit the metastasis and overcome the chemoresistance in pancreatic cancer.\n'
p3290
sg4
(lp3291
(dp3292
g7
I37
sg8
VP18065
p3293
sg10
I7
sg11
VIGFBP-2
p3294
sg13
I1
sasg29
(lp3295
(dp3296
g7
I82
sg32
VC0027627
p3297
sg10
I10
sg11
Vmetastasis
p3298
sg13
I1
sa(dp3299
g7
I129
sg32
VC0235974
p3300
sg10
I17
sg11
Vpancreatic cancer
p3301
sg13
I2
sasa(dp3302
g2
S'Of these proteins, four proteins (apolipoprotein A-IV, apolipoprotein CIII, insulin-like growth factor binding protein 2 and tissue inhibitor of metalloproteinase 1) were significantly altered in pancreatic cancer in both the discovery and validation phase (P &lt; 0.01).\n'
p3303
sg4
(lp3304
(dp3305
g7
I34
sg8
VP08519
p3306
sg10
I19
sg11
Vapolipoprotein A-IV
p3307
sg13
I2
sa(dp3308
g7
I55
sg8
VP02656
p3309
sg10
I19
sg11
Vapolipoprotein CIII
p3310
sg13
I2
sasg29
(lp3311
(dp3312
g7
I196
sg32
VC0235974
p3313
sg10
I17
sg11
Vpancreatic cancer
p3314
sg13
I2
sasa(dp3315
g2
S'To determine the prognostic role of three RBP genes: insulin-like growth factor-binding protein 2 (IGFBP2), RNA-binding motif protein 3 (RBM3), and cold-inducible RNA-binding protein (CIRP) in colon cancer.\n'
p3316
sg4
(lp3317
(dp3318
g7
I108
sg8
VP98179
p3319
sg10
I27
sg11
VRNA-binding motif protein 3
p3320
sg13
I4
sa(dp3321
g7
I184
sg8
g48
sg10
I4
sg11
VCIRP
p3322
sg13
I1
sa(dp3323
g7
I137
sg8
VP98179
p3324
sg10
I4
sg11
VRBM3
p3325
sg13
I1
sa(dp3326
g7
I53
sg8
VP01308
p3327
sg10
I44
sg11
Vinsulin-like growth factor-binding protein 2
p3328
sg13
I5
sa(dp3329
g7
I42
sg8
g48
sg10
I9
sg11
VRBP genes
p3330
sg13
I2
sa(dp3331
g7
I99
sg8
VP18065
p3332
sg10
I6
sg11
VIGFBP2
p3333
sg13
I1
sa(dp3334
g7
I148
sg8
g48
sg10
I34
sg11
Vcold-inducible RNA-binding protein
p3335
sg13
I3
sasg29
(lp3336
(dp3337
g7
I193
sg32
VC0699790
p3338
sg10
I12
sg11
Vcolon cancer
p3339
sg13
I2
sa(dp3340
g7
I148
sg32
VC0024117
p3341
sg10
I4
sg11
Vcold
p3342
sg13
I1
sasa(dp3343
g2
S'We examined the RNA expression of IGFBP2, RBM3, and CIRP in 94 human colon cancer samples along with matched normal tissue samples from each patient using quantitative real-time polymerase chain reaction (qRT-PCR).\n'
p3344
sg4
(lp3345
(dp3346
g7
I52
sg8
g48
sg10
I4
sg11
VCIRP
p3347
sg13
I1
sa(dp3348
g7
I42
sg8
VP98179
p3349
sg10
I4
sg11
VRBM3
p3350
sg13
I1
sa(dp3351
g7
I34
sg8
VP18065
p3352
sg10
I6
sg11
VIGFBP2
p3353
sg13
I1
sasg29
(lp3354
(dp3355
g7
I69
sg32
VC0699790
p3356
sg10
I12
sg11
Vcolon cancer
p3357
sg13
I2
sasa(dp3358
g2
S'The mean survival period was longer for patients with ABK, PBK, and secondary glaucoma, and shorter for patients who experienced graft ulcer or surface disorders.\n'
p3359
sg4
(lp3360
(dp3361
g7
I59
sg8
g48
sg10
I3
sg11
VPBK
p3362
sg13
I1
sasg29
(lp3363
(dp3364
g7
I68
sg32
VC0149893
p3365
sg10
I18
sg11
Vsecondary glaucoma
p3366
sg13
I2
sa(dp3367
g7
I135
sg32
VC0041582
p3368
sg10
I5
sg11
Vulcer
p3369
sg13
I1
sasa(dp3370
g2
S'In order to determine the prevalence of armadillos infected by Toxoplasma gondii and Leptospira spp., serum samples of 31 nine-banded armadillos (Dasypus novemcinctus), three six-banded armadillos (Euphractus sexcinctus), two naked-tailed armadillos (Cabassous tatouay) and two long-nosed armadillos (D. hybridus), captured in the mid-west region of the state of Sao Paulo, were analyzed for leptospirosis using the Microscopic Agglutination Test (MAT-l), and for toxoplasmosis using the Modified Agglutination Test (MAT-t).\n'
p3371
sg4
(lp3372
(dp3373
g7
I416
sg8
g48
sg10
I30
sg11
VMicroscopic Agglutination Test
p3374
sg13
I3
sa(dp3375
g7
I448
sg8
VP24752
p3376
sg10
I5
sg11
VMAT-l
p3377
sg13
I1
sa(dp3378
g7
I517
sg8
VP24752
p3379
sg10
I5
sg11
VMAT-t
p3380
sg13
I1
sa(dp3381
g7
I488
sg8
VP80511
p3382
sg10
I27
sg11
VModified Agglutination Test
p3383
sg13
I3
sasg29
(lp3384
(dp3385
g7
I464
sg32
VC0040558
p3386
sg10
I13
sg11
Vtoxoplasmosis
p3387
sg13
I1
sa(dp3388
g7
I392
sg32
VC0023364
p3389
sg10
I13
sg11
Vleptospirosis
p3390
sg13
I1
sasa(dp3391
g2
S'It is not known how phospho-HLXB9 acts as an oncogenic factor in insulin-secreting Beta-cell tumors (insulinomas).\n'
p3392
sg4
(lp3393
(dp3394
g7
I65
sg8
VP01308
p3395
sg10
I7
sg11
Vinsulin
p3396
sg13
I1
sa(dp3397
g7
I28
sg8
VP50219
p3398
sg10
I5
sg11
VHLXB9
p3399
sg13
I1
sasg29
(lp3400
(dp3401
g7
I101
sg32
VC0021670
p3402
sg10
I11
sg11
Vinsulinomas
p3403
sg13
I1
sa(dp3404
g7
I83
sg32
VC0021670
p3405
sg10
I16
sg11
VBeta-cell tumors
p3406
sg13
I2
sasa(dp3407
g2
S'In this study we investigated the binding partners and target genes of phospho-HLXB9 in mouse insulinoma MIN6 Beta-cells.\n'
p3408
sg4
(lp3409
(dp3410
g7
I71
sg8
VP50219
p3411
sg10
I13
sg11
Vphospho-HLXB9
p3412
sg13
I1
sasg29
(lp3413
(dp3414
g7
I88
sg32
VC1522248
p3415
sg10
I16
sg11
Vmouse insulinoma
p3416
sg13
I2
sasa(dp3417
g2
S'Also, increased phospho-HLXB9 coincided with reduced Cblb and increased c-Met in insulinomas of two mouse models of menin loss.\n'
p3418
sg4
(lp3419
(dp3420
g7
I53
sg8
g48
sg10
I4
sg11
VCblb
p3421
sg13
I1
sa(dp3422
g7
I24
sg8
VP50219
p3423
sg10
I5
sg11
VHLXB9
p3424
sg13
I1
sa(dp3425
g7
I72
sg8
VP08581
p3426
sg10
I5
sg11
Vc-Met
p3427
sg13
I1
sasg29
(lp3428
(dp3429
g7
I81
sg32
VC0021670
p3430
sg10
I11
sg11
Vinsulinomas
p3431
sg13
I1
sasa(dp3432
g2
S'These mechanisms have therapeutic implications for reducing Beta-cell proliferation in insulinomas by inhibiting phospho-HLXB9 or its interaction with Nono and modulating the expression of its direct (Cblb) or indirect (c-Met) targets.\n'
p3433
sg4
(lp3434
(dp3435
g7
I121
sg8
VP50219
p3436
sg10
I5
sg11
VHLXB9
p3437
sg13
I1
sasg29
(lp3438
(dp3439
g7
I87
sg32
VC0021670
p3440
sg10
I11
sg11
Vinsulinomas
p3441
sg13
I1
sa(dp3442
g7
I70
sg32
VC0334094
p3443
sg10
I13
sg11
Vproliferation
p3444
sg13
I1
sasa(dp3445
g2
S'Both pHLXB9 and active GSK-3Beta are elevated in Beta cells with menin knockdown, in MEN1-associated Beta cell tumors (insulinomas), and also in human sporadic insulinomas.\n'
p3446
sg4
(lp3447
(dp3448
g7
I23
sg8
VP49841
p3449
sg10
I9
sg11
VGSK-3Beta
p3450
sg13
I1
sa(dp3451
g7
I85
sg8
g48
sg10
I4
sg11
VMEN1
p3452
sg13
I1
sasg29
(lp3453
(dp3454
g7
I119
sg32
VC0021670
p3455
sg10
I11
sg11
Vinsulinomas
p3456
sg13
I1
sa(dp3457
g7
I85
sg32
VC0025267
p3458
sg10
I4
sg11
VMEN1
p3459
sg13
I1
sa(dp3460
g7
I119
sg32
VC0021670
p3461
sg10
I11
sg11
Vinsulinomas
p3462
sg13
I1
sa(dp3463
g7
I111
sg32
VC0027651
p3464
sg10
I6
sg11
Vtumors
p3465
sg13
I1
sasa(dp3466
g2
S'Taken together, these data suggest that the combination of GSK-3Beta and pHLXB9 forms a therapeutically targetable mechanism of insulinoma pathogenesis.\n'
p3467
sg4
(lp3468
(dp3469
g7
I59
sg8
VP49841
p3470
sg10
I9
sg11
VGSK-3Beta
p3471
sg13
I1
sasg29
(lp3472
(dp3473
g7
I139
sg32
VC0699748
p3474
sg10
I12
sg11
Vpathogenesis
p3475
sg13
I1
sa(dp3476
g7
I128
sg32
VC0021670
p3477
sg10
I10
sg11
Vinsulinoma
p3478
sg13
I1
sasa(dp3479
g2
S'Our results reveal that GSK-3Beta and pHLXB9 can serve as novel targets for insulinoma treatment and have implications for understanding the pathways associated with Beta cell proliferation.\n'
p3480
sg4
(lp3481
(dp3482
g7
I24
sg8
VP49841
p3483
sg10
I9
sg11
VGSK-3Beta
p3484
sg13
I1
sasg29
(lp3485
(dp3486
g7
I76
sg32
VC0021670
p3487
sg10
I10
sg11
Vinsulinoma
p3488
sg13
I1
sa(dp3489
g7
I176
sg32
VC0334094
p3490
sg10
I13
sg11
Vproliferation
p3491
sg13
I1
sasa(dp3492
g2
S'The presacral masses consistent with Currarino triad included anterior meningocoele in three patients, lipoma in two patients and anterior lipomeningocoele in one patient.\n'
p3493
sg4
(lp3494
sg29
(lp3495
(dp3496
g7
I103
sg32
VC3489413
p3497
sg10
I6
sg11
Vlipoma
p3498
sg13
I1
sa(dp3499
g7
I37
sg32
VC1531773
p3500
sg10
I15
sg11
VCurrarino triad
p3501
sg13
I2
sasa(dp3502
g2
S'Increased factor VII and its activity, and plasminogen activator inhibitor-1 are among several findings contributing to a prothrombotic state in subclinical hypothyroidism.\n'
p3503
sg4
(lp3504
(dp3505
g7
I43
sg8
VP00747
p3506
sg10
I11
sg11
Vplasminogen
p3507
sg13
I1
sa(dp3508
g7
I10
sg8
VP08709
p3509
sg10
I10
sg11
Vfactor VII
p3510
sg13
I2
sa(dp3511
g7
I65
sg8
g48
sg10
I11
sg11
Vinhibitor-1
p3512
sg13
I1
sasg29
(lp3513
(dp3514
g7
I145
sg32
VC0271790
p3515
sg10
I26
sg11
Vsubclinical hypothyroidism
p3516
sg13
I2
sasa(dp3517
g2
S'Clinical factors were assessed, including: onset during or shortly after HD, defined as occurring within 12 h of HD; the presence of a lesion on diffusion-weighted MRI; hypotension, hyponatremia, or hypoglycemia at symptom onset; the stroke etiology; the presence of focal neurologic deficits; whether the patient was in the window period for intravenous tissue plasminogen activator (IVtPA) upon presentation, and whether the patient received IVtPA.\n'
p3518
sg4
(lp3519
(dp3520
g7
I355
sg8
VP00747
p3521
sg10
I28
sg11
Vtissue plasminogen activator
p3522
sg13
I3
sasg29
(lp3523
(dp3524
g7
I234
sg32
VC0038454
p3525
sg10
I6
sg11
Vstroke
p3526
sg13
I1
sa(dp3527
g7
I215
sg32
VC1457887
p3528
sg10
I7
sg11
Vsymptom
p3529
sg13
I1
sa(dp3530
g7
I199
sg32
VC0020615
p3531
sg10
I12
sg11
Vhypoglycemia
p3532
sg13
I1
sasa(dp3533
g2
S'Mutations in Ceramide Kinase-Like (CERKL) cause autosomal recessive Retinitis Pigmentosa and Cone Rod Dystrophy.\n'
p3534
sg4
(lp3535
(dp3536
g7
I13
sg8
g48
sg10
I20
sg11
VCeramide Kinase-Like
p3537
sg13
I2
sa(dp3538
g7
I35
sg8
g48
sg10
I5
sg11
VCERKL
p3539
sg13
I1
sasg29
(lp3540
(dp3541
g7
I48
sg32
VC0339526
p3542
sg10
I40
sg11
Vautosomal recessive Retinitis Pigmentosa
p3543
sg13
I4
sa(dp3544
g7
I93
sg32
VC0035334
p3545
sg10
I18
sg11
VCone Rod Dystrophy
p3546
sg13
I3
sasa(dp3547
g2
S'Mutations in the Ceramide kinase like (CERKL) gene are associated with retinitis pigmentosa (RP26) and cone-rod dystrophy.\n'
p3548
sg4
(lp3549
(dp3550
g7
I39
sg8
g48
sg10
I5
sg11
VCERKL
p3551
sg13
I1
sa(dp3552
g7
I17
sg8
g48
sg10
I20
sg11
VCeramide kinase like
p3553
sg13
I3
sasg29
(lp3554
(dp3555
g7
I71
sg32
VC0035334
p3556
sg10
I20
sg11
Vretinitis pigmentosa
p3557
sg13
I2
sa(dp3558
g7
I93
sg32
VC1842127
p3559
sg10
I4
sg11
VRP26
p3560
sg13
I1
sa(dp3561
g7
I103
sg32
VC0035334
p3562
sg10
I18
sg11
Vcone-rod dystrophy
p3563
sg13
I2
sasa(dp3564
g2
S'CERKL mutations are associated with severe retinal degeneration.\n'
p3565
sg4
(lp3566
sg29
(lp3567
(dp3568
g7
I43
sg32
VC0035304
p3569
sg10
I20
sg11
Vretinal degeneration
p3570
sg13
I2
sasa(dp3571
g2
S'A novel gene (CERKL) has been described as associated with RP26.\n'
p3572
sg4
(lp3573
sg29
(lp3574
(dp3575
g7
I59
sg32
VC1842127
p3576
sg10
I4
sg11
VRP26
p3577
sg13
I1
sasa(dp3578
g2
S'A mutation in a new ceramide kinase (CERK) homologous gene, named CERK-like protein (CERKL), was found to cause autosomal recessive retinitis pigmentosa (RP26).\n'
p3579
sg4
(lp3580
(dp3581
g7
I20
sg8
g48
sg10
I15
sg11
Vceramide kinase
p3582
sg13
I2
sa(dp3583
g7
I37
sg8
g48
sg10
I4
sg11
VCERK
p3584
sg13
I1
sa(dp3585
g7
I85
sg8
g48
sg10
I5
sg11
VCERKL
p3586
sg13
I1
sa(dp3587
g7
I66
sg8
g48
sg10
I17
sg11
VCERK-like protein
p3588
sg13
I2
sasg29
(lp3589
(dp3590
g7
I154
sg32
VC1842127
p3591
sg10
I4
sg11
VRP26
p3592
sg13
I1
sa(dp3593
g7
I112
sg32
VC0339526
p3594
sg10
I40
sg11
Vautosomal recessive retinitis pigmentosa
p3595
sg13
I4
sasa(dp3596
g2
S'We also studied a naturally occurring CERKL mutant (R257X), recently linked to the pathology of retinitis pigmentosa.\n'
p3597
sg4
(lp3598
sg29
(lp3599
(dp3600
g7
I96
sg32
VC0035334
p3601
sg10
I20
sg11
Vretinitis pigmentosa
p3602
sg13
I2
sa(dp3603
g7
I44
sg32
VC0596988
p3604
sg10
I6
sg11
Vmutant
p3605
sg13
I1
sa(dp3606
g7
I83
sg32
VC0677042
p3607
sg10
I9
sg11
Vpathology
p3608
sg13
I1
sasa(dp3609
g2
S'Furthermore, we propose that the cause for retinitis pigmentosa in patients bearing the CERKL R257X mutation might be the accumulation of a truncated CERKL protein in the nucleus.\n'
p3610
sg4
(lp3611
sg29
(lp3612
(dp3613
g7
I43
sg32
VC0035334
p3614
sg10
I20
sg11
Vretinitis pigmentosa
p3615
sg13
I2
sasa(dp3616
g2
S'The present study examined predictors and moderators of treatment response among 165 adults meeting Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria for comorbid posttraumatic stress disorder (PTSD) and alcohol dependence (AD), who were randomized to 24 weeks of Naltrexone (NAL), NAL and prolonged exposure (PE), pill placebo, or pill placebo and PE.\n'
p3617
sg4
(lp3618
sg29
(lp3619
(dp3620
g7
I253
sg32
VC0001973
p3621
sg10
I2
sg11
VAD
p3622
sg13
I1
sa(dp3623
g7
I192
sg32
VC0038436
p3624
sg10
I29
sg11
Vposttraumatic stress disorder
p3625
sg13
I3
sa(dp3626
g7
I137
sg32
VC0004936
p3627
sg10
I16
sg11
VMental Disorders
p3628
sg13
I2
sa(dp3629
g7
I223
sg32
VC0038436
p3630
sg10
I4
sg11
VPTSD
p3631
sg13
I1
sa(dp3632
g7
I233
sg32
VC0001973
p3633
sg10
I18
sg11
Valcohol dependence
p3634
sg13
I2
sasa(dp3635
g2
S'To examine the mechanisms of prolonged exposure (PE) and naltrexone (NAL) that underlie symptom reduction among individuals with comorbid posttraumatic stress disorder (PTSD) and alcohol dependence (AD).\n'
p3636
sg4
(lp3637
sg29
(lp3638
(dp3639
g7
I199
sg32
VC0001973
p3640
sg10
I2
sg11
VAD
p3641
sg13
I1
sa(dp3642
g7
I169
sg32
VC0038436
p3643
sg10
I4
sg11
VPTSD
p3644
sg13
I1
sa(dp3645
g7
I88
sg32
VC1457887
p3646
sg10
I7
sg11
Vsymptom
p3647
sg13
I1
sa(dp3648
g7
I179
sg32
VC0001973
p3649
sg10
I18
sg11
Valcohol dependence
p3650
sg13
I2
sa(dp3651
g7
I138
sg32
VC0038436
p3652
sg10
I29
sg11
Vposttraumatic stress disorder
p3653
sg13
I3
sasa(dp3654
g2
S'Non-parametric analysis, using the NPL statistic or FBAT, also did not support any linkage or association between the markers and panic disorder.\n'
p3655
sg4
(lp3656
(dp3657
g7
I35
sg8
VP98179
p3658
sg10
I3
sg11
VNPL
p3659
sg13
I1
sasg29
(lp3660
(dp3661
g7
I130
sg32
VC1868649
p3662
sg10
I14
sg11
Vpanic disorder
p3663
sg13
I2
sasa(dp3664
g2
S'For agoraphobia, the most promising potential linkage was on chromosome 3 (NPL score = 2.75; P = 0.005).\n'
p3665
sg4
(lp3666
sg29
(lp3667
(dp3668
g7
I4
sg32
VC0001818
p3669
sg10
I11
sg11
Vagoraphobia
p3670
sg13
I1
sasa(dp3671
g2
S'We explored the association between obesity and periodontitis with the aim of determining the possible role of insulin resistance (IR) in this relationship.\n'
p3672
sg4
(lp3673
(dp3674
g7
I111
sg8
VP01308
p3675
sg10
I7
sg11
Vinsulin
p3676
sg13
I1
sasg29
(lp3677
(dp3678
g7
I111
sg32
VC0021655
p3679
sg10
I18
sg11
Vinsulin resistance
p3680
sg13
I2
sa(dp3681
g7
I36
sg32
VC0028754
p3682
sg10
I7
sg11
Vobesity
p3683
sg13
I1
sa(dp3684
g7
I48
sg32
VC0031099
p3685
sg10
I13
sg11
Vperiodontitis
p3686
sg13
I1
sa(dp3687
g7
I131
sg32
VC0021655
p3688
sg10
I2
sg11
VIR
p3689
sg13
I1
sasa(dp3690
g2
S'Epidemiological studies suggest a close association between periodontitis and prediabetes/insulin resistance (IR) but whether periodontitis causes prediabetes in humans is not known.\n'
p3691
sg4
(lp3692
(dp3693
g7
I90
sg8
VP01308
p3694
sg10
I7
sg11
Vinsulin
p3695
sg13
I1
sasg29
(lp3696
(dp3697
g7
I90
sg32
VC0021655
p3698
sg10
I18
sg11
Vinsulin resistance
p3699
sg13
I2
sa(dp3700
g7
I78
sg32
VC0362046
p3701
sg10
I11
sg11
Vprediabetes
p3702
sg13
I1
sa(dp3703
g7
I78
sg32
VC0362046
p3704
sg10
I11
sg11
Vprediabetes
p3705
sg13
I1
sa(dp3706
g7
I60
sg32
VC0031099
p3707
sg10
I13
sg11
Vperiodontitis
p3708
sg13
I1
sa(dp3709
g7
I60
sg32
VC0031099
p3710
sg10
I13
sg11
Vperiodontitis
p3711
sg13
I1
sasa(dp3712
g2
S'Using various animal models, we have recently established that periodontitis can be an initiator of prediabetes, which is characterized by glucose intolerance, hyperinsulinemia and IR.\n'
p3713
sg4
(lp3714
sg29
(lp3715
(dp3716
g7
I139
sg32
VC0271650
p3717
sg10
I19
sg11
Vglucose intolerance
p3718
sg13
I2
sa(dp3719
g7
I160
sg32
VC0020459
p3720
sg10
I16
sg11
Vhyperinsulinemia
p3721
sg13
I1
sa(dp3722
g7
I63
sg32
VC0031099
p3723
sg10
I13
sg11
Vperiodontitis
p3724
sg13
I1
sa(dp3725
g7
I100
sg32
VC0362046
p3726
sg10
I11
sg11
Vprediabetes
p3727
sg13
I1
sasa(dp3728
g2
S'To investigate the effect of periodontal therapy in controlling periodontitis and on insulin resistance and lipid metabolism in obese rats with periodontitis.\n'
p3729
sg4
(lp3730
(dp3731
g7
I85
sg8
VP01308
p3732
sg10
I7
sg11
Vinsulin
p3733
sg13
I1
sasg29
(lp3734
(dp3735
g7
I128
sg32
VC0028754
p3736
sg10
I5
sg11
Vobese
p3737
sg13
I1
sa(dp3738
g7
I64
sg32
VC0031099
p3739
sg10
I13
sg11
Vperiodontitis
p3740
sg13
I1
sa(dp3741
g7
I64
sg32
VC0031099
p3742
sg10
I13
sg11
Vperiodontitis
p3743
sg13
I1
sa(dp3744
g7
I85
sg32
VC0021655
p3745
sg10
I18
sg11
Vinsulin resistance
p3746
sg13
I2
sasa(dp3747
g2
S"Mutation of arylsulfatase A, arylsulfatase B, ceroid-lipofuscinosis neuronal 3, mucolipin, or Niemann-Pick disease type C1 respectively underlie several diseases of apparently insufficient autophagic flux that affect the eye, including: metachromatic leukodystrophy, mucopolysaccharidosis type VI, juvenile-onset Batten disease, mucolipidosis IV, and Niemann-Pick type C associated with myelin sheath destruction of corneal sensory and ciliary nerves and of the optic nerve; corneal clouding, ocular hypertension, glaucoma and optic nerve atrophy; accumulation of 'ceroid-lipofuscin' in surface conjunctival cells, and in ganglion and neuronal cells; decreased visual acuity and retinal dystrophy; and neurodegeneration.\n"
p3748
sg4
(lp3749
(dp3750
g7
I351
sg8
g48
sg10
I19
sg11
VNiemann-Pick type C
p3751
sg13
I3
sa(dp3752
g7
I12
sg8
VP15289
p3753
sg10
I15
sg11
Varylsulfatase A
p3754
sg13
I2
sa(dp3755
g7
I46
sg8
VP29475
p3756
sg10
I32
sg11
Vceroid-lipofuscinosis neuronal 3
p3757
sg13
I3
sa(dp3758
g7
I80
sg8
g48
sg10
I9
sg11
Vmucolipin
p3759
sg13
I1
sa(dp3760
g7
I29
sg8
VP15848
p3761
sg10
I15
sg11
Varylsulfatase B
p3762
sg13
I2
sasg29
(lp3763
(dp3764
g7
I53
sg32
VC0268279
p3765
sg10
I14
sg11
Vlipofuscinosis
p3766
sg13
I1
sa(dp3767
g7
I679
sg32
VC0854723
p3768
sg10
I17
sg11
Vretinal dystrophy
p3769
sg13
I2
sa(dp3770
g7
I527
sg32
VC0029124
p3771
sg10
I19
sg11
Voptic nerve atrophy
p3772
sg13
I3
sa(dp3773
g7
I267
sg32
VC0026709
p3774
sg10
I29
sg11
Vmucopolysaccharidosis type VI
p3775
sg13
I3
sa(dp3776
g7
I702
sg32
VC0027746
p3777
sg10
I17
sg11
Vneurodegeneration
p3778
sg13
I1
sa(dp3779
g7
I622
sg32
VC1258666
p3780
sg10
I8
sg11
Vganglion
p3781
sg13
I1
sa(dp3782
g7
I329
sg32
VC0238286
p3783
sg10
I16
sg11
Vmucolipidosis IV
p3784
sg13
I2
sa(dp3785
g7
I94
sg32
VC0268242
p3786
sg10
I25
sg11
VNiemann-Pick disease type
p3787
sg13
I3
sa(dp3788
g7
I313
sg32
VC0751383
p3789
sg10
I14
sg11
VBatten disease
p3790
sg13
I2
sa(dp3791
g7
I237
sg32
VC0023522
p3792
sg10
I28
sg11
Vmetachromatic leukodystrophy
p3793
sg13
I2
sa(dp3794
g7
I493
sg32
VC0028840
p3795
sg10
I19
sg11
Vocular hypertension
p3796
sg13
I2
sa(dp3797
g7
I514
sg32
VC0017601
p3798
sg10
I8
sg11
Vglaucoma
p3799
sg13
I1
sasa(dp3800
g2
S'To investigate whether nSR100 misregulation is causally linked to autism, we generated mutant mice with reduced levels of this protein and its target splicing program.\n'
p3801
sg4
(lp3802
sg29
(lp3803
(dp3804
g7
I66
sg32
VC0004352
p3805
sg10
I6
sg11
Vautism
p3806
sg13
I1
sa(dp3807
g7
I87
sg32
VC0596988
p3808
sg10
I6
sg11
Vmutant
p3809
sg13
I1
sasa(dp3810
g2
S'Moreover, increased neuronal activity, which is often associated with autism, results in a rapid decrease in nSR100 and splicing of microexons that significantly overlap those misregulated in autistic brains.\n'
p3811
sg4
(lp3812
sg29
(lp3813
(dp3814
g7
I70
sg32
VC0004352
p3815
sg10
I6
sg11
Vautism
p3816
sg13
I1
sa(dp3817
g7
I192
sg32
VC0004352
p3818
sg10
I8
sg11
Vautistic
p3819
sg13
I1
sasa(dp3820
g2
S'Collectively, our results provide evidence that misregulation of an nSR100-dependent splicing network controlled by changes in neuronal activity is causally linked to a substantial fraction of autism cases.\n'
p3821
sg4
(lp3822
(dp3823
g7
I68
sg8
g48
sg10
I6
sg11
VnSR100
p3824
sg13
I1
sasg29
(lp3825
(dp3826
g7
I193
sg32
VC0004352
p3827
sg10
I6
sg11
Vautism
p3828
sg13
I1
sasa(dp3829
g2
S'Neural microexons are frequently misregulated in the brains of individuals with autism spectrum disorder, and this misregulation is associated with reduced levels of nSR100.\n'
p3830
sg4
(lp3831
(dp3832
g7
I166
sg8
g48
sg10
I6
sg11
VnSR100
p3833
sg13
I1
sasg29
(lp3834
(dp3835
g7
I80
sg32
VC1510586
p3836
sg10
I24
sg11
Vautism spectrum disorder
p3837
sg13
I3
sasa(dp3838
g2
S'These results indicated that rs11134527 in pri-miR-218-2 and rs531564 in pri-miR-124-1 could be associated with CIN and cervical cancer in the Chinese Han population.\n'
p3839
sg4
(lp3840
(dp3841
g7
I73
sg8
VP13489
p3842
sg10
I13
sg11
Vpri-miR-124-1
p3843
sg13
I1
sa(dp3844
g7
I43
sg8
VP13489
p3845
sg10
I13
sg11
Vpri-miR-218-2
p3846
sg13
I1
sasg29
(lp3847
(dp3848
g7
I120
sg32
VC0302592
p3849
sg10
I15
sg11
Vcervical cancer
p3850
sg13
I2
sa(dp3851
g7
I112
sg32
VC0206708
p3852
sg10
I3
sg11
VCIN
p3853
sg13
I1
sasa(dp3854
g2
S'Blood samples were collected from patients with high and low grade gliomas, both before and after surgical resection, and the expression of miR-21, miR-222 and miR-124-3p was measured in exosomes isolated from serum.\n'
p3855
sg4
(lp3856
(dp3857
g7
I160
sg8
g48
sg10
I10
sg11
VmiR-124-3p
p3858
sg13
I1
sa(dp3859
g7
I140
sg8
g48
sg10
I6
sg11
VmiR-21
p3860
sg13
I1
sa(dp3861
g7
I148
sg8
g48
sg10
I7
sg11
VmiR-222
p3862
sg13
I1
sasg29
(lp3863
(dp3864
g7
I67
sg32
VC0017638
p3865
sg10
I7
sg11
Vgliomas
p3866
sg13
I1
sasa(dp3867
g2
S'The expression levels of miR-21, miR-222 and miR-124-3p in serum exosomes of patients with high grade gliomas were significantly higher than those of low grade gliomas and healthy controls and were sharply decreased in samples obtained after surgery.\n'
p3868
sg4
(lp3869
(dp3870
g7
I45
sg8
g48
sg10
I10
sg11
VmiR-124-3p
p3871
sg13
I1
sa(dp3872
g7
I25
sg8
g48
sg10
I6
sg11
VmiR-21
p3873
sg13
I1
sa(dp3874
g7
I33
sg8
g48
sg10
I7
sg11
VmiR-222
p3875
sg13
I1
sasg29
(lp3876
(dp3877
g7
I102
sg32
VC0017638
p3878
sg10
I7
sg11
Vgliomas
p3879
sg13
I1
sa(dp3880
g7
I102
sg32
VC0017638
p3881
sg10
I7
sg11
Vgliomas
p3882
sg13
I1
sasa(dp3883
g2
S'The analysis of miR-21, miR-222 and miR-124-3p in serum exosomes of patients affected by gliomas can provide a minimally invasive and innovative tool to help the differential diagnosis of gliomas at their onset in the brain and predict glioma grading and non glial metastases before surgery.\n'
p3884
sg4
(lp3885
(dp3886
g7
I36
sg8
g48
sg10
I10
sg11
VmiR-124-3p
p3887
sg13
I1
sa(dp3888
g7
I16
sg8
g48
sg10
I6
sg11
VmiR-21
p3889
sg13
I1
sa(dp3890
g7
I24
sg8
g48
sg10
I7
sg11
VmiR-222
p3891
sg13
I1
sasg29
(lp3892
(dp3893
g7
I89
sg32
VC0017638
p3894
sg10
I6
sg11
Vglioma
p3895
sg13
I1
sa(dp3896
g7
I89
sg32
VC0017638
p3897
sg10
I7
sg11
Vgliomas
p3898
sg13
I1
sa(dp3899
g7
I89
sg32
VC0017638
p3900
sg10
I7
sg11
Vgliomas
p3901
sg13
I1
sa(dp3902
g7
I265
sg32
VC0027627
p3903
sg10
I10
sg11
Vmetastases
p3904
sg13
I1
sasa(dp3905
g2
S'In the present study, we investigated the roles of MALAT1 and miR-124 in the regulation of retinoblastoma cell autophagy through evaluating the changes of autophagy-related proteins.\n'
p3906
sg4
(lp3907
(dp3908
g7
I155
sg8
VP02649
p3909
sg10
I26
sg11
Vautophagy-related proteins
p3910
sg13
I2
sa(dp3911
g7
I62
sg8
g48
sg10
I7
sg11
VmiR-124
p3912
sg13
I1
sa(dp3913
g7
I51
sg8
g48
sg10
I6
sg11
VMALAT1
p3914
sg13
I1
sasg29
(lp3915
(dp3916
g7
I91
sg32
VC0035335
p3917
sg10
I14
sg11
Vretinoblastoma
p3918
sg13
I1
sasa(dp3919
g2
S'Through direct targeting miR-124, MALAT1 promotes retinoblastoma cell autophagy.\n'
p3920
sg4
(lp3921
(dp3922
g7
I25
sg8
g48
sg10
I7
sg11
VmiR-124
p3923
sg13
I1
sa(dp3924
g7
I34
sg8
g48
sg10
I6
sg11
VMALAT1
p3925
sg13
I1
sa(dp3926
g7
I50
sg8
g48
sg10
I29
sg11
Vretinoblastoma cell autophagy
p3927
sg13
I3
sasg29
(lp3928
(dp3929
g7
I50
sg32
VC0035335
p3930
sg10
I14
sg11
Vretinoblastoma
p3931
sg13
I1
sasa(dp3932
g2
S'Further, we investigated whether Syntaxin 17 (STX17), a Soluble NSF Attachment Protein receptor of the autophagosome, is involved in MALAT1/miR-124 regulation of retinoblastoma cell autophagy, and the underlying mechanism.\n'
p3933
sg4
(lp3934
(dp3935
g7
I162
sg8
g48
sg10
I29
sg11
Vretinoblastoma cell autophagy
p3936
sg13
I3
sa(dp3937
g7
I33
sg8
VP56962
p3938
sg10
I11
sg11
VSyntaxin 17
p3939
sg13
I2
sa(dp3940
g7
I140
sg8
g48
sg10
I3
sg11
VmiR
p3941
sg13
I1
sa(dp3942
g7
I46
sg8
VP56962
p3943
sg10
I5
sg11
VSTX17
p3944
sg13
I1
sa(dp3945
g7
I133
sg8
g48
sg10
I6
sg11
VMALAT1
p3946
sg13
I1
sa(dp3947
g7
I64
sg8
VP46459
p3948
sg10
I31
sg11
VNSF Attachment Protein receptor
p3949
sg13
I4
sasg29
(lp3950
(dp3951
g7
I162
sg32
VC0035335
p3952
sg10
I14
sg11
Vretinoblastoma
p3953
sg13
I1
sasa(dp3954
g2
S'The present study demonstrated that the protein expression levels of human circadian locomoter output cycles protein kaput (hCLOCK) is significantly increased, while miR-124 is attenuated in high-grade human CRC tissues and in the more invasive colorectal cancer cell lines SW620 and LOVO.\n'
p3955
sg4
(lp3956
(dp3957
g7
I166
sg8
g48
sg10
I7
sg11
VmiR-124
p3958
sg13
I1
sa(dp3959
g7
I124
sg8
g48
sg10
I6
sg11
VhCLOCK
p3960
sg13
I1
sa(dp3961
g7
I69
sg8
g48
sg10
I53
sg11
Vhuman circadian locomoter output cycles protein kaput
p3962
sg13
I7
sasg29
(lp3963
(dp3964
g7
I208
sg32
VC1527249
p3965
sg10
I3
sg11
VCRC
p3966
sg13
I1
sa(dp3967
g7
I245
sg32
VC1527249
p3968
sg10
I17
sg11
Vcolorectal cancer
p3969
sg13
I2
sasa(dp3970
g2
S'This study investigated 15-PGDH expression in gastric adenocarcinoma, the associations between 15-PGDH expression and clinicopathological factors, and the correlation between 15-PGDH expression and the 5-year gastric-cancer-specific survival rate (5-year GCSS).\n'
p3971
sg4
(lp3972
sg29
(lp3973
(dp3974
g7
I217
sg32
VC0006826
p3975
sg10
I6
sg11
Vcancer
p3976
sg13
I1
sa(dp3977
g7
I46
sg32
VC0278701
p3978
sg10
I22
sg11
Vgastric adenocarcinoma
p3979
sg13
I2
sasa(dp3980
g2
S'Our findings indicate that 15-PGDH expression was low in gastric adenocarcinoma and was correlated with the clinicopathological factors associated with prognosis and a more advanced stage of gastric adenocarcinoma.\n'
p3981
sg4
(lp3982
sg29
(lp3983
(dp3984
g7
I57
sg32
VC0278701
p3985
sg10
I22
sg11
Vgastric adenocarcinoma
p3986
sg13
I2
sa(dp3987
g7
I57
sg32
VC0278701
p3988
sg10
I22
sg11
Vgastric adenocarcinoma
p3989
sg13
I2
sasa(dp3990
g2
S'The aim of this study was to investigate the expression of 15-PGDH in gastric adenocarcinoma tissue and the relationship between 15-PGDH expression and clinicopathologic features of gastric adenocarcinoma.\n'
p3991
sg4
(lp3992
sg29
(lp3993
(dp3994
g7
I70
sg32
VC0278701
p3995
sg10
I22
sg11
Vgastric adenocarcinoma
p3996
sg13
I2
sa(dp3997
g7
I70
sg32
VC0278701
p3998
sg10
I22
sg11
Vgastric adenocarcinoma
p3999
sg13
I2
sasa(dp4000
g2
S'In 62 patients (62.6%), 15-PGDH expression was lower in gastric adenocarcinoma tissue than in nonneoplastic tissue.\n'
p4001
sg4
(lp4002
sg29
(lp4003
(dp4004
g7
I56
sg32
VC0278701
p4005
sg10
I22
sg11
Vgastric adenocarcinoma
p4006
sg13
I2
sasa(dp4007
g2
S'We determined the correlations between pattern of expression of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a catabolic enzyme for biological inactivation of PGE(2), in gastric adenocarcinoma and various clinicopathological factors and patient outcome in an attempt to elucidate its biological significance.\n'
p4008
sg4
(lp4009
(dp4010
g7
I64
sg8
VP49366
p4011
sg10
I37
sg11
V15-hydroxyprostaglandin dehydrogenase
p4012
sg13
I2
sa(dp4013
g7
I103
sg8
VP52209
p4014
sg10
I7
sg11
V15-PGDH
p4015
sg13
I1
sasg29
(lp4016
(dp4017
g7
I147
sg32
VC0544461
p4018
sg10
I12
sg11
Vinactivation
p4019
sg13
I1
sa(dp4020
g7
I174
sg32
VC0278701
p4021
sg10
I22
sg11
Vgastric adenocarcinoma
p4022
sg13
I2
sasa(dp4023
g2
S'In 35 of 71 cases of gastric adenocarcinoma, expression of 15-PGDH protein was reduced in tumor tissues.\n'
p4024
sg4
(lp4025
(dp4026
g7
I59
sg8
VP52209
p4027
sg10
I15
sg11
V15-PGDH protein
p4028
sg13
I2
sasg29
(lp4029
(dp4030
g7
I90
sg32
VC0027651
p4031
sg10
I5
sg11
Vtumor
p4032
sg13
I1
sa(dp4033
g7
I21
sg32
VC0278701
p4034
sg10
I22
sg11
Vgastric adenocarcinoma
p4035
sg13
I2
sasa(dp4036
g2
S'These findings suggest that reduction of 15-PGDH is an independent predictor of poor survival associated with enhancement of cell proliferation in gastric adenocarcinoma.\n'
p4037
sg4
(lp4038
sg29
(lp4039
(dp4040
g7
I147
sg32
VC0278701
p4041
sg10
I22
sg11
Vgastric adenocarcinoma
p4042
sg13
I2
sa(dp4043
g7
I130
sg32
VC0334094
p4044
sg10
I13
sg11
Vproliferation
p4045
sg13
I1
sasa(dp4046
g2
S'Clinical gastric adenocarcinoma samples were analyzed by immunohistochemistry and quantitative real-time PCR for protein and mRNA expression of 15-PGDH and for methylation status of 15-PGDH promoter.\n'
p4047
sg4
(lp4048
sg29
(lp4049
(dp4050
g7
I9
sg32
VC0278701
p4051
sg10
I22
sg11
Vgastric adenocarcinoma
p4052
sg13
I2
sasa(dp4053
g2
S'In clinical gastric adenocarcinoma specimens, 15-PGDH mRNA levels were 5-fold lower in gastric cancer samples when compared with paired nonneoplastic tissues (n = 26) and 15-PGDH protein was lost in 65% of gastric adenocarcinomas (n = 210).\n'
p4054
sg4
(lp4055
(dp4056
g7
I171
sg8
VP52209
p4057
sg10
I15
sg11
V15-PGDH protein
p4058
sg13
I2
sasg29
(lp4059
(dp4060
g7
I214
sg32
VC0001418
p4061
sg10
I15
sg11
Vadenocarcinomas
p4062
sg13
I1
sa(dp4063
g7
I87
sg32
VC0024623
p4064
sg10
I14
sg11
Vgastric cancer
p4065
sg13
I2
sa(dp4066
g7
I12
sg32
VC0278701
p4067
sg10
I22
sg11
Vgastric adenocarcinoma
p4068
sg13
I2
sasa(dp4069
g2
S'Our findings suggest that we have cloned the long-sought RP3 gene, and that it may encode the GEF of a retina-specific GTP-binding protein.\n'
p4070
sg4
(lp4071
(dp4072
g7
I103
sg8
g48
sg10
I35
sg11
Vretina-specific GTP-binding protein
p4073
sg13
I3
sa(dp4074
g7
I94
sg8
VP10911
p4075
sg10
I3
sg11
VGEF
p4076
sg13
I1
sa(dp4077
g7
I45
sg8
VP51808
p4078
sg10
I20
sg11
Vlong-sought RP3 gene
p4079
sg13
I3
sasg29
(lp4080
(dp4081
g7
I57
sg32
VC1845667
p4082
sg10
I3
sg11
VRP3
p4083
sg13
I1
sasa(dp4084
g2
S'These experiments suggest that in the rod photoreceptors of patients with retinitis pigmentosa carrying a mutation at Lys-296, there is persistent activation of the GTP-binding protein-mediated cascade.\n'
p4085
sg4
(lp4086
(dp4087
g7
I165
sg8
VP61019
p4088
sg10
I19
sg11
VGTP-binding protein
p4089
sg13
I2
sasg29
(lp4090
(dp4091
g7
I74
sg32
VC0035334
p4092
sg10
I20
sg11
Vretinitis pigmentosa
p4093
sg13
I2
sasa(dp4094
g2
S'These results indicate that the abilities of PGD2 analogues to stimulate the adenylate cyclase of the iris-ciliary body complex in GTP-dependent manner are highly correlated with their ocular hypotensive activities, and suggest that a PGD2 receptor-stimulatory GTP-binding protein-adenylate cyclase complex is involved in the PGD2-induced ocular hypotension.\n'
p4095
sg4
(lp4096
(dp4097
g7
I235
sg8
g48
sg10
I71
sg11
VPGD2 receptor-stimulatory GTP-binding protein-adenylate cyclase complex
p4098
sg13
I6
sa(dp4099
g7
I45
sg8
VP41222
p4100
sg10
I4
sg11
VPGD2
p4101
sg13
I1
sa(dp4102
g7
I45
sg8
VP41222
p4103
sg10
I4
sg11
VPGD2
p4104
sg13
I1
sa(dp4105
g7
I77
sg8
g48
sg10
I17
sg11
Vadenylate cyclase
p4106
sg13
I2
sasg29
(lp4107
(dp4108
g7
I339
sg32
VC0028841
p4109
sg10
I18
sg11
Vocular hypotension
p4110
sg13
I2
sa(dp4111
g7
I192
sg32
VC0857353
p4112
sg10
I11
sg11
Vhypotensive
p4113
sg13
I1
sasa(dp4114
g2
S'Preincubation of human trophoblastic cells with 0.1 microgram/ml Islet-Activating-Protein (IAP; also called pertussis toxin) did not modify basal adenylate cyclase activity but abolished the inhibition of adenylate cyclase activity by EKC, indicating that the effect of opiates on cAMP production was mediated by an IAP-sensitive GTP binding protein.\n'
p4115
sg4
(lp4116
(dp4117
g7
I235
sg8
g48
sg10
I3
sg11
VEKC
p4118
sg13
I1
sa(dp4119
g7
I316
sg8
VP37268
p4120
sg10
I33
sg11
VIAP-sensitive GTP binding protein
p4121
sg13
I4
sa(dp4122
g7
I146
sg8
g48
sg10
I17
sg11
Vadenylate cyclase
p4123
sg13
I2
sa(dp4124
g7
I65
sg8
VP10997
p4125
sg10
I24
sg11
VIslet-Activating-Protein
p4126
sg13
I1
sa(dp4127
g7
I91
sg8
VP10997
p4128
sg10
I3
sg11
VIAP
p4129
sg13
I1
sa(dp4130
g7
I108
sg8
g48
sg10
I15
sg11
Vpertussis toxin
p4131
sg13
I2
sa(dp4132
g7
I146
sg8
g48
sg10
I17
sg11
Vadenylate cyclase
p4133
sg13
I2
sasg29
(lp4134
(dp4135
g7
I270
sg32
VC0029095
p4136
sg10
I7
sg11
Vopiates
p4137
sg13
I1
sa(dp4138
g7
I108
sg32
VC0043167
p4139
sg10
I9
sg11
Vpertussis
p4140
sg13
I1
sa(dp4141
g7
I235
sg32
VC0014493
p4142
sg10
I3
sg11
VEKC
p4143
sg13
I1
sasa(dp4144
g2
S"LINGO2, a member of LRR gene family, has been linked with both Essential tremor (ET) and Parkinson's disease (PD).\n"
p4145
sg4
(lp4146
(dp4147
g7
I20
sg8
VP22888
p4148
sg10
I15
sg11
VLRR gene family
p4149
sg13
I3
sa(dp4150
g7
I0
sg8
g48
sg10
I6
sg11
VLINGO2
p4151
sg13
I1
sasg29
(lp4152
(dp4153
g7
I110
sg32
VC0030567
p4154
sg10
I2
sg11
VPD
p4155
sg13
I1
sa(dp4156
g7
I81
sg32
VC0270736
p4157
sg10
I2
sg11
VET
p4158
sg13
I1
sa(dp4159
g7
I63
sg32
VC0270736
p4160
sg10
I16
sg11
VEssential tremor
p4161
sg13
I2
sa(dp4162
g7
I89
sg32
VC0030567
p4163
sg10
I19
sg11
VParkinson's disease
p4164
sg13
I2
sasa(dp4165
g2
S'We previously reported that CD109-deficient mice exhibit epidermal hyperplasia and chronic skin inflammation.\n'
p4166
sg4
(lp4167
sg29
(lp4168
(dp4169
g7
I91
sg32
VC0011603
p4170
sg10
I17
sg11
Vskin inflammation
p4171
sg13
I2
sa(dp4172
g7
I57
sg32
VC1707929
p4173
sg10
I21
sg11
Vepidermal hyperplasia
p4174
sg13
I2
sasa(dp4175
g2
S'In this study, we investigated the role of CD109 in skin tumorigenesis using a two-stage carcinogenesis model in CD109-deficient mice with chronic skin inflammation.\n'
p4176
sg4
(lp4177
sg29
(lp4178
(dp4179
g7
I57
sg32
VC0007621
p4180
sg10
I13
sg11
Vtumorigenesis
p4181
sg13
I1
sa(dp4182
g7
I89
sg32
VC0596263
p4183
sg10
I14
sg11
Vcarcinogenesis
p4184
sg13
I1
sa(dp4185
g7
I147
sg32
VC0011603
p4186
sg10
I17
sg11
Vskin inflammation
p4187
sg13
I2
sasa(dp4188
g2
S'CD109, a novel TGF-Beta co-receptor, which inhibits TGF-Beta signaling by enhancing Smad7-dependent degradation of TGF-Beta type I receptor (TGF-Beta RI), is abnormally expressed in psoriasis.\n'
p4189
sg4
(lp4190
(dp4191
g7
I141
sg8
VP18075
p4192
sg10
I11
sg11
VTGF-Beta RI
p4193
sg13
I2
sa(dp4194
g7
I15
sg8
VP18075
p4195
sg10
I20
sg11
VTGF-Beta co-receptor
p4196
sg13
I2
sa(dp4197
g7
I52
sg8
VP18075
p4198
sg10
I87
sg11
VTGF-Beta signaling by enhancing Smad7-dependent degradation of TGF-Beta type I receptor
p4199
sg13
I11
sasg29
(lp4200
(dp4201
g7
I182
sg32
VC0033860
p4202
sg10
I9
sg11
Vpsoriasis
p4203
sg13
I1
sasa(dp4204
g2
S'To date, the expression of Smad7 and the correlation between CD109 and Smad7 expression in psoriasis have not been fully elucidated.\n'
p4205
sg4
(lp4206
(dp4207
g7
I27
sg8
g48
sg10
I5
sg11
VSmad7
p4208
sg13
I1
sa(dp4209
g7
I27
sg8
g48
sg10
I5
sg11
VSmad7
p4210
sg13
I1
sasg29
(lp4211
(dp4212
g7
I91
sg32
VC0033860
p4213
sg10
I9
sg11
Vpsoriasis
p4214
sg13
I1
sasa(dp4215
g2
S'This study was designed to investigate the expression and the correlation of CD109 and TGF-Beta signaling associated proteins in psoriasis and their roles in the pathogenesis of psoriasis.\n'
p4216
sg4
(lp4217
(dp4218
g7
I87
sg8
VP18075
p4219
sg10
I8
sg11
VTGF-Beta
p4220
sg13
I1
sasg29
(lp4221
(dp4222
g7
I162
sg32
VC0699748
p4223
sg10
I12
sg11
Vpathogenesis
p4224
sg13
I1
sa(dp4225
g7
I129
sg32
VC0033860
p4226
sg10
I9
sg11
Vpsoriasis
p4227
sg13
I1
sa(dp4228
g7
I129
sg32
VC0033860
p4229
sg10
I9
sg11
Vpsoriasis
p4230
sg13
I1
sasa(dp4231
g2
S'Thirty-two psoriasis specimens were subjected to immunohistochemical staining for CD109, Smad7, TGF-Beta RI and Ki67.\n'
p4232
sg4
(lp4233
(dp4234
g7
I96
sg8
VP18075
p4235
sg10
I11
sg11
VTGF-Beta RI
p4236
sg13
I2
sa(dp4237
g7
I112
sg8
VP46013
p4238
sg10
I4
sg11
VKi67
p4239
sg13
I1
sa(dp4240
g7
I89
sg8
g48
sg10
I5
sg11
VSmad7
p4241
sg13
I1
sasg29
(lp4242
(dp4243
g7
I11
sg32
VC0033860
p4244
sg10
I9
sg11
Vpsoriasis
p4245
sg13
I1
sasa(dp4246
g2
S'The positive expression rate (% positive cells) of Smad7 and Ki67 in psoriasis was significantly higher than in NS (62.6%+/-19.9% vs. 17.2%+/-4.4%, and 50.7%+/-14.3% vs. 19.5%+/-3.2%, respectively, P&lt;0.001), and the expression levels of CD109 and TGF-Beta RI were reduced significantly in psoriasis as compared with NS (8.1%+/-6.7% vs. 35.8%+/-6.7% and 27.3%+/-3.4% vs. 3.0%+/-3.4%, respectively, P&lt;0.001).\n'
p4247
sg4
(lp4248
(dp4249
g7
I61
sg8
VP46013
p4250
sg10
I4
sg11
VKi67
p4251
sg13
I1
sa(dp4252
g7
I51
sg8
g48
sg10
I5
sg11
VSmad7
p4253
sg13
I1
sa(dp4254
g7
I250
sg8
VP18075
p4255
sg10
I11
sg11
VTGF-Beta RI
p4256
sg13
I2
sasg29
(lp4257
(dp4258
g7
I69
sg32
VC0033860
p4259
sg10
I9
sg11
Vpsoriasis
p4260
sg13
I1
sa(dp4261
g7
I69
sg32
VC0033860
p4262
sg10
I9
sg11
Vpsoriasis
p4263
sg13
I1
sasa(dp4264
g2
S'These findings indicated that CD109 might play a certain role in the pathogenesis of psoriasis.\n'
p4265
sg4
(lp4266
sg29
(lp4267
(dp4268
g7
I85
sg32
VC0033860
p4269
sg10
I9
sg11
Vpsoriasis
p4270
sg13
I1
sa(dp4271
g7
I69
sg32
VC0699748
p4272
sg10
I12
sg11
Vpathogenesis
p4273
sg13
I1
sasa(dp4274
g2
S'Lower expression of CD109 and TGF-Beta RI was highly correlated with higher expression of Smad7 and Ki67, suggesting that CD109 may induce the pathogenesis of psoriasis through Smad7-mediated degradation of TGF-Beta RI, and lead to the termination of TGF-Beta signaling.\n'
p4275
sg4
(lp4276
(dp4277
g7
I30
sg8
VP18075
p4278
sg10
I8
sg11
VTGF-Beta
p4279
sg13
I1
sa(dp4280
g7
I30
sg8
VP18075
p4281
sg10
I11
sg11
VTGF-Beta RI
p4282
sg13
I2
sa(dp4283
g7
I30
sg8
VP18075
p4284
sg10
I11
sg11
VTGF-Beta RI
p4285
sg13
I2
sa(dp4286
g7
I90
sg8
g48
sg10
I5
sg11
VSmad7
p4287
sg13
I1
sa(dp4288
g7
I90
sg8
g48
sg10
I5
sg11
VSmad7
p4289
sg13
I1
sa(dp4290
g7
I100
sg8
VP46013
p4291
sg10
I4
sg11
VKi67
p4292
sg13
I1
sasg29
(lp4293
(dp4294
g7
I143
sg32
VC0699748
p4295
sg10
I12
sg11
Vpathogenesis
p4296
sg13
I1
sa(dp4297
g7
I159
sg32
VC0033860
p4298
sg10
I9
sg11
Vpsoriasis
p4299
sg13
I1
sasa(dp4300
g2
S'Moreover, these effects are associated with an increase in phospho-STAT3 levels, enhanced total STAT3 and Bcl-2 expression and an increase in cell growth and survival, suggesting that released/soluble CD109 is able to induce molecular changes that are known to occur in psoriasis.\n'
p4301
sg4
(lp4302
(dp4303
g7
I67
sg8
VP40763
p4304
sg10
I5
sg11
VSTAT3
p4305
sg13
I1
sa(dp4306
g7
I106
sg8
VP10415
p4307
sg10
I5
sg11
VBcl-2
p4308
sg13
I1
sa(dp4309
g7
I67
sg8
VP40763
p4310
sg10
I5
sg11
VSTAT3
p4311
sg13
I1
sasg29
(lp4312
(dp4313
g7
I270
sg32
VC0033860
p4314
sg10
I9
sg11
Vpsoriasis
p4315
sg13
I1
sasa(dp4316
g2
S'Analysis of CD109 expression in psoriasis patients reveals that CD109 protein expression is markedly decreased in psoriatic epidermis as compared to adjacent uninvolved skin.\n'
p4317
sg4
(lp4318
sg29
(lp4319
(dp4320
g7
I32
sg32
VC0033860
p4321
sg10
I9
sg11
Vpsoriasis
p4322
sg13
I1
sasa(dp4323
g2
S'Together our findings suggest that aberrant CD109 release from the cell surface in human keratinocytes may induce molecular changes that are usually observed in psoriasis and may explain TGF-Beta receptor downregulation and decrease in TGF-Beta signalling in psoriasis.\n'
p4324
sg4
(lp4325
(dp4326
g7
I187
sg8
VP18075
p4327
sg10
I17
sg11
VTGF-Beta receptor
p4328
sg13
I2
sa(dp4329
g7
I187
sg8
VP18075
p4330
sg10
I8
sg11
VTGF-Beta
p4331
sg13
I1
sasg29
(lp4332
(dp4333
g7
I161
sg32
VC0033860
p4334
sg10
I9
sg11
Vpsoriasis
p4335
sg13
I1
sa(dp4336
g7
I161
sg32
VC0033860
p4337
sg10
I9
sg11
Vpsoriasis
p4338
sg13
I1
sasa(dp4339
g2
S'We report a case of allergic bronchopulmonary aspergillosis (ABPA) that occurred in a man receiving infliximab for systemic sarcoidosis.\n'
p4340
sg4
(lp4341
sg29
(lp4342
(dp4343
g7
I61
sg32
VC0004031
p4344
sg10
I4
sg11
VABPA
p4345
sg13
I1
sa(dp4346
g7
I124
sg32
VC0036202
p4347
sg10
I11
sg11
Vsarcoidosis
p4348
sg13
I1
sa(dp4349
g7
I20
sg32
VC0004031
p4350
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p4351
sg13
I3
sasa(dp4352
g2
S'To investigate the effect of antithrombin III (AT III) on retinal ischemia/reperfusion (I/R) injury in rats.\n'
p4353
sg4
(lp4354
(dp4355
g7
I47
sg8
VP05546
p4356
sg10
I6
sg11
VAT III
p4357
sg13
I2
sa(dp4358
g7
I29
sg8
VP05546
p4359
sg10
I16
sg11
Vantithrombin III
p4360
sg13
I2
sasg29
(lp4361
(dp4362
g7
I58
sg32
VC0162291
p4363
sg10
I16
sg11
Vretinal ischemia
p4364
sg13
I2
sasa(dp4365
g2
S'PMM2-CDG is a rare metabolic disease, and the diagnosis should be considered in a child with developmental delay, elevated serum transaminases, decreased antithrombin III activity, inverted nipples, abnormal subcutaneous fat pads, esotropia, and cerebellar atrophy on MRI.\n'
p4366
sg4
(lp4367
(dp4368
g7
I154
sg8
VP05546
p4369
sg10
I16
sg11
Vantithrombin III
p4370
sg13
I2
sa(dp4371
g7
I5
sg8
g48
sg10
I3
sg11
VCDG
p4372
sg13
I1
sa(dp4373
g7
I0
sg8
g48
sg10
I4
sg11
VPMM2
p4374
sg13
I1
sasg29
(lp4375
(dp4376
g7
I93
sg32
VC0424605
p4377
sg10
I19
sg11
Vdevelopmental delay
p4378
sg13
I2
sa(dp4379
g7
I19
sg32
VC0025517
p4380
sg10
I17
sg11
Vmetabolic disease
p4381
sg13
I2
sa(dp4382
g7
I246
sg32
VC0740279
p4383
sg10
I18
sg11
Vcerebellar atrophy
p4384
sg13
I2
sa(dp4385
g7
I181
sg32
VC0269269
p4386
sg10
I16
sg11
Vinverted nipples
p4387
sg13
I2
sa(dp4388
g7
I231
sg32
VC0014877
p4389
sg10
I9
sg11
Vesotropia
p4390
sg13
I1
sasa(dp4391
g2
S'Using stringent filtering criteria, Apolipoprotein A-IV (APOA-IV), Albumin and Antithrombin 3 (ANT3) were detected at significantly higher levels in PCG AH compared to control, whereas Transthyretin (TTR), Prostaglandin-H2 D-isomerase (PTGDS), Opticin (OPT) and Interphotoreceptor Retinoid Binding Protein (IRBP) were detected at significantly lower levels.\n'
p4392
sg4
(lp4393
(dp4394
g7
I307
sg8
VP48200
p4395
sg10
I4
sg11
VIRBP
p4396
sg13
I1
sa(dp4397
g7
I206
sg8
VP41222
p4398
sg10
I28
sg11
VProstaglandin-H2 D-isomerase
p4399
sg13
I2
sa(dp4400
g7
I57
sg8
VP06727
p4401
sg10
I7
sg11
VAPOA-IV
p4402
sg13
I1
sa(dp4403
g7
I95
sg8
VP12236
p4404
sg10
I4
sg11
VANT3
p4405
sg13
I1
sa(dp4406
g7
I36
sg8
VP08519
p4407
sg10
I19
sg11
VApolipoprotein A-IV
p4408
sg13
I2
sa(dp4409
g7
I200
sg8
VP02766
p4410
sg10
I3
sg11
VTTR
p4411
sg13
I1
sa(dp4412
g7
I262
sg8
VP48200
p4413
sg10
I43
sg11
VInterphotoreceptor Retinoid Binding Protein
p4414
sg13
I4
sa(dp4415
g7
I67
sg8
VP00441
p4416
sg10
I7
sg11
VAlbumin
p4417
sg13
I1
sa(dp4418
g7
I185
sg8
VP02766
p4419
sg10
I13
sg11
VTransthyretin
p4420
sg13
I1
sa(dp4421
g7
I79
sg8
VP05546
p4422
sg10
I14
sg11
VAntithrombin 3
p4423
sg13
I2
sa(dp4424
g7
I236
sg8
VP41222
p4425
sg10
I5
sg11
VPTGDS
p4426
sg13
I1
sasg29
(lp4427
sa(dp4428
g2
S'However, the overall OR for the CCR5-Delta32 allele was significantly higher in Kawasaki disease (KD; OR 1.746, 95 % CI 1.003-2.955, p = 0.038) and the meta-analysis of the Delta32Delta32 + Delta32 W genotype showed a trend indicating an association with KD (OR 1.683, 95 % CI 0.921-3.077, p = 0.091).\n'
p4429
sg4
(lp4430
(dp4431
g7
I32
sg8
VP32302
p4432
sg10
I19
sg11
VCCR5-Delta32 allele
p4433
sg13
I2
sasg29
(lp4434
(dp4435
g7
I98
sg32
VC0026691
p4436
sg10
I2
sg11
VKD
p4437
sg13
I1
sa(dp4438
g7
I80
sg32
VC0026691
p4439
sg10
I16
sg11
VKawasaki disease
p4440
sg13
I2
sa(dp4441
g7
I98
sg32
VC0026691
p4442
sg10
I2
sg11
VKD
p4443
sg13
I1
sasa(dp4444
g2
S'We present data on the differences in BMNP levels in health and disease (cancer, neurodegenerative disorders, and atherosclerosis), and discuss the existing hypotheses on the biological functions of BMNPs, with special attention paid to the role of the ferritin core and apoferritin.\n'
p4445
sg4
(lp4446
(dp4447
g7
I253
sg8
VP02794
p4448
sg10
I13
sg11
Vferritin core
p4449
sg13
I2
sa(dp4450
g7
I271
sg8
VP02794
p4451
sg10
I11
sg11
Vapoferritin
p4452
sg13
I1
sasg29
(lp4453
(dp4454
g7
I114
sg32
VC0004153
p4455
sg10
I15
sg11
Vatherosclerosis
p4456
sg13
I1
sa(dp4457
g7
I73
sg32
VC0006826
p4458
sg10
I6
sg11
Vcancer
p4459
sg13
I1
sa(dp4460
g7
I81
sg32
VC0524851
p4461
sg10
I27
sg11
Vneurodegenerative disorders
p4462
sg13
I2
sasa(dp4463
g2
S'Another study cited a 9.9% reoperation rate for ASD 1 year following PLIF; this increased to 80% at 5 postoperative years.\n'
p4464
sg4
(lp4465
(dp4466
g7
I48
sg8
VP51689
p4467
sg10
I5
sg11
VASD 1
p4468
sg13
I2
sasg29
(lp4469
(dp4470
g7
I48
sg32
VC1510586
p4471
sg10
I3
sg11
VASD
p4472
sg13
I1
sasa(dp4473
g2
S'Independent risk factors for nonattendance were: (i) age &lt;30 years (odds ratio (OR) 7.2; 95% CI: 3.2-16.3 versus &gt;=50 years); (ii) African region of origin (OR 2.8; 95% CI: 1.5-5.0 versus Western origin); (iii) having children &lt;12 years of age (OR 2.1; 95% CI: 1.1-4.1); (iv) history of drugs- or alcohol abuse (OR 4.4; 95% CI: 1.8-10.8); (v) no cART (OR 2.5; 95% CI: 1.1-5.3) or HIV-RNA &gt;400 copies/ml while receiving cART (OR 3.5; 95% CI: 1.3-9.6).\n'
p4474
sg4
(lp4475
sg29
(lp4476
(dp4477
g7
I389
sg32
VC0019693
p4478
sg10
I3
sg11
VHIV
p4479
sg13
I1
sa(dp4480
g7
I306
sg32
VC0085762
p4481
sg10
I13
sg11
Valcohol abuse
p4482
sg13
I2
sasa(dp4483
g2
S'These included age, sex, transmission route, smoking, alcohol abuse, prior AIDS diagnosis, duration of exposure to cART, and estimated duration of human immunodeficiency virus infection.\n'
p4484
sg4
(lp4485
sg29
(lp4486
(dp4487
g7
I147
sg32
VC0019693
p4488
sg10
I38
sg11
Vhuman immunodeficiency virus infection
p4489
sg13
I4
sa(dp4490
g7
I54
sg32
VC0085762
p4491
sg10
I13
sg11
Valcohol abuse
p4492
sg13
I2
sasa(dp4493
g2
S'Mutation in DnaJC19 results in dilated cardiomyopathy and ataxia syndrome, whereas expression of DnaJC15 regulates the response of cancer cells to chemotherapy.\n'
p4494
sg4
(lp4495
(dp4496
g7
I97
sg8
g48
sg10
I7
sg11
VDnaJC15
p4497
sg13
I1
sa(dp4498
g7
I12
sg8
g48
sg10
I7
sg11
VDnaJC19
p4499
sg13
I1
sasg29
(lp4500
(dp4501
g7
I131
sg32
VC0006826
p4502
sg10
I6
sg11
Vcancer
p4503
sg13
I1
sa(dp4504
g7
I65
sg32
VC0039082
p4505
sg10
I8
sg11
Vsyndrome
p4506
sg13
I1
sa(dp4507
g7
I58
sg32
VC0004134
p4508
sg10
I6
sg11
Vataxia
p4509
sg13
I1
sa(dp4510
g7
I31
sg32
VC0007193
p4511
sg10
I22
sg11
Vdilated cardiomyopathy
p4512
sg13
I2
sasa(dp4513
g2
S'Methylation-controlled J protein (MCJ, also known as DNAJC15) is a negative regulator of mitochondrial respiration and has been associated with chemotherapeutic drug sensitivity in cancer cell lines.\n'
p4514
sg4
(lp4515
(dp4516
g7
I34
sg8
g48
sg10
I3
sg11
VMCJ
p4517
sg13
I1
sa(dp4518
g7
I0
sg8
g48
sg10
I32
sg11
VMethylation-controlled J protein
p4519
sg13
I3
sasg29
(lp4520
(dp4521
g7
I181
sg32
VC0006826
p4522
sg10
I6
sg11
Vcancer
p4523
sg13
I1
sasa(dp4524
g2
S'Here we show, in a retrospective study of a large cohort of breast cancer patients, that low MCJ expression in breast tumors predicts high risk of relapse in patients treated with chemotherapy; however, MCJ expression does not correlate with response to endocrine therapy.\n'
p4525
sg4
(lp4526
sg29
(lp4527
(dp4528
g7
I60
sg32
VC0678222
p4529
sg10
I13
sg11
Vbreast cancer
p4530
sg13
I2
sa(dp4531
g7
I111
sg32
VC1458155
p4532
sg10
I13
sg11
Vbreast tumors
p4533
sg13
I2
sa(dp4534
g7
I147
sg32
VC0277556
p4535
sg10
I7
sg11
Vrelapse
p4536
sg13
I1
sasa(dp4537
g2
S'In a prospective study in breast cancer patients undergoing neoadjuvant therapy, low MCJ expression also correlates with poor clinical response to chemotherapy and decreased disease-free survival.\n'
p4538
sg4
(lp4539
sg29
(lp4540
(dp4541
g7
I26
sg32
VC0678222
p4542
sg10
I13
sg11
Vbreast cancer
p4543
sg13
I2
sasa(dp4544
g2
S'Using MCJ-deficient mice, we demonstrate that lack of MCJ is sufficient to induce mammary tumor chemoresistance in vivo.\n'
p4545
sg4
(lp4546
sg29
(lp4547
(dp4548
g7
I82
sg32
VC1458155
p4549
sg10
I13
sg11
Vmammary tumor
p4550
sg13
I2
sasa(dp4551
g2
S'CpG island methylation in cancer cells constitutes the only mechanism identified for the regulation of MCJ gene expression.\n'
p4552
sg4
(lp4553
(dp4554
g7
I103
sg8
g48
sg10
I8
sg11
VMCJ gene
p4555
sg13
I2
sasg29
(lp4556
(dp4557
g7
I26
sg32
VC0006826
p4558
sg10
I6
sg11
Vcancer
p4559
sg13
I1
sasa(dp4560
g2
S'Reduced expression of a mitochondrial J-protein DnaJC15 was associated with the development of chemoresistance in ovarian cancer cells.\n'
p4561
sg4
(lp4562
(dp4563
g7
I24
sg8
g48
sg10
I31
sg11
Vmitochondrial J-protein DnaJC15
p4564
sg13
I3
sasg29
(lp4565
(dp4566
g7
I114
sg32
VC1140680
p4567
sg10
I14
sg11
Vovarian cancer
p4568
sg13
I2
sasa(dp4569
g2
S'In the present study, we have provided evidence towards a novel function of DnaJC15 in regulation of mitochondrial permeability transition pore (MPTP) complex in normal and cancer cells.\n'
p4570
sg4
(lp4571
(dp4572
g7
I76
sg8
g48
sg10
I7
sg11
VDnaJC15
p4573
sg13
I1
sasg29
(lp4574
(dp4575
g7
I173
sg32
VC0006826
p4576
sg10
I6
sg11
Vcancer
p4577
sg13
I1
sa(dp4578
g7
I128
sg32
VC0599156
p4579
sg10
I10
sg11
Vtransition
p4580
sg13
I1
sasa(dp4581
g2
S'Hypermethylation-mediated transcriptional silencing of the MCJ gene has been associated with increased chemotherapeutic resistance in ovarian cancer.\n'
p4582
sg4
(lp4583
(dp4584
g7
I59
sg8
g48
sg10
I8
sg11
VMCJ gene
p4585
sg13
I2
sasg29
(lp4586
(dp4587
g7
I134
sg32
VC1140680
p4588
sg10
I14
sg11
Vovarian cancer
p4589
sg13
I2
sasa(dp4590
g2
S'MCJ is expressed in drug-sensitive breast cancer cells but not in multidrug-resistant cells.\n'
p4591
sg4
(lp4592
(dp4593
g7
I0
sg8
g48
sg10
I3
sg11
VMCJ
p4594
sg13
I1
sasg29
(lp4595
(dp4596
g7
I35
sg32
VC0678222
p4597
sg10
I13
sg11
Vbreast cancer
p4598
sg13
I2
sasa(dp4599
g2
S'To detect different expression patterns between the originally reported MCJ transcript and the LTR-related transcript, we performed a RT-PCR approach using various human tissues and cancer cells.\n'
p4600
sg4
(lp4601
(dp4602
g7
I95
sg8
g48
sg10
I22
sg11
VLTR-related transcript
p4603
sg13
I2
sasg29
(lp4604
(dp4605
g7
I182
sg32
VC0006826
p4606
sg10
I6
sg11
Vcancer
p4607
sg13
I1
sasa(dp4608
g2
S'The original MCJ transcript was detected in human tissues and cancer cells, whereas the LTR-related transcript was only revealed in some cancer cells (HCT106, MCF-3, TE-1, Hela, and CCHM).\n'
p4609
sg4
(lp4610
(dp4611
g7
I13
sg8
g48
sg10
I14
sg11
VMCJ transcript
p4612
sg13
I2
sa(dp4613
g7
I88
sg8
g48
sg10
I22
sg11
VLTR-related transcript
p4614
sg13
I2
sasg29
(lp4615
(dp4616
g7
I62
sg32
VC0006826
p4617
sg10
I6
sg11
Vcancer
p4618
sg13
I1
sa(dp4619
g7
I62
sg32
VC0006826
p4620
sg10
I6
sg11
Vcancer
p4621
sg13
I1
sasa(dp4622
g2
S"5'CpG of BCL2L10 and DNAJD1 was hypermethylated in 4 of 5 gastric cancer cell lines, whereas 5'CpG of DKK1 was hypermethylated in only 1 cell line.\n"
p4623
sg4
(lp4624
(dp4625
g7
I102
sg8
g48
sg10
I4
sg11
VDKK1
p4626
sg13
I1
sa(dp4627
g7
I21
sg8
g48
sg10
I6
sg11
VDNAJD1
p4628
sg13
I1
sa(dp4629
g7
I9
sg8
g48
sg10
I7
sg11
VBCL2L10
p4630
sg13
I1
sasg29
(lp4631
(dp4632
g7
I58
sg32
VC0024623
p4633
sg10
I14
sg11
Vgastric cancer
p4634
sg13
I2
sasa(dp4635
g2
S'We investigated the hypothesis that enhancing the activity of the protective axis of RAS by subretinal delivery of an AAV8 (Y733F)-ACE2 vector would protect against the ocular inflammation in experimental autoimmune uveitis (EAU) mice through regulating the local immune responses.\n'
p4636
sg4
(lp4637
(dp4638
g7
I118
sg8
g48
sg10
I17
sg11
VAAV8 (Y733F)-ACE2
p4639
sg13
I2
sa(dp4640
g7
I85
sg8
VP01116
p4641
sg10
I3
sg11
VRAS
p4642
sg13
I1
sasg29
(lp4643
(dp4644
g7
I216
sg32
VC0042164
p4645
sg10
I7
sg11
Vuveitis
p4646
sg13
I1
sa(dp4647
g7
I205
sg32
VC0443146
p4648
sg10
I10
sg11
Vautoimmune
p4649
sg13
I1
sa(dp4650
g7
I176
sg32
VC0021368
p4651
sg10
I12
sg11
Vinflammation
p4652
sg13
I1
sasa(dp4653
g2
S'This proof-of-concept study suggests that activation of ocular ACE2/Ang-(1-7)/Mas axis with AAV gene transfer modulates local immune responses and may be a promising, long-lasting therapeutic strategy for refractory and recurrent uveitis, as well as other inflammatory eye diseases.\n'
p4654
sg4
(lp4655
(dp4656
g7
I68
sg8
VP03950
p4657
sg10
I3
sg11
VAng
p4658
sg13
I1
sa(dp4659
g7
I63
sg8
g48
sg10
I4
sg11
VACE2
p4660
sg13
I1
sa(dp4661
g7
I78
sg8
VP04201
p4662
sg10
I3
sg11
VMas
p4663
sg13
I1
sasg29
(lp4664
(dp4665
g7
I78
sg32
VC0242292
p4666
sg10
I3
sg11
VMas
p4667
sg13
I1
sa(dp4668
g7
I230
sg32
VC0042164
p4669
sg10
I7
sg11
Vuveitis
p4670
sg13
I1
sa(dp4671
g7
I269
sg32
VC0015397
p4672
sg10
I12
sg11
Veye diseases
p4673
sg13
I2
sasa(dp4674
g2
S'One approach to activate ACE2 involves the drug DIZE, which has been shown to have beneficial effects in experimental models of hypertension, pulmonary hypertension, myocardial infarction, stroke, atherosclerosis, type 1 diabetes, and eye disease.\n'
p4675
sg4
(lp4676
(dp4677
g7
I25
sg8
g48
sg10
I4
sg11
VACE2
p4678
sg13
I1
sasg29
(lp4679
(dp4680
g7
I235
sg32
VC0015397
p4681
sg10
I11
sg11
Veye disease
p4682
sg13
I2
sa(dp4683
g7
I197
sg32
VC0004153
p4684
sg10
I15
sg11
Vatherosclerosis
p4685
sg13
I1
sa(dp4686
g7
I189
sg32
VC0038454
p4687
sg10
I6
sg11
Vstroke
p4688
sg13
I1
sa(dp4689
g7
I214
sg32
VC0011854
p4690
sg10
I15
sg11
Vtype 1 diabetes
p4691
sg13
I3
sa(dp4692
g7
I128
sg32
VC0020538
p4693
sg10
I12
sg11
Vhypertension
p4694
sg13
I1
sa(dp4695
g7
I166
sg32
VC0027051
p4696
sg10
I21
sg11
Vmyocardial infarction
p4697
sg13
I2
sa(dp4698
g7
I128
sg32
VC0020542
p4699
sg10
I23
sg11
Vhypertension, pulmonary
p4700
sg13
I2
sasa(dp4701
g2
S'We aimed to determine whether local retinal overexpression of adenoassociated virus (AAV)-ACE2 prevents or reverses diabetic retinopathy.\n'
p4702
sg4
(lp4703
(dp4704
g7
I90
sg8
g48
sg10
I4
sg11
VACE2
p4705
sg13
I1
sasg29
(lp4706
(dp4707
g7
I116
sg32
VC0011884
p4708
sg10
I20
sg11
Vdiabetic retinopathy
p4709
sg13
I2
sasa(dp4710
g2
S'The aim of this study was to develop and evaluate the effects of chitosan inserts for sustained release of the angiotensin-converting enzyme 2 (ACE2) activator, diminazene aceturate (DIZE), in experimental glaucoma.\n'
p4711
sg4
(lp4712
(dp4713
g7
I144
sg8
g48
sg10
I4
sg11
VACE2
p4714
sg13
I1
sa(dp4715
g7
I111
sg8
g48
sg10
I31
sg11
Vangiotensin-converting enzyme 2
p4716
sg13
I3
sasg29
(lp4717
(dp4718
g7
I206
sg32
VC0017601
p4719
sg10
I8
sg11
Vglaucoma
p4720
sg13
I1
sasa(dp4721
g2
S'Our previous study demonstrated that an intraperitoneal injection of Diminazene Aceturate (DIZE) attenuated uveitis by activating ocular angiotensin-converting enzyme 2 (ACE2).\n'
p4722
sg4
(lp4723
(dp4724
g7
I137
sg8
g48
sg10
I31
sg11
Vangiotensin-converting enzyme 2
p4725
sg13
I3
sa(dp4726
g7
I170
sg8
g48
sg10
I4
sg11
VACE2
p4727
sg13
I1
sasg29
(lp4728
(dp4729
g7
I108
sg32
VC0042164
p4730
sg10
I7
sg11
Vuveitis
p4731
sg13
I1
sasa(dp4732
g2
S'Oral feeding of mice with bioencapsulated ACE2/Ang-(1-7) significantly reduced endotoxin-induced uveitis (EIU) in mice.\n'
p4733
sg4
(lp4734
(dp4735
g7
I42
sg8
g48
sg10
I4
sg11
VACE2
p4736
sg13
I1
sasg29
(lp4737
(dp4738
g7
I97
sg32
VC0042164
p4739
sg10
I7
sg11
Vuveitis
p4740
sg13
I1
sasa(dp4741
g2
S'The purpose of this study was to investigate the effect of endogenous ACE2 activation in preventing endotoxin-induced uveitis (EIU) in mice.\n'
p4742
sg4
(lp4743
(dp4744
g7
I70
sg8
g48
sg10
I4
sg11
VACE2
p4745
sg13
I1
sasg29
(lp4746
(dp4747
g7
I118
sg32
VC0042164
p4748
sg10
I7
sg11
Vuveitis
p4749
sg13
I1
sasa(dp4750
g2
S'These results support the notions that RAS plays a role in modulating ocular immune response and that enhancing ACE2 provides a novel therapeutic strategy for uveitis.\n'
p4751
sg4
(lp4752
(dp4753
g7
I112
sg8
g48
sg10
I4
sg11
VACE2
p4754
sg13
I1
sa(dp4755
g7
I39
sg8
VP01116
p4756
sg10
I3
sg11
VRAS
p4757
sg13
I1
sasg29
(lp4758
(dp4759
g7
I159
sg32
VC0042164
p4760
sg10
I7
sg11
Vuveitis
p4761
sg13
I1
sasa(dp4762
g2
S'We had previously shown that the expression of heparin/heparan sulfate interacting protein/ribosomal protein L29 (HIP/RPL29) was upregulated in colon cancer tissues.\n'
p4763
sg4
(lp4764
(dp4765
g7
I114
sg8
g48
sg10
I9
sg11
VHIP/RPL29
p4766
sg13
I1
sa(dp4767
g7
I47
sg8
g48
sg10
I65
sg11
Vheparin/heparan sulfate interacting protein/ribosomal protein L29
p4768
sg13
I6
sasg29
(lp4769
(dp4770
g7
I144
sg32
VC0699790
p4771
sg10
I12
sg11
Vcolon cancer
p4772
sg13
I2
sasa(dp4773
g2
S'The present study investigated the role of HIP/RPL29 in differentiation in colon cancer cells.\n'
p4774
sg4
(lp4775
(dp4776
g7
I47
sg8
VP47914
p4777
sg10
I5
sg11
VRPL29
p4778
sg13
I1
sa(dp4779
g7
I43
sg8
VP47914
p4780
sg10
I3
sg11
VHIP
p4781
sg13
I1
sasg29
(lp4782
(dp4783
g7
I75
sg32
VC0699790
p4784
sg10
I12
sg11
Vcolon cancer
p4785
sg13
I2
sasa(dp4786
g2
S'In conclusion, HIP/RPL29 plays a role in the cellular differentiation process in colon cancer cells.\n'
p4787
sg4
(lp4788
(dp4789
g7
I15
sg8
VP47914
p4790
sg10
I3
sg11
VHIP
p4791
sg13
I1
sa(dp4792
g7
I19
sg8
VP47914
p4793
sg10
I5
sg11
VRPL29
p4794
sg13
I1
sasg29
(lp4795
(dp4796
g7
I81
sg32
VC0699790
p4797
sg10
I12
sg11
Vcolon cancer
p4798
sg13
I2
sasa(dp4799
g2
S'Particularly, the variants of GPR101, GPR161, and GPR88 are related to the genetic diseases: growth hormone-secreting pituitary adenoma 2, pituitary stalk interruption syndrome (not confirmed), and childhood-onset chorea with psychomotor retardation, respectively.\n'
p4800
sg4
(lp4801
(dp4802
g7
I30
sg8
g48
sg10
I6
sg11
VGPR101
p4803
sg13
I1
sa(dp4804
g7
I50
sg8
g48
sg10
I5
sg11
VGPR88
p4805
sg13
I1
sa(dp4806
g7
I38
sg8
g48
sg10
I6
sg11
VGPR161
p4807
sg13
I1
sasg29
(lp4808
(dp4809
g7
I149
sg32
VC0935572
p4810
sg10
I5
sg11
Vstalk
p4811
sg13
I1
sa(dp4812
g7
I214
sg32
VC0008489
p4813
sg10
I6
sg11
Vchorea
p4814
sg13
I1
sa(dp4815
g7
I168
sg32
VC0039082
p4816
sg10
I8
sg11
Vsyndrome
p4817
sg13
I1
sa(dp4818
g7
I93
sg32
VC0346302
p4819
sg10
I42
sg11
Vgrowth hormone-secreting pituitary adenoma
p4820
sg13
I4
sasa(dp4821
g2
S'For example, Kif5A, but not other Kinesin-1 heavy-chain family members, is implicated in Charcot-Marie-Tooth disease (CMT) and Hereditary Spastic Paraplegia (HSP), but the mechanism of its involvement in the progressive axonal degeneration characteristic of these diseases is not well understood.\n'
p4822
sg4
(lp4823
(dp4824
g7
I13
sg8
g48
sg10
I5
sg11
VKif5A
p4825
sg13
I1
sa(dp4826
g7
I34
sg8
g48
sg10
I36
sg11
VKinesin-1 heavy-chain family members
p4827
sg13
I4
sasg29
(lp4828
(dp4829
g7
I227
sg32
VC0011164
p4830
sg10
I12
sg11
Vdegeneration
p4831
sg13
I1
sa(dp4832
g7
I127
sg32
VC0037773
p4833
sg10
I29
sg11
VHereditary Spastic Paraplegia
p4834
sg13
I3
sa(dp4835
g7
I158
sg32
VC0034152
p4836
sg10
I3
sg11
VHSP
p4837
sg13
I1
sa(dp4838
g7
I118
sg32
VC0007959
p4839
sg10
I3
sg11
VCMT
p4840
sg13
I1
sa(dp4841
g7
I89
sg32
VC0007959
p4842
sg10
I27
sg11
VCharcot-Marie-Tooth disease
p4843
sg13
I2
sasa(dp4844
g2
S'Protrudin was found to interact with other HSP-related proteins including myelin proteolipid protein 1 (SPG2), atlastin-1 (SPG3A), REEP1 (SPG31), REEP5 (similar to REEP1), Kif5A (SPG10), Kif5B, Kif5C, and reticulon 1, 3, and 4 (similar to reticulon 2, SPG12).\n'
p4845
sg4
(lp4846
(dp4847
g7
I138
sg8
g48
sg10
I5
sg11
VSPG31
p4848
sg13
I1
sa(dp4849
g7
I187
sg8
VP33176
p4850
sg10
I5
sg11
VKif5B
p4851
sg13
I1
sa(dp4852
g7
I146
sg8
g48
sg10
I5
sg11
VREEP5
p4853
sg13
I1
sa(dp4854
g7
I111
sg8
g48
sg10
I10
sg11
Vatlastin-1
p4855
sg13
I1
sa(dp4856
g7
I74
sg8
VP60201
p4857
sg10
I28
sg11
Vmyelin proteolipid protein 1
p4858
sg13
I4
sa(dp4859
g7
I43
sg8
g48
sg10
I20
sg11
VHSP-related proteins
p4860
sg13
I2
sa(dp4861
g7
I131
sg8
g48
sg10
I5
sg11
VREEP1
p4862
sg13
I1
sa(dp4863
g7
I179
sg8
g48
sg10
I5
sg11
VSPG10
p4864
sg13
I1
sa(dp4865
g7
I172
sg8
g48
sg10
I5
sg11
VKif5A
p4866
sg13
I1
sa(dp4867
g7
I123
sg8
g48
sg10
I5
sg11
VSPG3A
p4868
sg13
I1
sa(dp4869
g7
I131
sg8
g48
sg10
I5
sg11
VREEP1
p4870
sg13
I1
sa(dp4871
g7
I194
sg8
g48
sg10
I5
sg11
VKif5C
p4872
sg13
I1
sa(dp4873
g7
I104
sg8
VP60201
p4874
sg10
I4
sg11
VSPG2
p4875
sg13
I1
sasg29
(lp4876
(dp4877
g7
I138
sg32
VC1853247
p4878
sg10
I5
sg11
VSPG31
p4879
sg13
I1
sa(dp4880
g7
I179
sg32
VC1858712
p4881
sg10
I5
sg11
VSPG10
p4882
sg13
I1
sa(dp4883
g7
I123
sg32
VC2931355
p4884
sg10
I5
sg11
VSPG3A
p4885
sg13
I1
sa(dp4886
g7
I104
sg32
VC1839264
p4887
sg10
I4
sg11
VSPG2
p4888
sg13
I1
sa(dp4889
g7
I43
sg32
VC0034152
p4890
sg10
I3
sg11
VHSP
p4891
sg13
I1
sa(dp4892
g7
I252
sg32
VC1858106
p4893
sg10
I5
sg11
VSPG12
p4894
sg13
I1
sasa(dp4895
g2
S'SPG10 is an autosomal dominant form of hereditary spastic paraplegia caused by mutations in KIF5A, which encodes one of the isoforms of kinesin-1 (KIF5A, KIF5B, and KIF5C).\n'
p4896
sg4
(lp4897
(dp4898
g7
I92
sg8
g48
sg10
I5
sg11
VKIF5A
p4899
sg13
I1
sa(dp4900
g7
I154
sg8
VP33176
p4901
sg10
I5
sg11
VKIF5B
p4902
sg13
I1
sa(dp4903
g7
I92
sg8
g48
sg10
I5
sg11
VKIF5A
p4904
sg13
I1
sa(dp4905
g7
I165
sg8
g48
sg10
I5
sg11
VKIF5C
p4906
sg13
I1
sa(dp4907
g7
I0
sg8
g48
sg10
I5
sg11
VSPG10
p4908
sg13
I1
sa(dp4909
g7
I136
sg8
g48
sg10
I9
sg11
Vkinesin-1
p4910
sg13
I1
sasg29
(lp4911
(dp4912
g7
I0
sg32
VC1858712
p4913
sg10
I5
sg11
VSPG10
p4914
sg13
I1
sa(dp4915
g7
I39
sg32
VC0037773
p4916
sg10
I29
sg11
Vhereditary spastic paraplegia
p4917
sg13
I3
sasa(dp4918
g2
S'The contribution of the sensory and autonomic nervous system to experimentally induced tennis elbow or lateral epicondylalgia was investigated by analyses of the release of neuropeptides from sensory (substance P, SP, neurokinin A, NKA, calcitonin gene-related peptide, CGRP) and sympathetic (neuropeptide Y, NPY) nerves.\n'
p4919
sg4
(lp4920
(dp4921
g7
I232
sg8
g48
sg10
I3
sg11
VNKA
p4922
sg13
I1
sa(dp4923
g7
I293
sg8
VP01303
p4924
sg10
I14
sg11
Vneuropeptide Y
p4925
sg13
I2
sa(dp4926
g7
I218
sg8
g48
sg10
I12
sg11
Vneurokinin A
p4927
sg13
I2
sa(dp4928
g7
I270
sg8
VP80511
p4929
sg10
I4
sg11
VCGRP
p4930
sg13
I1
sa(dp4931
g7
I309
sg8
VP25929
p4932
sg10
I3
sg11
VNPY
p4933
sg13
I1
sa(dp4934
g7
I237
sg8
VP06881
p4935
sg10
I31
sg11
Vcalcitonin gene-related peptide
p4936
sg13
I3
sasg29
(lp4937
(dp4938
g7
I87
sg32
VC0039516
p4939
sg10
I12
sg11
Vtennis elbow
p4940
sg13
I2
sa(dp4941
g7
I46
sg32
VC0027769
p4942
sg10
I7
sg11
Vnervous
p4943
sg13
I1
sasa(dp4944
g2
S'The DLST was positive in 3 of 6 cases of suspected drug-induced pneumonia, but the suspected drugs were ruled out by the provocation test.\n'
p4945
sg4
(lp4946
sg29
(lp4947
(dp4948
g7
I64
sg32
VC0032285
p4949
sg10
I9
sg11
Vpneumonia
p4950
sg13
I1
sasa(dp4951
g2
S'PBM was found focally in other interstitial lung diseases, which were assessed for this lesion: 59% of usual interstitial pneumonia (17 of 29), 50% of nonspecific interstitial pneumonia (10 of 20), desquamative interstitial pneumonia (3 of 6), hypersensitivity pneumonitis (9 of 18), and 11% of respiratory bronchiolitis (2 of 18).\n'
p4952
sg4
(lp4953
sg29
(lp4954
(dp4955
g7
I307
sg32
VC0006271
p4956
sg10
I13
sg11
Vbronchiolitis
p4957
sg13
I1
sa(dp4958
g7
I151
sg32
VC1290344
p4959
sg10
I34
sg11
Vnonspecific interstitial pneumonia
p4960
sg13
I3
sa(dp4961
g7
I103
sg32
VC0085786
p4962
sg10
I28
sg11
Vusual interstitial pneumonia
p4963
sg13
I3
sa(dp4964
g7
I198
sg32
VC0238378
p4965
sg10
I35
sg11
Vdesquamative interstitial pneumonia
p4966
sg13
I3
sa(dp4967
g7
I31
sg32
VC0206062
p4968
sg10
I26
sg11
Vinterstitial lung diseases
p4969
sg13
I3
sa(dp4970
g7
I244
sg32
VC0002390
p4971
sg10
I28
sg11
Vhypersensitivity pneumonitis
p4972
sg13
I2
sasa(dp4973
g2
S'Conditioning was aborted for 3 of 6 patients; none had progression to RSV pneumonia.\n'
p4974
sg4
(lp4975
sg29
(lp4976
(dp4977
g7
I74
sg32
VC0032285
p4978
sg10
I9
sg11
Vpneumonia
p4979
sg13
I1
sasa(dp4980
g2
S'Chronic obstructive pulmonary disease (COPD) patients who have had an episode of acute hypercapnic respiratory failure (AHRF) have a large 1-year risk of death or readmission.\n'
p4981
sg4
(lp4982
sg29
(lp4983
(dp4984
g7
I39
sg32
VC0024117
p4985
sg10
I4
sg11
VCOPD
p4986
sg13
I1
sa(dp4987
g7
I0
sg32
VC0024117
p4988
sg10
I37
sg11
VChronic obstructive pulmonary disease
p4989
sg13
I4
sa(dp4990
g7
I87
sg32
VC0398353
p4991
sg10
I31
sg11
Vhypercapnic respiratory failure
p4992
sg13
I3
sasa(dp4993
g2
S'Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease responsible for a large human and economic burden around the world.\n'
p4994
sg4
(lp4995
sg29
(lp4996
(dp4997
g7
I39
sg32
VC0024117
p4998
sg10
I4
sg11
VCOPD
p4999
sg13
I1
sa(dp5000
g7
I0
sg32
VC0024117
p5001
sg10
I37
sg11
VChronic obstructive pulmonary disease
p5002
sg13
I4
sasa(dp5003
g2
S'Three miRNA ratios (miR-17-5p/miR-135b, miR-92a-3p/miR135b, and miR-451a/miR-491-5p) were validated for discriminating patients with adenoma and those with CRC from the healthy control group, and 5 miRNA ratios (let-7b/miR-367-3p, miR-130a-3p/miR-409-3p, miR-148-3p/miR-27b, miR-148a-3p/miR-409-3p, and miR-21-5p/miR-367-3p) were validated for discriminating patients with CRC from those with adenoma and healthy controls.\n'
p5004
sg4
(lp5005
(dp5006
g7
I20
sg8
g48
sg10
I9
sg11
VmiR-17-5p
p5007
sg13
I1
sa(dp5008
g7
I64
sg8
g48
sg10
I8
sg11
VmiR-451a
p5009
sg13
I1
sa(dp5010
g7
I73
sg8
g48
sg10
I10
sg11
VmiR-491-5p
p5011
sg13
I1
sa(dp5012
g7
I6
sg8
g48
sg10
I3
sg11
VmiR
p5013
sg13
I1
sa(dp5014
g7
I243
sg8
g48
sg10
I10
sg11
VmiR-409-3p
p5015
sg13
I1
sa(dp5016
g7
I231
sg8
g48
sg10
I11
sg11
VmiR-130a-3p
p5017
sg13
I1
sa(dp5018
g7
I219
sg8
g48
sg10
I10
sg11
VmiR-367-3p
p5019
sg13
I1
sa(dp5020
g7
I219
sg8
g48
sg10
I10
sg11
VmiR-367-3p
p5021
sg13
I1
sa(dp5022
g7
I303
sg8
g48
sg10
I9
sg11
VmiR-21-5p
p5023
sg13
I1
sa(dp5024
g7
I243
sg8
g48
sg10
I10
sg11
VmiR-409-3p
p5025
sg13
I1
sa(dp5026
g7
I40
sg8
g48
sg10
I10
sg11
VmiR-92a-3p
p5027
sg13
I1
sa(dp5028
g7
I275
sg8
g48
sg10
I11
sg11
VmiR-148a-3p
p5029
sg13
I1
sa(dp5030
g7
I156
sg8
VP31749
p5031
sg10
I3
sg11
VCRC
p5032
sg13
I1
sa(dp5033
g7
I6
sg8
g48
sg10
I3
sg11
VmiR
p5034
sg13
I1
sa(dp5035
g7
I255
sg8
g48
sg10
I10
sg11
VmiR-148-3p
p5036
sg13
I1
sasg29
(lp5037
(dp5038
g7
I156
sg32
VC1527249
p5039
sg10
I3
sg11
VCRC
p5040
sg13
I1
sa(dp5041
g7
I133
sg32
VC0001430
p5042
sg10
I7
sg11
Vadenoma
p5043
sg13
I1
sa(dp5044
g7
I156
sg32
VC1527249
p5045
sg10
I3
sg11
VCRC
p5046
sg13
I1
sa(dp5047
g7
I133
sg32
VC0001430
p5048
sg10
I7
sg11
Vadenoma
p5049
sg13
I1
sasa(dp5050
g2
S'MicroRNA-92a (miR-92a) was recently reported to have an oncogenic role in cervical cancer; however, the underlying mechanism remains largely unclear.\n'
p5051
sg4
(lp5052
(dp5053
g7
I14
sg8
g48
sg10
I7
sg11
VmiR-92a
p5054
sg13
I1
sa(dp5055
g7
I0
sg8
g48
sg10
I12
sg11
VMicroRNA-92a
p5056
sg13
I1
sasg29
(lp5057
(dp5058
g7
I74
sg32
VC0302592
p5059
sg10
I15
sg11
Vcervical cancer
p5060
sg13
I2
sasa(dp5061
g2
S'The present study aimed to investigate the expression, clinical significance and regulatory mechanism of miR-92a in cervical cancer.\n'
p5062
sg4
(lp5063
(dp5064
g7
I105
sg8
g48
sg10
I7
sg11
VmiR-92a
p5065
sg13
I1
sasg29
(lp5066
(dp5067
g7
I116
sg32
VC0302592
p5068
sg10
I15
sg11
Vcervical cancer
p5069
sg13
I2
sasa(dp5070
g2
S'Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) data indicated that miR-92a was significantly upregulated in cervical cancer tissues compared with matched adjacent non-tumor tissues (P&lt;0.01).\n'
p5071
sg4
(lp5072
(dp5073
g7
I91
sg8
g48
sg10
I7
sg11
VmiR-92a
p5074
sg13
I1
sasg29
(lp5075
(dp5076
g7
I191
sg32
VC0027651
p5077
sg10
I5
sg11
Vtumor
p5078
sg13
I1
sa(dp5079
g7
I132
sg32
VC0302592
p5080
sg10
I15
sg11
Vcervical cancer
p5081
sg13
I2
sasa(dp5082
g2
S'Knockdown of miR-92a significantly inhibited the viability and invasion of cervical cancer HeLa cells, while overexpression of miR-92a significantly enhanced HeLa cell viability and invasion (P&lt;0.01).\n'
p5083
sg4
(lp5084
(dp5085
g7
I13
sg8
g48
sg10
I7
sg11
VmiR-92a
p5086
sg13
I1
sa(dp5087
g7
I13
sg8
g48
sg10
I7
sg11
VmiR-92a
p5088
sg13
I1
sasg29
(lp5089
(dp5090
g7
I63
sg32
VC2699153
p5091
sg10
I8
sg11
Vinvasion
p5092
sg13
I1
sa(dp5093
g7
I63
sg32
VC2699153
p5094
sg10
I8
sg11
Vinvasion
p5095
sg13
I1
sa(dp5096
g7
I75
sg32
VC0302592
p5097
sg10
I15
sg11
Vcervical cancer
p5098
sg13
I2
sasa(dp5099
g2
S'Additionally, DKK3 was significantly downregulated in cervical cancer tissues compared with adjacent non-tumor tissues (P&lt;0.01), inversely correlated to the miR-92a levels in cervical cancer tissues (P&lt;0.01).\n'
p5100
sg4
(lp5101
(dp5102
g7
I160
sg8
g48
sg10
I7
sg11
VmiR-92a
p5103
sg13
I1
sa(dp5104
g7
I14
sg8
g48
sg10
I4
sg11
VDKK3
p5105
sg13
I1
sasg29
(lp5106
(dp5107
g7
I105
sg32
VC0027651
p5108
sg10
I5
sg11
Vtumor
p5109
sg13
I1
sa(dp5110
g7
I54
sg32
VC0302592
p5111
sg10
I15
sg11
Vcervical cancer
p5112
sg13
I2
sa(dp5113
g7
I54
sg32
VC0302592
p5114
sg10
I15
sg11
Vcervical cancer
p5115
sg13
I2
sasa(dp5116
g2
S'In summary, the present study indicated that miR-92a promotes cell viability and invasion in cervical cancer, partly at least, via inhibiting the protein expression of DKK3.\n'
p5117
sg4
(lp5118
(dp5119
g7
I45
sg8
g48
sg10
I7
sg11
VmiR-92a
p5120
sg13
I1
sa(dp5121
g7
I168
sg8
g48
sg10
I4
sg11
VDKK3
p5122
sg13
I1
sasg29
(lp5123
(dp5124
g7
I81
sg32
VC2699153
p5125
sg10
I8
sg11
Vinvasion
p5126
sg13
I1
sa(dp5127
g7
I93
sg32
VC0302592
p5128
sg10
I15
sg11
Vcervical cancer
p5129
sg13
I2
sasa(dp5130
g2
S'Therefore, the present study highlights the clinical significance of the miR-92a/DKK3 axis in cervical cancer.\n'
p5131
sg4
(lp5132
(dp5133
g7
I81
sg8
g48
sg10
I4
sg11
VDKK3
p5134
sg13
I1
sa(dp5135
g7
I73
sg8
g48
sg10
I7
sg11
VmiR-92a
p5136
sg13
I1
sasg29
(lp5137
(dp5138
g7
I94
sg32
VC0302592
p5139
sg10
I15
sg11
Vcervical cancer
p5140
sg13
I2
sasa(dp5141
g2
S'Obesity is associated with local tissue hypoxia and elevated hypoxia-inducible factor 1 alpha (HIF-1Alfa) in metabolic tissues.\n'
p5142
sg4
(lp5143
(dp5144
g7
I61
sg8
g48
sg10
I32
sg11
Vhypoxia-inducible factor 1 alpha
p5145
sg13
I4
sasg29
(lp5146
(dp5147
g7
I0
sg32
VC0028754
p5148
sg10
I7
sg11
VObesity
p5149
sg13
I1
sa(dp5150
g7
I40
sg32
VC0242184
p5151
sg10
I7
sg11
Vhypoxia
p5152
sg13
I1
sa(dp5153
g7
I40
sg32
VC0242184
p5154
sg10
I7
sg11
Vhypoxia
p5155
sg13
I1
sasa(dp5156
g2
S'Whole exome sequencing analysis obtained ~2.0 Gb of data (an average of 60x depth for each targeted base), and further validation experiments identified two functional variants in two cancer-related genes (c.1218delA:p.E406fs in PDE4DIP and C1342A:p.L448I in CLTCL1).\n'
p5157
sg4
(lp5158
(dp5159
g7
I248
sg8
VP53675
p5160
sg10
I17
sg11
Vp.L448I in CLTCL1
p5161
sg13
I3
sasg29
(lp5162
(dp5163
g7
I184
sg32
VC0006826
p5164
sg10
I6
sg11
Vcancer
p5165
sg13
I1
sasa(dp5166
g2
S'Compared with amyloidosis glomeruli, FGN glomeruli exhibited a &gt;6-fold overexpression of DNAJB9 protein.\n'
p5167
sg4
(lp5168
(dp5169
g7
I37
sg8
g48
sg10
I13
sg11
VFGN glomeruli
p5170
sg13
I2
sa(dp5171
g7
I92
sg8
g48
sg10
I14
sg11
VDNAJB9 protein
p5172
sg13
I2
sasg29
(lp5173
(dp5174
g7
I14
sg32
VC0002726
p5175
sg10
I11
sg11
Vamyloidosis
p5176
sg13
I1
sasa(dp5177
g2
S'Approximately half of ERdj4(GT/GT) mice died perinatally associated with fetal growth restriction, reduced hepatic glycogen stores, and hypoglycemia.\n'
p5178
sg4
(lp5179
(dp5180
g7
I22
sg8
g48
sg10
I5
sg11
VERdj4
p5181
sg13
I1
sasg29
(lp5182
(dp5183
g7
I136
sg32
VC0020615
p5184
sg10
I12
sg11
Vhypoglycemia
p5185
sg13
I1
sa(dp5186
g7
I73
sg32
VC0015934
p5187
sg10
I24
sg11
Vfetal growth restriction
p5188
sg13
I3
sasa(dp5189
g2
S'Elevated ER stress in pancreatic Beta cells of ERdj4(GT/GT) mice was associated with Beta cell loss, hypoinsulinemia, and glucose intolerance.\n'
p5190
sg4
(lp5191
(dp5192
g7
I47
sg8
g48
sg10
I5
sg11
VERdj4
p5193
sg13
I1
sasg29
(lp5194
(dp5195
g7
I122
sg32
VC0271650
p5196
sg10
I19
sg11
Vglucose intolerance
p5197
sg13
I2
sa(dp5198
g7
I101
sg32
VC2748055
p5199
sg10
I15
sg11
Vhypoinsulinemia
p5200
sg13
I1
sasa(dp5201
g2
S'The study involved 110 cases of Philadelphia negative Myeloproliferative diseases (MPDs), 70 cases with Polycythemia Vera (PV), 24 cases with Essential Thrombocytosis (ET) and 16 cases with Idiopathic Myelofibrosis (IMF) and 20 cases as a control group which represented as; (10 cases with secondary erythrocytosis, 1 case with reactive thrombocytosis, 4 cases as normal control and 5 as Philadelphia positive Chronic Myeloid Leukemia cases), they were collected from National Cancer Institute (NCI) over 3 years.\n'
p5202
sg4
(lp5203
sg29
(lp5204
(dp5205
g7
I168
sg32
VC0040028
p5206
sg10
I2
sg11
VET
p5207
sg13
I1
sa(dp5208
g7
I190
sg32
VC0001815
p5209
sg10
I24
sg11
VIdiopathic Myelofibrosis
p5210
sg13
I2
sa(dp5211
g7
I104
sg32
VC0032463
p5212
sg10
I17
sg11
VPolycythemia Vera
p5213
sg13
I2
sa(dp5214
g7
I410
sg32
VC0023473
p5215
sg10
I24
sg11
VChronic Myeloid Leukemia
p5216
sg13
I3
sa(dp5217
g7
I142
sg32
VC0040028
p5218
sg10
I24
sg11
VEssential Thrombocytosis
p5219
sg13
I2
sa(dp5220
g7
I328
sg32
VC0457506
p5221
sg10
I23
sg11
Vreactive thrombocytosis
p5222
sg13
I2
sa(dp5223
g7
I477
sg32
VC0006826
p5224
sg10
I6
sg11
VCancer
p5225
sg13
I1
sa(dp5226
g7
I216
sg32
VC0001815
p5227
sg10
I3
sg11
VIMF
p5228
sg13
I1
sa(dp5229
g7
I123
sg32
VC0032463
p5230
sg10
I2
sg11
VPV
p5231
sg13
I1
sa(dp5232
g7
I290
sg32
VC1318533
p5233
sg10
I24
sg11
Vsecondary erythrocytosis
p5234
sg13
I2
sasa(dp5235
g2
S'Screening for the mutation in all cases suspected of chronic MPD could be beneficial in differentiating patients with reactive erthrocytosis or thrombocytosis from the true clonal MPDs especially polycythaemia vera.\n'
p5236
sg4
(lp5237
sg29
(lp5238
(dp5239
g7
I144
sg32
VC0836924
p5240
sg10
I14
sg11
Vthrombocytosis
p5241
sg13
I1
sa(dp5242
g7
I196
sg32
VC0032463
p5243
sg10
I18
sg11
Vpolycythaemia vera
p5244
sg13
I2
sasa(dp5245
g2
S'Hematologic disorders including myeloproliferative disorders (MPDs), myelodysplasia, paraproteinemias, and immune thrombocytopenia (ITP) can also be associated with hemorrhagic complications due to platelet dysfunction.\n'
p5246
sg4
(lp5247
sg29
(lp5248
(dp5249
g7
I32
sg32
VC0027022
p5250
sg10
I28
sg11
Vmyeloproliferative disorders
p5251
sg13
I2
sa(dp5252
g7
I62
sg32
VC0027022
p5253
sg10
I4
sg11
VMPDs
p5254
sg13
I1
sa(dp5255
g7
I69
sg32
VC0026985
p5256
sg10
I14
sg11
Vmyelodysplasia
p5257
sg13
I1
sa(dp5258
g7
I198
sg32
VC0679429
p5259
sg10
I20
sg11
Vplatelet dysfunction
p5260
sg13
I2
sa(dp5261
g7
I85
sg32
VC0030489
p5262
sg10
I16
sg11
Vparaproteinemias
p5263
sg13
I1
sa(dp5264
g7
I0
sg32
VC0018939
p5265
sg10
I21
sg11
VHematologic disorders
p5266
sg13
I2
sa(dp5267
g7
I107
sg32
VC0272286
p5268
sg10
I23
sg11
Vimmune thrombocytopenia
p5269
sg13
I2
sa(dp5270
g7
I132
sg32
VC0043117
p5271
sg10
I3
sg11
VITP
p5272
sg13
I1
sasa(dp5273
g2
S'Immunohistochemical staining and Western blotting were performed to evaluate the expression level of DJ-1 in oral leukoplakia (OLK) and OSCC tissues respectively.\n'
p5274
sg4
(lp5275
(dp5276
g7
I101
sg8
g48
sg10
I4
sg11
VDJ-1
p5277
sg13
I1
sasg29
(lp5278
(dp5279
g7
I109
sg32
VC0023532
p5280
sg10
I16
sg11
Voral leukoplakia
p5281
sg13
I2
sa(dp5282
g7
I127
sg32
VC0023532
p5283
sg10
I3
sg11
VOLK
p5284
sg13
I1
sasa(dp5285
g2
S'Then lentiviral mediated DJ-1 shRNA was constructed and used to infect the OSCC cell lines (Tca8113 and CAL-27).\n'
p5286
sg4
(lp5287
sg29
(lp5288
sa(dp5289
g2
S'The immunoreactivity and expression level of DJ-1 protein was significantly increased in OLK and OSCC tissues compared with the controls.\n'
p5290
sg4
(lp5291
(dp5292
g7
I45
sg8
g48
sg10
I12
sg11
VDJ-1 protein
p5293
sg13
I2
sasg29
(lp5294
sa(dp5295
g2
S'The proliferative and invasion ability of OSCC cell lines was significantly suppressed following DJ-1 inhibition (P&lt;0.01).\n'
p5296
sg4
(lp5297
(dp5298
g7
I97
sg8
g48
sg10
I4
sg11
VDJ-1
p5299
sg13
I1
sasg29
(lp5300
(dp5301
g7
I4
sg32
VC0334094
p5302
sg10
I13
sg11
Vproliferative
p5303
sg13
I1
sa(dp5304
g7
I22
sg32
VC2699153
p5305
sg10
I8
sg11
Vinvasion
p5306
sg13
I1
sasa(dp5307
g2
S'These findings suggest that DJ-1 might be actively involved in the development of OSCC.\n'
p5308
sg4
(lp5309
(dp5310
g7
I28
sg8
g48
sg10
I4
sg11
VDJ-1
p5311
sg13
I1
sasg29
(lp5312
sa(dp5313
g2
S'Future studies will investigate the potential of DJ-1 as a biomarker for early detection of OSCC.\n'
p5314
sg4
(lp5315
(dp5316
g7
I49
sg8
g48
sg10
I4
sg11
VDJ-1
p5317
sg13
I1
sasg29
(lp5318
sa(dp5319
g2
S'The correlation of DJ-1 expression with LPC markers was examined in the liver of patients with hepatitis B or hepatitis C virus (HBV and HCV, respectively) infection, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), nonalcoholic fatty liver disease (NAFLD), cirrhosis or hepatocellular carcinoma (HCC), respectively.\n'
p5320
sg4
(lp5321
(dp5322
g7
I19
sg8
g48
sg10
I4
sg11
VDJ-1
p5323
sg13
I1
sasg29
(lp5324
(dp5325
g7
I194
sg32
VC0008312
p5326
sg10
I3
sg11
VPBC
p5327
sg13
I1
sa(dp5328
g7
I110
sg32
VC0019196
p5329
sg10
I11
sg11
Vhepatitis C
p5330
sg13
I2
sa(dp5331
g7
I129
sg32
VC0019163
p5332
sg10
I3
sg11
VHBV
p5333
sg13
I1
sa(dp5334
g7
I293
sg32
VC2239176
p5335
sg10
I24
sg11
Vhepatocellular carcinoma
p5336
sg13
I2
sa(dp5337
g7
I272
sg32
VC0400966
p5338
sg10
I5
sg11
VNAFLD
p5339
sg13
I1
sa(dp5340
g7
I183
sg32
VC0023890
p5341
sg10
I9
sg11
Vcirrhosis
p5342
sg13
I1
sa(dp5343
g7
I95
sg32
VC0019163
p5344
sg10
I11
sg11
Vhepatitis B
p5345
sg13
I2
sa(dp5346
g7
I167
sg32
VC0008312
p5347
sg10
I25
sg11
Vprimary biliary cirrhosis
p5348
sg13
I3
sa(dp5349
g7
I200
sg32
VC0566602
p5350
sg10
I30
sg11
Vprimary sclerosing cholangitis
p5351
sg13
I3
sa(dp5352
g7
I232
sg32
VC0566602
p5353
sg10
I3
sg11
VPSC
p5354
sg13
I1
sa(dp5355
g7
I156
sg32
VC0009450
p5356
sg10
I9
sg11
Vinfection
p5357
sg13
I1
sa(dp5358
g7
I319
sg32
VC2239176
p5359
sg10
I3
sg11
VHCC
p5360
sg13
I1
sa(dp5361
g7
I238
sg32
VC0400966
p5362
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p5363
sg13
I4
sasa(dp5364
g2
S'Mechanistically, we found that HSCs isolated from DJ-1 KO mice had decreased secretion of macrophage-mobilizing chemokines, such as CCL2 and CX3CL1, resulting in impaired macrophage infiltration.\n'
p5365
sg4
(lp5366
(dp5367
g7
I132
sg8
VP13500
p5368
sg10
I4
sg11
VCCL2
p5369
sg13
I1
sa(dp5370
g7
I141
sg8
VP78423
p5371
sg10
I6
sg11
VCX3CL1
p5372
sg13
I1
sa(dp5373
g7
I90
sg8
VP09603
p5374
sg10
I32
sg11
Vmacrophage-mobilizing chemokines
p5375
sg13
I2
sasg29
(lp5376
(dp5377
g7
I162
sg32
VC0684336
p5378
sg10
I8
sg11
Vimpaired
p5379
sg13
I1
sa(dp5380
g7
I182
sg32
VC0332448
p5381
sg10
I12
sg11
Vinfiltration
p5382
sg13
I1
sasa(dp5383
g2
S'The aim of this study was to identify potential downstream effectors of the oncogene DJ-1 in hepatocellular carcinoma (HCC) cell lines, and examine its role in the Akt signaling pathway and HCC oncogenesis.\n'
p5384
sg4
(lp5385
(dp5386
g7
I164
sg8
g48
sg10
I3
sg11
VAkt
p5387
sg13
I1
sasg29
(lp5388
(dp5389
g7
I119
sg32
VC2239176
p5390
sg10
I3
sg11
VHCC
p5391
sg13
I1
sa(dp5392
g7
I93
sg32
VC2239176
p5393
sg10
I24
sg11
Vhepatocellular carcinoma
p5394
sg13
I2
sa(dp5395
g7
I194
sg32
VC0007621
p5396
sg10
I11
sg11
Voncogenesis
p5397
sg13
I1
sa(dp5398
g7
I119
sg32
VC2239176
p5399
sg10
I3
sg11
VHCC
p5400
sg13
I1
sasa(dp5401
g2
S'LP/NPL resulted in better glycaemic control than HR/NPH without increasing the risk of hypoglycaemia.\n'
p5402
sg4
(lp5403
sg29
(lp5404
(dp5405
g7
I52
sg32
VC0020258
p5406
sg10
I3
sg11
VNPH
p5407
sg13
I1
sa(dp5408
g7
I87
sg32
VC0020615
p5409
sg10
I13
sg11
Vhypoglycaemia
p5410
sg13
I1
sasa(dp5411
g2
S'We describe the case of a 6-year-old boy with both fragile X syndrome and Robertsonian Translocation (45, XY, der (13; 22) (q10; q10)).\n'
p5412
sg4
(lp5413
sg29
(lp5414
(dp5415
g7
I74
sg32
VC0333715
p5416
sg10
I26
sg11
VRobertsonian Translocation
p5417
sg13
I2
sa(dp5418
g7
I51
sg32
VC0016667
p5419
sg10
I18
sg11
Vfragile X syndrome
p5420
sg13
I3
sasa(dp5421
g2
S'Mosaic Turner syndrome (TSM) commonly occurs in the form of 45,X/46,XX and 45,X/46,X,i(X)(q10).\n'
p5422
sg4
(lp5423
sg29
(lp5424
(dp5425
g7
I24
sg32
VC0041408
p5426
sg10
I3
sg11
VTSM
p5427
sg13
I1
sa(dp5428
g7
I7
sg32
VC0041408
p5429
sg10
I15
sg11
VTurner syndrome
p5430
sg13
I2
sasa(dp5431
g2
S'We present here a 16-year-old Turner syndrome patient with a complex karyotype that includes a maternally-inherited balanced translocation between chromosomes 4 and 16 and mosaicism of the isochromosome Xq10.\n'
p5432
sg4
(lp5433
sg29
(lp5434
(dp5435
g7
I30
sg32
VC0041408
p5436
sg10
I15
sg11
VTurner syndrome
p5437
sg13
I2
sa(dp5438
g7
I61
sg32
VC3273253
p5439
sg10
I17
sg11
Vcomplex karyotype
p5440
sg13
I2
sa(dp5441
g7
I172
sg32
VC0392053
p5442
sg10
I9
sg11
Vmosaicism
p5443
sg13
I1
sa(dp5444
g7
I125
sg32
VC0040715
p5445
sg10
I13
sg11
Vtranslocation
p5446
sg13
I1
sa(dp5447
g7
I189
sg32
VC0242621
p5448
sg10
I13
sg11
Visochromosome
p5449
sg13
I1
sasa(dp5450
g2
S'Results discrepancies between karyotype and FISH were found in 10 patients, including detection of low-level monosomy X mosaicism in 6 patients with normal karyotype, and detection of mosaic aneuploidy chromosome 18 in 1 patient with 45,XX,rob(13;14)(q10;q10).Statistical analysis showed no significant association between the groups and the type of chromosomal abnormalities.\n'
p5451
sg4
(lp5452
sg29
(lp5453
(dp5454
g7
I120
sg32
VC0392053
p5455
sg10
I9
sg11
Vmosaicism
p5456
sg13
I1
sa(dp5457
g7
I350
sg32
VC0008625
p5458
sg10
I25
sg11
Vchromosomal abnormalities
p5459
sg13
I2
sa(dp5460
g7
I191
sg32
VC0002938
p5461
sg10
I10
sg11
Vaneuploidy
p5462
sg13
I1
sa(dp5463
g7
I109
sg32
VC0041408
p5464
sg10
I10
sg11
Vmonosomy X
p5465
sg13
I2
sasa(dp5466
g2
S'No obvious phenotype of Turner syndrome was observed in this patient and cytogenetic analysis revealed that her karyotype is 46,X,i(X)(q10).\n'
p5467
sg4
(lp5468
sg29
(lp5469
(dp5470
g7
I24
sg32
VC0041408
p5471
sg10
I15
sg11
VTurner syndrome
p5472
sg13
I2
sasa(dp5473
g2
S'Sixty-four children (11.6%) were confirmed with IEM by the MS/MS, including 33 cases of methylmalonic acidemia or propionic acidemias, 2 cases of phenylketonuria, 3 cases of carnitine palmotoyl transferase I deficiency, 1 case of long-chain acyl-CoA dehydrogenase deficiency, 2 cases of medium-chain acyl-CoA dehydrogenase deficiency, 6 cases of maple syrup urine disease, 2 cases of short-chain acyl-CoA dehydrogenase deficiency, 2 cases of glutaric acidemia type I, 2 cases of isovaleric acidemia, 2 cases of homocystinuria, 4 cases of carnitine deficiency, 1 case of tyrosinemia, 1 case of argininosuccinic aciduria, 2 cases of citrullinemia and 1 case of argininemia.\n'
p5474
sg4
(lp5475
(dp5476
g7
I241
sg8
VP49366
p5477
sg10
I22
sg11
Vacyl-CoA dehydrogenase
p5478
sg13
I2
sa(dp5479
g7
I241
sg8
VP49366
p5480
sg10
I22
sg11
Vacyl-CoA dehydrogenase
p5481
sg13
I2
sa(dp5482
g7
I174
sg8
VP49366
p5483
sg10
I89
sg11
Vcarnitine palmotoyl transferase I deficiency, 1 case of long-chain acyl-CoA dehydrogenase
p5484
sg13
I11
sasg29
(lp5485
(dp5486
g7
I146
sg32
VC0031485
p5487
sg10
I15
sg11
Vphenylketonuria
p5488
sg13
I1
sa(dp5489
g7
I241
sg32
VC0268635
p5490
sg10
I33
sg11
Vacyl-CoA dehydrogenase deficiency
p5491
sg13
I3
sa(dp5492
g7
I230
sg32
VC0220711
p5493
sg10
I44
sg11
Vlong-chain acyl-CoA dehydrogenase deficiency
p5494
sg13
I4
sa(dp5495
g7
I88
sg32
VC0268583
p5496
sg10
I22
sg11
Vmethylmalonic acidemia
p5497
sg13
I2
sa(dp5498
g7
I479
sg32
VC0268575
p5499
sg10
I19
sg11
Visovaleric acidemia
p5500
sg13
I2
sa(dp5501
g7
I593
sg32
VC0268547
p5502
sg10
I25
sg11
Vargininosuccinic aciduria
p5503
sg13
I2
sa(dp5504
g7
I346
sg32
VC0024776
p5505
sg10
I25
sg11
Vmaple syrup urine disease
p5506
sg13
I4
sa(dp5507
g7
I631
sg32
VC0175683
p5508
sg10
I13
sg11
Vcitrullinemia
p5509
sg13
I1
sa(dp5510
g7
I102
sg32
VC0268030
p5511
sg10
I8
sg11
Vacidemia
p5512
sg13
I1
sa(dp5513
g7
I538
sg32
VC1142132
p5514
sg10
I20
sg11
Vcarnitine deficiency
p5515
sg13
I2
sa(dp5516
g7
I114
sg32
VC0268579
p5517
sg10
I19
sg11
Vpropionic acidemias
p5518
sg13
I2
sa(dp5519
g7
I659
sg32
VC0268548
p5520
sg10
I11
sg11
Vargininemia
p5521
sg13
I1
sa(dp5522
g7
I570
sg32
VC0268483
p5523
sg10
I11
sg11
Vtyrosinemia
p5524
sg13
I1
sa(dp5525
g7
I287
sg32
VC0220710
p5526
sg10
I46
sg11
Vmedium-chain acyl-CoA dehydrogenase deficiency
p5527
sg13
I4
sa(dp5528
g7
I511
sg32
VC0019880
p5529
sg10
I14
sg11
Vhomocystinuria
p5530
sg13
I1
sasa(dp5531
g2
S'Genes that have been implicated in monogenic CVID include ICOS, TNFRSF13B (TACI), TNFRSF13C (BAFF-R), TNFSF12 (TWEAK), CD19, CD81, CR2 (CD21), MS4A1 (CD20), TNFRSF7 (CD27), IL21, IL21R, LRBA, CTLA4, PRKCD, PLCG2, NFKB1, NFKB2, PIK3CD, PIK3R1, VAV1, RAC2, BLK, IKZF1 (IKAROS) and IRF2BP2 With the increasing number of disease genes identified in CVID, it has become clear that CVID is an umbrella diagnosis and that many of these genetic defects cause distinct disease entities.\n'
p5532
sg4
(lp5533
(dp5534
g7
I111
sg8
g48
sg10
I5
sg11
VTWEAK
p5535
sg13
I1
sa(dp5536
g7
I82
sg8
g48
sg10
I9
sg11
VTNFRSF13C
p5537
sg13
I1
sa(dp5538
g7
I75
sg8
g48
sg10
I4
sg11
VTACI
p5539
sg13
I1
sa(dp5540
g7
I186
sg8
VP50851
p5541
sg10
I4
sg11
VLRBA
p5542
sg13
I1
sa(dp5543
g7
I213
sg8
VP19838
p5544
sg10
I5
sg11
VNFKB1
p5545
sg13
I1
sa(dp5546
g7
I235
sg8
VP27986
p5547
sg10
I6
sg11
VPIK3R1
p5548
sg13
I1
sa(dp5549
g7
I206
sg8
VP16885
p5550
sg10
I5
sg11
VPLCG2
p5551
sg13
I1
sa(dp5552
g7
I125
sg8
VP60033
p5553
sg10
I4
sg11
VCD81
p5554
sg13
I1
sa(dp5555
g7
I220
sg8
g48
sg10
I5
sg11
VNFKB2
p5556
sg13
I1
sa(dp5557
g7
I93
sg8
g48
sg10
I6
sg11
VBAFF-R
p5558
sg13
I1
sa(dp5559
g7
I279
sg8
g48
sg10
I7
sg11
VIRF2BP2
p5560
sg13
I1
sa(dp5561
g7
I119
sg8
VP15391
p5562
sg10
I4
sg11
VCD19
p5563
sg13
I1
sa(dp5564
g7
I45
sg8
g48
sg10
I4
sg11
VCVID
p5565
sg13
I1
sa(dp5566
g7
I45
sg8
g48
sg10
I4
sg11
VCVID
p5567
sg13
I1
sa(dp5568
g7
I227
sg8
g48
sg10
I6
sg11
VPIK3CD
p5569
sg13
I1
sa(dp5570
g7
I136
sg8
VP20023
p5571
sg10
I4
sg11
VCD21
p5572
sg13
I1
sa(dp5573
g7
I102
sg8
g48
sg10
I7
sg11
VTNFSF12
p5574
sg13
I1
sa(dp5575
g7
I58
sg8
VP16410
p5576
sg10
I4
sg11
VICOS
p5577
sg13
I1
sa(dp5578
g7
I249
sg8
VP15153
p5579
sg10
I4
sg11
VRAC2
p5580
sg13
I1
sa(dp5581
g7
I64
sg8
g48
sg10
I9
sg11
VTNFRSF13B
p5582
sg13
I1
sa(dp5583
g7
I243
sg8
VP15498
p5584
sg10
I4
sg11
VVAV1
p5585
sg13
I1
sa(dp5586
g7
I157
sg8
VP26842
p5587
sg10
I7
sg11
VTNFRSF7
p5588
sg13
I1
sa(dp5589
g7
I173
sg8
g48
sg10
I4
sg11
VIL21
p5590
sg13
I1
sa(dp5591
g7
I179
sg8
g48
sg10
I5
sg11
VIL21R
p5592
sg13
I1
sa(dp5593
g7
I166
sg8
VP26842
p5594
sg10
I4
sg11
VCD27
p5595
sg13
I1
sa(dp5596
g7
I260
sg8
g48
sg10
I5
sg11
VIKZF1
p5597
sg13
I1
sa(dp5598
g7
I150
sg8
VP35900
p5599
sg10
I4
sg11
VCD20
p5600
sg13
I1
sa(dp5601
g7
I192
sg8
VP16410
p5602
sg10
I5
sg11
VCTLA4
p5603
sg13
I1
sa(dp5604
g7
I267
sg8
g48
sg10
I6
sg11
VIKAROS
p5605
sg13
I1
sa(dp5606
g7
I143
sg8
VP11836
p5607
sg10
I5
sg11
VMS4A1
p5608
sg13
I1
sa(dp5609
g7
I199
sg8
g48
sg10
I5
sg11
VPRKCD
p5610
sg13
I1
sa(dp5611
g7
I131
sg8
VP20023
p5612
sg10
I3
sg11
VCR2
p5613
sg13
I1
sa(dp5614
g7
I255
sg8
VP51451
p5615
sg10
I3
sg11
VBLK
p5616
sg13
I1
sasg29
(lp5617
(dp5618
g7
I45
sg32
VC0009447
p5619
sg10
I4
sg11
VCVID
p5620
sg13
I1
sa(dp5621
g7
I45
sg32
VC0009447
p5622
sg10
I4
sg11
VCVID
p5623
sg13
I1
sa(dp5624
g7
I45
sg32
VC0009447
p5625
sg10
I4
sg11
VCVID
p5626
sg13
I1
sasa(dp5627
g2
S'Human IL-21 and IL-21R deficiencies cause severe, primary immunodeficiency reminiscent of common variable immunodeficiency.\n'
p5628
sg4
(lp5629
(dp5630
g7
I0
sg8
g48
sg10
I11
sg11
VHuman IL-21
p5631
sg13
I2
sasg29
(lp5632
(dp5633
g7
I50
sg32
VC0398686
p5634
sg10
I24
sg11
Vprimary immunodeficiency
p5635
sg13
I2
sa(dp5636
g7
I90
sg32
VC0009447
p5637
sg10
I32
sg11
Vcommon variable immunodeficiency
p5638
sg13
I3
sasa(dp5639
g2
S'The function of the IL-21R : IL-4R system seems not to be related to the aetiology of CVID in paediatric patients and might be suitable for a regenerative therapy.\n'
p5640
sg4
(lp5641
sg29
(lp5642
(dp5643
g7
I86
sg32
VC0009447
p5644
sg10
I4
sg11
VCVID
p5645
sg13
I1
sasa(dp5646
g2
S'The exonic, protein coding regions of the genes encoding: APRIL, BCMA, IL10, IL10Ralpha, IL10Rbeta, IL21, IL21R, and CCL18, were analyzed primarily in familial CVID cases, who showed evidence of genetic linkage to the respective candidate gene loci and CVID families with a recessive pattern of inheritance.\n'
p5647
sg4
(lp5648
(dp5649
g7
I106
sg8
g48
sg10
I5
sg11
VIL21R
p5650
sg13
I1
sa(dp5651
g7
I71
sg8
VP22301
p5652
sg10
I4
sg11
VIL10
p5653
sg13
I1
sa(dp5654
g7
I117
sg8
VP55774
p5655
sg10
I5
sg11
VCCL18
p5656
sg13
I1
sa(dp5657
g7
I58
sg8
g48
sg10
I5
sg11
VAPRIL
p5658
sg13
I1
sa(dp5659
g7
I100
sg8
g48
sg10
I4
sg11
VIL21
p5660
sg13
I1
sa(dp5661
g7
I65
sg8
g48
sg10
I4
sg11
VBCMA
p5662
sg13
I1
sasg29
(lp5663
(dp5664
g7
I160
sg32
VC0009447
p5665
sg10
I4
sg11
VCVID
p5666
sg13
I1
sa(dp5667
g7
I160
sg32
VC0009447
p5668
sg10
I4
sg11
VCVID
p5669
sg13
I1
sasa(dp5670
g2
S'Two novel SNPs were identified in exon 5 and exon 8 of the IL21R gene, which segregated with the disease phenotype in one CVID family.\n'
p5671
sg4
(lp5672
(dp5673
g7
I122
sg8
g48
sg10
I11
sg11
VCVID family
p5674
sg13
I2
sa(dp5675
g7
I59
sg8
g48
sg10
I10
sg11
VIL21R gene
p5676
sg13
I2
sasg29
(lp5677
(dp5678
g7
I122
sg32
VC0009447
p5679
sg10
I4
sg11
VCVID
p5680
sg13
I1
sasa(dp5681
g2
S'Mice lacking both IL-4 and IL-21R exhibited a significantly more pronounced phenotype, with dysgammaglobulinemia, characterized primarily by a severely impaired IgG response.\n'
p5682
sg4
(lp5683
(dp5684
g7
I18
sg8
VP05112
p5685
sg10
I4
sg11
VIL-4
p5686
sg13
I1
sasg29
(lp5687
(dp5688
g7
I152
sg32
VC0684336
p5689
sg10
I8
sg11
Vimpaired
p5690
sg13
I1
sa(dp5691
g7
I92
sg32
VC0013374
p5692
sg10
I20
sg11
Vdysgammaglobulinemia
p5693
sg13
I1
sasa(dp5694
g2
S'Here, we studied phenotypes associated with mutations in the schizophrenia susceptibility gene dysbindin (dysb), in isolation or in combination with null alleles in the dysb network component Blos1.\n'
p5695
sg4
(lp5696
sg29
(lp5697
(dp5698
g7
I61
sg32
VC0036341
p5699
sg10
I13
sg11
Vschizophrenia
p5700
sg13
I1
sasa(dp5701
g2
S'DEGs of NAMPT, TLR9, PTGS2, HBD, and PCSK1N might be associated with obesity.\n'
p5702
sg4
(lp5703
(dp5704
g7
I28
sg8
VP02042
p5705
sg10
I3
sg11
VHBD
p5706
sg13
I1
sa(dp5707
g7
I15
sg8
g48
sg10
I4
sg11
VTLR9
p5708
sg13
I1
sa(dp5709
g7
I0
sg8
g48
sg10
I4
sg11
VDEGs
p5710
sg13
I1
sa(dp5711
g7
I8
sg8
VP43490
p5712
sg10
I5
sg11
VNAMPT
p5713
sg13
I1
sa(dp5714
g7
I37
sg8
g48
sg10
I6
sg11
VPCSK1N
p5715
sg13
I1
sa(dp5716
g7
I21
sg8
VP35354
p5717
sg10
I5
sg11
VPTGS2
p5718
sg13
I1
sasg29
(lp5719
(dp5720
g7
I28
sg32
VC1840321
p5721
sg10
I3
sg11
VHBD
p5722
sg13
I1
sa(dp5723
g7
I69
sg32
VC0028754
p5724
sg10
I7
sg11
Vobesity
p5725
sg13
I1
sasa(dp5726
g2
S'We compared the prevalence of four polymorphisms, the sickle hemoglobin mutation (Beta globin E6V), the Alfa-thalassemia 3.7kb deletion, glucose-6-phosphate dehydrogenase deficiency caused by the common African variant (G6PD A-), and the CD36 T188G mutation in 1344 individuals residing in districts in eastern (Tororo), south-central (Jinja), and southwestern (Kanungu) Uganda.\n'
p5727
sg4
(lp5728
(dp5729
g7
I220
sg8
VP11441
p5730
sg10
I6
sg11
VG6PD A
p5731
sg13
I2
sa(dp5732
g7
I54
sg8
g48
sg10
I26
sg11
Vsickle hemoglobin mutation
p5733
sg13
I3
sa(dp5734
g7
I137
sg8
VP49366
p5735
sg10
I33
sg11
Vglucose-6-phosphate dehydrogenase
p5736
sg13
I2
sasg29
(lp5737
(dp5738
g7
I109
sg32
VC0039730
p5739
sg10
I11
sg11
Vthalassemia
p5740
sg13
I1
sa(dp5741
g7
I137
sg32
VC0017758
p5742
sg10
I44
sg11
Vglucose-6-phosphate dehydrogenase deficiency
p5743
sg13
I3
sasa(dp5744
g2
S'Conclusion: Renal hemosiderosis and asymptomatic renal dysfunction are prevalent among transfusion- dependent Beta-thalassemia major patients which necessitate regular screening with early markers of glomerular and tubular dysfunction.\n'
p5745
sg4
(lp5746
sg29
(lp5747
(dp5748
g7
I12
sg32
VC0268067
p5749
sg10
I19
sg11
VRenal hemosiderosis
p5750
sg13
I2
sa(dp5751
g7
I115
sg32
VC0002875
p5752
sg10
I17
sg11
Vthalassemia major
p5753
sg13
I2
sasa(dp5754
g2
S'Diabetes mellitus (DM) is one of the potential complications in patients with transfusion-dependent Beta-thalassemia major (Beta-TM).\n'
p5755
sg4
(lp5756
sg29
(lp5757
(dp5758
g7
I19
sg32
VC0011849
p5759
sg10
I2
sg11
VDM
p5760
sg13
I1
sa(dp5761
g7
I105
sg32
VC0002875
p5762
sg10
I17
sg11
Vthalassemia major
p5763
sg13
I2
sa(dp5764
g7
I0
sg32
VC0011849
p5765
sg10
I17
sg11
VDiabetes mellitus
p5766
sg13
I2
sasa(dp5767
g2
S'To evaluate the clinical course after early surgical treatment with excision of retinal hemangioblastomas (RHs) before development of major complications.\n'
p5768
sg4
(lp5769
sg29
(lp5770
(dp5771
g7
I80
sg32
VC0398739
p5772
sg10
I25
sg11
Vretinal hemangioblastomas
p5773
sg13
I2
sa(dp5774
g7
I107
sg32
VC0398739
p5775
sg10
I3
sg11
VRHs
p5776
sg13
I1
sasa(dp5777
g2
S'Nine of the cases had an involuted hemangioma, and 29 cases had a vascular malformation; of the vascular malformations, 13, 11, one, and four cases involved were capillary malformations (CMs), venous malformations (VMs), lymphatic malformations (LMs), and arteriovenous malformations (AVMs), respectively.\n'
p5778
sg4
(lp5779
sg29
(lp5780
(dp5781
g7
I256
sg32
VC0003857
p5782
sg10
I27
sg11
Varteriovenous malformations
p5783
sg13
I2
sa(dp5784
g7
I246
sg32
VC1851710
p5785
sg10
I3
sg11
VLMs
p5786
sg13
I1
sa(dp5787
g7
I105
sg32
VC0000768
p5788
sg10
I13
sg11
Vmalformations
p5789
sg13
I1
sa(dp5790
g7
I162
sg32
VC0340803
p5791
sg10
I23
sg11
Vcapillary malformations
p5792
sg13
I2
sa(dp5793
g7
I66
sg32
VC0158570
p5794
sg10
I21
sg11
Vvascular malformation
p5795
sg13
I2
sa(dp5796
g7
I285
sg32
VC0003857
p5797
sg10
I4
sg11
VAVMs
p5798
sg13
I1
sa(dp5799
g7
I221
sg32
VC0398368
p5800
sg10
I23
sg11
Vlymphatic malformations
p5801
sg13
I2
sa(dp5802
g7
I35
sg32
VC0018916
p5803
sg10
I10
sg11
Vhemangioma
p5804
sg13
I1
sa(dp5805
g7
I187
sg32
VC0340803
p5806
sg10
I3
sg11
VCMs
p5807
sg13
I1
sa(dp5808
g7
I96
sg32
VC0158570
p5809
sg10
I22
sg11
Vvascular malformations
p5810
sg13
I2
sasa(dp5811
g2
S'The overall average satisfaction score was 4.1 out of 5, while the satisfaction scores associated with each lesion type were 4.2 for hemangiomas, 3.9 for CMs, 4.2 for VMs, 5.0 for LMs, and 4.0 for AVMs.\n'
p5812
sg4
(lp5813
sg29
(lp5814
(dp5815
g7
I180
sg32
VC1851710
p5816
sg10
I3
sg11
VLMs
p5817
sg13
I1
sa(dp5818
g7
I133
sg32
VC0018916
p5819
sg10
I11
sg11
Vhemangiomas
p5820
sg13
I1
sasa(dp5821
g2
S'Human lymphatic vascular malformations (LMs), also known as cystic hygromas or lymphangioma, consist of multiple lymphatic endothelial cell-lined lymph-containing cysts.\n'
p5822
sg4
(lp5823
sg29
(lp5824
(dp5825
g7
I6
sg32
VC1851710
p5826
sg10
I32
sg11
Vlymphatic vascular malformations
p5827
sg13
I3
sa(dp5828
g7
I79
sg32
VC0024221
p5829
sg10
I12
sg11
Vlymphangioma
p5830
sg13
I1
sa(dp5831
g7
I163
sg32
VC0010709
p5832
sg10
I5
sg11
Vcysts
p5833
sg13
I1
sa(dp5834
g7
I40
sg32
VC1851710
p5835
sg10
I3
sg11
VLMs
p5836
sg13
I1
sa(dp5837
g7
I60
sg32
VC0206620
p5838
sg10
I15
sg11
Vcystic hygromas
p5839
sg13
I2
sasa(dp5840
g2
S'Although cutaneous epidermolysis bullosa is difficult to diagnose prenatally, shortening and deformity of extremities may provide a clue to the diagnosis, even when the maternal alpha-fetoprotein concentration is normal.\n'
p5841
sg4
(lp5842
sg29
(lp5843
(dp5844
g7
I19
sg32
VC0014527
p5845
sg10
I21
sg11
Vepidermolysis bullosa
p5846
sg13
I2
sa(dp5847
g7
I93
sg32
VC0302142
p5848
sg10
I9
sg11
Vdeformity
p5849
sg13
I1
sasa(dp5850
g2
S'The aim of this study was to investigate the possible relationship between cord bloodalpha-fetoprotein (AFP) level and development of subsequent neonatal hyperbilirubinemia.\n'
p5851
sg4
(lp5852
(dp5853
g7
I104
sg8
VP02771
p5854
sg10
I3
sg11
VAFP
p5855
sg13
I1
sa(dp5856
g7
I75
sg8
g48
sg10
I27
sg11
Vcord bloodalpha-fetoprotein
p5857
sg13
I2
sasg29
(lp5858
(dp5859
g7
I145
sg32
VC0857007
p5860
sg10
I27
sg11
Vneonatal hyperbilirubinemia
p5861
sg13
I2
sa(dp5862
g7
I75
sg32
VC0035334
p5863
sg10
I4
sg11
Vcord
p5864
sg13
I1
sasa(dp5865
g2
S'Repeat maternal serum alpha-fetoprotein assay allows identification of patients who should be offered amniocentesis to evaluate the risk of nephrotic syndrome and epidermolysis bullosa.\n'
p5866
sg4
(lp5867
sg29
(lp5868
(dp5869
g7
I140
sg32
VC0027726
p5870
sg10
I18
sg11
Vnephrotic syndrome
p5871
sg13
I2
sa(dp5872
g7
I163
sg32
VC0014527
p5873
sg10
I21
sg11
Vepidermolysis bullosa
p5874
sg13
I2
sasa(dp5875
g2
S'Intracardiac repair of pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries can be accomplished by a midline 1-stage repair including complete unifocalization of all pulmonary blood supply without individual collateral anastomosis in selected patients.\n'
p5876
sg4
(lp5877
sg29
(lp5878
(dp5879
g7
I260
sg32
VC0332853
p5880
sg10
I11
sg11
Vanastomosis
p5881
sg13
I1
sa(dp5882
g7
I23
sg32
VC0344976
p5883
sg10
I48
sg11
Vpulmonary atresia with ventricular septal defect
p5884
sg13
I6
sasa(dp5885
g2
S'Six of the PSENEN mutation carriers presented with comorbid acne inversa (AI), an inflammatory hair follicle disorder, and had a history of nicotine abuse and/or obesity, which are known trigger factors for AI.\n'
p5886
sg4
(lp5887
(dp5888
g7
I11
sg8
g48
sg10
I6
sg11
VPSENEN
p5889
sg13
I1
sasg29
(lp5890
(dp5891
g7
I60
sg32
VC0162836
p5892
sg10
I12
sg11
Vacne inversa
p5893
sg13
I2
sa(dp5894
g7
I74
sg32
VC0162836
p5895
sg10
I2
sg11
VAI
p5896
sg13
I1
sa(dp5897
g7
I95
sg32
VC0178668
p5898
sg10
I22
sg11
Vhair follicle disorder
p5899
sg13
I3
sa(dp5900
g7
I162
sg32
VC0028754
p5901
sg10
I7
sg11
Vobesity
p5902
sg13
I1
sa(dp5903
g7
I149
sg32
VC1328247
p5904
sg10
I5
sg11
Vabuse
p5905
sg13
I1
sa(dp5906
g7
I74
sg32
VC0162836
p5907
sg10
I2
sg11
VAI
p5908
sg13
I1
sasa(dp5909
g2
S'Furthermore, NSE/hPen-2 Tg mice exhibiting feeding behavior dysfunction were significantly more apt to display symptoms related to diabetes and obesity.\n'
p5910
sg4
(lp5911
(dp5912
g7
I17
sg8
g48
sg10
I9
sg11
VhPen-2 Tg
p5913
sg13
I2
sa(dp5914
g7
I13
sg8
VP09104
p5915
sg10
I3
sg11
VNSE
p5916
sg13
I1
sasg29
(lp5917
(dp5918
g7
I131
sg32
VC0011849
p5919
sg10
I8
sg11
Vdiabetes
p5920
sg13
I1
sa(dp5921
g7
I144
sg32
VC0028754
p5922
sg10
I7
sg11
Vobesity
p5923
sg13
I1
sasa(dp5924
g2
S'KD and Bmax values for [3H][D-Ala2,(Me)Phe4, Gly(ol)5]enkephalin and [3H][D-Pen2,D-Pen5]enkephalin to cerebral mu and delta opiate receptors were not altered by diabetes.\n'
p5925
sg4
(lp5926
(dp5927
g7
I102
sg8
VP28072
p5928
sg10
I38
sg11
Vcerebral mu and delta opiate receptors
p5929
sg13
I6
sa(dp5930
g7
I76
sg8
g48
sg10
I4
sg11
VPen2
p5931
sg13
I1
sasg29
(lp5932
(dp5933
g7
I161
sg32
VC0011849
p5934
sg10
I8
sg11
Vdiabetes
p5935
sg13
I1
sasa(dp5936
g2
S'The study was carried out in 60 insulin-dependent diabetes mellitus (IDDM) patients (33 women and 27 men) chosen according to two criteria: (1) the use of a Medisense Pen 2 or Companion 2; (2) autonomous self-monitoring of blood glucose, i.e.\n'
p5937
sg4
(lp5938
(dp5939
g7
I32
sg8
VP01308
p5940
sg10
I7
sg11
Vinsulin
p5941
sg13
I1
sasg29
(lp5942
(dp5943
g7
I69
sg32
VC0011854
p5944
sg10
I4
sg11
VIDDM
p5945
sg13
I1
sa(dp5946
g7
I32
sg32
VC0011854
p5947
sg10
I35
sg11
Vinsulin-dependent diabetes mellitus
p5948
sg13
I3
sasa(dp5949
g2
S'Separation was achieved with a Waters Atlantis dC18 column (LC-MS) or a Waters SymmetryShield RP18 column connected with an Atlantis dC18 (LC-UV).\n'
p5950
sg4
(lp5951
(dp5952
g7
I47
sg8
g48
sg10
I4
sg11
VdC18
p5953
sg13
I1
sasg29
(lp5954
(dp5955
g7
I0
sg32
VC0036679
p5956
sg10
I10
sg11
VSeparation
p5957
sg13
I1
sa(dp5958
g7
I94
sg32
VC1832378
p5959
sg10
I4
sg11
VRP18
p5960
sg13
I1
sasa(dp5961
g2
S'Separation was achieved with a SymmetryShield RP18 column and an Atlantis dC18 column using a 10 mM potassium phosphate buffer as mobile phase.\n'
p5962
sg4
(lp5963
(dp5964
g7
I74
sg8
g48
sg10
I4
sg11
VdC18
p5965
sg13
I1
sasg29
(lp5966
(dp5967
g7
I46
sg32
VC1832378
p5968
sg10
I4
sg11
VRP18
p5969
sg13
I1
sa(dp5970
g7
I0
sg32
VC0036679
p5971
sg10
I10
sg11
VSeparation
p5972
sg13
I1
sasa(dp5973
g2
S'The aim of the study was to investigate the effect of Plpp3 deletion on atherosclerosis development in mice.\n'
p5974
sg4
(lp5975
sg29
(lp5976
(dp5977
g7
I72
sg32
VC0004153
p5978
sg10
I15
sg11
Vatherosclerosis
p5979
sg13
I1
sasa(dp5980
g2
S'Lipidomic analysis showed that hepatic Plpp3 deletion significantly modified the levels of several plasma lipids involved in atherosclerosis, including lactosylceramides, lysophosphatidic acids, and lysophosphatidylinositols.\n'
p5981
sg4
(lp5982
sg29
(lp5983
(dp5984
g7
I125
sg32
VC0004153
p5985
sg10
I15
sg11
Vatherosclerosis
p5986
sg13
I1
sasa(dp5987
g2
S'In conclusion, Plpp3 ablation in mice worsened atherosclerosis development.\n'
p5988
sg4
(lp5989
sg29
(lp5990
(dp5991
g7
I47
sg32
VC0004153
p5992
sg10
I15
sg11
Vatherosclerosis
p5993
sg13
I1
sasa(dp5994
g2
S'Lipidomic analysis suggested that the hepatic Plpp3 deletion may promote atherosclerosis by increasing plasma levels of several low-abundant pro-atherogenic lipids, thus providing a molecular basis for the observed results.\n'
p5995
sg4
(lp5996
sg29
(lp5997
(dp5998
g7
I73
sg32
VC0004153
p5999
sg10
I15
sg11
Vatherosclerosis
p6000
sg13
I1
sasa(dp6001
g2
S'A polymorphism (rs17114036) in PPAP2B is associated with coronary artery disease, which prompted us to investigate the possible role of LPP3 in human endothelial dysfunction, a condition promoting atherosclerosis.\n'
p6002
sg4
(lp6003
(dp6004
g7
I136
sg8
g48
sg10
I4
sg11
VLPP3
p6005
sg13
I1
sa(dp6006
g7
I31
sg8
g48
sg10
I6
sg11
VPPAP2B
p6007
sg13
I1
sasg29
(lp6008
(dp6009
g7
I150
sg32
VC0856169
p6010
sg10
I23
sg11
Vendothelial dysfunction
p6011
sg13
I2
sa(dp6012
g7
I177
sg32
VC0012634
p6013
sg10
I9
sg11
Vcondition
p6014
sg13
I1
sa(dp6015
g7
I57
sg32
VC1956346
p6016
sg10
I23
sg11
Vcoronary artery disease
p6017
sg13
I3
sa(dp6018
g7
I197
sg32
VC0004153
p6019
sg10
I15
sg11
Vatherosclerosis
p6020
sg13
I1
sasa(dp6021
g2
S'However, it is unclear whether genome-wide association studies-identified coronary artery disease genes, including PPAP2B, participate in mechanotransduction mechanisms by which vascular endothelia respond to local atherorelevant hemodynamics that contribute to the regional nature of atherosclerosis.\n'
p6022
sg4
(lp6023
(dp6024
g7
I115
sg8
g48
sg10
I6
sg11
VPPAP2B
p6025
sg13
I1
sasg29
(lp6026
(dp6027
g7
I74
sg32
VC1956346
p6028
sg10
I23
sg11
Vcoronary artery disease
p6029
sg13
I3
sa(dp6030
g7
I285
sg32
VC0004153
p6031
sg10
I15
sg11
Vatherosclerosis
p6032
sg13
I1
sasa(dp6033
g2
S'Our results do not confirm association between ABO rs579459, PPAP2B rs17114036, ADAMTS7 rs3825807, PIK3CG rs17398575, and EDNRA rs1878406 and subclinical atherosclerosis and CV disease in RA.\n'
p6034
sg4
(lp6035
(dp6036
g7
I80
sg8
g48
sg10
I17
sg11
VADAMTS7 rs3825807
p6037
sg13
I2
sa(dp6038
g7
I99
sg8
VP48736
p6039
sg10
I17
sg11
VPIK3CG rs17398575
p6040
sg13
I2
sa(dp6041
g7
I61
sg8
g48
sg10
I17
sg11
VPPAP2B rs17114036
p6042
sg13
I2
sasg29
(lp6043
(dp6044
g7
I154
sg32
VC0004153
p6045
sg10
I15
sg11
Vatherosclerosis
p6046
sg13
I1
sasa(dp6047
g2
S'Although emerging evidence links lysophosphatidic acid to atherosclerosis and vascular injury responses, little is known about the role of vascular LPP3.\n'
p6048
sg4
(lp6049
(dp6050
g7
I139
sg8
g48
sg10
I13
sg11
Vvascular LPP3
p6051
sg13
I2
sasg29
(lp6052
(dp6053
g7
I58
sg32
VC0004153
p6054
sg10
I15
sg11
Vatherosclerosis
p6055
sg13
I1
sasa(dp6056
g2
S'The G-protein-coupled estrogen receptor (GPR30, GPER-1) is a member of the G-protein-coupled receptor 1 family and is expressed significantly in uterine leiomyomas.\n'
p6057
sg4
(lp6058
(dp6059
g7
I75
sg8
g48
sg10
I35
sg11
VG-protein-coupled receptor 1 family
p6060
sg13
I4
sa(dp6061
g7
I4
sg8
VP03372
p6062
sg10
I35
sg11
VG-protein-coupled estrogen receptor
p6063
sg13
I3
sasg29
(lp6064
(dp6065
g7
I153
sg32
VC0023267
p6066
sg10
I10
sg11
Vleiomyomas
p6067
sg13
I1
sasa(dp6068
g2
S'To understand the relationship between GPR30 single nucleotide polymorphisms and the risk of leiomyoma, we measured the follicle-stimulating hormone (FSH) and estradiol (E2) levels of 78 perimenopausal healthy women and 111 perimenopausal women with leiomyomas.\n'
p6069
sg4
(lp6070
(dp6071
g7
I150
sg8
VP01225
p6072
sg10
I3
sg11
VFSH
p6073
sg13
I1
sa(dp6074
g7
I120
sg8
VP01225
p6075
sg10
I28
sg11
Vfollicle-stimulating hormone
p6076
sg13
I2
sasg29
(lp6077
(dp6078
g7
I250
sg32
VC0023267
p6079
sg10
I10
sg11
Vleiomyomas
p6080
sg13
I1
sa(dp6081
g7
I93
sg32
VC0023267
p6082
sg10
I9
sg11
Vleiomyoma
p6083
sg13
I1
sasa(dp6084
g2
S'However, the GG genotype of the GPR30 rs3808351 polymorphism and G allele of the GPR30 rs3808351 polymorphism were associated with the risk of having a single leiomyoma.\n'
p6085
sg4
(lp6086
sg29
(lp6087
(dp6088
g7
I152
sg32
VC0349528
p6089
sg10
I16
sg11
Vsingle leiomyoma
p6090
sg13
I2
sasa(dp6091
g2
S'Our results suggest that the presence of the GG genotype of the GPR30 rs3808351 polymorphism and the G allele of the GPR30 rs3808351 polymorphism affect the characteristics and development of leiomyomas in the Turkish population.\n'
p6092
sg4
(lp6093
sg29
(lp6094
(dp6095
g7
I192
sg32
VC0023267
p6096
sg10
I10
sg11
Vleiomyomas
p6097
sg13
I1
sasa(dp6098
g2
S'G protein-coupled estrogen receptor 1 (GPER-1, formerly known as GPR30) has been proposed as the receptor for estrogen-induced, growth of leiomyomas though its precise mechanisms of action are not clear.\n'
p6099
sg4
(lp6100
(dp6101
g7
I0
sg8
g48
sg10
I9
sg11
VG protein
p6102
sg13
I2
sa(dp6103
g7
I18
sg8
VP03372
p6104
sg10
I19
sg11
Vestrogen receptor 1
p6105
sg13
I3
sasg29
(lp6106
(dp6107
g7
I138
sg32
VC0023267
p6108
sg10
I10
sg11
Vleiomyomas
p6109
sg13
I1
sasa(dp6110
g2
S'These observations indicate that GPER targeting for the therapy of Leydig cell tumor may represent a good alternative to cisplatin to preserve fertility in Leydig tumor patients.\n'
p6111
sg4
(lp6112
sg29
(lp6113
(dp6114
g7
I67
sg32
VC0023601
p6115
sg10
I17
sg11
VLeydig cell tumor
p6116
sg13
I3
sa(dp6117
g7
I79
sg32
VC0027651
p6118
sg10
I5
sg11
Vtumor
p6119
sg13
I1
sa(dp6120
g7
I143
sg32
VC0021359
p6121
sg10
I9
sg11
Vfertility
p6122
sg13
I1
sasa(dp6123
g2
S'Immunohistochemical analysis of tissue sections of murine lung adenomas as well as human lung adenocarcinomas, squamous cell carcinomas and non-small cell lung carcinomas showed consistently higher expression of GPER in the tumor relative to the surrounding non-tumor tissue.\n'
p6124
sg4
(lp6125
sg29
(lp6126
(dp6127
g7
I99
sg32
VC0007097
p6128
sg10
I10
sg11
Vcarcinomas
p6129
sg13
I1
sa(dp6130
g7
I224
sg32
VC0027651
p6131
sg10
I5
sg11
Vtumor
p6132
sg13
I1
sa(dp6133
g7
I224
sg32
VC0027651
p6134
sg10
I5
sg11
Vtumor
p6135
sg13
I1
sa(dp6136
g7
I94
sg32
VC0001418
p6137
sg10
I15
sg11
Vadenocarcinomas
p6138
sg13
I1
sa(dp6139
g7
I63
sg32
VC0001430
p6140
sg10
I8
sg11
Vadenomas
p6141
sg13
I1
sa(dp6142
g7
I111
sg32
VC0007137
p6143
sg10
I24
sg11
Vsquamous cell carcinomas
p6144
sg13
I3
sasa(dp6145
g2
S'To determine differential expression of G-protein-coupled receptor 30 (GPR30) in uterine leiomyoma and its matched myometrium.\n'
p6146
sg4
(lp6147
(dp6148
g7
I71
sg8
g48
sg10
I5
sg11
VGPR30
p6149
sg13
I1
sa(dp6150
g7
I40
sg8
g48
sg10
I29
sg11
VG-protein-coupled receptor 30
p6151
sg13
I3
sasg29
(lp6152
(dp6153
g7
I81
sg32
VC0042133
p6154
sg10
I17
sg11
Vuterine leiomyoma
p6155
sg13
I2
sasa(dp6156
g2
S'Using Western blot and real-time quantitative polymerase chain reaction analyses, we found that GPR30 was highly expressed in uterine leiomyomas compared with their matched myometrium.\n'
p6157
sg4
(lp6158
sg29
(lp6159
(dp6160
g7
I134
sg32
VC0023267
p6161
sg10
I10
sg11
Vleiomyomas
p6162
sg13
I1
sasa(dp6163
g2
S'In only three out of nine patients examined was GPR30 protein detectable by Western blot analysis in myometrial tissues, but at statistically significantly lower levels than in their leiomyomas.\n'
p6164
sg4
(lp6165
sg29
(lp6166
(dp6167
g7
I183
sg32
VC0023267
p6168
sg10
I10
sg11
Vleiomyomas
p6169
sg13
I1
sasa(dp6170
g2
S'Confocal microscopy revealed the nuclear localization of GPR30 in leiomyoma tissues and cultured leiomyoma smooth muscle cells (SMCs).\n'
p6171
sg4
(lp6172
sg29
(lp6173
(dp6174
g7
I66
sg32
VC0023267
p6175
sg10
I9
sg11
Vleiomyoma
p6176
sg13
I1
sa(dp6177
g7
I66
sg32
VC0023267
p6178
sg10
I9
sg11
Vleiomyoma
p6179
sg13
I1
sasa(dp6180
g2
S'Treatment with 0.1 myM 17Beta-estradiol increased mRNA expression of GPR30 in leiomyoma SMCs but decreased expression in myometrial SMCs.\n'
p6181
sg4
(lp6182
(dp6183
g7
I19
sg8
g48
sg10
I10
sg11
VmyM 17Beta
p6184
sg13
I2
sasg29
(lp6185
(dp6186
g7
I78
sg32
VC0023267
p6187
sg10
I9
sg11
Vleiomyoma
p6188
sg13
I1
sasa(dp6189
g2
S'GPR30 is abundantly expressed in uterine leiomyomas, likely resulting from estrogen stimulation.\n'
p6190
sg4
(lp6191
sg29
(lp6192
(dp6193
g7
I41
sg32
VC0023267
p6194
sg10
I10
sg11
Vleiomyomas
p6195
sg13
I1
sasa(dp6196
g2
S'The role of membrane estrogen receptor-alpha (mERalpha) in rapid nongenomic responses to 17beta-estradiol (E(2)) was tested in sublines of GH3/B6 rat prolactinoma cells selected for high (GH3/B6/F10) and low (GH3/B6/D9) mERalpha expression.\n'
p6197
sg4
(lp6198
(dp6199
g7
I21
sg8
VP03372
p6200
sg10
I23
sg11
Vestrogen receptor-alpha
p6201
sg13
I2
sa(dp6202
g7
I195
sg8
VP55197
p6203
sg10
I3
sg11
VF10
p6204
sg13
I1
sasg29
(lp6205
(dp6206
g7
I150
sg32
VC0033375
p6207
sg10
I12
sg11
Vprolactinoma
p6208
sg13
I1
sasa(dp6209
g2
S'Poikiloderma with Neutropenia (PN) is inherited genodermatosis which results from a biallelic mutation in the USB1 gene (U Six Biogenesis 1).\n'
p6210
sg4
(lp6211
(dp6212
g7
I121
sg8
g48
sg10
I18
sg11
VU Six Biogenesis 1
p6213
sg13
I4
sasg29
(lp6214
(dp6215
g7
I48
sg32
VC0037277
p6216
sg10
I14
sg11
Vgenodermatosis
p6217
sg13
I1
sa(dp6218
g7
I0
sg32
VC1858723
p6219
sg10
I29
sg11
VPoikiloderma with Neutropenia
p6220
sg13
I3
sa(dp6221
g7
I31
sg32
VC1858723
p6222
sg10
I2
sg11
VPN
p6223
sg13
I1
sasa(dp6224
g2
S'Our case series shows that biallelic variants in USB1, LIG4 and GRHL2, the genes mutated in poikiloderma with neutropenia, LIG4/Dubowitz syndrome and the recently recognized ectodermal dysplasia/short stature syndrome, respectively, cause features that overlap with dyskeratosis congenita.\n'
p6225
sg4
(lp6226
(dp6227
g7
I55
sg8
VP49917
p6228
sg10
I4
sg11
VLIG4
p6229
sg13
I1
sa(dp6230
g7
I55
sg8
VP49917
p6231
sg10
I4
sg11
VLIG4
p6232
sg13
I1
sa(dp6233
g7
I64
sg8
g48
sg10
I5
sg11
VGRHL2
p6234
sg13
I1
sasg29
(lp6235
(dp6236
g7
I128
sg32
VC0175691
p6237
sg10
I17
sg11
VDubowitz syndrome
p6238
sg13
I2
sa(dp6239
g7
I92
sg32
VC1858723
p6240
sg10
I29
sg11
Vpoikiloderma with neutropenia
p6241
sg13
I3
sa(dp6242
g7
I195
sg32
VC0013336
p6243
sg10
I13
sg11
Vshort stature
p6244
sg13
I2
sa(dp6245
g7
I174
sg32
VC0013575
p6246
sg10
I20
sg11
Vectodermal dysplasia
p6247
sg13
I2
sa(dp6248
g7
I266
sg32
VC0265965
p6249
sg10
I22
sg11
Vdyskeratosis congenita
p6250
sg13
I2
sa(dp6251
g7
I137
sg32
VC0039082
p6252
sg10
I8
sg11
Vsyndrome
p6253
sg13
I1
sasa(dp6254
g2
S'Patients with clinical features of dyskeratosis congenita need to have genetic analysis of USB1, LIG4 and GRHL2 in addition to the classical dyskeratosis congenita genes and telomere length measurements.\n'
p6255
sg4
(lp6256
(dp6257
g7
I106
sg8
g48
sg10
I5
sg11
VGRHL2
p6258
sg13
I1
sa(dp6259
g7
I97
sg8
VP49917
p6260
sg10
I4
sg11
VLIG4
p6261
sg13
I1
sasg29
(lp6262
(dp6263
g7
I35
sg32
VC0265965
p6264
sg10
I22
sg11
Vdyskeratosis congenita
p6265
sg13
I2
sa(dp6266
g7
I35
sg32
VC0265965
p6267
sg10
I22
sg11
Vdyskeratosis congenita
p6268
sg13
I2
sasa(dp6269
g2
S'Poikiloderma with neutropenia (PN, Clericuzio-type poikiloderma with neutropenia) is a rare autosomal recessive disorder caused by biallelic mutations in the USB1 gene (Alias C16orf57 and MPN1).\n'
p6270
sg4
(lp6271
(dp6272
g7
I169
sg8
g48
sg10
I14
sg11
VAlias C16orf57
p6273
sg13
I2
sasg29
(lp6274
(dp6275
g7
I51
sg32
VC1858723
p6276
sg10
I29
sg11
Vpoikiloderma with neutropenia
p6277
sg13
I3
sa(dp6278
g7
I0
sg32
VC1858723
p6279
sg10
I29
sg11
VPoikiloderma with neutropenia
p6280
sg13
I3
sa(dp6281
g7
I31
sg32
VC1858723
p6282
sg10
I2
sg11
VPN
p6283
sg13
I1
sasa(dp6284
g2
S'Germline mutations of the U6 biogenesis 1 (USB1) gene underlie Poikiloderma with Neutropenia (PN), a rare autosomal recessive genodermatosis conferring an increased risk of myelodysplasia.\n'
p6285
sg4
(lp6286
(dp6287
g7
I26
sg8
g48
sg10
I15
sg11
VU6 biogenesis 1
p6288
sg13
I3
sasg29
(lp6289
(dp6290
g7
I94
sg32
VC1858723
p6291
sg10
I2
sg11
VPN
p6292
sg13
I1
sa(dp6293
g7
I126
sg32
VC0037277
p6294
sg10
I14
sg11
Vgenodermatosis
p6295
sg13
I1
sa(dp6296
g7
I173
sg32
VC0026985
p6297
sg10
I14
sg11
Vmyelodysplasia
p6298
sg13
I1
sa(dp6299
g7
I63
sg32
VC1858723
p6300
sg10
I29
sg11
VPoikiloderma with Neutropenia
p6301
sg13
I3
sasa(dp6302
g2
S'Mutations in the human MPN1 gene are associated with the genodermatosis Clericuzio-type poikiloderma with neutropenia (PN).\n'
p6303
sg4
(lp6304
sg29
(lp6305
(dp6306
g7
I24
sg32
VC1858723
p6307
sg10
I2
sg11
VPN
p6308
sg13
I1
sa(dp6309
g7
I88
sg32
VC1858723
p6310
sg10
I29
sg11
Vpoikiloderma with neutropenia
p6311
sg13
I3
sa(dp6312
g7
I57
sg32
VC0037277
p6313
sg10
I14
sg11
Vgenodermatosis
p6314
sg13
I1
sasa(dp6315
g2
S'The schwannomatosis cell lines were stained with S100B antibodies to confirm Schwann cell identity.\n'
p6316
sg4
(lp6317
(dp6318
g7
I49
sg8
VP04271
p6319
sg10
I16
sg11
VS100B antibodies
p6320
sg13
I2
sasg29
(lp6321
(dp6322
g7
I4
sg32
VC1335929
p6323
sg10
I15
sg11
Vschwannomatosis
p6324
sg13
I1
sasa(dp6325
g2
S'The schwannomatosis cells also expressed the Schwann cell markers, p75NTR, S100B, and NGF after multiple passages.\n'
p6326
sg4
(lp6327
(dp6328
g7
I67
sg8
VP08138
p6329
sg10
I6
sg11
Vp75NTR
p6330
sg13
I1
sa(dp6331
g7
I75
sg8
VP04271
p6332
sg10
I5
sg11
VS100B
p6333
sg13
I1
sa(dp6334
g7
I86
sg8
VP01138
p6335
sg10
I3
sg11
VNGF
p6336
sg13
I1
sasg29
(lp6337
(dp6338
g7
I4
sg32
VC1335929
p6339
sg10
I15
sg11
Vschwannomatosis
p6340
sg13
I1
sasa(dp6341
g2
S'We calculated whole-body tumor burden in subjects with NF1, NF2, and schwannomatosis using whole-body MRI (WBMRI) and measured the concentration of S100Beta in plasma using ELISA.\n'
p6342
sg4
(lp6343
(dp6344
g7
I148
sg8
VP04271
p6345
sg10
I8
sg11
VS100Beta
p6346
sg13
I1
sa(dp6347
g7
I55
sg8
VP21359
p6348
sg10
I3
sg11
VNF1
p6349
sg13
I1
sasg29
(lp6350
(dp6351
g7
I69
sg32
VC1335929
p6352
sg10
I15
sg11
Vschwannomatosis
p6353
sg13
I1
sa(dp6354
g7
I60
sg32
VC0027832
p6355
sg10
I3
sg11
VNF2
p6356
sg13
I1
sa(dp6357
g7
I25
sg32
VC0027651
p6358
sg10
I5
sg11
Vtumor
p6359
sg13
I1
sa(dp6360
g7
I55
sg32
VC0027831
p6361
sg10
I3
sg11
VNF1
p6362
sg13
I1
sasa(dp6363
g2
S'In particular, we will highlight recent work done on the regulation of DNA double-strand breaks signalling and repair by the RNF8/RNF168 E3 ubiquitin ligases, the Fanconi anemia pathway and the role of protein degradation in the enforcement and termination of checkpoint signalling.\n'
p6364
sg4
(lp6365
(dp6366
g7
I125
sg8
g48
sg10
I4
sg11
VRNF8
p6367
sg13
I1
sa(dp6368
g7
I130
sg8
g48
sg10
I27
sg11
VRNF168 E3 ubiquitin ligases
p6369
sg13
I4
sasg29
(lp6370
(dp6371
g7
I163
sg32
VC3469521
p6372
sg10
I14
sg11
VFanconi anemia
p6373
sg13
I2
sasa(dp6374
g2
S'Serum tenascin-C levels of 33 patients with scleroderma (SSc), 10 patients with scleroderma spectrum disorder (SSD), 15 patients with localized scleroderma (LSc), 12 patients with dermatomyositis (DM), 10 patients with systemic lupus erythematosus (SLE) and 15 healthy controls were measured with specific enzyme-linked immunosorbent assays.\n'
p6375
sg4
(lp6376
(dp6377
g7
I6
sg8
VP63316
p6378
sg10
I10
sg11
Vtenascin-C
p6379
sg13
I1
sasg29
(lp6380
(dp6381
g7
I44
sg32
VC0011644
p6382
sg10
I11
sg11
Vscleroderma
p6383
sg13
I1
sa(dp6384
g7
I197
sg32
VC0221056
p6385
sg10
I2
sg11
VDM
p6386
sg13
I1
sa(dp6387
g7
I219
sg32
VC0024141
p6388
sg10
I28
sg11
Vsystemic lupus erythematosus
p6389
sg13
I3
sa(dp6390
g7
I134
sg32
VC0036420
p6391
sg10
I21
sg11
Vlocalized scleroderma
p6392
sg13
I2
sa(dp6393
g7
I92
sg32
VC1838022
p6394
sg10
I17
sg11
Vspectrum disorder
p6395
sg13
I2
sa(dp6396
g7
I44
sg32
VC0011644
p6397
sg10
I11
sg11
Vscleroderma
p6398
sg13
I1
sa(dp6399
g7
I249
sg32
VC0024141
p6400
sg10
I3
sg11
VSLE
p6401
sg13
I1
sa(dp6402
g7
I111
sg32
VC1838022
p6403
sg10
I3
sg11
VSSD
p6404
sg13
I1
sa(dp6405
g7
I157
sg32
VC0036420
p6406
sg10
I3
sg11
VLSc
p6407
sg13
I1
sa(dp6408
g7
I180
sg32
VC0221056
p6409
sg10
I15
sg11
Vdermatomyositis
p6410
sg13
I1
sasa(dp6411
g2
S'Because promoter methylation of GATA5 has previously been associated with gastric cancer, we also tested for the association of methylation status with more advanced histopathology scores in our samples and found a significant relationship (p = 0.001).\n'
p6412
sg4
(lp6413
(dp6414
g7
I32
sg8
g48
sg10
I5
sg11
VGATA5
p6415
sg13
I1
sasg29
(lp6416
(dp6417
g7
I74
sg32
VC0024623
p6418
sg10
I14
sg11
Vgastric cancer
p6419
sg13
I2
sasa(dp6420
g2
S'GATA5 is a transcription factor that is capable of suppressing the development of various types of human cancer.\n'
p6421
sg4
(lp6422
(dp6423
g7
I0
sg8
g48
sg10
I5
sg11
VGATA5
p6424
sg13
I1
sasg29
(lp6425
(dp6426
g7
I105
sg32
VC0006826
p6427
sg10
I6
sg11
Vcancer
p6428
sg13
I1
sasa(dp6429
g2
S'The present study investigated the expression of GATA5 and GATA4, and examined their roles in the proliferation and colony formation ability of hepatocellular carcinoma (HCC) tissues and cells.\n'
p6430
sg4
(lp6431
(dp6432
g7
I49
sg8
g48
sg10
I5
sg11
VGATA5
p6433
sg13
I1
sa(dp6434
g7
I59
sg8
VP43694
p6435
sg10
I5
sg11
VGATA4
p6436
sg13
I1
sasg29
(lp6437
(dp6438
g7
I98
sg32
VC0334094
p6439
sg10
I13
sg11
Vproliferation
p6440
sg13
I1
sa(dp6441
g7
I144
sg32
VC2239176
p6442
sg10
I24
sg11
Vhepatocellular carcinoma
p6443
sg13
I2
sa(dp6444
g7
I170
sg32
VC2239176
p6445
sg10
I3
sg11
VHCC
p6446
sg13
I1
sasa(dp6447
g2
S'To investigate GATA5, SFRP2, and ITGA4 methylation in plasma DNA as noninvasive biomarkers for colorectal cancer (CRC) or adenomas.\n'
p6448
sg4
(lp6449
(dp6450
g7
I33
sg8
VP13612
p6451
sg10
I5
sg11
VITGA4
p6452
sg13
I1
sa(dp6453
g7
I22
sg8
g48
sg10
I5
sg11
VSFRP2
p6454
sg13
I1
sa(dp6455
g7
I15
sg8
g48
sg10
I5
sg11
VGATA5
p6456
sg13
I1
sasg29
(lp6457
(dp6458
g7
I95
sg32
VC1527249
p6459
sg10
I17
sg11
Vcolorectal cancer
p6460
sg13
I2
sa(dp6461
g7
I122
sg32
VC0001430
p6462
sg10
I8
sg11
Vadenomas
p6463
sg13
I1
sa(dp6464
g7
I114
sg32
VC1527249
p6465
sg10
I3
sg11
VCRC
p6466
sg13
I1
sasa(dp6467
g2
S'Previously, we identified N-Myc downstream-regulated gene 4 (NDRG4) and GATA binding protein 5 (GATA5) methylation as promising biomarkers for colorectal cancer in stool DNA.\n'
p6468
sg4
(lp6469
(dp6470
g7
I61
sg8
g48
sg10
I5
sg11
VNDRG4
p6471
sg13
I1
sa(dp6472
g7
I26
sg8
g48
sg10
I33
sg11
VN-Myc downstream-regulated gene 4
p6473
sg13
I4
sa(dp6474
g7
I72
sg8
g48
sg10
I22
sg11
VGATA binding protein 5
p6475
sg13
I4
sa(dp6476
g7
I96
sg8
g48
sg10
I5
sg11
VGATA5
p6477
sg13
I1
sasg29
(lp6478
(dp6479
g7
I143
sg32
VC1527249
p6480
sg10
I17
sg11
Vcolorectal cancer
p6481
sg13
I2
sasa(dp6482
g2
S'The sensitivity of NDRG4, GATA5, FOXE1, and SYNE1 methylation in all stages of colorectal cancer (154 cases, 444 controls) was 27% [95% confidence interval (CI), 20%-34%), 18% (95% CI, 12%-24%), 46% (95% CI, 38%-54%), and 47% (95% CI, 39%-55%), with a specificity of 95% (95% CI, 93%-97%), 99% (95% CI, 98%-100%), 93% (95% CI, 91%-95%), and 96% (95% CI, 94%-98%), respectively.\n'
p6483
sg4
(lp6484
(dp6485
g7
I33
sg8
g48
sg10
I5
sg11
VFOXE1
p6486
sg13
I1
sa(dp6487
g7
I19
sg8
g48
sg10
I5
sg11
VNDRG4
p6488
sg13
I1
sa(dp6489
g7
I26
sg8
g48
sg10
I5
sg11
VGATA5
p6490
sg13
I1
sasg29
(lp6491
(dp6492
g7
I79
sg32
VC1527249
p6493
sg10
I17
sg11
Vcolorectal cancer
p6494
sg13
I2
sasa(dp6495
g2
S'To evaluate the diagnostic values of using autoantibodies in sera to a panel of eight tumor-associated antigens (TAAs) of P53, Koc, P62, C-myc, IMP1, Survivn, P16 and Cyclin B1 full-length recombinant proteins for early detection of patients with gastric cardia adenocarcinoma (GCA) and high-risk subjects screening.\n'
p6496
sg4
(lp6497
(dp6498
g7
I132
sg8
VP37198
p6499
sg10
I3
sg11
VP62
p6500
sg13
I1
sa(dp6501
g7
I144
sg8
g48
sg10
I4
sg11
VIMP1
p6502
sg13
I1
sa(dp6503
g7
I167
sg8
VP14635
p6504
sg10
I9
sg11
VCyclin B1
p6505
sg13
I2
sa(dp6506
g7
I137
sg8
VP12524
p6507
sg10
I5
sg11
VC-myc
p6508
sg13
I1
sa(dp6509
g7
I159
sg8
VP42771
p6510
sg10
I3
sg11
VP16
p6511
sg13
I1
sa(dp6512
g7
I127
sg8
g48
sg10
I3
sg11
VKoc
p6513
sg13
I1
sa(dp6514
g7
I122
sg8
VP42771
p6515
sg10
I3
sg11
VP53
p6516
sg13
I1
sa(dp6517
g7
I113
sg8
VP51572
p6518
sg10
I4
sg11
VTAAs
p6519
sg13
I1
sa(dp6520
g7
I86
sg8
VP51572
p6521
sg10
I25
sg11
Vtumor-associated antigens
p6522
sg13
I2
sasg29
(lp6523
(dp6524
g7
I247
sg32
VC1333762
p6525
sg10
I29
sg11
Vgastric cardia adenocarcinoma
p6526
sg13
I3
sa(dp6527
g7
I86
sg32
VC0027651
p6528
sg10
I5
sg11
Vtumor
p6529
sg13
I1
sa(dp6530
g7
I278
sg32
VC0039483
p6531
sg10
I3
sg11
VGCA
p6532
sg13
I1
sasa(dp6533
g2
S'To analyze retinal thickness (RT) and choroidal thickness (ChT) changes in patients with unilateral nongranulomatous acute anterior uveitis (AAU) using three-dimensional (3D) 1060-nm optical coherence tomography (OCT).\n'
p6534
sg4
(lp6535
sg29
(lp6536
(dp6537
g7
I141
sg32
VC0701807
p6538
sg10
I3
sg11
VAAU
p6539
sg13
I1
sa(dp6540
g7
I117
sg32
VC0701807
p6541
sg10
I22
sg11
Vacute anterior uveitis
p6542
sg13
I3
sasa(dp6543
g2
S'Refraction under cycloplegia, axial length, and subfoveal ChT were measured at baseline with comparative investigations at 15 months follow-up.\n'
p6544
sg4
(lp6545
sg29
(lp6546
(dp6547
g7
I17
sg32
VC0235238
p6548
sg10
I11
sg11
Vcycloplegia
p6549
sg13
I1
sasa(dp6550
g2
S'PurposeTo follow choroidal thickness (ChT) over time in birdshot retinochoroiditis (BRC) using enhanced depth imaging optical coherence tomography (EDI-OCT) and study the effect of early and sustained treatment on ChT.Patients and methodsEighteen patients were included and EDI-OCT measurements of ChT were analyzed retrospectively in five groups of patients with follow-up times ranging from 1 year to &gt;=15 years.\n'
p6551
sg4
(lp6552
sg29
(lp6553
(dp6554
g7
I65
sg32
VC0008513
p6555
sg10
I17
sg11
Vretinochoroiditis
p6556
sg13
I1
sasa(dp6557
g2
S'To investigate the changes in choroidal thickness (ChT) following panretinal photocoagulation (PRP) for diabetic retinopathy (DR) and compare ChT in relation to DR severity.\n'
p6558
sg4
(lp6559
(dp6560
g7
I95
sg8
g48
sg10
I3
sg11
VPRP
p6561
sg13
I1
sa(dp6562
g7
I66
sg8
g48
sg10
I27
sg11
Vpanretinal photocoagulation
p6563
sg13
I2
sasg29
(lp6564
(dp6565
g7
I126
sg32
VC0011884
p6566
sg10
I2
sg11
VDR
p6567
sg13
I1
sa(dp6568
g7
I126
sg32
VC0011884
p6569
sg10
I2
sg11
VDR
p6570
sg13
I1
sa(dp6571
g7
I104
sg32
VC0011884
p6572
sg10
I20
sg11
Vdiabetic retinopathy
p6573
sg13
I2
sasa(dp6574
g2
S'The central field ChT of severe NPDR (323.2 +/- 61.3 mym) was significantly thicker than that of normal (248.3 +/- 70.7 mym) and mild to moderate NPDR (230.0 +/- 70.3 mym, P = 0.0455 and 0.0099, respectively).\n'
p6575
sg4
(lp6576
sg29
(lp6577
(dp6578
g7
I25
sg32
VC0730278
p6579
sg10
I11
sg11
Vsevere NPDR
p6580
sg13
I2
sasa(dp6581
g2
S'ChT of severe NPDR and PDR was significantly thicker than that of mild to moderate NPDR.\n'
p6582
sg4
(lp6583
(dp6584
g7
I0
sg8
g48
sg10
I3
sg11
VChT
p6585
sg13
I1
sasg29
(lp6586
(dp6587
g7
I15
sg32
VC1845050
p6588
sg10
I3
sg11
VPDR
p6589
sg13
I1
sa(dp6590
g7
I7
sg32
VC0730278
p6591
sg10
I11
sg11
Vsevere NPDR
p6592
sg13
I2
sasa(dp6593
g2
S'Ten cases of presumed endophthalmitis were documented: 4 in 50,721 at CHT (95% CI: 0.0071-0.0087%), 2 in 44,666 at ZUH (95% CI: 0.0039-0.0051%), and 4 in 39,314 at UCB (95% CI: 0.0092-0.011%).\n'
p6594
sg4
(lp6595
sg29
(lp6596
(dp6597
g7
I22
sg32
VC0014236
p6598
sg10
I15
sg11
Vendophthalmitis
p6599
sg13
I1
sasa(dp6600
g2
S'To investigate longitudinal changes in intraocular pressure (IOP), axial length (AL), and choroidal thickness (ChT) in primary open-angle glaucoma (POAG) eyes after trabeculectomy and to evaluate the parameters that might influence those changes.\n'
p6601
sg4
(lp6602
sg29
(lp6603
(dp6604
g7
I39
sg32
VC0595921
p6605
sg10
I20
sg11
Vintraocular pressure
p6606
sg13
I2
sa(dp6607
g7
I148
sg32
VC0339573
p6608
sg10
I4
sg11
VPOAG
p6609
sg13
I1
sa(dp6610
g7
I61
sg32
VC0595921
p6611
sg10
I3
sg11
VIOP
p6612
sg13
I1
sa(dp6613
g7
I119
sg32
VC0339573
p6614
sg10
I27
sg11
Vprimary open-angle glaucoma
p6615
sg13
I3
sasa(dp6616
g2
S'The association between subfoveal ChT and systemic, as well as ocular factors, including age, sex, height, weight, body mass index, axial length, refractive error, intraocular pressure, preterm history, and the refractive status of parents were studied.\n'
p6617
sg4
(lp6618
sg29
(lp6619
(dp6620
g7
I146
sg32
VC0034951
p6621
sg10
I16
sg11
Vrefractive error
p6622
sg13
I2
sa(dp6623
g7
I164
sg32
VC0595921
p6624
sg10
I20
sg11
Vintraocular pressure
p6625
sg13
I2
sasa(dp6626
g2
S'ChT differed significantly between males and females 2-mm temporal to the fovea in the emmetropia group (P&lt;0.05), and 1-mm temporal to the fovea in the mild myopia group (P&lt;0.05).\n'
p6627
sg4
(lp6628
sg29
(lp6629
(dp6630
g7
I160
sg32
VC0027092
p6631
sg10
I6
sg11
Vmyopia
p6632
sg13
I1
sasa(dp6633
g2
S'The aim of this study was to investigate variants in UCP2 genes in type 2 diabetes mellitus (DM) and diabetic retinopathy (DR) in Chinese population.\n'
p6634
sg4
(lp6635
(dp6636
g7
I53
sg8
VP55851
p6637
sg10
I10
sg11
VUCP2 genes
p6638
sg13
I2
sasg29
(lp6639
(dp6640
g7
I67
sg32
VC0011860
p6641
sg10
I24
sg11
Vtype 2 diabetes mellitus
p6642
sg13
I4
sa(dp6643
g7
I101
sg32
VC0011884
p6644
sg10
I20
sg11
Vdiabetic retinopathy
p6645
sg13
I2
sa(dp6646
g7
I123
sg32
VC0011884
p6647
sg10
I2
sg11
VDR
p6648
sg13
I1
sasa(dp6649
g2
S'This may provide experimental evidence for the application of UCP2 as a new protective factor for diabetic complications, such as diabetic retinopathy.\n'
p6650
sg4
(lp6651
(dp6652
g7
I62
sg8
VP55851
p6653
sg10
I4
sg11
VUCP2
p6654
sg13
I1
sasg29
(lp6655
(dp6656
g7
I130
sg32
VC0011884
p6657
sg10
I20
sg11
Vdiabetic retinopathy
p6658
sg13
I2
sa(dp6659
g7
I98
sg32
VC0342257
p6660
sg10
I22
sg11
Vdiabetic complications
p6661
sg13
I2
sasa(dp6662
g2
S'The aim of this study was to investigate the expression of uncoupling protein 2 (UCP2) and zonula occludens-1 (ZO-1) in the trabecular meshwork (TM) of neovascular glaucoma (NVG) patients treated with trabeculectomy.\n'
p6663
sg4
(lp6664
(dp6665
g7
I59
sg8
VP55851
p6666
sg10
I20
sg11
Vuncoupling protein 2
p6667
sg13
I3
sa(dp6668
g7
I81
sg8
VP55851
p6669
sg10
I4
sg11
VUCP2
p6670
sg13
I1
sasg29
(lp6671
(dp6672
g7
I174
sg32
VC0017609
p6673
sg10
I3
sg11
VNVG
p6674
sg13
I1
sa(dp6675
g7
I152
sg32
VC0017609
p6676
sg10
I20
sg11
Vneovascular glaucoma
p6677
sg13
I2
sasa(dp6678
g2
S'ZC4H2 is involved in human brain development, and, if mutated, can be responsible for a rare X-linked disorder, originally presented in literature as Wieacker-Wolff syndrome and Miles-Carpenter syndrome.\n'
p6679
sg4
(lp6680
(dp6681
g7
I0
sg8
g48
sg10
I5
sg11
VZC4H2
p6682
sg13
I1
sasg29
(lp6683
(dp6684
g7
I150
sg32
VC0796200
p6685
sg10
I23
sg11
VWieacker-Wolff syndrome
p6686
sg13
I2
sa(dp6687
g7
I184
sg32
VC0085860
p6688
sg10
I18
sg11
VCarpenter syndrome
p6689
sg13
I2
sasa(dp6690
g2
S'To compare the relevant indicators of coagulation and fibrinolysis in patients with varying severity of community-acquired pneumonia (CAP).\n'
p6691
sg4
(lp6692
sg29
(lp6693
(dp6694
g7
I104
sg32
VC1855179
p6695
sg10
I28
sg11
Vcommunity-acquired pneumonia
p6696
sg13
I2
sa(dp6697
g7
I134
sg32
VC1855179
p6698
sg10
I3
sg11
VCAP
p6699
sg13
I1
sasa(dp6700
g2
S'The D-dimer, fibrinogen degradation products (FDPs), fibrinogen (FIB), activated partial thromboplastin time (APTT) and prothrombin time (PT) in pneumonia group were significantly higher than those in control group ((1.86 +/- 1.28) vs (0.48 +/- 0.38) mg/L, (6.42 +/- 3.27) vs (2.17 +/- 1.46) mg/L, (3.87 +/- 1.17) vs (3.42 +/- 0.96) g/L, (35.64 +/- 8.34) vs (31.29 +/- 11.19) s, (12.21 +/- 1.40) vs (11.36 +/- 2.19) s, all P &lt; 0.05) while thromboplastin time (TT) was lower than that in control group ((13.43 +/- 3.38) vs (16.16 +/- 2.89) s, P &lt; 0.05).\n'
p6701
sg4
(lp6702
(dp6703
g7
I4
sg8
g48
sg10
I7
sg11
VD-dimer
p6704
sg13
I1
sa(dp6705
g7
I13
sg8
VP22087
p6706
sg10
I10
sg11
Vfibrinogen
p6707
sg13
I1
sa(dp6708
g7
I13
sg8
VP14324
p6709
sg10
I31
sg11
Vfibrinogen degradation products
p6710
sg13
I3
sa(dp6711
g7
I120
sg8
VP00734
p6712
sg10
I11
sg11
Vprothrombin
p6713
sg13
I1
sa(dp6714
g7
I89
sg8
VP13726
p6715
sg10
I14
sg11
Vthromboplastin
p6716
sg13
I1
sa(dp6717
g7
I46
sg8
VP14324
p6718
sg10
I4
sg11
VFDPs
p6719
sg13
I1
sa(dp6720
g7
I65
sg8
VP22087
p6721
sg10
I3
sg11
VFIB
p6722
sg13
I1
sa(dp6723
g7
I89
sg8
VP13726
p6724
sg10
I14
sg11
Vthromboplastin
p6725
sg13
I1
sasg29
(lp6726
(dp6727
g7
I145
sg32
VC0032285
p6728
sg10
I9
sg11
Vpneumonia
p6729
sg13
I1
sasa(dp6730
g2
S'And the patients with pneumonia have coagulation and fibrinolysis disorders.\n'
p6731
sg4
(lp6732
sg29
(lp6733
(dp6734
g7
I22
sg32
VC0032285
p6735
sg10
I9
sg11
Vpneumonia
p6736
sg13
I1
sasa(dp6737
g2
S'To explore and evaluate the predictive value of coagulopathy in patients with community-acquired pneumonia (CAP) METHODS: A retrospective study was performed by investigating the prothrombin time (PT), activated partial thromboplastin time (APTT), plasma fibrinogen (FIB), thrombin time (TT), platelets (PLT), and D-dimer in 385 patients with CAP, who were admitted to the Respiratory Medical Department of the First Affiliated Hospital of Xiamen University from June, 2010 to May, 2011.\n'
p6738
sg4
(lp6739
(dp6740
g7
I182
sg8
VP00734
p6741
sg10
I8
sg11
Vthrombin
p6742
sg13
I1
sa(dp6743
g7
I179
sg8
VP00734
p6744
sg10
I11
sg11
Vprothrombin
p6745
sg13
I1
sa(dp6746
g7
I267
sg8
VP22087
p6747
sg10
I3
sg11
VFIB
p6748
sg13
I1
sa(dp6749
g7
I248
sg8
VP22087
p6750
sg10
I17
sg11
Vplasma fibrinogen
p6751
sg13
I2
sa(dp6752
g7
I220
sg8
VP13726
p6753
sg10
I14
sg11
Vthromboplastin
p6754
sg13
I1
sasg29
(lp6755
(dp6756
g7
I48
sg32
VC0005779
p6757
sg10
I12
sg11
Vcoagulopathy
p6758
sg13
I1
sa(dp6759
g7
I108
sg32
VC1855179
p6760
sg10
I3
sg11
VCAP
p6761
sg13
I1
sa(dp6762
g7
I78
sg32
VC1855179
p6763
sg10
I28
sg11
Vcommunity-acquired pneumonia
p6764
sg13
I2
sa(dp6765
g7
I108
sg32
VC1855179
p6766
sg10
I3
sg11
VCAP
p6767
sg13
I1
sasa(dp6768
g2
S"To identify whether the helper T lymphocyte 1 (Th1)/helper T lymphocyte 2 (Th2) of patients' serum and bronchoalveolar lavage fluid (BALF) at admission could represent the severity of idiopathic pulmonary fibrosis (IPF) and whether its change at six months could predict the progression of the disease.\n"
p6769
sg4
(lp6770
sg29
(lp6771
(dp6772
g7
I184
sg32
VC3161101
p6773
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p6774
sg13
I3
sa(dp6775
g7
I215
sg32
VC3161101
p6776
sg10
I3
sg11
VIPF
p6777
sg13
I1
sasa(dp6778
g2
S'The DNA binding activities of NF-KB, the contents of TNF-Alfa, PCT, CRP, fibrinogen (Fib), D-dimer in hospitalized subjects with severe pneumonia were higher before treatment than those in healthy control group, while the prothrombin time (PT), thrombin time (TT) were significantly lower (P&lt;0.05 or P&lt;0.01).\n'
p6779
sg4
(lp6780
(dp6781
g7
I63
sg8
VP06132
p6782
sg10
I3
sg11
VPCT
p6783
sg13
I1
sa(dp6784
g7
I73
sg8
VP22087
p6785
sg10
I10
sg11
Vfibrinogen
p6786
sg13
I1
sa(dp6787
g7
I222
sg8
VP00734
p6788
sg10
I11
sg11
Vprothrombin
p6789
sg13
I1
sa(dp6790
g7
I225
sg8
VP00734
p6791
sg10
I8
sg11
Vthrombin
p6792
sg13
I1
sa(dp6793
g7
I85
sg8
VP22087
p6794
sg10
I3
sg11
VFib
p6795
sg13
I1
sa(dp6796
g7
I53
sg8
VP01375
p6797
sg10
I8
sg11
VTNF-Alfa
p6798
sg13
I1
sa(dp6799
g7
I68
sg8
VP02741
p6800
sg10
I3
sg11
VCRP
p6801
sg13
I1
sasg29
(lp6802
(dp6803
g7
I63
sg32
VC0162566
p6804
sg10
I3
sg11
VPCT
p6805
sg13
I1
sa(dp6806
g7
I136
sg32
VC0032285
p6807
sg10
I9
sg11
Vpneumonia
p6808
sg13
I1
sasa(dp6809
g2
S'Idiopathic pulmonary fibrosis (IPF) is associated with significant morbidity and mortality despite aggressive therapy.\n'
p6810
sg4
(lp6811
sg29
(lp6812
(dp6813
g7
I0
sg32
VC3161101
p6814
sg10
I29
sg11
VIdiopathic pulmonary fibrosis
p6815
sg13
I3
sa(dp6816
g7
I99
sg32
VC0001807
p6817
sg10
I10
sg11
Vaggressive
p6818
sg13
I1
sa(dp6819
g7
I31
sg32
VC3161101
p6820
sg10
I3
sg11
VIPF
p6821
sg13
I1
sasa(dp6822
g2
S'Evaluate the prognostic and predictive impact of HPV-associated p16-expression and assess the combined prognostic impact of p16 and smoking on altered fractionated radiotherapy (AFRT) for oropharyngeal cancer (OPC) within the frames of the update of the Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH).\n'
p6823
sg4
(lp6824
(dp6825
g7
I64
sg8
VP42771
p6826
sg10
I3
sg11
Vp16
p6827
sg13
I1
sa(dp6828
g7
I64
sg8
VP42771
p6829
sg10
I3
sg11
Vp16
p6830
sg13
I1
sasg29
(lp6831
(dp6832
g7
I188
sg32
VC0153382
p6833
sg10
I20
sg11
Voropharyngeal cancer
p6834
sg13
I2
sa(dp6835
g7
I287
sg32
VC0007097
p6836
sg10
I10
sg11
VCarcinomas
p6837
sg13
I1
sa(dp6838
g7
I210
sg32
VC0153382
p6839
sg10
I3
sg11
VOPC
p6840
sg13
I1
sasa(dp6841
g2
S'Twelve patients with p16 positive oropharyngeal cancer were enrolled.\n'
p6842
sg4
(lp6843
(dp6844
g7
I21
sg8
VP42771
p6845
sg10
I3
sg11
Vp16
p6846
sg13
I1
sasg29
(lp6847
(dp6848
g7
I34
sg32
VC0153382
p6849
sg10
I20
sg11
Voropharyngeal cancer
p6850
sg13
I2
sasa(dp6851
g2
S'For patients with p16-negative pharyngeal cancer receiving radiotherapy, treatment outcomes can be stratified by VEGF and GLUT1 expression and CT-based gross tumor volume.\n'
p6852
sg4
(lp6853
(dp6854
g7
I122
sg8
VP11166
p6855
sg10
I5
sg11
VGLUT1
p6856
sg13
I1
sa(dp6857
g7
I18
sg8
VP42771
p6858
sg10
I3
sg11
Vp16
p6859
sg13
I1
sasg29
(lp6860
(dp6861
g7
I31
sg32
VC0153405
p6862
sg10
I17
sg11
Vpharyngeal cancer
p6863
sg13
I2
sa(dp6864
g7
I158
sg32
VC0027651
p6865
sg10
I5
sg11
Vtumor
p6866
sg13
I1
sasa(dp6867
g2
S'Nodal staging has dramatically changed so that there are different tables for human papillomavirus/p16(+) oropharyngeal squamous cell carcinoma, Epstein-Barr virus-related nasopharyngeal carcinoma, and all other head and neck squamous cell carcinomas.\n'
p6868
sg4
(lp6869
(dp6870
g7
I0
sg8
g48
sg10
I5
sg11
VNodal
p6871
sg13
I1
sasg29
(lp6872
(dp6873
g7
I226
sg32
VC0007137
p6874
sg10
I24
sg11
Vsquamous cell carcinomas
p6875
sg13
I3
sa(dp6876
g7
I172
sg32
VC2931822
p6877
sg10
I24
sg11
Vnasopharyngeal carcinoma
p6878
sg13
I2
sa(dp6879
g7
I106
sg32
VC0280313
p6880
sg10
I37
sg11
Voropharyngeal squamous cell carcinoma
p6881
sg13
I4
sasa(dp6882
g2
S'Taken together, our results suggest that targeting druggable proteins in the MEK1/MP1/ERK1/BCL2 axis, such as MEK1 or BCL2, with currently available FDA approved drugs is a currently feasible approach to improve clinical outcomes of mesenchymal lung cancer patients.\n'
p6883
sg4
(lp6884
(dp6885
g7
I77
sg8
g48
sg10
I4
sg11
VMEK1
p6886
sg13
I1
sa(dp6887
g7
I91
sg8
VP10415
p6888
sg10
I4
sg11
VBCL2
p6889
sg13
I1
sa(dp6890
g7
I91
sg8
VP10415
p6891
sg10
I4
sg11
VBCL2
p6892
sg13
I1
sa(dp6893
g7
I86
sg8
VP27361
p6894
sg10
I4
sg11
VERK1
p6895
sg13
I1
sa(dp6896
g7
I77
sg8
g48
sg10
I4
sg11
VMEK1
p6897
sg13
I1
sa(dp6898
g7
I82
sg8
g48
sg10
I3
sg11
VMP1
p6899
sg13
I1
sasg29
(lp6900
(dp6901
g7
I245
sg32
VC0684249
p6902
sg10
I11
sg11
Vlung cancer
p6903
sg13
I2
sasa(dp6904
g2
S'Our data report for the first time that Cks1b employs Hsp90 and MEK1/2 pathways in lung cancer cells to develop chemoresistance and identify 3-COA as a potential antitumor drug for clinical treatment of chemoresistant lung cancer.\n'
p6905
sg4
(lp6906
(dp6907
g7
I40
sg8
VP61024
p6908
sg10
I5
sg11
VCks1b
p6909
sg13
I1
sa(dp6910
g7
I54
sg8
VP07900
p6911
sg10
I5
sg11
VHsp90
p6912
sg13
I1
sa(dp6913
g7
I64
sg8
g48
sg10
I4
sg11
VMEK1
p6914
sg13
I1
sasg29
(lp6915
(dp6916
g7
I83
sg32
VC0684249
p6917
sg10
I11
sg11
Vlung cancer
p6918
sg13
I2
sa(dp6919
g7
I83
sg32
VC0684249
p6920
sg10
I11
sg11
Vlung cancer
p6921
sg13
I2
sa(dp6922
g7
I143
sg32
VC2678439
p6923
sg10
I3
sg11
VCOA
p6924
sg13
I1
sasa(dp6925
g2
S'To further dissect the mechanisms regulating CD13-dependent trafficking we used the murine model of thioglycollate-induced sterile peritonitis.\n'
p6926
sg4
(lp6927
(dp6928
g7
I45
sg8
VP15144
p6929
sg10
I4
sg11
VCD13
p6930
sg13
I1
sasg29
(lp6931
(dp6932
g7
I123
sg32
VC0338375
p6933
sg10
I19
sg11
Vsterile peritonitis
p6934
sg13
I2
sasa(dp6935
g2
S'Furthermore, treatment with anti-CD13 antibodies in a murine model of peritonitis results in a decrease in leukocyte infiltration into the peritoneum, suggesting a potential role for CD13 in leukocyte trafficking in vivo.\n'
p6936
sg4
(lp6937
(dp6938
g7
I28
sg8
VP15144
p6939
sg10
I20
sg11
Vanti-CD13 antibodies
p6940
sg13
I2
sa(dp6941
g7
I33
sg8
VP15144
p6942
sg10
I4
sg11
VCD13
p6943
sg13
I1
sasg29
(lp6944
(dp6945
g7
I70
sg32
VC0031154
p6946
sg10
I11
sg11
Vperitonitis
p6947
sg13
I1
sa(dp6948
g7
I117
sg32
VC0332448
p6949
sg10
I12
sg11
Vinfiltration
p6950
sg13
I1
sasa(dp6951
g2
S'Our results indicate that miR-335 expression is an independent prognostic factor for patients with esophageal cancer, which might be a potential valuable biomarker for ESCC.\n'
p6952
sg4
(lp6953
sg29
(lp6954
(dp6955
g7
I99
sg32
VC0014859
p6956
sg10
I17
sg11
Vesophageal cancer
p6957
sg13
I2
sasa(dp6958
g2
S'The following disorders will be discussed in this review: supravalvular aortic stenosis; Williams-Beuren syndrome; cutis laxa; Marfan syndrome; ectopia lentis; familial thoracic aortic aneurysms and dissections; MASS syndrome; isolated skeletal features of Marfan syndrome; Shprintzen-Goldberg syndrome; and congenital contractural arachnodactyly.\n'
p6959
sg4
(lp6960
sg29
(lp6961
(dp6962
g7
I274
sg32
VC1321551
p6963
sg10
I28
sg11
VShprintzen-Goldberg syndrome
p6964
sg13
I2
sa(dp6965
g7
I212
sg32
VC1858556
p6966
sg10
I13
sg11
VMASS syndrome
p6967
sg13
I2
sa(dp6968
g7
I115
sg32
VC0010495
p6969
sg10
I10
sg11
Vcutis laxa
p6970
sg13
I2
sa(dp6971
g7
I169
sg32
VC0162872
p6972
sg10
I25
sg11
Vthoracic aortic aneurysms
p6973
sg13
I3
sa(dp6974
g7
I144
sg32
VC0013581
p6975
sg10
I14
sg11
Vectopia lentis
p6976
sg13
I2
sa(dp6977
g7
I308
sg32
VC0220668
p6978
sg10
I38
sg11
Vcongenital contractural arachnodactyly
p6979
sg13
I3
sa(dp6980
g7
I127
sg32
VC0024796
p6981
sg10
I15
sg11
VMarfan syndrome
p6982
sg13
I2
sa(dp6983
g7
I89
sg32
VC0175702
p6984
sg10
I24
sg11
VWilliams-Beuren syndrome
p6985
sg13
I2
sa(dp6986
g7
I58
sg32
VC0003499
p6987
sg10
I29
sg11
Vsupravalvular aortic stenosis
p6988
sg13
I3
sa(dp6989
g7
I127
sg32
VC0024796
p6990
sg10
I15
sg11
VMarfan syndrome
p6991
sg13
I2
sasa(dp6992
g2
S'Although the labor inspection had disclosed considerable exposure to carbon disulfide (CS&amp;inf2;) in a Belgian viscose rayon factory, the company medical officer had not diagnosed any case of polyneuropathy in association with CS&amp;inf2; exposure, although this finding had been extensively reported in the literature.\n'
p6993
sg4
(lp6994
(dp6995
g7
I94
sg8
g48
sg10
I4
sg11
Vinf2
p6996
sg13
I1
sa(dp6997
g7
I94
sg8
g48
sg10
I4
sg11
Vinf2
p6998
sg13
I1
sasg29
(lp6999
(dp7000
g7
I195
sg32
VC0152025
p7001
sg10
I14
sg11
Vpolyneuropathy
p7002
sg13
I1
sasa(dp7003
g2
S'Significant associations were found between the cumulative CS&amp;inf2; index and symptoms consistent with polyneuropathy in the legs and with abnormal recruitment pattern and decrease of motor conduction velocities of the peroneal nerves.\n'
p7004
sg4
(lp7005
sg29
(lp7006
(dp7007
g7
I152
sg32
VC0271510
p7008
sg10
I11
sg11
Vrecruitment
p7009
sg13
I1
sa(dp7010
g7
I107
sg32
VC0152025
p7011
sg10
I14
sg11
Vpolyneuropathy
p7012
sg13
I1
sasa(dp7013
g2
S'We describe a moyamoya (MMD) patient with bilateral consecutive branch retinal vein occlusion (BRVO).\n'
p7014
sg4
(lp7015
sg29
(lp7016
(dp7017
g7
I14
sg32
VC0026654
p7018
sg10
I8
sg11
Vmoyamoya
p7019
sg13
I1
sa(dp7020
g7
I95
sg32
VC0339505
p7021
sg10
I4
sg11
VBRVO
p7022
sg13
I1
sa(dp7023
g7
I64
sg32
VC0339505
p7024
sg10
I29
sg11
Vbranch retinal vein occlusion
p7025
sg13
I4
sasa(dp7026
g2
S'The random amphiphilic polymeric aggregation, self-assembled from poly (methyl methacrylate-co-methacrylic acid) (P(MMA-co-MAA)), was explored as a novel pseudostationary phase (PSP) in electrokinetic chromatography (EKC) in our previous report.\n'
p7027
sg4
(lp7028
sg29
(lp7029
(dp7030
g7
I154
sg32
VC0038868
p7031
sg10
I22
sg11
Vpseudostationary phase
p7032
sg13
I2
sa(dp7033
g7
I116
sg32
VC0276096
p7034
sg10
I3
sg11
VMMA
p7035
sg13
I1
sa(dp7036
g7
I186
sg32
VC0014493
p7037
sg10
I29
sg11
Velectrokinetic chromatography
p7038
sg13
I2
sa(dp7039
g7
I178
sg32
VC0038868
p7040
sg10
I3
sg11
VPSP
p7041
sg13
I1
sa(dp7042
g7
I217
sg32
VC0014493
p7043
sg10
I3
sg11
VEKC
p7044
sg13
I1
sasa(dp7045
g2
S'PGA increased MMA in therapy-naive glaucomatous patients, indicating a possible enhancement of the trans-conjunctival aqueous humor outflow.\n'
p7046
sg4
(lp7047
sg29
(lp7048
(dp7049
g7
I14
sg32
VC0276096
p7050
sg10
I3
sg11
VMMA
p7051
sg13
I1
sa(dp7052
g7
I0
sg32
VC0085409
p7053
sg10
I3
sg11
VPGA
p7054
sg13
I1
sa(dp7055
g7
I118
sg32
VC0595936
p7056
sg10
I13
sg11
Vaqueous humor
p7057
sg13
I2
sasa(dp7058
g2
S'In addition to confirming known associations, a systemic lupus erythematosus-associated risk variant at TNXB was also associated with CKD attributed to type 1 diabetes (p = 2.5 x 10-7), a membranous nephropathy-associated variant at HLA-DQA1 was also associated with CKD attributed to systemic lupus erythematosus (p = 5.9 x 10-6), and an IgA risk variant at HLA-DRB1 was associated with both CKD attributed to granulomatosis with polyangiitis (p = 2.0 x 10-4) and to type 1 diabetes (p = 4.6 x 10-11).\n'
p7059
sg4
(lp7060
(dp7061
g7
I233
sg8
VP30486
p7062
sg10
I3
sg11
VHLA
p7063
sg13
I1
sa(dp7064
g7
I363
sg8
g48
sg10
I4
sg11
VDRB1
p7065
sg13
I1
sa(dp7066
g7
I339
sg8
VP11912
p7067
sg10
I16
sg11
VIgA risk variant
p7068
sg13
I3
sa(dp7069
g7
I233
sg8
VP30486
p7070
sg10
I3
sg11
VHLA
p7071
sg13
I1
sasg29
(lp7072
(dp7073
g7
I188
sg32
VC0017665
p7074
sg10
I22
sg11
Vmembranous nephropathy
p7075
sg13
I2
sa(dp7076
g7
I152
sg32
VC0011854
p7077
sg10
I15
sg11
Vtype 1 diabetes
p7078
sg13
I3
sa(dp7079
g7
I152
sg32
VC0011854
p7080
sg10
I15
sg11
Vtype 1 diabetes
p7081
sg13
I3
sa(dp7082
g7
I48
sg32
VC0024141
p7083
sg10
I28
sg11
Vsystemic lupus erythematosus
p7084
sg13
I3
sa(dp7085
g7
I48
sg32
VC0024141
p7086
sg10
I28
sg11
Vsystemic lupus erythematosus
p7087
sg13
I3
sa(dp7088
g7
I411
sg32
VC0521173
p7089
sg10
I14
sg11
Vgranulomatosis
p7090
sg13
I1
sasa(dp7091
g2
S'We found significantly higher frequency of HLA-DRB1*13 (OR = 5.1; 95% CI, 1.7 to 15.4; P = 0.03) and development of end-stage renal disease (OR = 5.8; 95% CI, 1.7 to 19.7; P = 0.008) in hAPLN compared with lupus nephritis.\n'
p7092
sg4
(lp7093
(dp7094
g7
I43
sg8
VP30486
p7095
sg10
I3
sg11
VHLA
p7096
sg13
I1
sasg29
(lp7097
(dp7098
g7
I116
sg32
VC0022661
p7099
sg10
I23
sg11
Vend-stage renal disease
p7100
sg13
I3
sa(dp7101
g7
I206
sg32
VC0024143
p7102
sg10
I15
sg11
Vlupus nephritis
p7103
sg13
I2
sasa(dp7104
g2
S'ESRD patients were examined for HLA-DRB1 alleles according to a reverse hybridization line probe assay.\n'
p7105
sg4
(lp7106
(dp7107
g7
I32
sg8
VP20039
p7108
sg10
I16
sg11
VHLA-DRB1 alleles
p7109
sg13
I2
sasg29
(lp7110
(dp7111
g7
I0
sg32
VC0022661
p7112
sg10
I4
sg11
VESRD
p7113
sg13
I1
sasa(dp7114
g2
S'Polymerase chain reaction-sequence specific primer method was used to analyze the HLA polymorphisms (including HLA-A, HLA-B and HLA-DRB1 loci) in both ESRD patients and controls.\n'
p7115
sg4
(lp7116
(dp7117
g7
I128
sg8
VP20039
p7118
sg10
I13
sg11
VHLA-DRB1 loci
p7119
sg13
I2
sa(dp7120
g7
I118
sg8
VP30461
p7121
sg10
I5
sg11
VHLA-B
p7122
sg13
I1
sa(dp7123
g7
I111
sg8
VP30447
p7124
sg10
I5
sg11
VHLA-A
p7125
sg13
I1
sa(dp7126
g7
I82
sg8
VP30486
p7127
sg10
I3
sg11
VHLA
p7128
sg13
I1
sasg29
(lp7129
(dp7130
g7
I151
sg32
VC0022661
p7131
sg10
I4
sg11
VESRD
p7132
sg13
I1
sasa(dp7133
g2
S'The frequencies of five alleles, HLA-A*24, HLA-B*55, HLA-B*54, HLA-B*40(60), HLA-DRB1*04, and one haplotype (HLA-A*11-B*27-DRB1*04) in ESRD patients are significantly higher than those in the controls, respectively.\n'
p7134
sg4
(lp7135
(dp7136
g7
I109
sg8
VP30447
p7137
sg10
I21
sg11
VHLA-A*11-B*27-DRB1*04
p7138
sg13
I1
sa(dp7139
g7
I33
sg8
VP30486
p7140
sg10
I3
sg11
VHLA
p7141
sg13
I1
sa(dp7142
g7
I77
sg8
VP20039
p7143
sg10
I11
sg11
VHLA-DRB1*04
p7144
sg13
I1
sa(dp7145
g7
I43
sg8
VP30461
p7146
sg10
I8
sg11
VHLA-B*55
p7147
sg13
I1
sa(dp7148
g7
I33
sg8
VP30447
p7149
sg10
I8
sg11
VHLA-A*24
p7150
sg13
I1
sa(dp7151
g7
I53
sg8
VP30461
p7152
sg10
I8
sg11
VHLA-B*54
p7153
sg13
I1
sasg29
(lp7154
(dp7155
g7
I135
sg32
VC0022661
p7156
sg10
I4
sg11
VESRD
p7157
sg13
I1
sasa(dp7158
g2
S'Five HLA alleles and one haplotype at the HLA-A, HLA-B and HLA-DRB1 loci appear to be associated with ESRD within the Cantonese population.\n'
p7159
sg4
(lp7160
(dp7161
g7
I5
sg8
VP30486
p7162
sg10
I3
sg11
VHLA
p7163
sg13
I1
sa(dp7164
g7
I59
sg8
VP20039
p7165
sg10
I13
sg11
VHLA-DRB1 loci
p7166
sg13
I2
sa(dp7167
g7
I49
sg8
VP30461
p7168
sg10
I5
sg11
VHLA-B
p7169
sg13
I1
sa(dp7170
g7
I42
sg8
VP30447
p7171
sg10
I5
sg11
VHLA-A
p7172
sg13
I1
sasg29
(lp7173
(dp7174
g7
I102
sg32
VC0022661
p7175
sg10
I4
sg11
VESRD
p7176
sg13
I1
sasa(dp7177
g2
S'Here we describe a different function for MMP-9 in B-CLL, which involves the hemopexin domain rather than its catalytic function.\n'
p7178
sg4
(lp7179
(dp7180
g7
I51
sg8
g48
sg10
I5
sg11
VB-CLL
p7181
sg13
I1
sa(dp7182
g7
I77
sg8
VP02790
p7183
sg10
I9
sg11
Vhemopexin
p7184
sg13
I1
sa(dp7185
g7
I42
sg8
VP14780
p7186
sg10
I5
sg11
VMMP-9
p7187
sg13
I1
sasg29
(lp7188
(dp7189
g7
I53
sg32
VC0023434
p7190
sg10
I3
sg11
VCLL
p7191
sg13
I1
sasa(dp7192
g2
S'Binding of soluble or immobilized (pro)MMP-9, a catalytically inactive proMMP-9 mutant, or the MMP-9 hemopexin domain to its docking receptors alpha4beta1 integrin and CD44v, induces an intracellular signaling pathway that prevents B-CLL apoptosis.\n'
p7193
sg4
(lp7194
(dp7195
g7
I71
sg8
g48
sg10
I15
sg11
VproMMP-9 mutant
p7196
sg13
I2
sa(dp7197
g7
I133
sg8
g48
sg10
I30
sg11
Vreceptors alpha4beta1 integrin
p7198
sg13
I3
sa(dp7199
g7
I95
sg8
VP14780
p7200
sg10
I15
sg11
VMMP-9 hemopexin
p7201
sg13
I2
sasg29
(lp7202
(dp7203
g7
I80
sg32
VC0596988
p7204
sg10
I6
sg11
Vmutant
p7205
sg13
I1
sa(dp7206
g7
I234
sg32
VC0023434
p7207
sg10
I3
sg11
VCLL
p7208
sg13
I1
sasa(dp7209
g2
S'Immunoinhibition experiments using the antibody against the placental receptor revealed inhibition of binding of 125I-hemopexin to human leukemia K562 and HL 60 cells, thereby strongly supporting that the polypeptide isolated from the human placenta was the hemopexin receptor.\n'
p7210
sg4
(lp7211
(dp7212
g7
I258
sg8
VP02790
p7213
sg10
I18
sg11
Vhemopexin receptor
p7214
sg13
I2
sa(dp7215
g7
I113
sg8
VP02790
p7216
sg10
I14
sg11
V125I-hemopexin
p7217
sg13
I1
sasg29
(lp7218
(dp7219
g7
I137
sg32
VC0023418
p7220
sg10
I8
sg11
Vleukemia
p7221
sg13
I1
sasa(dp7222
g2
S'The binding of 125I-labeled human hemopexin to human leukemia HL60 cell at 4 degrees C was saturable with time and with increasing concentrations of 125I-hemopexin.\n'
p7223
sg4
(lp7224
(dp7225
g7
I28
sg8
VP02790
p7226
sg10
I15
sg11
Vhuman hemopexin
p7227
sg13
I2
sa(dp7228
g7
I149
sg8
VP02790
p7229
sg10
I14
sg11
V125I-hemopexin
p7230
sg13
I1
sasg29
(lp7231
(dp7232
g7
I53
sg32
VC0023418
p7233
sg10
I8
sg11
Vleukemia
p7234
sg13
I1
sasa(dp7235
g2
S'Cells expressing markers Islet-1 and Hb9 are also generated from the LCCS NPCs, suggesting that the pathogenic mechanism of LCCS does not directly affect the differentiation capacity or survival of the cells, but the absence of motoneurons in LCCS may be caused by a noncell autonomous mechanism.\n'
p7236
sg4
(lp7237
(dp7238
g7
I37
sg8
VP50219
p7239
sg10
I3
sg11
VHb9
p7240
sg13
I1
sa(dp7241
g7
I25
sg8
VP61371
p7242
sg10
I7
sg11
VIslet-1
p7243
sg13
I1
sasg29
(lp7244
(dp7245
g7
I69
sg32
VC1854664
p7246
sg10
I4
sg11
VLCCS
p7247
sg13
I1
sa(dp7248
g7
I69
sg32
VC1854664
p7249
sg10
I4
sg11
VLCCS
p7250
sg13
I1
sa(dp7251
g7
I69
sg32
VC1854664
p7252
sg10
I4
sg11
VLCCS
p7253
sg13
I1
sasa(dp7254
g2
S'Described disorders caused by mutations in the ARX gene include: hydrocephaly with abnormal genitalia (HYD-AG), lissencephaly with abnormal genitalia (XLAG), agenesis of corpus callosum with abnormal genitalia (ACC-AG), Partington syndrome (PRTS), X-linked infantile spasms (ISSX), myoclonic epilepsy with spasticity and mental retardation (XMESID), and nonspecific mental retardation (NS-XLMR).\n'
p7255
sg4
(lp7256
(dp7257
g7
I47
sg8
g48
sg10
I8
sg11
VARX gene
p7258
sg13
I2
sasg29
(lp7259
(dp7260
g7
I241
sg32
VC0796250
p7261
sg10
I4
sg11
VPRTS
p7262
sg13
I1
sa(dp7263
g7
I158
sg32
VC0175754
p7264
sg10
I27
sg11
Vagenesis of corpus callosum
p7265
sg13
I4
sa(dp7266
g7
I65
sg32
VC0020255
p7267
sg10
I12
sg11
Vhydrocephaly
p7268
sg13
I1
sa(dp7269
g7
I112
sg32
VC0266463
p7270
sg10
I13
sg11
Vlissencephaly
p7271
sg13
I1
sa(dp7272
g7
I248
sg32
VC2931919
p7273
sg10
I25
sg11
VX-linked infantile spasms
p7274
sg13
I3
sa(dp7275
g7
I220
sg32
VC0796250
p7276
sg10
I19
sg11
VPartington syndrome
p7277
sg13
I2
sa(dp7278
g7
I306
sg32
VC0026838
p7279
sg10
I10
sg11
Vspasticity
p7280
sg13
I1
sa(dp7281
g7
I211
sg32
VC0175754
p7282
sg10
I3
sg11
VACC
p7283
sg13
I1
sa(dp7284
g7
I341
sg32
VC0037769
p7285
sg10
I6
sg11
VXMESID
p7286
sg13
I1
sa(dp7287
g7
I321
sg32
VC0025362
p7288
sg10
I18
sg11
Vmental retardation
p7289
sg13
I2
sa(dp7290
g7
I151
sg32
VC1846171
p7291
sg10
I4
sg11
VXLAG
p7292
sg13
I1
sa(dp7293
g7
I282
sg32
VC0014550
p7294
sg10
I18
sg11
Vmyoclonic epilepsy
p7295
sg13
I2
sa(dp7296
g7
I321
sg32
VC0025362
p7297
sg10
I18
sg11
Vmental retardation
p7298
sg13
I2
sasa(dp7299
g2
S'A previous study provided evidence for a genetic association between PPP2CA on 5q31.1 and systemic lupus erythematosus (SLE) across multi-ancestral cohorts, but failed to find significant evidence for an association in the Han Chinese population.\n'
p7300
sg4
(lp7301
(dp7302
g7
I69
sg8
VP67775
p7303
sg10
I6
sg11
VPPP2CA
p7304
sg13
I1
sasg29
(lp7305
(dp7306
g7
I120
sg32
VC0024141
p7307
sg10
I3
sg11
VSLE
p7308
sg13
I1
sa(dp7309
g7
I90
sg32
VC0024141
p7310
sg10
I28
sg11
Vsystemic lupus erythematosus
p7311
sg13
I3
sasa(dp7312
g2
S'T cells from patients with systemic lupus erythematosus (SLE) express high levels of the catalytic subunit of PP2A (PP2Ac).\n'
p7313
sg4
(lp7314
(dp7315
g7
I110
sg8
g48
sg10
I4
sg11
VPP2A
p7316
sg13
I1
sa(dp7317
g7
I116
sg8
VP67775
p7318
sg10
I5
sg11
VPP2Ac
p7319
sg13
I1
sasg29
(lp7320
(dp7321
g7
I57
sg32
VC0024141
p7322
sg10
I3
sg11
VSLE
p7323
sg13
I1
sa(dp7324
g7
I27
sg32
VC0024141
p7325
sg10
I28
sg11
Vsystemic lupus erythematosus
p7326
sg13
I3
sasa(dp7327
g2
S'T cells from patients with systemic lupus erythematosus (SLE) express increased amounts of PP2Ac, which contributes to decreased production of interleukin-2 (IL-2).\n'
p7328
sg4
(lp7329
(dp7330
g7
I91
sg8
VP67775
p7331
sg10
I5
sg11
VPP2Ac
p7332
sg13
I1
sa(dp7333
g7
I158
sg8
VP60568
p7334
sg10
I4
sg11
VIL-2
p7335
sg13
I1
sa(dp7336
g7
I143
sg8
VP60568
p7337
sg10
I13
sg11
Vinterleukin-2
p7338
sg13
I1
sasg29
(lp7339
(dp7340
g7
I57
sg32
VC0024141
p7341
sg10
I3
sg11
VSLE
p7342
sg13
I1
sa(dp7343
g7
I27
sg32
VC0024141
p7344
sg10
I28
sg11
Vsystemic lupus erythematosus
p7345
sg13
I3
sasa(dp7346
g2
S'The envelope glycoprotein gp70 of endogenous retroviruses implicated in murine lupus nephritis is secreted by hepatocytes and its expression is controlled by Sgp3 (serum gp70 production 3) and Sgp4 loci derived from lupus-prone mice.\n'
p7347
sg4
(lp7348
(dp7349
g7
I158
sg8
g48
sg10
I4
sg11
VSgp3
p7350
sg13
I1
sa(dp7351
g7
I164
sg8
g48
sg10
I23
sg11
Vserum gp70 production 3
p7352
sg13
I4
sa(dp7353
g7
I4
sg8
g48
sg10
I26
sg11
Venvelope glycoprotein gp70
p7354
sg13
I3
sasg29
(lp7355
(dp7356
g7
I79
sg32
VC0024131
p7357
sg10
I5
sg11
Vlupus
p7358
sg13
I1
sa(dp7359
g7
I79
sg32
VC0024143
p7360
sg10
I15
sg11
Vlupus nephritis
p7361
sg13
I2
sasa(dp7362
g2
S'The endogenous retroviral envelope glycoprotein, gp70, implicated in murine lupus nephritis is secreted by hepatocytes, and its expression is largely regulated by the Sgp3 (serum gp70 production 3) locus derived from lupus-prone mice.\n'
p7363
sg4
(lp7364
(dp7365
g7
I173
sg8
g48
sg10
I23
sg11
Vserum gp70 production 3
p7366
sg13
I4
sa(dp7367
g7
I49
sg8
g48
sg10
I4
sg11
Vgp70
p7368
sg13
I1
sa(dp7369
g7
I15
sg8
g48
sg10
I32
sg11
Vretroviral envelope glycoprotein
p7370
sg13
I3
sa(dp7371
g7
I167
sg8
g48
sg10
I4
sg11
VSgp3
p7372
sg13
I1
sasg29
(lp7373
(dp7374
g7
I76
sg32
VC0024143
p7375
sg10
I15
sg11
Vlupus nephritis
p7376
sg13
I2
sa(dp7377
g7
I76
sg32
VC0024131
p7378
sg10
I5
sg11
Vlupus
p7379
sg13
I1
sasa(dp7380
g2
S'Moreover, the demonstration that TLR7 is involved in the acute phase expression of serum gp70 uncovers an additional pathogenic role of TLR7 in murine lupus nephritis by promoting the expression of nephritogenic gp70 autoantigen.\n'
p7381
sg4
(lp7382
(dp7383
g7
I198
sg8
g48
sg10
I30
sg11
Vnephritogenic gp70 autoantigen
p7384
sg13
I3
sa(dp7385
g7
I83
sg8
g48
sg10
I10
sg11
Vserum gp70
p7386
sg13
I2
sa(dp7387
g7
I33
sg8
g48
sg10
I4
sg11
VTLR7
p7388
sg13
I1
sa(dp7389
g7
I33
sg8
g48
sg10
I4
sg11
VTLR7
p7390
sg13
I1
sasg29
(lp7391
(dp7392
g7
I151
sg32
VC0024143
p7393
sg10
I15
sg11
Vlupus nephritis
p7394
sg13
I2
sasa(dp7395
g2
S'Our results uncovered an additional pathogenic role of TLR7 and TLR9 in murine lupus nephritis by promoting the expression of nephritogenic gp70 autoantigen.\n'
p7396
sg4
(lp7397
(dp7398
g7
I55
sg8
g48
sg10
I4
sg11
VTLR7
p7399
sg13
I1
sa(dp7400
g7
I126
sg8
g48
sg10
I30
sg11
Vnephritogenic gp70 autoantigen
p7401
sg13
I3
sa(dp7402
g7
I64
sg8
g48
sg10
I4
sg11
VTLR9
p7403
sg13
I1
sasg29
(lp7404
(dp7405
g7
I79
sg32
VC0024143
p7406
sg10
I15
sg11
Vlupus nephritis
p7407
sg13
I2
sasa(dp7408
g2
S'TLR9-deficient B6.Nba2 mice displayed increased production of autoantibodies against nuclear antigens, serum retroviral gp70 and glomerular matrix antigens, and developed a markedly accelerated form of lupus nephritis.\n'
p7409
sg4
(lp7410
(dp7411
g7
I109
sg8
g48
sg10
I46
sg11
Vretroviral gp70 and glomerular matrix antigens
p7412
sg13
I6
sa(dp7413
g7
I0
sg8
g48
sg10
I4
sg11
VTLR9
p7414
sg13
I1
sasg29
(lp7415
(dp7416
g7
I202
sg32
VC0024143
p7417
sg10
I15
sg11
Vlupus nephritis
p7418
sg13
I2
sasa(dp7419
g2
S'The endogenous retroviral envelope glycoprotein, gp70, implicated in murine lupus nephritis is secreted by hepatocytes as an acute phase protein, and it has been thought to be a product of an endogenous xenotropic virus, NZB-X1.\n'
p7420
sg4
(lp7421
(dp7422
g7
I49
sg8
g48
sg10
I4
sg11
Vgp70
p7423
sg13
I1
sa(dp7424
g7
I15
sg8
g48
sg10
I32
sg11
Vretroviral envelope glycoprotein
p7425
sg13
I3
sasg29
(lp7426
(dp7427
g7
I76
sg32
VC0024143
p7428
sg10
I15
sg11
Vlupus nephritis
p7429
sg13
I2
sasa(dp7430
g2
S'However, the protection was not complete, because these mice still developed high titers of anti-chromatin autoantibodies and retroviral gp70-anti-gp70 immune complexes, and severe lupus nephritis, which was not the case in male B6.Nba2 mice lacking the Yaa mutation.\n'
p7431
sg4
(lp7432
(dp7433
g7
I126
sg8
g48
sg10
I25
sg11
Vretroviral gp70-anti-gp70
p7434
sg13
I2
sasg29
(lp7435
(dp7436
g7
I181
sg32
VC0024143
p7437
sg10
I15
sg11
Vlupus nephritis
p7438
sg13
I2
sasa(dp7439
g2
S'High levels of the retroviral envelope protein gp70 and gp70 immune complexes have been linked to a single locus on chromosome 13 (Bxs6) in the BXSB model, to which linkage of nephritis was also seen.\n'
p7440
sg4
(lp7441
(dp7442
g7
I47
sg8
g48
sg10
I4
sg11
Vgp70
p7443
sg13
I1
sa(dp7444
g7
I19
sg8
g48
sg10
I32
sg11
Vretroviral envelope protein gp70
p7445
sg13
I4
sasg29
(lp7446
(dp7447
g7
I176
sg32
VC0027697
p7448
sg10
I9
sg11
Vnephritis
p7449
sg13
I1
sasa(dp7450
g2
S'The presence of retinopathy or polyneuropathy did not differ across RBP4 quartiles.\n'
p7451
sg4
(lp7452
sg29
(lp7453
(dp7454
g7
I16
sg32
VC0035309
p7455
sg10
I11
sg11
Vretinopathy
p7456
sg13
I1
sa(dp7457
g7
I31
sg32
VC0152025
p7458
sg10
I14
sg11
Vpolyneuropathy
p7459
sg13
I1
sasa(dp7460
g2
S'Next generation sequencing showed BRAF V600E mutation in the primary papillary carcinoma and NRAS Q61R mutation in the primary follicular carcinoma and bony metastasis.\n'
p7461
sg4
(lp7462
(dp7463
g7
I93
sg8
VP01111
p7464
sg10
I9
sg11
VNRAS Q61R
p7465
sg13
I2
sa(dp7466
g7
I34
sg8
VP15056
p7467
sg10
I4
sg11
VBRAF
p7468
sg13
I1
sasg29
(lp7469
(dp7470
g7
I34
sg32
VC3273990
p7471
sg10
I10
sg11
VBRAF V600E
p7472
sg13
I2
sa(dp7473
g7
I93
sg32
VC3274104
p7474
sg10
I9
sg11
VNRAS Q61R
p7475
sg13
I2
sa(dp7476
g7
I152
sg32
VC0153690
p7477
sg10
I15
sg11
Vbony metastasis
p7478
sg13
I2
sa(dp7479
g7
I69
sg32
VC0007133
p7480
sg10
I19
sg11
Vpapillary carcinoma
p7481
sg13
I2
sa(dp7482
g7
I127
sg32
VC0206682
p7483
sg10
I20
sg11
Vfollicular carcinoma
p7484
sg13
I2
sasa(dp7485
g2
S'NGS revealed a BRAF p.K601E mutation in both the clear cell papillary carcinoma and poorly differentiated carcinoma and a KRAS p.G12R mutation in the papillary carcinoma, follicular variant.\n'
p7486
sg4
(lp7487
(dp7488
g7
I15
sg8
VP15056
p7489
sg10
I6
sg11
VBRAF p
p7490
sg13
I2
sa(dp7491
g7
I122
sg8
VP01116
p7492
sg10
I6
sg11
VKRAS p
p7493
sg13
I2
sasg29
(lp7494
(dp7495
g7
I84
sg32
VC0741899
p7496
sg10
I31
sg11
Vpoorly differentiated carcinoma
p7497
sg13
I3
sa(dp7498
g7
I122
sg32
VC3274033
p7499
sg10
I11
sg11
VKRAS p.G12R
p7500
sg13
I2
sa(dp7501
g7
I60
sg32
VC0007133
p7502
sg10
I19
sg11
Vpapillary carcinoma
p7503
sg13
I2
sa(dp7504
g7
I150
sg32
VC0206683
p7505
sg10
I39
sg11
Vpapillary carcinoma, follicular variant
p7506
sg13
I4
sasa(dp7507
g2
S'No mutations including BRAF and KRAS were seen in the conventional papillary carcinoma.\n'
p7508
sg4
(lp7509
(dp7510
g7
I23
sg8
VP15056
p7511
sg10
I4
sg11
VBRAF
p7512
sg13
I1
sa(dp7513
g7
I32
sg8
VP01116
p7514
sg10
I4
sg11
VKRAS
p7515
sg13
I1
sasg29
(lp7516
(dp7517
g7
I67
sg32
VC0007133
p7518
sg10
I19
sg11
Vpapillary carcinoma
p7519
sg13
I2
sasa(dp7520
g2
S'Novel BRAF and KRAS mutations were identified in two of three tumors suggesting that mutations in PCSO may differ from those commonly identified in papillary carcinoma of the eutopic thyroid.\n'
p7521
sg4
(lp7522
(dp7523
g7
I15
sg8
VP01116
p7524
sg10
I4
sg11
VKRAS
p7525
sg13
I1
sa(dp7526
g7
I6
sg8
VP15056
p7527
sg10
I4
sg11
VBRAF
p7528
sg13
I1
sasg29
(lp7529
(dp7530
g7
I62
sg32
VC0027651
p7531
sg10
I6
sg11
Vtumors
p7532
sg13
I1
sa(dp7533
g7
I148
sg32
VC0007133
p7534
sg10
I19
sg11
Vpapillary carcinoma
p7535
sg13
I2
sasa(dp7536
g2
S'Total mutations found in the FNA and in the corresponding histological specimen in both series were: one PAX8/PPARG rearrangement in a follicular carcinoma (FC), four NRAS mutations [in two FCs, one papillary carcinoma and one follicular adenoma (FA)] and one HRAS mutation in one FA.\n'
p7537
sg4
(lp7538
(dp7539
g7
I105
sg8
g48
sg10
I4
sg11
VPAX8
p7540
sg13
I1
sa(dp7541
g7
I260
sg8
VP01112
p7542
sg10
I4
sg11
VHRAS
p7543
sg13
I1
sa(dp7544
g7
I110
sg8
g48
sg10
I5
sg11
VPPARG
p7545
sg13
I1
sasg29
(lp7546
(dp7547
g7
I199
sg32
VC0007133
p7548
sg10
I19
sg11
Vpapillary carcinoma
p7549
sg13
I2
sa(dp7550
g7
I227
sg32
VC0205647
p7551
sg10
I18
sg11
Vfollicular adenoma
p7552
sg13
I2
sa(dp7553
g7
I157
sg32
VC0206682
p7554
sg10
I2
sg11
VFC
p7555
sg13
I1
sa(dp7556
g7
I247
sg32
VC0205647
p7557
sg10
I2
sg11
VFA
p7558
sg13
I1
sa(dp7559
g7
I247
sg32
VC0205647
p7560
sg10
I2
sg11
VFA
p7561
sg13
I1
sa(dp7562
g7
I135
sg32
VC0206682
p7563
sg10
I20
sg11
Vfollicular carcinoma
p7564
sg13
I2
sasa(dp7565
g2
S'Sixteen patients with genotyped LCA (having the CRB1, CRX, RetGC, RPE65, and AIPL1 mutations) were recruited from one ophthalmology practice and examined for the presence of keratoconus.\n'
p7566
sg4
(lp7567
(dp7568
g7
I54
sg8
g48
sg10
I3
sg11
VCRX
p7569
sg13
I1
sa(dp7570
g7
I59
sg8
g48
sg10
I5
sg11
VRetGC
p7571
sg13
I1
sa(dp7572
g7
I66
sg8
g48
sg10
I5
sg11
VRPE65
p7573
sg13
I1
sa(dp7574
g7
I77
sg8
g48
sg10
I5
sg11
VAIPL1
p7575
sg13
I1
sa(dp7576
g7
I48
sg8
VP82279
p7577
sg10
I4
sg11
VCRB1
p7578
sg13
I1
sasg29
(lp7579
(dp7580
g7
I174
sg32
VC0022578
p7581
sg10
I11
sg11
Vkeratoconus
p7582
sg13
I1
sa(dp7583
g7
I32
sg32
VC0339527
p7584
sg10
I3
sg11
VLCA
p7585
sg13
I1
sasa(dp7586
g2
S'The phenotype of LCA in patients with AIPL1 mutations is relatively severe, with a maculopathy in most patients and keratoconus and cataract in a large subset.\n'
p7587
sg4
(lp7588
(dp7589
g7
I38
sg8
g48
sg10
I15
sg11
VAIPL1 mutations
p7590
sg13
I2
sasg29
(lp7591
(dp7592
g7
I132
sg32
VC0086543
p7593
sg10
I8
sg11
Vcataract
p7594
sg13
I1
sa(dp7595
g7
I17
sg32
VC0339527
p7596
sg10
I3
sg11
VLCA
p7597
sg13
I1
sa(dp7598
g7
I116
sg32
VC0022578
p7599
sg10
I11
sg11
Vkeratoconus
p7600
sg13
I1
sa(dp7601
g7
I83
sg32
VC0730362
p7602
sg10
I11
sg11
Vmaculopathy
p7603
sg13
I1
sasa(dp7604
g2
S'Less is known about PON3; however, recent experiments with PON3 knockout mice show them to be susceptible to obesity, gallstone formation and atherosclerosis.\n'
p7605
sg4
(lp7606
(dp7607
g7
I20
sg8
g48
sg10
I4
sg11
VPON3
p7608
sg13
I1
sa(dp7609
g7
I20
sg8
g48
sg10
I4
sg11
VPON3
p7610
sg13
I1
sasg29
(lp7611
(dp7612
g7
I142
sg32
VC0004153
p7613
sg10
I15
sg11
Vatherosclerosis
p7614
sg13
I1
sa(dp7615
g7
I109
sg32
VC0028754
p7616
sg10
I7
sg11
Vobesity
p7617
sg13
I1
sa(dp7618
g7
I118
sg32
VC0947622
p7619
sg10
I9
sg11
Vgallstone
p7620
sg13
I1
sasa(dp7621
g2
S'The aim of the present study was to investigate the effect of streptozotocin-induced diabetes mellitus and lipoic acid treatment on serum paraoxonase-1 and paraoxonase-3 protein levels and paraoxonase, arylesterase and lactonase activities.36 rats were equally and randomly divided into 4 groups as control, lipoic acid, diabetes and diabetes+lipoic acid.\n'
p7622
sg4
(lp7623
(dp7624
g7
I202
sg8
VP27169
p7625
sg10
I12
sg11
Varylesterase
p7626
sg13
I1
sa(dp7627
g7
I138
sg8
VP14222
p7628
sg10
I11
sg11
Vparaoxonase
p7629
sg13
I1
sa(dp7630
g7
I132
sg8
VP14222
p7631
sg10
I45
sg11
Vserum paraoxonase-1 and paraoxonase-3 protein
p7632
sg13
I5
sasg29
(lp7633
(dp7634
g7
I85
sg32
VC0011849
p7635
sg10
I8
sg11
Vdiabetes
p7636
sg13
I1
sa(dp7637
g7
I85
sg32
VC0011849
p7638
sg10
I17
sg11
Vdiabetes mellitus
p7639
sg13
I2
sasa(dp7640
g2
S'Serum paraoxonase, arylesterase and lactonase activities were determined by the measuring initial rate of substrate (paraoxon, phenylacetate and dihydrocoumarin) hydrolysis.Streptozotocin-induced diabetes mellitus caused a significant decrease whereas lipoic acid treatment caused a significant increase in serum PON1 and PON3 protein levels and paraoxonase, arylesterase and lactonase activities.\n'
p7641
sg4
(lp7642
(dp7643
g7
I6
sg8
VP14222
p7644
sg10
I11
sg11
Vparaoxonase
p7645
sg13
I1
sa(dp7646
g7
I0
sg8
VP14222
p7647
sg10
I17
sg11
VSerum paraoxonase
p7648
sg13
I2
sa(dp7649
g7
I322
sg8
g48
sg10
I12
sg11
VPON3 protein
p7650
sg13
I2
sa(dp7651
g7
I19
sg8
VP27169
p7652
sg10
I12
sg11
Varylesterase
p7653
sg13
I1
sa(dp7654
g7
I19
sg8
VP27169
p7655
sg10
I12
sg11
Varylesterase
p7656
sg13
I1
sa(dp7657
g7
I313
sg8
VP27169
p7658
sg10
I4
sg11
VPON1
p7659
sg13
I1
sasg29
(lp7660
(dp7661
g7
I196
sg32
VC0011849
p7662
sg10
I17
sg11
Vdiabetes mellitus
p7663
sg13
I2
sasa(dp7664
g2
S'The increase percent of serum PON3 protein was higher than that of serum PON1 protein and the increase percent of serum lactonase activity was higher than that of serum paraoxonase and arylesterase activities in diabetes+lipoic acid group.We can report that, like PON1 protein, PON3 protein and actually its lactonase activity may also have a role as an antioxidant in diabetes mellitus and lipoic acid treatment may be useful for the prevention of the atherosclerotic complications of diabetes by increasing serum PON1 and PON3 protein levels and serum enzyme activities.\n'
p7665
sg4
(lp7666
(dp7667
g7
I30
sg8
g48
sg10
I12
sg11
VPON3 protein
p7668
sg13
I2
sa(dp7669
g7
I548
sg8
g48
sg10
I12
sg11
Vserum enzyme
p7670
sg13
I2
sa(dp7671
g7
I30
sg8
g48
sg10
I12
sg11
VPON3 protein
p7672
sg13
I2
sa(dp7673
g7
I30
sg8
g48
sg10
I12
sg11
VPON3 protein
p7674
sg13
I2
sa(dp7675
g7
I73
sg8
VP27169
p7676
sg10
I12
sg11
VPON1 protein
p7677
sg13
I2
sa(dp7678
g7
I185
sg8
VP27169
p7679
sg10
I12
sg11
Varylesterase
p7680
sg13
I1
sa(dp7681
g7
I67
sg8
VP27169
p7682
sg10
I18
sg11
Vserum PON1 protein
p7683
sg13
I3
sa(dp7684
g7
I163
sg8
VP14222
p7685
sg10
I17
sg11
Vserum paraoxonase
p7686
sg13
I2
sa(dp7687
g7
I114
sg8
g48
sg10
I15
sg11
Vserum lactonase
p7688
sg13
I2
sa(dp7689
g7
I67
sg8
VP27169
p7690
sg10
I10
sg11
Vserum PON1
p7691
sg13
I2
sasg29
(lp7692
(dp7693
g7
I369
sg32
VC0011849
p7694
sg10
I17
sg11
Vdiabetes mellitus
p7695
sg13
I2
sa(dp7696
g7
I212
sg32
VC0011849
p7697
sg10
I8
sg11
Vdiabetes
p7698
sg13
I1
sasa(dp7699
g2
S'Our study suggests a role for PON3 in the metabolism of lipid and bile acid as well as protection against atherosclerosis, gallstone disease, and obesity.\n'
p7700
sg4
(lp7701
(dp7702
g7
I30
sg8
g48
sg10
I4
sg11
VPON3
p7703
sg13
I1
sasg29
(lp7704
(dp7705
g7
I123
sg32
VC0008350
p7706
sg10
I17
sg11
Vgallstone disease
p7707
sg13
I2
sa(dp7708
g7
I146
sg32
VC0028754
p7709
sg10
I7
sg11
Vobesity
p7710
sg13
I1
sa(dp7711
g7
I106
sg32
VC0004153
p7712
sg10
I15
sg11
Vatherosclerosis
p7713
sg13
I1
sasa(dp7714
g2
S'Flash frozen brain tissue of a series of 20 pathologically confirmed MSA patients [9 olivopontocerebellar atrophy (OPCA) type, 6 striatonigral degeneration (SND) type, and 5 mixed type] was used for this study.\n'
p7715
sg4
(lp7716
sg29
(lp7717
(dp7718
g7
I157
sg32
VC0270733
p7719
sg10
I3
sg11
VSND
p7720
sg13
I1
sa(dp7721
g7
I69
sg32
VC0393571
p7722
sg10
I3
sg11
VMSA
p7723
sg13
I1
sa(dp7724
g7
I85
sg32
VC0028968
p7725
sg10
I28
sg11
Volivopontocerebellar atrophy
p7726
sg13
I2
sa(dp7727
g7
I129
sg32
VC0270733
p7728
sg10
I26
sg11
Vstriatonigral degeneration
p7729
sg13
I2
sa(dp7730
g7
I115
sg32
VC0028968
p7731
sg10
I4
sg11
VOPCA
p7732
sg13
I1
sasa(dp7733
g2
S'Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that encompasses olivopontocerebellar atrophy (OPCA), striatonigral degeneration (SND) and Shy-Drager syndrome (SDS).\n'
p7734
sg4
(lp7735
sg29
(lp7736
(dp7737
g7
I125
sg32
VC0270733
p7738
sg10
I26
sg11
Vstriatonigral degeneration
p7739
sg13
I2
sa(dp7740
g7
I162
sg32
VC0037019
p7741
sg10
I19
sg11
VShy-Drager syndrome
p7742
sg13
I2
sa(dp7743
g7
I183
sg32
VC0272170
p7744
sg10
I3
sg11
VSDS
p7745
sg13
I1
sa(dp7746
g7
I153
sg32
VC0270733
p7747
sg10
I3
sg11
VSND
p7748
sg13
I1
sa(dp7749
g7
I25
sg32
VC0393571
p7750
sg10
I3
sg11
VMSA
p7751
sg13
I1
sa(dp7752
g7
I88
sg32
VC0028968
p7753
sg10
I28
sg11
Volivopontocerebellar atrophy
p7754
sg13
I2
sa(dp7755
g7
I0
sg32
VC0393571
p7756
sg10
I23
sg11
VMultiple system atrophy
p7757
sg13
I3
sa(dp7758
g7
I118
sg32
VC0028968
p7759
sg10
I4
sg11
VOPCA
p7760
sg13
I1
sa(dp7761
g7
I44
sg32
VC0524851
p7762
sg10
I26
sg11
Vneurodegenerative disorder
p7763
sg13
I2
sasa(dp7764
g2
S'Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that encompasses olivopontocerebellar atrophy (OPCA), striatonigral degeneration (SND) and Shy-Drager syndrome (SDS).\n'
p7765
sg4
(lp7766
sg29
(lp7767
(dp7768
g7
I125
sg32
VC0270733
p7769
sg10
I26
sg11
Vstriatonigral degeneration
p7770
sg13
I2
sa(dp7771
g7
I162
sg32
VC0037019
p7772
sg10
I19
sg11
VShy-Drager syndrome
p7773
sg13
I2
sa(dp7774
g7
I183
sg32
VC0272170
p7775
sg10
I3
sg11
VSDS
p7776
sg13
I1
sa(dp7777
g7
I153
sg32
VC0270733
p7778
sg10
I3
sg11
VSND
p7779
sg13
I1
sa(dp7780
g7
I25
sg32
VC0393571
p7781
sg10
I3
sg11
VMSA
p7782
sg13
I1
sa(dp7783
g7
I88
sg32
VC0028968
p7784
sg10
I28
sg11
Volivopontocerebellar atrophy
p7785
sg13
I2
sa(dp7786
g7
I0
sg32
VC0393571
p7787
sg10
I23
sg11
VMultiple system atrophy
p7788
sg13
I3
sa(dp7789
g7
I118
sg32
VC0028968
p7790
sg10
I4
sg11
VOPCA
p7791
sg13
I1
sa(dp7792
g7
I44
sg32
VC0524851
p7793
sg10
I26
sg11
Vneurodegenerative disorder
p7794
sg13
I2
sasa(dp7795
g2
S'Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that encompasses olivopontocerebellar atrophy (OPCA), striatonigral degeneration (SND) and Shy-Drager syndrome (SDS).\n'
p7796
sg4
(lp7797
sg29
(lp7798
(dp7799
g7
I125
sg32
VC0270733
p7800
sg10
I26
sg11
Vstriatonigral degeneration
p7801
sg13
I2
sa(dp7802
g7
I162
sg32
VC0037019
p7803
sg10
I19
sg11
VShy-Drager syndrome
p7804
sg13
I2
sa(dp7805
g7
I183
sg32
VC0272170
p7806
sg10
I3
sg11
VSDS
p7807
sg13
I1
sa(dp7808
g7
I153
sg32
VC0270733
p7809
sg10
I3
sg11
VSND
p7810
sg13
I1
sa(dp7811
g7
I25
sg32
VC0393571
p7812
sg10
I3
sg11
VMSA
p7813
sg13
I1
sa(dp7814
g7
I88
sg32
VC0028968
p7815
sg10
I28
sg11
Volivopontocerebellar atrophy
p7816
sg13
I2
sa(dp7817
g7
I0
sg32
VC0393571
p7818
sg10
I23
sg11
VMultiple system atrophy
p7819
sg13
I3
sa(dp7820
g7
I118
sg32
VC0028968
p7821
sg10
I4
sg11
VOPCA
p7822
sg13
I1
sa(dp7823
g7
I44
sg32
VC0524851
p7824
sg10
I26
sg11
Vneurodegenerative disorder
p7825
sg13
I2
sasa(dp7826
g2
S'Multiple system atrophy (MSA), a sporadic progressive synucleinopathy of advanced age, is separated into two clinic opathological subtypes: MSA-P (striatonigral degeneration [SND]) with predominant parkinsonian features and MSA-C (olivopontocerebellar atrophy [OPCA]) with predominant cerebellar ataxia.\n'
p7827
sg4
(lp7828
sg29
(lp7829
(dp7830
g7
I147
sg32
VC0270733
p7831
sg10
I26
sg11
Vstriatonigral degeneration
p7832
sg13
I2
sa(dp7833
g7
I231
sg32
VC0028968
p7834
sg10
I28
sg11
Volivopontocerebellar atrophy
p7835
sg13
I2
sa(dp7836
g7
I25
sg32
VC0393571
p7837
sg10
I3
sg11
VMSA
p7838
sg13
I1
sa(dp7839
g7
I0
sg32
VC0393571
p7840
sg10
I23
sg11
VMultiple system atrophy
p7841
sg13
I3
sa(dp7842
g7
I25
sg32
VC0393571
p7843
sg10
I3
sg11
VMSA
p7844
sg13
I1
sa(dp7845
g7
I285
sg32
VC0007758
p7846
sg10
I17
sg11
Vcerebellar ataxia
p7847
sg13
I2
sa(dp7848
g7
I25
sg32
VC0393571
p7849
sg10
I3
sg11
VMSA
p7850
sg13
I1
sasa(dp7851
g2
S'Multiple system atrophy (MSA) has varying clinical (MSA-P versus MSA-C) and pathological [striatonigral degeneration (SND) versus olivopontocerebellar atrophy (OPCA)] phenotypes.\n'
p7852
sg4
(lp7853
sg29
(lp7854
(dp7855
g7
I25
sg32
VC0393571
p7856
sg10
I3
sg11
VMSA
p7857
sg13
I1
sa(dp7858
g7
I25
sg32
VC0393571
p7859
sg10
I3
sg11
VMSA
p7860
sg13
I1
sa(dp7861
g7
I0
sg32
VC0393571
p7862
sg10
I23
sg11
VMultiple system atrophy
p7863
sg13
I3
sa(dp7864
g7
I90
sg32
VC0270733
p7865
sg10
I26
sg11
Vstriatonigral degeneration
p7866
sg13
I2
sa(dp7867
g7
I25
sg32
VC0393571
p7868
sg10
I3
sg11
VMSA
p7869
sg13
I1
sa(dp7870
g7
I130
sg32
VC0028968
p7871
sg10
I28
sg11
Volivopontocerebellar atrophy
p7872
sg13
I2
sa(dp7873
g7
I160
sg32
VC0028968
p7874
sg10
I4
sg11
VOPCA
p7875
sg13
I1
sasa(dp7876
g2
S'The subjects were 28 patients with MSA (14 striato-nigral degeneration; SND, 14 olivo-ponto-cerebellar atrophy; OPCA.\n'
p7877
sg4
(lp7878
sg29
(lp7879
(dp7880
g7
I80
sg32
VC0028968
p7881
sg10
I30
sg11
Volivo-ponto-cerebellar atrophy
p7882
sg13
I2
sa(dp7883
g7
I58
sg32
VC0011164
p7884
sg10
I12
sg11
Vdegeneration
p7885
sg13
I1
sa(dp7886
g7
I35
sg32
VC0393571
p7887
sg10
I3
sg11
VMSA
p7888
sg13
I1
sasa(dp7889
g2
S'We divided the patients into three clinical subtypes according to initial and predominant symptoms: 14 with olivopontocerebellar atrophy (OPCA), eight with the Shy-Drager syndrome (SDS) and seven with striatonigral degeneration (SND).\n'
p7890
sg4
(lp7891
sg29
(lp7892
(dp7893
g7
I160
sg32
VC0037019
p7894
sg10
I19
sg11
VShy-Drager syndrome
p7895
sg13
I2
sa(dp7896
g7
I229
sg32
VC0270733
p7897
sg10
I3
sg11
VSND
p7898
sg13
I1
sa(dp7899
g7
I201
sg32
VC0270733
p7900
sg10
I26
sg11
Vstriatonigral degeneration
p7901
sg13
I2
sa(dp7902
g7
I181
sg32
VC0272170
p7903
sg10
I3
sg11
VSDS
p7904
sg13
I1
sa(dp7905
g7
I108
sg32
VC0028968
p7906
sg10
I28
sg11
Volivopontocerebellar atrophy
p7907
sg13
I2
sa(dp7908
g7
I138
sg32
VC0028968
p7909
sg10
I4
sg11
VOPCA
p7910
sg13
I1
sasa(dp7911
g2
S'MSA is a sporadic degenerative disease that occurs in striatonigral degeneration (SND), SDS and most cases of sporadic OPCA.\n'
p7912
sg4
(lp7913
(dp7914
g7
I0
sg8
VP40225
p7915
sg10
I3
sg11
VMSA
p7916
sg13
I1
sasg29
(lp7917
(dp7918
g7
I54
sg32
VC0270733
p7919
sg10
I26
sg11
Vstriatonigral degeneration
p7920
sg13
I2
sa(dp7921
g7
I82
sg32
VC0270733
p7922
sg10
I3
sg11
VSND
p7923
sg13
I1
sa(dp7924
g7
I18
sg32
VC1285162
p7925
sg10
I20
sg11
Vdegenerative disease
p7926
sg13
I2
sa(dp7927
g7
I0
sg32
VC0393571
p7928
sg10
I3
sg11
VMSA
p7929
sg13
I1
sa(dp7930
g7
I88
sg32
VC0272170
p7931
sg10
I3
sg11
VSDS
p7932
sg13
I1
sasa(dp7933
g2
S"Notably, samples from patients suffering from chronic inflammatory bowel disease (Crohn's disease, CD; ulcerative coliltis, UC) or autoimmune gastritis revealed variable amounts of cathepsin W-expressing cells.\n"
p7934
sg4
(lp7935
(dp7936
g7
I181
sg8
VP56202
p7937
sg10
I11
sg11
Vcathepsin W
p7938
sg13
I2
sasg29
(lp7939
(dp7940
g7
I82
sg32
VC0010346
p7941
sg10
I15
sg11
VCrohn's disease
p7942
sg13
I2
sa(dp7943
g7
I31
sg32
VC0683278
p7944
sg10
I9
sg11
Vsuffering
p7945
sg13
I1
sa(dp7946
g7
I54
sg32
VC0021390
p7947
sg10
I26
sg11
Vinflammatory bowel disease
p7948
sg13
I3
sa(dp7949
g7
I103
sg32
VC0041582
p7950
sg10
I10
sg11
Vulcerative
p7951
sg13
I1
sa(dp7952
g7
I131
sg32
VC0017154
p7953
sg10
I20
sg11
Vautoimmune gastritis
p7954
sg13
I2
sasa(dp7955
g2
S'In autoimmune gastritis, cathepsin W-expressing cells made up for 65% of all CD45+ cells, whereas the corresponding values for CD and UC were 11% and 6%, respectively.\n'
p7956
sg4
(lp7957
(dp7958
g7
I77
sg8
VP08575
p7959
sg10
I5
sg11
VCD45+
p7960
sg13
I1
sa(dp7961
g7
I25
sg8
VP56202
p7962
sg10
I11
sg11
Vcathepsin W
p7963
sg13
I2
sasg29
(lp7964
(dp7965
g7
I3
sg32
VC0017154
p7966
sg10
I20
sg11
Vautoimmune gastritis
p7967
sg13
I2
sasa(dp7968
g2
S'The major complications included intraoperative posterior capsular tear in 3 cases, secondary glaucoma due to residual cortex in 2 cases, posterior capsular opacity in 7 cases, cystoid macular edema in 1 case, and retinal detachment in 1 case.\n'
p7969
sg4
(lp7970
sg29
(lp7971
(dp7972
g7
I214
sg32
VC0035305
p7973
sg10
I18
sg11
Vretinal detachment
p7974
sg13
I2
sa(dp7975
g7
I177
sg32
VC0024440
p7976
sg10
I21
sg11
Vcystoid macular edema
p7977
sg13
I3
sa(dp7978
g7
I157
sg32
VC1265876
p7979
sg10
I7
sg11
Vopacity
p7980
sg13
I1
sa(dp7981
g7
I84
sg32
VC0149893
p7982
sg10
I18
sg11
Vsecondary glaucoma
p7983
sg13
I2
sasa(dp7984
g2
S'The present study was conducted to determine the clinical relationship between HSP27 and atrial fibrillation (AF).\n'
p7985
sg4
(lp7986
(dp7987
g7
I79
sg8
g48
sg10
I5
sg11
VHSP27
p7988
sg13
I1
sasg29
(lp7989
(dp7990
g7
I89
sg32
VC0004238
p7991
sg10
I19
sg11
Vatrial fibrillation
p7992
sg13
I2
sa(dp7993
g7
I110
sg32
VC0004238
p7994
sg10
I2
sg11
VAF
p7995
sg13
I1
sasa(dp7996
g2
S'Circulating ANGPTL2 is increased in chronic kidney disease (CKD), where the risk of CVD is amplified.\n'
p7997
sg4
(lp7998
(dp7999
g7
I12
sg8
g48
sg10
I7
sg11
VANGPTL2
p8000
sg13
I1
sasg29
(lp8001
(dp8002
g7
I60
sg32
VC1561643
p8003
sg10
I3
sg11
VCKD
p8004
sg13
I1
sa(dp8005
g7
I36
sg32
VC1561643
p8006
sg10
I22
sg11
Vchronic kidney disease
p8007
sg13
I3
sa(dp8008
g7
I84
sg32
VC0007222
p8009
sg10
I3
sg11
VCVD
p8010
sg13
I1
sasa(dp8011
g2
S'The positive association between post-KTx ANGPTL2, aortic stiffness and mortality, suggests that ANGPTL2 may play a biological role in CKD-related CVD.\n'
p8012
sg4
(lp8013
(dp8014
g7
I42
sg8
g48
sg10
I7
sg11
VANGPTL2
p8015
sg13
I1
sa(dp8016
g7
I42
sg8
g48
sg10
I7
sg11
VANGPTL2
p8017
sg13
I1
sasg29
(lp8018
(dp8019
g7
I147
sg32
VC0007222
p8020
sg10
I3
sg11
VCVD
p8021
sg13
I1
sa(dp8022
g7
I51
sg32
VC3178782
p8023
sg10
I16
sg11
Vaortic stiffness
p8024
sg13
I2
sasa(dp8025
g2
S'Furthermore, ANGPTL2 deficiency in a mouse unilateral ureteral obstruction model significantly reduced renal fibrosis by decreasing TGF-Beta1 signal amplification in kidney.\n'
p8026
sg4
(lp8027
(dp8028
g7
I132
sg8
VP01137
p8029
sg10
I9
sg11
VTGF-Beta1
p8030
sg13
I1
sa(dp8031
g7
I13
sg8
g48
sg10
I7
sg11
VANGPTL2
p8032
sg13
I1
sasg29
(lp8033
(dp8034
g7
I103
sg32
VC0151650
p8035
sg10
I14
sg11
Vrenal fibrosis
p8036
sg13
I2
sa(dp8037
g7
I54
sg32
VC0041956
p8038
sg10
I20
sg11
Vureteral obstruction
p8039
sg13
I2
sa(dp8040
g7
I149
sg32
VC1705759
p8041
sg10
I13
sg11
Vamplification
p8042
sg13
I1
sasa(dp8043
g2
S'demonstrated that genetic depletion of Angptl2 confers amelioration of the mouse kidney fibrosis induced by a unilateral ureteral obstruction, implicating that ANGPTL2, predominantly in the renal tubular compartments, activates the transforming growth factor-Beta signaling and vice versa through miR-221.\n'
p8044
sg4
(lp8045
(dp8046
g7
I160
sg8
g48
sg10
I7
sg11
VANGPTL2
p8047
sg13
I1
sa(dp8048
g7
I39
sg8
g48
sg10
I7
sg11
VAngptl2
p8049
sg13
I1
sa(dp8050
g7
I232
sg8
VP18075
p8051
sg10
I31
sg11
Vtransforming growth factor-Beta
p8052
sg13
I3
sasg29
(lp8053
(dp8054
g7
I81
sg32
VC0151650
p8055
sg10
I15
sg11
Vkidney fibrosis
p8056
sg13
I2
sa(dp8057
g7
I121
sg32
VC0041956
p8058
sg10
I20
sg11
Vureteral obstruction
p8059
sg13
I2
sasa(dp8060
g2
S'The aim of this study was to investigate the relationship between serum Angptl2 level and chronic kidney disease (CKD).\n'
p8061
sg4
(lp8062
(dp8063
g7
I72
sg8
g48
sg10
I7
sg11
VAngptl2
p8064
sg13
I1
sasg29
(lp8065
(dp8066
g7
I90
sg32
VC1561643
p8067
sg10
I22
sg11
Vchronic kidney disease
p8068
sg13
I3
sa(dp8069
g7
I114
sg32
VC1561643
p8070
sg10
I3
sg11
VCKD
p8071
sg13
I1
sasa(dp8072
g2
S'The age- and sex-adjusted ORs for the presence of CKD increased with higher serum Angptl2 level.\n'
p8073
sg4
(lp8074
(dp8075
g7
I82
sg8
g48
sg10
I7
sg11
VAngptl2
p8076
sg13
I1
sasg29
(lp8077
sa(dp8078
g2
S'Elevated serum Angptl2 is associated with the likelihood of CKD in the general population.\n'
p8079
sg4
(lp8080
(dp8081
g7
I9
sg8
g48
sg10
I13
sg11
Vserum Angptl2
p8082
sg13
I2
sasg29
(lp8083
sa(dp8084
g2
S'In conclusion, we propose that metabolic regulation of the Kv2.1/Kv9.3 heteromultimer may play an important role in hypoxic PA vasoconstriction and in the possible development of PA hypertension.\n'
p8085
sg4
(lp8086
(dp8087
g7
I59
sg8
g48
sg10
I5
sg11
VKv2.1
p8088
sg13
I1
sasg29
(lp8089
(dp8090
g7
I116
sg32
VC0242184
p8091
sg10
I7
sg11
Vhypoxic
p8092
sg13
I1
sa(dp8093
g7
I127
sg32
VC1456863
p8094
sg10
I16
sg11
Vvasoconstriction
p8095
sg13
I1
sa(dp8096
g7
I182
sg32
VC0020538
p8097
sg10
I12
sg11
Vhypertension
p8098
sg13
I1
sasa(dp8099
g2
S'Monoclonal antibodies to human complement component C9 were used to localise the membrane attack complex (MAC) of human complement on muscle fibres from patients with autoimmune myositis.\n'
p8100
sg4
(lp8101
(dp8102
g7
I25
sg8
g48
sg10
I16
sg11
Vhuman complement
p8103
sg13
I2
sa(dp8104
g7
I25
sg8
VP02748
p8105
sg10
I29
sg11
Vhuman complement component C9
p8106
sg13
I4
sasg29
(lp8107
(dp8108
g7
I167
sg32
VC2732697
p8109
sg10
I19
sg11
Vautoimmune myositis
p8110
sg13
I2
sasa(dp8111
g2
S'Thus, eosinophil trafficking to the heart is dependent on the eotaxin-CCR3 pathway in a mouse model of EAM and associated with cardiac eotaxin expression in patients with eosinophilic myocarditis.\n'
p8112
sg4
(lp8113
(dp8114
g7
I62
sg8
VP51671
p8115
sg10
I7
sg11
Veotaxin
p8116
sg13
I1
sa(dp8117
g7
I70
sg8
VP51677
p8118
sg10
I4
sg11
VCCR3
p8119
sg13
I1
sa(dp8120
g7
I62
sg8
VP51671
p8121
sg10
I7
sg11
Veotaxin
p8122
sg13
I1
sasg29
(lp8123
(dp8124
g7
I103
sg32
VC1719788
p8125
sg10
I3
sg11
VEAM
p8126
sg13
I1
sa(dp8127
g7
I171
sg32
VC0151788
p8128
sg10
I24
sg11
Veosinophilic myocarditis
p8129
sg13
I2
sasa(dp8130
g2
S'Interleukin (IL)-5, RANTES and CC chemokine receptor 3 (CCR3) are essential for induction of eosinophil recruitment in organs, but the precise pathogenesis of eosinophilic myocarditis is still unclear.\n'
p8131
sg4
(lp8132
(dp8133
g7
I0
sg8
VP60568
p8134
sg10
I18
sg11
VInterleukin (IL)-5
p8135
sg13
I2
sa(dp8136
g7
I20
sg8
VP13501
p8137
sg10
I6
sg11
VRANTES
p8138
sg13
I1
sa(dp8139
g7
I56
sg8
VP51677
p8140
sg10
I4
sg11
VCCR3
p8141
sg13
I1
sa(dp8142
g7
I31
sg8
VP51677
p8143
sg10
I23
sg11
VCC chemokine receptor 3
p8144
sg13
I4
sasg29
(lp8145
(dp8146
g7
I143
sg32
VC0699748
p8147
sg10
I12
sg11
Vpathogenesis
p8148
sg13
I1
sa(dp8149
g7
I159
sg32
VC0151788
p8150
sg10
I24
sg11
Veosinophilic myocarditis
p8151
sg13
I2
sa(dp8152
g7
I104
sg32
VC0271510
p8153
sg10
I11
sg11
Vrecruitment
p8154
sg13
I1
sasa(dp8155
g2
S'Eosinophilic myocarditis was usually associated with animals having several degenerative changes in myocardial cells, and IL-5, RANTES and CCR3 expressions were usually present in these eosinophils (p &lt; 0.05).\n'
p8156
sg4
(lp8157
(dp8158
g7
I128
sg8
VP13501
p8159
sg10
I6
sg11
VRANTES
p8160
sg13
I1
sa(dp8161
g7
I122
sg8
VP05113
p8162
sg10
I4
sg11
VIL-5
p8163
sg13
I1
sa(dp8164
g7
I139
sg8
VP51677
p8165
sg10
I4
sg11
VCCR3
p8166
sg13
I1
sasg29
(lp8167
(dp8168
g7
I0
sg32
VC0151788
p8169
sg10
I24
sg11
VEosinophilic myocarditis
p8170
sg13
I2
sa(dp8171
g7
I76
sg32
VC0011164
p8172
sg10
I12
sg11
Vdegenerative
p8173
sg13
I1
sasa(dp8174
g2
S'Farber disease (MIM 228000) is a rare autosomal recessive condition caused by deficiency of lysosomal acid ceramidase (EC 3.5.1.23).\n'
p8175
sg4
(lp8176
(dp8177
g7
I92
sg8
g48
sg10
I25
sg11
Vlysosomal acid ceramidase
p8178
sg13
I3
sasg29
(lp8179
(dp8180
g7
I0
sg32
VC0268255
p8181
sg10
I14
sg11
VFarber disease
p8182
sg13
I2
sa(dp8183
g7
I58
sg32
VC0012634
p8184
sg10
I9
sg11
Vcondition
p8185
sg13
I1
sasa(dp8186
g2
S'The specific activity of acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23) was measured at pH4.5 in normal fibroblasts and in fibroblasts from patients with Farber disease and obligate heterozygotes.\n'
p8187
sg4
(lp8188
(dp8189
g7
I42
sg8
VP0C7U2
p8190
sg10
I27
sg11
VN-acylsphingosine deacylase
p8191
sg13
I2
sa(dp8192
g7
I25
sg8
g48
sg10
I15
sg11
Vacid ceramidase
p8193
sg13
I2
sasg29
(lp8194
(dp8195
g7
I166
sg32
VC0268255
p8196
sg10
I14
sg11
VFarber disease
p8197
sg13
I2
sasa(dp8198
g2
S'Laxity of skin and tissue over the tarsal plate and spasm of the orbicular muscle along the lid margin lead to senile entropion.\n'
p8199
sg4
(lp8200
sg29
(lp8201
(dp8202
g7
I52
sg32
VC0037763
p8203
sg10
I5
sg11
Vspasm
p8204
sg13
I1
sa(dp8205
g7
I111
sg32
VC0155188
p8206
sg10
I16
sg11
Vsenile entropion
p8207
sg13
I2
sasa(dp8208
g2
S'The tested material was mitochondrial DNA (mtDNA) isolated from specimens of ductal carcinoma (carcinoma ductale) Tp1-2Np0-1Mp0, blood and non-cancerous tissue of mammary gland (control), sampled from 50 patients who had been operated for breast cancer.\n'
p8209
sg4
(lp8210
(dp8211
g7
I114
sg8
VP09430
p8212
sg10
I13
sg11
VTp1-2Np0-1Mp0
p8213
sg13
I1
sasg29
(lp8214
(dp8215
g7
I84
sg32
VC0007097
p8216
sg10
I9
sg11
Vcarcinoma
p8217
sg13
I1
sa(dp8218
g7
I239
sg32
VC0678222
p8219
sg10
I13
sg11
Vbreast cancer
p8220
sg13
I2
sa(dp8221
g7
I77
sg32
VC1176475
p8222
sg10
I16
sg11
Vductal carcinoma
p8223
sg13
I2
sasa(dp8224
g2
S'The present case-control study was conducted to determine the influence of ADH2, ADH3 and ALDH2 polymorphisms in Fukuoka, Japan, with 685 incident cases of histologically confirmed colorectal adenocarcinomas and 778 community controls selected randomly from the study area.\n'
p8225
sg4
(lp8226
(dp8227
g7
I75
sg8
VP00326
p8228
sg10
I4
sg11
VADH2
p8229
sg13
I1
sa(dp8230
g7
I90
sg8
VP05091
p8231
sg10
I5
sg11
VALDH2
p8232
sg13
I1
sa(dp8233
g7
I81
sg8
VP00326
p8234
sg10
I4
sg11
VADH3
p8235
sg13
I1
sasg29
(lp8236
(dp8237
g7
I192
sg32
VC0001418
p8238
sg10
I15
sg11
Vadenocarcinomas
p8239
sg13
I1
sasa(dp8240
g2
S'The SPINK1 N34S polymorphism was detected in 5 of 172 (2.9%) patients with chronic pancreatitis, in 4 of 200 (2.0%) patients with sporadic pancreatic adenocarcinoma, in 0 of 36 (0%) of patients with familial pancreatic cancer and in 3 of 177 (1.7%) controls of chronic cholecystitis.\n'
p8241
sg4
(lp8242
(dp8243
g7
I4
sg8
VP00995
p8244
sg10
I11
sg11
VSPINK1 N34S
p8245
sg13
I2
sasg29
(lp8246
(dp8247
g7
I261
sg32
VC0085694
p8248
sg10
I21
sg11
Vchronic cholecystitis
p8249
sg13
I2
sa(dp8250
g7
I199
sg32
VC2931038
p8251
sg10
I26
sg11
Vfamilial pancreatic cancer
p8252
sg13
I3
sa(dp8253
g7
I75
sg32
VC0149521
p8254
sg10
I20
sg11
Vchronic pancreatitis
p8255
sg13
I2
sa(dp8256
g7
I139
sg32
VC0281361
p8257
sg10
I25
sg11
Vpancreatic adenocarcinoma
p8258
sg13
I2
sasa(dp8259
g2
S'Recent biochemical investigations fuel the hope that inhibition of DHCR24, resulting in an accumulation of desmosterol, can open new therapeutic options for treating hepatitis C virus infections, certain forms of cancer and atherosclerosis.\n'
p8260
sg4
(lp8261
(dp8262
g7
I67
sg8
g48
sg10
I6
sg11
VDHCR24
p8263
sg13
I1
sasg29
(lp8264
(dp8265
g7
I213
sg32
VC0006826
p8266
sg10
I6
sg11
Vcancer
p8267
sg13
I1
sa(dp8268
g7
I184
sg32
VC0021311
p8269
sg10
I10
sg11
Vinfections
p8270
sg13
I1
sa(dp8271
g7
I224
sg32
VC0004153
p8272
sg10
I15
sg11
Vatherosclerosis
p8273
sg13
I1
sa(dp8274
g7
I166
sg32
VC0019196
p8275
sg10
I11
sg11
Vhepatitis C
p8276
sg13
I2
sasa(dp8277
g2
S'However, the function of DHCR24 in endometrial cancer (EC) remains largely elusive.\n'
p8278
sg4
(lp8279
(dp8280
g7
I25
sg8
g48
sg10
I6
sg11
VDHCR24
p8281
sg13
I1
sasg29
(lp8282
(dp8283
g7
I35
sg32
VC0476089
p8284
sg10
I18
sg11
Vendometrial cancer
p8285
sg13
I2
sa(dp8286
g7
I55
sg32
VC0476089
p8287
sg10
I2
sg11
VEC
p8288
sg13
I1
sasa(dp8289
g2
S'Here, we analyzed the expression profile of DHCR24 and the progesterone receptor (PGR) in our tissue microarray of EC (n = 258), the existing EC database in GEO (Gene Expression Omnibus), and TCGA (The Cancer Genome Atlas).\n'
p8290
sg4
(lp8291
(dp8292
g7
I59
sg8
VP06401
p8293
sg10
I21
sg11
Vprogesterone receptor
p8294
sg13
I2
sa(dp8295
g7
I82
sg8
VP06401
p8296
sg10
I3
sg11
VPGR
p8297
sg13
I1
sa(dp8298
g7
I44
sg8
g48
sg10
I6
sg11
VDHCR24
p8299
sg13
I1
sasg29
(lp8300
(dp8301
g7
I202
sg32
VC0006826
p8302
sg10
I6
sg11
VCancer
p8303
sg13
I1
sasa(dp8304
g2
S'Furthermore, genetically silencing DHCR24 inhibited the metastatic ability of endometrial cancer cells and up-regulated PGR expression, which made cells more sensitive to progestin.\n'
p8305
sg4
(lp8306
(dp8307
g7
I35
sg8
g48
sg10
I6
sg11
VDHCR24
p8308
sg13
I1
sasg29
(lp8309
(dp8310
g7
I78
sg32
VC0476089
p8311
sg10
I18
sg11
Vendometrial cancer
p8312
sg13
I2
sasa(dp8313
g2
S'In addition, PCAT1 interacts with AR and LSD1 and is required for their recruitment to the enhancers of GNMT and DHCR24, two androgen late-response genes implicated in prostate cancer development and progression.\n'
p8314
sg4
(lp8315
(dp8316
g7
I104
sg8
g48
sg10
I4
sg11
VGNMT
p8317
sg13
I1
sa(dp8318
g7
I125
sg8
VP01893
p8319
sg10
I28
sg11
Vandrogen late-response genes
p8320
sg13
I3
sa(dp8321
g7
I113
sg8
g48
sg10
I6
sg11
VDHCR24
p8322
sg13
I1
sasg29
(lp8323
(dp8324
g7
I168
sg32
VC0600139
p8325
sg10
I15
sg11
Vprostate cancer
p8326
sg13
I2
sa(dp8327
g7
I72
sg32
VC0271510
p8328
sg10
I11
sg11
Vrecruitment
p8329
sg13
I1
sasa(dp8330
g2
S'Herein, we investigated whether serum 3Beta-hydroxysterol Delta24-reductase antibody (DHCR24 Ab) may serve as a prognostic marker for hepatitis C infection progression to hepatocellular carcinoma (HCC).\n'
p8331
sg4
(lp8332
(dp8333
g7
I86
sg8
g48
sg10
I6
sg11
VDHCR24
p8334
sg13
I1
sa(dp8335
g7
I32
sg8
g48
sg10
I52
sg11
Vserum 3Beta-hydroxysterol Delta24-reductase antibody
p8336
sg13
I4
sasg29
(lp8337
(dp8338
g7
I171
sg32
VC2239176
p8339
sg10
I24
sg11
Vhepatocellular carcinoma
p8340
sg13
I2
sa(dp8341
g7
I197
sg32
VC2239176
p8342
sg10
I3
sg11
VHCC
p8343
sg13
I1
sa(dp8344
g7
I134
sg32
VC0019196
p8345
sg10
I21
sg11
Vhepatitis C infection
p8346
sg13
I3
sasa(dp8347
g2
S'Over-expression of receptor interacting protein 140 (RIP140) suppressed thyroid hormone (T3) induction of cellular retinoic acid binding I protein (CRABPI) gene in P19 embryonal carcinoma cells.\n'
p8348
sg4
(lp8349
(dp8350
g7
I148
sg8
VP29762
p8351
sg10
I6
sg11
VCRABPI
p8352
sg13
I1
sa(dp8353
g7
I19
sg8
VP48552
p8354
sg10
I32
sg11
Vreceptor interacting protein 140
p8355
sg13
I4
sa(dp8356
g7
I106
sg8
VP63244
p8357
sg10
I40
sg11
Vcellular retinoic acid binding I protein
p8358
sg13
I6
sa(dp8359
g7
I53
sg8
VP48552
p8360
sg10
I6
sg11
VRIP140
p8361
sg13
I1
sasg29
(lp8362
(dp8363
g7
I168
sg32
VC0206659
p8364
sg10
I19
sg11
Vembryonal carcinoma
p8365
sg13
I2
sasa(dp8366
g2
S'The present study was set up to examine the possible effects of alcohol on cellular RA binding protein I (CRABP-I) expression during embryonic development by using transgenic mouse embryos and P19 embryonal carcinoma cells as experimental models.\n'
p8367
sg4
(lp8368
(dp8369
g7
I75
sg8
VP14222
p8370
sg10
I29
sg11
Vcellular RA binding protein I
p8371
sg13
I5
sa(dp8372
g7
I106
sg8
VP29762
p8373
sg10
I7
sg11
VCRABP-I
p8374
sg13
I1
sasg29
(lp8375
(dp8376
g7
I197
sg32
VC0206659
p8377
sg10
I19
sg11
Vembryonal carcinoma
p8378
sg13
I2
sasa(dp8379
g2
S'The regulation of mouse cellular retinoic acid-binding protein-I (CRABP-I) gene expression by the retinoids and thyroid hormones was examined, by using a beta-galactosidase (lacZ) reporter gene and a CRABP-I specific antibody, in transgenic mouse embryos and a mouse embryonal carcinoma cell line P19.\n'
p8380
sg4
(lp8381
(dp8382
g7
I154
sg8
VP16278
p8383
sg10
I18
sg11
Vbeta-galactosidase
p8384
sg13
I1
sa(dp8385
g7
I66
sg8
VP29762
p8386
sg10
I7
sg11
VCRABP-I
p8387
sg13
I1
sa(dp8388
g7
I18
sg8
VP29762
p8389
sg10
I46
sg11
Vmouse cellular retinoic acid-binding protein-I
p8390
sg13
I5
sa(dp8391
g7
I200
sg8
VP29762
p8392
sg10
I25
sg11
VCRABP-I specific antibody
p8393
sg13
I3
sasg29
(lp8394
(dp8395
g7
I267
sg32
VC0206659
p8396
sg10
I19
sg11
Vembryonal carcinoma
p8397
sg13
I2
sasa(dp8398
g2
S'The promoter and its upstream regulatory region of the mouse cellular retinoic acid-binding protein I (crabp-I) gene were examined in transgenic mouse embryos, a mouse embryonal carcinoma cell line P19, and a mouse embryonic fibroblast cell line 3T6.\n'
p8399
sg4
(lp8400
(dp8401
g7
I103
sg8
VP29762
p8402
sg10
I7
sg11
Vcrabp-I
p8403
sg13
I1
sa(dp8404
g7
I55
sg8
VP29762
p8405
sg10
I46
sg11
Vmouse cellular retinoic acid-binding protein I
p8406
sg13
I6
sasg29
(lp8407
(dp8408
g7
I168
sg32
VC0206659
p8409
sg10
I19
sg11
Vembryonal carcinoma
p8410
sg13
I2
sasa(dp8411
g2
S'Cellular retinoic acid-binding protein-I (CRABP-I) gene expression is induced in mouse embryonal carcinoma P19 cells specifically by retinoic acid (RA) and the induction is enhanced by sphinganine.\n'
p8412
sg4
(lp8413
(dp8414
g7
I0
sg8
VP29762
p8415
sg10
I40
sg11
VCellular retinoic acid-binding protein-I
p8416
sg13
I4
sa(dp8417
g7
I42
sg8
VP29762
p8418
sg10
I7
sg11
VCRABP-I
p8419
sg13
I1
sasg29
(lp8420
(dp8421
g7
I87
sg32
VC0206659
p8422
sg10
I19
sg11
Vembryonal carcinoma
p8423
sg13
I2
sasa(dp8424
g2
S'The neuropathic groups did not differ in duration of diabetes onset (DG = 13 years +/- 8; UDG = 14 years +/- 5; P = 0.243) and they presented similar mean for symptoms according to MNSI score (DG = 6.94 +/- 1.81; UDG = 6.78 +/- 2.44; P = 0.352).\n'
p8425
sg4
(lp8426
sg29
(lp8427
(dp8428
g7
I53
sg32
VC0011849
p8429
sg10
I8
sg11
Vdiabetes
p8430
sg13
I1
sasa(dp8431
g2
S"We also sequenced eight genes (AICDA, BTK, CD40, CD154, NEMO, TACI, SH2D1A, UNG) implicated in immunoglobulin deficiency in 19 Waldenstroem's macroglobulinemia patients with IgA and/or IgG hypogammaglobulinemia.\n"
p8432
sg4
(lp8433
(dp8434
g7
I56
sg8
g48
sg10
I4
sg11
VNEMO
p8435
sg13
I1
sa(dp8436
g7
I68
sg8
g48
sg10
I6
sg11
VSH2D1A
p8437
sg13
I1
sa(dp8438
g7
I38
sg8
g48
sg10
I3
sg11
VBTK
p8439
sg13
I1
sa(dp8440
g7
I95
sg8
g48
sg10
I14
sg11
Vimmunoglobulin
p8441
sg13
I1
sa(dp8442
g7
I174
sg8
VP11912
p8443
sg10
I3
sg11
VIgA
p8444
sg13
I1
sa(dp8445
g7
I62
sg8
g48
sg10
I4
sg11
VTACI
p8446
sg13
I1
sa(dp8447
g7
I31
sg8
g48
sg10
I5
sg11
VAICDA
p8448
sg13
I1
sa(dp8449
g7
I76
sg8
VP13051
p8450
sg10
I3
sg11
VUNG
p8451
sg13
I1
sa(dp8452
g7
I43
sg8
VP25942
p8453
sg10
I4
sg11
VCD40
p8454
sg13
I1
sa(dp8455
g7
I49
sg8
VP29965
p8456
sg10
I5
sg11
VCD154
p8457
sg13
I1
sasg29
(lp8458
(dp8459
g7
I189
sg32
VC0086438
p8460
sg10
I21
sg11
Vhypogammaglobulinemia
p8461
sg13
I1
sa(dp8462
g7
I142
sg32
VC0024419
p8463
sg10
I17
sg11
Vmacroglobulinemia
p8464
sg13
I1
sasa(dp8465
g2
S"A missense mutation in the highly conserved catalytic site of UNG was observed in a patient with hypogammaglobulinemia, warranting further study of this pathway in Waldenstroem's macroglobulinemia.\n"
p8466
sg4
(lp8467
(dp8468
g7
I62
sg8
VP13051
p8469
sg10
I3
sg11
VUNG
p8470
sg13
I1
sasg29
(lp8471
(dp8472
g7
I179
sg32
VC0024419
p8473
sg10
I17
sg11
Vmacroglobulinemia
p8474
sg13
I1
sa(dp8475
g7
I97
sg32
VC0086438
p8476
sg10
I21
sg11
Vhypogammaglobulinemia
p8477
sg13
I1
sasa(dp8478
g2
S'HMGB1, MICB, PSMB8, PSMB2, PSME2, HDAC1, HDAC2 and DNMT3B showed consistent down regulation of gene expression in melioidosis patients compared to other sepsis infection, irrespective of comorbidities such as diabetes, duration of clinical symptoms and antibiotic treatment.\n'
p8479
sg4
(lp8480
(dp8481
g7
I34
sg8
g48
sg10
I5
sg11
VHDAC1
p8482
sg13
I1
sa(dp8483
g7
I41
sg8
g48
sg10
I5
sg11
VHDAC2
p8484
sg13
I1
sa(dp8485
g7
I0
sg8
VP09429
p8486
sg10
I5
sg11
VHMGB1
p8487
sg13
I1
sa(dp8488
g7
I51
sg8
g48
sg10
I6
sg11
VDNMT3B
p8489
sg13
I1
sa(dp8490
g7
I27
sg8
g48
sg10
I5
sg11
VPSME2
p8491
sg13
I1
sa(dp8492
g7
I20
sg8
VP49721
p8493
sg10
I5
sg11
VPSMB2
p8494
sg13
I1
sa(dp8495
g7
I13
sg8
VP28062
p8496
sg10
I5
sg11
VPSMB8
p8497
sg13
I1
sasg29
(lp8498
(dp8499
g7
I147
sg32
VC2887087
p8500
sg10
I12
sg11
Vother sepsis
p8501
sg13
I2
sa(dp8502
g7
I209
sg32
VC0011849
p8503
sg10
I8
sg11
Vdiabetes
p8504
sg13
I1
sa(dp8505
g7
I160
sg32
VC0009450
p8506
sg10
I9
sg11
Vinfection
p8507
sg13
I1
sa(dp8508
g7
I114
sg32
VC0025229
p8509
sg10
I11
sg11
Vmelioidosis
p8510
sg13
I1
sasa(dp8511
g2
S'Thirty patients with upper abdominal pain requiring narcotic analgesia and suspected or known intra-abdominal malignancy were selected for EUS CPN.\n'
p8512
sg4
(lp8513
sg29
(lp8514
(dp8515
g7
I21
sg32
VC0232492
p8516
sg10
I20
sg11
Vupper abdominal pain
p8517
sg13
I3
sa(dp8518
g7
I61
sg32
VC0344307
p8519
sg10
I9
sg11
Vanalgesia
p8520
sg13
I1
sa(dp8521
g7
I110
sg32
VC0006826
p8522
sg10
I10
sg11
Vmalignancy
p8523
sg13
I1
sasa(dp8524
g2
S'Pepsinogen A, combined with pepsinogen C or gastrin, should be the first option in evaluating patients with suspected cobalamin deficiency who have not previously undergone gastrointestinal surgery.\n'
p8525
sg4
(lp8526
(dp8527
g7
I28
sg8
VP20142
p8528
sg10
I12
sg11
Vpepsinogen C
p8529
sg13
I2
sa(dp8530
g7
I44
sg8
VP01350
p8531
sg10
I7
sg11
Vgastrin
p8532
sg13
I1
sa(dp8533
g7
I0
sg8
VP00790
p8534
sg10
I12
sg11
VPepsinogen A
p8535
sg13
I2
sasg29
(lp8536
(dp8537
g7
I118
sg32
VC0042847
p8538
sg10
I20
sg11
Vcobalamin deficiency
p8539
sg13
I2
sasa(dp8540
g2
S'No statistically significant trends were seen between serum inflammatory markers and risk of penile cancer, but higher albumin levels increased the risk of testicular cancer [HR for albumin (g/L): 1.10 (95% CI: 1.03-1.18)].\n'
p8541
sg4
(lp8542
(dp8543
g7
I119
sg8
VP00441
p8544
sg10
I7
sg11
Valbumin
p8545
sg13
I1
sa(dp8546
g7
I119
sg8
VP00441
p8547
sg10
I7
sg11
Valbumin
p8548
sg13
I1
sasg29
(lp8549
(dp8550
g7
I156
sg32
VC0153594
p8551
sg10
I17
sg11
Vtesticular cancer
p8552
sg13
I2
sa(dp8553
g7
I93
sg32
VC0153601
p8554
sg10
I13
sg11
Vpenile cancer
p8555
sg13
I2
sasa(dp8556
g2
S'Interestingly, CDK12 protein absence was associated with reduced expression of a number of DDR proteins including ATR, Ku70/Ku80, PARP1, DNA-PK and gamma-H2AX, suggesting a novel mechanism of CDK12 associated DDR dysregulation in breast cancer.\n'
p8557
sg4
(lp8558
(dp8559
g7
I148
sg8
VP16104
p8560
sg10
I10
sg11
Vgamma-H2AX
p8561
sg13
I1
sa(dp8562
g7
I124
sg8
VP13010
p8563
sg10
I4
sg11
VKu80
p8564
sg13
I1
sa(dp8565
g7
I15
sg8
g48
sg10
I13
sg11
VCDK12 protein
p8566
sg13
I2
sa(dp8567
g7
I114
sg8
VP20848
p8568
sg10
I3
sg11
VATR
p8569
sg13
I1
sa(dp8570
g7
I15
sg8
g48
sg10
I5
sg11
VCDK12
p8571
sg13
I1
sa(dp8572
g7
I130
sg8
VP09874
p8573
sg10
I5
sg11
VPARP1
p8574
sg13
I1
sa(dp8575
g7
I137
sg8
g48
sg10
I6
sg11
VDNA-PK
p8576
sg13
I1
sa(dp8577
g7
I91
sg8
VP02649
p8578
sg10
I12
sg11
VDDR proteins
p8579
sg13
I2
sa(dp8580
g7
I119
sg8
VP12956
p8581
sg10
I4
sg11
VKu70
p8582
sg13
I1
sasg29
(lp8583
(dp8584
g7
I230
sg32
VC0678222
p8585
sg10
I13
sg11
Vbreast cancer
p8586
sg13
I2
sasa(dp8587
g2
S'In this study, we identified XRCC5 as a binding protein of the COX-2 gene promoter in colon cancer cells with streptavidin-agarose pulldown assay and mass spectrometry analysis, and found that XRCC5 promoted colon cancer growth through modulation of COX-2 signaling.\n'
p8588
sg4
(lp8589
(dp8590
g7
I63
sg8
VP35354
p8591
sg10
I5
sg11
VCOX-2
p8592
sg13
I1
sa(dp8593
g7
I29
sg8
VP13010
p8594
sg10
I5
sg11
VXRCC5
p8595
sg13
I1
sa(dp8596
g7
I29
sg8
VP13010
p8597
sg10
I5
sg11
VXRCC5
p8598
sg13
I1
sa(dp8599
g7
I63
sg8
VP35354
p8600
sg10
I19
sg11
VCOX-2 gene promoter
p8601
sg13
I3
sasg29
(lp8602
(dp8603
g7
I86
sg32
VC0699790
p8604
sg10
I12
sg11
Vcolon cancer
p8605
sg13
I2
sa(dp8606
g7
I86
sg32
VC0699790
p8607
sg10
I12
sg11
Vcolon cancer
p8608
sg13
I2
sasa(dp8609
g2
S'Knockdown of XRCC5 by siRNAs inhibited the growth of colon cancer cells in vitro and of tumor xenografts in a mouse model in vivo by suppressing COX-2 promoter activity and COX-2 protein expression.\n'
p8610
sg4
(lp8611
(dp8612
g7
I173
sg8
VP35354
p8613
sg10
I13
sg11
VCOX-2 protein
p8614
sg13
I2
sa(dp8615
g7
I145
sg8
VP35354
p8616
sg10
I14
sg11
VCOX-2 promoter
p8617
sg13
I2
sa(dp8618
g7
I13
sg8
VP13010
p8619
sg10
I5
sg11
VXRCC5
p8620
sg13
I1
sasg29
(lp8621
(dp8622
g7
I53
sg32
VC0699790
p8623
sg10
I12
sg11
Vcolon cancer
p8624
sg13
I2
sa(dp8625
g7
I88
sg32
VC0027651
p8626
sg10
I5
sg11
Vtumor
p8627
sg13
I1
sasa(dp8628
g2
S'Conversely, overexpression of XRCC5 promoted the growth of colon cancer cells by activating COX-2 promoter and increasing COX-2 protein expression.\n'
p8629
sg4
(lp8630
(dp8631
g7
I92
sg8
VP35354
p8632
sg10
I14
sg11
VCOX-2 promoter
p8633
sg13
I2
sa(dp8634
g7
I30
sg8
VP13010
p8635
sg10
I5
sg11
VXRCC5
p8636
sg13
I1
sa(dp8637
g7
I122
sg8
VP35354
p8638
sg10
I13
sg11
VCOX-2 protein
p8639
sg13
I2
sasg29
(lp8640
(dp8641
g7
I59
sg32
VC0699790
p8642
sg10
I12
sg11
Vcolon cancer
p8643
sg13
I2
sasa(dp8644
g2
S'Immunofluorescence assay and confocal microscopy showed that XRCC5 and p300 proteins were co-located in the nucleus of colon cancer cells.\n'
p8645
sg4
(lp8646
(dp8647
g7
I61
sg8
VP13010
p8648
sg10
I5
sg11
VXRCC5
p8649
sg13
I1
sa(dp8650
g7
I71
sg8
g48
sg10
I13
sg11
Vp300 proteins
p8651
sg13
I2
sasg29
(lp8652
(dp8653
g7
I119
sg32
VC0699790
p8654
sg10
I12
sg11
Vcolon cancer
p8655
sg13
I2
sasa(dp8656
g2
S'Co-immunoprecipitation assay also proved the interaction between XRCC5 and p300 in nuclear proteins of colon cancer cells.\n'
p8657
sg4
(lp8658
(dp8659
g7
I75
sg8
g48
sg10
I4
sg11
Vp300
p8660
sg13
I1
sa(dp8661
g7
I65
sg8
VP13010
p8662
sg10
I5
sg11
VXRCC5
p8663
sg13
I1
sasg29
(lp8664
(dp8665
g7
I103
sg32
VC0699790
p8666
sg10
I12
sg11
Vcolon cancer
p8667
sg13
I2
sasa(dp8668
g2
S'Cell viability assay indicated that the overexpression of wild-type p300, but not its histone acetyltransferase (HAT) domain deletion mutant, increased XRCC5 acetylation, thereby up-regulated COX-2 expression and promoted the growth of colon cancer cells.\n'
p8669
sg4
(lp8670
(dp8671
g7
I152
sg8
VP13010
p8672
sg10
I5
sg11
VXRCC5
p8673
sg13
I1
sa(dp8674
g7
I86
sg8
g48
sg10
I25
sg11
Vhistone acetyltransferase
p8675
sg13
I2
sa(dp8676
g7
I192
sg8
VP35354
p8677
sg10
I5
sg11
VCOX-2
p8678
sg13
I1
sa(dp8679
g7
I68
sg8
g48
sg10
I4
sg11
Vp300
p8680
sg13
I1
sa(dp8681
g7
I113
sg8
g48
sg10
I3
sg11
VHAT
p8682
sg13
I1
sasg29
(lp8683
(dp8684
g7
I236
sg32
VC0699790
p8685
sg10
I12
sg11
Vcolon cancer
p8686
sg13
I2
sa(dp8687
g7
I134
sg32
VC0596988
p8688
sg10
I6
sg11
Vmutant
p8689
sg13
I1
sasa(dp8690
g2
S'Taken together, our results demonstrated that XRCC5 promoted colon cancer growth by cooperating with p300 to regulate COX-2 expression, and suggested that the XRCC5/p300/COX-2 signaling pathway was a potential target in the treatment of colon cancers.\n'
p8691
sg4
(lp8692
(dp8693
g7
I101
sg8
g48
sg10
I4
sg11
Vp300
p8694
sg13
I1
sa(dp8695
g7
I46
sg8
VP13010
p8696
sg10
I5
sg11
VXRCC5
p8697
sg13
I1
sa(dp8698
g7
I46
sg8
VP13010
p8699
sg10
I5
sg11
VXRCC5
p8700
sg13
I1
sa(dp8701
g7
I101
sg8
g48
sg10
I4
sg11
Vp300
p8702
sg13
I1
sa(dp8703
g7
I118
sg8
VP35354
p8704
sg10
I5
sg11
VCOX-2
p8705
sg13
I1
sa(dp8706
g7
I118
sg8
VP35354
p8707
sg10
I5
sg11
VCOX-2
p8708
sg13
I1
sasg29
(lp8709
(dp8710
g7
I237
sg32
VC0007102
p8711
sg10
I13
sg11
Vcolon cancers
p8712
sg13
I2
sa(dp8713
g7
I61
sg32
VC0007102
p8714
sg10
I12
sg11
Vcolon cancer
p8715
sg13
I2
sasa(dp8716
g2
S'The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.\n'
p8717
sg4
(lp8718
(dp8719
g7
I195
sg8
g48
sg10
I5
sg11
VXRCC4
p8720
sg13
I1
sa(dp8721
g7
I188
sg8
VP18887
p8722
sg10
I5
sg11
VXRCC1
p8723
sg13
I1
sa(dp8724
g7
I214
sg8
g48
sg10
I8
sg11
VDNA-PKcs
p8725
sg13
I1
sa(dp8726
g7
I161
sg8
g48
sg10
I16
sg11
VDNA repair genes
p8727
sg13
I3
sa(dp8728
g7
I227
sg8
VP49917
p8729
sg10
I4
sg11
VLIG4
p8730
sg13
I1
sa(dp8731
g7
I179
sg8
VP24522
p8732
sg10
I7
sg11
VGADD45A
p8733
sg13
I1
sa(dp8734
g7
I208
sg8
VP13010
p8735
sg10
I4
sg11
VKu80
p8736
sg13
I1
sa(dp8737
g7
I202
sg8
VP12956
p8738
sg10
I4
sg11
VKu70
p8739
sg13
I1
sasg29
(lp8740
(dp8741
g7
I243
sg32
VC0678222
p8742
sg10
I13
sg11
Vbreast cancer
p8743
sg13
I2
sa(dp8744
g7
I271
sg32
VC0027819
p8745
sg10
I13
sg11
Vneuroblastoma
p8746
sg13
I1
sasa(dp8747
g2
S'Moreover, diarrhea occurrence, antigen-specific IgE and intestinal mastocytosis were comparable between WT and IL-4RAlfa(Y500F) mice.\n'
p8748
sg4
(lp8749
(dp8750
g7
I48
sg8
VP01854
p8751
sg10
I3
sg11
VIgE
p8752
sg13
I1
sasg29
(lp8753
(dp8754
g7
I10
sg32
VC0011991
p8755
sg10
I8
sg11
Vdiarrhea
p8756
sg13
I1
sa(dp8757
g7
I67
sg32
VC0042111
p8758
sg10
I12
sg11
Vmastocytosis
p8759
sg13
I1
sa(dp8760
g7
I48
sg32
VC0270850
p8761
sg10
I3
sg11
VIgE
p8762
sg13
I1
sasa(dp8763
g2
S'Cutaneous eosinophilia persisted in Sharpin(-/-) , Il4ra(-/-) mice, although expression of Il5 mRNA was reduced and the expression of Ccl11 and Ccl24 was completely abolished.\n'
p8764
sg4
(lp8765
(dp8766
g7
I144
sg8
g48
sg10
I5
sg11
VCcl24
p8767
sg13
I1
sa(dp8768
g7
I134
sg8
VP51671
p8769
sg10
I5
sg11
VCcl11
p8770
sg13
I1
sa(dp8771
g7
I36
sg8
g48
sg10
I7
sg11
VSharpin
p8772
sg13
I1
sa(dp8773
g7
I91
sg8
VP05113
p8774
sg10
I8
sg11
VIl5 mRNA
p8775
sg13
I2
sasg29
(lp8776
(dp8777
g7
I10
sg32
VC0014457
p8778
sg10
I12
sg11
Veosinophilia
p8779
sg13
I1
sasa(dp8780
g2
S'Th cell-specific deletion of Il4ra attenuated Th2 responses and abolished the immunopathophysiology upon reinfection, including airway hyper-reactivity, eosinophilia, and mucus hyperproduction in mice infected initially as neonates.\n'
p8781
sg4
(lp8782
sg29
(lp8783
(dp8784
g7
I153
sg32
VC0014457
p8785
sg10
I12
sg11
Veosinophilia
p8786
sg13
I1
sasa(dp8787
g2
S'Deletion of IL-4Ralpha abolished transient mucous secretory cell (MuSC) abundance and eosinophilia normally observed in neonatal wild-type mice.\n'
p8788
sg4
(lp8789
sg29
(lp8790
(dp8791
g7
I86
sg32
VC0014457
p8792
sg10
I12
sg11
Veosinophilia
p8793
sg13
I1
sasa(dp8794
g2
S'These studies demonstrate that: 1) normal neonatal mouse airway development entails an IL-4Ralpha-dependent, transient abundance of MuSC and eosinophils; 2) absence of IL-4Ralpha improved neonatal survival of Scnn1b-Tg mice, likely reflecting decreased formation of asphyxiating mucus plugs; and 3) in Scnn1b-Tg mice, neutrophilia, mucus obstruction, and airspace enlargement are IL-4Ralpha- and TNF-alpha-independent, and only MuSC and eosinophilia are sensitive to glucocorticoids.\n'
p8795
sg4
(lp8796
(dp8797
g7
I396
sg8
VP01375
p8798
sg10
I9
sg11
VTNF-alpha
p8799
sg13
I1
sa(dp8800
g7
I209
sg8
VP51168
p8801
sg10
I6
sg11
VScnn1b
p8802
sg13
I1
sa(dp8803
g7
I209
sg8
VP51168
p8804
sg10
I6
sg11
VScnn1b
p8805
sg13
I1
sasg29
(lp8806
(dp8807
g7
I364
sg32
VC2711450
p8808
sg10
I11
sg11
Venlargement
p8809
sg13
I1
sa(dp8810
g7
I338
sg32
VC0028778
p8811
sg10
I11
sg11
Vobstruction
p8812
sg13
I1
sa(dp8813
g7
I437
sg32
VC0014457
p8814
sg10
I12
sg11
Veosinophilia
p8815
sg13
I1
sa(dp8816
g7
I279
sg32
VC0333133
p8817
sg10
I11
sg11
Vmucus plugs
p8818
sg13
I2
sasa(dp8819
g2
S'Homeobox (HOX) transcript antisense RNA (HOTAIR), a long intergenic noncoding RNA (lincRNA), has been reported to play an oncogenic role in various cancers including small cell lung cancer (SCLC).\n'
p8820
sg4
(lp8821
sg29
(lp8822
(dp8823
g7
I166
sg32
VC0149925
p8824
sg10
I22
sg11
Vsmall cell lung cancer
p8825
sg13
I4
sa(dp8826
g7
I148
sg32
VC0006826
p8827
sg10
I7
sg11
Vcancers
p8828
sg13
I1
sa(dp8829
g7
I190
sg32
VC0149925
p8830
sg10
I4
sg11
VSCLC
p8831
sg13
I1
sasa(dp8832
g2
S'Homeobox (HOX) transcript antisense intergenic RNA (HOTAIR), a long non-coding RNA (lncRNA), is associated with a variety of human cancers, such as breast, liver and lung cancer.\n'
p8833
sg4
(lp8834
sg29
(lp8835
(dp8836
g7
I131
sg32
VC0006826
p8837
sg10
I7
sg11
Vcancers
p8838
sg13
I1
sa(dp8839
g7
I166
sg32
VC0684249
p8840
sg10
I11
sg11
Vlung cancer
p8841
sg13
I2
sasa(dp8842
g2
S'Furthermore, glial fibrillary acidic protein levels were significantly different between haemorrhagic stroke and ischaemic stroke patients (MD 224.58 ng l-1; 95% CI 25.84, 423.32; P= 0.03), high levels of admission glucose were a strong predictor of poor prognosis after ischaemic stroke and symptomatic intracerebral haemorrhage post-thrombolysis, glutamate was found to be an indicator of progressive (unstable) stroke (MD 172.65 mymol l-1, 95% CI 130.54, 214.75; P= 0.00001), D-dimer predicted in-hospital death (MD 0.67 myg ml-1, 95% CI 0.35, 1.00; P= 0.0001), and high fibrinogen levels were associated with poor outcome at 3 months (MD 47.90 mg l-1, 95% CI 14.88, 80.93; P= 0.004) following ischaemic stroke.\n'
p8843
sg4
(lp8844
(dp8845
g7
I13
sg8
VP05230
p8846
sg10
I31
sg11
Vglial fibrillary acidic protein
p8847
sg13
I4
sa(dp8848
g7
I574
sg8
VP22087
p8849
sg10
I10
sg11
Vfibrinogen
p8850
sg13
I1
sasg29
(lp8851
(dp8852
g7
I89
sg32
VC0553692
p8853
sg10
I19
sg11
Vhaemorrhagic stroke
p8854
sg13
I2
sa(dp8855
g7
I113
sg32
VC0948008
p8856
sg10
I16
sg11
Vischaemic stroke
p8857
sg13
I2
sa(dp8858
g7
I113
sg32
VC0948008
p8859
sg10
I16
sg11
Vischaemic stroke
p8860
sg13
I2
sa(dp8861
g7
I304
sg32
VC2937358
p8862
sg10
I25
sg11
Vintracerebral haemorrhage
p8863
sg13
I2
sa(dp8864
g7
I113
sg32
VC0948008
p8865
sg10
I16
sg11
Vischaemic stroke
p8866
sg13
I2
sa(dp8867
g7
I102
sg32
VC0038454
p8868
sg10
I6
sg11
Vstroke
p8869
sg13
I1
sasa(dp8870
g2
S'Microalbuminuria (20-200 mg L-1) was present in 7.2% of the subjects and independently associated with age, gender, hypertension, diabetes, smoking, previous myocardial infarction and stroke.\n'
p8871
sg4
(lp8872
sg29
(lp8873
(dp8874
g7
I158
sg32
VC0027051
p8875
sg10
I21
sg11
Vmyocardial infarction
p8876
sg13
I2
sa(dp8877
g7
I130
sg32
VC0011849
p8878
sg10
I8
sg11
Vdiabetes
p8879
sg13
I1
sa(dp8880
g7
I116
sg32
VC0020538
p8881
sg10
I12
sg11
Vhypertension
p8882
sg13
I1
sa(dp8883
g7
I0
sg32
VC0730345
p8884
sg10
I16
sg11
VMicroalbuminuria
p8885
sg13
I1
sa(dp8886
g7
I184
sg32
VC0038454
p8887
sg10
I6
sg11
Vstroke
p8888
sg13
I1
sasa(dp8889
g2
S'There was a high morbidity from diabetes and other conditions: the prevalence of hypertension (untreated blood pressure of 160/95 mmHg or more or antihypertensive medication) was 52%, of stroke 5%, of nephropathy (urinary albumin concentration greater than or equal to 300 mg l-1) 3%, of lower limb amputations 4%, and of foot ulcers 7%.\n'
p8890
sg4
(lp8891
(dp8892
g7
I222
sg8
VP00441
p8893
sg10
I7
sg11
Valbumin
p8894
sg13
I1
sasg29
(lp8895
(dp8896
g7
I32
sg32
VC0011849
p8897
sg10
I8
sg11
Vdiabetes
p8898
sg13
I1
sa(dp8899
g7
I81
sg32
VC0020538
p8900
sg10
I12
sg11
Vhypertension
p8901
sg13
I1
sa(dp8902
g7
I187
sg32
VC0038454
p8903
sg10
I6
sg11
Vstroke
p8904
sg13
I1
sa(dp8905
g7
I322
sg32
VC0085119
p8906
sg10
I11
sg11
Vfoot ulcers
p8907
sg13
I2
sa(dp8908
g7
I201
sg32
VC0022658
p8909
sg10
I11
sg11
Vnephropathy
p8910
sg13
I1
sasa(dp8911
g2
S"Desmoglein 2 (Dsg2), an adhesion molecule of desmosomes and the only Dsg isoform expressed in enterocytes, is required for epithelial barrier properties and may contribute to barrier defects in Crohn's disease.\n"
p8912
sg4
(lp8913
(dp8914
g7
I14
sg8
g48
sg10
I4
sg11
VDsg2
p8915
sg13
I1
sa(dp8916
g7
I14
sg8
g48
sg10
I3
sg11
VDsg
p8917
sg13
I1
sa(dp8918
g7
I0
sg8
g48
sg10
I12
sg11
VDesmoglein 2
p8919
sg13
I2
sasg29
(lp8920
(dp8921
g7
I24
sg32
VC0001511
p8922
sg10
I8
sg11
Vadhesion
p8923
sg13
I1
sa(dp8924
g7
I194
sg32
VC0010346
p8925
sg10
I15
sg11
VCrohn's disease
p8926
sg13
I2
sasa(dp8927
g2
S'Offspring of mothers with NLRP5 mutations have heterogenous clinical and epigenetic features, but cases include a discordant monozygotic twin pair, individuals with idiopathic developmental delay and autism, and families affected by infertility and reproductive wastage.\n'
p8928
sg4
(lp8929
(dp8930
g7
I26
sg8
VP59047
p8931
sg10
I15
sg11
VNLRP5 mutations
p8932
sg13
I2
sasg29
(lp8933
(dp8934
g7
I176
sg32
VC0424605
p8935
sg10
I19
sg11
Vdevelopmental delay
p8936
sg13
I2
sa(dp8937
g7
I233
sg32
VC0021359
p8938
sg10
I11
sg11
Vinfertility
p8939
sg13
I1
sa(dp8940
g7
I200
sg32
VC0004352
p8941
sg10
I6
sg11
Vautism
p8942
sg13
I1
sasa(dp8943
g2
S'Tandem repeats of a novel, putative, zinc-binding motif (MYM) have been described within the products of two, highly homologous genes: ZNF198/RAMP/FIM and ZNF261/DXS6673E.\n'
p8944
sg4
(lp8945
(dp8946
g7
I155
sg8
g48
sg10
I6
sg11
VZNF261
p8947
sg13
I1
sa(dp8948
g7
I142
sg8
g48
sg10
I4
sg11
VRAMP
p8949
sg13
I1
sa(dp8950
g7
I147
sg8
VP28329
p8951
sg10
I3
sg11
VFIM
p8952
sg13
I1
sa(dp8953
g7
I162
sg8
g48
sg10
I8
sg11
VDXS6673E
p8954
sg13
I1
sasg29
(lp8955
(dp8956
g7
I147
sg32
VC0393929
p8957
sg10
I3
sg11
VFIM
p8958
sg13
I1
sasa(dp8959
g2
S'Furthermore, very little has been reported for the targeting of nanomedicines to lymph node metastases (LNMs) of prostate cancer.\n'
p8960
sg4
(lp8961
sg29
(lp8962
(dp8963
g7
I81
sg32
VC0686619
p8964
sg10
I21
sg11
Vlymph node metastases
p8965
sg13
I3
sa(dp8966
g7
I104
sg32
VC0686619
p8967
sg10
I4
sg11
VLNMs
p8968
sg13
I1
sa(dp8969
g7
I113
sg32
VC0600139
p8970
sg10
I15
sg11
Vprostate cancer
p8971
sg13
I2
sasa(dp8972
g2
S'We here report the simple and aqueous coating of iron oxide nanoparticles (IONPs) with FA for theranostics of LNMs of prostate cancer.\n'
p8973
sg4
(lp8974
sg29
(lp8975
(dp8976
g7
I118
sg32
VC0600139
p8977
sg10
I15
sg11
Vprostate cancer
p8978
sg13
I2
sasa(dp8979
g2
S'We also show that FA-IONPs are specifically uptaken by prostate cancer cells expressing the prostate specific membrane antigen, including LNMs cells.\n'
p8980
sg4
(lp8981
(dp8982
g7
I92
sg8
VP49221
p8983
sg10
I34
sg11
Vprostate specific membrane antigen
p8984
sg13
I4
sasg29
(lp8985
(dp8986
g7
I55
sg32
VC0600139
p8987
sg10
I15
sg11
Vprostate cancer
p8988
sg13
I2
sasa(dp8989
g2
S'Our study provides a theranostic platform for targeting LNMs of prostate cancer with high potential for their detection by MRI and treatment by hyperthermia.\n'
p8990
sg4
(lp8991
sg29
(lp8992
(dp8993
g7
I64
sg32
VC0600139
p8994
sg10
I15
sg11
Vprostate cancer
p8995
sg13
I2
sasa(dp8996
g2
S'A total of 88 primary breast cancer, 91 LNMs, 54 intraductal carcinoma and 26 normal adjacent breast tissue samples from tissue microarrays were studied.\n'
p8997
sg4
(lp8998
sg29
(lp8999
(dp9000
g7
I49
sg32
VC0007124
p9001
sg10
I21
sg11
Vintraductal carcinoma
p9002
sg13
I2
sa(dp9003
g7
I22
sg32
VC0678222
p9004
sg10
I13
sg11
Vbreast cancer
p9005
sg13
I2
sasa(dp9006
g2
S'Even though it was not significant, moesin expression varied between primary tumors, intraductal carcinoma, normal breast adjacent tissue and LNMs.\n'
p9007
sg4
(lp9008
(dp9009
g7
I36
sg8
VP26038
p9010
sg10
I6
sg11
Vmoesin
p9011
sg13
I1
sasg29
(lp9012
(dp9013
g7
I85
sg32
VC0007124
p9014
sg10
I21
sg11
Vintraductal carcinoma
p9015
sg13
I2
sa(dp9016
g7
I69
sg32
VC0677930
p9017
sg10
I14
sg11
Vprimary tumors
p9018
sg13
I2
sasa(dp9019
g2
S'According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of &gt;=10 axillary LNMs.\n'
p9020
sg4
(lp9021
sg29
(lp9022
(dp9023
g7
I162
sg32
VC0686619
p9024
sg10
I21
sg11
Vlymph node metastasis
p9025
sg13
I3
sa(dp9026
g7
I96
sg32
VC0678222
p9027
sg10
I13
sg11
Vbreast cancer
p9028
sg13
I2
sa(dp9029
g7
I185
sg32
VC0686619
p9030
sg10
I3
sg11
VLNM
p9031
sg13
I1
sa(dp9032
g7
I36
sg32
VC0027651
p9033
sg10
I6
sg11
Vtumour
p9034
sg13
I1
sa(dp9035
g7
I48
sg32
VC0027627
p9036
sg10
I10
sg11
Vmetastasis
p9037
sg13
I1
sasa(dp9038
g2
S'To evaluate the frequency of TERT promoter (TERTp), BRAF, and NRAS mutations in metastatic thyroid carcinomas, analyzing primary thyroid tumors, lymph node metastases (LNMs), and distant metastases.\n'
p9039
sg4
(lp9040
(dp9041
g7
I62
sg8
VP01111
p9042
sg10
I14
sg11
VNRAS mutations
p9043
sg13
I2
sa(dp9044
g7
I29
sg8
g48
sg10
I13
sg11
VTERT promoter
p9045
sg13
I2
sa(dp9046
g7
I44
sg8
g48
sg10
I5
sg11
VTERTp
p9047
sg13
I1
sa(dp9048
g7
I52
sg8
VP15056
p9049
sg10
I4
sg11
VBRAF
p9050
sg13
I1
sasg29
(lp9051
(dp9052
g7
I168
sg32
VC0686619
p9053
sg10
I4
sg11
VLNMs
p9054
sg13
I1
sa(dp9055
g7
I129
sg32
VC0040136
p9056
sg10
I14
sg11
Vthyroid tumors
p9057
sg13
I2
sa(dp9058
g7
I145
sg32
VC0686619
p9059
sg10
I21
sg11
Vlymph node metastases
p9060
sg13
I3
sa(dp9061
g7
I156
sg32
VC0027627
p9062
sg10
I10
sg11
Vmetastases
p9063
sg13
I1
sa(dp9064
g7
I99
sg32
VC0007097
p9065
sg10
I10
sg11
Vcarcinomas
p9066
sg13
I1
sasa(dp9067
g2
S'Mutation analysis was performed in 437 tissue samples from 204 patients, mainly with papillary thyroid carcinomas (PTCs; n = 180), including 196 LNMs and 56 distant metastases.\n'
p9068
sg4
(lp9069
sg29
(lp9070
(dp9071
g7
I165
sg32
VC0027627
p9072
sg10
I10
sg11
Vmetastases
p9073
sg13
I1
sa(dp9074
g7
I103
sg32
VC0007097
p9075
sg10
I10
sg11
Vcarcinomas
p9076
sg13
I1
sasa(dp9077
g2
S'Arterial blood gas showed Type 1 Respiratory Failure (p02 was only 10 kPa on 4 L per minute of oxygen).\n'
p9078
sg4
(lp9079
(dp9080
g7
I54
sg8
VP13693
p9081
sg10
I3
sg11
Vp02
p9082
sg13
I1
sasg29
(lp9083
(dp9084
g7
I26
sg32
VC0340194
p9085
sg10
I26
sg11
VType 1 Respiratory Failure
p9086
sg13
I4
sasa(dp9087
g2
S'Previously, we showed that histamine-releasing factor (HRF), a multifunctional protein secreted during allergy, interacts with a subset of IgE molecules and that the HRF dimer activates mast cells in an HRF-reactive IgE-dependent manner.\n'
p9088
sg4
(lp9089
(dp9090
g7
I55
sg8
VP13693
p9091
sg10
I3
sg11
VHRF
p9092
sg13
I1
sa(dp9093
g7
I203
sg8
VP13693
p9094
sg10
I16
sg11
VHRF-reactive IgE
p9095
sg13
I2
sa(dp9096
g7
I27
sg8
VP13693
p9097
sg10
I26
sg11
Vhistamine-releasing factor
p9098
sg13
I2
sa(dp9099
g7
I139
sg8
VP01854
p9100
sg10
I13
sg11
VIgE molecules
p9101
sg13
I2
sa(dp9102
g7
I166
sg8
VP13693
p9103
sg10
I9
sg11
VHRF dimer
p9104
sg13
I2
sasg29
(lp9105
(dp9106
g7
I103
sg32
VC0020517
p9107
sg10
I7
sg11
Vallergy
p9108
sg13
I1
sa(dp9109
g7
I139
sg32
VC0270850
p9110
sg10
I3
sg11
VIgE
p9111
sg13
I1
sa(dp9112
g7
I139
sg32
VC0270850
p9113
sg10
I3
sg11
VIgE
p9114
sg13
I1
sasa(dp9115
g2
S'In this study, we investigated whether HRF plays any role in food allergy.\n'
p9116
sg4
(lp9117
sg29
(lp9118
(dp9119
g7
I61
sg32
VC0016470
p9120
sg10
I12
sg11
Vfood allergy
p9121
sg13
I2
sasa(dp9122
g2
S'Specifically, we determined that prophylactic and therapeutic administration of HRF inhibitors that block HRF-IgE interactions reduces the incidence of diarrhea and mastocytosis in a murine model of food allergy.\n'
p9123
sg4
(lp9124
(dp9125
g7
I110
sg8
VP01854
p9126
sg10
I3
sg11
VIgE
p9127
sg13
I1
sa(dp9128
g7
I80
sg8
VP13693
p9129
sg10
I3
sg11
VHRF
p9130
sg13
I1
sa(dp9131
g7
I80
sg8
VP13693
p9132
sg10
I3
sg11
VHRF
p9133
sg13
I1
sasg29
(lp9134
(dp9135
g7
I110
sg32
VC0270850
p9136
sg10
I3
sg11
VIgE
p9137
sg13
I1
sa(dp9138
g7
I165
sg32
VC0042111
p9139
sg10
I12
sg11
Vmastocytosis
p9140
sg13
I1
sa(dp9141
g7
I199
sg32
VC0016470
p9142
sg10
I12
sg11
Vfood allergy
p9143
sg13
I2
sa(dp9144
g7
I152
sg32
VC0011991
p9145
sg10
I8
sg11
Vdiarrhea
p9146
sg13
I1
sasa(dp9147
g2
S'Food allergy-associated intestinal inflammation was accompanied by increased secretion of the HRF dimer into the intestine in response to proinflammatory, Th2, and epithelial-derived cytokines and HRF-reactive IgE levels at the elicitation phase.\n'
p9148
sg4
(lp9149
(dp9150
g7
I94
sg8
VP13693
p9151
sg10
I9
sg11
VHRF dimer
p9152
sg13
I2
sa(dp9153
g7
I197
sg8
VP13693
p9154
sg10
I16
sg11
VHRF-reactive IgE
p9155
sg13
I2
sa(dp9156
g7
I164
sg8
VP12830
p9157
sg10
I28
sg11
Vepithelial-derived cytokines
p9158
sg13
I2
sasg29
(lp9159
(dp9160
g7
I35
sg32
VC0021368
p9161
sg10
I12
sg11
Vinflammation
p9162
sg13
I1
sa(dp9163
g7
I0
sg32
VC0016470
p9164
sg10
I12
sg11
VFood allergy
p9165
sg13
I2
sa(dp9166
g7
I210
sg32
VC0270850
p9167
sg10
I3
sg11
VIgE
p9168
sg13
I1
sasa(dp9169
g2
S'Consistent with these data, patients with egg allergy had higher blood levels of HRF-reactive IgE compared with individuals that were not hypersensitive.\n'
p9170
sg4
(lp9171
(dp9172
g7
I81
sg8
VP13693
p9173
sg10
I16
sg11
VHRF-reactive IgE
p9174
sg13
I2
sasg29
(lp9175
(dp9176
g7
I42
sg32
VC0559469
p9177
sg10
I11
sg11
Vegg allergy
p9178
sg13
I2
sa(dp9179
g7
I94
sg32
VC0270850
p9180
sg10
I3
sg11
VIgE
p9181
sg13
I1
sasa(dp9182
g2
S'Successful oral immunotherapy in egg-allergy patients and food-allergic mice reduced HRF-reactive IgE levels, thereby suggesting a pathological role for HRF in food allergy.\n'
p9183
sg4
(lp9184
(dp9185
g7
I85
sg8
VP13693
p9186
sg10
I16
sg11
VHRF-reactive IgE
p9187
sg13
I2
sa(dp9188
g7
I85
sg8
VP13693
p9189
sg10
I3
sg11
VHRF
p9190
sg13
I1
sasg29
(lp9191
(dp9192
g7
I98
sg32
VC0270850
p9193
sg10
I3
sg11
VIgE
p9194
sg13
I1
sa(dp9195
g7
I160
sg32
VC0016470
p9196
sg10
I12
sg11
Vfood allergy
p9197
sg13
I2
sa(dp9198
g7
I37
sg32
VC0020517
p9199
sg10
I7
sg11
Vallergy
p9200
sg13
I1
sasa(dp9201
g2
S'Together, these results suggest that antigen and HRF dimer amplify intestinal inflammation by synergistically activating mast cells and indicate that HRF has potential as a therapeutic target in food allergy.\n'
p9202
sg4
(lp9203
(dp9204
g7
I49
sg8
VP13693
p9205
sg10
I3
sg11
VHRF
p9206
sg13
I1
sasg29
(lp9207
(dp9208
g7
I78
sg32
VC0021368
p9209
sg10
I12
sg11
Vinflammation
p9210
sg13
I1
sa(dp9211
g7
I195
sg32
VC0016470
p9212
sg10
I12
sg11
Vfood allergy
p9213
sg13
I2
sasa(dp9214
g2
S'provide a causal link between histamine-releasing factor (HRF) interactions with IgE and food allergy in a murine model.\n'
p9215
sg4
(lp9216
(dp9217
g7
I81
sg8
VP01854
p9218
sg10
I3
sg11
VIgE
p9219
sg13
I1
sa(dp9220
g7
I58
sg8
VP13693
p9221
sg10
I3
sg11
VHRF
p9222
sg13
I1
sa(dp9223
g7
I30
sg8
VP13693
p9224
sg10
I26
sg11
Vhistamine-releasing factor
p9225
sg13
I2
sasg29
(lp9226
(dp9227
g7
I81
sg32
VC0270850
p9228
sg10
I3
sg11
VIgE
p9229
sg13
I1
sa(dp9230
g7
I89
sg32
VC0016470
p9231
sg10
I12
sg11
Vfood allergy
p9232
sg13
I2
sasa(dp9233
g2
S'These results support a role for HRF-IgE interactions in the amplification of intestinal inflammation and suggest HRF as a therapeutic target in food allergy.\n'
p9234
sg4
(lp9235
(dp9236
g7
I33
sg8
VP13693
p9237
sg10
I3
sg11
VHRF
p9238
sg13
I1
sa(dp9239
g7
I33
sg8
VP13693
p9240
sg10
I3
sg11
VHRF
p9241
sg13
I1
sa(dp9242
g7
I37
sg8
VP01854
p9243
sg10
I3
sg11
VIgE
p9244
sg13
I1
sasg29
(lp9245
(dp9246
g7
I89
sg32
VC0021368
p9247
sg10
I12
sg11
Vinflammation
p9248
sg13
I1
sa(dp9249
g7
I37
sg32
VC0270850
p9250
sg10
I3
sg11
VIgE
p9251
sg13
I1
sa(dp9252
g7
I145
sg32
VC0016470
p9253
sg10
I12
sg11
Vfood allergy
p9254
sg13
I2
sa(dp9255
g7
I61
sg32
VC1705759
p9256
sg10
I13
sg11
Vamplification
p9257
sg13
I1
sasa(dp9258
g2
S'Fortilin facilitates the development of atherosclerosis, contributes to both systemic and pulmonary arterial hypertension, participates in the development of cancers, and worsens diabetic nephropathy.\n'
p9259
sg4
(lp9260
(dp9261
g7
I0
sg8
VP13693
p9262
sg10
I8
sg11
VFortilin
p9263
sg13
I1
sasg29
(lp9264
(dp9265
g7
I90
sg32
VC2973725
p9266
sg10
I31
sg11
Vpulmonary arterial hypertension
p9267
sg13
I3
sa(dp9268
g7
I179
sg32
VC0011881
p9269
sg10
I20
sg11
Vdiabetic nephropathy
p9270
sg13
I2
sa(dp9271
g7
I158
sg32
VC0006826
p9272
sg10
I7
sg11
Vcancers
p9273
sg13
I1
sa(dp9274
g7
I40
sg32
VC0004153
p9275
sg10
I15
sg11
Vatherosclerosis
p9276
sg13
I1
sasa(dp9277
g2
S'Further translational research could prove fortilin to be a viable molecular target for treatment of various human diseases including and not limited to atherosclerosis, hypertension, certain tumors, diabetes mellitus, diabetic nephropathy, hepatic injury, and aberrant immunity and host defense.\n'
p9278
sg4
(lp9279
sg29
(lp9280
(dp9281
g7
I170
sg32
VC0020538
p9282
sg10
I12
sg11
Vhypertension
p9283
sg13
I1
sa(dp9284
g7
I153
sg32
VC0004153
p9285
sg10
I15
sg11
Vatherosclerosis
p9286
sg13
I1
sa(dp9287
g7
I200
sg32
VC0011849
p9288
sg10
I17
sg11
Vdiabetes mellitus
p9289
sg13
I2
sa(dp9290
g7
I219
sg32
VC0011881
p9291
sg10
I20
sg11
Vdiabetic nephropathy
p9292
sg13
I2
sa(dp9293
g7
I192
sg32
VC0027651
p9294
sg10
I6
sg11
Vtumors
p9295
sg13
I1
sasa(dp9296
g2
S'Among eyes with DME, those with submacular fluid, no HRF, and a continuous IS-OS layer responded better to DEX implants than those without these features.\n'
p9297
sg4
(lp9298
(dp9299
g7
I53
sg8
VP13693
p9300
sg10
I3
sg11
VHRF
p9301
sg13
I1
sasg29
(lp9302
sa(dp9303
g2
S'HRFs included hydronephrosis, abnormal examination under anesthesia, lymphovascular invasion, or variant histology.\n'
p9304
sg4
(lp9305
sg29
(lp9306
(dp9307
g7
I57
sg32
VC0278134
p9308
sg10
I10
sg11
Vanesthesia
p9309
sg13
I1
sa(dp9310
g7
I84
sg32
VC2699153
p9311
sg10
I8
sg11
Vinvasion
p9312
sg13
I1
sa(dp9313
g7
I14
sg32
VC0020295
p9314
sg10
I14
sg11
Vhydronephrosis
p9315
sg13
I1
sasa(dp9316
g2
S'MAb 9E1 significantly decreases invasion in pancreatic, lung squamous and breast cancer cells and silencing of its target antigen, which was revealed as AnxA6, leads to markedly reduced invasive capacity of pancreatic and lung squamous cancer in vitro.\n'
p9317
sg4
(lp9318
(dp9319
g7
I153
sg8
VP08133
p9320
sg10
I5
sg11
VAnxA6
p9321
sg13
I1
sasg29
(lp9322
(dp9323
g7
I74
sg32
VC0678222
p9324
sg10
I13
sg11
Vbreast cancer
p9325
sg13
I2
sa(dp9326
g7
I32
sg32
VC2699153
p9327
sg10
I8
sg11
Vinvasion
p9328
sg13
I1
sa(dp9329
g7
I81
sg32
VC0006826
p9330
sg10
I6
sg11
Vcancer
p9331
sg13
I1
sasa(dp9332
g2
S'In pancreatic ductal adenocarcinoma, high AnxA6 IHC score correlated with the presence of tumour budding at the invasive front of tumours (P=0.082), the presence of perineural invasion (P= &lt;0.0001) and showed a weak correlation with reduced survival (P=0.2242).\n'
p9333
sg4
(lp9334
(dp9335
g7
I42
sg8
VP08133
p9336
sg10
I9
sg11
VAnxA6 IHC
p9337
sg13
I2
sasg29
(lp9338
(dp9339
g7
I3
sg32
VC1335302
p9340
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p9341
sg13
I3
sa(dp9342
g7
I176
sg32
VC2699153
p9343
sg10
I8
sg11
Vinvasion
p9344
sg13
I1
sa(dp9345
g7
I130
sg32
VC0027651
p9346
sg10
I7
sg11
Vtumours
p9347
sg13
I1
sa(dp9348
g7
I90
sg32
VC0027651
p9349
sg10
I6
sg11
Vtumour
p9350
sg13
I1
sasa(dp9351
g2
S'Moreover, through characterisation of the 9E1 target antigen, AnxA6, our findings support further investigation of AnxA6 as a potential candidate target for antibody-mediated inhibition of pancreatic cancer.\n'
p9352
sg4
(lp9353
(dp9354
g7
I62
sg8
VP08133
p9355
sg10
I5
sg11
VAnxA6
p9356
sg13
I1
sa(dp9357
g7
I62
sg8
VP08133
p9358
sg10
I5
sg11
VAnxA6
p9359
sg13
I1
sa(dp9360
g7
I42
sg8
VP14209
p9361
sg10
I18
sg11
V9E1 target antigen
p9362
sg13
I3
sasg29
(lp9363
(dp9364
g7
I189
sg32
VC0235974
p9365
sg10
I17
sg11
Vpancreatic cancer
p9366
sg13
I2
sasa(dp9367
g2
S'In addition, we observed the positive association between blood BPA levels and mRNA expression of the ANXA6 and VCP not in normal but thyroid cancer tissues.\n'
p9368
sg4
(lp9369
(dp9370
g7
I112
sg8
VP55072
p9371
sg10
I3
sg11
VVCP
p9372
sg13
I1
sa(dp9373
g7
I102
sg8
VP08133
p9374
sg10
I5
sg11
VANXA6
p9375
sg13
I1
sasg29
(lp9376
(dp9377
g7
I134
sg32
VC0007115
p9378
sg10
I14
sg11
Vthyroid cancer
p9379
sg13
I2
sasa(dp9380
g2
S"Our study provides ANXA6 and VCP as proteomic biomarkers for BPA- early life exposure and their potential for women's thyroid cancer.\n"
p9381
sg4
(lp9382
(dp9383
g7
I29
sg8
VP55072
p9384
sg10
I3
sg11
VVCP
p9385
sg13
I1
sa(dp9386
g7
I19
sg8
VP08133
p9387
sg10
I5
sg11
VANXA6
p9388
sg13
I1
sasg29
(lp9389
(dp9390
g7
I118
sg32
VC0007115
p9391
sg10
I14
sg11
Vthyroid cancer
p9392
sg13
I2
sasa(dp9393
g2
S'More recently, we and others identified roles for AnxA6 in cancer cell migration and invasion.\n'
p9394
sg4
(lp9395
(dp9396
g7
I50
sg8
VP08133
p9397
sg10
I5
sg11
VAnxA6
p9398
sg13
I1
sasg29
(lp9399
(dp9400
g7
I85
sg32
VC2699153
p9401
sg10
I8
sg11
Vinvasion
p9402
sg13
I1
sa(dp9403
g7
I59
sg32
VC0006826
p9404
sg10
I6
sg11
Vcancer
p9405
sg13
I1
sasa(dp9406
g2
S'Formation of the ANXA6/LRP1/TSP1 complex was restricted to cancer-associated fibroblasts (CAFs) and required physiopathologic culture conditions that improved tumor cell survival and migration.\n'
p9407
sg4
(lp9408
(dp9409
g7
I17
sg8
VP08133
p9410
sg10
I5
sg11
VANXA6
p9411
sg13
I1
sa(dp9412
g7
I28
sg8
VP07996
p9413
sg10
I4
sg11
VTSP1
p9414
sg13
I1
sa(dp9415
g7
I23
sg8
g48
sg10
I4
sg11
VLRP1
p9416
sg13
I1
sasg29
(lp9417
(dp9418
g7
I90
sg32
VC0795907
p9419
sg10
I4
sg11
VCAFs
p9420
sg13
I1
sa(dp9421
g7
I59
sg32
VC0795907
p9422
sg10
I29
sg11
Vcancer-associated fibroblasts
p9423
sg13
I2
sa(dp9424
g7
I159
sg32
VC0027651
p9425
sg10
I5
sg11
Vtumor
p9426
sg13
I1
sasa(dp9427
g2
S'The current study shows that AnxA6 is specifically reduced in human hepatocellular carcinoma suggesting a role of this protein in hepatocarcinogenesis.\n'
p9428
sg4
(lp9429
(dp9430
g7
I29
sg8
VP08133
p9431
sg10
I5
sg11
VAnxA6
p9432
sg13
I1
sasg29
(lp9433
(dp9434
g7
I130
sg32
VC1512409
p9435
sg10
I20
sg11
Vhepatocarcinogenesis
p9436
sg13
I1
sa(dp9437
g7
I68
sg32
VC1512411
p9438
sg10
I24
sg11
Vhepatocellular carcinoma
p9439
sg13
I2
sasa(dp9440
g2
S'The expression levels of AnxA6 are closely associated with melanoma, cervical cancer, epithelial carcinoma, breast cancer, gastric cancer, prostate cancer, acute lymphoblastic leukemia, chronic myeloid leukemia, large-cell lymphoma and myeloma.\n'
p9441
sg4
(lp9442
(dp9443
g7
I25
sg8
VP08133
p9444
sg10
I5
sg11
VAnxA6
p9445
sg13
I1
sasg29
(lp9446
(dp9447
g7
I194
sg32
VC0023470
p9448
sg10
I16
sg11
Vmyeloid leukemia
p9449
sg13
I2
sa(dp9450
g7
I78
sg32
VC0006826
p9451
sg10
I6
sg11
Vcancer
p9452
sg13
I1
sa(dp9453
g7
I59
sg32
VC0025202
p9454
sg10
I8
sg11
Vmelanoma
p9455
sg13
I1
sa(dp9456
g7
I131
sg32
VC0376358
p9457
sg10
I16
sg11
Vcancer, prostate
p9458
sg13
I2
sa(dp9459
g7
I212
sg32
VC0079744
p9460
sg10
I19
sg11
Vlarge-cell lymphoma
p9461
sg13
I2
sa(dp9462
g7
I236
sg32
VC0026764
p9463
sg10
I7
sg11
Vmyeloma
p9464
sg13
I1
sa(dp9465
g7
I86
sg32
VC0007097
p9466
sg10
I20
sg11
Vepithelial carcinoma
p9467
sg13
I2
sa(dp9468
g7
I115
sg32
VC0024623
p9469
sg10
I15
sg11
Vcancer, gastric
p9470
sg13
I2
sa(dp9471
g7
I69
sg32
VC0302592
p9472
sg10
I15
sg11
Vcervical cancer
p9473
sg13
I2
sa(dp9474
g7
I162
sg32
VC0023434
p9475
sg10
I31
sg11
Vlymphoblastic leukemia, chronic
p9476
sg13
I3
sasa(dp9477
g2
S'AnxA6 exhibits dual functions in cancer, acting either as a tumor suppressor or promoter, depending on the type of cancer and the degree of malignancy.\n'
p9478
sg4
(lp9479
(dp9480
g7
I0
sg8
VP08133
p9481
sg10
I5
sg11
VAnxA6
p9482
sg13
I1
sasg29
(lp9483
(dp9484
g7
I33
sg32
VC0006826
p9485
sg10
I6
sg11
Vcancer
p9486
sg13
I1
sa(dp9487
g7
I60
sg32
VC0027651
p9488
sg10
I5
sg11
Vtumor
p9489
sg13
I1
sa(dp9490
g7
I140
sg32
VC0006826
p9491
sg10
I10
sg11
Vmalignancy
p9492
sg13
I1
sa(dp9493
g7
I33
sg32
VC0006826
p9494
sg10
I6
sg11
Vcancer
p9495
sg13
I1
sasa(dp9496
g2
S'In several types of cancer, AnxA6 acts via Ras, Ras/MAPK and/or FAK/PI3K signaling pathways by mainly mediating PKCAlfa, p120GAP, Bcr-Abl and YY1.\n'
p9497
sg4
(lp9498
(dp9499
g7
I68
sg8
VP42336
p9500
sg10
I4
sg11
VPI3K
p9501
sg13
I1
sa(dp9502
g7
I121
sg8
VP20936
p9503
sg10
I7
sg11
Vp120GAP
p9504
sg13
I1
sa(dp9505
g7
I64
sg8
g48
sg10
I3
sg11
VFAK
p9506
sg13
I1
sa(dp9507
g7
I142
sg8
VP25490
p9508
sg10
I3
sg11
VYY1
p9509
sg13
I1
sa(dp9510
g7
I134
sg8
VP55157
p9511
sg10
I3
sg11
VAbl
p9512
sg13
I1
sa(dp9513
g7
I43
sg8
VP01116
p9514
sg10
I3
sg11
VRas
p9515
sg13
I1
sa(dp9516
g7
I52
sg8
VP53779
p9517
sg10
I4
sg11
VMAPK
p9518
sg13
I1
sa(dp9519
g7
I28
sg8
VP08133
p9520
sg10
I5
sg11
VAnxA6
p9521
sg13
I1
sa(dp9522
g7
I130
sg8
VP11274
p9523
sg10
I3
sg11
VBcr
p9524
sg13
I1
sa(dp9525
g7
I43
sg8
VP01116
p9526
sg10
I3
sg11
VRas
p9527
sg13
I1
sasg29
(lp9528
(dp9529
g7
I20
sg32
VC0006826
p9530
sg10
I6
sg11
Vcancer
p9531
sg13
I1
sa(dp9532
g7
I134
sg32
VC0000744
p9533
sg10
I3
sg11
VAbl
p9534
sg13
I1
sasa(dp9535
g2
S'In the present review, the roles of AnxA6 in different types of cancer are summarized.\n'
p9536
sg4
(lp9537
(dp9538
g7
I36
sg8
VP08133
p9539
sg10
I5
sg11
VAnxA6
p9540
sg13
I1
sasg29
(lp9541
(dp9542
g7
I64
sg32
VC0006826
p9543
sg10
I6
sg11
Vcancer
p9544
sg13
I1
sasa(dp9545
g2
S'Here, we studied the effects of NO synthesis inhibition during the induction phase of morphine dependence on the expression of brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and insulin-like growth factor 1 (IGF1) as well as their receptors in rat brain regions after spontaneous morphine withdrawal in dependent animals.\n'
p9546
sg4
(lp9547
(dp9548
g7
I127
sg8
g48
sg10
I82
sg11
Vbrain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF)
p9549
sg13
I8
sa(dp9550
g7
I242
sg8
VP01308
p9551
sg10
I28
sg11
Vinsulin-like growth factor 1
p9552
sg13
I4
sa(dp9553
g7
I211
sg8
VP01138
p9554
sg10
I19
sg11
Vnerve growth factor
p9555
sg13
I3
sa(dp9556
g7
I272
sg8
VP01343
p9557
sg10
I4
sg11
VIGF1
p9558
sg13
I1
sa(dp9559
g7
I232
sg8
VP01138
p9560
sg10
I3
sg11
VNGF
p9561
sg13
I1
sasg29
(lp9562
(dp9563
g7
I353
sg32
VC2825032
p9564
sg10
I10
sg11
Vwithdrawal
p9565
sg13
I1
sa(dp9566
g7
I86
sg32
VC0026552
p9567
sg10
I19
sg11
Vmorphine dependence
p9568
sg13
I2
sasa(dp9569
g2
S'(2) The occurrence rate of the heat-sensitized acupoints was high in the site of Xiaguan (ST 7) and Sibai (ST 2), and was secondarily high in the site of Jiachengjiang (Extra), Fengchi (GB 20) and Yuyao (EX-HN 4) in the high incidence region of heat sensitization in patients with trigeminal neuralgia.\n'
p9570
sg4
(lp9571
sg29
(lp9572
(dp9573
g7
I281
sg32
VC0040997
p9574
sg10
I20
sg11
Vtrigeminal neuralgia
p9575
sg13
I2
sasa(dp9576
g2
S"A quantitative assessment of the density of the protein gene product 9.5 (PGP9.5), the neural cell adhesion molecule (NCAM), and the low-affinity nerve growth factor receptor (NGFR) expressing nerve fibers in the circular muscle layer in the colon was carried out by morphometric analyses from 13 patients with Hirschsprung's disease (HD).\n"
p9577
sg4
(lp9578
(dp9579
g7
I176
sg8
VP08138
p9580
sg10
I4
sg11
VNGFR
p9581
sg13
I1
sa(dp9582
g7
I118
sg8
g48
sg10
I4
sg11
VNCAM
p9583
sg13
I1
sa(dp9584
g7
I87
sg8
g48
sg10
I29
sg11
Vneural cell adhesion molecule
p9585
sg13
I4
sa(dp9586
g7
I146
sg8
VP08138
p9587
sg10
I28
sg11
Vnerve growth factor receptor
p9588
sg13
I4
sasg29
(lp9589
(dp9590
g7
I311
sg32
VC0019569
p9591
sg10
I22
sg11
VHirschsprung's disease
p9592
sg13
I2
sa(dp9593
g7
I335
sg32
VC0019569
p9594
sg10
I2
sg11
VHD
p9595
sg13
I1
sa(dp9596
g7
I99
sg32
VC0001511
p9597
sg10
I8
sg11
Vadhesion
p9598
sg13
I1
sasa(dp9599
g2
S'The elevation of culture temperatures of C6 cells that were persistently infected with the Lec strain of the subacute sclerosing panencephalitis (SSPE) virus (C6/SSPE) resulted in immediate selective inhibition of membrane (M) protein synthesis.\n'
p9600
sg4
(lp9601
(dp9602
g7
I91
sg8
g48
sg10
I3
sg11
VLec
p9603
sg13
I1
sasg29
(lp9604
(dp9605
g7
I146
sg32
VC0038522
p9606
sg10
I4
sg11
VSSPE
p9607
sg13
I1
sa(dp9608
g7
I109
sg32
VC0038522
p9609
sg10
I35
sg11
Vsubacute sclerosing panencephalitis
p9610
sg13
I3
sa(dp9611
g7
I146
sg32
VC0038522
p9612
sg10
I4
sg11
VSSPE
p9613
sg13
I1
sasa(dp9614
g2
S'The sensitivity of newborn hamsters to inoculation with the vaccine L-16 strain of measles virus and the Lec strain isolated from a patient with subacute sclerosing panencephalitis as well as the possibility of persistence of these viruses in the animals were studied.\n'
p9615
sg4
(lp9616
sg29
(lp9617
(dp9618
g7
I145
sg32
VC0038522
p9619
sg10
I35
sg11
Vsubacute sclerosing panencephalitis
p9620
sg13
I3
sa(dp9621
g7
I83
sg32
VC0025007
p9622
sg10
I7
sg11
Vmeasles
p9623
sg13
I1
sasa(dp9624
g2
S'This endothelin 1-induced Ca2+ signal was not observed when the cells were persistently infected with a measles virus strain of subacute sclerosing panencephalitis (SSPE, strain Lec).\n'
p9625
sg4
(lp9626
(dp9627
g7
I5
sg8
VP05305
p9628
sg10
I12
sg11
Vendothelin 1
p9629
sg13
I2
sasg29
(lp9630
(dp9631
g7
I104
sg32
VC0025007
p9632
sg10
I7
sg11
Vmeasles
p9633
sg13
I1
sa(dp9634
g7
I128
sg32
VC0038522
p9635
sg10
I35
sg11
Vsubacute sclerosing panencephalitis
p9636
sg13
I3
sa(dp9637
g7
I165
sg32
VC0038522
p9638
sg10
I4
sg11
VSSPE
p9639
sg13
I1
sasa(dp9640
g2
S'Establishment and characteristics of a baby hamster kidney cell line (BHK 0-853) persistently infected with a subacute sclerosing panencephalitis (SSPE) strain of measles virus (Lec strain) is described.\n'
p9641
sg4
(lp9642
(dp9643
g7
I178
sg8
g48
sg10
I3
sg11
VLec
p9644
sg13
I1
sasg29
(lp9645
(dp9646
g7
I110
sg32
VC0038522
p9647
sg10
I35
sg11
Vsubacute sclerosing panencephalitis
p9648
sg13
I3
sa(dp9649
g7
I147
sg32
VC0038522
p9650
sg10
I4
sg11
VSSPE
p9651
sg13
I1
sa(dp9652
g7
I163
sg32
VC0025007
p9653
sg10
I7
sg11
Vmeasles
p9654
sg13
I1
sasa(dp9655
g2
S'The DRAIC lncRNA was identified from RNA-seq data and is downregulated as prostate cancer cells progress from an androgen-dependent (AD) to a castration-resistant (CR) state.\n'
p9656
sg4
(lp9657
sg29
(lp9658
(dp9659
g7
I74
sg32
VC0600139
p9660
sg10
I15
sg11
Vprostate cancer
p9661
sg13
I2
sasa(dp9662
g2
S'Prostate cancers persisting in patients after androgen deprivation therapy (ADT) select for decreased DRAIC expression, and higher levels of DRAIC in prostate cancer are associated with longer disease-free survival (DFS).\n'
p9663
sg4
(lp9664
sg29
(lp9665
(dp9666
g7
I0
sg32
VC0376358
p9667
sg10
I16
sg11
VProstate cancers
p9668
sg13
I2
sa(dp9669
g7
I150
sg32
VC0376358
p9670
sg10
I15
sg11
Vprostate cancer
p9671
sg13
I2
sasa(dp9672
g2
S'The decrease of FOXA1 and NKX3-1, and aberrant activation of AR, thus accounts for the decrease of DRAIC during prostate cancer progression to the CR state.\n'
p9673
sg4
(lp9674
(dp9675
g7
I26
sg8
g48
sg10
I6
sg11
VNKX3-1
p9676
sg13
I1
sa(dp9677
g7
I16
sg8
VP55317
p9678
sg10
I5
sg11
VFOXA1
p9679
sg13
I1
sasg29
(lp9680
(dp9681
g7
I121
sg32
VC0178874
p9682
sg10
I18
sg11
Vcancer progression
p9683
sg13
I2
sasa(dp9684
g2
S'Taken together, these findings reveal that SC79 could accelerate the recovery of reversible muscular atrophy induced by BTX and subsequently promote fracture healing through activation of the Akt signaling pathway, which suggests its therapeutic potential in orthopedics.\n'
p9685
sg4
(lp9686
(dp9687
g7
I192
sg8
g48
sg10
I3
sg11
VAkt
p9688
sg13
I1
sasg29
(lp9689
(dp9690
g7
I92
sg32
VC0026846
p9691
sg10
I16
sg11
Vmuscular atrophy
p9692
sg13
I2
sasa(dp9693
g2
S'Moreover, rhPDGF-BB promoted the proliferation of hADSCs via miR-363/PI3K/Akt pathway, indicating that rhPDGF-BB combined with ADSCs could treat Achilles tendinitis via miR-363/PI3K/Akt pathway.\n'
p9694
sg4
(lp9695
(dp9696
g7
I69
sg8
VP42336
p9697
sg10
I4
sg11
VPI3K
p9698
sg13
I1
sa(dp9699
g7
I61
sg8
g48
sg10
I7
sg11
VmiR-363
p9700
sg13
I1
sa(dp9701
g7
I61
sg8
g48
sg10
I7
sg11
VmiR-363
p9702
sg13
I1
sa(dp9703
g7
I74
sg8
g48
sg10
I3
sg11
VAkt
p9704
sg13
I1
sa(dp9705
g7
I74
sg8
g48
sg10
I3
sg11
VAkt
p9706
sg13
I1
sa(dp9707
g7
I69
sg8
VP42336
p9708
sg10
I4
sg11
VPI3K
p9709
sg13
I1
sasg29
(lp9710
(dp9711
g7
I33
sg32
VC0334094
p9712
sg10
I13
sg11
Vproliferation
p9713
sg13
I1
sa(dp9714
g7
I145
sg32
VC0263933
p9715
sg10
I19
sg11
VAchilles tendinitis
p9716
sg13
I2
sasa(dp9717
g2
S'Immunohistochemical staining using cholangiocarcinoma tissues showed that the expression of Ambra1 positively correlated with the expression of Snail, one of the major transcriptional factors of EMT.\n'
p9718
sg4
(lp9719
(dp9720
g7
I92
sg8
g48
sg10
I6
sg11
VAmbra1
p9721
sg13
I1
sa(dp9722
g7
I195
sg8
g48
sg10
I3
sg11
VEMT
p9723
sg13
I1
sasg29
(lp9724
(dp9725
g7
I35
sg32
VC0206698
p9726
sg10
I18
sg11
Vcholangiocarcinoma
p9727
sg13
I1
sasa(dp9728
g2
S'Tumors of blood and lymph vessel origin accounted for nine patients; giant-cell tumors of tendon sheaths and tumoral calcinosis occurred in four patients each and soft-tissue chondroma in three.\n'
p9729
sg4
(lp9730
sg29
(lp9731
(dp9732
g7
I0
sg32
VC0027651
p9733
sg10
I6
sg11
VTumors
p9734
sg13
I1
sa(dp9735
g7
I80
sg32
VC0027651
p9736
sg10
I6
sg11
Vtumors
p9737
sg13
I1
sa(dp9738
g7
I109
sg32
VC0263628
p9739
sg10
I18
sg11
Vtumoral calcinosis
p9740
sg13
I2
sa(dp9741
g7
I175
sg32
VC0936248
p9742
sg10
I9
sg11
Vchondroma
p9743
sg13
I1
sa(dp9744
g7
I69
sg32
VC0017547
p9745
sg10
I5
sg11
Vgiant
p9746
sg13
I1
sasa(dp9747
g2
S'DEAF-1 is an important transcriptional regulator that is required for embryonic development and is linked to clinical depression and suicidal behavior in humans.\n'
p9748
sg4
(lp9749
sg29
(lp9750
(dp9751
g7
I109
sg32
VC2362914
p9752
sg10
I19
sg11
Vclinical depression
p9753
sg13
I2
sasa(dp9754
g2
S'The serotonin 1A receptor (5-HT1A) and its associated transcriptional regulators, five prime repressor element under dual repression (Freud-1) and nuclear-deformed epidermal autoregulatory factor (NUDR/Deaf-1) have been previously found to be the repressors for 5-HT1A in the serotonergic raphe neurons, and are also altered in postmortem brains of individuals with major depressive disorder (MDD) and in rats exposed to chronic restraint stress.\n'
p9755
sg4
(lp9756
(dp9757
g7
I147
sg8
g48
sg10
I48
sg11
Vnuclear-deformed epidermal autoregulatory factor
p9758
sg13
I4
sa(dp9759
g7
I4
sg8
g48
sg10
I21
sg11
Vserotonin 1A receptor
p9760
sg13
I3
sa(dp9761
g7
I27
sg8
VP08908
p9762
sg10
I6
sg11
V5-HT1A
p9763
sg13
I1
sasg29
(lp9764
(dp9765
g7
I393
sg32
VC1269683
p9766
sg10
I3
sg11
VMDD
p9767
sg13
I1
sa(dp9768
g7
I366
sg32
VC1269683
p9769
sg10
I25
sg11
Vmajor depressive disorder
p9770
sg13
I3
sasa(dp9771
g2
S'Deformed epidermal autoregulatory factor-1 (DEAF-1) is a DNA-binding protein required for embryonic development and linked to clinical depression and suicidal behavior in humans.\n'
p9772
sg4
(lp9773
(dp9774
g7
I9
sg8
g48
sg10
I33
sg11
Vepidermal autoregulatory factor-1
p9775
sg13
I3
sasg29
(lp9776
(dp9777
g7
I126
sg32
VC2362914
p9778
sg10
I19
sg11
Vclinical depression
p9779
sg13
I2
sasa(dp9780
g2
S'This metabolic syndrome represents a "Cluster" of metabolic disorders and cardiovascular risk factors which has been collected and summarized by the author and such a cluster includes: insulin resistance/hyperinsulinemia, central obesity, glucose intolerance/DM, atherogenic dyslipidemia (increase TG, decrease HDL-cholesterol, increase Apo-B, increase small dense LDL), hypertension, prothrombotic state (increase PAI-1, increase F-VII, increase fibrinogen, increase vWF, increase adhesion molecules), endothelial dysfunction, hyperuricemia, and increased hsC-RP and cytokines.\n'
p9781
sg4
(lp9782
(dp9783
g7
I185
sg8
VP01308
p9784
sg10
I7
sg11
Vinsulin
p9785
sg13
I1
sa(dp9786
g7
I415
sg8
VP05121
p9787
sg10
I5
sg11
VPAI-1
p9788
sg13
I1
sa(dp9789
g7
I337
sg8
g48
sg10
I5
sg11
VApo-B
p9790
sg13
I1
sa(dp9791
g7
I311
sg8
VP28845
p9792
sg10
I15
sg11
VHDL-cholesterol
p9793
sg13
I1
sa(dp9794
g7
I468
sg8
VP04275
p9795
sg10
I3
sg11
VvWF
p9796
sg13
I1
sa(dp9797
g7
I447
sg8
VP22087
p9798
sg10
I10
sg11
Vfibrinogen
p9799
sg13
I1
sa(dp9800
g7
I557
sg8
VP19526
p9801
sg10
I3
sg11
VhsC
p9802
sg13
I1
sasg29
(lp9803
(dp9804
g7
I503
sg32
VC0856169
p9805
sg10
I23
sg11
Vendothelial dysfunction
p9806
sg13
I2
sa(dp9807
g7
I50
sg32
VC0025517
p9808
sg10
I19
sg11
Vmetabolic disorders
p9809
sg13
I2
sa(dp9810
g7
I222
sg32
VC0311277
p9811
sg10
I15
sg11
Vcentral obesity
p9812
sg13
I2
sa(dp9813
g7
I275
sg32
VC0242339
p9814
sg10
I12
sg11
Vdyslipidemia
p9815
sg13
I1
sa(dp9816
g7
I239
sg32
VC0271650
p9817
sg10
I19
sg11
Vglucose intolerance
p9818
sg13
I2
sa(dp9819
g7
I371
sg32
VC0020538
p9820
sg10
I12
sg11
Vhypertension
p9821
sg13
I1
sa(dp9822
g7
I5
sg32
VC0524620
p9823
sg10
I18
sg11
Vmetabolic syndrome
p9824
sg13
I2
sa(dp9825
g7
I528
sg32
VC0740394
p9826
sg10
I13
sg11
Vhyperuricemia
p9827
sg13
I1
sa(dp9828
g7
I185
sg32
VC0021655
p9829
sg10
I18
sg11
Vinsulin resistance
p9830
sg13
I2
sa(dp9831
g7
I204
sg32
VC0020459
p9832
sg10
I16
sg11
Vhyperinsulinemia
p9833
sg13
I1
sa(dp9834
g7
I482
sg32
VC0001511
p9835
sg10
I8
sg11
Vadhesion
p9836
sg13
I1
sasa(dp9837
g2
S'The mortality rates for esophageal declined from 1994 to 2002 (APC -2.5 (95% CI -4.1 to -0.8)) and from 2002 to 2013 (APC -5.2 (95% CI -5.7 to -4.7)) and laryngeal cancer declined from 1995 to 2013 (average annual percent change (AAPC): -3.3 (95% CI -4.7 to -1.8)).\n'
p9838
sg4
(lp9839
sg29
(lp9840
(dp9841
g7
I230
sg32
VC1868019
p9842
sg10
I4
sg11
VAAPC
p9843
sg13
I1
sa(dp9844
g7
I63
sg32
VC0033036
p9845
sg10
I3
sg11
VAPC
p9846
sg13
I1
sa(dp9847
g7
I63
sg32
VC0033036
p9848
sg10
I3
sg11
VAPC
p9849
sg13
I1
sa(dp9850
g7
I154
sg32
VC0595989
p9851
sg10
I16
sg11
Vlaryngeal cancer
p9852
sg13
I2
sasa(dp9853
g2
S'Trends in background rates were notable for liver (APC 5.6%) and lung (-3.2%) cancers.\n'
p9854
sg4
(lp9855
sg29
(lp9856
(dp9857
g7
I78
sg32
VC0006826
p9858
sg10
I7
sg11
Vcancers
p9859
sg13
I1
sa(dp9860
g7
I51
sg32
VC0033036
p9861
sg10
I3
sg11
VAPC
p9862
sg13
I1
sasa(dp9863
g2
S'The increase for small primary tonsillar cancer from 2004 to 2008 is associated with increased ipsilateral disease (ie, T1-2N2a-b, APC 10.6%; p &lt; .05) rather than bilateral neck disease (T1-2N2c, APC 5.9%, APC = NS).\n'
p9864
sg4
(lp9865
(dp9866
g7
I131
sg8
VP25054
p9867
sg10
I6
sg11
VAPC 10
p9868
sg13
I2
sasg29
(lp9869
(dp9870
g7
I31
sg32
VC0751560
p9871
sg10
I16
sg11
Vtonsillar cancer
p9872
sg13
I2
sa(dp9873
g7
I176
sg32
VC0558385
p9874
sg10
I12
sg11
Vneck disease
p9875
sg13
I2
sa(dp9876
g7
I131
sg32
VC0033036
p9877
sg10
I3
sg11
VAPC
p9878
sg13
I1
sa(dp9879
g7
I131
sg32
VC0033036
p9880
sg10
I3
sg11
VAPC
p9881
sg13
I1
sa(dp9882
g7
I131
sg32
VC0033036
p9883
sg10
I3
sg11
VAPC
p9884
sg13
I1
sasa(dp9885
g2
S'While laryngeal cancer mortality rates decreased among men (APC -5.5%) and women (APC -0.03%) alike, incidence rates decreased (-1.28%) among men but not among women (3.95%).\n'
p9886
sg4
(lp9887
sg29
(lp9888
(dp9889
g7
I6
sg32
VC0595989
p9890
sg10
I16
sg11
Vlaryngeal cancer
p9891
sg13
I2
sa(dp9892
g7
I60
sg32
VC0033036
p9893
sg10
I3
sg11
VAPC
p9894
sg13
I1
sa(dp9895
g7
I60
sg32
VC0033036
p9896
sg10
I3
sg11
VAPC
p9897
sg13
I1
sasa(dp9898
g2
S'The aim of this study was to investigate the potential roles of Protein Kinase C Zeta (PRKCZ) in ovarian cancer.\n'
p9899
sg4
(lp9900
(dp9901
g7
I87
sg8
g48
sg10
I5
sg11
VPRKCZ
p9902
sg13
I1
sa(dp9903
g7
I64
sg8
g48
sg10
I21
sg11
VProtein Kinase C Zeta
p9904
sg13
I4
sasg29
(lp9905
(dp9906
g7
I97
sg32
VC1140680
p9907
sg10
I14
sg11
Vovarian cancer
p9908
sg13
I2
sasa(dp9909
g2
S'Herein, we observe a significant increase in cell survival upon PRKCZ over-expression in SKOV3 ovarian cancer cells; additionally, when the cells are treated with small interference RNA (siRNA) targeting PRKCZ, the motility of SKOV3 cells decreased.\n'
p9910
sg4
(lp9911
(dp9912
g7
I64
sg8
g48
sg10
I5
sg11
VPRKCZ
p9913
sg13
I1
sa(dp9914
g7
I64
sg8
g48
sg10
I5
sg11
VPRKCZ
p9915
sg13
I1
sasg29
(lp9916
(dp9917
g7
I95
sg32
VC1140680
p9918
sg10
I14
sg11
Vovarian cancer
p9919
sg13
I2
sasa(dp9920
g2
S'However, the in vivo role of PKCZeta and its mechanisms of action in prostate cancer remain unclear.\n'
p9921
sg4
(lp9922
sg29
(lp9923
(dp9924
g7
I69
sg32
VC0600139
p9925
sg10
I15
sg11
Vprostate cancer
p9926
sg13
I2
sasa(dp9927
g2
S'Here we demonstrate that the genetic inactivation of PKCZeta in mice results in invasive prostate carcinoma in vivo in the context of phosphatase and tensin homolog deficiency.\n'
p9928
sg4
(lp9929
(dp9930
g7
I150
sg8
g48
sg10
I14
sg11
Vtensin homolog
p9931
sg13
I2
sasg29
(lp9932
(dp9933
g7
I80
sg32
VC1708566
p9934
sg10
I27
sg11
Vinvasive prostate carcinoma
p9935
sg13
I3
sa(dp9936
g7
I37
sg32
VC0544461
p9937
sg10
I12
sg11
Vinactivation
p9938
sg13
I1
sasa(dp9939
g2
S'Bioinformatic analysis of human prostate cancer gene-expression sets revealed increased c-Myc transcriptional activity in PKCZeta-inactive cells, which correlated with increased cell growth, invasion, and metastasis.\n'
p9940
sg4
(lp9941
(dp9942
g7
I88
sg8
VP12524
p9943
sg10
I5
sg11
Vc-Myc
p9944
sg13
I1
sa(dp9945
g7
I26
sg8
g48
sg10
I26
sg11
Vhuman prostate cancer gene
p9946
sg13
I4
sasg29
(lp9947
(dp9948
g7
I32
sg32
VC0600139
p9949
sg10
I15
sg11
Vprostate cancer
p9950
sg13
I2
sa(dp9951
g7
I191
sg32
VC2699153
p9952
sg10
I8
sg11
Vinvasion
p9953
sg13
I1
sa(dp9954
g7
I205
sg32
VC0027627
p9955
sg10
I10
sg11
Vmetastasis
p9956
sg13
I1
sasa(dp9957
g2
S'Analysis of prostate cancer samples demonstrated increased expression and decreased phosphorylation of c-Myc at Ser-373 in PKCZeta knockout tumors.\n'
p9958
sg4
(lp9959
(dp9960
g7
I103
sg8
VP12524
p9961
sg10
I5
sg11
Vc-Myc
p9962
sg13
I1
sasg29
(lp9963
(dp9964
g7
I12
sg32
VC0600139
p9965
sg10
I15
sg11
Vprostate cancer
p9966
sg13
I2
sa(dp9967
g7
I140
sg32
VC0027651
p9968
sg10
I6
sg11
Vtumors
p9969
sg13
I1
sasa(dp9970
g2
S'Collectively, these results establish PKCZeta as an important tumor suppressor and regulator of c-Myc function in prostate cancer.\n'
p9971
sg4
(lp9972
(dp9973
g7
I96
sg8
VP12524
p9974
sg10
I5
sg11
Vc-Myc
p9975
sg13
I1
sasg29
(lp9976
(dp9977
g7
I114
sg32
VC0600139
p9978
sg10
I15
sg11
Vprostate cancer
p9979
sg13
I2
sa(dp9980
g7
I62
sg32
VC0027651
p9981
sg10
I5
sg11
Vtumor
p9982
sg13
I1
sasa(dp9983
g2
S'Previously, using gene-knockdown techniques together with genome expression array analysis, we showed the gene protein Kinase C (PKC)-zeta (PRKCZ) to mediate the malignant phenotype of human prostate cancer.\n'
p9984
sg4
(lp9985
(dp9986
g7
I140
sg8
g48
sg10
I5
sg11
VPRKCZ
p9987
sg13
I1
sa(dp9988
g7
I106
sg8
VP17252
p9989
sg10
I32
sg11
Vgene protein Kinase C (PKC)-zeta
p9990
sg13
I5
sasg29
(lp9991
(dp9992
g7
I191
sg32
VC0600139
p9993
sg10
I15
sg11
Vprostate cancer
p9994
sg13
I2
sa(dp9995
g7
I129
sg32
VC1868682
p9996
sg10
I3
sg11
VPKC
p9997
sg13
I1
sa(dp9998
g7
I111
sg32
VC1868682
p9999
sg10
I16
sg11
Vprotein Kinase C
p10000
sg13
I3
sasa(dp10001
g2
S"A novel sequence was identified within the 3'-terminal domain of human PRKCZ that, in prostate cancer cell lines and tissues, is expressed during transcription and thereafter translated into protein (designated PKC-Zeta(-PrC)) independent of conventional PKC-Zeta(-a).\n"
p10002
sg4
(lp10003
(dp10004
g7
I211
sg8
g48
sg10
I8
sg11
VPKC-Zeta
p10005
sg13
I1
sa(dp10006
g7
I65
sg8
g48
sg10
I11
sg11
Vhuman PRKCZ
p10007
sg13
I2
sasg29
(lp10008
(dp10009
g7
I211
sg32
VC1868682
p10010
sg10
I3
sg11
VPKC
p10011
sg13
I1
sa(dp10012
g7
I86
sg32
VC0600139
p10013
sg10
I15
sg11
Vprostate cancer
p10014
sg13
I2
sa(dp10015
g7
I211
sg32
VC1868682
p10016
sg10
I3
sg11
VPKC
p10017
sg13
I1
sasa(dp10018
g2
S'Thirty-eight PPARGamma direct target genes were found to be involved in prostate cancer and two key (hub) PPARGamma direct target genes, PRKCZ and PGK1, were experimentally validated to be repressed upon PPARGamma activation by its natural ligand, 15d-PGJ(2) in three prostrate cancer cell lines.\n'
p10019
sg4
(lp10020
(dp10021
g7
I137
sg8
g48
sg10
I5
sg11
VPRKCZ
p10022
sg13
I1
sa(dp10023
g7
I147
sg8
VP00558
p10024
sg10
I4
sg11
VPGK1
p10025
sg13
I1
sasg29
(lp10026
(dp10027
g7
I72
sg32
VC0600139
p10028
sg10
I15
sg11
Vprostate cancer
p10029
sg13
I2
sa(dp10030
g7
I81
sg32
VC0006826
p10031
sg10
I6
sg11
Vcancer
p10032
sg13
I1
sasa(dp10033
g2
S'We proposed that PRKCZ and PGK1 could be novel therapeutic targets for prostate cancer.\n'
p10034
sg4
(lp10035
(dp10036
g7
I17
sg8
g48
sg10
I5
sg11
VPRKCZ
p10037
sg13
I1
sa(dp10038
g7
I27
sg8
VP00558
p10039
sg10
I4
sg11
VPGK1
p10040
sg13
I1
sasg29
(lp10041
(dp10042
g7
I71
sg32
VC0600139
p10043
sg10
I15
sg11
Vprostate cancer
p10044
sg13
I2
sasa(dp10045
g2
S'The role that PKCzeta, PKClambda/iota, and Par-4 have in lung and prostate cancer in vivo and in humans will be extensively covered in this article, as will the multifunctional role of p62 as a novel hub in cell signaling during cancer and inflammation, and the mechanistic details and controversial data published on its potential role in aggregate formation and signaling.\n'
p10046
sg4
(lp10047
(dp10048
g7
I23
sg8
VP60900
p10049
sg10
I14
sg11
VPKClambda/iota
p10050
sg13
I1
sa(dp10051
g7
I185
sg8
VP37198
p10052
sg10
I3
sg11
Vp62
p10053
sg13
I1
sa(dp10054
g7
I200
sg8
g48
sg10
I3
sg11
Vhub
p10055
sg13
I1
sa(dp10056
g7
I43
sg8
g48
sg10
I5
sg11
VPar-4
p10057
sg13
I1
sasg29
(lp10058
(dp10059
g7
I240
sg32
VC0021368
p10060
sg10
I12
sg11
Vinflammation
p10061
sg13
I1
sa(dp10062
g7
I75
sg32
VC0006826
p10063
sg10
I6
sg11
Vcancer
p10064
sg13
I1
sa(dp10065
g7
I66
sg32
VC0600139
p10066
sg10
I15
sg11
Vprostate cancer
p10067
sg13
I2
sasa(dp10068
g2
S'In lung tissue from pulmonary fibrosis patients with relatively normal lung function, lumican is present at low levels throughout the tissue, whereas patients with advanced disease have pronounced lumican expression in the fibrotic lesions.\n'
p10069
sg4
(lp10070
(dp10071
g7
I86
sg8
VP51884
p10072
sg10
I7
sg11
Vlumican
p10073
sg13
I1
sasg29
(lp10074
(dp10075
g7
I20
sg32
VC0034069
p10076
sg10
I18
sg11
Vpulmonary fibrosis
p10077
sg13
I2
sasa(dp10078
g2
S'Transcripts with increased expression included fibronectin, lumican, thrombospondin and collagen types I and VIII, each of which has been reported upregulated in pulmonary fibrosis.\n'
p10079
sg4
(lp10080
(dp10081
g7
I69
sg8
VP07996
p10082
sg10
I14
sg11
Vthrombospondin
p10083
sg13
I1
sa(dp10084
g7
I60
sg8
VP51884
p10085
sg10
I7
sg11
Vlumican
p10086
sg13
I1
sa(dp10087
g7
I88
sg8
VP10176
p10088
sg10
I25
sg11
Vcollagen types I and VIII
p10089
sg13
I5
sasg29
(lp10090
(dp10091
g7
I162
sg32
VC0034069
p10092
sg10
I18
sg11
Vpulmonary fibrosis
p10093
sg13
I2
sasa(dp10094
g2
S'Intent-to-treat analyses indicated that SEPA decreased positive urine samples for Chlamydia; improved condom use, decreased substance abuse and IPV; improved communication with partner, improved HIV-related knowledge, improved intentions to use condoms, decreased barriers to condom use, and increased community prevention attitudes.\n'
p10095
sg4
(lp10096
sg29
(lp10097
(dp10098
g7
I124
sg32
VC0740858
p10099
sg10
I15
sg11
Vsubstance abuse
p10100
sg13
I2
sa(dp10101
g7
I195
sg32
VC0019693
p10102
sg10
I3
sg11
VHIV
p10103
sg13
I1
sa(dp10104
g7
I144
sg32
VC0276240
p10105
sg10
I3
sg11
VIPV
p10106
sg13
I1
sasa(dp10107
g2
S'The results indicate that IL-6 expression is essential for angiotensin II-induced increases in retinal VEGF expression, leukostasis, and vascular remodeling.\n'
p10108
sg4
(lp10109
(dp10110
g7
I26
sg8
VP05231
p10111
sg10
I4
sg11
VIL-6
p10112
sg13
I1
sa(dp10113
g7
I95
sg8
VP55283
p10114
sg10
I12
sg11
Vretinal VEGF
p10115
sg13
I2
sa(dp10116
g7
I59
sg8
VP01019
p10117
sg10
I14
sg11
Vangiotensin II
p10118
sg13
I2
sasg29
(lp10119
(dp10120
g7
I120
sg32
VC0282548
p10121
sg10
I11
sg11
Vleukostasis
p10122
sg13
I1
sasa(dp10123
g2
S'Although high expression and prognostic value of TMEM45A has been recently reported in various types of human tumors, the association of TMEM45A expression and glioma is still unknown.\n'
p10124
sg4
(lp10125
(dp10126
g7
I49
sg8
g48
sg10
I7
sg11
VTMEM45A
p10127
sg13
I1
sa(dp10128
g7
I49
sg8
g48
sg10
I7
sg11
VTMEM45A
p10129
sg13
I1
sasg29
(lp10130
(dp10131
g7
I110
sg32
VC0027651
p10132
sg10
I6
sg11
Vtumors
p10133
sg13
I1
sa(dp10134
g7
I160
sg32
VC0017638
p10135
sg10
I6
sg11
Vglioma
p10136
sg13
I1
sasa(dp10137
g2
S'Here, we reported that TMEM45A was significantly overexpressed in glioma tissues compared to non-tumorous brain tissues.\n'
p10138
sg4
(lp10139
(dp10140
g7
I23
sg8
g48
sg10
I7
sg11
VTMEM45A
p10141
sg13
I1
sasg29
(lp10142
(dp10143
g7
I66
sg32
VC0017638
p10144
sg10
I6
sg11
Vglioma
p10145
sg13
I1
sasa(dp10146
g2
S'Furthermore, TMEM45A mRNA levels were gradually increased with the increasing severity of histological grade of glioma.\n'
p10147
sg4
(lp10148
(dp10149
g7
I13
sg8
g48
sg10
I12
sg11
VTMEM45A mRNA
p10150
sg13
I2
sasg29
(lp10151
(dp10152
g7
I112
sg32
VC0017638
p10153
sg10
I6
sg11
Vglioma
p10154
sg13
I1
sasa(dp10155
g2
S'Moreover, high TMEM45A expression level was correlated with short survival time of glioma patients.\n'
p10156
sg4
(lp10157
(dp10158
g7
I15
sg8
g48
sg10
I7
sg11
VTMEM45A
p10159
sg13
I1
sasg29
(lp10160
(dp10161
g7
I83
sg32
VC0017638
p10162
sg10
I6
sg11
Vglioma
p10163
sg13
I1
sasa(dp10164
g2
S'Down-regulation of TMEM45A in two glioma cell lines, U251 and U373 by transected with TMEM45A siRNA resulted in a significant reduction of cell proliferation and G1-phase arrest.\n'
p10165
sg4
(lp10166
(dp10167
g7
I86
sg8
g48
sg10
I13
sg11
VTMEM45A siRNA
p10168
sg13
I2
sa(dp10169
g7
I19
sg8
g48
sg10
I7
sg11
VTMEM45A
p10170
sg13
I1
sasg29
(lp10171
(dp10172
g7
I34
sg32
VC0017638
p10173
sg10
I6
sg11
Vglioma
p10174
sg13
I1
sa(dp10175
g7
I144
sg32
VC0334094
p10176
sg10
I13
sg11
Vproliferation
p10177
sg13
I1
sasa(dp10178
g2
S'Additionally, we found that suppressing of TMEM45A expression in glioma cells remarkably suppressed cell migration and cell invasion.\n'
p10179
sg4
(lp10180
(dp10181
g7
I43
sg8
g48
sg10
I7
sg11
VTMEM45A
p10182
sg13
I1
sasg29
(lp10183
(dp10184
g7
I119
sg32
VC2699153
p10185
sg10
I13
sg11
Vcell invasion
p10186
sg13
I2
sa(dp10187
g7
I65
sg32
VC0017638
p10188
sg10
I6
sg11
Vglioma
p10189
sg13
I1
sasa(dp10190
g2
S'More importantly, TMEM45A siRNA treatment significantly down-regulated the proteins promoting cell cycles transition (Cyclin D1, CDK4 and PCNA) and cell invasion (MMP-2 and MMP-9), which indicted a possible mechanism underlying its functions on glioma.\n'
p10191
sg4
(lp10192
(dp10193
g7
I138
sg8
VP12004
p10194
sg10
I4
sg11
VPCNA
p10195
sg13
I1
sa(dp10196
g7
I18
sg8
g48
sg10
I13
sg11
VTMEM45A siRNA
p10197
sg13
I2
sa(dp10198
g7
I118
sg8
VP24385
p10199
sg10
I9
sg11
VCyclin D1
p10200
sg13
I2
sa(dp10201
g7
I163
sg8
VP08253
p10202
sg10
I5
sg11
VMMP-2
p10203
sg13
I1
sa(dp10204
g7
I173
sg8
VP14780
p10205
sg10
I5
sg11
VMMP-9
p10206
sg13
I1
sa(dp10207
g7
I129
sg8
VP11802
p10208
sg10
I4
sg11
VCDK4
p10209
sg13
I1
sasg29
(lp10210
(dp10211
g7
I106
sg32
VC0599156
p10212
sg10
I10
sg11
Vtransition
p10213
sg13
I1
sa(dp10214
g7
I148
sg32
VC2699153
p10215
sg10
I13
sg11
Vcell invasion
p10216
sg13
I2
sa(dp10217
g7
I245
sg32
VC0017638
p10218
sg10
I6
sg11
Vglioma
p10219
sg13
I1
sasa(dp10220
g2
S'In summary, our study suggests that TMEM45A may work as an oncogene and a new effective therapeutic target for glioma treatment.\n'
p10221
sg4
(lp10222
(dp10223
g7
I36
sg8
g48
sg10
I7
sg11
VTMEM45A
p10224
sg13
I1
sasg29
(lp10225
(dp10226
g7
I111
sg32
VC0017638
p10227
sg10
I6
sg11
Vglioma
p10228
sg13
I1
sasa(dp10229
g2
S'The association of TMEM45A with various cancers has been recently reported.\n'
p10230
sg4
(lp10231
(dp10232
g7
I19
sg8
g48
sg10
I7
sg11
VTMEM45A
p10233
sg13
I1
sasg29
(lp10234
(dp10235
g7
I40
sg32
VC0006826
p10236
sg10
I7
sg11
Vcancers
p10237
sg13
I1
sasa(dp10238
g2
S'However, the biological function of TMEM45A in ovarian cancer remains unclear.\n'
p10239
sg4
(lp10240
(dp10241
g7
I36
sg8
g48
sg10
I7
sg11
VTMEM45A
p10242
sg13
I1
sasg29
(lp10243
(dp10244
g7
I47
sg32
VC1140680
p10245
sg10
I14
sg11
Vovarian cancer
p10246
sg13
I2
sasa(dp10247
g2
S'The present study aimed to elucidate the role of TMEM45A in regulating the biological behavior of ovarian cancer cells.\n'
p10248
sg4
(lp10249
(dp10250
g7
I49
sg8
g48
sg10
I7
sg11
VTMEM45A
p10251
sg13
I1
sasg29
(lp10252
(dp10253
g7
I98
sg32
VC1140680
p10254
sg10
I14
sg11
Vovarian cancer
p10255
sg13
I2
sasa(dp10256
g2
S'We compared the expression of TMEM45A between ovarian cancer tissues and normal tissues based on RNA-sequencing data of the ovarian cancer cohort from The Cancer Genome Atlas (TCGA) project and our real-time PCR data from 25 pairs of ovarian cancer and their matched non-cancerous tissue samples.\n'
p10257
sg4
(lp10258
(dp10259
g7
I30
sg8
g48
sg10
I7
sg11
VTMEM45A
p10260
sg13
I1
sasg29
(lp10261
(dp10262
g7
I155
sg32
VC0006826
p10263
sg10
I6
sg11
VCancer
p10264
sg13
I1
sa(dp10265
g7
I46
sg32
VC1140680
p10266
sg10
I14
sg11
Vovarian cancer
p10267
sg13
I2
sa(dp10268
g7
I46
sg32
VC1140680
p10269
sg10
I14
sg11
Vovarian cancer
p10270
sg13
I2
sa(dp10271
g7
I46
sg32
VC1140680
p10272
sg10
I14
sg11
Vovarian cancer
p10273
sg13
I2
sasa(dp10274
g2
S'The expression of TMEM45A was then suppressed in two ovarian cancer cell lines, HO-8910 and A2780, by RNA interference.\n'
p10275
sg4
(lp10276
(dp10277
g7
I18
sg8
g48
sg10
I7
sg11
VTMEM45A
p10278
sg13
I1
sasg29
(lp10279
(dp10280
g7
I53
sg32
VC1140680
p10281
sg10
I14
sg11
Vovarian cancer
p10282
sg13
I2
sasa(dp10283
g2
S'TCGA data and our real-time PCR results demonstrated the overexpression of TMEM45A in ovarian cancer.\n'
p10284
sg4
(lp10285
(dp10286
g7
I75
sg8
g48
sg10
I7
sg11
VTMEM45A
p10287
sg13
I1
sasg29
(lp10288
(dp10289
g7
I86
sg32
VC1140680
p10290
sg10
I14
sg11
Vovarian cancer
p10291
sg13
I2
sasa(dp10292
g2
S'In conclusion, TMEM45A may function as an oncogene for ovarian cancer, and inhibition of TMEM45A may be a therapeutic strategy for ovarian cancer.\n'
p10293
sg4
(lp10294
(dp10295
g7
I15
sg8
g48
sg10
I7
sg11
VTMEM45A
p10296
sg13
I1
sa(dp10297
g7
I15
sg8
g48
sg10
I7
sg11
VTMEM45A
p10298
sg13
I1
sasg29
(lp10299
(dp10300
g7
I55
sg32
VC1140680
p10301
sg10
I14
sg11
Vovarian cancer
p10302
sg13
I2
sa(dp10303
g7
I55
sg32
VC1140680
p10304
sg10
I14
sg11
Vovarian cancer
p10305
sg13
I2
sasa(dp10306
g2
S'We report that a 14-amino acid peptide derived from transmembrane protein 45A shows multimodal inhibition of lymphangiogenesis and angiogenesis in breast cancer.\n'
p10307
sg4
(lp10308
(dp10309
g7
I17
sg8
g48
sg10
I60
sg11
V14-amino acid peptide derived from transmembrane protein 45A
p10310
sg13
I8
sasg29
(lp10311
(dp10312
g7
I147
sg32
VC0678222
p10313
sg10
I13
sg11
Vbreast cancer
p10314
sg13
I2
sasa(dp10315
g2
S'TMEM45A expression was increased both in MDA-MB-231 human breast cancer cells and in HepG2 human hepatoma cells in conditions where protection of cells against apoptosis induced by chemotherapeutic agents was observed, i.e.\n'
p10316
sg4
(lp10317
(dp10318
g7
I0
sg8
g48
sg10
I7
sg11
VTMEM45A
p10319
sg13
I1
sasg29
(lp10320
(dp10321
g7
I58
sg32
VC0678222
p10322
sg10
I13
sg11
Vbreast cancer
p10323
sg13
I2
sa(dp10324
g7
I97
sg32
VC0023903
p10325
sg10
I8
sg11
Vhepatoma
p10326
sg13
I1
sasa(dp10327
g2
S'Kaplan Meier curve showed an association between high TMEM45A expression and poor prognostic in breast cancer patients.\n'
p10328
sg4
(lp10329
(dp10330
g7
I54
sg8
g48
sg10
I7
sg11
VTMEM45A
p10331
sg13
I1
sasg29
(lp10332
(dp10333
g7
I96
sg32
VC0678222
p10334
sg10
I13
sg11
Vbreast cancer
p10335
sg13
I2
sasa(dp10336
g2
S'High levels of TMEM45A expression in tumors may be indicative of potential resistance to cancer therapy, making TMEM45A an interesting biomarker for resistance.\n'
p10337
sg4
(lp10338
(dp10339
g7
I15
sg8
g48
sg10
I7
sg11
VTMEM45A
p10340
sg13
I1
sa(dp10341
g7
I15
sg8
g48
sg10
I7
sg11
VTMEM45A
p10342
sg13
I1
sasg29
(lp10343
(dp10344
g7
I89
sg32
VC0006826
p10345
sg10
I6
sg11
Vcancer
p10346
sg13
I1
sa(dp10347
g7
I37
sg32
VC0027651
p10348
sg10
I6
sg11
Vtumors
p10349
sg13
I1
sasa(dp10350
g2
S'Progression of xenografts to invasive breast cancer was dramatically increased by suppressing four genes that were usually elevated in clinical samples of DCIS, including a protease inhibitor (CSTA) and genes involved in cell adhesion and signaling (FAT1, DST, and TMEM45A), strongly suggesting that they normally function to suppress progression.\n'
p10351
sg4
(lp10352
(dp10353
g7
I173
sg8
g48
sg10
I18
sg11
Vprotease inhibitor
p10354
sg13
I2
sa(dp10355
g7
I265
sg8
g48
sg10
I7
sg11
VTMEM45A
p10356
sg13
I1
sa(dp10357
g7
I193
sg8
VP01040
p10358
sg10
I4
sg11
VCSTA
p10359
sg13
I1
sa(dp10360
g7
I250
sg8
g48
sg10
I4
sg11
VFAT1
p10361
sg13
I1
sasg29
(lp10362
(dp10363
g7
I29
sg32
VC0853879
p10364
sg10
I22
sg11
Vinvasive breast cancer
p10365
sg13
I3
sa(dp10366
g7
I155
sg32
VC0007124
p10367
sg10
I4
sg11
VDCIS
p10368
sg13
I1
sa(dp10369
g7
I226
sg32
VC0001511
p10370
sg10
I8
sg11
Vadhesion
p10371
sg13
I1
sasa(dp10372
g2
S'Here, we report that a previously unidentified target of miR-93, neural precursor cell expressed developmentally downregulated gene 4-like (NEDD4L), is able to mediate TGF-Beta-mediated EMT in lung cancer cells.\n'
p10373
sg4
(lp10374
(dp10375
g7
I168
sg8
VP18075
p10376
sg10
I8
sg11
VTGF-Beta
p10377
sg13
I1
sa(dp10378
g7
I57
sg8
g48
sg10
I6
sg11
VmiR-93
p10379
sg13
I1
sasg29
(lp10380
(dp10381
g7
I193
sg32
VC0684249
p10382
sg10
I11
sg11
Vlung cancer
p10383
sg13
I2
sasa(dp10384
g2
S'We next demonstrated that the downregulation of NEDD4L enhanced, while overexpression of NEDD4L reduced TGF-Beta signaling, reflected by increased phosphorylation of SMAD2 in the lung cancer cell line after TGF-Beta treatment.\n'
p10385
sg4
(lp10386
(dp10387
g7
I104
sg8
VP18075
p10388
sg10
I8
sg11
VTGF-Beta
p10389
sg13
I1
sa(dp10390
g7
I104
sg8
VP18075
p10391
sg10
I8
sg11
VTGF-Beta
p10392
sg13
I1
sa(dp10393
g7
I166
sg8
g48
sg10
I5
sg11
VSMAD2
p10394
sg13
I1
sasg29
(lp10395
(dp10396
g7
I179
sg32
VC0684249
p10397
sg10
I11
sg11
Vlung cancer
p10398
sg13
I2
sasa(dp10399
g2
S'Furthermore, overexpression of miR-93 in lung cancer cells promoted TGF-Beta-induced EMT through downregulation of NEDD4L.\n'
p10400
sg4
(lp10401
(dp10402
g7
I31
sg8
g48
sg10
I6
sg11
VmiR-93
p10403
sg13
I1
sa(dp10404
g7
I68
sg8
VP18075
p10405
sg10
I8
sg11
VTGF-Beta
p10406
sg13
I1
sasg29
(lp10407
(dp10408
g7
I41
sg32
VC0684249
p10409
sg10
I11
sg11
Vlung cancer
p10410
sg13
I2
sasa(dp10411
g2
S'The analysis of publicly available gene expression array datasets indicates that low NEDD4L expression correlates with poor outcomes among patients with lung cancer, further supporting the oncogenic role of miR-93 in lung tumorigenesis and metastasis.\n'
p10412
sg4
(lp10413
(dp10414
g7
I207
sg8
g48
sg10
I6
sg11
VmiR-93
p10415
sg13
I1
sasg29
(lp10416
(dp10417
g7
I153
sg32
VC0684249
p10418
sg10
I11
sg11
Vlung cancer
p10419
sg13
I2
sa(dp10420
g7
I240
sg32
VC0027627
p10421
sg10
I10
sg11
Vmetastasis
p10422
sg13
I1
sa(dp10423
g7
I222
sg32
VC0007621
p10424
sg10
I13
sg11
Vtumorigenesis
p10425
sg13
I1
sasa(dp10426
g2
S'Recent studies have demonstrated that the neural precursor cell expressed, developmentally downregulated 4-like (Nedd4L) gene plays a role in the progression of various cancers.\n'
p10427
sg4
(lp10428
sg29
(lp10429
(dp10430
g7
I169
sg32
VC0006826
p10431
sg10
I7
sg11
Vcancers
p10432
sg13
I1
sasa(dp10433
g2
S'However, reports describing Nedd4L expression in ovarian cancer tissues are limited.\n'
p10434
sg4
(lp10435
sg29
(lp10436
(dp10437
g7
I49
sg32
VC1140680
p10438
sg10
I14
sg11
Vovarian cancer
p10439
sg13
I2
sasa(dp10440
g2
S'A cohort (n = 117) of archival formalin-fixed, paraffin embedded resected normal ovarian epithelial tissues (n = 10), benign ovarian epithelial tumor tissues (n = 10), serous borderline ovarian epithelial tumor tissues (n = 14), mucous borderline ovarian epithelial tumor tissues (n = 11), and invasive ovarian epithelial cancer tissues (n = 72) were assessed for Nedd4L protein expression using immunohistochemistry.\n'
p10441
sg4
(lp10442
sg29
(lp10443
(dp10444
g7
I125
sg32
VC0341823
p10445
sg10
I24
sg11
Vovarian epithelial tumor
p10446
sg13
I3
sa(dp10447
g7
I125
sg32
VC0341823
p10448
sg10
I24
sg11
Vovarian epithelial tumor
p10449
sg13
I3
sa(dp10450
g7
I125
sg32
VC0341823
p10451
sg10
I24
sg11
Vovarian epithelial tumor
p10452
sg13
I3
sa(dp10453
g7
I303
sg32
VC0677886
p10454
sg10
I25
sg11
Vovarian epithelial cancer
p10455
sg13
I3
sasa(dp10456
g2
S'Nedd4L protein expression was significantly decreased in invasive ovarian epithelial cancer tissues compared to non-cancer tissues (P &lt; 0.05).\n'
p10457
sg4
(lp10458
sg29
(lp10459
(dp10460
g7
I66
sg32
VC0677886
p10461
sg10
I25
sg11
Vovarian epithelial cancer
p10462
sg13
I3
sa(dp10463
g7
I85
sg32
VC0006826
p10464
sg10
I6
sg11
Vcancer
p10465
sg13
I1
sasa(dp10466
g2
S'Nedd4L protein expression may be an independent prognostic marker of ovarian cancer development.\n'
p10467
sg4
(lp10468
sg29
(lp10469
(dp10470
g7
I69
sg32
VC1140680
p10471
sg10
I14
sg11
Vovarian cancer
p10472
sg13
I2
sasa(dp10473
g2
S'Given that NEDD4L plays an important role in constraining transforming growth factor Beta signaling by targeting activated Smad2/Smad3 for degradation, we investigated the role of DDB2 in the regulation of TGF-Beta signaling in ovarian cancer cells.\n'
p10474
sg4
(lp10475
(dp10476
g7
I180
sg8
g48
sg10
I4
sg11
VDDB2
p10477
sg13
I1
sa(dp10478
g7
I123
sg8
g48
sg10
I5
sg11
VSmad2
p10479
sg13
I1
sa(dp10480
g7
I206
sg8
VP18075
p10481
sg10
I8
sg11
VTGF-Beta
p10482
sg13
I1
sa(dp10483
g7
I58
sg8
VP18075
p10484
sg10
I31
sg11
Vtransforming growth factor Beta
p10485
sg13
I4
sasg29
(lp10486
(dp10487
g7
I228
sg32
VC1140680
p10488
sg10
I14
sg11
Vovarian cancer
p10489
sg13
I2
sasa(dp10490
g2
S'The study has uncovered an unappreciated regulatory mode that hinges on the interaction between DDB2 and NEDD4L in human ovarian cancer cells.\n'
p10491
sg4
(lp10492
(dp10493
g7
I96
sg8
g48
sg10
I4
sg11
VDDB2
p10494
sg13
I1
sasg29
(lp10495
(dp10496
g7
I121
sg32
VC1140680
p10497
sg10
I14
sg11
Vovarian cancer
p10498
sg13
I2
sasa(dp10499
g2
S'CD56(bright)CD16(-) NK cells isolated from the synovial fluid of juvenile idiopathic arthritis patients failed to inhibit autologous CD4(+) T cell proliferation.\n'
p10500
sg4
(lp10501
(dp10502
g7
I0
sg8
g48
sg10
I16
sg11
VCD56(bright)CD16
p10503
sg13
I1
sa(dp10504
g7
I133
sg8
VP01730
p10505
sg10
I3
sg11
VCD4
p10506
sg13
I1
sasg29
(lp10507
(dp10508
g7
I147
sg32
VC0334094
p10509
sg10
I13
sg11
Vproliferation
p10510
sg13
I1
sa(dp10511
g7
I65
sg32
VC0553662
p10512
sg10
I29
sg11
Vjuvenile idiopathic arthritis
p10513
sg13
I3
sasa(dp10514
g2
S'The adenovirus E1A 243R oncoprotein targets TRRAP, a scaffold protein that assembles histone acetyltransferase (HAT) complexes, such as the NuA4/Tip60 complex which mediates transcriptional activity of the proto-oncogene MYC and helps determine the cancer cell phenotype.\n'
p10515
sg4
(lp10516
(dp10517
g7
I112
sg8
g48
sg10
I3
sg11
VHAT
p10518
sg13
I1
sa(dp10519
g7
I206
sg8
VP08581
p10520
sg10
I18
sg11
Vproto-oncogene MYC
p10521
sg13
I2
sa(dp10522
g7
I145
sg8
VP43631
p10523
sg10
I5
sg11
VTip60
p10524
sg13
I1
sa(dp10525
g7
I44
sg8
g48
sg10
I5
sg11
VTRRAP
p10526
sg13
I1
sa(dp10527
g7
I85
sg8
g48
sg10
I25
sg11
Vhistone acetyltransferase
p10528
sg13
I2
sasg29
(lp10529
(dp10530
g7
I249
sg32
VC0006826
p10531
sg10
I6
sg11
Vcancer
p10532
sg13
I1
sa(dp10533
g7
I4
sg32
VC0001486
p10534
sg10
I10
sg11
Vadenovirus
p10535
sg13
I1
sasa(dp10536
g2
S'This study was designed to assess the protein levels of transformation/transcription domain-associated protein (TRRAP) in invasive ductal breast carcinomas, and investigated the association between TRRAP and the clinicopathological features of breast cancer.\n'
p10537
sg4
(lp10538
(dp10539
g7
I112
sg8
g48
sg10
I5
sg11
VTRRAP
p10540
sg13
I1
sa(dp10541
g7
I112
sg8
g48
sg10
I5
sg11
VTRRAP
p10542
sg13
I1
sa(dp10543
g7
I56
sg8
g48
sg10
I54
sg11
Vtransformation/transcription domain-associated protein
p10544
sg13
I3
sasg29
(lp10545
(dp10546
g7
I138
sg32
VC0678222
p10547
sg10
I17
sg11
Vbreast carcinomas
p10548
sg13
I2
sa(dp10549
g7
I56
sg32
VC1510411
p10550
sg10
I14
sg11
Vtransformation
p10551
sg13
I1
sa(dp10552
g7
I244
sg32
VC0678222
p10553
sg10
I13
sg11
Vbreast cancer
p10554
sg13
I2
sasa(dp10555
g2
S'We examined TRRAP protein expression in 470 breast cancer tissues and normal breast tissues by tissue microarray to study the correlation between TRRAP expression and clinicopathological features.\n'
p10556
sg4
(lp10557
(dp10558
g7
I12
sg8
g48
sg10
I5
sg11
VTRRAP
p10559
sg13
I1
sa(dp10560
g7
I12
sg8
g48
sg10
I13
sg11
VTRRAP protein
p10561
sg13
I2
sasg29
(lp10562
(dp10563
g7
I44
sg32
VC0678222
p10564
sg10
I13
sg11
Vbreast cancer
p10565
sg13
I2
sasa(dp10566
g2
S'The data demonstrated that expression of TRRAP was significantly lower in breast carcinomas (36.6%) than in corresponding normal breast tissues (50.8%).\n'
p10567
sg4
(lp10568
(dp10569
g7
I41
sg8
g48
sg10
I5
sg11
VTRRAP
p10570
sg13
I1
sasg29
(lp10571
(dp10572
g7
I74
sg32
VC0678222
p10573
sg10
I17
sg11
Vbreast carcinomas
p10574
sg13
I2
sasa(dp10575
g2
S'Univariate analyses identified TRRAP and progesterone receptor as independent protective factors for breast cancer prognosis.\n'
p10576
sg4
(lp10577
(dp10578
g7
I41
sg8
VP06401
p10579
sg10
I21
sg11
Vprogesterone receptor
p10580
sg13
I2
sa(dp10581
g7
I31
sg8
g48
sg10
I5
sg11
VTRRAP
p10582
sg13
I1
sasg29
(lp10583
(dp10584
g7
I101
sg32
VC0678222
p10585
sg10
I13
sg11
Vbreast cancer
p10586
sg13
I2
sasa(dp10587
g2
S'The findings indicate a significant correlation between TRRAP protein levels and adverse prognosis in breast cancer.\n'
p10588
sg4
(lp10589
(dp10590
g7
I56
sg8
g48
sg10
I13
sg11
VTRRAP protein
p10591
sg13
I2
sasg29
(lp10592
(dp10593
g7
I102
sg32
VC0678222
p10594
sg10
I13
sg11
Vbreast cancer
p10595
sg13
I2
sasa(dp10596
g2
S'Therefore, TRRAP could be a prognostic biomarker for breast cancer.\n'
p10597
sg4
(lp10598
(dp10599
g7
I11
sg8
g48
sg10
I5
sg11
VTRRAP
p10600
sg13
I1
sasg29
(lp10601
(dp10602
g7
I53
sg32
VC0678222
p10603
sg10
I13
sg11
Vbreast cancer
p10604
sg13
I2
sasa(dp10605
g2
S'In addition, TRRAP is also a predictive biomarker of breast cancer treatment.\n'
p10606
sg4
(lp10607
(dp10608
g7
I13
sg8
g48
sg10
I5
sg11
VTRRAP
p10609
sg13
I1
sasg29
(lp10610
(dp10611
g7
I53
sg32
VC0678222
p10612
sg10
I13
sg11
Vbreast cancer
p10613
sg13
I2
sasa(dp10614
g2
S'Down-regulation of CDK6 and Cyclin D1 in Tca8113 transfected with miR-9 mimics indicate that the complex formed by both proteins may be the effector of the antiproliferative function of miR-9 in OSCCs.\n'
p10615
sg4
(lp10616
(dp10617
g7
I28
sg8
VP24385
p10618
sg10
I9
sg11
VCyclin D1
p10619
sg13
I2
sa(dp10620
g7
I19
sg8
g48
sg10
I4
sg11
VCDK6
p10621
sg13
I1
sa(dp10622
g7
I66
sg8
g48
sg10
I5
sg11
VmiR-9
p10623
sg13
I1
sasg29
(lp10624
sa(dp10625
g2
S'Moreover, the silencing of GSK3Beta recapitulated the cellular and molecular effects in a similar manner to the overexpression of miR-99b-3p, which included inhibition of OSCC cell proliferation and suppression of p65 (RelA) and G1 regulators (cyclin D1, CDK4 and CDK6) in vitro.\n'
p10626
sg4
(lp10627
(dp10628
g7
I219
sg8
g48
sg10
I4
sg11
VRelA
p10629
sg13
I1
sa(dp10630
g7
I229
sg8
g48
sg10
I13
sg11
VG1 regulators
p10631
sg13
I2
sa(dp10632
g7
I264
sg8
g48
sg10
I4
sg11
VCDK6
p10633
sg13
I1
sa(dp10634
g7
I214
sg8
VP21579
p10635
sg10
I3
sg11
Vp65
p10636
sg13
I1
sa(dp10637
g7
I130
sg8
g48
sg10
I10
sg11
VmiR-99b-3p
p10638
sg13
I1
sa(dp10639
g7
I255
sg8
VP11802
p10640
sg10
I4
sg11
VCDK4
p10641
sg13
I1
sa(dp10642
g7
I244
sg8
VP24385
p10643
sg10
I9
sg11
Vcyclin D1
p10644
sg13
I2
sasg29
(lp10645
(dp10646
g7
I181
sg32
VC0334094
p10647
sg10
I13
sg11
Vproliferation
p10648
sg13
I1
sa(dp10649
g7
I199
sg32
VC0221103
p10650
sg10
I11
sg11
Vsuppression
p10651
sg13
I1
sasa(dp10652
g2
S'Our data suggest that miR-145 exerts its tumor suppressor function by targeting c-Myc and Cdk6, leading to the inhibition of OSCC cell growth.\n'
p10653
sg4
(lp10654
(dp10655
g7
I80
sg8
VP12524
p10656
sg10
I5
sg11
Vc-Myc
p10657
sg13
I1
sa(dp10658
g7
I22
sg8
g48
sg10
I7
sg11
VmiR-145
p10659
sg13
I1
sa(dp10660
g7
I90
sg8
g48
sg10
I4
sg11
VCdk6
p10661
sg13
I1
sasg29
(lp10662
(dp10663
g7
I41
sg32
VC0027651
p10664
sg10
I5
sg11
Vtumor
p10665
sg13
I1
sasa(dp10666
g2
S'Metformin treatment led to a remarkable decrease of cyclin D1, cyclin-dependent kinase (CDK) 4 and CDK6 protein levels and phosphorylation of retinoblastoma protein, but did not affect p21 or p27 protein expression in OSCC cells.\n'
p10667
sg4
(lp10668
(dp10669
g7
I192
sg8
VP40305
p10670
sg10
I11
sg11
Vp27 protein
p10671
sg13
I2
sa(dp10672
g7
I142
sg8
g48
sg10
I22
sg11
Vretinoblastoma protein
p10673
sg13
I2
sa(dp10674
g7
I185
sg8
VP42857
p10675
sg10
I3
sg11
Vp21
p10676
sg13
I1
sa(dp10677
g7
I99
sg8
g48
sg10
I12
sg11
VCDK6 protein
p10678
sg13
I2
sa(dp10679
g7
I63
sg8
VP49336
p10680
sg10
I31
sg11
Vcyclin-dependent kinase (CDK) 4
p10681
sg13
I4
sa(dp10682
g7
I52
sg8
VP24385
p10683
sg10
I9
sg11
Vcyclin D1
p10684
sg13
I2
sasg29
(lp10685
(dp10686
g7
I142
sg32
VC0035335
p10687
sg10
I14
sg11
Vretinoblastoma
p10688
sg13
I1
sasa(dp10689
g2
S'The pex1 and pex2 mutations responsible for the effect decrease the precise excision of Tn5 from R100.1 as well as from RP4 genomes.\n'
p10690
sg4
(lp10691
(dp10692
g7
I120
sg8
VP29973
p10693
sg10
I11
sg11
VRP4 genomes
p10694
sg13
I2
sa(dp10695
g7
I4
sg8
g48
sg10
I4
sg11
Vpex1
p10696
sg13
I1
sa(dp10697
g7
I13
sg8
VP28328
p10698
sg10
I4
sg11
Vpex2
p10699
sg13
I1
sasg29
(lp10700
(dp10701
g7
I120
sg32
VC3151001
p10702
sg10
I3
sg11
VRP4
p10703
sg13
I1
sasa(dp10704
g2
S'The drug had a pronounced clinical effect in virtually all forms of lichen planus, which may be due to suppression of the activity of TH1 cells producing inflammatory cytokines and an increase in the functional activity of TH2 cells producing antiinflammatory cytokines and to normalization of the functional activity of T lymphocytes, manifesting by a higher expression of early activation antigen CD69 involved in the production of IL-2.\n'
p10705
sg4
(lp10706
(dp10707
g7
I434
sg8
VP60568
p10708
sg10
I4
sg11
VIL-2
p10709
sg13
I1
sa(dp10710
g7
I374
sg8
g48
sg10
I29
sg11
Vearly activation antigen CD69
p10711
sg13
I4
sasg29
(lp10712
(dp10713
g7
I103
sg32
VC0221103
p10714
sg10
I11
sg11
Vsuppression
p10715
sg13
I1
sa(dp10716
g7
I68
sg32
VC0023646
p10717
sg10
I13
sg11
Vlichen planus
p10718
sg13
I2
sasa(dp10719
g2
S'Separation was achieved with a Waters Atlantis dC18 column (LC-MS) or a Waters SymmetryShield RP18 column connected with an Atlantis dC18 (LC-UV).\n'
p10720
sg4
(lp10721
(dp10722
g7
I47
sg8
g48
sg10
I4
sg11
VdC18
p10723
sg13
I1
sasg29
(lp10724
(dp10725
g7
I0
sg32
VC0036679
p10726
sg10
I10
sg11
VSeparation
p10727
sg13
I1
sa(dp10728
g7
I94
sg32
VC1832378
p10729
sg10
I4
sg11
VRP18
p10730
sg13
I1
sasa(dp10731
g2
S'Separation was achieved with a SymmetryShield RP18 column and an Atlantis dC18 column using a 10 mM potassium phosphate buffer as mobile phase.\n'
p10732
sg4
(lp10733
(dp10734
g7
I74
sg8
g48
sg10
I4
sg11
VdC18
p10735
sg13
I1
sasg29
(lp10736
(dp10737
g7
I46
sg32
VC1832378
p10738
sg10
I4
sg11
VRP18
p10739
sg13
I1
sa(dp10740
g7
I0
sg32
VC0036679
p10741
sg10
I10
sg11
VSeparation
p10742
sg13
I1
sasa(dp10743
g2
S'Analyses were performed on a sub-2-mym-particle-size RP-18 column with an acidified (0.02% acetic acid) 12 min water/acetonitrile solvent gradient.\n'
p10744
sg4
(lp10745
sg29
(lp10746
sa(dp10747
g2
S'A significant association was found between IL-34 expression and synovitis severity.\n'
p10748
sg4
(lp10749
sg29
(lp10750
(dp10751
g7
I65
sg32
VC0039103
p10752
sg10
I9
sg11
Vsynovitis
p10753
sg13
I1
sasa(dp10754
g2
S'A whole genome expression analysis of peripheral blood mononuclear cells yielded 12 protein-coding genes (ADM, APBB3, CD160, CFD, CITED2, CTSZ, IER5, NFKBIZ, NR4A2, NUCKS1, SERTAD1, TNF) that were differentially expressed between 29 unmedicated depressed patients with a mood disorder (8 bipolar disorder, 21 major depressive disorder) and 24 healthy controls (HCs).\n'
p10755
sg4
(lp10756
(dp10757
g7
I144
sg8
g48
sg10
I4
sg11
VIER5
p10758
sg13
I1
sa(dp10759
g7
I182
sg8
VP01375
p10760
sg10
I3
sg11
VTNF
p10761
sg13
I1
sa(dp10762
g7
I111
sg8
VP48436
p10763
sg10
I5
sg11
VAPBB3
p10764
sg13
I1
sa(dp10765
g7
I150
sg8
g48
sg10
I6
sg11
VNFKBIZ
p10766
sg13
I1
sa(dp10767
g7
I138
sg8
g48
sg10
I4
sg11
VCTSZ
p10768
sg13
I1
sa(dp10769
g7
I125
sg8
VP00746
p10770
sg10
I3
sg11
VCFD
p10771
sg13
I1
sa(dp10772
g7
I173
sg8
g48
sg10
I7
sg11
VSERTAD1
p10773
sg13
I1
sa(dp10774
g7
I158
sg8
VP43354
p10775
sg10
I5
sg11
VNR4A2
p10776
sg13
I1
sa(dp10777
g7
I106
sg8
VP35318
p10778
sg10
I3
sg11
VADM
p10779
sg13
I1
sa(dp10780
g7
I130
sg8
g48
sg10
I6
sg11
VCITED2
p10781
sg13
I1
sa(dp10782
g7
I165
sg8
g48
sg10
I6
sg11
VNUCKS1
p10783
sg13
I1
sa(dp10784
g7
I118
sg8
g48
sg10
I5
sg11
VCD160
p10785
sg13
I1
sasg29
(lp10786
(dp10787
g7
I125
sg32
VC1562113
p10788
sg10
I3
sg11
VCFD
p10789
sg13
I1
sa(dp10790
g7
I288
sg32
VC0005586
p10791
sg10
I16
sg11
Vbipolar disorder
p10792
sg13
I2
sa(dp10793
g7
I271
sg32
VC0525045
p10794
sg10
I13
sg11
Vmood disorder
p10795
sg13
I2
sa(dp10796
g7
I309
sg32
VC1269683
p10797
sg10
I25
sg11
Vmajor depressive disorder
p10798
sg13
I3
sasa(dp10799
g2
S'CELF1 levels peak in the heart during embryogenesis, and aberrant up-regulation of CELF1 in the adult heart has been implicated in cardiac pathogenesis in myotonic dystrophy type 1, as well as in diabetic cardiomyopathy.\n'
p10800
sg4
(lp10801
(dp10802
g7
I0
sg8
g48
sg10
I5
sg11
VCELF1
p10803
sg13
I1
sa(dp10804
g7
I155
sg8
g48
sg10
I25
sg11
Vmyotonic dystrophy type 1
p10805
sg13
I4
sa(dp10806
g7
I0
sg8
g48
sg10
I5
sg11
VCELF1
p10807
sg13
I1
sasg29
(lp10808
(dp10809
g7
I139
sg32
VC0699748
p10810
sg10
I12
sg11
Vpathogenesis
p10811
sg13
I1
sa(dp10812
g7
I196
sg32
VC0853897
p10813
sg10
I23
sg11
Vdiabetic cardiomyopathy
p10814
sg13
I2
sa(dp10815
g7
I155
sg32
VC0027126
p10816
sg10
I18
sg11
Vmyotonic dystrophy
p10817
sg13
I2
sasa(dp10818
g2
S'Either inhibition of CELF activity or over-expression of CELF1 in heart muscle causes cardiomyopathy in transgenic mice.\n'
p10819
sg4
(lp10820
(dp10821
g7
I57
sg8
g48
sg10
I5
sg11
VCELF1
p10822
sg13
I1
sa(dp10823
g7
I21
sg8
VP49716
p10824
sg10
I4
sg11
VCELF
p10825
sg13
I1
sasg29
(lp10826
(dp10827
g7
I86
sg32
VC0878544
p10828
sg10
I14
sg11
Vcardiomyopathy
p10829
sg13
I1
sasa(dp10830
g2
S'Repression of CELF-mediated splicing activity via expression of a nuclear dominant negative CELF protein in heart muscle was previously shown to induce dysregulation of alternative splicing, cardiac dysfunction, cardiac hypertrophy, and dilated cardiomyopathy in MHC-CELFDelta transgenic mice.\n'
p10831
sg4
(lp10832
(dp10833
g7
I14
sg8
VP49716
p10834
sg10
I4
sg11
VCELF
p10835
sg13
I1
sa(dp10836
g7
I263
sg8
VP13747
p10837
sg10
I13
sg11
VMHC-CELFDelta
p10838
sg13
I1
sasg29
(lp10839
(dp10840
g7
I237
sg32
VC0007193
p10841
sg10
I22
sg11
Vdilated cardiomyopathy
p10842
sg13
I2
sa(dp10843
g7
I212
sg32
VC1383860
p10844
sg10
I19
sg11
Vcardiac hypertrophy
p10845
sg13
I2
sa(dp10846
g7
I74
sg32
VC1512032
p10847
sg10
I17
sg11
Vdominant negative
p10848
sg13
I2
sasa(dp10849
g2
S'A "mild" line of MHC-CELFDelta mice that expresses a lower level of the dominant negative protein exhibits cardiac dysfunction and myopathy at a young age, but spontaneously recovers normal cardiac function and heart size with age despite the persistence of splicing defects.\n'
p10850
sg4
(lp10851
(dp10852
g7
I17
sg8
VP13747
p10853
sg10
I13
sg11
VMHC-CELFDelta
p10854
sg13
I1
sasg29
(lp10855
(dp10856
g7
I72
sg32
VC1512032
p10857
sg10
I17
sg11
Vdominant negative
p10858
sg13
I2
sa(dp10859
g7
I131
sg32
VC0026848
p10860
sg10
I8
sg11
Vmyopathy
p10861
sg13
I1
sasa(dp10862
g2
S'Using CCAAT/enhancer-binding protein Delta (C/EBPDelta) KO mice and C2C12 myotubes with knockdown of C/EBPDelta or myostatin, we determined that p-Stat3 initiates muscle wasting via C/EBPDelta, stimulating myostatin, a negative muscle growth regulator.\n'
p10863
sg4
(lp10864
(dp10865
g7
I44
sg8
g48
sg10
I10
sg11
VC/EBPDelta
p10866
sg13
I1
sa(dp10867
g7
I44
sg8
g48
sg10
I10
sg11
VC/EBPDelta
p10868
sg13
I1
sa(dp10869
g7
I145
sg8
VP40763
p10870
sg10
I7
sg11
Vp-Stat3
p10871
sg13
I1
sa(dp10872
g7
I115
sg8
g48
sg10
I9
sg11
Vmyostatin
p10873
sg13
I1
sa(dp10874
g7
I115
sg8
g48
sg10
I9
sg11
Vmyostatin
p10875
sg13
I1
sa(dp10876
g7
I6
sg8
g48
sg10
I36
sg11
VCCAAT/enhancer-binding protein Delta
p10877
sg13
I3
sa(dp10878
g7
I44
sg8
g48
sg10
I10
sg11
VC/EBPDelta
p10879
sg13
I1
sasg29
(lp10880
(dp10881
g7
I163
sg32
VC0026846
p10882
sg10
I14
sg11
Vmuscle wasting
p10883
sg13
I2
sasa(dp10884
g2
S'The pathway from p-Stat3 to C/EBPDelta to myostatin and muscle wasting could identify therapeutic targets that prevent muscle wasting.\n'
p10885
sg4
(lp10886
(dp10887
g7
I42
sg8
g48
sg10
I9
sg11
Vmyostatin
p10888
sg13
I1
sa(dp10889
g7
I17
sg8
VP40763
p10890
sg10
I7
sg11
Vp-Stat3
p10891
sg13
I1
sasg29
(lp10892
(dp10893
g7
I56
sg32
VC0026846
p10894
sg10
I14
sg11
Vmuscle wasting
p10895
sg13
I2
sa(dp10896
g7
I56
sg32
VC0026846
p10897
sg10
I14
sg11
Vmuscle wasting
p10898
sg13
I2
sasa(dp10899
g2
S'The indices of coagulometry and thromboelastography (THEG) were determined in 60 patients, suffering various forms of an acute cholecystitis.\n'
p10900
sg4
(lp10901
sg29
(lp10902
(dp10903
g7
I121
sg32
VC0149520
p10904
sg10
I19
sg11
Vacute cholecystitis
p10905
sg13
I2
sa(dp10906
g7
I91
sg32
VC0683278
p10907
sg10
I9
sg11
Vsuffering
p10908
sg13
I1
sasa(dp10909
g2
S"Additionally, sulforaphane reduced the expression of histone deacetylase1, 2, and 3, up-regulated p75 neurotrophin receptor, and increased levels of acetylated histone 3 lysine 9 and acetylated histone 4 lysine 12 in the cerebral cortex of Alzheimer's disease model mice as well as in ABeta-exposed SH-SY5Y cells.\n"
p10910
sg4
(lp10911
(dp10912
g7
I98
sg8
VP20333
p10913
sg10
I25
sg11
Vp75 neurotrophin receptor
p10914
sg13
I3
sa(dp10915
g7
I194
sg8
VP62805
p10916
sg10
I19
sg11
Vhistone 4 lysine 12
p10917
sg13
I4
sa(dp10918
g7
I53
sg8
VP62805
p10919
sg10
I20
sg11
Vhistone deacetylase1
p10920
sg13
I2
sa(dp10921
g7
I160
sg8
VP62805
p10922
sg10
I18
sg11
Vhistone 3 lysine 9
p10923
sg13
I4
sasg29
(lp10924
(dp10925
g7
I240
sg32
VC1521724
p10926
sg10
I19
sg11
VAlzheimer's disease
p10927
sg13
I2
sasa(dp10928
g2
S"In conclusion, this study demonstrates that sulforaphane can ameliorate neurobehavioral deficits and reduce the ABeta burden in Alzheimer's disease model mice, and the mechanism underlying these effects may be associated with up-regulation of p75 neurotrophin receptor mediated, apparently at least in part, via reducing the expression of histone deacetylase1 and 3.\n"
p10929
sg4
(lp10930
(dp10931
g7
I339
sg8
VP62805
p10932
sg10
I20
sg11
Vhistone deacetylase1
p10933
sg13
I2
sa(dp10934
g7
I243
sg8
VP20333
p10935
sg10
I25
sg11
Vp75 neurotrophin receptor
p10936
sg13
I3
sasg29
(lp10937
(dp10938
g7
I128
sg32
VC1521724
p10939
sg10
I19
sg11
VAlzheimer's disease
p10940
sg13
I2
sasa(dp10941
g2
S'We assessed the functions of AdipoR1 and AdipoR2 in endometrial cancer cells to determine whether the AMPK/ERK and Akt pathways mediate the effects of adiponectin-induced apoptosis and anti-proliferation.\n'
p10942
sg4
(lp10943
(dp10944
g7
I29
sg8
g48
sg10
I7
sg11
VAdipoR1
p10945
sg13
I1
sa(dp10946
g7
I102
sg8
VP54646
p10947
sg10
I4
sg11
VAMPK
p10948
sg13
I1
sa(dp10949
g7
I115
sg8
g48
sg10
I3
sg11
VAkt
p10950
sg13
I1
sa(dp10951
g7
I107
sg8
VP29323
p10952
sg10
I3
sg11
VERK
p10953
sg13
I1
sa(dp10954
g7
I41
sg8
g48
sg10
I7
sg11
VAdipoR2
p10955
sg13
I1
sa(dp10956
g7
I151
sg8
g48
sg10
I11
sg11
Vadiponectin
p10957
sg13
I1
sasg29
(lp10958
(dp10959
g7
I190
sg32
VC0334094
p10960
sg10
I13
sg11
Vproliferation
p10961
sg13
I1
sa(dp10962
g7
I52
sg32
VC0476089
p10963
sg10
I18
sg11
Vendometrial cancer
p10964
sg13
I2
sasa(dp10965
g2
S'To clarify the roles of adiponectin receptor (AdipoR) and leptin receptor (ObR) in endometrial carcinoma, the expression of AdipoR-1 and -2 and ObR in endometrial cancer was examined immunohistochemically, and correlations with clinicopathological implications were also analysed.\n'
p10966
sg4
(lp10967
(dp10968
g7
I58
sg8
VP48357
p10969
sg10
I15
sg11
Vleptin receptor
p10970
sg13
I2
sa(dp10971
g7
I46
sg8
g48
sg10
I6
sg11
VAdipoR
p10972
sg13
I1
sa(dp10973
g7
I46
sg8
g48
sg10
I6
sg11
VAdipoR
p10974
sg13
I1
sa(dp10975
g7
I75
sg8
VP48357
p10976
sg10
I3
sg11
VObR
p10977
sg13
I1
sa(dp10978
g7
I75
sg8
VP48357
p10979
sg10
I3
sg11
VObR
p10980
sg13
I1
sa(dp10981
g7
I24
sg8
g48
sg10
I20
sg11
Vadiponectin receptor
p10982
sg13
I2
sasg29
(lp10983
(dp10984
g7
I83
sg32
VC0476089
p10985
sg10
I21
sg11
Vendometrial carcinoma
p10986
sg13
I2
sa(dp10987
g7
I151
sg32
VC0476089
p10988
sg10
I18
sg11
Vendometrial cancer
p10989
sg13
I2
sasa(dp10990
g2
S'Paraffin-embedded tissues were obtained from 77 patients with endometrial carcinoma and were stained immunohistochemically using antibodies against AdipoR-1, AdipoR-2 and ObR.\n'
p10991
sg4
(lp10992
(dp10993
g7
I171
sg8
VP48357
p10994
sg10
I3
sg11
VObR
p10995
sg13
I1
sasg29
(lp10996
(dp10997
g7
I62
sg32
VC0476089
p10998
sg10
I21
sg11
Vendometrial carcinoma
p10999
sg13
I2
sasa(dp11000
g2
S'In 77 cases of endometrial cancer, positive expression was observed in 46 cases (59.7%) for AdipoR-1, 47 cases (61.0%) for AdipoR-2 and 33 cases (42.9%) for ObR.\n'
p11001
sg4
(lp11002
(dp11003
g7
I157
sg8
VP48357
p11004
sg10
I3
sg11
VObR
p11005
sg13
I1
sasg29
(lp11006
(dp11007
g7
I15
sg32
VC0476089
p11008
sg10
I18
sg11
Vendometrial cancer
p11009
sg13
I2
sasa(dp11010
g2
S'Poor expression of AdipoR-1, thus, appears to be associated with tumour grade, myometrial invasion, adnexal invasion, lymph-vascular space involvement and lymph node metastasis, as well as poor prognosis, in endometrial cancer.\n'
p11011
sg4
(lp11012
sg29
(lp11013
(dp11014
g7
I90
sg32
VC2699153
p11015
sg10
I8
sg11
Vinvasion
p11016
sg13
I1
sa(dp11017
g7
I208
sg32
VC0476089
p11018
sg10
I18
sg11
Vendometrial cancer
p11019
sg13
I2
sa(dp11020
g7
I155
sg32
VC0686619
p11021
sg10
I21
sg11
Vlymph node metastasis
p11022
sg13
I3
sa(dp11023
g7
I65
sg32
VC0027651
p11024
sg10
I6
sg11
Vtumour
p11025
sg13
I1
sa(dp11026
g7
I90
sg32
VC2699153
p11027
sg10
I8
sg11
Vinvasion
p11028
sg13
I1
sasa(dp11029
g2
S'In addition, the expression of adiponectin receptors (AdipoR1 and AdipoR2) has been documented in several human cancer tissues, but the expression has previously not been assessed in human endometrial cancer tissues.\n'
p11030
sg4
(lp11031
(dp11032
g7
I66
sg8
g48
sg10
I7
sg11
VAdipoR2
p11033
sg13
I1
sa(dp11034
g7
I31
sg8
g48
sg10
I21
sg11
Vadiponectin receptors
p11035
sg13
I2
sa(dp11036
g7
I54
sg8
g48
sg10
I7
sg11
VAdipoR1
p11037
sg13
I1
sasg29
(lp11038
(dp11039
g7
I112
sg32
VC0006826
p11040
sg10
I6
sg11
Vcancer
p11041
sg13
I1
sa(dp11042
g7
I189
sg32
VC0476089
p11043
sg10
I18
sg11
Vendometrial cancer
p11044
sg13
I2
sasa(dp11045
g2
S'Transcripts for Acrp30 receptors (AdipoR1             and AdipoR2) and leptin receptor (Ob-Rb) were detected by quantitative real-time             RT-PCR (qRT-PCR) in six endometrial cancer cell lines.\n'
p11046
sg4
(lp11047
(dp11048
g7
I16
sg8
g48
sg10
I16
sg11
VAcrp30 receptors
p11049
sg13
I2
sa(dp11050
g7
I34
sg8
g48
sg10
I7
sg11
VAdipoR1
p11051
sg13
I1
sa(dp11052
g7
I58
sg8
g48
sg10
I7
sg11
VAdipoR2
p11053
sg13
I1
sa(dp11054
g7
I71
sg8
VP48357
p11055
sg10
I15
sg11
Vleptin receptor
p11056
sg13
I2
sasg29
(lp11057
(dp11058
g7
I171
sg32
VC0476089
p11059
sg10
I18
sg11
Vendometrial cancer
p11060
sg13
I2
sasa(dp11061
g2
S'Little is known about whether single nucleotide polymorphisms (SNPs) in the genes that encode adiponectin (ADIPOQ), leptin (LEP), adiponectin receptor 1 (ADIPOR1), adiponectin receptor 2 (ADIPOR2), and leptin receptor (LEPR) are associated with endometrial cancer.\n'
p11062
sg4
(lp11063
(dp11064
g7
I219
sg8
VP48357
p11065
sg10
I4
sg11
VLEPR
p11066
sg13
I1
sa(dp11067
g7
I188
sg8
g48
sg10
I7
sg11
VADIPOR2
p11068
sg13
I1
sa(dp11069
g7
I164
sg8
g48
sg10
I22
sg11
Vadiponectin receptor 2
p11070
sg13
I3
sa(dp11071
g7
I130
sg8
g48
sg10
I22
sg11
Vadiponectin receptor 1
p11072
sg13
I3
sa(dp11073
g7
I116
sg8
VP41159
p11074
sg10
I6
sg11
Vleptin
p11075
sg13
I1
sa(dp11076
g7
I124
sg8
VP41159
p11077
sg10
I3
sg11
VLEP
p11078
sg13
I1
sa(dp11079
g7
I154
sg8
g48
sg10
I7
sg11
VADIPOR1
p11080
sg13
I1
sa(dp11081
g7
I94
sg8
g48
sg10
I20
sg11
Vadiponectin (ADIPOQ)
p11082
sg13
I2
sa(dp11083
g7
I202
sg8
VP48357
p11084
sg10
I15
sg11
Vleptin receptor
p11085
sg13
I2
sasg29
(lp11086
(dp11087
g7
I245
sg32
VC0476089
p11088
sg10
I18
sg11
Vendometrial cancer
p11089
sg13
I2
sasa(dp11090
g2
S'We first examined the expression of adiponectin receptor 1 (AdipoR1) and 2 (AdipoR2) in normal human endometrium and in endometrial cancer tissues ex vivo.\n'
p11091
sg4
(lp11092
(dp11093
g7
I60
sg8
g48
sg10
I7
sg11
VAdipoR1
p11094
sg13
I1
sa(dp11095
g7
I36
sg8
g48
sg10
I22
sg11
Vadiponectin receptor 1
p11096
sg13
I3
sasg29
(lp11097
(dp11098
g7
I120
sg32
VC0476089
p11099
sg10
I18
sg11
Vendometrial cancer
p11100
sg13
I2
sasa(dp11101
g2
S'We report for the first time that the relative expression level of AdipoR1 is higher than AdipoR2 in human endometrial cancer tissue, but the expression of AdipoRs is not statistically different from nonneoplastic tissues.\n'
p11102
sg4
(lp11103
(dp11104
g7
I90
sg8
g48
sg10
I7
sg11
VAdipoR2
p11105
sg13
I1
sa(dp11106
g7
I67
sg8
g48
sg10
I7
sg11
VAdipoR1
p11107
sg13
I1
sasg29
(lp11108
(dp11109
g7
I107
sg32
VC0476089
p11110
sg10
I18
sg11
Vendometrial cancer
p11111
sg13
I2
sasa(dp11112
g2
S'In the present study, we evaluated the role of FAM9C in human hepatocellular carcinoma.\n'
p11113
sg4
(lp11114
(dp11115
g7
I47
sg8
g48
sg10
I5
sg11
VFAM9C
p11116
sg13
I1
sasg29
(lp11117
(dp11118
g7
I62
sg32
VC1512411
p11119
sg10
I24
sg11
Vhepatocellular carcinoma
p11120
sg13
I2
sasa(dp11121
g2
S'Taken together, our data demonstrate that FAM9C as a novel cancer testis gene plays an anti-apoptotic role in human hepatocellular carcinoma through activating the PI3K/Akt signaling pathway, and serves as a promising target for HCC therapy.\n'
p11122
sg4
(lp11123
(dp11124
g7
I164
sg8
VP42336
p11125
sg10
I4
sg11
VPI3K
p11126
sg13
I1
sa(dp11127
g7
I169
sg8
g48
sg10
I3
sg11
VAkt
p11128
sg13
I1
sa(dp11129
g7
I42
sg8
g48
sg10
I5
sg11
VFAM9C
p11130
sg13
I1
sasg29
(lp11131
(dp11132
g7
I229
sg32
VC2239176
p11133
sg10
I3
sg11
VHCC
p11134
sg13
I1
sa(dp11135
g7
I116
sg32
VC2239176
p11136
sg10
I24
sg11
Vhepatocellular carcinoma
p11137
sg13
I2
sa(dp11138
g7
I59
sg32
VC0153594
p11139
sg10
I13
sg11
Vcancer testis
p11140
sg13
I2
sasa(dp11141
g2
S'Using cell-based assays with recombinant full-length, conformationally intact MOG, several recent studies have revealed that MOG Abs can be found in a subset of predominantly pediatric patients with acute disseminated encephalomyelitis (ADEM), aquaporin-4 (AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD), monophasic or recurrent isolated optic neuritis (ON), or transverse myelitis, in atypical MS and in N-methyl-d-aspartate receptor-encephalitis with overlapping demyelinating syndromes.\n'
p11142
sg4
(lp11143
(dp11144
g7
I257
sg8
VP55087
p11145
sg10
I4
sg11
VAQP4
p11146
sg13
I1
sa(dp11147
g7
I78
sg8
g48
sg10
I3
sg11
VMOG
p11148
sg13
I1
sa(dp11149
g7
I244
sg8
VP55087
p11150
sg10
I11
sg11
Vaquaporin-4
p11151
sg13
I1
sa(dp11152
g7
I125
sg8
g48
sg10
I7
sg11
VMOG Abs
p11153
sg13
I2
sasg29
(lp11154
(dp11155
g7
I237
sg32
VC0014059
p11156
sg10
I4
sg11
VADEM
p11157
sg13
I1
sa(dp11158
g7
I358
sg32
VC0029134
p11159
sg10
I14
sg11
Voptic neuritis
p11160
sg13
I2
sa(dp11161
g7
I374
sg32
VC0029134
p11162
sg10
I2
sg11
VON
p11163
sg13
I1
sa(dp11164
g7
I276
sg32
VC0027873
p11165
sg10
I20
sg11
Vneuromyelitis optica
p11166
sg13
I2
sa(dp11167
g7
I382
sg32
VC0026976
p11168
sg10
I19
sg11
Vtransverse myelitis
p11169
sg13
I2
sa(dp11170
g7
I499
sg32
VC0039082
p11171
sg10
I9
sg11
Vsyndromes
p11172
sg13
I1
sa(dp11173
g7
I199
sg32
VC0014059
p11174
sg10
I36
sg11
Vacute disseminated encephalomyelitis
p11175
sg13
I3
sa(dp11176
g7
I455
sg32
VC0014038
p11177
sg10
I12
sg11
Vencephalitis
p11178
sg13
I1
sasa(dp11179
g2
S'During vitrectomy, the ABs were observed to be concentrated in the anterior vitreous cavity, and a complete posterior vitreous detachment (PVD) was present.\n'
p11180
sg4
(lp11181
sg29
(lp11182
(dp11183
g7
I139
sg32
VC0085096
p11184
sg10
I3
sg11
VPVD
p11185
sg13
I1
sa(dp11186
g7
I108
sg32
VC0423361
p11187
sg10
I29
sg11
Vposterior vitreous detachment
p11188
sg13
I3
sa(dp11189
g7
I85
sg32
VC0011334
p11190
sg10
I6
sg11
Vcavity
p11191
sg13
I1
sasa(dp11192
g2
S'New criteria for the diagnosis of multiple sclerosis (MS) and discovery of myelin oligodendrocyte glycoprotein (MOG) or aquaporin-4 (AQP4) antibodies (Abs) have changed the management of optic neuritis (ON).\n'
p11193
sg4
(lp11194
(dp11195
g7
I75
sg8
VP23515
p11196
sg10
I41
sg11
Vmyelin oligodendrocyte glycoprotein (MOG)
p11197
sg13
I4
sa(dp11198
g7
I120
sg8
VP55087
p11199
sg10
I11
sg11
Vaquaporin-4
p11200
sg13
I1
sa(dp11201
g7
I133
sg8
VP55087
p11202
sg10
I4
sg11
VAQP4
p11203
sg13
I1
sasg29
(lp11204
(dp11205
g7
I203
sg32
VC0029134
p11206
sg10
I2
sg11
VON
p11207
sg13
I1
sa(dp11208
g7
I34
sg32
VC0026769
p11209
sg10
I18
sg11
Vmultiple sclerosis
p11210
sg13
I2
sa(dp11211
g7
I187
sg32
VC0029134
p11212
sg10
I14
sg11
Voptic neuritis
p11213
sg13
I2
sa(dp11214
g7
I54
sg32
VC0026769
p11215
sg10
I2
sg11
VMS
p11216
sg13
I1
sasa(dp11217
g2
S'However, optic neuritis associated with MOG-Abs has not been elucidated using new methods such as cell-based assay.\n'
p11218
sg4
(lp11219
(dp11220
g7
I40
sg8
g48
sg10
I7
sg11
VMOG-Abs
p11221
sg13
I1
sasg29
(lp11222
(dp11223
g7
I9
sg32
VC0029134
p11224
sg10
I14
sg11
Voptic neuritis
p11225
sg13
I2
sasa(dp11226
g2
S'Serum samples from 70 patients (17 males and 53 females, mean age 43.1 years) with optic neuritis were tested for MOG-Abs by cell-based assay.\n'
p11227
sg4
(lp11228
(dp11229
g7
I114
sg8
g48
sg10
I7
sg11
VMOG-Abs
p11230
sg13
I1
sasg29
(lp11231
(dp11232
g7
I83
sg32
VC0029134
p11233
sg10
I14
sg11
Voptic neuritis
p11234
sg13
I2
sasa(dp11235
g2
S'MOG-Abs may contribute to the heterogeneous clinical picture of optic neuritis, and although visual acuity outcome is favourable, there is a tendency of residual visual field deficit and a possibility of repeated relapses.\n'
p11236
sg4
(lp11237
(dp11238
g7
I0
sg8
g48
sg10
I7
sg11
VMOG-Abs
p11239
sg13
I1
sasg29
(lp11240
(dp11241
g7
I175
sg32
VC0162429
p11242
sg10
I7
sg11
Vdeficit
p11243
sg13
I1
sa(dp11244
g7
I64
sg32
VC0029134
p11245
sg10
I14
sg11
Voptic neuritis
p11246
sg13
I2
sasa(dp11247
g2
S'IgG1-Abs to FL-MOG were associated with optic neuritis (n = 11), AQP4-seronegative neuromyelitis optica spectrum disorder (n = 4), and acute disseminated encephalomyelitis (n = 1).\n'
p11248
sg4
(lp11249
(dp11250
g7
I65
sg8
VP55087
p11251
sg10
I4
sg11
VAQP4
p11252
sg13
I1
sa(dp11253
g7
I0
sg8
VP01857
p11254
sg10
I8
sg11
VIgG1-Abs
p11255
sg13
I1
sa(dp11256
g7
I12
sg8
g48
sg10
I6
sg11
VFL-MOG
p11257
sg13
I1
sasg29
(lp11258
(dp11259
g7
I135
sg32
VC0014059
p11260
sg10
I36
sg11
Vacute disseminated encephalomyelitis
p11261
sg13
I3
sa(dp11262
g7
I40
sg32
VC0029134
p11263
sg10
I14
sg11
Voptic neuritis
p11264
sg13
I2
sa(dp11265
g7
I83
sg32
VC0027873
p11266
sg10
I20
sg11
Vneuromyelitis optica
p11267
sg13
I2
sasa(dp11268
g2
S'Significant increase of both the expression level and DNA binding activity of NF-KB /P65 subunit together with serum HIF-1 alpha levels was noted in HCC patients compared to liver cirrhosis and control subjects, with significant positive correlation with parameters for bad prognosis of HCC.\n'
p11269
sg4
(lp11270
(dp11271
g7
I117
sg8
g48
sg10
I11
sg11
VHIF-1 alpha
p11272
sg13
I2
sa(dp11273
g7
I85
sg8
VP21579
p11274
sg10
I3
sg11
VP65
p11275
sg13
I1
sasg29
(lp11276
(dp11277
g7
I149
sg32
VC2239176
p11278
sg10
I3
sg11
VHCC
p11279
sg13
I1
sa(dp11280
g7
I149
sg32
VC2239176
p11281
sg10
I3
sg11
VHCC
p11282
sg13
I1
sa(dp11283
g7
I174
sg32
VC0023890
p11284
sg10
I15
sg11
Vliver cirrhosis
p11285
sg13
I2
sasa(dp11286
g2
S'This outcome suggests that serum miR-21 and miR-106a expression level was closely related with kidney cancer tissue.\n'
p11287
sg4
(lp11288
(dp11289
g7
I44
sg8
g48
sg10
I8
sg11
VmiR-106a
p11290
sg13
I1
sasg29
(lp11291
(dp11292
g7
I95
sg32
VC0740457
p11293
sg10
I13
sg11
Vkidney cancer
p11294
sg13
I2
sasa(dp11295
g2
S'Overexpression of tissue factor (TF) has been associated with increased tumor growth, tumor angiogenesis, and metastatic potential in many malignancies, including pancreatic cancer.\n'
p11296
sg4
(lp11297
(dp11298
g7
I18
sg8
VP13726
p11299
sg10
I18
sg11
Vtissue factor (TF)
p11300
sg13
I3
sasg29
(lp11301
(dp11302
g7
I139
sg32
VC0006826
p11303
sg10
I12
sg11
Vmalignancies
p11304
sg13
I1
sa(dp11305
g7
I86
sg32
VC1519670
p11306
sg10
I18
sg11
Vtumor angiogenesis
p11307
sg13
I2
sa(dp11308
g7
I163
sg32
VC0235974
p11309
sg10
I17
sg11
Vpancreatic cancer
p11310
sg13
I2
sa(dp11311
g7
I72
sg32
VC0598934
p11312
sg10
I12
sg11
Vtumor growth
p11313
sg13
I2
sasa(dp11314
g2
S'To assess correlation of cytokines levels and therapy regimes a relationship of the time course of changes in the cytokines IFN-Gamma, IFN-Alfa, IL-18, and TNF-Alfa to the treatment option for influenza A (H1N1) pdm09 with umifenovir (Arbidol) 800 mg/day for 5 days (n=50); oseltamivir (Tamiflu) 150 mg/day for 5 days (n=50); umifenovir (Arbidol) 800 mg/day for 5 days in combination with Kagocel 72 mg/day for 2 days.\n'
p11315
sg4
(lp11316
(dp11317
g7
I193
sg8
g48
sg10
I24
sg11
Vinfluenza A (H1N1) pdm09
p11318
sg13
I4
sa(dp11319
g7
I135
sg8
VP01562
p11320
sg10
I8
sg11
VIFN-Alfa
p11321
sg13
I1
sa(dp11322
g7
I156
sg8
VP01375
p11323
sg10
I8
sg11
VTNF-Alfa
p11324
sg13
I1
sa(dp11325
g7
I114
sg8
VP01579
p11326
sg10
I19
sg11
Vcytokines IFN-Gamma
p11327
sg13
I2
sasg29
(lp11328
(dp11329
g7
I193
sg32
VC0021400
p11330
sg10
I9
sg11
Vinfluenza
p11331
sg13
I1
sasa(dp11332
g2
S'The infection efficiency of H1N1 pdm2009 influenza virus in the HUVEC-C cells was subsequently examined, and the expression of MMP-9 and proinflammatory cytokines, including tumor necrosis factor (TNF)-Alfa, interleukin (IL)-1Beta and IL-6, were determined in the virus-infected HUVEC-C cells, with or without oxLDL treatment.\n'
p11333
sg4
(lp11334
(dp11335
g7
I174
sg8
VP01375
p11336
sg10
I32
sg11
Vtumor necrosis factor (TNF)-Alfa
p11337
sg13
I4
sa(dp11338
g7
I235
sg8
VP05231
p11339
sg10
I4
sg11
VIL-6
p11340
sg13
I1
sa(dp11341
g7
I127
sg8
VP14780
p11342
sg10
I5
sg11
VMMP-9
p11343
sg13
I1
sa(dp11344
g7
I208
sg8
VP60568
p11345
sg10
I22
sg11
Vinterleukin (IL)-1Beta
p11346
sg13
I2
sasg29
(lp11347
(dp11348
g7
I41
sg32
VC0021400
p11349
sg10
I9
sg11
Vinfluenza
p11350
sg13
I1
sa(dp11351
g7
I4
sg32
VC0009450
p11352
sg10
I9
sg11
Vinfection
p11353
sg13
I1
sa(dp11354
g7
I174
sg32
VC0333516
p11355
sg10
I14
sg11
Vtumor necrosis
p11356
sg13
I2
sasa(dp11357
g2
S'H1N1 pdm2009 influenza virus efficiently infected the HUVEC-C cells and significantly promoted the expression of MMP-9, TNF-Alfa, IL-1Beta and IL-6, synergistically with the oxLDL treatment.\n'
p11358
sg4
(lp11359
(dp11360
g7
I143
sg8
VP05231
p11361
sg10
I4
sg11
VIL-6
p11362
sg13
I1
sa(dp11363
g7
I120
sg8
VP01375
p11364
sg10
I8
sg11
VTNF-Alfa
p11365
sg13
I1
sa(dp11366
g7
I113
sg8
VP14780
p11367
sg10
I5
sg11
VMMP-9
p11368
sg13
I1
sa(dp11369
g7
I130
sg8
VP01584
p11370
sg10
I8
sg11
VIL-1Beta
p11371
sg13
I1
sasg29
(lp11372
(dp11373
g7
I13
sg32
VC0021400
p11374
sg10
I9
sg11
Vinfluenza
p11375
sg13
I1
sasa(dp11376
g2
S'In the present study, using immunohistochemical staining analysis, the expression of LAIR-1 in human cervical cancer (HCC) and nontumor-adjacent tissue specimens was determined, and the results indicated that the expression of LAIR-1 in HCC tissue was higher compared with that in noncancerous tissue.\n'
p11377
sg4
(lp11378
(dp11379
g7
I85
sg8
g48
sg10
I6
sg11
VLAIR-1
p11380
sg13
I1
sasg29
(lp11381
(dp11382
g7
I95
sg32
VC2239176
p11383
sg10
I21
sg11
Vhuman cervical cancer
p11384
sg13
I3
sa(dp11385
g7
I118
sg32
VC2239176
p11386
sg10
I3
sg11
VHCC
p11387
sg13
I1
sa(dp11388
g7
I118
sg32
VC2239176
p11389
sg10
I3
sg11
VHCC
p11390
sg13
I1
sasa(dp11391
g2
S'In this study, a tissue microarray containing 78 ovarian cancer cases was stained following a standard immunohistochemical protocol for LAIR-1 and the correlation of LAIR-1 expression with clinicopathologic features was assessed.\n'
p11392
sg4
(lp11393
sg29
(lp11394
(dp11395
g7
I49
sg32
VC1140680
p11396
sg10
I14
sg11
Vovarian cancer
p11397
sg13
I2
sasa(dp11398
g2
S'LAIR-1 was detected to express in tumor cells of ovarian cancer tissues (73.1%) and EOC cell lines COC1 and HO8910, not in normal ovarian tissues.\n'
p11399
sg4
(lp11400
sg29
(lp11401
(dp11402
g7
I34
sg32
VC0027651
p11403
sg10
I5
sg11
Vtumor
p11404
sg13
I1
sa(dp11405
g7
I49
sg32
VC1140680
p11406
sg10
I14
sg11
Vovarian cancer
p11407
sg13
I2
sasa(dp11408
g2
S'Previous studies have suggested debatable roles of Tax and HBZ gene expression in the pathogenesis of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).\n'
p11409
sg4
(lp11410
(dp11411
g7
I165
sg8
VP07996
p11412
sg10
I3
sg11
VTSP
p11413
sg13
I1
sa(dp11414
g7
I161
sg8
g48
sg10
I3
sg11
VHAM
p11415
sg13
I1
sa(dp11416
g7
I59
sg8
VP02008
p11417
sg10
I8
sg11
VHBZ gene
p11418
sg13
I2
sa(dp11419
g7
I51
sg8
g48
sg10
I3
sg11
VTax
p11420
sg13
I1
sasg29
(lp11421
(dp11422
g7
I102
sg32
VC0030481
p11423
sg10
I28
sg11
VHTLV-1-associated myelopathy
p11424
sg13
I2
sa(dp11425
g7
I131
sg32
VC0030481
p11426
sg10
I28
sg11
Vtropical spastic paraparesis
p11427
sg13
I3
sa(dp11428
g7
I86
sg32
VC0699748
p11429
sg10
I12
sg11
Vpathogenesis
p11430
sg13
I1
sa(dp11431
g7
I161
sg32
VC0030481
p11432
sg10
I3
sg11
VHAM
p11433
sg13
I1
sasa(dp11434
g2
S'Human T cell leukemia virus type 1 (HTLV-1) basic leucine zipper factor (HBZ), which is encoded by a minus strand mRNA, is thought to play important roles in the development of adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).\n'
p11435
sg4
(lp11436
(dp11437
g7
I73
sg8
VP02008
p11438
sg10
I3
sg11
VHBZ
p11439
sg13
I1
sa(dp11440
g7
I0
sg8
VP30740
p11441
sg10
I71
sg11
VHuman T cell leukemia virus type 1 (HTLV-1) basic leucine zipper factor
p11442
sg13
I12
sa(dp11443
g7
I268
sg8
g48
sg10
I3
sg11
VHAM
p11444
sg13
I1
sa(dp11445
g7
I272
sg8
VP07996
p11446
sg10
I3
sg11
VTSP
p11447
sg13
I1
sasg29
(lp11448
(dp11449
g7
I268
sg32
VC0030481
p11450
sg10
I3
sg11
VHAM
p11451
sg13
I1
sa(dp11452
g7
I209
sg32
VC0030481
p11453
sg10
I28
sg11
VHTLV-1-associated myelopathy
p11454
sg13
I2
sa(dp11455
g7
I200
sg32
VC0023493
p11456
sg10
I3
sg11
VATL
p11457
sg13
I1
sa(dp11458
g7
I0
sg32
VC0023493
p11459
sg10
I21
sg11
VHuman T cell leukemia
p11460
sg13
I4
sa(dp11461
g7
I238
sg32
VC0030481
p11462
sg10
I28
sg11
Vtropical spastic paraparesis
p11463
sg13
I3
sa(dp11464
g7
I177
sg32
VC0023493
p11465
sg10
I21
sg11
Vadult T-cell leukemia
p11466
sg13
I3
sasa(dp11467
g2
S'TIGIT was expressed on CD4+ T cells from HBZ-transgenic (HBZ-Tg) mice, and on ATL cells and HTLV-1 infected CD4+ T cells of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in vivo.\n'
p11468
sg4
(lp11469
(dp11470
g7
I23
sg8
VP01730
p11471
sg10
I4
sg11
VCD4+
p11472
sg13
I1
sa(dp11473
g7
I187
sg8
VP07996
p11474
sg10
I3
sg11
VTSP
p11475
sg13
I1
sa(dp11476
g7
I41
sg8
VP02008
p11477
sg10
I14
sg11
VHBZ-transgenic
p11478
sg13
I1
sa(dp11479
g7
I183
sg8
g48
sg10
I3
sg11
VHAM
p11480
sg13
I1
sa(dp11481
g7
I23
sg8
VP01730
p11482
sg10
I4
sg11
VCD4+
p11483
sg13
I1
sa(dp11484
g7
I0
sg8
g48
sg10
I5
sg11
VTIGIT
p11485
sg13
I1
sa(dp11486
g7
I57
sg8
VP02008
p11487
sg10
I6
sg11
VHBZ-Tg
p11488
sg13
I1
sasg29
(lp11489
(dp11490
g7
I124
sg32
VC0030481
p11491
sg10
I28
sg11
VHTLV-1-associated myelopathy
p11492
sg13
I2
sa(dp11493
g7
I153
sg32
VC0030481
p11494
sg10
I28
sg11
Vtropical spastic paraparesis
p11495
sg13
I3
sa(dp11496
g7
I183
sg32
VC0030481
p11497
sg10
I3
sg11
VHAM
p11498
sg13
I1
sasa(dp11499
g2
S'Combining a neprilysin inhibitor with an angiotensin II type 1 receptor blockers avoids the risk for angioedema.\n'
p11500
sg4
(lp11501
(dp11502
g7
I41
sg8
VP30556
p11503
sg10
I30
sg11
Vangiotensin II type 1 receptor
p11504
sg13
I5
sa(dp11505
g7
I12
sg8
VP08473
p11506
sg10
I10
sg11
Vneprilysin
p11507
sg13
I1
sasg29
(lp11508
(dp11509
g7
I101
sg32
VC0002994
p11510
sg10
I10
sg11
Vangioedema
p11511
sg13
I1
sasa(dp11512
g2
S'ObcneAoBanN 40 namyNeHToB c aKc-CnA (KpNTepNN ASAS, 2009; Bo3pacT 38,5+/-12,1 roAa; 29 (72,5%) MyX4NH; AnNTenbHocTb aKc-CnA 6,67+/-5,8 roAa; NHAeKc BASDAI &gt;=4,0), KoTopble B cny4aNHoM nopRAKe pa3AeneHbl Ha rpynnbl: 20 bonbHblx npNHNManN myeneKoKcNb no 400 Mr/cyT B Te4eHNe 30 AHeN, 20 namyNeHToB - B Te4eHNe 7 AHeN myeneKoKcNb no 600 Mr/cyT, 3aTeM npoAonXNnN npNeM npenapaTa no 200 Mr/cyT Ao 1 Mec.\n'
p11513
sg4
(lp11514
(dp11515
g7
I12
sg8
g48
sg10
I23
sg11
V40 namyNeHToB c aKc-CnA
p11516
sg13
I4
sa(dp11517
g7
I388
sg8
g48
sg10
I12
sg11
VcyT Ao 1 Mec
p11518
sg13
I4
sa(dp11519
g7
I262
sg8
g48
sg10
I21
sg11
VcyT B Te4eHNe 30 AHeN
p11520
sg13
I5
sa(dp11521
g7
I103
sg8
g48
sg10
I36
sg11
VAnNTenbHocTb aKc-CnA 6,67+/-5,8 roAa
p11522
sg13
I4
sa(dp11523
g7
I37
sg8
g48
sg10
I13
sg11
VKpNTepNN ASAS
p11524
sg13
I2
sa(dp11525
g7
I262
sg8
g48
sg10
I3
sg11
VcyT
p11526
sg13
I1
sasg29
(lp11527
sa(dp11528
g2
S'NamyNeHTbl HapRAy co cTaHAapTHoN cxeMoN ne4eHNR nony4anN MenaKceH 3 Mr/cyT B Te4eHNe 3 Mec.\n'
p11529
sg4
(lp11530
(dp11531
g7
I11
sg8
VP08235
p11532
sg10
I59
sg11
VHapRAy co cTaHAapTHoN cxeMoN ne4eHNR nony4anN MenaKceH 3 Mr
p11533
sg13
I9
sa(dp11534
g7
I71
sg8
g48
sg10
I19
sg11
VcyT B Te4eHNe 3 Mec
p11535
sg13
I5
sasg29
(lp11536
sa(dp11537
g2
S'NonoBNHa ETNx namyNeHToB bblnN onepNpoBaHbl cpa3y, a ApyrNe - nocne oapMaKonorN4ecKoro npeKoHANmyNoHNpoBaHNR aKToBerNHoM B Ao3e 1200 Mr/cyT B Te4eHNe 1,5 Mec.\n'
p11538
sg4
(lp11539
(dp11540
g7
I136
sg8
g48
sg10
I21
sg11
VcyT B Te4eHNe 1,5 Mec
p11541
sg13
I5
sa(dp11542
g7
I133
sg8
VP08235
p11543
sg10
I2
sg11
VMr
p11544
sg13
I1
sasg29
(lp11545
sa(dp11546
g2
S'NamyNeHTbl npNHNManN MarHepoT B cpeAHeM no 1878+/-823 Mr/cyT B Te4eHNe 4,2+/-29 Mec.\n'
p11547
sg4
(lp11548
(dp11549
g7
I57
sg8
g48
sg10
I15
sg11
VcyT B Te4eHNe 4
p11550
sg13
I4
sasg29
(lp11551
sa(dp11552
g2
S'We investigated the tissue-specific features of the production of adipokines (leptin and adipsin) by adipose tissue in obese patients depending on the degree of obesity and the state of carbohydrate metabolism.\n'
p11553
sg4
(lp11554
(dp11555
g7
I89
sg8
VP00746
p11556
sg10
I7
sg11
Vadipsin
p11557
sg13
I1
sa(dp11558
g7
I78
sg8
VP41159
p11559
sg10
I6
sg11
Vleptin
p11560
sg13
I1
sasg29
(lp11561
(dp11562
g7
I161
sg32
VC0028754
p11563
sg10
I7
sg11
Vobesity
p11564
sg13
I1
sa(dp11565
g7
I119
sg32
VC0028754
p11566
sg10
I5
sg11
Vobese
p11567
sg13
I1
sasa(dp11568
g2
S'In patients with varying degrees of obesity with and without type 2 diabetes mellitus (DM 2), we determined the level of tissue-specific expression of LEP and CFD genes encoding leptin and adipsin, respectively.\n'
p11569
sg4
(lp11570
(dp11571
g7
I159
sg8
VP41159
p11572
sg10
I25
sg11
VCFD genes encoding leptin
p11573
sg13
I4
sa(dp11574
g7
I151
sg8
VP41159
p11575
sg10
I3
sg11
VLEP
p11576
sg13
I1
sa(dp11577
g7
I189
sg8
VP00746
p11578
sg10
I7
sg11
Vadipsin
p11579
sg13
I1
sasg29
(lp11580
(dp11581
g7
I36
sg32
VC0028754
p11582
sg10
I7
sg11
Vobesity
p11583
sg13
I1
sa(dp11584
g7
I159
sg32
VC1562113
p11585
sg10
I3
sg11
VCFD
p11586
sg13
I1
sa(dp11587
g7
I61
sg32
VC0011860
p11588
sg10
I24
sg11
Vtype 2 diabetes mellitus
p11589
sg13
I4
sasa(dp11590
g2
S'The disturbance of reciprocal relationships between adipsin and leptin in obesity is associated with the development of insulin resistance.\n'
p11591
sg4
(lp11592
(dp11593
g7
I52
sg8
VP00746
p11594
sg10
I7
sg11
Vadipsin
p11595
sg13
I1
sa(dp11596
g7
I120
sg8
VP01308
p11597
sg10
I7
sg11
Vinsulin
p11598
sg13
I1
sa(dp11599
g7
I64
sg8
VP41159
p11600
sg10
I6
sg11
Vleptin
p11601
sg13
I1
sasg29
(lp11602
(dp11603
g7
I120
sg32
VC0021655
p11604
sg10
I18
sg11
Vinsulin resistance
p11605
sg13
I2
sa(dp11606
g7
I74
sg32
VC0028754
p11607
sg10
I7
sg11
Vobesity
p11608
sg13
I1
sasa(dp11609
g2
S'While one of the most common forms of HBM is CLCN7-related autosomal dominant osteopetrosis type II (ADO II), there is no consensus on diagnostic thresholds.\n'
p11610
sg4
(lp11611
(dp11612
g7
I38
sg8
g48
sg10
I3
sg11
VHBM
p11613
sg13
I1
sasg29
(lp11614
(dp11615
g7
I78
sg32
VC0029454
p11616
sg10
I13
sg11
Vosteopetrosis
p11617
sg13
I1
sasa(dp11618
g2
S'We therefore wanted to assess whether CLCN7-osteopetrosis patients differ from benign HBM cases in terms of (1) bone mineral density, (2) bone structure, and (3) microarchitectural abnormalities.\n'
p11619
sg4
(lp11620
sg29
(lp11621
(dp11622
g7
I44
sg32
VC0029454
p11623
sg10
I13
sg11
Vosteopetrosis
p11624
sg13
I1
sasa(dp11625
g2
S'Defects in the chloride channel 7 (CLCN7) gene lead to autosomal dominant osteopetrosis type II (ADOII, OPTA2 MIM 166600) and autosomal recessive osteopetrosis, autosomal recessive 4 (ARO, OPTB4 MIM 611490).\n'
p11626
sg4
(lp11627
(dp11628
g7
I104
sg8
VP51798
p11629
sg10
I9
sg11
VOPTA2 MIM
p11630
sg13
I2
sa(dp11631
g7
I189
sg8
VP51798
p11632
sg10
I9
sg11
VOPTB4 MIM
p11633
sg13
I2
sa(dp11634
g7
I15
sg8
VP51798
p11635
sg10
I18
sg11
Vchloride channel 7
p11636
sg13
I3
sa(dp11637
g7
I35
sg8
VP51798
p11638
sg10
I5
sg11
VCLCN7
p11639
sg13
I1
sa(dp11640
g7
I97
sg8
VP56715
p11641
sg10
I5
sg11
VADOII
p11642
sg13
I1
sa(dp11643
g7
I55
sg8
VP56715
p11644
sg10
I40
sg11
Vautosomal dominant osteopetrosis type II
p11645
sg13
I5
sasg29
(lp11646
(dp11647
g7
I74
sg32
VC0029454
p11648
sg10
I13
sg11
Vosteopetrosis
p11649
sg13
I1
sa(dp11650
g7
I189
sg32
VC1969106
p11651
sg10
I5
sg11
VOPTB4
p11652
sg13
I1
sa(dp11653
g7
I104
sg32
VC3179239
p11654
sg10
I5
sg11
VOPTA2
p11655
sg13
I1
sa(dp11656
g7
I146
sg32
VC1969106
p11657
sg10
I36
sg11
Vosteopetrosis, autosomal recessive 4
p11658
sg13
I4
sasa(dp11659
g2
S'Dominant negative mutations in CLCN7, which encodes a homodimeric chloride channel needed for matrix acidification by osteoclasts, cause Albers-Schoenberg disease (also known as autosomal dominant osteopetrosis type 2).\n'
p11660
sg4
(lp11661
(dp11662
g7
I178
sg8
VP56715
p11663
sg10
I39
sg11
Vautosomal dominant osteopetrosis type 2
p11664
sg13
I5
sa(dp11665
g7
I31
sg8
VP51798
p11666
sg10
I5
sg11
VCLCN7
p11667
sg13
I1
sasg29
(lp11668
(dp11669
g7
I178
sg32
VC3179239
p11670
sg10
I39
sg11
Vautosomal dominant osteopetrosis type 2
p11671
sg13
I5
sa(dp11672
g7
I137
sg32
VC0029454
p11673
sg10
I25
sg11
VAlbers-Schoenberg disease
p11674
sg13
I2
sa(dp11675
g7
I0
sg32
VC1512032
p11676
sg10
I17
sg11
VDominant negative
p11677
sg13
I2
sasa(dp11678
g2
S'Here we describe a mouse with a different osteopetrosis-causing mutation (Clcn7F318L).\n'
p11679
sg4
(lp11680
sg29
(lp11681
(dp11682
g7
I42
sg32
VC0029454
p11683
sg10
I13
sg11
Vosteopetrosis
p11684
sg13
I1
sasa(dp11685
g2
S'Mutations of CLCN7 are observed in dominant form of osteopetrosis .The recessive form of ostreopetrosis, i.e., malignant infantile osteopetrosis (MIOP) presents early in life with extreme sclerosis of the skeleton and reduction of marrow space.\n'
p11686
sg4
(lp11687
(dp11688
g7
I13
sg8
VP51798
p11689
sg10
I5
sg11
VCLCN7
p11690
sg13
I1
sasg29
(lp11691
(dp11692
g7
I52
sg32
VC0029454
p11693
sg10
I13
sg11
Vosteopetrosis
p11694
sg13
I1
sa(dp11695
g7
I188
sg32
VC0036429
p11696
sg10
I9
sg11
Vsclerosis
p11697
sg13
I1
sa(dp11698
g7
I52
sg32
VC0029454
p11699
sg10
I13
sg11
Vosteopetrosis
p11700
sg13
I1
sasa(dp11701
g2
S'Dominant osteopetrosis is so far associated only with mutations in the CLCN7 gene and, although described as a benign form, it can be severely debilitating, although not at the same level as recessive forms, and can rarely result in reduced life expectancy.\n'
p11702
sg4
(lp11703
(dp11704
g7
I71
sg8
VP51798
p11705
sg10
I10
sg11
VCLCN7 gene
p11706
sg13
I2
sasg29
(lp11707
(dp11708
g7
I9
sg32
VC0029454
p11709
sg10
I13
sg11
Vosteopetrosis
p11710
sg13
I1
sasa(dp11711
g2
S'Type II autosomal dominant osteopetrosis (ADO2), which is the most common form of osteopetrosis, is caused by heterozygous mutations in the chloride channel 7 (CLCN7) gene.\n'
p11712
sg4
(lp11713
(dp11714
g7
I123
sg8
VP51798
p11715
sg10
I35
sg11
Vmutations in the chloride channel 7
p11716
sg13
I6
sa(dp11717
g7
I160
sg8
VP51798
p11718
sg10
I5
sg11
VCLCN7
p11719
sg13
I1
sasg29
(lp11720
(dp11721
g7
I27
sg32
VC0029454
p11722
sg10
I13
sg11
Vosteopetrosis
p11723
sg13
I1
sa(dp11724
g7
I27
sg32
VC0029454
p11725
sg10
I13
sg11
Vosteopetrosis
p11726
sg13
I1
sasa(dp11727
g2
S'ADO2 is caused by missense mutations in the chloride channel 7 (CLCN7) gene characterized by osteosclerosis with multiple fractures.\n'
p11728
sg4
(lp11729
sg29
(lp11730
(dp11731
g7
I93
sg32
VC0029464
p11732
sg10
I14
sg11
Vosteosclerosis
p11733
sg13
I1
sasa(dp11734
g2
S'CLC-7 mutations are known to cause autosomal dominant OPT type 2, also called Albers-Schonberg disease, which is characterized by osteosclerosis, predominantly of the spine, pelvis and skull base, resulting in bone fragility and fractures.\n'
p11735
sg4
(lp11736
(dp11737
g7
I35
sg8
VP56715
p11738
sg10
I29
sg11
Vautosomal dominant OPT type 2
p11739
sg13
I5
sa(dp11740
g7
I0
sg8
VP51798
p11741
sg10
I15
sg11
VCLC-7 mutations
p11742
sg13
I2
sasg29
(lp11743
(dp11744
g7
I210
sg32
VC1390474
p11745
sg10
I14
sg11
Vbone fragility
p11746
sg13
I2
sa(dp11747
g7
I130
sg32
VC0029464
p11748
sg10
I14
sg11
Vosteosclerosis
p11749
sg13
I1
sa(dp11750
g7
I78
sg32
VC0029454
p11751
sg10
I24
sg11
VAlbers-Schonberg disease
p11752
sg13
I2
sasa(dp11753
g2
S'Thus, we identified a CLCN7 mutation in a family with autosomal dominant osteopetrosis, RTA, renal stones, epilepsy, and blindness.\n'
p11754
sg4
(lp11755
(dp11756
g7
I22
sg8
VP51798
p11757
sg10
I14
sg11
VCLCN7 mutation
p11758
sg13
I2
sasg29
(lp11759
(dp11760
g7
I88
sg32
VC0001126
p11761
sg10
I3
sg11
VRTA
p11762
sg13
I1
sa(dp11763
g7
I121
sg32
VC0456909
p11764
sg10
I9
sg11
Vblindness
p11765
sg13
I1
sa(dp11766
g7
I93
sg32
VC0022650
p11767
sg10
I12
sg11
Vrenal stones
p11768
sg13
I2
sa(dp11769
g7
I107
sg32
VC0014544
p11770
sg10
I8
sg11
Vepilepsy
p11771
sg13
I1
sa(dp11772
g7
I73
sg32
VC0029454
p11773
sg10
I13
sg11
Vosteopetrosis
p11774
sg13
I1
sasa(dp11775
g2
S'In addition, with respect to the CLCN7 gene, we suggest that synonymous variants might also contribute to the large spectrum of severity typical of CLCN7-dependent osteopetrosis through more subtle, but not negligible, effects on protein availability and functionality.\n'
p11776
sg4
(lp11777
(dp11778
g7
I33
sg8
VP51798
p11779
sg10
I5
sg11
VCLCN7
p11780
sg13
I1
sa(dp11781
g7
I33
sg8
VP51798
p11782
sg10
I10
sg11
VCLCN7 gene
p11783
sg13
I2
sasg29
(lp11784
(dp11785
g7
I164
sg32
VC0029454
p11786
sg10
I13
sg11
Vosteopetrosis
p11787
sg13
I1
sasa(dp11788
g2
S'Due to its predicted targeting of several genes involved in control of cellular growth, we examined the expression of miR-498 in colon cancer cell lines and a large cohort of patients with colorectal adenocarcinoma.\n'
p11789
sg4
(lp11790
(dp11791
g7
I118
sg8
g48
sg10
I7
sg11
VmiR-498
p11792
sg13
I1
sasg29
(lp11793
(dp11794
g7
I129
sg32
VC0699790
p11795
sg10
I12
sg11
Vcolon cancer
p11796
sg13
I2
sa(dp11797
g7
I189
sg32
VC1319315
p11798
sg10
I25
sg11
Vcolorectal adenocarcinoma
p11799
sg13
I2
sasa(dp11800
g2
S'The colon cancer cell lines showed reduced expression of miR-498 compared to a normal colonic epithelial cell line.\n'
p11801
sg4
(lp11802
sg29
(lp11803
(dp11804
g7
I4
sg32
VC0699790
p11805
sg10
I12
sg11
Vcolon cancer
p11806
sg13
I2
sasa(dp11807
g2
S'In tissues, miR-498 expression was too low to be detected in all colorectal adenocarcinoma compared to non-neoplastic tissues.\n'
p11808
sg4
(lp11809
sg29
(lp11810
(dp11811
g7
I65
sg32
VC1319315
p11812
sg10
I25
sg11
Vcolorectal adenocarcinoma
p11813
sg13
I2
sasa(dp11814
g2
S'This suggests that the down regulation of miR-498 in colorectal cancer tissues and the direct suppressive cellular effect noted in cancer cell lines implies that miR-498 has some direct or indirect role in the pathogenesis of colorectal adenocarcinomas.\n'
p11815
sg4
(lp11816
(dp11817
g7
I42
sg8
g48
sg10
I7
sg11
VmiR-498
p11818
sg13
I1
sasg29
(lp11819
(dp11820
g7
I53
sg32
VC1527249
p11821
sg10
I17
sg11
Vcolorectal cancer
p11822
sg13
I2
sa(dp11823
g7
I237
sg32
VC0001418
p11824
sg10
I15
sg11
Vadenocarcinomas
p11825
sg13
I1
sa(dp11826
g7
I210
sg32
VC0699748
p11827
sg10
I12
sg11
Vpathogenesis
p11828
sg13
I1
sa(dp11829
g7
I64
sg32
VC0006826
p11830
sg10
I6
sg11
Vcancer
p11831
sg13
I1
sasa(dp11832
g2
S'Exosomal RNA NGS revealed that of 15 different classes of transcripts detected, 4 circulating exosomal sequences within the miRNA category were differentially expressed in RRMS patients versus HC: hsa-miR-122-5p, hsa-miR-196b-5p, hsa-miR-301a-3p, and hsa-miR-532-5p.\n'
p11833
sg4
(lp11834
(dp11835
g7
I251
sg8
g48
sg10
I14
sg11
Vhsa-miR-532-5p
p11836
sg13
I1
sa(dp11837
g7
I0
sg8
g48
sg10
I16
sg11
VExosomal RNA NGS
p11838
sg13
I3
sa(dp11839
g7
I213
sg8
g48
sg10
I15
sg11
Vhsa-miR-196b-5p
p11840
sg13
I1
sa(dp11841
g7
I197
sg8
g48
sg10
I14
sg11
Vhsa-miR-122-5p
p11842
sg13
I1
sa(dp11843
g7
I230
sg8
g48
sg10
I15
sg11
Vhsa-miR-301a-3p
p11844
sg13
I1
sasg29
(lp11845
(dp11846
g7
I197
sg32
VC0393754
p11847
sg10
I3
sg11
Vhsa
p11848
sg13
I1
sa(dp11849
g7
I197
sg32
VC0393754
p11850
sg10
I3
sg11
Vhsa
p11851
sg13
I1
sa(dp11852
g7
I197
sg32
VC0393754
p11853
sg10
I3
sg11
Vhsa
p11854
sg13
I1
sa(dp11855
g7
I197
sg32
VC0393754
p11856
sg10
I3
sg11
Vhsa
p11857
sg13
I1
sasa(dp11858
g2
S'Significant NDI (sNDI) was defined as any Bayley Scales of Infant Development (BSID-III) score &lt;70, cerebral palsy &gt;= grade three, or severe vision or hearing impairment.\n'
p11859
sg4
(lp11860
(dp11861
g7
I0
sg8
VP37198
p11862
sg10
I15
sg11
VSignificant NDI
p11863
sg13
I2
sa(dp11864
g7
I17
sg8
VP37198
p11865
sg10
I4
sg11
VsNDI
p11866
sg13
I1
sasg29
(lp11867
(dp11868
g7
I165
sg32
VC0684336
p11869
sg10
I10
sg11
Vimpairment
p11870
sg13
I1
sa(dp11871
g7
I0
sg32
VC0795996
p11872
sg10
I15
sg11
VSignificant NDI
p11873
sg13
I2
sa(dp11874
g7
I103
sg32
VC0007789
p11875
sg10
I14
sg11
Vcerebral palsy
p11876
sg13
I2
sa(dp11877
g7
I17
sg32
VC0795996
p11878
sg10
I4
sg11
VsNDI
p11879
sg13
I1
sasa(dp11880
g2
S'HIF-1Alfa co-localized with karyopherin Beta1 in the cytoplasm of AHCs and karyopherin Beta1 co-localized with nucleoporin 62 (Nup62) on the nuclear envelope.\n'
p11881
sg4
(lp11882
(dp11883
g7
I127
sg8
VP37198
p11884
sg10
I5
sg11
VNup62
p11885
sg13
I1
sa(dp11886
g7
I111
sg8
VP49792
p11887
sg10
I14
sg11
Vnucleoporin 62
p11888
sg13
I2
sasg29
(lp11889
sa(dp11890
g2
S'From the presymptomatic stage of mSOD1 transgenic mice, karyopherin Beta1 immunoreactivity in AHC nuclei significantly decreased and morphological irregularities of the Nup62-immunostained nuclear envelope became more pronounced with disease progression.\n'
p11891
sg4
(lp11892
(dp11893
g7
I169
sg8
VP37198
p11894
sg10
I5
sg11
VNup62
p11895
sg13
I1
sa(dp11896
g7
I94
sg8
VP51843
p11897
sg10
I3
sg11
VAHC
p11898
sg13
I1
sasg29
(lp11899
(dp11900
g7
I234
sg32
VC0242656
p11901
sg10
I19
sg11
Vdisease progression
p11902
sg13
I2
sa(dp11903
g7
I94
sg32
VC0220766
p11904
sg10
I3
sg11
VAHC
p11905
sg13
I1
sasa(dp11906
g2
S'These potential distribution maps for raptors were superimposed on avian influenza A risk maps of Japan, created from data on incidence of the virus in wild birds throughout Japan from October 2010 to March 2011.\n'
p11907
sg4
(lp11908
sg29
(lp11909
(dp11910
g7
I67
sg32
VC0016627
p11911
sg10
I15
sg11
Vavian influenza
p11912
sg13
I2
sasa(dp11913
g2
S'Our results identify FKBP51 as an important regulator of PPARGamma in WAT and as a potential new target in the treatment of obesity and diabetes.\n'
p11914
sg4
(lp11915
(dp11916
g7
I21
sg8
g48
sg10
I6
sg11
VFKBP51
p11917
sg13
I1
sasg29
(lp11918
(dp11919
g7
I124
sg32
VC0028754
p11920
sg10
I7
sg11
Vobesity
p11921
sg13
I1
sa(dp11922
g7
I136
sg32
VC0011849
p11923
sg10
I8
sg11
Vdiabetes
p11924
sg13
I1
sasa(dp11925
g2
S'These findings indicate that maternal obesity parallels the deleterious effects of adult chronic stress exposure, and furthermore identifies GR/FKBP51 signaling as a novel candidate pathway regulated by maternal obesity.\n'
p11926
sg4
(lp11927
(dp11928
g7
I141
sg8
VP00390
p11929
sg10
I2
sg11
VGR
p11930
sg13
I1
sa(dp11931
g7
I144
sg8
g48
sg10
I6
sg11
VFKBP51
p11932
sg13
I1
sasg29
(lp11933
(dp11934
g7
I38
sg32
VC0028754
p11935
sg10
I7
sg11
Vobesity
p11936
sg13
I1
sa(dp11937
g7
I38
sg32
VC0028754
p11938
sg10
I7
sg11
Vobesity
p11939
sg13
I1
sasa(dp11940
g2
S'Our combined investigations have uncovered FKBP51 as a key regulator of adipogenesis via the Akt-p38 pathway and as a potential target in the treatment of obesity and related disorders.\n'
p11941
sg4
(lp11942
(dp11943
g7
I43
sg8
g48
sg10
I6
sg11
VFKBP51
p11944
sg13
I1
sa(dp11945
g7
I93
sg8
g48
sg10
I3
sg11
VAkt
p11946
sg13
I1
sa(dp11947
g7
I97
sg8
VP46108
p11948
sg10
I3
sg11
Vp38
p11949
sg13
I1
sasg29
(lp11950
(dp11951
g7
I155
sg32
VC0028754
p11952
sg10
I7
sg11
Vobesity
p11953
sg13
I1
sasa(dp11954
g2
S'To assess if hypothalamic Fkbp51 promotes obesity, the gene was transferred to the hypothalamus via an adeno-associated virus vector.\n'
p11955
sg4
(lp11956
(dp11957
g7
I26
sg8
g48
sg10
I6
sg11
VFkbp51
p11958
sg13
I1
sasg29
(lp11959
(dp11960
g7
I42
sg32
VC0028754
p11961
sg10
I7
sg11
Vobesity
p11962
sg13
I1
sasa(dp11963
g2
S'To address this question, FKBP52(+/-) mice were placed on a high-fat (HF) diet known to induce obesity, hepatic steatosis, and insulin resistance.\n'
p11964
sg4
(lp11965
(dp11966
g7
I127
sg8
VP01308
p11967
sg10
I7
sg11
Vinsulin
p11968
sg13
I1
sa(dp11969
g7
I26
sg8
g48
sg10
I6
sg11
VFKBP52
p11970
sg13
I1
sasg29
(lp11971
(dp11972
g7
I127
sg32
VC0021655
p11973
sg10
I18
sg11
Vinsulin resistance
p11974
sg13
I2
sa(dp11975
g7
I104
sg32
VC0015695
p11976
sg10
I17
sg11
Vhepatic steatosis
p11977
sg13
I2
sa(dp11978
g7
I95
sg32
VC0028754
p11979
sg10
I7
sg11
Vobesity
p11980
sg13
I1
sasa(dp11981
g2
S'To assess the efficacy of an original DAC-7 regimen: daunorubicine (DNR) 60 mg/m2/day, days 1-3; cytarabine (AraC) 200 mg/m2/day, days 1-7; cladribine (2-CdA) 5 mg/m2/day, days 1-5, 400 untreated adult acute myeloid leukemia patients (including 63 with preceding myelodysplastic syndrome), aged 45 (16-60) years were randomized to either DAC-7 (n=200) or DA-7 (without 2-CdA, n=200).\n'
p11982
sg4
(lp11983
(dp11984
g7
I38
sg8
VP57775
p11985
sg10
I5
sg11
VDAC-7
p11986
sg13
I1
sasg29
(lp11987
(dp11988
g7
I196
sg32
VC0220615
p11989
sg10
I28
sg11
Vadult acute myeloid leukemia
p11990
sg13
I4
sa(dp11991
g7
I263
sg32
VC0033027
p11992
sg10
I24
sg11
Vmyelodysplastic syndrome
p11993
sg13
I2
sa(dp11994
g7
I154
sg32
VC0002876
p11995
sg10
I3
sg11
VCdA
p11996
sg13
I1
sa(dp11997
g7
I154
sg32
VC0002876
p11998
sg10
I3
sg11
VCdA
p11999
sg13
I1
sasa(dp12000
g2
S'The probability of 3-year leukemia-free survival (LFS) for DAC-7 and DA-7 group equaled 43 and 34%, respectively (P=NS).\n'
p12001
sg4
(lp12002
sg29
(lp12003
(dp12004
g7
I26
sg32
VC0023418
p12005
sg10
I8
sg11
Vleukemia
p12006
sg13
I1
sasa(dp12007
g2
S'Severe combined immunodeficient mice were injected with one of two human T-cell acute lymphoblastic leukemia cell lines (Molt 3 and Molt 13) and were either left untreated or were treated with DA7, an immunotoxin specific for the T cell-associated antigen CD7.\n'
p12008
sg4
(lp12009
(dp12010
g7
I230
sg8
VP14209
p12011
sg10
I29
sg11
VT cell-associated antigen CD7
p12012
sg13
I4
sasg29
(lp12013
(dp12014
g7
I16
sg32
VC0021051
p12015
sg10
I15
sg11
Vimmunodeficient
p12016
sg13
I1
sa(dp12017
g7
I73
sg32
VC1961099
p12018
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p12019
sg13
I4
sa(dp12020
g7
I193
sg32
VC0265226
p12021
sg10
I3
sg11
VDA7
p12022
sg13
I1
sasa(dp12023
g2
S'In vivo, SPDP-DA7 showed a significant anti-tumor effect against CEM cells administered to scid/scid mice, but even more importantly was effective against primary T cell leukemias taken from patients and injected into scid/scid mice.\n'
p12024
sg4
(lp12025
(dp12026
g7
I9
sg8
VP13535
p12027
sg10
I8
sg11
VSPDP-DA7
p12028
sg13
I1
sasg29
(lp12029
(dp12030
g7
I91
sg32
VC0085110
p12031
sg10
I4
sg11
Vscid
p12032
sg13
I1
sa(dp12033
g7
I44
sg32
VC0027651
p12034
sg10
I5
sg11
Vtumor
p12035
sg13
I1
sa(dp12036
g7
I14
sg32
VC0265226
p12037
sg10
I3
sg11
VDA7
p12038
sg13
I1
sa(dp12039
g7
I91
sg32
VC0085110
p12040
sg10
I4
sg11
Vscid
p12041
sg13
I1
sa(dp12042
g7
I91
sg32
VC0085110
p12043
sg10
I4
sg11
Vscid
p12044
sg13
I1
sa(dp12045
g7
I91
sg32
VC0085110
p12046
sg10
I4
sg11
Vscid
p12047
sg13
I1
sa(dp12048
g7
I170
sg32
VC0023418
p12049
sg10
I9
sg11
Vleukemias
p12050
sg13
I1
sa(dp12051
g7
I65
sg32
VC0276037
p12052
sg10
I3
sg11
VCEM
p12053
sg13
I1
sasa(dp12054
g2
S'To study possible therapeutic approaches for disseminated leukemia we utilized an immunotoxin, DA7, constructed by chemically linking the mouse IgG2b anti-CD7(3A1E) monoclonal antibody which recognizes a pan-T-cell marker expressed on almost all T-cell leukemias to deglycosylated ricin A-chain, a catalytic plant toxin and inhibitor of protein synthesis.\n'
p12055
sg4
(lp12056
(dp12057
g7
I138
sg8
VP09564
p12058
sg10
I20
sg11
Vmouse IgG2b anti-CD7
p12059
sg13
I3
sa(dp12060
g7
I95
sg8
VP13535
p12061
sg10
I3
sg11
VDA7
p12062
sg13
I1
sa(dp12063
g7
I298
sg8
g48
sg10
I21
sg11
Vcatalytic plant toxin
p12064
sg13
I3
sasg29
(lp12065
(dp12066
g7
I95
sg32
VC0265226
p12067
sg10
I3
sg11
VDA7
p12068
sg13
I1
sa(dp12069
g7
I246
sg32
VC0023492
p12070
sg10
I16
sg11
VT-cell leukemias
p12071
sg13
I2
sa(dp12072
g7
I58
sg32
VC0023418
p12073
sg10
I8
sg11
Vleukemia
p12074
sg13
I1
sasa(dp12075
g2
S'We conclude that DA7 is an effective in vivo therapeutic agent against human MT-ALL in the SCID mouse system, suggesting potential usefulness for therapy of humans with poor prognosis T-cell leukemia.\n'
p12076
sg4
(lp12077
(dp12078
g7
I17
sg8
VP13535
p12079
sg10
I3
sg11
VDA7
p12080
sg13
I1
sasg29
(lp12081
(dp12082
g7
I184
sg32
VC0023492
p12083
sg10
I15
sg11
VT-cell leukemia
p12084
sg13
I2
sa(dp12085
g7
I91
sg32
VC0085110
p12086
sg10
I4
sg11
VSCID
p12087
sg13
I1
sa(dp12088
g7
I17
sg32
VC0265226
p12089
sg10
I3
sg11
VDA7
p12090
sg13
I1
sasa(dp12091
g2
S'We prospectively investigated in a private academically-affiliated infertility center 94 consecutive IVF cycles based on 6 criteria for oocyte quality: morphology, cytoplasm, perivitelline space (PVS), zona pellucida (ZP), polar body (PB) and oocyte size, each assigned a value of -1 (worst), 0 (average) or +1 (best), so establishing an average total oocyte score (TOS).\n'
p12092
sg4
(lp12093
sg29
(lp12094
(dp12095
g7
I346
sg32
VC0039984
p12096
sg10
I18
sg11
Vtotal oocyte score
p12097
sg13
I3
sa(dp12098
g7
I202
sg32
VC0019360
p12099
sg10
I4
sg11
Vzona
p12100
sg13
I1
sa(dp12101
g7
I67
sg32
VC0021359
p12102
sg10
I11
sg11
Vinfertility
p12103
sg13
I1
sa(dp12104
g7
I366
sg32
VC0039984
p12105
sg10
I3
sg11
VTOS
p12106
sg13
I1
sasa(dp12107
g2
S'Though a larger study would possibly show a lower pregnancy rate in those women with unexplained infertility empirically treated with P vs the women with ovulation defects, the empirical use of P allows easy treatment without the side-effects of follicle-maturing drugs, e.g., hostile cervical mucus, vasomotor symptoms or ovarian cysts.\n'
p12108
sg4
(lp12109
sg29
(lp12110
(dp12111
g7
I323
sg32
VC0029927
p12112
sg10
I13
sg11
Vovarian cysts
p12113
sg13
I2
sa(dp12114
g7
I85
sg32
VC0404585
p12115
sg10
I23
sg11
Vunexplained infertility
p12116
sg13
I2
sasa(dp12117
g2
S'The presence of coarse granules in the PVS correlates with low implantation and pregnancy rates in IVF-ICSI cycles and might be regarded as a distinct entity, part of the yet poorly defined condition of "egg factor infertility."'
p12118
sg4
(lp12119
sg29
(lp12120
(dp12121
g7
I190
sg32
VC0012634
p12122
sg10
I9
sg11
Vcondition
p12123
sg13
I1
sa(dp12124
g7
I215
sg32
VC0021359
p12125
sg10
I11
sg11
Vinfertility
p12126
sg13
I1
sasa(dp12127
g2
S'MiR-29c directly suppressed the following Wnt upstream regulators: frequently rearranged in advanced T-cell lymphomas 2 (FRAT2), low-density lipoprotein receptor-related protein 6 (LRP6), Frizzled-4 (FZD4) and Frizzled-5 (FZD5).\n'
p12128
sg4
(lp12129
(dp12130
g7
I188
sg8
g48
sg10
I10
sg11
VFrizzled-4
p12131
sg13
I1
sa(dp12132
g7
I222
sg8
g48
sg10
I4
sg11
VFZD5
p12133
sg13
I1
sa(dp12134
g7
I42
sg8
VP08397
p12135
sg10
I23
sg11
VWnt upstream regulators
p12136
sg13
I3
sa(dp12137
g7
I0
sg8
g48
sg10
I7
sg11
VMiR-29c
p12138
sg13
I1
sa(dp12139
g7
I129
sg8
g48
sg10
I50
sg11
Vlow-density lipoprotein receptor-related protein 6
p12140
sg13
I5
sa(dp12141
g7
I121
sg8
g48
sg10
I5
sg11
VFRAT2
p12142
sg13
I1
sa(dp12143
g7
I210
sg8
g48
sg10
I10
sg11
VFrizzled-5
p12144
sg13
I1
sa(dp12145
g7
I67
sg8
g48
sg10
I52
sg11
Vfrequently rearranged in advanced T-cell lymphomas 2
p12146
sg13
I7
sa(dp12147
g7
I181
sg8
g48
sg10
I4
sg11
VLRP6
p12148
sg13
I1
sa(dp12149
g7
I200
sg8
g48
sg10
I4
sg11
VFZD4
p12150
sg13
I1
sasg29
(lp12151
(dp12152
g7
I101
sg32
VC0079772
p12153
sg10
I16
sg11
VT-cell lymphomas
p12154
sg13
I2
sasa(dp12155
g2
S'Here, we demonstrate that MLL fusion oncogenes maintain leukemia-associated Rac activity by regulating Frat gene expression, specifically Frat2.\n'
p12156
sg4
(lp12157
(dp12158
g7
I26
sg8
g48
sg10
I3
sg11
VMLL
p12159
sg13
I1
sa(dp12160
g7
I76
sg8
VP31749
p12161
sg10
I3
sg11
VRac
p12162
sg13
I1
sasg29
(lp12163
(dp12164
g7
I56
sg32
VC0023418
p12165
sg10
I8
sg11
Vleukemia
p12166
sg13
I1
sasa(dp12167
g2
S'Modulation of FRAT2 leads to concomitant changes in Rac activity, and transformation of Frat knockout hematopoietic progenitor cells by MLL fusions results in leukemias displaying reduced Rac activation and increased sensitivity to chemotherapeutic drugs.\n'
p12168
sg4
(lp12169
(dp12170
g7
I52
sg8
VP31749
p12171
sg10
I3
sg11
VRac
p12172
sg13
I1
sa(dp12173
g7
I14
sg8
g48
sg10
I5
sg11
VFRAT2
p12174
sg13
I1
sa(dp12175
g7
I52
sg8
VP31749
p12176
sg10
I3
sg11
VRac
p12177
sg13
I1
sa(dp12178
g7
I136
sg8
g48
sg10
I11
sg11
VMLL fusions
p12179
sg13
I2
sasg29
(lp12180
(dp12181
g7
I70
sg32
VC1510411
p12182
sg10
I14
sg11
Vtransformation
p12183
sg13
I1
sa(dp12184
g7
I159
sg32
VC0023418
p12185
sg10
I9
sg11
Vleukemias
p12186
sg13
I1
sasa(dp12187
g2
S'Of the 1,383 genes, 159 genes, including oncogenes ELK1, FRAT2, R-RAS, RHOB, and RHO6, were further selected as gene candidates that are silenced by DNA methylation in normal stomach mucosa but are activated by DNA demethylation in a subset of gastric cancers.\n'
p12188
sg4
(lp12189
(dp12190
g7
I71
sg8
VP62745
p12191
sg10
I4
sg11
VRHOB
p12192
sg13
I1
sa(dp12193
g7
I66
sg8
VP01116
p12194
sg10
I3
sg11
VRAS
p12195
sg13
I1
sa(dp12196
g7
I51
sg8
VP19419
p12197
sg10
I4
sg11
VELK1
p12198
sg13
I1
sa(dp12199
g7
I57
sg8
g48
sg10
I5
sg11
VFRAT2
p12200
sg13
I1
sa(dp12201
g7
I81
sg8
g48
sg10
I4
sg11
VRHO6
p12202
sg13
I1
sasg29
(lp12203
(dp12204
g7
I244
sg32
VC0024623
p12205
sg10
I15
sg11
Vgastric cancers
p12206
sg13
I2
sasa(dp12207
g2
S'We have isolated the entire coding sequence of human FRAT2 (frequently rearranged in advanced T-cell lymphomas-2).\n'
p12208
sg4
(lp12209
(dp12210
g7
I60
sg8
g48
sg10
I52
sg11
Vfrequently rearranged in advanced T-cell lymphomas-2
p12211
sg13
I6
sa(dp12212
g7
I47
sg8
g48
sg10
I11
sg11
Vhuman FRAT2
p12213
sg13
I2
sasg29
(lp12214
(dp12215
g7
I94
sg32
VC0079772
p12216
sg10
I16
sg11
VT-cell lymphomas
p12217
sg13
I2
sasa(dp12218
g2
S'Results: Expressions of hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all up regulated in high invasion capable cell lines (SNU423, SNU449) and vascular invasion patients with hepatocellular carcinoma (logFC&gt;1, P&lt;0.05).\n'
p12219
sg4
(lp12220
(dp12221
g7
I24
sg8
g48
sg10
I3
sg11
Vhsa
p12222
sg13
I1
sa(dp12223
g7
I38
sg8
g48
sg10
I11
sg11
Vhsa-mir-149
p12224
sg13
I1
sa(dp12225
g7
I51
sg8
g48
sg10
I11
sg11
Vhsa-mir-744
p12226
sg13
I1
sa(dp12227
g7
I24
sg8
g48
sg10
I12
sg11
Vhsa-mir-1180
p12228
sg13
I1
sasg29
(lp12229
(dp12230
g7
I24
sg32
VC0393754
p12231
sg10
I3
sg11
Vhsa
p12232
sg13
I1
sa(dp12233
g7
I24
sg32
VC0393754
p12234
sg10
I3
sg11
Vhsa
p12235
sg13
I1
sa(dp12236
g7
I24
sg32
VC0393754
p12237
sg10
I3
sg11
Vhsa
p12238
sg13
I1
sa(dp12239
g7
I24
sg32
VC0393754
p12240
sg10
I3
sg11
Vhsa
p12241
sg13
I1
sa(dp12242
g7
I109
sg32
VC2699153
p12243
sg10
I8
sg11
Vinvasion
p12244
sg13
I1
sa(dp12245
g7
I190
sg32
VC1512411
p12246
sg10
I24
sg11
Vhepatocellular carcinoma
p12247
sg13
I2
sa(dp12248
g7
I109
sg32
VC2699153
p12249
sg10
I8
sg11
Vinvasion
p12250
sg13
I1
sasa(dp12251
g2
S'Results from the Survival analysis showed that hsa-mir-1180 (HR=1.623, 95% CI: 1.114-2.365, P=0.012), hsa-mir-149 (HR=2.400, 95% CI: 1.639-3.514) and hsa-mir-940 (HR=1.704, 95%CI: 1.188-2.443, P=0.004) were independent risk factors on the prognosis of patients with hepatocellular carcinoma (P&lt;0.05).\n'
p12252
sg4
(lp12253
(dp12254
g7
I47
sg8
g48
sg10
I3
sg11
Vhsa
p12255
sg13
I1
sa(dp12256
g7
I47
sg8
g48
sg10
I3
sg11
Vhsa
p12257
sg13
I1
sa(dp12258
g7
I47
sg8
g48
sg10
I3
sg11
Vhsa
p12259
sg13
I1
sasg29
(lp12260
(dp12261
g7
I47
sg32
VC0393754
p12262
sg10
I3
sg11
Vhsa
p12263
sg13
I1
sa(dp12264
g7
I47
sg32
VC0393754
p12265
sg10
I3
sg11
Vhsa
p12266
sg13
I1
sa(dp12267
g7
I266
sg32
VC1512411
p12268
sg10
I24
sg11
Vhepatocellular carcinoma
p12269
sg13
I2
sa(dp12270
g7
I47
sg32
VC0393754
p12271
sg10
I3
sg11
Vhsa
p12272
sg13
I1
sasa(dp12273
g2
S'Conclusion: With TCGA and GEO data mining, we found that hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all highly related to the prognosis of hepatocellular carcinoma, that enabled it to be used to further study the biomarkers related to the prognosis of hepatocellular carcinoma.\n'
p12274
sg4
(lp12275
(dp12276
g7
I57
sg8
g48
sg10
I12
sg11
Vhsa-mir-1180
p12277
sg13
I1
sa(dp12278
g7
I71
sg8
g48
sg10
I11
sg11
Vhsa-mir-149
p12279
sg13
I1
sa(dp12280
g7
I84
sg8
g48
sg10
I11
sg11
Vhsa-mir-744
p12281
sg13
I1
sa(dp12282
g7
I57
sg8
g48
sg10
I3
sg11
Vhsa
p12283
sg13
I1
sasg29
(lp12284
(dp12285
g7
I57
sg32
VC0393754
p12286
sg10
I3
sg11
Vhsa
p12287
sg13
I1
sa(dp12288
g7
I156
sg32
VC1512411
p12289
sg10
I24
sg11
Vhepatocellular carcinoma
p12290
sg13
I2
sa(dp12291
g7
I156
sg32
VC1512411
p12292
sg10
I24
sg11
Vhepatocellular carcinoma
p12293
sg13
I2
sa(dp12294
g7
I57
sg32
VC0393754
p12295
sg10
I3
sg11
Vhsa
p12296
sg13
I1
sa(dp12297
g7
I57
sg32
VC0393754
p12298
sg10
I3
sg11
Vhsa
p12299
sg13
I1
sa(dp12300
g7
I57
sg32
VC0393754
p12301
sg10
I3
sg11
Vhsa
p12302
sg13
I1
sasa(dp12303
g2
S'Recently, several studies have investigated the association between polymorphisms in miR-146a rs2910164, miR-196a2 rs11614913, miR-499 rs3746444, miR-149 rs229283, miR-34b/c rs4938723, and hepatocellular carcinoma (HCC), which showed inconclusive results.\n'
p12304
sg4
(lp12305
(dp12306
g7
I146
sg8
g48
sg10
I16
sg11
VmiR-149 rs229283
p12307
sg13
I2
sa(dp12308
g7
I105
sg8
g48
sg10
I20
sg11
VmiR-196a2 rs11614913
p12309
sg13
I2
sa(dp12310
g7
I127
sg8
g48
sg10
I17
sg11
VmiR-499 rs3746444
p12311
sg13
I2
sa(dp12312
g7
I164
sg8
g48
sg10
I19
sg11
VmiR-34b/c rs4938723
p12313
sg13
I2
sa(dp12314
g7
I85
sg8
g48
sg10
I18
sg11
VmiR-146a rs2910164
p12315
sg13
I2
sasg29
(lp12316
(dp12317
g7
I189
sg32
VC2239176
p12318
sg10
I24
sg11
Vhepatocellular carcinoma
p12319
sg13
I2
sa(dp12320
g7
I215
sg32
VC2239176
p12321
sg10
I3
sg11
VHCC
p12322
sg13
I1
sasa(dp12323
g2
S'Numerous studies have explored the association between MIR-149 gene rs2292832 polymorphism and hepatocellular carcinoma (HCC) risk, but the results remains inconsistent.\n'
p12324
sg4
(lp12325
sg29
(lp12326
(dp12327
g7
I121
sg32
VC2239176
p12328
sg10
I3
sg11
VHCC
p12329
sg13
I1
sa(dp12330
g7
I95
sg32
VC2239176
p12331
sg10
I24
sg11
Vhepatocellular carcinoma
p12332
sg13
I2
sasa(dp12333
g2
S'When all the eligible studies were pooled into this meta-analysis, a significant association between MIR-149 gene rs2292832 polymorphism and hepatocellular carcinoma risk was found, while no association was found between this gene polymorphism and overall cancer risk.\n'
p12334
sg4
(lp12335
sg29
(lp12336
(dp12337
g7
I141
sg32
VC1512411
p12338
sg10
I24
sg11
Vhepatocellular carcinoma
p12339
sg13
I2
sa(dp12340
g7
I256
sg32
VC0006826
p12341
sg10
I6
sg11
Vcancer
p12342
sg13
I1
sasa(dp12343
g2
S'We used"hepatocellular carcinoma/HCC","miRNA-149/miR-149/microRNA-149", and"miRNA-499/miR-499/microRNA-499"as key words to search papers in databases including China National Knowledge Internet (CNKI), Chinese BioMedical Literature (CBM), Vip Citation Databases (VIP), Wanfang, PubMed and Web of Science databases, and collected the case-control studies on the association of rs2292832 or rs3746444 and the susceptibility to hepatocellular carcinoma from updated to May 31st 2015.\n'
p12344
sg4
(lp12345
sg29
(lp12346
(dp12347
g7
I8
sg32
VC2239176
p12348
sg10
I24
sg11
Vhepatocellular carcinoma
p12349
sg13
I2
sa(dp12350
g7
I8
sg32
VC2239176
p12351
sg10
I24
sg11
Vhepatocellular carcinoma
p12352
sg13
I2
sa(dp12353
g7
I33
sg32
VC2239176
p12354
sg10
I3
sg11
VHCC
p12355
sg13
I1
sa(dp12356
g7
I289
sg32
VC0332875
p12357
sg10
I3
sg11
VWeb
p12358
sg13
I1
sasa(dp12359
g2
S'Numerous studies have explored the association between miR-149 gene rs2292832 polymorphism and hepatocellular carcinoma risk, but the results remains inconsistent.\n'
p12360
sg4
(lp12361
(dp12362
g7
I55
sg8
g48
sg10
I12
sg11
VmiR-149 gene
p12363
sg13
I2
sasg29
(lp12364
(dp12365
g7
I95
sg32
VC1512411
p12366
sg10
I24
sg11
Vhepatocellular carcinoma
p12367
sg13
I2
sasa(dp12368
g2
S'Odds ratios (OR) with 95% confidence intervals (CI), calculated by STATA software, were used to determine whether miR-149 gene rs2292832 polymorphism contributes to the risk of Hepatocellular carcinoma.\n'
p12369
sg4
(lp12370
(dp12371
g7
I114
sg8
g48
sg10
I12
sg11
VmiR-149 gene
p12372
sg13
I2
sasg29
(lp12373
(dp12374
g7
I177
sg32
VC1512411
p12375
sg10
I24
sg11
VHepatocellular carcinoma
p12376
sg13
I2
sasa(dp12377
g2
S'When all the eligible studies were pooled into this meta-analysis, a significant association between miR-149 gene rs2292832 polymorphism and hepatocellular carcinoma risk was found.\n'
p12378
sg4
(lp12379
(dp12380
g7
I101
sg8
g48
sg10
I12
sg11
VmiR-149 gene
p12381
sg13
I2
sasg29
(lp12382
(dp12383
g7
I141
sg32
VC1512411
p12384
sg10
I24
sg11
Vhepatocellular carcinoma
p12385
sg13
I2
sasa(dp12386
g2
S'Our meta-analysis supports that the miR-149 gene rs2292832 polymorphism contributed to the risk of hepatocellular carcinoma from currently available evidence.\n'
p12387
sg4
(lp12388
(dp12389
g7
I36
sg8
g48
sg10
I12
sg11
VmiR-149 gene
p12390
sg13
I2
sasg29
(lp12391
(dp12392
g7
I99
sg32
VC1512411
p12393
sg10
I24
sg11
Vhepatocellular carcinoma
p12394
sg13
I2
sasa(dp12395
g2
S'However, a study with a larger sample size is needed to further evaluate gene-environment interaction on MiR-149 gene rs2292832 polymorphism and hepatocellular carcinoma risk.\n'
p12396
sg4
(lp12397
(dp12398
g7
I105
sg8
g48
sg10
I12
sg11
VMiR-149 gene
p12399
sg13
I2
sasg29
(lp12400
(dp12401
g7
I145
sg32
VC1512411
p12402
sg10
I24
sg11
Vhepatocellular carcinoma
p12403
sg13
I2
sasa(dp12404
g2
S'We conducted a case-control study to evaluate the association of miR-146a rs2910164 (C&gt;G), miR-149 rs2292832 (T&gt;C), miR-196a2 rs11614913 (T&gt;C) and miR-499 rs3746444 (T&gt;C) polymorphisms with the risk of hepatocellular carcinoma.\n'
p12405
sg4
(lp12406
(dp12407
g7
I65
sg8
g48
sg10
I18
sg11
VmiR-146a rs2910164
p12408
sg13
I2
sa(dp12409
g7
I94
sg8
g48
sg10
I17
sg11
VmiR-149 rs2292832
p12410
sg13
I2
sa(dp12411
g7
I122
sg8
g48
sg10
I20
sg11
VmiR-196a2 rs11614913
p12412
sg13
I2
sa(dp12413
g7
I156
sg8
g48
sg10
I17
sg11
VmiR-499 rs3746444
p12414
sg13
I2
sasg29
(lp12415
(dp12416
g7
I214
sg32
VC1512411
p12417
sg10
I24
sg11
Vhepatocellular carcinoma
p12418
sg13
I2
sasa(dp12419
g2
S'DM prevalence was 25.3% (95% CI 22.6-28.5) and that of pre-diabetes 24.5% (95% CI 20.4-27.6).\n'
p12420
sg4
(lp12421
sg29
(lp12422
(dp12423
g7
I55
sg32
VC0362046
p12424
sg10
I12
sg11
Vpre-diabetes
p12425
sg13
I1
sasa(dp12426
g2
S'This study aimed to use the National Cancer Institute (NCI) markers BAT25, BAT26, D2S123, D5S346 and D17S250 to evaluate MSI in patients with ovarian serous cystadenocarcinoma, compared with ovarian serous cystadenoma and normal ovaries.\n'
p12427
sg4
(lp12428
(dp12429
g7
I90
sg8
g48
sg10
I6
sg11
VD5S346
p12430
sg13
I1
sasg29
(lp12431
(dp12432
g7
I121
sg32
VC0920269
p12433
sg10
I3
sg11
VMSI
p12434
sg13
I1
sa(dp12435
g7
I142
sg32
VC0279663
p12436
sg10
I33
sg11
Vovarian serous cystadenocarcinoma
p12437
sg13
I3
sa(dp12438
g7
I37
sg32
VC0006826
p12439
sg10
I6
sg11
VCancer
p12440
sg13
I1
sa(dp12441
g7
I191
sg32
VC0346170
p12442
sg10
I26
sg11
Vovarian serous cystadenoma
p12443
sg13
I3
sasa(dp12444
g2
S"This study was undertaken to determine gemcitabine's efficacy against bladder cancer cell lines of different origins (HTB2, a papilloma; HTB3, a squamous cell carcinoma; and HTB4, a transitional cell carcinoma).\n"
p12445
sg4
(lp12446
sg29
(lp12447
(dp12448
g7
I145
sg32
VC0007137
p12449
sg10
I23
sg11
Vsquamous cell carcinoma
p12450
sg13
I3
sa(dp12451
g7
I126
sg32
VC0030354
p12452
sg10
I9
sg11
Vpapilloma
p12453
sg13
I1
sa(dp12454
g7
I70
sg32
VC0699885
p12455
sg10
I14
sg11
Vbladder cancer
p12456
sg13
I2
sa(dp12457
g7
I182
sg32
VC0007138
p12458
sg10
I27
sg11
Vtransitional cell carcinoma
p12459
sg13
I3
sasa(dp12460
g2
S'Four cases showed silent p53 mutations upon direct sequencing and 4 revealed loss of heterozygosity at the loci evaluated, including 1 at D5S346 [adenomatous polyposis coli (APC) gene], 1 at D17S250 (p53 gene), and 2 at MYCL (chromosome 1p34).\n'
p12461
sg4
(lp12462
(dp12463
g7
I200
sg8
VP42771
p12464
sg10
I8
sg11
Vp53 gene
p12465
sg13
I2
sa(dp12466
g7
I138
sg8
g48
sg10
I6
sg11
VD5S346
p12467
sg13
I1
sa(dp12468
g7
I25
sg8
VP42771
p12469
sg10
I13
sg11
Vp53 mutations
p12470
sg13
I2
sasg29
(lp12471
(dp12472
g7
I174
sg32
VC0033036
p12473
sg10
I3
sg11
VAPC
p12474
sg13
I1
sa(dp12475
g7
I145
sg32
VC0033036
p12476
sg10
I27
sg11
V[adenomatous polyposis coli
p12477
sg13
I3
sasa(dp12478
g2
S'Frequent allelic losses were identified at D17S802 (41%), D7S518 (40%), D18S53 (38%), D10S249 (32%), D2S391 (29%), D16S419 (27%), D15S1005 and D15S120 (24%), D9S274 and D11S1318 (23%), D14S65 (20%), D14S274 and D17S953 (19%), D19S424 (18%), D5S346 and D1S397 (15%), and D6S468 (13%) in multiple FAP adenomas.\n'
p12479
sg4
(lp12480
(dp12481
g7
I241
sg8
g48
sg10
I6
sg11
VD5S346
p12482
sg13
I1
sasg29
(lp12483
(dp12484
g7
I299
sg32
VC0001430
p12485
sg10
I8
sg11
Vadenomas
p12486
sg13
I1
sa(dp12487
g7
I295
sg32
VC0032580
p12488
sg10
I3
sg11
VFAP
p12489
sg13
I1
sasa(dp12490
g2
S'In addition, allele-specific LOH at D5S346, D15S1005, and D15S120 was observed in multiple FAP adenomas (P &lt; 0.01) and at D2S206 and D16S423 in multiple CRC (P &lt; 0.05).\n'
p12491
sg4
(lp12492
(dp12493
g7
I36
sg8
g48
sg10
I6
sg11
VD5S346
p12494
sg13
I1
sasg29
(lp12495
(dp12496
g7
I91
sg32
VC0032580
p12497
sg10
I3
sg11
VFAP
p12498
sg13
I1
sa(dp12499
g7
I156
sg32
VC1527249
p12500
sg10
I3
sg11
VCRC
p12501
sg13
I1
sa(dp12502
g7
I95
sg32
VC0001430
p12503
sg10
I8
sg11
Vadenomas
p12504
sg13
I1
sasa(dp12505
g2
S'Our purpose was to investigate the possible association of ERAP1 and ERAP2 gene SNPs with psoriatic arthritis susceptibility in Romanian population.\n'
p12506
sg4
(lp12507
(dp12508
g7
I59
sg8
g48
sg10
I5
sg11
VERAP1
p12509
sg13
I1
sa(dp12510
g7
I69
sg8
g48
sg10
I15
sg11
VERAP2 gene SNPs
p12511
sg13
I3
sasg29
(lp12512
(dp12513
g7
I90
sg32
VC0003872
p12514
sg10
I19
sg11
Vpsoriatic arthritis
p12515
sg13
I2
sasa(dp12516
g2
S'Psoriatic arthritis patients (N = 98) and random healthy controls (N = 139) were genotyped for ERAP1/2 genes SNPs rs30187, rs27044, rs2910686, and rs2248374 by TaqMan Allelic Discrimination Assays.\n'
p12517
sg4
(lp12518
(dp12519
g7
I95
sg8
g48
sg10
I26
sg11
VERAP1/2 genes SNPs rs30187
p12520
sg13
I4
sasg29
(lp12521
(dp12522
g7
I0
sg32
VC0003872
p12523
sg10
I19
sg11
VPsoriatic arthritis
p12524
sg13
I2
sasa(dp12525
g2
S"These associations include ERAP1, CCR1-CCR3, STAT4, KLRC4, GIMAP4, and TNFAIP3 in Behcet's disease; BLK and CD40 in Kawasaki disease; SERPINA1 and SEMA6A in antineutrophil cytoplasmic antibody associated vasculitides; IL12B and FCGR2A/ FCGR2A in Takayasu arteritis; and CECR1 in a newly defined vascular inflammatory syndrome associated with adenosine deaminase (ADA2) deficiency.\n"
p12526
sg4
(lp12527
(dp12528
g7
I27
sg8
g48
sg10
I5
sg11
VERAP1
p12529
sg13
I1
sa(dp12530
g7
I59
sg8
g48
sg10
I6
sg11
VGIMAP4
p12531
sg13
I1
sa(dp12532
g7
I45
sg8
g48
sg10
I5
sg11
VSTAT4
p12533
sg13
I1
sa(dp12534
g7
I270
sg8
g48
sg10
I5
sg11
VCECR1
p12535
sg13
I1
sa(dp12536
g7
I228
sg8
VP12318
p12537
sg10
I6
sg11
VFCGR2A
p12538
sg13
I1
sa(dp12539
g7
I228
sg8
VP12318
p12540
sg10
I6
sg11
VFCGR2A
p12541
sg13
I1
sa(dp12542
g7
I71
sg8
VP21580
p12543
sg10
I7
sg11
VTNFAIP3
p12544
sg13
I1
sa(dp12545
g7
I218
sg8
VP29460
p12546
sg10
I5
sg11
VIL12B
p12547
sg13
I1
sa(dp12548
g7
I342
sg8
VP00813
p12549
sg10
I19
sg11
Vadenosine deaminase
p12550
sg13
I2
sa(dp12551
g7
I363
sg8
g48
sg10
I4
sg11
VADA2
p12552
sg13
I1
sa(dp12553
g7
I39
sg8
VP51677
p12554
sg10
I4
sg11
VCCR3
p12555
sg13
I1
sa(dp12556
g7
I108
sg8
VP25942
p12557
sg10
I24
sg11
VCD40 in Kawasaki disease
p12558
sg13
I4
sa(dp12559
g7
I52
sg8
VP26718
p12560
sg10
I5
sg11
VKLRC4
p12561
sg13
I1
sa(dp12562
g7
I34
sg8
VP32246
p12563
sg10
I4
sg11
VCCR1
p12564
sg13
I1
sa(dp12565
g7
I147
sg8
g48
sg10
I6
sg11
VSEMA6A
p12566
sg13
I1
sasg29
(lp12567
(dp12568
g7
I204
sg32
VC0042384
p12569
sg10
I12
sg11
Vvasculitides
p12570
sg13
I1
sa(dp12571
g7
I246
sg32
VC0039263
p12572
sg10
I18
sg11
VTakayasu arteritis
p12573
sg13
I2
sa(dp12574
g7
I116
sg32
VC0026691
p12575
sg10
I16
sg11
VKawasaki disease
p12576
sg13
I2
sa(dp12577
g7
I82
sg32
VC0004943
p12578
sg10
I16
sg11
VBehcet's disease
p12579
sg13
I2
sa(dp12580
g7
I317
sg32
VC0039082
p12581
sg10
I8
sg11
Vsyndrome
p12582
sg13
I1
sasa(dp12583
g2
S'The quarter-embryos were sexed by polymerase chain reaction (PCR) using BRY.1, Bov97M and ZFX/ZFY loci, and then genotyped for k-casein, bovine leukocyte adhesion deficiency (BLAD) and microsatellite D9S1.\n'
p12584
sg4
(lp12585
(dp12586
g7
I94
sg8
VP08048
p12587
sg10
I8
sg11
VZFY loci
p12588
sg13
I2
sa(dp12589
g7
I90
sg8
VP17010
p12590
sg10
I3
sg11
VZFX
p12591
sg13
I1
sa(dp12592
g7
I137
sg8
VP05107
p12593
sg10
I43
sg11
Vbovine leukocyte adhesion deficiency (BLAD)
p12594
sg13
I5
sa(dp12595
g7
I185
sg8
g48
sg10
I19
sg11
Vmicrosatellite D9S1
p12596
sg13
I2
sasg29
(lp12597
(dp12598
g7
I144
sg32
VC0272187
p12599
sg10
I29
sg11
Vleukocyte adhesion deficiency
p12600
sg13
I3
sasa(dp12601
g2
S'At day 7 EPS, P wave and induced atrial fibrillation (AF) durations were significantly longer in the mutant groups when compared to wtCx40 controls (p&lt;0.05).\n'
p12602
sg4
(lp12603
sg29
(lp12604
(dp12605
g7
I33
sg32
VC0004238
p12606
sg10
I19
sg11
Vatrial fibrillation
p12607
sg13
I2
sa(dp12608
g7
I101
sg32
VC0596988
p12609
sg10
I6
sg11
Vmutant
p12610
sg13
I1
sa(dp12611
g7
I54
sg32
VC0004238
p12612
sg10
I2
sg11
VAF
p12613
sg13
I1
sa(dp12614
g7
I9
sg32
VC0221271
p12615
sg10
I3
sg11
VEPS
p12616
sg13
I1
sasa(dp12617
g2
S'In multivariate analysis, preoperative digoxin exposure (odds ratio [OR] 2.4, 95% confidence interval [CI] 1.3-4.4), aortic cross-clamp time (OR 1.08, 95% CI 1.04-1.11), ventricular septal defect closure (OR 2.2, 95% CI 1.2-4.1), and a common polymorphism in the gene encoding connexin-40 (GJA5 rs10465885 TT genotype; OR 2.1, 95% CI 1.2-3.8) were independently associated with postoperative CHB.\n'
p12618
sg4
(lp12619
(dp12620
g7
I290
sg8
VP36382
p12621
sg10
I18
sg11
VGJA5 rs10465885 TT
p12622
sg13
I3
sa(dp12623
g7
I277
sg8
VP36382
p12624
sg10
I11
sg11
Vconnexin-40
p12625
sg13
I1
sasg29
(lp12626
(dp12627
g7
I392
sg32
VC0151517
p12628
sg10
I3
sg11
VCHB
p12629
sg13
I1
sa(dp12630
g7
I170
sg32
VC0018818
p12631
sg10
I25
sg11
Vventricular septal defect
p12632
sg13
I3
sasa(dp12633
g2
S'In fact intracellular pathways related to immunological alterations, endothelial dysfunction and insulin resistance in preeclampsia converge on these molecules.\n'
p12634
sg4
(lp12635
(dp12636
g7
I97
sg8
VP01308
p12637
sg10
I7
sg11
Vinsulin
p12638
sg13
I1
sasg29
(lp12639
(dp12640
g7
I69
sg32
VC0856169
p12641
sg10
I23
sg11
Vendothelial dysfunction
p12642
sg13
I2
sa(dp12643
g7
I119
sg32
VC0032914
p12644
sg10
I12
sg11
Vpreeclampsia
p12645
sg13
I1
sa(dp12646
g7
I97
sg32
VC0021655
p12647
sg10
I18
sg11
Vinsulin resistance
p12648
sg13
I2
sasa(dp12649
g2
S'There was no clear evidence of a difference between those who had been treated with insulin and those who had been treated with an oral anti-diabetic pharmacological therapy for the risk of pre-eclampsia (RR 1.14, 95% CI 0.86 to 1.52; 10 studies, 2060 women; moderate-quality evidence); the risk of birth by caesarean section (RR 1.03, 95% CI 0.93 to 1.14; 17 studies, 1988 women; moderate-quality evidence); or the risk of developing type 2 diabetes (metformin only) (RR 1.39, 95% CI 0.80 to 2.44; two studies, 754 women; moderate-quality evidence).\n'
p12650
sg4
(lp12651
(dp12652
g7
I84
sg8
VP01308
p12653
sg10
I7
sg11
Vinsulin
p12654
sg13
I1
sasg29
(lp12655
(dp12656
g7
I435
sg32
VC0011860
p12657
sg10
I15
sg11
Vtype 2 diabetes
p12658
sg13
I3
sa(dp12659
g7
I190
sg32
VC0032914
p12660
sg10
I13
sg11
Vpre-eclampsia
p12661
sg13
I1
sasa(dp12662
g2
S'We assessed the quality of the evidence for selected important outcomes using GRADE; the evidence was low- or very low-quality, due to downgrading because of design limitations (risk of bias) and imprecise effect estimates (for many outcomes only one or two RCTs contributed data).For our primary outcomes there was no clear difference between metformin and insulin groups for pre-eclampsia (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.33 to 1.20; RCTs = 2; participants = 227; very low-quality evidence) although in one RCT women receiving metformin were less likely to have pregnancy-induced hypertension (RR 0.58, 95% CI 0.37 to 0.91; RCTs = 1; participants = 206; low-quality evidence).\n'
p12663
sg4
(lp12664
(dp12665
g7
I358
sg8
VP01308
p12666
sg10
I7
sg11
Vinsulin
p12667
sg13
I1
sasg29
(lp12668
(dp12669
g7
I585
sg32
VC0340274
p12670
sg10
I30
sg11
Vpregnancy-induced hypertension
p12671
sg13
I2
sa(dp12672
g7
I377
sg32
VC0032914
p12673
sg10
I13
sg11
Vpre-eclampsia
p12674
sg13
I1
sasa(dp12675
g2
S'Low to very low-quality evidence suggests possible reductions in pregnancy-induced hypertension, caesarean section birth and neonatal hypoglycaemia with metformin compared with insulin for women with type 2 diabetes diagnosed before or during their pregnancy, and no clear differences in pre-eclampsia, induction of labour and babies that are large-for-gestational age.\n'
p12676
sg4
(lp12677
(dp12678
g7
I177
sg8
VP01308
p12679
sg10
I7
sg11
Vinsulin
p12680
sg13
I1
sasg29
(lp12681
(dp12682
g7
I65
sg32
VC0340274
p12683
sg10
I30
sg11
Vpregnancy-induced hypertension
p12684
sg13
I2
sa(dp12685
g7
I200
sg32
VC0011860
p12686
sg10
I15
sg11
Vtype 2 diabetes
p12687
sg13
I3
sa(dp12688
g7
I288
sg32
VC0032914
p12689
sg10
I13
sg11
Vpre-eclampsia
p12690
sg13
I1
sa(dp12691
g7
I125
sg32
VC0158986
p12692
sg10
I22
sg11
Vneonatal hypoglycaemia
p12693
sg13
I2
sasa(dp12694
g2
S'To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during, pregnancy.\n'
p12695
sg4
(lp12696
(dp12697
g7
I86
sg8
VP01308
p12698
sg10
I7
sg11
Vinsulin
p12699
sg13
I1
sasg29
(lp12700
(dp12701
g7
I59
sg32
VC0032914
p12702
sg10
I13
sg11
Vpre-eclampsia
p12703
sg13
I1
sasa(dp12704
g2
S'A meta-analysis of eight randomized controlled trials comparing metformin (n=838) with insulin (n=836), however, showed a reduced risk of pre-eclampsia with metformin (risk ratio 0.68, 95% CI 0.48-0.95; P = 0.02; I2 =0%).\n'
p12705
sg4
(lp12706
(dp12707
g7
I87
sg8
VP01308
p12708
sg10
I7
sg11
Vinsulin
p12709
sg13
I1
sasg29
(lp12710
(dp12711
g7
I138
sg32
VC0032914
p12712
sg10
I13
sg11
Vpre-eclampsia
p12713
sg13
I1
sasa(dp12714
g2
S'In studies randomizing pregnant women to glucose-lowering therapy, metformin was associated with lower gestational weight gain and a lower risk of pre-eclampsia compared with insulin.\n'
p12715
sg4
(lp12716
(dp12717
g7
I175
sg8
VP01308
p12718
sg10
I7
sg11
Vinsulin
p12719
sg13
I1
sasg29
(lp12720
(dp12721
g7
I147
sg32
VC0032914
p12722
sg10
I13
sg11
Vpre-eclampsia
p12723
sg13
I1
sasa(dp12724
g2
S'Ranking results showed that glyburide might be the optimum treatment regarding average glucose control, and metformin is the fastest in glucose control for GDM patients; glyburide have the highest incidence of macrosomia, preeclampsia, hyperbilirubinemia, neonatal hypoglycemia, shortest gestational age at delivery, and lowest mean birth weight; metformin (plus insulin when required) have the lowest incidence of macrosomia, PIH, LGA, RDS, low gestational age at delivery, and low birth weight.\n'
p12725
sg4
(lp12726
(dp12727
g7
I363
sg8
VP01308
p12728
sg10
I7
sg11
Vinsulin
p12729
sg13
I1
sasg29
(lp12730
(dp12731
g7
I222
sg32
VC0032914
p12732
sg10
I12
sg11
Vpreeclampsia
p12733
sg13
I1
sa(dp12734
g7
I236
sg32
VC0857007
p12735
sg10
I28
sg11
Vhyperbilirubinemia, neonatal
p12736
sg13
I2
sa(dp12737
g7
I156
sg32
VC0085207
p12738
sg10
I3
sg11
VGDM
p12739
sg13
I1
sa(dp12740
g7
I256
sg32
VC0158986
p12741
sg10
I21
sg11
Vneonatal hypoglycemia
p12742
sg13
I2
sasa(dp12743
g2
S'The incidence of pre-eclampsia, a multisystem disorder of pregnancy, is fourfold higher in type 1 diabetic than non-diabetic women; it is also increased in women with features of the metabolic syndrome and insulin resistance.\n'
p12744
sg4
(lp12745
(dp12746
g7
I206
sg8
VP01308
p12747
sg10
I7
sg11
Vinsulin
p12748
sg13
I1
sasg29
(lp12749
(dp12750
g7
I46
sg32
VC0151864
p12751
sg10
I21
sg11
Vdisorder of pregnancy
p12752
sg13
I3
sa(dp12753
g7
I17
sg32
VC0032914
p12754
sg10
I13
sg11
Vpre-eclampsia
p12755
sg13
I1
sa(dp12756
g7
I206
sg32
VC0021655
p12757
sg10
I18
sg11
Vinsulin resistance
p12758
sg13
I2
sa(dp12759
g7
I183
sg32
VC0524620
p12760
sg10
I18
sg11
Vmetabolic syndrome
p12761
sg13
I2
sasa(dp12762
g2
S'In a prospective study of pregnant women with type 1 diabetes, we measured plasma levels of adipokines known to be associated with insulin resistance: leptin, fatty acid binding protein 4 (FABP4), adiponectin (total and high molecular weight [HMW]; also known as high molecular mass), retinol binding protein 4 (RBP4) and resistin and evaluated associations with the subsequent development of pre-eclampsia.\n'
p12763
sg4
(lp12764
(dp12765
g7
I131
sg8
VP01308
p12766
sg10
I7
sg11
Vinsulin
p12767
sg13
I1
sa(dp12768
g7
I159
sg8
VP05413
p12769
sg10
I28
sg11
Vfatty acid binding protein 4
p12770
sg13
I5
sa(dp12771
g7
I312
sg8
VP02753
p12772
sg10
I4
sg11
VRBP4
p12773
sg13
I1
sa(dp12774
g7
I189
sg8
VP15090
p12775
sg10
I5
sg11
VFABP4
p12776
sg13
I1
sa(dp12777
g7
I285
sg8
VP02753
p12778
sg10
I25
sg11
Vretinol binding protein 4
p12779
sg13
I4
sa(dp12780
g7
I197
sg8
g48
sg10
I11
sg11
Vadiponectin
p12781
sg13
I1
sa(dp12782
g7
I151
sg8
VP41159
p12783
sg10
I6
sg11
Vleptin
p12784
sg13
I1
sasg29
(lp12785
(dp12786
g7
I46
sg32
VC0011854
p12787
sg10
I15
sg11
Vtype 1 diabetes
p12788
sg13
I3
sa(dp12789
g7
I393
sg32
VC0032914
p12790
sg10
I13
sg11
Vpre-eclampsia
p12791
sg13
I1
sa(dp12792
g7
I131
sg32
VC0021655
p12793
sg10
I18
sg11
Vinsulin resistance
p12794
sg13
I2
sasa(dp12795
g2
S'By logistic regression analyses after covariate adjustment (HbA1c, insulin kg-1 day-1 and gestational age), the best predictive models for pre-eclampsia were as follows: Visit 1, doubling of leptin, OR 9.0 (p &lt; 0.01); Visit 2, doubling of the leptin:total adiponectin ratio, OR 3.7 (p &lt; 0.05); and Visit 3, doubling of FABP4 concentration, OR 25.1 (p &lt; 0.01).\n'
p12796
sg4
(lp12797
(dp12798
g7
I259
sg8
g48
sg10
I11
sg11
Vadiponectin
p12799
sg13
I1
sa(dp12800
g7
I191
sg8
VP41159
p12801
sg10
I6
sg11
Vleptin
p12802
sg13
I1
sa(dp12803
g7
I67
sg8
VP01308
p12804
sg10
I7
sg11
Vinsulin
p12805
sg13
I1
sa(dp12806
g7
I325
sg8
VP15090
p12807
sg10
I5
sg11
VFABP4
p12808
sg13
I1
sa(dp12809
g7
I191
sg8
VP41159
p12810
sg10
I6
sg11
Vleptin
p12811
sg13
I1
sasg29
(lp12812
(dp12813
g7
I139
sg32
VC0032914
p12814
sg10
I13
sg11
Vpre-eclampsia
p12815
sg13
I1
sasa(dp12816
g2
S'As early as the first trimester in type 1 diabetic women, adipokine profiles that suggest insulin resistance are associated with subsequent pre-eclampsia, possibly reflecting maternal characteristics that precede pregnancy.\n'
p12817
sg4
(lp12818
(dp12819
g7
I90
sg8
VP01308
p12820
sg10
I7
sg11
Vinsulin
p12821
sg13
I1
sasg29
(lp12822
(dp12823
g7
I90
sg32
VC0021655
p12824
sg10
I18
sg11
Vinsulin resistance
p12825
sg13
I2
sa(dp12826
g7
I140
sg32
VC0032914
p12827
sg10
I13
sg11
Vpre-eclampsia
p12828
sg13
I1
sasa(dp12829
g2
S'Insulin resistance may predispose women with type 1 diabetes to pre-eclampsia.\n'
p12830
sg4
(lp12831
(dp12832
g7
I0
sg8
VP01308
p12833
sg10
I7
sg11
VInsulin
p12834
sg13
I1
sasg29
(lp12835
(dp12836
g7
I0
sg32
VC0021655
p12837
sg10
I18
sg11
VInsulin resistance
p12838
sg13
I2
sa(dp12839
g7
I45
sg32
VC0011854
p12840
sg10
I15
sg11
Vtype 1 diabetes
p12841
sg13
I3
sa(dp12842
g7
I64
sg32
VC0032914
p12843
sg10
I13
sg11
Vpre-eclampsia
p12844
sg13
I1
sasa(dp12845
g2
S'To evaluate the anterior segment biometric features and corneal endothelial changes in eyes with pseudoexfoliation (PEX) syndrome and senile cataract.\n'
p12846
sg4
(lp12847
sg29
(lp12848
(dp12849
g7
I121
sg32
VC0039082
p12850
sg10
I8
sg11
Vsyndrome
p12851
sg13
I1
sa(dp12852
g7
I134
sg32
VC0036646
p12853
sg10
I15
sg11
Vsenile cataract
p12854
sg13
I2
sasa(dp12855
g2
S'To investigate the prevalence of pseudoexfoliation syndrome (PEX) among Turkish patients with senile cataract.\n'
p12856
sg4
(lp12857
sg29
(lp12858
(dp12859
g7
I61
sg32
VC0206368
p12860
sg10
I3
sg11
VPEX
p12861
sg13
I1
sa(dp12862
g7
I33
sg32
VC0206368
p12863
sg10
I26
sg11
Vpseudoexfoliation syndrome
p12864
sg13
I2
sa(dp12865
g7
I94
sg32
VC0036646
p12866
sg10
I15
sg11
Vsenile cataract
p12867
sg13
I2
sasa(dp12868
g2
S'To compare the intraoperative and immediate postoperative behavior and complications in eyes with pseudoexfoliation (PEX) syndrome with eyes having senile cataract without PEX during cataract surgery using phacoemulsification (PKE).\n'
p12869
sg4
(lp12870
sg29
(lp12871
(dp12872
g7
I122
sg32
VC0039082
p12873
sg10
I8
sg11
Vsyndrome
p12874
sg13
I1
sa(dp12875
g7
I155
sg32
VC0086543
p12876
sg10
I8
sg11
Vcataract
p12877
sg13
I1
sa(dp12878
g7
I148
sg32
VC0036646
p12879
sg10
I15
sg11
Vsenile cataract
p12880
sg13
I2
sasa(dp12881
g2
S'In this prospective study, 68 eyes of 68 patients were divided into two groups: Group 1 (test) comprised 34 eyes with immature senile cataract with PEX and Group 2 (control) included 34 eyes with immature senile cataract without PEX and any coexisting ocular pathology.\n'
p12882
sg4
(lp12883
sg29
(lp12884
(dp12885
g7
I127
sg32
VC0036646
p12886
sg10
I15
sg11
Vsenile cataract
p12887
sg13
I2
sa(dp12888
g7
I259
sg32
VC0677042
p12889
sg10
I9
sg11
Vpathology
p12890
sg13
I1
sa(dp12891
g7
I127
sg32
VC0036646
p12892
sg10
I15
sg11
Vsenile cataract
p12893
sg13
I2
sasa(dp12894
g2
S'The most common cataract type in the PEX patients was mature cataract observed in 40.7% of patients.\n'
p12895
sg4
(lp12896
sg29
(lp12897
(dp12898
g7
I16
sg32
VC0086543
p12899
sg10
I8
sg11
Vcataract
p12900
sg13
I1
sa(dp12901
g7
I54
sg32
VC0152257
p12902
sg10
I15
sg11
Vmature cataract
p12903
sg13
I2
sasa(dp12904
g2
S'Evaluation of central corneal thickness (CCT) and endothelial cell density (ECD) in patients with senile cataract and coexisting pseudoexfoliation (PEX) syndrome with glaucoma (PEXG) and without glaucoma using specular microscopy.\n'
p12905
sg4
(lp12906
sg29
(lp12907
(dp12908
g7
I153
sg32
VC0039082
p12909
sg10
I8
sg11
Vsyndrome
p12910
sg13
I1
sa(dp12911
g7
I41
sg32
VC2752078
p12912
sg10
I3
sg11
VCCT
p12913
sg13
I1
sa(dp12914
g7
I167
sg32
VC0017601
p12915
sg10
I8
sg11
Vglaucoma
p12916
sg13
I1
sa(dp12917
g7
I14
sg32
VC2752078
p12918
sg10
I25
sg11
Vcentral corneal thickness
p12919
sg13
I3
sa(dp12920
g7
I177
sg32
VC0206368
p12921
sg10
I4
sg11
VPEXG
p12922
sg13
I1
sa(dp12923
g7
I167
sg32
VC0017601
p12924
sg10
I8
sg11
Vglaucoma
p12925
sg13
I1
sa(dp12926
g7
I50
sg32
VC0344783
p12927
sg10
I24
sg11
Vendothelial cell density
p12928
sg13
I3
sa(dp12929
g7
I98
sg32
VC0036646
p12930
sg10
I15
sg11
Vsenile cataract
p12931
sg13
I2
sa(dp12932
g7
I76
sg32
VC0344783
p12933
sg10
I3
sg11
VECD
p12934
sg13
I1
sasa(dp12935
g2
S'The characteristics of the corneal endothelium in patients with/without pseudoexfoliation syndrome (PEX) with senile cataract in Paraguay are unknown.\n'
p12936
sg4
(lp12937
sg29
(lp12938
(dp12939
g7
I110
sg32
VC0036646
p12940
sg10
I15
sg11
Vsenile cataract
p12941
sg13
I2
sa(dp12942
g7
I72
sg32
VC0206368
p12943
sg10
I26
sg11
Vpseudoexfoliation syndrome
p12944
sg13
I2
sa(dp12945
g7
I100
sg32
VC0206368
p12946
sg10
I3
sg11
VPEX
p12947
sg13
I1
sasa(dp12948
g2
S'We evaluated the preventive role of the capsular tension ring (CTR) in zonular and capsular complications in the phacoemulsification surgery of cataracts with pseudoexfoliation (PEX) in two groups of eyes with senile cataract associated with PEX, with (Group A) or without (Group B) CTR implantation.\n'
p12949
sg4
(lp12950
sg29
(lp12951
(dp12952
g7
I49
sg32
VC0233494
p12953
sg10
I7
sg11
Vtension
p12954
sg13
I1
sa(dp12955
g7
I210
sg32
VC0036646
p12956
sg10
I15
sg11
Vsenile cataract
p12957
sg13
I2
sa(dp12958
g7
I144
sg32
VC0521707
p12959
sg10
I9
sg11
Vcataracts
p12960
sg13
I1
sa(dp12961
g7
I274
sg32
VC0348801
p12962
sg10
I7
sg11
VGroup B
p12963
sg13
I2
sasa(dp12964
g2
S'The present study used a rat model with bile duct ligation to examine the effect of cholestasis, to the localization of occludin in brain capillary endothelium by means of electronic microscopy.\n'
p12965
sg4
(lp12966
(dp12967
g7
I120
sg8
g48
sg10
I8
sg11
Voccludin
p12968
sg13
I1
sasg29
(lp12969
(dp12970
g7
I84
sg32
VC0008370
p12971
sg10
I11
sg11
Vcholestasis
p12972
sg13
I1
sasa(dp12973
g2
S'The aim of this study was to assess the diagnostic value of hepatocyte growth factor (HGF) as a new predictor of severity in patients with acute pancreatitis (AP) at early phase of disease.\n'
p12974
sg4
(lp12975
(dp12976
g7
I60
sg8
VP05231
p12977
sg10
I24
sg11
Vhepatocyte growth factor
p12978
sg13
I3
sa(dp12979
g7
I86
sg8
VP05231
p12980
sg10
I3
sg11
VHGF
p12981
sg13
I1
sasg29
(lp12982
(dp12983
g7
I60
sg32
VC0399440
p12984
sg10
I24
sg11
Vhepatocyte growth factor
p12985
sg13
I3
sa(dp12986
g7
I159
sg32
VC0001339
p12987
sg10
I2
sg11
VAP
p12988
sg13
I1
sa(dp12989
g7
I139
sg32
VC0001339
p12990
sg10
I18
sg11
Vacute pancreatitis
p12991
sg13
I2
sa(dp12992
g7
I86
sg32
VC0399440
p12993
sg10
I3
sg11
VHGF
p12994
sg13
I1
sasa(dp12995
g2
S'Serum HGF correlates with several inflammatory markers and clinical scores (Glasgow, Imrie) in patients with AP and may be considered a new promising tool in assessing the severity of acute pancreatitis.\n'
p12996
sg4
(lp12997
(dp12998
g7
I6
sg8
VP05231
p12999
sg10
I3
sg11
VHGF
p13000
sg13
I1
sasg29
(lp13001
(dp13002
g7
I184
sg32
VC0001339
p13003
sg10
I18
sg11
Vacute pancreatitis
p13004
sg13
I2
sa(dp13005
g7
I6
sg32
VC0399440
p13006
sg10
I3
sg11
VHGF
p13007
sg13
I1
sasa(dp13008
g2
S'Hepatocyte growth factor (HGF) overexpression is observed in experimental and clinical acute pancreatitis.\n'
p13009
sg4
(lp13010
(dp13011
g7
I0
sg8
VP05231
p13012
sg10
I24
sg11
VHepatocyte growth factor
p13013
sg13
I3
sa(dp13014
g7
I26
sg8
VP05231
p13015
sg10
I3
sg11
VHGF
p13016
sg13
I1
sasg29
(lp13017
(dp13018
g7
I0
sg32
VC0399440
p13019
sg10
I24
sg11
VHepatocyte growth factor
p13020
sg13
I3
sa(dp13021
g7
I87
sg32
VC0001339
p13022
sg10
I18
sg11
Vacute pancreatitis
p13023
sg13
I2
sa(dp13024
g7
I26
sg32
VC0399440
p13025
sg10
I3
sg11
VHGF
p13026
sg13
I1
sasa(dp13027
g2
S'Administration of HGF without induction of acute pancreatitis increased pancreatic prostaglandin E(2) generation and plasma interleukin-10, and this effect was abolished by the cyclooxygenase-2 inhibitor, rofecoxib.\n'
p13028
sg4
(lp13029
(dp13030
g7
I117
sg8
VP22301
p13031
sg10
I21
sg11
Vplasma interleukin-10
p13032
sg13
I2
sa(dp13033
g7
I18
sg8
VP05231
p13034
sg10
I3
sg11
VHGF
p13035
sg13
I1
sa(dp13036
g7
I177
sg8
VP35354
p13037
sg10
I16
sg11
Vcyclooxygenase-2
p13038
sg13
I1
sasg29
(lp13039
(dp13040
g7
I18
sg32
VC0399440
p13041
sg10
I3
sg11
VHGF
p13042
sg13
I1
sa(dp13043
g7
I43
sg32
VC0001339
p13044
sg10
I18
sg11
Vacute pancreatitis
p13045
sg13
I2
sasa(dp13046
g2
S'We conclude that: (1) HGF induces cyclooxygenase-2 but not cyclooxygenase-1 expression; (2) inhibition of cyclooxygenase-2 in HGF-treated rats decreases the release of anti-inflammatory interleukin-10, increases the production of pro-inflammatory interleukin-1 beta and reduces pancreatic blood flow; (3) cyclooxygenase-2 activity is necessary for the protective effect of HGF in acute pancreatitis.\n'
p13047
sg4
(lp13048
(dp13049
g7
I22
sg8
VP05231
p13050
sg10
I3
sg11
VHGF
p13051
sg13
I1
sa(dp13052
g7
I22
sg8
VP05231
p13053
sg10
I3
sg11
VHGF
p13054
sg13
I1
sa(dp13055
g7
I247
sg8
VP01584
p13056
sg10
I18
sg11
Vinterleukin-1 beta
p13057
sg13
I2
sa(dp13058
g7
I34
sg8
VP35354
p13059
sg10
I16
sg11
Vcyclooxygenase-2
p13060
sg13
I1
sa(dp13061
g7
I59
sg8
VP23219
p13062
sg10
I16
sg11
Vcyclooxygenase-1
p13063
sg13
I1
sa(dp13064
g7
I186
sg8
VP22301
p13065
sg10
I14
sg11
Vinterleukin-10
p13066
sg13
I1
sa(dp13067
g7
I34
sg8
VP35354
p13068
sg10
I16
sg11
Vcyclooxygenase-2
p13069
sg13
I1
sa(dp13070
g7
I34
sg8
VP35354
p13071
sg10
I16
sg11
Vcyclooxygenase-2
p13072
sg13
I1
sa(dp13073
g7
I22
sg8
VP05231
p13074
sg10
I3
sg11
VHGF
p13075
sg13
I1
sasg29
(lp13076
(dp13077
g7
I22
sg32
VC0399440
p13078
sg10
I3
sg11
VHGF
p13079
sg13
I1
sa(dp13080
g7
I380
sg32
VC0001339
p13081
sg10
I18
sg11
Vacute pancreatitis
p13082
sg13
I2
sa(dp13083
g7
I22
sg32
VC0399440
p13084
sg10
I3
sg11
VHGF
p13085
sg13
I1
sa(dp13086
g7
I22
sg32
VC0399440
p13087
sg10
I3
sg11
VHGF
p13088
sg13
I1
sasa(dp13089
g2
S'Previous studies have shown the protective effect of epidermal growth factor (EGF), Hepatocyte Growth Factor (HGF) and Fibroblast Growth Factor (FGF) in the course of experimental acute pancreatitis.\n'
p13090
sg4
(lp13091
(dp13092
g7
I119
sg8
g48
sg10
I24
sg11
VFibroblast Growth Factor
p13093
sg13
I3
sa(dp13094
g7
I145
sg8
g48
sg10
I3
sg11
VFGF
p13095
sg13
I1
sa(dp13096
g7
I84
sg8
VP05231
p13097
sg10
I24
sg11
VHepatocyte Growth Factor
p13098
sg13
I3
sa(dp13099
g7
I110
sg8
VP05231
p13100
sg10
I3
sg11
VHGF
p13101
sg13
I1
sa(dp13102
g7
I53
sg8
VP01133
p13103
sg10
I23
sg11
Vepidermal growth factor
p13104
sg13
I3
sa(dp13105
g7
I78
sg8
VP01133
p13106
sg10
I3
sg11
VEGF
p13107
sg13
I1
sasg29
(lp13108
(dp13109
g7
I180
sg32
VC0001339
p13110
sg10
I18
sg11
Vacute pancreatitis
p13111
sg13
I2
sa(dp13112
g7
I110
sg32
VC0399440
p13113
sg10
I3
sg11
VHGF
p13114
sg13
I1
sa(dp13115
g7
I84
sg32
VC0399440
p13116
sg10
I24
sg11
VHepatocyte Growth Factor
p13117
sg13
I3
sasa(dp13118
g2
S'Hepatocyte growth factor (HGF) overexpression was reported in experimental and clinical acute pancreatitis.\n'
p13119
sg4
(lp13120
(dp13121
g7
I0
sg8
VP05231
p13122
sg10
I24
sg11
VHepatocyte growth factor
p13123
sg13
I3
sa(dp13124
g7
I26
sg8
VP05231
p13125
sg10
I3
sg11
VHGF
p13126
sg13
I1
sasg29
(lp13127
(dp13128
g7
I88
sg32
VC0001339
p13129
sg10
I18
sg11
Vacute pancreatitis
p13130
sg13
I2
sa(dp13131
g7
I0
sg32
VC0399440
p13132
sg10
I24
sg11
VHepatocyte growth factor
p13133
sg13
I3
sa(dp13134
g7
I26
sg32
VC0399440
p13135
sg10
I3
sg11
VHGF
p13136
sg13
I1
sasa(dp13137
g2
S'Acute pancreatitis was induced by s.c. infusion of caerulein (10 microg/kg/h) for 5 h. HGF was administrated twice (30 min before caerulein or saline infusion and 3 h later) at the doses: 0.4, 2, 10 or 50 microg/kg s.c.\n'
p13138
sg4
(lp13139
(dp13140
g7
I87
sg8
VP05231
p13141
sg10
I3
sg11
VHGF
p13142
sg13
I1
sasg29
(lp13143
(dp13144
g7
I0
sg32
VC0001339
p13145
sg10
I18
sg11
VAcute pancreatitis
p13146
sg13
I2
sa(dp13147
g7
I87
sg32
VC0399440
p13148
sg10
I3
sg11
VHGF
p13149
sg13
I1
sasa(dp13150
g2
S'We previously reported that serum hepatocyte growth factor (HGF) levels are elevated in patients with acute pancreatitis and that pancreatitis-associated ascitic fluid (PAAF) contains cytotoxic factor(s) inducing apoptosis on Madin-Darby canine kidney (MDCK) cells.\n'
p13151
sg4
(lp13152
(dp13153
g7
I60
sg8
VP05231
p13154
sg10
I3
sg11
VHGF
p13155
sg13
I1
sa(dp13156
g7
I28
sg8
g48
sg10
I30
sg11
Vserum hepatocyte growth factor
p13157
sg13
I4
sasg29
(lp13158
(dp13159
g7
I102
sg32
VC0001339
p13160
sg10
I18
sg11
Vacute pancreatitis
p13161
sg13
I2
sa(dp13162
g7
I60
sg32
VC0399440
p13163
sg10
I3
sg11
VHGF
p13164
sg13
I1
sa(dp13165
g7
I34
sg32
VC0399440
p13166
sg10
I24
sg11
Vhepatocyte growth factor
p13167
sg13
I3
sa(dp13168
g7
I108
sg32
VC0030305
p13169
sg10
I12
sg11
Vpancreatitis
p13170
sg13
I1
sasa(dp13171
g2
S'In this study, plasma HGF levels and HGF tissue distribution were investigated in rats with experimental acute pancreatitis, and the effects of HGF on the cytotoxic activity and apoptosis-inducing activity of PAAF also were examined.\n'
p13172
sg4
(lp13173
(dp13174
g7
I22
sg8
VP05231
p13175
sg10
I3
sg11
VHGF
p13176
sg13
I1
sa(dp13177
g7
I22
sg8
VP05231
p13178
sg10
I3
sg11
VHGF
p13179
sg13
I1
sa(dp13180
g7
I22
sg8
VP05231
p13181
sg10
I3
sg11
VHGF
p13182
sg13
I1
sa(dp13183
g7
I209
sg8
g48
sg10
I4
sg11
VPAAF
p13184
sg13
I1
sasg29
(lp13185
(dp13186
g7
I22
sg32
VC0399440
p13187
sg10
I3
sg11
VHGF
p13188
sg13
I1
sa(dp13189
g7
I22
sg32
VC0399440
p13190
sg10
I3
sg11
VHGF
p13191
sg13
I1
sa(dp13192
g7
I22
sg32
VC0399440
p13193
sg10
I3
sg11
VHGF
p13194
sg13
I1
sa(dp13195
g7
I105
sg32
VC0001339
p13196
sg10
I18
sg11
Vacute pancreatitis
p13197
sg13
I2
sasa(dp13198
g2
S'These results suggest that HGF is produced in injured organs and may function as an organotrophic and antiapoptotic factor against the organ injuries in acute pancreatitis.\n'
p13199
sg4
(lp13200
(dp13201
g7
I27
sg8
VP05231
p13202
sg10
I3
sg11
VHGF
p13203
sg13
I1
sasg29
(lp13204
(dp13205
g7
I153
sg32
VC0001339
p13206
sg10
I18
sg11
Vacute pancreatitis
p13207
sg13
I2
sa(dp13208
g7
I27
sg32
VC0399440
p13209
sg10
I3
sg11
VHGF
p13210
sg13
I1
sasa(dp13211
g2
S'Among the various neurological features, aseptic meningitis is the most common myeloradiculopathy, myelopathy, cerebellar dysfunction, transverse myelitis, Guillain-Barre syndrome, optic neuritis, peripheral neuropathy hare also described.\n'
p13212
sg4
(lp13213
sg29
(lp13214
(dp13215
g7
I197
sg32
VC0031117
p13216
sg10
I21
sg11
Vperipheral neuropathy
p13217
sg13
I2
sa(dp13218
g7
I135
sg32
VC0026976
p13219
sg10
I19
sg11
Vtransverse myelitis
p13220
sg13
I2
sa(dp13221
g7
I99
sg32
VC0037928
p13222
sg10
I10
sg11
Vmyelopathy
p13223
sg13
I1
sa(dp13224
g7
I111
sg32
VC0007760
p13225
sg10
I22
sg11
Vcerebellar dysfunction
p13226
sg13
I2
sa(dp13227
g7
I156
sg32
VC0018378
p13228
sg10
I23
sg11
VGuillain-Barre syndrome
p13229
sg13
I2
sa(dp13230
g7
I79
sg32
VC1096335
p13231
sg10
I18
sg11
Vmyeloradiculopathy
p13232
sg13
I1
sa(dp13233
g7
I41
sg32
VC0025290
p13234
sg10
I18
sg11
Vaseptic meningitis
p13235
sg13
I2
sasa(dp13236
g2
S'To study was to study the expression of CD40/CD40L in colon cancer and investigate the effects of CD40/CD40L overexpression on the proliferation and apoptosis of SW48 colon cancer cell line.\n'
p13237
sg4
(lp13238
(dp13239
g7
I45
sg8
VP29965
p13240
sg10
I5
sg11
VCD40L
p13241
sg13
I1
sa(dp13242
g7
I45
sg8
VP29965
p13243
sg10
I5
sg11
VCD40L
p13244
sg13
I1
sa(dp13245
g7
I40
sg8
VP25942
p13246
sg10
I4
sg11
VCD40
p13247
sg13
I1
sa(dp13248
g7
I40
sg8
VP25942
p13249
sg10
I4
sg11
VCD40
p13250
sg13
I1
sasg29
(lp13251
(dp13252
g7
I54
sg32
VC0699790
p13253
sg10
I12
sg11
Vcolon cancer
p13254
sg13
I2
sa(dp13255
g7
I54
sg32
VC0699790
p13256
sg10
I12
sg11
Vcolon cancer
p13257
sg13
I2
sa(dp13258
g7
I131
sg32
VC0334094
p13259
sg10
I13
sg11
Vproliferation
p13260
sg13
I1
sasa(dp13261
g2
S'A CD40L gene-containing plasmid was transfected into SW48 colon cancer cells using lipofectamine 2000.\n'
p13262
sg4
(lp13263
(dp13264
g7
I2
sg8
VP29965
p13265
sg10
I10
sg11
VCD40L gene
p13266
sg13
I2
sasg29
(lp13267
(dp13268
g7
I58
sg32
VC0699790
p13269
sg10
I12
sg11
Vcolon cancer
p13270
sg13
I2
sasa(dp13271
g2
S'In conclusion, CD40 protein expression was significantly higher in colon cancer tissue compared with normal tissue, and the apoptosis of SW48 colon cancer cells can be induced by CD40L gene transfection.\n'
p13272
sg4
(lp13273
(dp13274
g7
I15
sg8
VP25942
p13275
sg10
I12
sg11
VCD40 protein
p13276
sg13
I2
sa(dp13277
g7
I179
sg8
VP29965
p13278
sg10
I10
sg11
VCD40L gene
p13279
sg13
I2
sasg29
(lp13280
(dp13281
g7
I67
sg32
VC0699790
p13282
sg10
I12
sg11
Vcolon cancer
p13283
sg13
I2
sa(dp13284
g7
I67
sg32
VC0699790
p13285
sg10
I12
sg11
Vcolon cancer
p13286
sg13
I2
sasa(dp13287
g2
S'Upon CD40 ligand (CD40L) binding, CD40/CD40L signaling inhibited colon cancer proliferation, induced apoptosis, stalled cells at G0/G1, and influenced cell adhesion and metastasis.\n'
p13288
sg4
(lp13289
(dp13290
g7
I5
sg8
VP25942
p13291
sg10
I4
sg11
VCD40
p13292
sg13
I1
sa(dp13293
g7
I5
sg8
VP29965
p13294
sg10
I11
sg11
VCD40 ligand
p13295
sg13
I2
sa(dp13296
g7
I18
sg8
VP29965
p13297
sg10
I5
sg11
VCD40L
p13298
sg13
I1
sa(dp13299
g7
I18
sg8
VP29965
p13300
sg10
I5
sg11
VCD40L
p13301
sg13
I1
sasg29
(lp13302
(dp13303
g7
I65
sg32
VC0699790
p13304
sg10
I12
sg11
Vcolon cancer
p13305
sg13
I2
sa(dp13306
g7
I169
sg32
VC0027627
p13307
sg10
I10
sg11
Vmetastasis
p13308
sg13
I1
sa(dp13309
g7
I156
sg32
VC0001511
p13310
sg10
I8
sg11
Vadhesion
p13311
sg13
I1
sa(dp13312
g7
I78
sg32
VC0334094
p13313
sg10
I13
sg11
Vproliferation
p13314
sg13
I1
sasa(dp13315
g2
S'Real-time PCR and western blotting analysis showed that AHRR expression in colon cancer cells was up-regulated by CD40L binding.\n'
p13316
sg4
(lp13317
(dp13318
g7
I114
sg8
VP29965
p13319
sg10
I5
sg11
VCD40L
p13320
sg13
I1
sa(dp13321
g7
I56
sg8
VP04798
p13322
sg10
I4
sg11
VAHRR
p13323
sg13
I1
sasg29
(lp13324
(dp13325
g7
I75
sg32
VC0699790
p13326
sg10
I12
sg11
Vcolon cancer
p13327
sg13
I2
sasa(dp13328
g2
S'It has been observed previously that MG patients with clinically suspected myocarditis had anti-Kv1.4 antibodies.\n'
p13329
sg4
(lp13330
(dp13331
g7
I91
sg8
VP22459
p13332
sg10
I21
sg11
Vanti-Kv1.4 antibodies
p13333
sg13
I2
sasg29
(lp13334
(dp13335
g7
I75
sg32
VC0027059
p13336
sg10
I11
sg11
Vmyocarditis
p13337
sg13
I1
sasa(dp13338
g2
S'Cardiac findings including electrocardiography (ECG) and clinical features of clinically suspected myocarditis in MG patients with anti-Kv1.4 antibodies were investigated.\n'
p13339
sg4
(lp13340
(dp13341
g7
I131
sg8
VP22459
p13342
sg10
I21
sg11
Vanti-Kv1.4 antibodies
p13343
sg13
I2
sasg29
(lp13344
(dp13345
g7
I99
sg32
VC0027059
p13346
sg10
I11
sg11
Vmyocarditis
p13347
sg13
I1
sasa(dp13348
g2
S'Clinically suspected myocarditis was found in eight MG patients with anti-Kv1.4 antibodies but in none of the MG patients without anti-Kv1.4 antibodies.\n'
p13349
sg4
(lp13350
(dp13351
g7
I69
sg8
VP22459
p13352
sg10
I21
sg11
Vanti-Kv1.4 antibodies
p13353
sg13
I2
sa(dp13354
g7
I69
sg8
VP22459
p13355
sg10
I21
sg11
Vanti-Kv1.4 antibodies
p13356
sg13
I2
sasg29
(lp13357
(dp13358
g7
I21
sg32
VC0027059
p13359
sg10
I11
sg11
Vmyocarditis
p13360
sg13
I1
sasa(dp13361
g2
S'This contrasts to the Japanese anti-Kv1.4 antibody-positive patients who suffered from severe MG with bulbar symptoms, myasthenic crisis, thymoma, myocarditis and prolonged QT time on electrocardiography, despite equal anti-Kv1.4 antibody occurrence in both populations.\n'
p13362
sg4
(lp13363
(dp13364
g7
I31
sg8
VP22459
p13365
sg10
I19
sg11
Vanti-Kv1.4 antibody
p13366
sg13
I2
sa(dp13367
g7
I22
sg8
VP22459
p13368
sg10
I28
sg11
VJapanese anti-Kv1.4 antibody
p13369
sg13
I3
sasg29
(lp13370
(dp13371
g7
I119
sg32
VC0270942
p13372
sg10
I17
sg11
Vmyasthenic crisis
p13373
sg13
I2
sa(dp13374
g7
I138
sg32
VC0040100
p13375
sg10
I7
sg11
Vthymoma
p13376
sg13
I1
sa(dp13377
g7
I73
sg32
VC0683278
p13378
sg10
I8
sg11
Vsuffered
p13379
sg13
I1
sa(dp13380
g7
I147
sg32
VC0027059
p13381
sg10
I11
sg11
Vmyocarditis
p13382
sg13
I1
sasa(dp13383
g2
S'Anti-Kv1.4 antibody is a useful marker for the potential development of lethal autoimmune myocarditis and response to calcineurin inhibitors.\n'
p13384
sg4
(lp13385
(dp13386
g7
I0
sg8
VP22459
p13387
sg10
I19
sg11
VAnti-Kv1.4 antibody
p13388
sg13
I2
sasg29
(lp13389
(dp13390
g7
I79
sg32
VC1608389
p13391
sg10
I22
sg11
Vautoimmune myocarditis
p13392
sg13
I2
sasa(dp13393
g2
S'Autoimmune myocarditis may develop in MG patients who have the anti-Kv1.4 antibody.\n'
p13394
sg4
(lp13395
(dp13396
g7
I63
sg8
VP22459
p13397
sg10
I19
sg11
Vanti-Kv1.4 antibody
p13398
sg13
I2
sasg29
(lp13399
(dp13400
g7
I0
sg32
VC1608389
p13401
sg10
I22
sg11
VAutoimmune myocarditis
p13402
sg13
I2
sasa(dp13403
g2
S'Clinical associations were found between anti-Kv1.4 and bulbar involvement, myasthenic crisis, thymoma, and concomitant myocarditis and/or myositis; between antititin and older-onset MG; between anti-acetylcholine receptor alone and younger-onset MG; and between seronegativity and ocular MG.\n'
p13404
sg4
(lp13405
(dp13406
g7
I195
sg8
g48
sg10
I27
sg11
Vanti-acetylcholine receptor
p13407
sg13
I2
sa(dp13408
g7
I41
sg8
VP22459
p13409
sg10
I10
sg11
Vanti-Kv1.4
p13410
sg13
I1
sasg29
(lp13411
(dp13412
g7
I76
sg32
VC0270942
p13413
sg10
I17
sg11
Vmyasthenic crisis
p13414
sg13
I2
sa(dp13415
g7
I120
sg32
VC0027059
p13416
sg10
I11
sg11
Vmyocarditis
p13417
sg13
I1
sa(dp13418
g7
I95
sg32
VC0040100
p13419
sg10
I7
sg11
Vthymoma
p13420
sg13
I1
sa(dp13421
g7
I139
sg32
VC0027121
p13422
sg10
I8
sg11
Vmyositis
p13423
sg13
I1
sasa(dp13424
g2
S'Clinical features associated with anti-Kv1.4 antibody included bulbar involvement, myasthenic crisis, thymoma, myocarditis, and QT prolongation on electrocardiogram.\n'
p13425
sg4
(lp13426
(dp13427
g7
I34
sg8
VP22459
p13428
sg10
I19
sg11
Vanti-Kv1.4 antibody
p13429
sg13
I2
sasg29
(lp13430
(dp13431
g7
I111
sg32
VC0027059
p13432
sg10
I11
sg11
Vmyocarditis
p13433
sg13
I1
sa(dp13434
g7
I83
sg32
VC0270942
p13435
sg10
I17
sg11
Vmyasthenic crisis
p13436
sg13
I2
sa(dp13437
g7
I102
sg32
VC0040100
p13438
sg10
I7
sg11
Vthymoma
p13439
sg13
I1
sasa(dp13440
g2
S'During the active myocarditis phase, the effective refractory period (ERP), the duration of the monophasic action potential (MAPD) was extracted from the left ventricular free wall, and the mRNA levels of Kv1.4, 4.2, 4.3 and L type Ca2+ channel were determined by RNase protection assays.\n'
p13441
sg4
(lp13442
(dp13443
g7
I264
sg8
VP07998
p13444
sg10
I5
sg11
VRNase
p13445
sg13
I1
sa(dp13446
g7
I205
sg8
VP22459
p13447
sg10
I39
sg11
VKv1.4, 4.2, 4.3 and L type Ca2+ channel
p13448
sg13
I8
sasg29
(lp13449
(dp13450
g7
I18
sg32
VC0027059
p13451
sg10
I11
sg11
Vmyocarditis
p13452
sg13
I1
sasa(dp13453
g2
S'Of the three tumours described, one tumour showed a mixture of a proliferating pilar tumour and syringocystadenoma papilliferum, the second lesion was composed of a proliferating pilar tumour and tubulopapillary hidradenoma and the third tumour exhibited a syringocystadenoma papilliferum and tubulopapillary hidradenoma in combination.\n'
p13454
sg4
(lp13455
sg29
(lp13456
(dp13457
g7
I79
sg32
VC0345992
p13458
sg10
I12
sg11
Vpilar tumour
p13459
sg13
I2
sa(dp13460
g7
I96
sg32
VC0406803
p13461
sg10
I31
sg11
Vsyringocystadenoma papilliferum
p13462
sg13
I2
sa(dp13463
g7
I79
sg32
VC0345992
p13464
sg10
I12
sg11
Vpilar tumour
p13465
sg13
I2
sa(dp13466
g7
I13
sg32
VC0027651
p13467
sg10
I6
sg11
Vtumour
p13468
sg13
I1
sa(dp13469
g7
I13
sg32
VC0027651
p13470
sg10
I7
sg11
Vtumours
p13471
sg13
I1
sa(dp13472
g7
I212
sg32
VC0206671
p13473
sg10
I11
sg11
Vhidradenoma
p13474
sg13
I1
sa(dp13475
g7
I212
sg32
VC0206671
p13476
sg10
I11
sg11
Vhidradenoma
p13477
sg13
I1
sa(dp13478
g7
I13
sg32
VC0027651
p13479
sg10
I6
sg11
Vtumour
p13480
sg13
I1
sa(dp13481
g7
I96
sg32
VC0406803
p13482
sg10
I31
sg11
Vsyringocystadenoma papilliferum
p13483
sg13
I2
sasa(dp13484
g2
S'We studied the baseline expression level of 25 interferon-regulated genes (MxA, GPR3, IL17RC, ISG15, TRAIL, OASL, IFIT1, IFIT2, RSAD2, OAS3, IFI44L, TRIM22, IL10, CXCL10, STAT1, OAS1, OAS2, IFNAR1, IFNAR2, IFNBeta, ISG20, IFI6, PKR, IRF7, USP18), recurrently proposed in the literature as predictive biomarkers of interferon-beta treatment response, in whole blood of 10 "responders" and 10 "non-responders" multiple sclerosis relapsing-remitting patients, retrospectively selected on the basis of stringent clinical criteria after a five years follow-up.\n'
p13485
sg4
(lp13486
(dp13487
g7
I228
sg8
g48
sg10
I3
sg11
VPKR
p13488
sg13
I1
sa(dp13489
g7
I157
sg8
VP22301
p13490
sg10
I4
sg11
VIL10
p13491
sg13
I1
sa(dp13492
g7
I190
sg8
VP17181
p13493
sg10
I6
sg11
VIFNAR1
p13494
sg13
I1
sa(dp13495
g7
I86
sg8
g48
sg10
I6
sg11
VIL17RC
p13496
sg13
I1
sa(dp13497
g7
I114
sg8
VP09914
p13498
sg10
I5
sg11
VIFIT1
p13499
sg13
I1
sa(dp13500
g7
I75
sg8
VP20591
p13501
sg10
I3
sg11
VMxA
p13502
sg13
I1
sa(dp13503
g7
I141
sg8
g48
sg10
I6
sg11
VIFI44L
p13504
sg13
I1
sa(dp13505
g7
I121
sg8
VP09913
p13506
sg10
I5
sg11
VIFIT2
p13507
sg13
I1
sa(dp13508
g7
I128
sg8
g48
sg10
I5
sg11
VRSAD2
p13509
sg13
I1
sa(dp13510
g7
I171
sg8
VP42224
p13511
sg10
I5
sg11
VSTAT1
p13512
sg13
I1
sa(dp13513
g7
I233
sg8
g48
sg10
I4
sg11
VIRF7
p13514
sg13
I1
sa(dp13515
g7
I163
sg8
VP02778
p13516
sg10
I6
sg11
VCXCL10
p13517
sg13
I1
sa(dp13518
g7
I198
sg8
VP48551
p13519
sg10
I6
sg11
VIFNAR2
p13520
sg13
I1
sa(dp13521
g7
I108
sg8
g48
sg10
I4
sg11
VOASL
p13522
sg13
I1
sa(dp13523
g7
I222
sg8
VP09912
p13524
sg10
I4
sg11
VIFI6
p13525
sg13
I1
sa(dp13526
g7
I149
sg8
g48
sg10
I6
sg11
VTRIM22
p13527
sg13
I1
sa(dp13528
g7
I314
sg8
VP01563
p13529
sg10
I15
sg11
Vinterferon-beta
p13530
sg13
I1
sa(dp13531
g7
I94
sg8
VP05161
p13532
sg10
I5
sg11
VISG15
p13533
sg13
I1
sa(dp13534
g7
I215
sg8
g48
sg10
I5
sg11
VISG20
p13535
sg13
I1
sa(dp13536
g7
I135
sg8
g48
sg10
I4
sg11
VOAS3
p13537
sg13
I1
sa(dp13538
g7
I80
sg8
VP46089
p13539
sg10
I4
sg11
VGPR3
p13540
sg13
I1
sa(dp13541
g7
I239
sg8
g48
sg10
I5
sg11
VUSP18
p13542
sg13
I1
sa(dp13543
g7
I101
sg8
VP50591
p13544
sg10
I5
sg11
VTRAIL
p13545
sg13
I1
sa(dp13546
g7
I44
sg8
VP01563
p13547
sg10
I29
sg11
V25 interferon-regulated genes
p13548
sg13
I3
sa(dp13549
g7
I184
sg8
VP29728
p13550
sg10
I4
sg11
VOAS2
p13551
sg13
I1
sasg29
(lp13552
(dp13553
g7
I408
sg32
VC0026769
p13554
sg10
I18
sg11
Vmultiple sclerosis
p13555
sg13
I2
sasa(dp13556
g2
S'In addition to having SI, Dpcd/Poll(-/-) mice (for: deleted in a mouse model of primary ciliary dyskinesia) and Nme7(-/-) mice (for: nonmetastatic cells 7) had lesions consistent with deficient ciliary motility: Hydrocephalus, sinusitis, and male infertility developed in Dpcd/Poll(-/-) mice, whereas hydrocephalus and excessive nasal exudates were seen in Nme7(-/-) mice.\n'
p13557
sg4
(lp13558
(dp13559
g7
I31
sg8
g48
sg10
I4
sg11
VPoll
p13560
sg13
I1
sa(dp13561
g7
I31
sg8
g48
sg10
I4
sg11
VPoll
p13562
sg13
I1
sa(dp13563
g7
I26
sg8
g48
sg10
I4
sg11
VDpcd
p13564
sg13
I1
sa(dp13565
g7
I112
sg8
g48
sg10
I4
sg11
VNme7
p13566
sg13
I1
sa(dp13567
g7
I112
sg8
g48
sg10
I4
sg11
VNme7
p13568
sg13
I1
sa(dp13569
g7
I26
sg8
g48
sg10
I4
sg11
VDpcd
p13570
sg13
I1
sasg29
(lp13571
(dp13572
g7
I80
sg32
VC0022521
p13573
sg10
I26
sg11
Vprimary ciliary dyskinesia
p13574
sg13
I3
sa(dp13575
g7
I227
sg32
VC0037199
p13576
sg10
I9
sg11
Vsinusitis
p13577
sg13
I1
sa(dp13578
g7
I242
sg32
VC0021364
p13579
sg10
I16
sg11
Vmale infertility
p13580
sg13
I2
sa(dp13581
g7
I301
sg32
VC0020255
p13582
sg10
I13
sg11
Vhydrocephalus
p13583
sg13
I1
sa(dp13584
g7
I212
sg32
VC0020255
p13585
sg10
I13
sg11
VHydrocephalus
p13586
sg13
I1
sasa(dp13587
g2
S'As a proof of concept, we designed a multiplex ligation-dependent probe amplification assay targeted to screen the six genes that are most frequently mutated in Diamond-Blackfan anemia patients: RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A.\n'
p13588
sg4
(lp13589
(dp13590
g7
I202
sg8
VP39019
p13591
sg10
I5
sg11
VRPS19
p13592
sg13
I1
sa(dp13593
g7
I209
sg8
VP62854
p13594
sg10
I5
sg11
VRPS26
p13595
sg13
I1
sa(dp13596
g7
I216
sg8
VP46777
p13597
sg10
I4
sg11
VRPL5
p13598
sg13
I1
sa(dp13599
g7
I195
sg8
VP08708
p13600
sg10
I5
sg11
VRPS17
p13601
sg13
I1
sa(dp13602
g7
I233
sg8
VP18077
p13603
sg10
I6
sg11
VRPL35A
p13604
sg13
I1
sa(dp13605
g7
I222
sg8
VP62913
p13606
sg10
I5
sg11
VRPL11
p13607
sg13
I1
sasg29
(lp13608
(dp13609
g7
I161
sg32
VC0398550
p13610
sg10
I23
sg11
VDiamond-Blackfan anemia
p13611
sg13
I2
sa(dp13612
g7
I72
sg32
VC1705759
p13613
sg10
I13
sg11
Vamplification
p13614
sg13
I1
sasa(dp13615
g2
S'Mutations in a number of genes encoding transcription factors - such as HESX1, SOX2, SOX3, LHX3, LHX4, PROP1, POU1F1, PITX, GLI3, GLI2, OTX2, ARNT2, IGSF1, FGF8, FGFR1, PROKR2, PROK2, CHD7, WDR11, NFKB2, PAX6, TCF7L1, IFT72, GPR161 and CDON - have been associated with pituitary dysfunction and abnormal pituitary gland development; the correlation of genetic mutations to endocrine and MRI phenotypes has improved our knowledge of pituitary development and management of patients with hypopituitarism, both in terms of possible genetic counseling, and of early diagnosis of evolving anterior pituitary hormone deficiencies.\n'
p13616
sg4
(lp13617
(dp13618
g7
I204
sg8
VP26367
p13619
sg10
I4
sg11
VPAX6
p13620
sg13
I1
sa(dp13621
g7
I79
sg8
VP48431
p13622
sg10
I4
sg11
VSOX2
p13623
sg13
I1
sa(dp13624
g7
I149
sg8
g48
sg10
I5
sg11
VIGSF1
p13625
sg13
I1
sa(dp13626
g7
I110
sg8
VP28069
p13627
sg10
I6
sg11
VPOU1F1
p13628
sg13
I1
sa(dp13629
g7
I162
sg8
VP20930
p13630
sg10
I5
sg11
VFGFR1
p13631
sg13
I1
sa(dp13632
g7
I197
sg8
g48
sg10
I5
sg11
VNFKB2
p13633
sg13
I1
sa(dp13634
g7
I97
sg8
g48
sg10
I4
sg11
VLHX4
p13635
sg13
I1
sa(dp13636
g7
I142
sg8
g48
sg10
I5
sg11
VARNT2
p13637
sg13
I1
sa(dp13638
g7
I169
sg8
g48
sg10
I6
sg11
VPROKR2
p13639
sg13
I1
sa(dp13640
g7
I593
sg8
VP18509
p13641
sg10
I17
sg11
Vpituitary hormone
p13642
sg13
I2
sa(dp13643
g7
I210
sg8
g48
sg10
I6
sg11
VTCF7L1
p13644
sg13
I1
sa(dp13645
g7
I72
sg8
g48
sg10
I5
sg11
VHESX1
p13646
sg13
I1
sa(dp13647
g7
I91
sg8
g48
sg10
I4
sg11
VLHX3
p13648
sg13
I1
sa(dp13649
g7
I124
sg8
VP10071
p13650
sg10
I4
sg11
VGLI3
p13651
sg13
I1
sa(dp13652
g7
I156
sg8
VP55075
p13653
sg10
I4
sg11
VFGF8
p13654
sg13
I1
sa(dp13655
g7
I85
sg8
VP41225
p13656
sg10
I4
sg11
VSOX3
p13657
sg13
I1
sa(dp13658
g7
I136
sg8
VP32243
p13659
sg10
I4
sg11
VOTX2
p13660
sg13
I1
sa(dp13661
g7
I225
sg8
g48
sg10
I6
sg11
VGPR161
p13662
sg13
I1
sa(dp13663
g7
I236
sg8
g48
sg10
I4
sg11
VCDON
p13664
sg13
I1
sa(dp13665
g7
I177
sg8
g48
sg10
I5
sg11
VPROK2
p13666
sg13
I1
sa(dp13667
g7
I184
sg8
g48
sg10
I4
sg11
VCHD7
p13668
sg13
I1
sa(dp13669
g7
I103
sg8
g48
sg10
I5
sg11
VPROP1
p13670
sg13
I1
sa(dp13671
g7
I130
sg8
VP10070
p13672
sg10
I4
sg11
VGLI2
p13673
sg13
I1
sa(dp13674
g7
I190
sg8
g48
sg10
I5
sg11
VWDR11
p13675
sg13
I1
sasg29
(lp13676
(dp13677
g7
I486
sg32
VC0020635
p13678
sg10
I15
sg11
Vhypopituitarism
p13679
sg13
I1
sa(dp13680
g7
I269
sg32
VC0281947
p13681
sg10
I21
sg11
Vpituitary dysfunction
p13682
sg13
I2
sasa(dp13683
g2
S'Musashi-1 (Msi-1), an RNA-binding protein associated with neural progenitor cells, has been shown by others to increase the accumulation of tau isoforms in intracellular inclusions in frontotemporal dementia and parkinsonism linked to chromosome 17.\n'
p13684
sg4
(lp13685
(dp13686
g7
I0
sg8
g48
sg10
I9
sg11
VMusashi-1
p13687
sg13
I1
sa(dp13688
g7
I11
sg8
g48
sg10
I5
sg11
VMsi-1
p13689
sg13
I1
sasg29
(lp13690
(dp13691
g7
I212
sg32
VC0242422
p13692
sg10
I12
sg11
Vparkinsonism
p13693
sg13
I1
sa(dp13694
g7
I184
sg32
VC0338451
p13695
sg10
I23
sg11
Vfrontotemporal dementia
p13696
sg13
I2
sa(dp13697
g7
I11
sg32
VC0920269
p13698
sg10
I3
sg11
VMsi
p13699
sg13
I1
sasa(dp13700
g2
S'The HOXA11-AS1 lncRNA and HOXA9, HOXA10, HOXA11, and HOXA13 mRNA were expressed at significantly lower levels in the EU than in the EC, that is, in women with peritoneal endometriosis ( P &lt; .05).\n'
p13701
sg4
(lp13702
(dp13703
g7
I33
sg8
VP31260
p13704
sg10
I6
sg11
VHOXA10
p13705
sg13
I1
sa(dp13706
g7
I26
sg8
VP31269
p13707
sg10
I5
sg11
VHOXA9
p13708
sg13
I1
sa(dp13709
g7
I4
sg8
VP31270
p13710
sg10
I6
sg11
VHOXA11
p13711
sg13
I1
sa(dp13712
g7
I4
sg8
VP31270
p13713
sg10
I17
sg11
VHOXA11-AS1 lncRNA
p13714
sg13
I2
sa(dp13715
g7
I53
sg8
VP31271
p13716
sg10
I11
sg11
VHOXA13 mRNA
p13717
sg13
I2
sasg29
(lp13718
(dp13719
g7
I170
sg32
VC0014175
p13720
sg10
I13
sg11
Vendometriosis
p13721
sg13
I1
sa(dp13722
g7
I11
sg32
VC1846534
p13723
sg10
I3
sg11
VAS1
p13724
sg13
I1
sasa(dp13725
g2
S'The expression levels of HOXA10 and HOXA11 in the EU were significantly lower in women with peritoneal endometriosis compared to the control group participants ( P &lt; .05), whereas the levels of lncRNA ( HOXA11-AS1), HOXA9, and HOXA13 did not differ significantly between the 2 patient groups ( P &gt; .05).\n'
p13726
sg4
(lp13727
(dp13728
g7
I25
sg8
VP31260
p13729
sg10
I6
sg11
VHOXA10
p13730
sg13
I1
sa(dp13731
g7
I36
sg8
VP31270
p13732
sg10
I6
sg11
VHOXA11
p13733
sg13
I1
sa(dp13734
g7
I230
sg8
VP31271
p13735
sg10
I6
sg11
VHOXA13
p13736
sg13
I1
sa(dp13737
g7
I219
sg8
VP31269
p13738
sg10
I5
sg11
VHOXA9
p13739
sg13
I1
sa(dp13740
g7
I206
sg8
VP31270
p13741
sg10
I10
sg11
VHOXA11-AS1
p13742
sg13
I1
sasg29
(lp13743
(dp13744
g7
I213
sg32
VC1846534
p13745
sg10
I3
sg11
VAS1
p13746
sg13
I1
sa(dp13747
g7
I103
sg32
VC0014175
p13748
sg10
I13
sg11
Vendometriosis
p13749
sg13
I1
sasa(dp13750
g2
S'In conclusion, the study findings suggest that HOXA11-AS1 lncRNA may play a role in the development of peritoneal endometriosis, but HOXA11-AS1 may not influence endometrial receptivity in endometriosis-associated infertility.\n'
p13751
sg4
(lp13752
(dp13753
g7
I47
sg8
VP31270
p13754
sg10
I17
sg11
VHOXA11-AS1 lncRNA
p13755
sg13
I2
sa(dp13756
g7
I47
sg8
VP31270
p13757
sg10
I6
sg11
VHOXA11
p13758
sg13
I1
sa(dp13759
g7
I54
sg8
g48
sg10
I3
sg11
VAS1
p13760
sg13
I1
sasg29
(lp13761
(dp13762
g7
I54
sg32
VC1846534
p13763
sg10
I3
sg11
VAS1
p13764
sg13
I1
sa(dp13765
g7
I214
sg32
VC0021359
p13766
sg10
I11
sg11
Vinfertility
p13767
sg13
I1
sa(dp13768
g7
I114
sg32
VC0014175
p13769
sg10
I13
sg11
Vendometriosis
p13770
sg13
I1
sa(dp13771
g7
I114
sg32
VC0014175
p13772
sg10
I13
sg11
Vendometriosis
p13773
sg13
I1
sa(dp13774
g7
I54
sg32
VC1846534
p13775
sg10
I3
sg11
VAS1
p13776
sg13
I1
sasa(dp13777
g2
S'Genome-wide conjunctional analysis identified 17 novel loci at false discovery rate less than 0.05 with overlap between PD and autoimmune diseases, including known PD loci adjacent to GAK, HLA-DRB5, LRRK2, and MAPT for rheumatoid arthritis, ulcerative colitis and Crohn disease.\n'
p13778
sg4
(lp13779
(dp13780
g7
I184
sg8
g48
sg10
I3
sg11
VGAK
p13781
sg13
I1
sa(dp13782
g7
I199
sg8
g48
sg10
I5
sg11
VLRRK2
p13783
sg13
I1
sa(dp13784
g7
I189
sg8
g48
sg10
I8
sg11
VHLA-DRB5
p13785
sg13
I1
sasg29
(lp13786
(dp13787
g7
I127
sg32
VC0004364
p13788
sg10
I19
sg11
Vautoimmune diseases
p13789
sg13
I2
sa(dp13790
g7
I264
sg32
VC0010346
p13791
sg10
I13
sg11
VCrohn disease
p13792
sg13
I2
sa(dp13793
g7
I219
sg32
VC0003873
p13794
sg10
I20
sg11
Vrheumatoid arthritis
p13795
sg13
I2
sa(dp13796
g7
I241
sg32
VC0009324
p13797
sg10
I18
sg11
Vulcerative colitis
p13798
sg13
I2
sasa(dp13799
g2
S'The genetic association of HLA-DRB1 with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) is well documented, but association with other HLA-DR beta genes (HLA-DRB3, HLA-DRB4 and HLA-DRB5) has not been thoroughly studied, despite their similar functions and chromosomal positions.\n'
p13800
sg4
(lp13801
(dp13802
g7
I27
sg8
VP30486
p13803
sg10
I3
sg11
VHLA
p13804
sg13
I1
sa(dp13805
g7
I27
sg8
VP30486
p13806
sg10
I3
sg11
VHLA
p13807
sg13
I1
sa(dp13808
g7
I195
sg8
g48
sg10
I8
sg11
VHLA-DRB5
p13809
sg13
I1
sa(dp13810
g7
I27
sg8
VP30486
p13811
sg10
I3
sg11
VHLA
p13812
sg13
I1
sa(dp13813
g7
I153
sg8
VP30486
p13814
sg10
I17
sg11
VHLA-DR beta genes
p13815
sg13
I3
sa(dp13816
g7
I31
sg8
g48
sg10
I4
sg11
VDRB1
p13817
sg13
I1
sasg29
(lp13818
(dp13819
g7
I63
sg32
VC0003873
p13820
sg10
I2
sg11
VRA
p13821
sg13
I1
sa(dp13822
g7
I41
sg32
VC0003873
p13823
sg10
I20
sg11
Vrheumatoid arthritis
p13824
sg13
I2
sa(dp13825
g7
I71
sg32
VC0024141
p13826
sg10
I28
sg11
Vsystemic lupus erythematosus
p13827
sg13
I3
sa(dp13828
g7
I101
sg32
VC0024141
p13829
sg10
I3
sg11
VSLE
p13830
sg13
I1
sasa(dp13831
g2
S'Using intravital two-photon microscopy in the mouse model of multiple sclerosis, we detected antigen recognition motility of the OT-1 CD8(+) T cells within the CNS leading to a selective enrichment in inflammatory lesions.\n'
p13832
sg4
(lp13833
(dp13834
g7
I129
sg8
VP01732
p13835
sg10
I8
sg11
VOT-1 CD8
p13836
sg13
I2
sasg29
(lp13837
(dp13838
g7
I61
sg32
VC0026769
p13839
sg10
I18
sg11
Vmultiple sclerosis
p13840
sg13
I2
sasa(dp13841
g2
S'In the histological analysis, acute tubular necrosis was only marginally ameliorated following EPO administration.\n'
p13842
sg4
(lp13843
sg29
(lp13844
(dp13845
g7
I30
sg32
VC0022672
p13846
sg10
I22
sg11
Vacute tubular necrosis
p13847
sg13
I3
sasa(dp13848
g2
S'The results showed that BMSCs transplantation or EPO injection alone decreased the BUN and Scr levels and the acute tubular necrosis (ATN) scoring in varied degrees.\n'
p13849
sg4
(lp13850
(dp13851
g7
I49
sg8
VP01588
p13852
sg10
I3
sg11
VEPO
p13853
sg13
I1
sa(dp13854
g7
I91
sg8
g48
sg10
I3
sg11
VScr
p13855
sg13
I1
sasg29
(lp13856
(dp13857
g7
I134
sg32
VC0268494
p13858
sg10
I3
sg11
VATN
p13859
sg13
I1
sa(dp13860
g7
I110
sg32
VC0022672
p13861
sg10
I22
sg11
Vacute tubular necrosis
p13862
sg13
I3
sasa(dp13863
g2
S'In animals, recombinant erythropoietin (RhuEPO) leads to faster recovery after acute tubular necrosis.\n'
p13864
sg4
(lp13865
(dp13866
g7
I24
sg8
VP01588
p13867
sg10
I14
sg11
Verythropoietin
p13868
sg13
I1
sasg29
(lp13869
(dp13870
g7
I79
sg32
VC0022672
p13871
sg10
I22
sg11
Vacute tubular necrosis
p13872
sg13
I3
sasa(dp13873
g2
S'Group 2: 4 patients with acute tubular necrosis had no reticulocytes peak before d29 despite one or several erythropoietin peaks.\n'
p13874
sg4
(lp13875
(dp13876
g7
I108
sg8
VP01588
p13877
sg10
I14
sg11
Verythropoietin
p13878
sg13
I1
sasg29
(lp13879
(dp13880
g7
I25
sg32
VC0022672
p13881
sg10
I22
sg11
Vacute tubular necrosis
p13882
sg13
I3
sasa(dp13883
g2
S'Serum erythropoietin (EPO) concentrations were markedly depressed relative to the degree of anaemia in 10 patients with acute tubular necrosis, and remained low long after restoration of excretory renal function as estimated by glomerular filtration rate.\n'
p13884
sg4
(lp13885
(dp13886
g7
I22
sg8
VP01588
p13887
sg10
I3
sg11
VEPO
p13888
sg13
I1
sa(dp13889
g7
I6
sg8
VP01588
p13890
sg10
I14
sg11
Verythropoietin
p13891
sg13
I1
sasg29
(lp13892
(dp13893
g7
I92
sg32
VC0002871
p13894
sg10
I7
sg11
Vanaemia
p13895
sg13
I1
sa(dp13896
g7
I120
sg32
VC0022672
p13897
sg10
I22
sg11
Vacute tubular necrosis
p13898
sg13
I3
sasa(dp13899
g2
S'It is suggested that the predominantly are generatory anaemia found in prolonged cases of acute tubular necrosis, and the slow restoration of red cell mass during recovery, are due to the deficient synthesis of EPO.\n'
p13900
sg4
(lp13901
(dp13902
g7
I211
sg8
VP01588
p13903
sg10
I3
sg11
VEPO
p13904
sg13
I1
sasg29
(lp13905
(dp13906
g7
I90
sg32
VC0022672
p13907
sg10
I22
sg11
Vacute tubular necrosis
p13908
sg13
I3
sa(dp13909
g7
I54
sg32
VC0002871
p13910
sg10
I7
sg11
Vanaemia
p13911
sg13
I1
sasa(dp13912
g2
S'HDAC inhibitor BA could inhibit LPS-induced pulmonary fibrosis and Thy-1 gene silencing through inhibiting activation of HDAC and deacetylation of histone H4.\n'
p13913
sg4
(lp13914
(dp13915
g7
I0
sg8
VP56524
p13916
sg10
I4
sg11
VHDAC
p13917
sg13
I1
sa(dp13918
g7
I147
sg8
VP62805
p13919
sg10
I10
sg11
Vhistone H4
p13920
sg13
I2
sa(dp13921
g7
I0
sg8
VP56524
p13922
sg10
I4
sg11
VHDAC
p13923
sg13
I1
sasg29
(lp13924
(dp13925
g7
I44
sg32
VC0034069
p13926
sg10
I18
sg11
Vpulmonary fibrosis
p13927
sg13
I2
sa(dp13928
g7
I32
sg32
VC0175697
p13929
sg10
I3
sg11
VLPS
p13930
sg13
I1
sasa(dp13931
g2
S'We found that CS-induced distinct posttranslational histone modification patterns in histone H3 and histone H4 in lung cells, which may be considered as usable biomarkers for CS-induced chronic lung diseases.\n'
p13932
sg4
(lp13933
(dp13934
g7
I52
sg8
VP62805
p13935
sg10
I7
sg11
Vhistone
p13936
sg13
I1
sa(dp13937
g7
I85
sg8
g48
sg10
I10
sg11
Vhistone H3
p13938
sg13
I2
sa(dp13939
g7
I100
sg8
VP62805
p13940
sg10
I10
sg11
Vhistone H4
p13941
sg13
I2
sasg29
(lp13942
(dp13943
g7
I194
sg32
VC0024115
p13944
sg10
I13
sg11
Vlung diseases
p13945
sg13
I2
sasa(dp13946
g2
S'These identified histone marks (histone H3 and histone H4) may play an important role in the epigenetic state during the pathogenesis of smoking-induced chronic lung diseases, such as chronic obstructive pulmonary disease and lung cancer.\n'
p13947
sg4
(lp13948
(dp13949
g7
I17
sg8
VP62805
p13950
sg10
I13
sg11
Vhistone marks
p13951
sg13
I2
sa(dp13952
g7
I32
sg8
g48
sg10
I10
sg11
Vhistone H3
p13953
sg13
I2
sa(dp13954
g7
I47
sg8
VP62805
p13955
sg10
I10
sg11
Vhistone H4
p13956
sg13
I2
sasg29
(lp13957
(dp13958
g7
I226
sg32
VC0684249
p13959
sg10
I11
sg11
Vlung cancer
p13960
sg13
I2
sa(dp13961
g7
I161
sg32
VC0024115
p13962
sg10
I13
sg11
Vlung diseases
p13963
sg13
I2
sa(dp13964
g7
I121
sg32
VC0699748
p13965
sg10
I12
sg11
Vpathogenesis
p13966
sg13
I1
sa(dp13967
g7
I184
sg32
VC0024117
p13968
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p13969
sg13
I4
sasa(dp13970
g2
S'Since VDR and CD86 expression are decreased in the setting of melanoma and non-melanoma skin cancers, our findings suggest a potential role of vitamin D-deficiency in the progression of skin malignancies.\n'
p13971
sg4
(lp13972
(dp13973
g7
I14
sg8
VP42081
p13974
sg10
I4
sg11
VCD86
p13975
sg13
I1
sa(dp13976
g7
I6
sg8
VP11473
p13977
sg10
I3
sg11
VVDR
p13978
sg13
I1
sasg29
(lp13979
(dp13980
g7
I62
sg32
VC0025202
p13981
sg10
I8
sg11
Vmelanoma
p13982
sg13
I1
sa(dp13983
g7
I93
sg32
VC0006826
p13984
sg10
I7
sg11
Vcancers
p13985
sg13
I1
sa(dp13986
g7
I79
sg32
VC0151779
p13987
sg10
I13
sg11
Vmelanoma skin
p13988
sg13
I2
sa(dp13989
g7
I191
sg32
VC0006826
p13990
sg10
I12
sg11
Vmalignancies
p13991
sg13
I1
sasa(dp13992
g2
S'In the search for a more consistent apocrine marker, immunoreactivity for MAb B72.3 was examined in apocrine carcinomas at different stages and compared with GCDFP-15.\n'
p13993
sg4
(lp13994
(dp13995
g7
I74
sg8
VP42081
p13996
sg10
I9
sg11
VMAb B72.3
p13997
sg13
I2
sasg29
(lp13998
(dp13999
g7
I109
sg32
VC0007097
p14000
sg10
I10
sg11
Vcarcinomas
p14001
sg13
I1
sasa(dp14002
g2
S'47 of 51 apocrine carcinomas (92%) and 9 of 62 ordinary carcinomas (15%) were MAb B72.3 positive, while 39 of 51 apocrine carcinomas (76%) and 13 of 62 ordinary carcinomas (21%) were GCDFP-15 positive.\n'
p14003
sg4
(lp14004
(dp14005
g7
I78
sg8
VP42081
p14006
sg10
I9
sg11
VMAb B72.3
p14007
sg13
I2
sasg29
(lp14008
(dp14009
g7
I18
sg32
VC0007097
p14010
sg10
I10
sg11
Vcarcinomas
p14011
sg13
I1
sa(dp14012
g7
I18
sg32
VC0007097
p14013
sg10
I10
sg11
Vcarcinomas
p14014
sg13
I1
sa(dp14015
g7
I18
sg32
VC0007097
p14016
sg10
I10
sg11
Vcarcinomas
p14017
sg13
I1
sa(dp14018
g7
I18
sg32
VC0007097
p14019
sg10
I10
sg11
Vcarcinomas
p14020
sg13
I1
sasa(dp14021
g2
S'The combined usage of MAb B72.3 with GCDFP-15 was useful to confirm the diagnosis of apocrine carcinoma, especially for advanced tumors, with only two cases being negative for both MAb B72.3 and GCDFP-15.\n'
p14022
sg4
(lp14023
sg29
(lp14024
(dp14025
g7
I85
sg32
VC1706827
p14026
sg10
I18
sg11
Vapocrine carcinoma
p14027
sg13
I2
sa(dp14028
g7
I129
sg32
VC0027651
p14029
sg10
I6
sg11
Vtumors
p14030
sg13
I1
sasa(dp14031
g2
S'Double-deficient mice showed significantly reduced UV-induced skin tumor development, whereas CD86(-/-) mice produced skin cancer earlier compared with CD80(-/-) and control mice.\n'
p14032
sg4
(lp14033
(dp14034
g7
I152
sg8
VP33681
p14035
sg10
I4
sg11
VCD80
p14036
sg13
I1
sa(dp14037
g7
I94
sg8
VP42081
p14038
sg10
I9
sg11
VCD86(-/-)
p14039
sg13
I1
sasg29
(lp14040
(dp14041
g7
I118
sg32
VC0007114
p14042
sg10
I11
sg11
Vskin cancer
p14043
sg13
I2
sa(dp14044
g7
I62
sg32
VC0037286
p14045
sg10
I10
sg11
Vskin tumor
p14046
sg13
I2
sasa(dp14047
g2
S'We determined the concentration of peripheral blood lymphocytes, which expressed the CD80/CD86 or CD28/CTLA-4 molecules, in 38 patients with cutaneous melanoma and 27 controls.\n'
p14048
sg4
(lp14049
(dp14050
g7
I85
sg8
VP33681
p14051
sg10
I4
sg11
VCD80
p14052
sg13
I1
sa(dp14053
g7
I90
sg8
VP42081
p14054
sg10
I4
sg11
VCD86
p14055
sg13
I1
sa(dp14056
g7
I98
sg8
VP16410
p14057
sg10
I21
sg11
VCD28/CTLA-4 molecules
p14058
sg13
I2
sasg29
(lp14059
(dp14060
g7
I141
sg32
VC0025202
p14061
sg10
I18
sg11
Vcutaneous melanoma
p14062
sg13
I2
sasa(dp14063
g2
S'In the Neuro2a-ATD2 cells, the IC50 of acrolein increased from 4.2 to 6.8myM, and the levels of FosB and C/EBPBeta - transcription factors involved in the transcription of AcPAO and SMO genes - were reduced.\n'
p14064
sg4
(lp14065
(dp14066
g7
I96
sg8
VP53539
p14067
sg10
I4
sg11
VFosB
p14068
sg13
I1
sa(dp14069
g7
I182
sg8
g48
sg10
I9
sg11
VSMO genes
p14070
sg13
I2
sa(dp14071
g7
I105
sg8
VP19883
p14072
sg10
I33
sg11
VC/EBPBeta - transcription factors
p14073
sg13
I4
sa(dp14074
g7
I7
sg8
g48
sg10
I12
sg11
VNeuro2a-ATD2
p14075
sg13
I1
sasg29
(lp14076
(dp14077
g7
I15
sg32
VC1970005
p14078
sg10
I4
sg11
VATD2
p14079
sg13
I1
sasa(dp14080
g2
S'It was also found that transfection of siRNA for C/EBPBeta decreased SMO promoter activity in Neuro2a cells but not in ATD2 cells confirming that a decrease in C/EBPBeta is involved in the reduced SMO activity in Neuro2a-ATD2 cells.\n'
p14081
sg4
(lp14082
(dp14083
g7
I69
sg8
g48
sg10
I3
sg11
VSMO
p14084
sg13
I1
sa(dp14085
g7
I213
sg8
g48
sg10
I12
sg11
VNeuro2a-ATD2
p14086
sg13
I1
sa(dp14087
g7
I69
sg8
g48
sg10
I12
sg11
VSMO promoter
p14088
sg13
I2
sasg29
(lp14089
(dp14090
g7
I119
sg32
VC1970005
p14091
sg10
I4
sg11
VATD2
p14092
sg13
I1
sa(dp14093
g7
I119
sg32
VC1970005
p14094
sg10
I4
sg11
VATD2
p14095
sg13
I1
sasa(dp14096
g2
S"When glucose records from self-blood glucose monitoring (SBGM) do not reflect estimated average glucose from HgBA1, or when patients' clinical symptoms are not explained by their SBGM records, clinical management of diabetes becomes a challenge.\n"
p14097
sg4
(lp14098
sg29
(lp14099
(dp14100
g7
I216
sg32
VC0011849
p14101
sg10
I8
sg11
Vdiabetes
p14102
sg13
I1
sasa(dp14103
g2
S'CDE = Certified Diabetes Educator; CGM = Continuous glucose monitoring; HgBA1 = Glycosylated hemoglobin; MAD = Mean absolute difference; SBGM = Self-blood glucose monitoring; T1DM = Type 1 diabetes; T2DM = Type 2 diabetes.\n'
p14104
sg4
(lp14105
(dp14106
g7
I93
sg8
g48
sg10
I10
sg11
Vhemoglobin
p14107
sg13
I1
sasg29
(lp14108
(dp14109
g7
I182
sg32
VC0011854
p14110
sg10
I15
sg11
VType 1 diabetes
p14111
sg13
I3
sa(dp14112
g7
I16
sg32
VC0011849
p14113
sg10
I8
sg11
VDiabetes
p14114
sg13
I1
sa(dp14115
g7
I206
sg32
VC0011860
p14116
sg10
I15
sg11
VType 2 diabetes
p14117
sg13
I3
sasa(dp14118
g2
S'This study was designed to assess the reliability of blood glucose level estimation in gingival crevicular blood(GCB) for screening diabetes mellitus.\n'
p14119
sg4
(lp14120
sg29
(lp14121
(dp14122
g7
I132
sg32
VC0011849
p14123
sg10
I17
sg11
Vdiabetes mellitus
p14124
sg13
I2
sasa(dp14125
g2
S'Cases of gCB are defined as those with CB, diabetes mellitus and high signal intensities (HSIs) in the putamen on T1 weighted imaging (T1WI).\n'
p14126
sg4
(lp14127
(dp14128
g7
I9
sg8
VP04062
p14129
sg10
I3
sg11
VgCB
p14130
sg13
I1
sasg29
(lp14131
(dp14132
g7
I43
sg32
VC0011849
p14133
sg10
I17
sg11
Vdiabetes mellitus
p14134
sg13
I2
sasa(dp14135
g2
S'screen for diabetes control, this study compared glycosylated hemoglobin (HbAlc) levels found in GCB and serum.\n'
p14136
sg4
(lp14137
(dp14138
g7
I62
sg8
g48
sg10
I10
sg11
Vhemoglobin
p14139
sg13
I1
sasg29
(lp14140
(dp14141
g7
I11
sg32
VC0011849
p14142
sg10
I8
sg11
Vdiabetes
p14143
sg13
I1
sasa(dp14144
g2
S'This study was designed to explore the expression and role of IQGAP3 in pancreatic cancer, a highly lethal disease.\n'
p14145
sg4
(lp14146
(dp14147
g7
I62
sg8
g48
sg10
I6
sg11
VIQGAP3
p14148
sg13
I1
sasg29
(lp14149
(dp14150
g7
I72
sg32
VC0235974
p14151
sg10
I17
sg11
Vpancreatic cancer
p14152
sg13
I2
sasa(dp14153
g2
S'IQGAP3 mRNA expression was significantly increased in pancreatic cancer tissues, compared with non-cancerous tissues.\n'
p14154
sg4
(lp14155
(dp14156
g7
I0
sg8
g48
sg10
I11
sg11
VIQGAP3 mRNA
p14157
sg13
I2
sasg29
(lp14158
(dp14159
g7
I54
sg32
VC0235974
p14160
sg10
I17
sg11
Vpancreatic cancer
p14161
sg13
I2
sasa(dp14162
g2
S'Gene set enrichment analysis (GSEA) on The Cancer Genome Atlas (TCGA) dataset showed that cell apoptosis, metastasis and Cdc42 pathways were strongly associated with IQGAP3 expression in pancreatic cancer patients.\n'
p14163
sg4
(lp14164
(dp14165
g7
I166
sg8
g48
sg10
I6
sg11
VIQGAP3
p14166
sg13
I1
sa(dp14167
g7
I121
sg8
VP60953
p14168
sg10
I5
sg11
VCdc42
p14169
sg13
I1
sasg29
(lp14170
(dp14171
g7
I43
sg32
VC0006826
p14172
sg10
I6
sg11
VCancer
p14173
sg13
I1
sa(dp14174
g7
I106
sg32
VC0027627
p14175
sg10
I10
sg11
Vmetastasis
p14176
sg13
I1
sa(dp14177
g7
I187
sg32
VC0235974
p14178
sg10
I17
sg11
Vpancreatic cancer
p14179
sg13
I2
sasa(dp14180
g2
S'Knocking down of IQGAP3 in two pancreatic cancer cell lines with high level of IQGAP3 (BXPC-3 and SW1990) significantly inhibited cell proliferation, migration and invasion, and induced cell apoptosis.\n'
p14181
sg4
(lp14182
(dp14183
g7
I17
sg8
g48
sg10
I6
sg11
VIQGAP3
p14184
sg13
I1
sa(dp14185
g7
I17
sg8
g48
sg10
I6
sg11
VIQGAP3
p14186
sg13
I1
sasg29
(lp14187
(dp14188
g7
I31
sg32
VC0235974
p14189
sg10
I17
sg11
Vpancreatic cancer
p14190
sg13
I2
sa(dp14191
g7
I135
sg32
VC0334094
p14192
sg10
I13
sg11
Vproliferation
p14193
sg13
I1
sa(dp14194
g7
I164
sg32
VC2699153
p14195
sg10
I8
sg11
Vinvasion
p14196
sg13
I1
sasa(dp14197
g2
S'In conclusion, IQGAP3 may act as an oncogene in pancreatic cancer through regulating Cdc42 expression.\n'
p14198
sg4
(lp14199
(dp14200
g7
I15
sg8
g48
sg10
I6
sg11
VIQGAP3
p14201
sg13
I1
sa(dp14202
g7
I85
sg8
VP60953
p14203
sg10
I5
sg11
VCdc42
p14204
sg13
I1
sasg29
(lp14205
(dp14206
g7
I48
sg32
VC0235974
p14207
sg10
I17
sg11
Vpancreatic cancer
p14208
sg13
I2
sasa(dp14209
g2
S'The combination of ATRA and ATO targeting PML-RARA fusions has proven to be effective in acute promyelocytic leukemia (APL).\n'
p14210
sg4
(lp14211
(dp14212
g7
I42
sg8
g48
sg10
I3
sg11
VPML
p14213
sg13
I1
sa(dp14214
g7
I46
sg8
VP10276
p14215
sg10
I4
sg11
VRARA
p14216
sg13
I1
sasg29
(lp14217
(dp14218
g7
I89
sg32
VC0023487
p14219
sg10
I28
sg11
Vacute promyelocytic leukemia
p14220
sg13
I3
sa(dp14221
g7
I42
sg32
VC0023524
p14222
sg10
I3
sg11
VPML
p14223
sg13
I1
sa(dp14224
g7
I119
sg32
VC0023487
p14225
sg10
I3
sg11
VAPL
p14226
sg13
I1
sasa(dp14227
g2
S'In this work, a simple and enzyme-free surface plasmon resonance (SPR) biosensing strategy has been developed for highly sensitive detection of two major PML/RARAlfa (promyelocytic leukemia, retinoic acid receptor alpha) subtypes based on the heterogeneous fusion gene-triggered nonlinear hybridization chain reaction (HCR).\n'
p14228
sg4
(lp14229
(dp14230
g7
I191
sg8
VP10276
p14231
sg10
I28
sg11
Vretinoic acid receptor alpha
p14232
sg13
I4
sa(dp14233
g7
I154
sg8
g48
sg10
I3
sg11
VPML
p14234
sg13
I1
sasg29
(lp14235
(dp14236
g7
I167
sg32
VC2745900
p14237
sg10
I22
sg11
Vpromyelocytic leukemia
p14238
sg13
I2
sa(dp14239
g7
I154
sg32
VC0023524
p14240
sg10
I3
sg11
VPML
p14241
sg13
I1
sasa(dp14242
g2
S'Acute promyelocytic leukemia (APL) is a rare form of AML, which generally presents with a t(15;17) translocation causing expression of the fusion protein PML-RARA.\n'
p14243
sg4
(lp14244
(dp14245
g7
I154
sg8
g48
sg10
I8
sg11
VPML-RARA
p14246
sg13
I1
sasg29
(lp14247
(dp14248
g7
I0
sg32
VC0023487
p14249
sg10
I28
sg11
VAcute promyelocytic leukemia
p14250
sg13
I3
sa(dp14251
g7
I30
sg32
VC0023487
p14252
sg10
I3
sg11
VAPL
p14253
sg13
I1
sa(dp14254
g7
I53
sg32
VC0023467
p14255
sg10
I3
sg11
VAML
p14256
sg13
I1
sa(dp14257
g7
I154
sg32
VC0023524
p14258
sg10
I3
sg11
VPML
p14259
sg13
I1
sa(dp14260
g7
I99
sg32
VC0040715
p14261
sg10
I13
sg11
Vtranslocation
p14262
sg13
I1
sasa(dp14263
g2
S"The authors' analysis led to the discovery of a novel RARA superenhancer found in a subset of patients with AML, rendering these leukemia cells highly sensitive to SY-1425, a highly potent RARA agonist able to induce myeloid differentiation in these high-expressing RARA AML subtypes.\n"
p14264
sg4
(lp14265
(dp14266
g7
I54
sg8
VP10276
p14267
sg10
I4
sg11
VRARA
p14268
sg13
I1
sa(dp14269
g7
I54
sg8
VP10276
p14270
sg10
I4
sg11
VRARA
p14271
sg13
I1
sa(dp14272
g7
I54
sg8
VP10276
p14273
sg10
I4
sg11
VRARA
p14274
sg13
I1
sasg29
(lp14275
(dp14276
g7
I108
sg32
VC0023467
p14277
sg10
I3
sg11
VAML
p14278
sg13
I1
sa(dp14279
g7
I129
sg32
VC0023418
p14280
sg10
I8
sg11
Vleukemia
p14281
sg13
I1
sa(dp14282
g7
I108
sg32
VC0023467
p14283
sg10
I3
sg11
VAML
p14284
sg13
I1
sasa(dp14285
g2
S'Immunohistochemistry for TLR2, 4 and 5 was performed with anti-TLR2-TLR4-TLR5 antibodies in 117 histological samples of normal gastric mucosa (n = 22), HP+ gastritis (n = 20), intestinal metaplasia (n = 33), dysplasia (mucosectomy specimens, n = 20) and intestinal type adenocarcinoma (surgery specimens,n = 22); quantification of expression was performed independently by two pathologists taking into account the percentage of positive epithelial cells and the degree of expression (zero to three score).\n'
p14286
sg4
(lp14287
(dp14288
g7
I58
sg8
g48
sg10
I9
sg11
Vanti-TLR2
p14289
sg13
I1
sa(dp14290
g7
I73
sg8
g48
sg10
I4
sg11
VTLR5
p14291
sg13
I1
sasg29
(lp14292
(dp14293
g7
I208
sg32
VC0334044
p14294
sg10
I9
sg11
Vdysplasia
p14295
sg13
I1
sa(dp14296
g7
I176
sg32
VC0334037
p14297
sg10
I21
sg11
Vintestinal metaplasia
p14298
sg13
I2
sa(dp14299
g7
I254
sg32
VC0334279
p14300
sg10
I30
sg11
Vintestinal type adenocarcinoma
p14301
sg13
I3
sa(dp14302
g7
I156
sg32
VC0017152
p14303
sg10
I9
sg11
Vgastritis
p14304
sg13
I1
sasa(dp14305
g2
S'For the first time TLR4, TLR5 and TLR9 have been microanatomically localized in patients with noninflamed gastric mucosa and Helicobacter pylori gastritis by immunohistochemistry.\n'
p14306
sg4
(lp14307
(dp14308
g7
I34
sg8
g48
sg10
I4
sg11
VTLR9
p14309
sg13
I1
sa(dp14310
g7
I25
sg8
g48
sg10
I4
sg11
VTLR5
p14311
sg13
I1
sasg29
(lp14312
(dp14313
g7
I125
sg32
VC0343378
p14314
sg10
I29
sg11
VHelicobacter pylori gastritis
p14315
sg13
I3
sasa(dp14316
g2
S'TLR4, TLR5 and TLR9 were expressed by gastric epithelium in antrum and corpus of all patients with H. pylori gastritis (n = 14) and with noninflamed gastric mucosa (n = 5).\n'
p14317
sg4
(lp14318
(dp14319
g7
I15
sg8
g48
sg10
I4
sg11
VTLR9
p14320
sg13
I1
sa(dp14321
g7
I6
sg8
g48
sg10
I4
sg11
VTLR5
p14322
sg13
I1
sasg29
(lp14323
(dp14324
g7
I109
sg32
VC0017152
p14325
sg10
I9
sg11
Vgastritis
p14326
sg13
I1
sasa(dp14327
g2
S'However, in H. pylori gastritis TLR5 and TLR9 expression on the gastric epithelium changed to an exclusive basolateral localization without detectable expression at the apical pole.\n'
p14328
sg4
(lp14329
(dp14330
g7
I12
sg8
g48
sg10
I24
sg11
VH. pylori gastritis TLR5
p14331
sg13
I4
sa(dp14332
g7
I41
sg8
g48
sg10
I4
sg11
VTLR9
p14333
sg13
I1
sasg29
(lp14334
(dp14335
g7
I22
sg32
VC0017152
p14336
sg10
I9
sg11
Vgastritis
p14337
sg13
I1
sasa(dp14338
g2
S'The majority of NF1-associated spine neurofibromas are asymptomatic; however, a minority of patients will experience neurologic symptoms that can range from mild paresthesia, radiculopathy, myelopathy, and focal weakness to quadriplegia in extreme cases.\n'
p14339
sg4
(lp14340
(dp14341
g7
I16
sg8
VP21359
p14342
sg10
I3
sg11
VNF1
p14343
sg13
I1
sasg29
(lp14344
(dp14345
g7
I224
sg32
VC0034372
p14346
sg10
I12
sg11
Vquadriplegia
p14347
sg13
I1
sa(dp14348
g7
I37
sg32
VC0027830
p14349
sg10
I13
sg11
Vneurofibromas
p14350
sg13
I1
sa(dp14351
g7
I162
sg32
VC0030554
p14352
sg10
I11
sg11
Vparesthesia
p14353
sg13
I1
sa(dp14354
g7
I190
sg32
VC0037928
p14355
sg10
I10
sg11
Vmyelopathy
p14356
sg13
I1
sa(dp14357
g7
I175
sg32
VC0700594
p14358
sg10
I13
sg11
Vradiculopathy
p14359
sg13
I1
sa(dp14360
g7
I16
sg32
VC0027831
p14361
sg10
I3
sg11
VNF1
p14362
sg13
I1
sa(dp14363
g7
I117
sg32
VC0235031
p14364
sg10
I19
sg11
Vneurologic symptoms
p14365
sg13
I2
sa(dp14366
g7
I212
sg32
VC1883552
p14367
sg10
I8
sg11
Vweakness
p14368
sg13
I1
sasa(dp14369
g2
S'Our patient, unlike those in other reports, illustrates multiple aetiologies of hip dislocation in NF1 including local factors, lumbar radiculopathy and polyneuropathy, reinforcing the importance of a multidisciplinary approach in the management of such cases.\n'
p14370
sg4
(lp14371
(dp14372
g7
I99
sg8
VP21359
p14373
sg10
I3
sg11
VNF1
p14374
sg13
I1
sasg29
(lp14375
(dp14376
g7
I128
sg32
VC1263855
p14377
sg10
I20
sg11
Vlumbar radiculopathy
p14378
sg13
I2
sa(dp14379
g7
I153
sg32
VC0152025
p14380
sg10
I14
sg11
Vpolyneuropathy
p14381
sg13
I1
sa(dp14382
g7
I99
sg32
VC0027831
p14383
sg10
I3
sg11
VNF1
p14384
sg13
I1
sasa(dp14385
g2
S'Thus, ruptured extracranial vertebral artery aneurysm should be considered in the differential diagnosis of patients with NF1 with sudden-onset radiculopathy, even in the absence of typical symptoms.\n'
p14386
sg4
(lp14387
(dp14388
g7
I122
sg8
VP21359
p14389
sg10
I3
sg11
VNF1
p14390
sg13
I1
sasg29
(lp14391
(dp14392
g7
I144
sg32
VC0700594
p14393
sg10
I13
sg11
Vradiculopathy
p14394
sg13
I1
sa(dp14395
g7
I28
sg32
VC0574027
p14396
sg10
I25
sg11
Vvertebral artery aneurysm
p14397
sg13
I3
sa(dp14398
g7
I122
sg32
VC0027831
p14399
sg10
I3
sg11
VNF1
p14400
sg13
I1
sasa(dp14401
g2
S'The coexistence of polyneuropathy which has the definite clinical and electromyographical findings consistent with Charcot-Marie-Tooth (CMT) syndrome and neurofibromatosis type 1 (NF1) has infrequently been reported.\n'
p14402
sg4
(lp14403
sg29
(lp14404
(dp14405
g7
I141
sg32
VC0039082
p14406
sg10
I8
sg11
Vsyndrome
p14407
sg13
I1
sa(dp14408
g7
I19
sg32
VC0152025
p14409
sg10
I14
sg11
Vpolyneuropathy
p14410
sg13
I1
sa(dp14411
g7
I154
sg32
VC0027831
p14412
sg10
I24
sg11
Vneurofibromatosis type 1
p14413
sg13
I3
sa(dp14414
g7
I180
sg32
VC0027831
p14415
sg10
I3
sg11
VNF1
p14416
sg13
I1
sasa(dp14417
g2
S'An 18-year-old woman with previously diagnosed NF1 presented with a C6 radiculopathy.\n'
p14418
sg4
(lp14419
(dp14420
g7
I47
sg8
VP21359
p14421
sg10
I3
sg11
VNF1
p14422
sg13
I1
sasg29
(lp14423
(dp14424
g7
I71
sg32
VC0700594
p14425
sg10
I13
sg11
Vradiculopathy
p14426
sg13
I1
sa(dp14427
g7
I47
sg32
VC0027831
p14428
sg10
I3
sg11
VNF1
p14429
sg13
I1
sasa(dp14430
g2
S'Neuropathies are typically observed in young men with subcutaneous neurofibromas (NF1) or cutaneous schwannomas (NF2) and are characterized by a chronic slowly worsening sensorimotor polyneuropathy of the lower limbs.\n'
p14431
sg4
(lp14432
(dp14433
g7
I82
sg8
VP21359
p14434
sg10
I3
sg11
VNF1
p14435
sg13
I1
sasg29
(lp14436
(dp14437
g7
I170
sg32
VC0271682
p14438
sg10
I27
sg11
Vsensorimotor polyneuropathy
p14439
sg13
I2
sa(dp14440
g7
I113
sg32
VC0027832
p14441
sg10
I3
sg11
VNF2
p14442
sg13
I1
sa(dp14443
g7
I82
sg32
VC0027831
p14444
sg10
I3
sg11
VNF1
p14445
sg13
I1
sa(dp14446
g7
I67
sg32
VC0027830
p14447
sg10
I13
sg11
Vneurofibromas
p14448
sg13
I1
sa(dp14449
g7
I0
sg32
VC0442874
p14450
sg10
I12
sg11
VNeuropathies
p14451
sg13
I1
sa(dp14452
g7
I100
sg32
VC0027809
p14453
sg10
I11
sg11
Vschwannomas
p14454
sg13
I1
sasa(dp14455
g2
S'We conducted genome-wide association studies (GWAS) to identify susceptibility loci for glomerular filtration rate, estimated by serum creatinine (eGFRcrea) and cystatin C (eGFRcys), and CKD (eGFRcrea &lt; 60 ml/min/1.73 m(2)) in European-ancestry participants of four population-based cohorts (ARIC, CHS, FHS, RS; n = 19,877; 2,388 CKD cases), and tested for replication in 21,466 participants (1,932 CKD cases).\n'
p14456
sg4
(lp14457
(dp14458
g7
I161
sg8
VP01034
p14459
sg10
I10
sg11
Vcystatin C
p14460
sg13
I2
sasg29
(lp14461
(dp14462
g7
I306
sg32
VC0265372
p14463
sg10
I3
sg11
VFHS
p14464
sg13
I1
sa(dp14465
g7
I301
sg32
VC0007965
p14466
sg10
I3
sg11
VCHS
p14467
sg13
I1
sasa(dp14468
g2
S"Although several genetic associations have been identified between CCR6 polymorphisms and immune system disorders (e.g., rheumatoid arthritis and Crohn's disease), the pharmacological effects of naturally occurring missense mutations in this receptor have yet to be characterized.\n"
p14469
sg4
(lp14470
(dp14471
g7
I67
sg8
VP51684
p14472
sg10
I4
sg11
VCCR6
p14473
sg13
I1
sasg29
(lp14474
(dp14475
g7
I121
sg32
VC0003873
p14476
sg10
I20
sg11
Vrheumatoid arthritis
p14477
sg13
I2
sa(dp14478
g7
I146
sg32
VC0010346
p14479
sg10
I15
sg11
VCrohn's disease
p14480
sg13
I2
sasa(dp14481
g2
S'A genome-wide association study in Japan identified the C-C chemokine receptor type 6 gene (CCR6) as associated with rheumatoid arthritis (RA).\n'
p14482
sg4
(lp14483
(dp14484
g7
I92
sg8
VP51684
p14485
sg10
I4
sg11
VCCR6
p14486
sg13
I1
sa(dp14487
g7
I56
sg8
VP61073
p14488
sg10
I34
sg11
VC-C chemokine receptor type 6 gene
p14489
sg13
I6
sasg29
(lp14490
(dp14491
g7
I139
sg32
VC0003873
p14492
sg10
I2
sg11
VRA
p14493
sg13
I1
sa(dp14494
g7
I117
sg32
VC0003873
p14495
sg10
I20
sg11
Vrheumatoid arthritis
p14496
sg13
I2
sasa(dp14497
g2
S"This evidence supports loci for the genes encoding for both catalase and the aniridia-Wilms' tumor association within the bands p13-p14 of the short arm of chromosome 11; the normal activity of LDH-A supports a locus outside this region.\n"
p14498
sg4
(lp14499
(dp14500
g7
I128
sg8
g48
sg10
I3
sg11
Vp13
p14501
sg13
I1
sa(dp14502
g7
I60
sg8
VP04040
p14503
sg10
I8
sg11
Vcatalase
p14504
sg13
I1
sa(dp14505
g7
I132
sg8
VP03971
p14506
sg10
I3
sg11
Vp14
p14507
sg13
I1
sa(dp14508
g7
I194
sg8
VP00338
p14509
sg10
I5
sg11
VLDH-A
p14510
sg13
I1
sasg29
(lp14511
(dp14512
g7
I86
sg32
VC0027708
p14513
sg10
I12
sg11
VWilms' tumor
p14514
sg13
I2
sa(dp14515
g7
I77
sg32
VC0003076
p14516
sg10
I8
sg11
Vaniridia
p14517
sg13
I1
sasa(dp14518
g2
S'Observed familial clustering of hepatic iron overload with A1ATD suggests a genetic cause, but genotypes known to be associated with hemochromatosis were absent.\n'
p14519
sg4
(lp14520
sg29
(lp14521
(dp14522
g7
I133
sg32
VC0018995
p14523
sg10
I15
sg11
Vhemochromatosis
p14524
sg13
I1
sa(dp14525
g7
I40
sg32
VC0282193
p14526
sg10
I13
sg11
Viron overload
p14527
sg13
I2
sasa(dp14528
g2
S'Our aim was to estimate the frequency of hemochromatosis gene (HFE) mutant alleles (C282Y and H63D) and alpha-1 antitrypsin S/Z variants among Egyptian HCV cirrhotic patients and in hepatocellular carcinoma patients and to evaluate their effects on disease progression.\n'
p14529
sg4
(lp14530
(dp14531
g7
I112
sg8
g48
sg10
I24
sg11
Vantitrypsin S/Z variants
p14532
sg13
I3
sasg29
(lp14533
(dp14534
g7
I41
sg32
VC0018995
p14535
sg10
I15
sg11
Vhemochromatosis
p14536
sg13
I1
sa(dp14537
g7
I249
sg32
VC0242656
p14538
sg10
I19
sg11
Vdisease progression
p14539
sg13
I2
sa(dp14540
g7
I68
sg32
VC0596988
p14541
sg10
I6
sg11
Vmutant
p14542
sg13
I1
sa(dp14543
g7
I182
sg32
VC1512411
p14544
sg10
I24
sg11
Vhepatocellular carcinoma
p14545
sg13
I2
sasa(dp14546
g2
S'In this review, we focus our description of this phenomenon on inherited disorders affecting the liver, with a particular emphasis on Wilson disease (WD), genetic hemochromatosis, and Alfa-1 anti-trypsin disease (A1-AT).\n'
p14547
sg4
(lp14548
(dp14549
g7
I184
sg8
VP35030
p14550
sg10
I19
sg11
VAlfa-1 anti-trypsin
p14551
sg13
I2
sasg29
(lp14552
(dp14553
g7
I134
sg32
VC0019202
p14554
sg10
I14
sg11
VWilson disease
p14555
sg13
I2
sa(dp14556
g7
I163
sg32
VC0018995
p14557
sg10
I15
sg11
Vhemochromatosis
p14558
sg13
I1
sa(dp14559
g7
I150
sg32
VC0019202
p14560
sg10
I2
sg11
VWD
p14561
sg13
I1
sasa(dp14562
g2
S'Other much less frequent (yet not rare) causes of persistent non-virus non-alcohol related elevations in aminotransferase levels are celiac disease and hemochromatosis, whereas autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and alpha-1-anti-trypsin deficit are rare.\n'
p14563
sg4
(lp14564
(dp14565
g7
I262
sg8
VP35030
p14566
sg10
I20
sg11
Valpha-1-anti-trypsin
p14567
sg13
I1
sasg29
(lp14568
(dp14569
g7
I283
sg32
VC0162429
p14570
sg10
I7
sg11
Vdeficit
p14571
sg13
I1
sa(dp14572
g7
I226
sg32
VC0566602
p14573
sg10
I30
sg11
Vprimary sclerosing cholangitis
p14574
sg13
I3
sa(dp14575
g7
I152
sg32
VC0018995
p14576
sg10
I15
sg11
Vhemochromatosis
p14577
sg13
I1
sa(dp14578
g7
I177
sg32
VC0241910
p14579
sg10
I20
sg11
Vautoimmune hepatitis
p14580
sg13
I2
sa(dp14581
g7
I133
sg32
VC0007570
p14582
sg10
I14
sg11
Vceliac disease
p14583
sg13
I2
sasa(dp14584
g2
S'This retrospective study includes patients with vulvar squamous cell carcinoma who underwent inguinofemoral lymphadenectomy (IFL) between 1998 and 2011.\n'
p14585
sg4
(lp14586
sg29
(lp14587
(dp14588
g7
I48
sg32
VC0280856
p14589
sg10
I30
sg11
Vvulvar squamous cell carcinoma
p14590
sg13
I4
sasa(dp14591
g2
S'Our aim was to compare the risk of groin recurrence and morbidity in patients with lymph node positive VSCC after standard full inguinofemoral lymphadenectomy (IFL) versus less radical debulking of clinically involved lymph nodes or removal of sentinel nodes only followed by radiotherapy.\n'
p14592
sg4
(lp14593
sg29
(lp14594
(dp14595
g7
I41
sg32
VC1458156
p14596
sg10
I10
sg11
Vrecurrence
p14597
sg13
I1
sasa(dp14598
g2
S'The objective of the study is to determine the risk factors for groin recurrence (GR) in patients with primary vulvar squamous cell carcinoma (SCC) after inguinofemoral lymphadenectomy (IFL) without lymph node metastases and/or adjuvant chemoradiotherapy.\n'
p14599
sg4
(lp14600
(dp14601
g7
I64
sg8
g48
sg10
I16
sg11
Vgroin recurrence
p14602
sg13
I2
sa(dp14603
g7
I82
sg8
VP00390
p14604
sg10
I2
sg11
VGR
p14605
sg13
I1
sasg29
(lp14606
(dp14607
g7
I111
sg32
VC0280856
p14608
sg10
I30
sg11
Vvulvar squamous cell carcinoma
p14609
sg13
I4
sa(dp14610
g7
I70
sg32
VC1458156
p14611
sg10
I10
sg11
Vrecurrence
p14612
sg13
I1
sa(dp14613
g7
I199
sg32
VC0686619
p14614
sg10
I21
sg11
Vlymph node metastases
p14615
sg13
I3
sasa(dp14616
g2
S'All cytokines, with the exception of IFN alpha, showed inhibitory effects on DNA synthesis by vulvar carcinoma cells.\n'
p14617
sg4
(lp14618
(dp14619
g7
I37
sg8
VP01562
p14620
sg10
I9
sg11
VIFN alpha
p14621
sg13
I2
sasg29
(lp14622
(dp14623
g7
I94
sg32
VC0677055
p14624
sg10
I16
sg11
Vvulvar carcinoma
p14625
sg13
I2
sasa(dp14626
g2
S'Using genetic murine models, we found that proximal tubule-specific deletion of Drp1 prevented the renal ischemia-reperfusion-induced kidney injury, inflammation, and programmed cell death observed in wild-type mice and promoted epithelial recovery, which associated with activation of the renoprotective Beta-hydroxybutyrate signaling pathway.\n'
p14627
sg4
(lp14628
(dp14629
g7
I80
sg8
VP46939
p14630
sg10
I4
sg11
VDrp1
p14631
sg13
I1
sasg29
(lp14632
(dp14633
g7
I99
sg32
VC0920646
p14634
sg10
I14
sg11
Vrenal ischemia
p14635
sg13
I2
sa(dp14636
g7
I149
sg32
VC0021368
p14637
sg10
I12
sg11
Vinflammation
p14638
sg13
I1
sasa(dp14639
g2
S'Lastly, proximal tubule deletion of DRP1 after ischemia-reperfusion injury attenuated progressive kidney injury and fibrosis.\n'
p14640
sg4
(lp14641
(dp14642
g7
I36
sg8
VP46939
p14643
sg10
I4
sg11
VDRP1
p14644
sg13
I1
sasg29
(lp14645
(dp14646
g7
I116
sg32
VC0016059
p14647
sg10
I8
sg11
Vfibrosis
p14648
sg13
I1
sa(dp14649
g7
I47
sg32
VC0022116
p14650
sg10
I8
sg11
Vischemia
p14651
sg13
I1
sasa(dp14652
g2
S'Neurodegenerative diseases are associated with mitochondrial dysfunction, and the downregulation of DLP-1 has been previously identified in a stroke animal model.\n'
p14653
sg4
(lp14654
(dp14655
g7
I100
sg8
g48
sg10
I5
sg11
VDLP-1
p14656
sg13
I1
sasg29
(lp14657
(dp14658
g7
I142
sg32
VC0038454
p14659
sg10
I6
sg11
Vstroke
p14660
sg13
I1
sa(dp14661
g7
I0
sg32
VC0524851
p14662
sg10
I26
sg11
VNeurodegenerative diseases
p14663
sg13
I2
sasa(dp14664
g2
S'Here, we investigated the changes in DLP-1 protein expression in an animal model of focal cerebral ischemia with induced hyperglycemia.\n'
p14665
sg4
(lp14666
(dp14667
g7
I37
sg8
g48
sg10
I13
sg11
VDLP-1 protein
p14668
sg13
I2
sasg29
(lp14669
(dp14670
g7
I121
sg32
VC0020456
p14671
sg10
I13
sg11
Vhyperglycemia
p14672
sg13
I1
sa(dp14673
g7
I90
sg32
VC0917798
p14674
sg10
I17
sg11
Vcerebral ischemia
p14675
sg13
I2
sasa(dp14676
g2
S'To investigate the protective effect of dynamin-related protein 1 (Drp1) in rats with myocardial ischemia/reperfusion injury (IRI).\n'
p14677
sg4
(lp14678
(dp14679
g7
I40
sg8
VP14222
p14680
sg10
I25
sg11
Vdynamin-related protein 1
p14681
sg13
I3
sa(dp14682
g7
I67
sg8
VP46939
p14683
sg10
I4
sg11
VDrp1
p14684
sg13
I1
sasg29
(lp14685
(dp14686
g7
I86
sg32
VC0151744
p14687
sg10
I19
sg11
Vmyocardial ischemia
p14688
sg13
I2
sasa(dp14689
g2
S'Furthermore, trimetazidine improved mitochondrial biosynthesis and fission/fusion, as demonstrated by the promotion of peroxisome proliferator-activated receptor gamma (PPARGamma) co-activator 1Alfa (PGC-1Alfa), mitofusins 1 (Mfn1), dynamin-related protein 1 (Drp1), and optic atrophy 1 (Opa1) expressions in rats with acute myocardial ischemia.\n'
p14690
sg4
(lp14691
(dp14692
g7
I226
sg8
g48
sg10
I4
sg11
VMfn1
p14693
sg13
I1
sa(dp14694
g7
I233
sg8
VP14222
p14695
sg10
I25
sg11
Vdynamin-related protein 1
p14696
sg13
I3
sa(dp14697
g7
I271
sg8
g48
sg10
I15
sg11
Voptic atrophy 1
p14698
sg13
I3
sa(dp14699
g7
I260
sg8
VP46939
p14700
sg10
I4
sg11
VDrp1
p14701
sg13
I1
sa(dp14702
g7
I212
sg8
g48
sg10
I12
sg11
Vmitofusins 1
p14703
sg13
I2
sa(dp14704
g7
I288
sg8
g48
sg10
I4
sg11
VOpa1
p14705
sg13
I1
sa(dp14706
g7
I119
sg8
g48
sg10
I79
sg11
Vperoxisome proliferator-activated receptor gamma (PPARGamma) co-activator 1Alfa
p14707
sg13
I7
sasg29
(lp14708
(dp14709
g7
I319
sg32
VC0746731
p14710
sg10
I25
sg11
Vacute myocardial ischemia
p14711
sg13
I3
sa(dp14712
g7
I271
sg32
VC0338508
p14713
sg10
I15
sg11
Voptic atrophy 1
p14714
sg13
I3
sa(dp14715
g7
I288
sg32
VC0338508
p14716
sg10
I4
sg11
VOpa1
p14717
sg13
I1
sasa(dp14718
g2
S'For example, TRIM39/RPP21 read through transcript is a known mediator of the interferon response, a central pathway involved in the pathogenesis of CLE and systemic lupus erythematosus (SLE).\n'
p14719
sg4
(lp14720
(dp14721
g7
I13
sg8
g48
sg10
I6
sg11
VTRIM39
p14722
sg13
I1
sa(dp14723
g7
I77
sg8
VP01563
p14724
sg10
I10
sg11
Vinterferon
p14725
sg13
I1
sasg29
(lp14726
(dp14727
g7
I132
sg32
VC0699748
p14728
sg10
I12
sg11
Vpathogenesis
p14729
sg13
I1
sa(dp14730
g7
I156
sg32
VC0024141
p14731
sg10
I28
sg11
Vsystemic lupus erythematosus
p14732
sg13
I3
sa(dp14733
g7
I148
sg32
VC2931489
p14734
sg10
I3
sg11
VCLE
p14735
sg13
I1
sa(dp14736
g7
I186
sg32
VC0024141
p14737
sg10
I3
sg11
VSLE
p14738
sg13
I1
sasa(dp14739
g2
S'Taken together, this genomewide analysis of disease association of CLE identified candidate genes and genomic regions that may contribute to pathogenic mechanisms in CLE via dysregulated antigen presentation (HLA-DQA1), apoptosis regulation, RNA processing and interferon response (MICA, MICB, MSH5, TRIM39 and RPP21).\n'
p14740
sg4
(lp14741
(dp14742
g7
I294
sg8
g48
sg10
I4
sg11
VMSH5
p14743
sg13
I1
sa(dp14744
g7
I67
sg8
g48
sg10
I3
sg11
VCLE
p14745
sg13
I1
sa(dp14746
g7
I209
sg8
VP30486
p14747
sg10
I3
sg11
VHLA
p14748
sg13
I1
sa(dp14749
g7
I300
sg8
g48
sg10
I6
sg11
VTRIM39
p14750
sg13
I1
sa(dp14751
g7
I261
sg8
VP01563
p14752
sg10
I10
sg11
Vinterferon
p14753
sg13
I1
sasg29
(lp14754
(dp14755
g7
I67
sg32
VC2931489
p14756
sg10
I3
sg11
VCLE
p14757
sg13
I1
sa(dp14758
g7
I67
sg32
VC2931489
p14759
sg10
I3
sg11
VCLE
p14760
sg13
I1
sa(dp14761
g7
I282
sg32
VC0700319
p14762
sg10
I4
sg11
VMICA
p14763
sg13
I1
sasa(dp14764
g2
S'Non-O BG type predicted invasive carcinoma independently from high serum CA19-9 and male gender.\n'
p14765
sg4
(lp14766
(dp14767
g7
I62
sg8
g48
sg10
I17
sg11
Vhigh serum CA19-9
p14768
sg13
I3
sasg29
(lp14769
(dp14770
g7
I24
sg32
VC1334274
p14771
sg10
I18
sg11
Vinvasive carcinoma
p14772
sg13
I2
sasa(dp14773
g2
S'The results of the study suggest that in pancreatic IPMN, non-O BG type predicted invasive carcinoma, whereas for intratumor BG-antigen expression no specific patterns were detected with regard to the progression of glandular epithelial dysplasia or invasion.\n'
p14774
sg4
(lp14775
(dp14776
g7
I125
sg8
VP14209
p14777
sg10
I10
sg11
VBG-antigen
p14778
sg13
I1
sasg29
(lp14779
(dp14780
g7
I82
sg32
VC1334274
p14781
sg10
I18
sg11
Vinvasive carcinoma
p14782
sg13
I2
sa(dp14783
g7
I250
sg32
VC2699153
p14784
sg10
I8
sg11
Vinvasion
p14785
sg13
I1
sa(dp14786
g7
I41
sg32
VC1518869
p14787
sg10
I15
sg11
Vpancreatic IPMN
p14788
sg13
I2
sa(dp14789
g7
I226
sg32
VC0878500
p14790
sg10
I20
sg11
Vepithelial dysplasia
p14791
sg13
I2
sasa(dp14792
g2
S'Analysis of the UOK-109 renal carcinoma cell line confirmed the break-apart TFE3 probe set can distinguish the subtle TFE3/NONO fusion-associated inversion of chromosome X.\n'
p14793
sg4
(lp14794
(dp14795
g7
I123
sg8
g48
sg10
I4
sg11
VNONO
p14796
sg13
I1
sa(dp14797
g7
I76
sg8
VP19532
p14798
sg10
I4
sg11
VTFE3
p14799
sg13
I1
sa(dp14800
g7
I76
sg8
VP19532
p14801
sg10
I4
sg11
VTFE3
p14802
sg13
I1
sasg29
(lp14803
(dp14804
g7
I146
sg32
VC0021943
p14805
sg10
I9
sg11
Vinversion
p14806
sg13
I1
sa(dp14807
g7
I24
sg32
VC0007134
p14808
sg10
I15
sg11
Vrenal carcinoma
p14809
sg13
I2
sasa(dp14810
g2
S'Treatment with HA-1A also had a significant positive effect on resolution of the major complications of sepsis (shock, disseminated intravascular coagulation, acute renal failure, acute hepatic failure, or adult respiratory distress syndrome) in patients with documented gram-negative bacteremia.\n'
p14811
sg4
(lp14812
sg29
(lp14813
(dp14814
g7
I271
sg32
VC0744471
p14815
sg10
I24
sg11
Vgram-negative bacteremia
p14816
sg13
I2
sa(dp14817
g7
I206
sg32
VC0035222
p14818
sg10
I35
sg11
Vadult respiratory distress syndrome
p14819
sg13
I4
sa(dp14820
g7
I119
sg32
VC0012739
p14821
sg10
I38
sg11
Vdisseminated intravascular coagulation
p14822
sg13
I3
sa(dp14823
g7
I104
sg32
VC0243026
p14824
sg10
I6
sg11
Vsepsis
p14825
sg13
I1
sa(dp14826
g7
I171
sg32
VC0162557
p14827
sg10
I22
sg11
Vfailure, acute hepatic
p14828
sg13
I3
sasa(dp14829
g2
S'Interestingly, miR-124 was down-regulated in the spinal cord in cancer pain conditions, leading to an up-regulation of Synpo.\n'
p14830
sg4
(lp14831
(dp14832
g7
I15
sg8
g48
sg10
I7
sg11
VmiR-124
p14833
sg13
I1
sa(dp14834
g7
I119
sg8
g48
sg10
I5
sg11
VSynpo
p14835
sg13
I1
sasg29
(lp14836
(dp14837
g7
I64
sg32
VC0596240
p14838
sg10
I11
sg11
Vcancer pain
p14839
sg13
I2
sa(dp14840
g7
I56
sg32
VC0035334
p14841
sg10
I4
sg11
Vcord
p14842
sg13
I1
sasa(dp14843
g2
S'Furthermore, intrathecal injections of miR-124 mimics in cancerous mice normalized Synpo expression and completely alleviated cancer pain in the early phase of the cancer.\n'
p14844
sg4
(lp14845
(dp14846
g7
I83
sg8
g48
sg10
I5
sg11
VSynpo
p14847
sg13
I1
sasg29
(lp14848
(dp14849
g7
I57
sg32
VC0006826
p14850
sg10
I6
sg11
Vcancer
p14851
sg13
I1
sa(dp14852
g7
I126
sg32
VC0596240
p14853
sg10
I11
sg11
Vcancer pain
p14854
sg13
I2
sasa(dp14855
g2
S"Podocyte loss was measured by Wilms' Tumor 1-positive podocyte nuclear counting and density, glomerular epithelial protein 1 or synaptopodin-positive podocyte tuft area and urinary podocyte mRNA excretion rate.\n"
p14856
sg4
(lp14857
(dp14858
g7
I128
sg8
g48
sg10
I12
sg11
Vsynaptopodin
p14859
sg13
I1
sa(dp14860
g7
I104
sg8
VP14222
p14861
sg10
I20
sg11
Vepithelial protein 1
p14862
sg13
I3
sasg29
(lp14863
(dp14864
g7
I30
sg32
VC0027708
p14865
sg10
I12
sg11
VWilms' Tumor
p14866
sg13
I2
sasa(dp14867
g2
S"Using an immunohistochemical technique, we examined the natural course of nephrin, Wilms' tumor-1 (WT1) and synaptopodin at 16.5 days of embryonic age (E16.5d) and E19.5d, 7 days of post-neonatal age (P7d) and P42d during renal development of mice.\n"
p14868
sg4
(lp14869
(dp14870
g7
I99
sg8
g48
sg10
I3
sg11
VWT1
p14871
sg13
I1
sa(dp14872
g7
I74
sg8
g48
sg10
I7
sg11
Vnephrin
p14873
sg13
I1
sa(dp14874
g7
I83
sg8
g48
sg10
I14
sg11
VWilms' tumor-1
p14875
sg13
I2
sa(dp14876
g7
I152
sg8
g48
sg10
I6
sg11
VE16.5d
p14877
sg13
I1
sasg29
(lp14878
(dp14879
g7
I99
sg32
VC0027708
p14880
sg10
I3
sg11
VWT1
p14881
sg13
I1
sa(dp14882
g7
I83
sg32
VC0027708
p14883
sg10
I14
sg11
VWilms' tumor-1
p14884
sg13
I2
sasa(dp14885
g2
S"Expression of Wilms' tumor-1 (WT1) and synaptopodin were detected by immunofluorescence and western blotting.\n"
p14886
sg4
(lp14887
(dp14888
g7
I30
sg8
g48
sg10
I3
sg11
VWT1
p14889
sg13
I1
sa(dp14890
g7
I14
sg8
g48
sg10
I14
sg11
VWilms' tumor-1
p14891
sg13
I2
sa(dp14892
g7
I39
sg8
g48
sg10
I12
sg11
Vsynaptopodin
p14893
sg13
I1
sasg29
(lp14894
(dp14895
g7
I30
sg32
VC0027708
p14896
sg10
I3
sg11
VWT1
p14897
sg13
I1
sa(dp14898
g7
I14
sg32
VC0027708
p14899
sg10
I14
sg11
VWilms' tumor-1
p14900
sg13
I2
sasa(dp14901
g2
S'We generated a rabbit polyclonal antibody against the conjugated peptide from human INF2 and studied the glomerular expression of INF2 and synaptopodin using normal human adult kidney tissues and tissues from children with glomerular diseases such as minimal change disease (MCD), FSGS, IgA nephropathy (IgAN), non-IgA mesangial proliferative glomerulonephritis (non-IgAN), and Henoch-Schoenlein purpura nephritis (HSPN).\n'
p14902
sg4
(lp14903
(dp14904
g7
I304
sg8
VP11912
p14905
sg10
I4
sg11
VIgAN
p14906
sg13
I1
sa(dp14907
g7
I130
sg8
g48
sg10
I21
sg11
VINF2 and synaptopodin
p14908
sg13
I3
sa(dp14909
g7
I287
sg8
VP11912
p14910
sg10
I15
sg11
VIgA nephropathy
p14911
sg13
I2
sa(dp14912
g7
I287
sg8
VP11912
p14913
sg10
I3
sg11
VIgA
p14914
sg13
I1
sa(dp14915
g7
I281
sg8
g48
sg10
I4
sg11
VFSGS
p14916
sg13
I1
sa(dp14917
g7
I304
sg8
VP11912
p14918
sg10
I4
sg11
VIgAN
p14919
sg13
I1
sasg29
(lp14920
(dp14921
g7
I304
sg32
VC0017661
p14922
sg10
I4
sg11
VIgAN
p14923
sg13
I1
sa(dp14924
g7
I319
sg32
VC0221238
p14925
sg10
I42
sg11
Vmesangial proliferative glomerulonephritis
p14926
sg13
I3
sa(dp14927
g7
I251
sg32
VC1704320
p14928
sg10
I22
sg11
Vminimal change disease
p14929
sg13
I3
sa(dp14930
g7
I287
sg32
VC0017661
p14931
sg10
I15
sg11
VIgA nephropathy
p14932
sg13
I2
sa(dp14933
g7
I275
sg32
VC1636149
p14934
sg10
I3
sg11
VMCD
p14935
sg13
I1
sa(dp14936
g7
I352
sg32
VC0027697
p14937
sg10
I9
sg11
Vnephritis
p14938
sg13
I1
sa(dp14939
g7
I304
sg32
VC0017661
p14940
sg10
I4
sg11
VIgAN
p14941
sg13
I1
sa(dp14942
g7
I378
sg32
VC0034152
p14943
sg10
I25
sg11
VHenoch-Schoenlein purpura
p14944
sg13
I2
sa(dp14945
g7
I223
sg32
VC0268731
p14946
sg10
I19
sg11
Vglomerular diseases
p14947
sg13
I2
sasa(dp14948
g2
S"Mouse podocyte cells (MPC5) were treated with TAC and/or TGF-Beta1 for 48 h. The mRNA levels and protein expression of synaptopodin and Wilms' tumor 1 (WT1) were determined by real-time PCR, Western blotting and/or immunofluorescence, respectively.\n"
p14949
sg4
(lp14950
(dp14951
g7
I119
sg8
g48
sg10
I12
sg11
Vsynaptopodin
p14952
sg13
I1
sa(dp14953
g7
I57
sg8
VP01137
p14954
sg10
I9
sg11
VTGF-Beta1
p14955
sg13
I1
sa(dp14956
g7
I152
sg8
g48
sg10
I3
sg11
VWT1
p14957
sg13
I1
sa(dp14958
g7
I136
sg8
g48
sg10
I14
sg11
VWilms' tumor 1
p14959
sg13
I3
sasg29
(lp14960
(dp14961
g7
I152
sg32
VC0027708
p14962
sg10
I3
sg11
VWT1
p14963
sg13
I1
sa(dp14964
g7
I136
sg32
VC0027708
p14965
sg10
I14
sg11
VWilms' tumor 1
p14966
sg13
I3
sasa(dp14967
g2
S'In contrast, only a small percentage of tumor cells (~10%) show p-ERK1/2 expression in Burkitt lymphoma and double hit lymphoma.\n'
p14968
sg4
(lp14969
(dp14970
g7
I66
sg8
VP27361
p14971
sg10
I6
sg11
VERK1/2
p14972
sg13
I1
sasg29
(lp14973
(dp14974
g7
I87
sg32
VC0006413
p14975
sg10
I16
sg11
VBurkitt lymphoma
p14976
sg13
I2
sa(dp14977
g7
I95
sg32
VC0024299
p14978
sg10
I8
sg11
Vlymphoma
p14979
sg13
I1
sa(dp14980
g7
I40
sg32
VC0027651
p14981
sg10
I5
sg11
Vtumor
p14982
sg13
I1
sasa(dp14983
g2
S'Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).\n'
p14984
sg4
(lp14985
(dp14986
g7
I133
sg8
VP02545
p14987
sg10
I6
sg11
VCMT2B1
p14988
sg13
I1
sa(dp14989
g7
I112
sg8
g48
sg10
I6
sg11
VCMT2A2
p14990
sg13
I1
sa(dp14991
g7
I140
sg8
VP02545
p14992
sg10
I4
sg11
VLMNA
p14993
sg13
I1
sa(dp14994
g7
I127
sg8
g48
sg10
I4
sg11
VMFN2
p14995
sg13
I1
sa(dp14996
g7
I214
sg8
g48
sg10
I6
sg11
VLRSAM1
p14997
sg13
I1
sa(dp14998
g7
I195
sg8
g48
sg10
I5
sg11
VCMT2K
p14999
sg13
I1
sa(dp15000
g7
I235
sg8
g48
sg10
I5
sg11
VCMT2S
p15001
sg13
I1
sa(dp15002
g7
I294
sg8
g48
sg10
I3
sg11
VGAN
p15003
sg13
I1
sa(dp15004
g7
I449
sg8
g48
sg10
I5
sg11
VSPG15
p15005
sg13
I1
sa(dp15006
g7
I439
sg8
g48
sg10
I4
sg11
VSPG7
p15007
sg13
I1
sa(dp15008
g7
I294
sg8
g48
sg10
I3
sg11
VGAN
p15009
sg13
I1
sa(dp15010
g7
I483
sg8
g48
sg10
I4
sg11
VFA2H
p15011
sg13
I1
sa(dp15012
g7
I455
sg8
g48
sg10
I7
sg11
VZFYVE26
p15013
sg13
I1
sa(dp15014
g7
I241
sg8
VP38935
p15015
sg10
I7
sg11
VIGHMBP2
p15016
sg13
I1
sa(dp15017
g7
I256
sg8
VP25686
p15018
sg10
I4
sg11
VHSJ1
p15019
sg13
I1
sa(dp15020
g7
I444
sg8
VP00747
p15021
sg10
I3
sg11
VPGN
p15022
sg13
I1
sa(dp15023
g7
I228
sg8
g48
sg10
I5
sg11
VTRIM2
p15024
sg13
I1
sa(dp15025
g7
I153
sg8
g48
sg10
I5
sg11
VMED25
p15026
sg13
I1
sa(dp15027
g7
I495
sg8
g48
sg10
I4
sg11
VGBA2
p15028
sg13
I1
sa(dp15029
g7
I167
sg8
VP07196
p15030
sg10
I4
sg11
VNEFL
p15031
sg13
I1
sa(dp15032
g7
I285
sg8
VP49773
p15033
sg10
I4
sg11
VHINT
p15034
sg13
I1
sa(dp15035
g7
I507
sg8
g48
sg10
I8
sg11
VC12orf65
p15036
sg13
I1
sa(dp15037
g7
I470
sg8
g48
sg10
I5
sg11
VACP33
p15038
sg13
I1
sa(dp15039
g7
I520
sg8
g48
sg10
I12
sg11
VSPG56/CYP2U1
p15040
sg13
I1
sa(dp15041
g7
I201
sg8
g48
sg10
I5
sg11
VGDAP1
p15042
sg13
I1
sa(dp15043
g7
I119
sg8
g48
sg10
I7
sg11
VHMSN2A2
p15044
sg13
I1
sa(dp15045
g7
I464
sg8
g48
sg10
I5
sg11
VSPG21
p15046
sg13
I1
sa(dp15047
g7
I269
sg8
VP12074
p15048
sg10
I6
sg11
VCOX6A1
p15049
sg13
I1
sasg29
(lp15050
(dp15051
g7
I208
sg32
VC3280797
p15052
sg10
I5
sg11
VCMT2P
p15053
sg13
I1
sa(dp15054
g7
I146
sg32
VC1854150
p15055
sg10
I6
sg11
VCMT2B2
p15056
sg13
I1
sa(dp15057
g7
I294
sg32
VC1850386
p15058
sg10
I3
sg11
VGAN
p15059
sg13
I1
sa(dp15060
g7
I449
sg32
VC1849128
p15061
sg10
I5
sg11
VSPG15
p15062
sg13
I1
sa(dp15063
g7
I439
sg32
VC1846564
p15064
sg10
I4
sg11
VSPG7
p15065
sg13
I1
sa(dp15066
g7
I133
sg32
VC1854154
p15067
sg10
I6
sg11
VCMT2B1
p15068
sg13
I1
sa(dp15069
g7
I294
sg32
VC1850386
p15070
sg10
I3
sg11
VGAN
p15071
sg13
I1
sa(dp15072
g7
I83
sg32
VC0007959
p15073
sg10
I27
sg11
VCharcot-Marie-Tooth disease
p15074
sg13
I2
sa(dp15075
g7
I112
sg32
VC1836485
p15076
sg10
I6
sg11
VCMT2A2
p15077
sg13
I1
sa(dp15078
g7
I119
sg32
VC1836485
p15079
sg10
I7
sg11
VHMSN2A2
p15080
sg13
I1
sa(dp15081
g7
I409
sg32
VC1263857
p15082
sg10
I28
sg11
Vaxonal peripheral neuropathy
p15083
sg13
I3
sa(dp15084
g7
I181
sg32
VC2608087
p15085
sg10
I6
sg11
VdHMN2B
p15086
sg13
I1
sa(dp15087
g7
I610
sg32
VC0175754
p15088
sg10
I31
sg11
Vagenesis of the corpus callosum
p15089
sg13
I5
sa(dp15090
g7
I464
sg32
VC1855346
p15091
sg10
I5
sg11
VSPG21
p15092
sg13
I1
sa(dp15093
g7
I329
sg32
VC0751603
p15094
sg10
I49
sg11
Vautosomal recessive hereditary spastic paraplegia
p15095
sg13
I5
sa(dp15096
g7
I416
sg32
VC0031117
p15097
sg10
I21
sg11
Vperipheral neuropathy
p15098
sg13
I2
sa(dp15099
g7
I195
sg32
VC1842983
p15100
sg10
I5
sg11
VCMT2K
p15101
sg13
I1
sasa(dp15102
g2
S'Genetic testing demonstrated heterozygous mutation Pro209Leu (c.626C &gt; T) in exon 3 of BAG3 gene causing severe myopathy and neuropathy, often associated with restrictive cardiomyopathy.\n'
p15103
sg4
(lp15104
(dp15105
g7
I90
sg8
g48
sg10
I9
sg11
VBAG3 gene
p15106
sg13
I2
sasg29
(lp15107
(dp15108
g7
I162
sg32
VC0007196
p15109
sg10
I26
sg11
Vrestrictive cardiomyopathy
p15110
sg13
I2
sa(dp15111
g7
I115
sg32
VC0026848
p15112
sg10
I8
sg11
Vmyopathy
p15113
sg13
I1
sa(dp15114
g7
I128
sg32
VC0442874
p15115
sg10
I10
sg11
Vneuropathy
p15116
sg13
I1
sasa(dp15117
g2
S'The women with amenorrhea at Treatment Month 3 had significantly better scores on all UFS-QoL subscales and HRQL Total than women with menstrual bleeding, indicating acceptable discriminant validity.\n'
p15118
sg4
(lp15119
sg29
(lp15120
(dp15121
g7
I145
sg32
VC0019080
p15122
sg10
I8
sg11
Vbleeding
p15123
sg13
I1
sa(dp15124
g7
I15
sg32
VC0002453
p15125
sg10
I10
sg11
Vamenorrhea
p15126
sg13
I1
sa(dp15127
g7
I86
sg32
VC0403555
p15128
sg10
I3
sg11
VUFS
p15129
sg13
I1
sasa(dp15130
g2
S'UFS features incomplete urinary bladder emptying and vesicoureteric reflux, with a high risk of recurrent urosepsis and end-stage renal disease.\n'
p15131
sg4
(lp15132
sg29
(lp15133
(dp15134
g7
I53
sg32
VC0042580
p15135
sg10
I21
sg11
Vvesicoureteric reflux
p15136
sg13
I2
sa(dp15137
g7
I0
sg32
VC0403555
p15138
sg10
I3
sg11
VUFS
p15139
sg13
I1
sa(dp15140
g7
I120
sg32
VC0022661
p15141
sg10
I23
sg11
Vend-stage renal disease
p15142
sg13
I3
sa(dp15143
g7
I106
sg32
VC0149801
p15144
sg10
I9
sg11
Vurosepsis
p15145
sg13
I1
sasa(dp15146
g2
S'Non-neurogenic neurogenic bladder (NNNB) has a bladder identical to UFS without typical facial features.\n'
p15147
sg4
(lp15148
sg29
(lp15149
(dp15150
g7
I68
sg32
VC0403555
p15151
sg10
I3
sg11
VUFS
p15152
sg13
I1
sa(dp15153
g7
I15
sg32
VC0005697
p15154
sg10
I18
sg11
Vneurogenic bladder
p15155
sg13
I2
sasa(dp15156
g2
S'HPSE2 mutations were absent in 23 non-neurogenic neurogenic bladder probands and, of 439 families with nonsyndromic vesicoureteric reflux, only one carried a putative pathogenic HPSE2 variant.\n'
p15157
sg4
(lp15158
(dp15159
g7
I0
sg8
g48
sg10
I5
sg11
VHPSE2
p15160
sg13
I1
sa(dp15161
g7
I0
sg8
g48
sg10
I5
sg11
VHPSE2
p15162
sg13
I1
sasg29
(lp15163
(dp15164
g7
I49
sg32
VC0005697
p15165
sg10
I18
sg11
Vneurogenic bladder
p15166
sg13
I2
sa(dp15167
g7
I116
sg32
VC0042580
p15168
sg10
I21
sg11
Vvesicoureteric reflux
p15169
sg13
I2
sasa(dp15170
g2
S'Urofacial syndrome (UFS) (or Ochoa syndrome) is an autosomal-recessive disease characterized by congenital urinary bladder dysfunction, associated with a significant risk of kidney failure, and an abnormal facial expression upon smiling, laughing, and crying.\n'
p15171
sg4
(lp15172
sg29
(lp15173
(dp15174
g7
I174
sg32
VC0035078
p15175
sg10
I14
sg11
Vkidney failure
p15176
sg13
I2
sa(dp15177
g7
I115
sg32
VC0232841
p15178
sg10
I19
sg11
Vbladder dysfunction
p15179
sg13
I2
sa(dp15180
g7
I20
sg32
VC0403555
p15181
sg10
I3
sg11
VUFS
p15182
sg13
I1
sa(dp15183
g7
I0
sg32
VC0403555
p15184
sg10
I18
sg11
VUrofacial syndrome
p15185
sg13
I2
sa(dp15186
g7
I29
sg32
VC0403555
p15187
sg10
I14
sg11
VOchoa syndrome
p15188
sg13
I2
sasa(dp15189
g2
S'Atopy and the Th2 profile therefore seem to be associated with chronic dermatophytosis.\n'
p15190
sg4
(lp15191
sg29
(lp15192
(dp15193
g7
I0
sg32
VC0392707
p15194
sg10
I5
sg11
VAtopy
p15195
sg13
I1
sa(dp15196
g7
I71
sg32
VC0040247
p15197
sg10
I15
sg11
Vdermatophytosis
p15198
sg13
I1
sasa(dp15199
g2
S'In addition, several new PheWAS findings were identified including a cluster of association near the NDFIP1 gene for mental retardation (best SNP rs10057309, p = 4.33 x 10(-7), OR = 1.70, 95%CI = 1.38 - 2.09); association near PLCL1 gene for developmental delays and speech disorder [best SNP rs1595825, p = 1.13 x 10(-8), OR = 0.65(0.57 - 0.76)]; a cluster of associations in the IL5-IL13 region with Eosinophilic Esophagitis (EoE) [best at rs12653750, p = 3.03 x 10(-9), OR = 1.73 95%CI = (1.44 - 2.07)], previously implicated in asthma, allergy, and eosinophilia; and association of variants in GCKR and JAZF1 with allergic rhinitis in our pediatric cohorts [best SNP rs780093, p = 2.18 x 10(-5), OR = 1.39, 95%CI = (1.19 - 1.61)], previously demonstrated in metabolic disease and diabetes in adults.\n'
p15200
sg4
(lp15201
(dp15202
g7
I101
sg8
g48
sg10
I11
sg11
VNDFIP1 gene
p15203
sg13
I2
sa(dp15204
g7
I227
sg8
g48
sg10
I10
sg11
VPLCL1 gene
p15205
sg13
I2
sa(dp15206
g7
I598
sg8
g48
sg10
I4
sg11
VGCKR
p15207
sg13
I1
sa(dp15208
g7
I607
sg8
g48
sg10
I5
sg11
VJAZF1
p15209
sg13
I1
sa(dp15210
g7
I381
sg8
VP05113
p15211
sg10
I15
sg11
VIL5-IL13 region
p15212
sg13
I2
sasg29
(lp15213
(dp15214
g7
I428
sg32
VC0341106
p15215
sg10
I3
sg11
VEoE
p15216
sg13
I1
sa(dp15217
g7
I762
sg32
VC0025517
p15218
sg10
I17
sg11
Vmetabolic disease
p15219
sg13
I2
sa(dp15220
g7
I784
sg32
VC0011849
p15221
sg10
I8
sg11
Vdiabetes
p15222
sg13
I1
sa(dp15223
g7
I553
sg32
VC0014457
p15224
sg10
I12
sg11
Veosinophilia
p15225
sg13
I1
sa(dp15226
g7
I267
sg32
VC0037822
p15227
sg10
I15
sg11
Vspeech disorder
p15228
sg13
I2
sa(dp15229
g7
I540
sg32
VC0020517
p15230
sg10
I7
sg11
Vallergy
p15231
sg13
I1
sa(dp15232
g7
I117
sg32
VC0025362
p15233
sg10
I18
sg11
Vmental retardation
p15234
sg13
I2
sa(dp15235
g7
I618
sg32
VC2607914
p15236
sg10
I17
sg11
Vallergic rhinitis
p15237
sg13
I2
sa(dp15238
g7
I402
sg32
VC0341106
p15239
sg10
I24
sg11
VEosinophilic Esophagitis
p15240
sg13
I2
sa(dp15241
g7
I532
sg32
VC0004096
p15242
sg10
I6
sg11
Vasthma
p15243
sg13
I1
sasa(dp15244
g2
S'Twenty-seven SNPs in VHL, HGF, IL18, PRKACB, ABCB1, CYP2C8, ERCC2, and ERCC1 previously associated with ovarian cancer outcome were genotyped in 10,084 invasive cases from 28 studies from the Ovarian Cancer Association Consortium with over 37,000-observed person-years and 4,478 deaths.\n'
p15245
sg4
(lp15246
(dp15247
g7
I45
sg8
VP08183
p15248
sg10
I5
sg11
VABCB1
p15249
sg13
I1
sa(dp15250
g7
I71
sg8
VP07992
p15251
sg10
I5
sg11
VERCC1
p15252
sg13
I1
sa(dp15253
g7
I26
sg8
VP05231
p15254
sg10
I3
sg11
VHGF
p15255
sg13
I1
sa(dp15256
g7
I52
sg8
VP10632
p15257
sg10
I6
sg11
VCYP2C8
p15258
sg13
I1
sa(dp15259
g7
I21
sg8
VP40337
p15260
sg10
I3
sg11
VVHL
p15261
sg13
I1
sa(dp15262
g7
I60
sg8
VP18074
p15263
sg10
I5
sg11
VERCC2
p15264
sg13
I1
sa(dp15265
g7
I31
sg8
g48
sg10
I4
sg11
VIL18
p15266
sg13
I1
sasg29
(lp15267
(dp15268
g7
I192
sg32
VC1140680
p15269
sg10
I14
sg11
VOvarian Cancer
p15270
sg13
I2
sa(dp15271
g7
I21
sg32
VC0019562
p15272
sg10
I3
sg11
VVHL
p15273
sg13
I1
sa(dp15274
g7
I104
sg32
VC1140680
p15275
sg10
I14
sg11
Vovarian cancer
p15276
sg13
I2
sa(dp15277
g7
I26
sg32
VC0399440
p15278
sg10
I3
sg11
VHGF
p15279
sg13
I1
sasa(dp15280
g2
S'Using the most comprehensive approach to selecting polymorphisms to date, we sought to examine whether time to recurrence in ovarian cancer was associated with common inherited variation in eight genes involved in drug metabolism, multi-drug resistance, or DNA repair, namely ABCB1, CYP2C8, CYP3A4, ERCC1, ERCC2, GSTM1, XPC, and XRCC1.\n'
p15281
sg4
(lp15282
(dp15283
g7
I276
sg8
VP08183
p15284
sg10
I5
sg11
VABCB1
p15285
sg13
I1
sa(dp15286
g7
I320
sg8
g48
sg10
I3
sg11
VXPC
p15287
sg13
I1
sa(dp15288
g7
I291
sg8
VP08684
p15289
sg10
I6
sg11
VCYP3A4
p15290
sg13
I1
sa(dp15291
g7
I306
sg8
VP18074
p15292
sg10
I5
sg11
VERCC2
p15293
sg13
I1
sa(dp15294
g7
I283
sg8
VP10632
p15295
sg10
I6
sg11
VCYP2C8
p15296
sg13
I1
sa(dp15297
g7
I299
sg8
VP07992
p15298
sg10
I5
sg11
VERCC1
p15299
sg13
I1
sa(dp15300
g7
I313
sg8
VP09488
p15301
sg10
I5
sg11
VGSTM1
p15302
sg13
I1
sa(dp15303
g7
I329
sg8
VP18887
p15304
sg10
I5
sg11
VXRCC1
p15305
sg13
I1
sasg29
(lp15306
(dp15307
g7
I111
sg32
VC1458156
p15308
sg10
I10
sg11
Vrecurrence
p15309
sg13
I1
sa(dp15310
g7
I320
sg32
VC2752147
p15311
sg10
I3
sg11
VXPC
p15312
sg13
I1
sa(dp15313
g7
I125
sg32
VC1140680
p15314
sg10
I14
sg11
Vovarian cancer
p15315
sg13
I2
sasa(dp15316
g2
S'CYP2C8*3 and the ABCB1 SNPs C1236T, G2677T/A, and C3435T were not statistically significantly correlated to overall survival, sensoric neuropathy, and neutropenia in 119 patients treated for ovarian cancer with paclitaxel/carboplatin.\n'
p15317
sg4
(lp15318
(dp15319
g7
I0
sg8
VP10632
p15320
sg10
I8
sg11
VCYP2C8*3
p15321
sg13
I1
sa(dp15322
g7
I17
sg8
VP08183
p15323
sg10
I10
sg11
VABCB1 SNPs
p15324
sg13
I2
sasg29
(lp15325
(dp15326
g7
I135
sg32
VC0442874
p15327
sg10
I10
sg11
Vneuropathy
p15328
sg13
I1
sa(dp15329
g7
I191
sg32
VC1140680
p15330
sg10
I14
sg11
Vovarian cancer
p15331
sg13
I2
sasa(dp15332
g2
S'The purpose of this study was to evaluate the role of sequence variants in the CYP2C8, ABCB1 and CYP3A4 genes and the CYP3A4 phenotype for the pharmacokinetics and toxicity of paclitaxel in ovarian cancer patients.\n'
p15333
sg4
(lp15334
(dp15335
g7
I118
sg8
VP08684
p15336
sg10
I16
sg11
VCYP3A4 phenotype
p15337
sg13
I2
sa(dp15338
g7
I79
sg8
VP10632
p15339
sg10
I6
sg11
VCYP2C8
p15340
sg13
I1
sa(dp15341
g7
I97
sg8
VP08684
p15342
sg10
I12
sg11
VCYP3A4 genes
p15343
sg13
I2
sa(dp15344
g7
I87
sg8
VP08183
p15345
sg10
I5
sg11
VABCB1
p15346
sg13
I1
sasg29
(lp15347
(dp15348
g7
I190
sg32
VC1140680
p15349
sg10
I14
sg11
Vovarian cancer
p15350
sg13
I2
sasa(dp15351
g2
S'We assessed 27 selected polymorphisms based on previously described associations or putative functional effects in 16 key genes from pathways that may influence cellular sensitivity to taxanes (ABCB1, ABCC1, ABCC2, ABCG2, CDKN1A, CYP1B1, CYP2C8, CYP3A4, CYP3A5, MAPT, and TP53) and platinum (ABCC2, ABCG2, ERCC1, ERCC2, GSTP1, MPO, and XRCC1) using polymerase chain reaction and Pyrosequencing in 914 ovarian cancer patients from the Scottish Randomised Trial in Ovarian Cancer phase III trial who were treated at presentation with carboplatin and taxane regimens after cytoreductive surgery.\n'
p15352
sg4
(lp15353
(dp15354
g7
I246
sg8
VP08684
p15355
sg10
I6
sg11
VCYP3A4
p15356
sg13
I1
sa(dp15357
g7
I327
sg8
VP05164
p15358
sg10
I3
sg11
VMPO
p15359
sg13
I1
sa(dp15360
g7
I208
sg8
g48
sg10
I5
sg11
VABCC2
p15361
sg13
I1
sa(dp15362
g7
I238
sg8
VP10632
p15363
sg10
I6
sg11
VCYP2C8
p15364
sg13
I1
sa(dp15365
g7
I320
sg8
VP09211
p15366
sg10
I5
sg11
VGSTP1
p15367
sg13
I1
sa(dp15368
g7
I222
sg8
VP38936
p15369
sg10
I6
sg11
VCDKN1A
p15370
sg13
I1
sa(dp15371
g7
I230
sg8
g48
sg10
I6
sg11
VCYP1B1
p15372
sg13
I1
sa(dp15373
g7
I336
sg8
VP18887
p15374
sg10
I5
sg11
VXRCC1
p15375
sg13
I1
sa(dp15376
g7
I254
sg8
VP20815
p15377
sg10
I22
sg11
VCYP3A5, MAPT, and TP53
p15378
sg13
I4
sa(dp15379
g7
I313
sg8
VP18074
p15380
sg10
I5
sg11
VERCC2
p15381
sg13
I1
sa(dp15382
g7
I194
sg8
VP08183
p15383
sg10
I5
sg11
VABCB1
p15384
sg13
I1
sa(dp15385
g7
I306
sg8
VP07992
p15386
sg10
I5
sg11
VERCC1
p15387
sg13
I1
sa(dp15388
g7
I208
sg8
g48
sg10
I5
sg11
VABCC2
p15389
sg13
I1
sasg29
(lp15390
(dp15391
g7
I401
sg32
VC1140680
p15392
sg10
I14
sg11
Vovarian cancer
p15393
sg13
I2
sa(dp15394
g7
I463
sg32
VC1140680
p15395
sg10
I14
sg11
VOvarian Cancer
p15396
sg13
I2
sasa(dp15397
g2
S'Paclitaxel, an antineoplastic agent used for the treatment of ovarian cancer, is metabolized by cytochrome P450 (CYP)3A4 and CYP2C8 and is excreted from cells by ATP-binding cassette (ABCB1) (multi-drug resistance [MDR1], P-glycoprotein).\n'
p15398
sg4
(lp15399
(dp15400
g7
I162
sg8
g48
sg10
I20
sg11
VATP-binding cassette
p15401
sg13
I2
sa(dp15402
g7
I113
sg8
g48
sg10
I3
sg11
VCYP
p15403
sg13
I1
sa(dp15404
g7
I96
sg8
VP20853
p15405
sg10
I15
sg11
Vcytochrome P450
p15406
sg13
I2
sa(dp15407
g7
I125
sg8
VP10632
p15408
sg10
I6
sg11
VCYP2C8
p15409
sg13
I1
sa(dp15410
g7
I222
sg8
VP08183
p15411
sg10
I14
sg11
VP-glycoprotein
p15412
sg13
I1
sa(dp15413
g7
I184
sg8
VP08183
p15414
sg10
I5
sg11
VABCB1
p15415
sg13
I1
sasg29
(lp15416
(dp15417
g7
I62
sg32
VC1140680
p15418
sg10
I14
sg11
Vovarian cancer
p15419
sg13
I2
sasa(dp15420
g2
S'We therefore examined the relationship of the paclitaxel pharmacokinetics in 13 patients with ovarian cancer to polymorphisms in CYP2C8, CYP3A5, ABCB1, and PXR.\n'
p15421
sg4
(lp15422
(dp15423
g7
I145
sg8
VP08183
p15424
sg10
I5
sg11
VABCB1
p15425
sg13
I1
sa(dp15426
g7
I137
sg8
VP20815
p15427
sg10
I6
sg11
VCYP3A5
p15428
sg13
I1
sa(dp15429
g7
I129
sg8
VP10632
p15430
sg10
I6
sg11
VCYP2C8
p15431
sg13
I1
sasg29
(lp15432
(dp15433
g7
I94
sg32
VC1140680
p15434
sg10
I14
sg11
Vovarian cancer
p15435
sg13
I2
sasa(dp15436
g2
S'Interindividual differences in the pharmacokinetics of paclitaxel and its metabolites in Japanese ovarian cancer patients were investigated in relation to genetic polymorphisms of the CYP2C8, CYP3A4, and MDR1 genes.\n'
p15437
sg4
(lp15438
(dp15439
g7
I204
sg8
VP08183
p15440
sg10
I10
sg11
VMDR1 genes
p15441
sg13
I2
sa(dp15442
g7
I184
sg8
VP10632
p15443
sg10
I6
sg11
VCYP2C8
p15444
sg13
I1
sa(dp15445
g7
I192
sg8
VP08684
p15446
sg10
I6
sg11
VCYP3A4
p15447
sg13
I1
sasg29
(lp15448
(dp15449
g7
I98
sg32
VC1140680
p15450
sg10
I14
sg11
Vovarian cancer
p15451
sg13
I2
sasa(dp15452
g2
S'In the inner ear, the role of KCNE3 is undefined, despite its association with Meniere disease and tinnitus.\n'
p15453
sg4
(lp15454
(dp15455
g7
I30
sg8
g48
sg10
I5
sg11
VKCNE3
p15456
sg13
I1
sasg29
(lp15457
(dp15458
g7
I79
sg32
VC0025281
p15459
sg10
I15
sg11
VMeniere disease
p15460
sg13
I2
sasa(dp15461
g2
S'Somatic cell hybrid clones were isolated from the fusion of RPC 5,4 mouse myeloma cells and B lymphocytes from three patients with agammaglobulinemia.\n'
p15462
sg4
(lp15463
(dp15464
g7
I60
sg8
g48
sg10
I7
sg11
VRPC 5,4
p15465
sg13
I2
sasg29
(lp15466
(dp15467
g7
I131
sg32
VC0001768
p15468
sg10
I18
sg11
Vagammaglobulinemia
p15469
sg13
I1
sa(dp15470
g7
I74
sg32
VC0026764
p15471
sg10
I7
sg11
Vmyeloma
p15472
sg13
I1
sa(dp15473
g7
I60
sg32
VC1857624
p15474
sg10
I3
sg11
VRPC
p15475
sg13
I1
sasa(dp15476
g2
S'Microarray analysis of miRNAs expressed by Gtl2((-/+)) teratomas revealed decreased expression of 28 miRNAs encoded by the Dlk1-Dio3 domain, low expression of embryonic stem cell-specific miRNAs and dysregulation of miRNAs involved in tumorigenesis.\n'
p15477
sg4
(lp15478
(dp15479
g7
I43
sg8
g48
sg10
I4
sg11
VGtl2
p15480
sg13
I1
sa(dp15481
g7
I123
sg8
VP80370
p15482
sg10
I16
sg11
VDlk1-Dio3 domain
p15483
sg13
I2
sasg29
(lp15484
(dp15485
g7
I55
sg32
VC0039538
p15486
sg10
I9
sg11
Vteratomas
p15487
sg13
I1
sa(dp15488
g7
I235
sg32
VC0007621
p15489
sg10
I13
sg11
Vtumorigenesis
p15490
sg13
I1
sasa(dp15491
g2
S'This study suggests that downregulation of ncRNAs in the Dlk1-Dio3 domain leads to enhanced teratoma growth and repression of stem cell markers.\n'
p15492
sg4
(lp15493
(dp15494
g7
I57
sg8
VP80370
p15495
sg10
I16
sg11
VDlk1-Dio3 domain
p15496
sg13
I2
sasg29
(lp15497
(dp15498
g7
I92
sg32
VC0039538
p15499
sg10
I8
sg11
Vteratoma
p15500
sg13
I1
sasa(dp15501
g2
S'Together, our results showed that the inflammatory environment mimic TNF-Alfa inhibits osteogenesis via upregulation of miR-146a and subsequent downregulation of Smad4, thus suggesting that therapeutic manipulation of miR-146a maybe a potential strategy to improve osteogenesis in the context of osteoporosis.\n'
p15502
sg4
(lp15503
(dp15504
g7
I162
sg8
g48
sg10
I5
sg11
VSmad4
p15505
sg13
I1
sa(dp15506
g7
I120
sg8
g48
sg10
I8
sg11
VmiR-146a
p15507
sg13
I1
sa(dp15508
g7
I120
sg8
g48
sg10
I8
sg11
VmiR-146a
p15509
sg13
I1
sa(dp15510
g7
I69
sg8
VP01375
p15511
sg10
I8
sg11
VTNF-Alfa
p15512
sg13
I1
sasg29
(lp15513
(dp15514
g7
I296
sg32
VC0029456
p15515
sg10
I12
sg11
Vosteoporosis
p15516
sg13
I1
sasa(dp15517
g2
S'Smad4 is an intracellular effector of the TGFBeta family that has been implicated in Myhre syndrome, a skeletal dysplasia characterized by short stature, brachydactyly and stiff joints.\n'
p15518
sg4
(lp15519
(dp15520
g7
I42
sg8
VP01137
p15521
sg10
I14
sg11
VTGFBeta family
p15522
sg13
I2
sa(dp15523
g7
I0
sg8
g48
sg10
I5
sg11
VSmad4
p15524
sg13
I1
sasg29
(lp15525
(dp15526
g7
I154
sg32
VC0221357
p15527
sg10
I13
sg11
Vbrachydactyly
p15528
sg13
I1
sa(dp15529
g7
I172
sg32
VC0162298
p15530
sg10
I12
sg11
Vstiff joints
p15531
sg13
I2
sa(dp15532
g7
I139
sg32
VC0013336
p15533
sg10
I13
sg11
Vshort stature
p15534
sg13
I2
sa(dp15535
g7
I85
sg32
VC0796081
p15536
sg10
I14
sg11
VMyhre syndrome
p15537
sg13
I2
sa(dp15538
g7
I103
sg32
VC0410528
p15539
sg10
I18
sg11
Vskeletal dysplasia
p15540
sg13
I2
sasa(dp15541
g2
S'In acute myeloid leukemia (AML), the transcription factors CEBPA and KLF4 as well as the universal tumor suppressor p53 are frequently deregulated.\n'
p15542
sg4
(lp15543
(dp15544
g7
I69
sg8
g48
sg10
I4
sg11
VKLF4
p15545
sg13
I1
sa(dp15546
g7
I99
sg8
VP42771
p15547
sg10
I20
sg11
Vtumor suppressor p53
p15548
sg13
I3
sa(dp15549
g7
I37
sg8
VP19883
p15550
sg10
I27
sg11
Vtranscription factors CEBPA
p15551
sg13
I3
sasg29
(lp15552
(dp15553
g7
I27
sg32
VC0023467
p15554
sg10
I3
sg11
VAML
p15555
sg13
I1
sa(dp15556
g7
I3
sg32
VC0023467
p15557
sg10
I22
sg11
Vacute myeloid leukemia
p15558
sg13
I3
sa(dp15559
g7
I99
sg32
VC0027651
p15560
sg10
I5
sg11
Vtumor
p15561
sg13
I1
sasa(dp15562
g2
S'Furthermore, screening with a defined threshold identified 6 genes that were highly expressed in GBM, including AFF2, CACNA2D3 and ARPP21, while the 6 highly expressed genes in OD notably included CNTN2.\n'
p15563
sg4
(lp15564
(dp15565
g7
I131
sg8
g48
sg10
I6
sg11
VARPP21
p15566
sg13
I1
sa(dp15567
g7
I118
sg8
g48
sg10
I8
sg11
VCACNA2D3
p15568
sg13
I1
sa(dp15569
g7
I197
sg8
g48
sg10
I5
sg11
VCNTN2
p15570
sg13
I1
sasg29
(lp15571
(dp15572
g7
I97
sg32
VC0017636
p15573
sg10
I3
sg11
VGBM
p15574
sg13
I1
sasa(dp15575
g2
S'lilliputian (lilli), the sole Drosophila member of the FMR2/AF4 (Fragile X Mental Retardation/Acute Lymphoblastic Leukemia) family of transcription factors, is widely expressed with roles in segmentation, cellularization, and gastrulation during early embryogenesis with additional distinct roles at later stages of embryonic and postembryonic development.\n'
p15576
sg4
(lp15577
(dp15578
g7
I60
sg8
VP51825
p15579
sg10
I3
sg11
VAF4
p15580
sg13
I1
sasg29
(lp15581
(dp15582
g7
I94
sg32
VC1961102
p15583
sg10
I28
sg11
VAcute Lymphoblastic Leukemia
p15584
sg13
I3
sa(dp15585
g7
I75
sg32
VC0025362
p15586
sg10
I18
sg11
VMental Retardation
p15587
sg13
I2
sasa(dp15588
g2
S'AF4 gene, frequently translocated with mixed-lineage leukemia (MLL) in childhood acute leukemia, encodes a putative transcriptional activator of the AF4/LAF4/FMR2 (ALF) protein family previously implicated in lymphopoiesis and Purkinje cell function in the cerebellum.\n'
p15589
sg4
(lp15590
(dp15591
g7
I149
sg8
VP43652
p15592
sg10
I13
sg11
VAF4/LAF4/FMR2
p15593
sg13
I1
sa(dp15594
g7
I0
sg8
VP51825
p15595
sg10
I8
sg11
VAF4 gene
p15596
sg13
I2
sa(dp15597
g7
I164
sg8
VP43652
p15598
sg10
I3
sg11
VALF
p15599
sg13
I1
sasg29
(lp15600
(dp15601
g7
I53
sg32
VC0023418
p15602
sg10
I8
sg11
Vleukemia
p15603
sg13
I1
sa(dp15604
g7
I81
sg32
VC0085669
p15605
sg10
I14
sg11
Vacute leukemia
p15606
sg13
I2
sasa(dp15607
g2
S'Members of the AF4/FMR2 family of nuclear proteins are involved in human diseases such as acute lymphoblastic leukemia and mental retardation.\n'
p15608
sg4
(lp15609
(dp15610
g7
I15
sg8
VP51825
p15611
sg10
I3
sg11
VAF4
p15612
sg13
I1
sasg29
(lp15613
(dp15614
g7
I123
sg32
VC0025362
p15615
sg10
I18
sg11
Vmental retardation
p15616
sg13
I2
sa(dp15617
g7
I90
sg32
VC1961102
p15618
sg10
I28
sg11
Vacute lymphoblastic leukemia
p15619
sg13
I3
sasa(dp15620
g2
S'Importantly, glioblastoma multiforme (GBM) patient tumors bearing TERT promoter mutations (C228T and C250T) known to be associated with increased telomerase activity; exhibited elevated Nrf2 and TKT expression and decreased glycogen accumulation.\n'
p15621
sg4
(lp15622
(dp15623
g7
I66
sg8
g48
sg10
I13
sg11
VTERT promoter
p15624
sg13
I2
sa(dp15625
g7
I186
sg8
g48
sg10
I4
sg11
VNrf2
p15626
sg13
I1
sa(dp15627
g7
I195
sg8
g48
sg10
I3
sg11
VTKT
p15628
sg13
I1
sasg29
(lp15629
(dp15630
g7
I13
sg32
VC1621958
p15631
sg10
I23
sg11
Vglioblastoma multiforme
p15632
sg13
I2
sa(dp15633
g7
I38
sg32
VC1621958
p15634
sg10
I3
sg11
VGBM
p15635
sg13
I1
sa(dp15636
g7
I51
sg32
VC0027651
p15637
sg10
I6
sg11
Vtumors
p15638
sg13
I1
sasa(dp15639
g2
S'To investigate the functional mechanism of metadherin (MTDH), hypoxia-inducible factor-1 alpha (HIF-1Alfa) and transketolase-like gene 1 (TKTL1) and their interaction with each other in laryngeal carcinoma development.\n'
p15640
sg4
(lp15641
(dp15642
g7
I55
sg8
g48
sg10
I4
sg11
VMTDH
p15643
sg13
I1
sa(dp15644
g7
I138
sg8
VP51854
p15645
sg10
I5
sg11
VTKTL1
p15646
sg13
I1
sa(dp15647
g7
I43
sg8
g48
sg10
I10
sg11
Vmetadherin
p15648
sg13
I1
sa(dp15649
g7
I111
sg8
VP29401
p15650
sg10
I25
sg11
Vtransketolase-like gene 1
p15651
sg13
I3
sa(dp15652
g7
I62
sg8
g48
sg10
I32
sg11
Vhypoxia-inducible factor-1 alpha
p15653
sg13
I3
sasg29
(lp15654
(dp15655
g7
I62
sg32
VC0242184
p15656
sg10
I7
sg11
Vhypoxia
p15657
sg13
I1
sa(dp15658
g7
I186
sg32
VC0595989
p15659
sg10
I19
sg11
Vlaryngeal carcinoma
p15660
sg13
I2
sasa(dp15661
g2
S'The positive expression rate of MTDH, HIF-1Alfa and TKTL1 in the 30 cases of laryngeal carcinoma was 56.67%, 60.00% and 63.33%, respectively, which was 20.00%,10.00% and 15.00% respectively in the para-carcinoma tissue, the difference of the positive expression rate of the tested objects between these two groups was statistically significant (P &lt; 0.05 or P &lt; 0.01).\n'
p15662
sg4
(lp15663
(dp15664
g7
I32
sg8
g48
sg10
I4
sg11
VMTDH
p15665
sg13
I1
sa(dp15666
g7
I52
sg8
VP51854
p15667
sg10
I5
sg11
VTKTL1
p15668
sg13
I1
sasg29
(lp15669
(dp15670
g7
I87
sg32
VC0007097
p15671
sg10
I9
sg11
Vcarcinoma
p15672
sg13
I1
sa(dp15673
g7
I77
sg32
VC0595989
p15674
sg10
I19
sg11
Vlaryngeal carcinoma
p15675
sg13
I2
sasa(dp15676
g2
S'Of the 30 cases of laryngeal carcinoma, the positive expression rate of MTDH, HIF-1Alfa and TKTL1 in the cases with lymphnode metastasis was 84.62%, 84.62% and 79.62%, respectively, compared with the rate in those without lymph nodes metastasis, which was 35.29%, 41.18% and 35.29%.\n'
p15677
sg4
(lp15678
(dp15679
g7
I72
sg8
g48
sg10
I4
sg11
VMTDH
p15680
sg13
I1
sa(dp15681
g7
I92
sg8
VP51854
p15682
sg10
I5
sg11
VTKTL1
p15683
sg13
I1
sasg29
(lp15684
(dp15685
g7
I126
sg32
VC0027627
p15686
sg10
I10
sg11
Vmetastasis
p15687
sg13
I1
sa(dp15688
g7
I126
sg32
VC0027627
p15689
sg10
I10
sg11
Vmetastasis
p15690
sg13
I1
sa(dp15691
g7
I19
sg32
VC0595989
p15692
sg10
I19
sg11
Vlaryngeal carcinoma
p15693
sg13
I2
sasa(dp15694
g2
S'The positive expression rate of TKTL1 in laryngeal carcinoma at stage I-II was 25.00% and that at stage III-IV was 72.22%, the difference between which was statistically significant (P &lt; 0.05).\n'
p15695
sg4
(lp15696
(dp15697
g7
I32
sg8
VP51854
p15698
sg10
I5
sg11
VTKTL1
p15699
sg13
I1
sasg29
(lp15700
(dp15701
g7
I41
sg32
VC0595989
p15702
sg10
I19
sg11
Vlaryngeal carcinoma
p15703
sg13
I2
sasa(dp15704
g2
S"The Spearman's rank correlation analysis showed that the positive expression rates of MTDH and HIF-1Alfa in laryngeal carcinoma had positive correlation (r = 0.384, P &lt; 0.05); the positive expression rates of TKTL1 and HIF-1Alfa in laryngeal carcinoma had positive correlation (r = 0.508, P &lt; 0.01); But there was no significant correlation between the positive expression rates of MTDH and TKTL1 in laryngeal carcinoma (r = -0.107, P &gt; 0.05).\n"
p15705
sg4
(lp15706
(dp15707
g7
I86
sg8
g48
sg10
I4
sg11
VMTDH
p15708
sg13
I1
sa(dp15709
g7
I212
sg8
VP51854
p15710
sg10
I5
sg11
VTKTL1
p15711
sg13
I1
sa(dp15712
g7
I212
sg8
VP51854
p15713
sg10
I5
sg11
VTKTL1
p15714
sg13
I1
sa(dp15715
g7
I86
sg8
g48
sg10
I4
sg11
VMTDH
p15716
sg13
I1
sasg29
(lp15717
(dp15718
g7
I108
sg32
VC0595989
p15719
sg10
I19
sg11
Vlaryngeal carcinoma
p15720
sg13
I2
sa(dp15721
g7
I108
sg32
VC0595989
p15722
sg10
I19
sg11
Vlaryngeal carcinoma
p15723
sg13
I2
sa(dp15724
g7
I108
sg32
VC0595989
p15725
sg10
I19
sg11
Vlaryngeal carcinoma
p15726
sg13
I2
sasa(dp15727
g2
S'MTDH and TKTL1 may be expected to be new clinical targets for laryngeal carcinoma treatment and it could offer theoretical basis for the prognosis of the laryngeal carcinoma.\n'
p15728
sg4
(lp15729
(dp15730
g7
I0
sg8
g48
sg10
I4
sg11
VMTDH
p15731
sg13
I1
sa(dp15732
g7
I9
sg8
VP51854
p15733
sg10
I5
sg11
VTKTL1
p15734
sg13
I1
sasg29
(lp15735
(dp15736
g7
I62
sg32
VC0595989
p15737
sg10
I19
sg11
Vlaryngeal carcinoma
p15738
sg13
I2
sa(dp15739
g7
I62
sg32
VC0595989
p15740
sg10
I19
sg11
Vlaryngeal carcinoma
p15741
sg13
I2
sasa(dp15742
g2
S'The present study evaluates the role of TKTL1 as a mediator of disease progression in melanoma associated with a defective methylation phenotype.\n'
p15743
sg4
(lp15744
(dp15745
g7
I40
sg8
VP51854
p15746
sg10
I5
sg11
VTKTL1
p15747
sg13
I1
sasg29
(lp15748
(dp15749
g7
I63
sg32
VC0242656
p15750
sg10
I19
sg11
Vdisease progression
p15751
sg13
I2
sa(dp15752
g7
I86
sg32
VC0025202
p15753
sg10
I8
sg11
Vmelanoma
p15754
sg13
I1
sasa(dp15755
g2
S'The expression of TKTL1 in metastatic melanoma tumors and cell lines was analysed by qRT-PCR and immunohistochemistry.\n'
p15756
sg4
(lp15757
(dp15758
g7
I18
sg8
VP51854
p15759
sg10
I5
sg11
VTKTL1
p15760
sg13
I1
sasg29
(lp15761
(dp15762
g7
I47
sg32
VC0027651
p15763
sg10
I6
sg11
Vtumors
p15764
sg13
I1
sa(dp15765
g7
I27
sg32
VC0278883
p15766
sg10
I19
sg11
Vmetastatic melanoma
p15767
sg13
I2
sasa(dp15768
g2
S'The promoter methylation status of TKTL1 in melanoma cells was evaluated by quantitative methylation specific PCR.\n'
p15769
sg4
(lp15770
(dp15771
g7
I35
sg8
VP51854
p15772
sg10
I5
sg11
VTKTL1
p15773
sg13
I1
sasg29
(lp15774
(dp15775
g7
I44
sg32
VC0025202
p15776
sg10
I8
sg11
Vmelanoma
p15777
sg13
I1
sasa(dp15778
g2
S'Biochemical and molecular analyses such as glucose consumption, lactate production, invasion, proliferation and cell cycle progression together with ectopic expression and siRNA mediated knockdown were used to investigate the role of TKTL1 in melanoma cells.\n'
p15779
sg4
(lp15780
(dp15781
g7
I234
sg8
VP51854
p15782
sg10
I5
sg11
VTKTL1
p15783
sg13
I1
sasg29
(lp15784
(dp15785
g7
I84
sg32
VC2699153
p15786
sg10
I8
sg11
Vinvasion
p15787
sg13
I1
sa(dp15788
g7
I243
sg32
VC0025202
p15789
sg10
I8
sg11
Vmelanoma
p15790
sg13
I1
sa(dp15791
g7
I94
sg32
VC0334094
p15792
sg10
I13
sg11
Vproliferation
p15793
sg13
I1
sasa(dp15794
g2
S'Expression of TKTL1 was highly restricted in normal adult tissues and was overexpressed in a subset of metastatic melanoma tumors and derived cell lines.\n'
p15795
sg4
(lp15796
(dp15797
g7
I14
sg8
VP51854
p15798
sg10
I5
sg11
VTKTL1
p15799
sg13
I1
sasg29
(lp15800
(dp15801
g7
I103
sg32
VC0278883
p15802
sg10
I19
sg11
Vmetastatic melanoma
p15803
sg13
I2
sa(dp15804
g7
I123
sg32
VC0027651
p15805
sg10
I6
sg11
Vtumors
p15806
sg13
I1
sasa(dp15807
g2
S'The TKTL1 promoter was activated by hypomethylation and treatment with 5aza induced TKTL1 expression in melanoma cells.\n'
p15808
sg4
(lp15809
(dp15810
g7
I4
sg8
VP51854
p15811
sg10
I14
sg11
VTKTL1 promoter
p15812
sg13
I2
sa(dp15813
g7
I4
sg8
VP51854
p15814
sg10
I5
sg11
VTKTL1
p15815
sg13
I1
sasg29
(lp15816
(dp15817
g7
I104
sg32
VC0025202
p15818
sg10
I8
sg11
Vmelanoma
p15819
sg13
I1
sasa(dp15820
g2
S'Augmented expression of TKTL1 in melanoma cells was associated with a glycolytic phenotype.\n'
p15821
sg4
(lp15822
(dp15823
g7
I24
sg8
VP51854
p15824
sg10
I5
sg11
VTKTL1
p15825
sg13
I1
sasg29
(lp15826
(dp15827
g7
I33
sg32
VC0025202
p15828
sg10
I8
sg11
Vmelanoma
p15829
sg13
I1
sasa(dp15830
g2
S'Loss and gain of function studies revealed that TKTL1 contributed to enhanced invasion of melanoma cells.\n'
p15831
sg4
(lp15832
(dp15833
g7
I48
sg8
VP51854
p15834
sg10
I5
sg11
VTKTL1
p15835
sg13
I1
sasg29
(lp15836
(dp15837
g7
I90
sg32
VC0025202
p15838
sg10
I8
sg11
Vmelanoma
p15839
sg13
I1
sa(dp15840
g7
I78
sg32
VC2699153
p15841
sg10
I8
sg11
Vinvasion
p15842
sg13
I1
sasa(dp15843
g2
S'Our data provide evidence for an important role of TKTL1 in aerobic glycolysis and tumor promotion in melanoma that may result from defective promoter methylation.\n'
p15844
sg4
(lp15845
(dp15846
g7
I51
sg8
VP51854
p15847
sg10
I5
sg11
VTKTL1
p15848
sg13
I1
sasg29
(lp15849
(dp15850
g7
I102
sg32
VC0025202
p15851
sg10
I8
sg11
Vmelanoma
p15852
sg13
I1
sa(dp15853
g7
I83
sg32
VC1519689
p15854
sg10
I15
sg11
Vtumor promotion
p15855
sg13
I2
sasa(dp15856
g2
S'This epigenetic change may enable the natural selection of tumor cells with a metabolic phenotype and thereby provide a potential therapeutic target for a subset of melanoma tumors with elevated TKTL1 expression.\n'
p15857
sg4
(lp15858
(dp15859
g7
I195
sg8
VP51854
p15860
sg10
I5
sg11
VTKTL1
p15861
sg13
I1
sasg29
(lp15862
(dp15863
g7
I174
sg32
VC0027651
p15864
sg10
I6
sg11
Vtumors
p15865
sg13
I1
sa(dp15866
g7
I59
sg32
VC0027651
p15867
sg10
I5
sg11
Vtumor
p15868
sg13
I1
sa(dp15869
g7
I165
sg32
VC0025202
p15870
sg10
I8
sg11
Vmelanoma
p15871
sg13
I1
sasa(dp15872
g2
S'After curative R0 tumor resection of primary OSCC (buccal mucosa), elevated epitope detection in monocytes (EDIM)-Apo10, EDIM-transketolase-like-1 (TKTL1), squamous cell carcinoma antigen (SCC-Ag), total serum lactate dehydrogenase (LDH), and its anaerobic isoforms (LDH-4, LDH-5) decreased to normal levels.\n'
p15873
sg4
(lp15874
(dp15875
g7
I210
sg8
VP49366
p15876
sg10
I21
sg11
Vlactate dehydrogenase
p15877
sg13
I2
sa(dp15878
g7
I148
sg8
VP51854
p15879
sg10
I5
sg11
VTKTL1
p15880
sg13
I1
sa(dp15881
g7
I233
sg8
g48
sg10
I3
sg11
VLDH
p15882
sg13
I1
sa(dp15883
g7
I267
sg8
g48
sg10
I5
sg11
VLDH-4
p15884
sg13
I1
sa(dp15885
g7
I121
sg8
VP29401
p15886
sg10
I25
sg11
VEDIM-transketolase-like-1
p15887
sg13
I1
sa(dp15888
g7
I274
sg8
g48
sg10
I5
sg11
VLDH-5
p15889
sg13
I1
sasg29
(lp15890
(dp15891
g7
I18
sg32
VC0027651
p15892
sg10
I5
sg11
Vtumor
p15893
sg13
I1
sa(dp15894
g7
I108
sg32
VC0276468
p15895
sg10
I4
sg11
VEDIM
p15896
sg13
I1
sa(dp15897
g7
I108
sg32
VC0276468
p15898
sg10
I4
sg11
VEDIM
p15899
sg13
I1
sa(dp15900
g7
I156
sg32
VC0007137
p15901
sg10
I23
sg11
Vsquamous cell carcinoma
p15902
sg13
I3
sa(dp15903
g7
I76
sg32
VC0276468
p15904
sg10
I30
sg11
Vepitope detection in monocytes
p15905
sg13
I4
sasa(dp15906
g2
S'The morphology and immunoprofile of these renal neoplasms was compared with a control group of other sarcomas with BCOR genetic abnormalities, including clear cell sarcoma of the kidney (CCSK), infantile undifferentiated round cell sarcomas of soft tissue/primitive myxoid mesenchymal tumor of infancy, and bone/soft tissue sarcomas with BCOR-CCNB3 gene fusion; along with primary renal synovial sarcoma.\n'
p15907
sg4
(lp15908
(dp15909
g7
I343
sg8
g48
sg10
I5
sg11
VCCNB3
p15910
sg13
I1
sasg29
(lp15911
(dp15912
g7
I312
sg32
VC1261473
p15913
sg10
I20
sg11
Vsoft tissue sarcomas
p15914
sg13
I3
sa(dp15915
g7
I187
sg32
VC0334488
p15916
sg10
I4
sg11
VCCSK
p15917
sg13
I1
sa(dp15918
g7
I101
sg32
VC1261473
p15919
sg10
I8
sg11
Vsarcomas
p15920
sg13
I1
sa(dp15921
g7
I387
sg32
VC0039101
p15922
sg10
I16
sg11
Vsynovial sarcoma
p15923
sg13
I2
sa(dp15924
g7
I101
sg32
VC1261473
p15925
sg10
I8
sg11
Vsarcomas
p15926
sg13
I1
sa(dp15927
g7
I42
sg32
VC0022665
p15928
sg10
I15
sg11
Vrenal neoplasms
p15929
sg13
I2
sa(dp15930
g7
I273
sg32
VC1334699
p15931
sg10
I17
sg11
Vmesenchymal tumor
p15932
sg13
I2
sa(dp15933
g7
I349
sg32
VC1705736
p15934
sg10
I11
sg11
Vgene fusion
p15935
sg13
I2
sa(dp15936
g7
I153
sg32
VC0334488
p15937
sg10
I32
sg11
Vclear cell sarcoma of the kidney
p15938
sg13
I6
sasa(dp15939
g2
S'These results are in keeping with a "BCOR-alteration family" of renal and extrarenal neoplasms which includes CCSK and undifferentiated round cell sarcomas of soft tissue/primitive myxoid mesenchymal tumor of infancy (which typically harbor BCOR internal tandem duplication), and BCOR-CCNB3 sarcomas, all of which are primarily driven by BCOR overexpression and have overlapping (but not identical) clinicopathologic features.\n'
p15940
sg4
(lp15941
(dp15942
g7
I285
sg8
g48
sg10
I5
sg11
VCCNB3
p15943
sg13
I1
sasg29
(lp15944
(dp15945
g7
I147
sg32
VC1261473
p15946
sg10
I8
sg11
Vsarcomas
p15947
sg13
I1
sa(dp15948
g7
I85
sg32
VC0027651
p15949
sg10
I9
sg11
Vneoplasms
p15950
sg13
I1
sa(dp15951
g7
I262
sg32
VC1705960
p15952
sg10
I11
sg11
Vduplication
p15953
sg13
I1
sa(dp15954
g7
I147
sg32
VC1261473
p15955
sg10
I8
sg11
Vsarcomas
p15956
sg13
I1
sa(dp15957
g7
I188
sg32
VC1334699
p15958
sg10
I17
sg11
Vmesenchymal tumor
p15959
sg13
I2
sasa(dp15960
g2
S'Interaction of butyrate with its respective receptor (HCAR2) and transporter (SLC5A8), both expressed in the intestine, is associated with water and electrolyte absorption as well as providing defense against colon cancer and inflammation.\n'
p15961
sg4
(lp15962
(dp15963
g7
I78
sg8
g48
sg10
I6
sg11
VSLC5A8
p15964
sg13
I1
sa(dp15965
g7
I44
sg8
g48
sg10
I32
sg11
Vreceptor (HCAR2) and transporter
p15966
sg13
I4
sasg29
(lp15967
(dp15968
g7
I226
sg32
VC0021368
p15969
sg10
I12
sg11
Vinflammation
p15970
sg13
I1
sa(dp15971
g7
I209
sg32
VC0699790
p15972
sg10
I12
sg11
Vcolon cancer
p15973
sg13
I2
sasa(dp15974
g2
S'Furthermore, Slc5a8 protects against colitis and colon cancer under conditions of low-fibre intake but not when dietary fibre intake is optimal.\n'
p15975
sg4
(lp15976
(dp15977
g7
I13
sg8
g48
sg10
I6
sg11
VSlc5a8
p15978
sg13
I1
sasg29
(lp15979
(dp15980
g7
I49
sg32
VC0699790
p15981
sg10
I12
sg11
Vcolon cancer
p15982
sg13
I2
sa(dp15983
g7
I37
sg32
VC0009319
p15984
sg10
I7
sg11
Vcolitis
p15985
sg13
I1
sasa(dp15986
g2
S'SLC5A8 (Solute carrier family 5, member 8), proposed to be a potential tumor suppressor gene, is down-regulated by epigenetic changes in some colorectal cancer cells, and ectopic expression of SLC5A8 in SLC5A8-deficient colon cancer cell lines leads to suppression of the colony-forming ability of these cells.\n'
p15987
sg4
(lp15988
(dp15989
g7
I0
sg8
g48
sg10
I6
sg11
VSLC5A8
p15990
sg13
I1
sa(dp15991
g7
I0
sg8
g48
sg10
I6
sg11
VSLC5A8
p15992
sg13
I1
sa(dp15993
g7
I8
sg8
g48
sg10
I33
sg11
VSolute carrier family 5, member 8
p15994
sg13
I6
sa(dp15995
g7
I0
sg8
g48
sg10
I6
sg11
VSLC5A8
p15996
sg13
I1
sasg29
(lp15997
(dp15998
g7
I253
sg32
VC0221103
p15999
sg10
I11
sg11
Vsuppression
p16000
sg13
I1
sa(dp16001
g7
I142
sg32
VC1527249
p16002
sg10
I17
sg11
Vcolorectal cancer
p16003
sg13
I2
sa(dp16004
g7
I71
sg32
VC0027651
p16005
sg10
I5
sg11
Vtumor
p16006
sg13
I1
sa(dp16007
g7
I220
sg32
VC0699790
p16008
sg10
I12
sg11
Vcolon cancer
p16009
sg13
I2
sasa(dp16010
g2
S'In this study, we showed that activin A up-regulated SLC5A8 expression in colorectal cancer RKO cells and human embryonic kidney (HEK) 293T cells.\n'
p16011
sg4
(lp16012
(dp16013
g7
I30
sg8
VP08476
p16014
sg10
I29
sg11
Vactivin A up-regulated SLC5A8
p16015
sg13
I4
sasg29
(lp16016
(dp16017
g7
I74
sg32
VC1527249
p16018
sg10
I17
sg11
Vcolorectal cancer
p16019
sg13
I2
sasa(dp16020
g2
S"miR-132 and miR-212 are tandem miRNAs whose expression is necessary for the proper development, maturation and function of neurons and whose deregulation is associated with several neurological disorders, such as Alzheimer's disease and tauopathies (neurodegenerative diseases resulting from the pathological aggregation of tau protein in the human brain).\n"
p16021
sg4
(lp16022
(dp16023
g7
I324
sg8
VP49768
p16024
sg10
I11
sg11
Vtau protein
p16025
sg13
I2
sa(dp16026
g7
I0
sg8
g48
sg10
I7
sg11
VmiR-132
p16027
sg13
I1
sa(dp16028
g7
I12
sg8
g48
sg10
I7
sg11
VmiR-212
p16029
sg13
I1
sasg29
(lp16030
(dp16031
g7
I250
sg32
VC0524851
p16032
sg10
I26
sg11
Vneurodegenerative diseases
p16033
sg13
I2
sa(dp16034
g7
I213
sg32
VC1521724
p16035
sg10
I19
sg11
VAlzheimer's disease
p16036
sg13
I2
sa(dp16037
g7
I237
sg32
VC0949664
p16038
sg10
I11
sg11
Vtauopathies
p16039
sg13
I1
sa(dp16040
g7
I181
sg32
VC0027765
p16041
sg10
I22
sg11
Vneurological disorders
p16042
sg13
I2
sasa(dp16043
g2
S'As such, the 5-HT1A agonist, tandospirone, may be effective in preventing and/or treating motion sickness and/or space sickness.\n'
p16044
sg4
(lp16045
(dp16046
g7
I13
sg8
VP08908
p16047
sg10
I6
sg11
V5-HT1A
p16048
sg13
I1
sasg29
(lp16049
(dp16050
g7
I90
sg32
VC0026603
p16051
sg10
I15
sg11
Vmotion sickness
p16052
sg13
I2
sasa(dp16053
g2
S'Since 5-HT1A receptors are implicated in the pathogenesis of anxiety, depression, hallucinogenic behaviour, motion sickness and eating disorders, they are an important target for drug therapy.\n'
p16054
sg4
(lp16055
(dp16056
g7
I6
sg8
VP08908
p16057
sg10
I16
sg11
V5-HT1A receptors
p16058
sg13
I2
sasg29
(lp16059
(dp16060
g7
I70
sg32
VC0011581
p16061
sg10
I10
sg11
Vdepression
p16062
sg13
I1
sa(dp16063
g7
I128
sg32
VC0013473
p16064
sg10
I16
sg11
Veating disorders
p16065
sg13
I2
sa(dp16066
g7
I45
sg32
VC0699748
p16067
sg10
I12
sg11
Vpathogenesis
p16068
sg13
I1
sa(dp16069
g7
I108
sg32
VC0026603
p16070
sg10
I15
sg11
Vmotion sickness
p16071
sg13
I2
sasa(dp16072
g2
S'Effective drugs for combating motion sickness include antihistamines, antimuscarinics, 5-HT1A (serotonergic) receptor agonists and neurokinin type 1 receptor antagonists.\n'
p16073
sg4
(lp16074
(dp16075
g7
I131
sg8
g48
sg10
I26
sg11
Vneurokinin type 1 receptor
p16076
sg13
I4
sa(dp16077
g7
I70
sg8
VP08908
p16078
sg10
I47
sg11
Vantimuscarinics, 5-HT1A (serotonergic) receptor
p16079
sg13
I4
sasg29
(lp16080
(dp16081
g7
I30
sg32
VC0026603
p16082
sg10
I15
sg11
Vmotion sickness
p16083
sg13
I2
sasa(dp16084
g2
S'Collectively, these results indicate that LY228729 is potent 5-HT1A agonist with bioavailability properties sufficient for clinical evaluation and with efficacy in preclinical models of anxiety, sexual disorders and motion sickness.\n'
p16085
sg4
(lp16086
sg29
(lp16087
(dp16088
g7
I216
sg32
VC0026603
p16089
sg10
I15
sg11
Vmotion sickness
p16090
sg13
I2
sasa(dp16091
g2
S'The antiemetic effects of six serotonergic 5-HT1A-receptor agonists, 8-hydroxy-2-(di-n-propylamino)tetrarin (8-OH-DPAT), 4-(4-[4-(2-pyrimidinyl)piperazin-1-yl]butyl)-2,3,4,5- tetrahydro-1,4-benzoxazepine-3,5-dione (SUN8399), buspirone, gepirone, ipsapirone and tandospirone, against motion sickness were investigated in Suncus murinus.\n'
p16092
sg4
(lp16093
(dp16094
g7
I30
sg8
VP08908
p16095
sg10
I28
sg11
Vserotonergic 5-HT1A-receptor
p16096
sg13
I2
sasg29
(lp16097
(dp16098
g7
I283
sg32
VC0026603
p16099
sg10
I15
sg11
Vmotion sickness
p16100
sg13
I2
sasa(dp16101
g2
S'These results suggest that serotonergic 5-HT1A-receptor agonists are effective as anti-motion sickness drugs, and these drugs may block a common mechanism(s) for the emetic reflex of the suncus because the antiemetic effects of the 5-HT1A-receptor agonists were exerted irrespective of the stimulus.\n'
p16102
sg4
(lp16103
(dp16104
g7
I27
sg8
VP08908
p16105
sg10
I28
sg11
Vserotonergic 5-HT1A-receptor
p16106
sg13
I2
sa(dp16107
g7
I40
sg8
VP08908
p16108
sg10
I15
sg11
V5-HT1A-receptor
p16109
sg13
I1
sasg29
(lp16110
(dp16111
g7
I87
sg32
VC0026603
p16112
sg10
I15
sg11
Vmotion sickness
p16113
sg13
I2
sasa(dp16114
g2
S'Although metergoline produced a decrease in the antiemetic effect of DPAT, the decrease could not be clearly attributed to interactions with 5-HT1A receptors because metergoline alone slightly enhanced motion sickness.\n'
p16115
sg4
(lp16116
(dp16117
g7
I141
sg8
VP08908
p16118
sg10
I16
sg11
V5-HT1A receptors
p16119
sg13
I2
sasg29
(lp16120
(dp16121
g7
I202
sg32
VC0026603
p16122
sg10
I15
sg11
Vmotion sickness
p16123
sg13
I2
sasa(dp16124
g2
S'These data indicate that there are different lncRNAs expressed in pancreatic cancer biology and that lncRNA BC008363 may be a novel biomarker for the prognosis of pancreatic cancer.\n'
p16125
sg4
(lp16126
sg29
(lp16127
(dp16128
g7
I66
sg32
VC0235974
p16129
sg10
I17
sg11
Vpancreatic cancer
p16130
sg13
I2
sa(dp16131
g7
I66
sg32
VC0235974
p16132
sg10
I17
sg11
Vpancreatic cancer
p16133
sg13
I2
sasa(dp16134
g2
S'We identified a number of novel target genes downstream of ATP6AP2 knock-down that were related to the primary cilium (Bbs-1, Bbs-3, Bbs-7, Rabl5, Ttc26, Mks-11, Mks-5, Mks-2, Tctn2, Nme7) and the cell cycle (Pierce1, Clock, Ppif).\n'
p16135
sg4
(lp16136
(dp16137
g7
I169
sg8
VP21741
p16138
sg10
I5
sg11
VMks-2
p16139
sg13
I1
sa(dp16140
g7
I154
sg8
VP21741
p16141
sg10
I6
sg11
VMks-11
p16142
sg13
I1
sa(dp16143
g7
I119
sg8
g48
sg10
I5
sg11
VBbs-1
p16144
sg13
I1
sa(dp16145
g7
I140
sg8
g48
sg10
I5
sg11
VRabl5
p16146
sg13
I1
sa(dp16147
g7
I126
sg8
g48
sg10
I5
sg11
VBbs-3
p16148
sg13
I1
sa(dp16149
g7
I147
sg8
g48
sg10
I5
sg11
VTtc26
p16150
sg13
I1
sa(dp16151
g7
I162
sg8
VP21741
p16152
sg10
I5
sg11
VMks-5
p16153
sg13
I1
sa(dp16154
g7
I176
sg8
g48
sg10
I5
sg11
VTctn2
p16155
sg13
I1
sa(dp16156
g7
I183
sg8
g48
sg10
I4
sg11
VNme7
p16157
sg13
I1
sa(dp16158
g7
I133
sg8
g48
sg10
I5
sg11
VBbs-7
p16159
sg13
I1
sasg29
(lp16160
(dp16161
g7
I154
sg32
VC0265215
p16162
sg10
I3
sg11
VMks
p16163
sg13
I1
sa(dp16164
g7
I119
sg32
VC0398791
p16165
sg10
I3
sg11
VBbs
p16166
sg13
I1
sa(dp16167
g7
I154
sg32
VC0265215
p16168
sg10
I3
sg11
VMks
p16169
sg13
I1
sa(dp16170
g7
I154
sg32
VC0265215
p16171
sg10
I3
sg11
VMks
p16172
sg13
I1
sa(dp16173
g7
I119
sg32
VC0398791
p16174
sg10
I3
sg11
VBbs
p16175
sg13
I1
sa(dp16176
g7
I119
sg32
VC0398791
p16177
sg10
I3
sg11
VBbs
p16178
sg13
I1
sasa(dp16179
g2
S'We identified 17 individuals with exon-disruptive CNVs (18.5%), including 13 different deletions in eight BBS genes (BBS1, BBS2, ARL6/BBS3, BBS4, BBS5, BBS7, BBS9, and NPHP1) and a deletion and a duplication in other ciliopathy-associated genes (ALMS1 and NPHP4, respectively).\n'
p16180
sg4
(lp16181
(dp16182
g7
I134
sg8
g48
sg10
I4
sg11
VBBS3
p16183
sg13
I1
sa(dp16184
g7
I117
sg8
g48
sg10
I4
sg11
VBBS1
p16185
sg13
I1
sa(dp16186
g7
I152
sg8
g48
sg10
I4
sg11
VBBS7
p16187
sg13
I1
sa(dp16188
g7
I123
sg8
g48
sg10
I4
sg11
VBBS2
p16189
sg13
I1
sa(dp16190
g7
I256
sg8
g48
sg10
I5
sg11
VNPHP4
p16191
sg13
I1
sa(dp16192
g7
I140
sg8
g48
sg10
I4
sg11
VBBS4
p16193
sg13
I1
sa(dp16194
g7
I129
sg8
VP49703
p16195
sg10
I4
sg11
VARL6
p16196
sg13
I1
sa(dp16197
g7
I246
sg8
g48
sg10
I5
sg11
VALMS1
p16198
sg13
I1
sa(dp16199
g7
I106
sg8
g48
sg10
I9
sg11
VBBS genes
p16200
sg13
I2
sa(dp16201
g7
I168
sg8
g48
sg10
I5
sg11
VNPHP1
p16202
sg13
I1
sa(dp16203
g7
I146
sg8
g48
sg10
I4
sg11
VBBS5
p16204
sg13
I1
sasg29
(lp16205
(dp16206
g7
I134
sg32
VC1859564
p16207
sg10
I4
sg11
VBBS3
p16208
sg13
I1
sa(dp16209
g7
I106
sg32
VC0398791
p16210
sg10
I3
sg11
VBBS
p16211
sg13
I1
sa(dp16212
g7
I152
sg32
VC1859565
p16213
sg10
I4
sg11
VBBS7
p16214
sg13
I1
sa(dp16215
g7
I196
sg32
VC1705960
p16216
sg10
I11
sg11
Vduplication
p16217
sg13
I1
sa(dp16218
g7
I256
sg32
VC1847013
p16219
sg10
I5
sg11
VNPHP4
p16220
sg13
I1
sa(dp16221
g7
I158
sg32
VC1859567
p16222
sg10
I4
sg11
VBBS9
p16223
sg13
I1
sa(dp16224
g7
I168
sg32
VC1855681
p16225
sg10
I5
sg11
VNPHP1
p16226
sg13
I1
sasa(dp16227
g2
S'Screening of the remaining patients for six other genes (BBS3, BBS4, BBS6, BBS7, BBS9 and BBS12) revealed five novel mutations.\n'
p16228
sg4
(lp16229
(dp16230
g7
I69
sg8
g48
sg10
I4
sg11
VBBS6
p16231
sg13
I1
sa(dp16232
g7
I75
sg8
g48
sg10
I4
sg11
VBBS7
p16233
sg13
I1
sa(dp16234
g7
I57
sg8
g48
sg10
I4
sg11
VBBS3
p16235
sg13
I1
sa(dp16236
g7
I90
sg8
g48
sg10
I5
sg11
VBBS12
p16237
sg13
I1
sa(dp16238
g7
I63
sg8
g48
sg10
I4
sg11
VBBS4
p16239
sg13
I1
sasg29
(lp16240
(dp16241
g7
I75
sg32
VC1859565
p16242
sg10
I4
sg11
VBBS7
p16243
sg13
I1
sa(dp16244
g7
I90
sg32
VC1859570
p16245
sg10
I5
sg11
VBBS12
p16246
sg13
I1
sa(dp16247
g7
I57
sg32
VC1859564
p16248
sg10
I4
sg11
VBBS3
p16249
sg13
I1
sa(dp16250
g7
I81
sg32
VC1859567
p16251
sg10
I4
sg11
VBBS9
p16252
sg13
I1
sa(dp16253
g7
I69
sg32
VC1858054
p16254
sg10
I4
sg11
VBBS6
p16255
sg13
I1
sasa(dp16256
g2
S"About 95% of phytoplasmas detected were very closely related to BBS phytoplasma strains BBS3-AR (subgroup 16SrI-E) and BBS1-MI (unidentified) identified previously, and 4.4% of phytoplasmas detected belonged to the pigeon pea witches'-broom phytoplasma group (16SrIX).\n"
p16257
sg4
(lp16258
(dp16259
g7
I64
sg8
g48
sg10
I15
sg11
VBBS phytoplasma
p16260
sg13
I2
sa(dp16261
g7
I119
sg8
g48
sg10
I4
sg11
VBBS1
p16262
sg13
I1
sa(dp16263
g7
I88
sg8
g48
sg10
I4
sg11
VBBS3
p16264
sg13
I1
sasg29
(lp16265
(dp16266
g7
I88
sg32
VC1859564
p16267
sg10
I4
sg11
VBBS3
p16268
sg13
I1
sa(dp16269
g7
I64
sg32
VC0398791
p16270
sg10
I3
sg11
VBBS
p16271
sg13
I1
sasa(dp16272
g2
S'Seventeen patients harbored mutations in BBS1, 10 in BBS10, and 10 in other genes (BBS2, BBS3, BBS5, BBS7, and BBS12).\n'
p16273
sg4
(lp16274
(dp16275
g7
I41
sg8
g48
sg10
I4
sg11
VBBS1
p16276
sg13
I1
sa(dp16277
g7
I53
sg8
g48
sg10
I5
sg11
VBBS10
p16278
sg13
I1
sa(dp16279
g7
I101
sg8
g48
sg10
I4
sg11
VBBS7
p16280
sg13
I1
sa(dp16281
g7
I111
sg8
g48
sg10
I5
sg11
VBBS12
p16282
sg13
I1
sa(dp16283
g7
I95
sg8
g48
sg10
I4
sg11
VBBS5
p16284
sg13
I1
sa(dp16285
g7
I89
sg8
g48
sg10
I4
sg11
VBBS3
p16286
sg13
I1
sa(dp16287
g7
I83
sg8
g48
sg10
I4
sg11
VBBS2
p16288
sg13
I1
sasg29
(lp16289
(dp16290
g7
I89
sg32
VC1859564
p16291
sg10
I4
sg11
VBBS3
p16292
sg13
I1
sa(dp16293
g7
I111
sg32
VC1859570
p16294
sg10
I5
sg11
VBBS12
p16295
sg13
I1
sa(dp16296
g7
I53
sg32
VC1859568
p16297
sg10
I5
sg11
VBBS10
p16298
sg13
I1
sa(dp16299
g7
I101
sg32
VC1859565
p16300
sg10
I4
sg11
VBBS7
p16301
sg13
I1
sasa(dp16302
g2
S'We identified the disease-causing mutation in six of the families studied, five of which had novel sequence variants in BBS3, BBS6, and BBS12.\n'
p16303
sg4
(lp16304
(dp16305
g7
I120
sg8
g48
sg10
I4
sg11
VBBS3
p16306
sg13
I1
sa(dp16307
g7
I126
sg8
g48
sg10
I4
sg11
VBBS6
p16308
sg13
I1
sa(dp16309
g7
I136
sg8
g48
sg10
I5
sg11
VBBS12
p16310
sg13
I1
sasg29
(lp16311
(dp16312
g7
I120
sg32
VC1859564
p16313
sg10
I4
sg11
VBBS3
p16314
sg13
I1
sa(dp16315
g7
I18
sg32
VC2985434
p16316
sg10
I24
sg11
Vdisease-causing mutation
p16317
sg13
I2
sa(dp16318
g7
I126
sg32
VC1858054
p16319
sg10
I4
sg11
VBBS6
p16320
sg13
I1
sa(dp16321
g7
I136
sg32
VC1859570
p16322
sg10
I5
sg11
VBBS12
p16323
sg13
I1
sasa(dp16324
g2
S'Here, we demonstrate that individual knockdown of bbs1 and bbs3 results in the same prototypical phenotypes as reported previously for other BBS genes.\n'
p16325
sg4
(lp16326
(dp16327
g7
I50
sg8
g48
sg10
I4
sg11
Vbbs1
p16328
sg13
I1
sa(dp16329
g7
I59
sg8
g48
sg10
I4
sg11
Vbbs3
p16330
sg13
I1
sa(dp16331
g7
I141
sg8
g48
sg10
I9
sg11
VBBS genes
p16332
sg13
I2
sasg29
(lp16333
(dp16334
g7
I141
sg32
VC0398791
p16335
sg10
I3
sg11
VBBS
p16336
sg13
I1
sa(dp16337
g7
I59
sg32
VC1859564
p16338
sg10
I4
sg11
Vbbs3
p16339
sg13
I1
sasa(dp16340
g2
S'Risks for SDB and insomnia + SDB were both linked to heightened risk of CVD and diabetes; SLD was consistently linked with greater risk of CVD and diabetes in non-Veterans but less strongly and consistently in Veterans.\n'
p16341
sg4
(lp16342
sg29
(lp16343
(dp16344
g7
I18
sg32
VC0917801
p16345
sg10
I8
sg11
Vinsomnia
p16346
sg13
I1
sa(dp16347
g7
I72
sg32
VC0007222
p16348
sg10
I3
sg11
VCVD
p16349
sg13
I1
sa(dp16350
g7
I72
sg32
VC0007222
p16351
sg10
I3
sg11
VCVD
p16352
sg13
I1
sa(dp16353
g7
I80
sg32
VC0011849
p16354
sg10
I8
sg11
Vdiabetes
p16355
sg13
I1
sa(dp16356
g7
I80
sg32
VC0011849
p16357
sg10
I8
sg11
Vdiabetes
p16358
sg13
I1
sasa(dp16359
g2
S'This study assessed the effects of surgical debridement (SD) and nonsurgical debridement (NSD), associated with amoxicillin and metronidazole, on clinical and immunological outcomes of residual pockets and adjacent healthy sites in patients with type 2 diabetes.\n'
p16360
sg4
(lp16361
sg29
(lp16362
(dp16363
g7
I90
sg32
VC2930923
p16364
sg10
I3
sg11
VNSD
p16365
sg13
I1
sa(dp16366
g7
I246
sg32
VC0011860
p16367
sg10
I15
sg11
Vtype 2 diabetes
p16368
sg13
I3
sa(dp16369
g7
I65
sg32
VC2930923
p16370
sg10
I23
sg11
Vnonsurgical debridement
p16371
sg13
I2
sasa(dp16372
g2
S'Diabetic macular edema (DME) with neurosensory retinal detachment (NSD) remains an important cause of visual loss in patients with diabetes.\n'
p16373
sg4
(lp16374
sg29
(lp16375
(dp16376
g7
I102
sg32
VC0042798
p16377
sg10
I11
sg11
Vvisual loss
p16378
sg13
I2
sa(dp16379
g7
I0
sg32
VC0730285
p16380
sg10
I22
sg11
VDiabetic macular edema
p16381
sg13
I3
sa(dp16382
g7
I131
sg32
VC0011849
p16383
sg10
I8
sg11
Vdiabetes
p16384
sg13
I1
sa(dp16385
g7
I34
sg32
VC2930923
p16386
sg10
I31
sg11
Vneurosensory retinal detachment
p16387
sg13
I3
sa(dp16388
g7
I24
sg32
VC0730285
p16389
sg10
I3
sg11
VDME
p16390
sg13
I1
sa(dp16391
g7
I67
sg32
VC2930923
p16392
sg10
I3
sg11
VNSD
p16393
sg13
I1
sasa(dp16394
g2
S'Sulindac (SLD) exhibits both the highest inhibitory activity towards human aldose reductase (AR) among popular non-steroidal anti-inflammatory drugs and clear beneficial clinical effects on Type 2 diabetes.\n'
p16395
sg4
(lp16396
(dp16397
g7
I69
sg8
VP15121
p16398
sg10
I22
sg11
Vhuman aldose reductase
p16399
sg13
I3
sa(dp16400
g7
I10
sg8
g48
sg10
I3
sg11
VSLD
p16401
sg13
I1
sa(dp16402
g7
I0
sg8
g48
sg10
I8
sg11
VSulindac
p16403
sg13
I1
sasg29
(lp16404
(dp16405
g7
I190
sg32
VC0011860
p16406
sg10
I15
sg11
VType 2 diabetes
p16407
sg13
I3
sasa(dp16408
g2
S'We evaluated the effect of sulodexide (SLD), a natural GSG used in albuminuria and ischemic diabetes treatment, on arterial relaxation and vascular morphological changes in a diabetic type I model.\n'
p16409
sg4
(lp16410
sg29
(lp16411
(dp16412
g7
I92
sg32
VC0011849
p16413
sg10
I8
sg11
Vdiabetes
p16414
sg13
I1
sasa(dp16415
g2
S'Our experiments support the conclusion that SLD is a potential drug for improving endothelial dysfunction in diabetes.\n'
p16416
sg4
(lp16417
(dp16418
g7
I44
sg8
g48
sg10
I3
sg11
VSLD
p16419
sg13
I1
sasg29
(lp16420
(dp16421
g7
I109
sg32
VC0011849
p16422
sg10
I8
sg11
Vdiabetes
p16423
sg13
I1
sa(dp16424
g7
I82
sg32
VC0856169
p16425
sg10
I23
sg11
Vendothelial dysfunction
p16426
sg13
I2
sasa(dp16427
g2
S'The experimental design was appropriate since hypoglycemia and hyperglycemia were observed in fish under NSD whereas in normoglycaemic fish HSD induced changes in stress-related parameters similar to those reported in fish literature, such as increased levels of cortisol and glucose in plasma and decreased levels of glycogen in liver.\n'
p16428
sg4
(lp16429
sg29
(lp16430
(dp16431
g7
I105
sg32
VC2930923
p16432
sg10
I3
sg11
VNSD
p16433
sg13
I1
sa(dp16434
g7
I63
sg32
VC0020456
p16435
sg10
I13
sg11
Vhyperglycemia
p16436
sg13
I1
sa(dp16437
g7
I140
sg32
VC1840471
p16438
sg10
I3
sg11
VHSD
p16439
sg13
I1
sa(dp16440
g7
I46
sg32
VC0020615
p16441
sg10
I12
sg11
Vhypoglycemia
p16442
sg13
I1
sasa(dp16443
g2
S'At day 30, diabetic animals with NSD or HSD exhibited hyperglycemia, lower body weight, glycosuria, diuresis, decrease natriuresis, increased SBP values and SGLT2 expression.\n'
p16444
sg4
(lp16445
(dp16446
g7
I157
sg8
VP31639
p16447
sg10
I5
sg11
VSGLT2
p16448
sg13
I1
sasg29
(lp16449
(dp16450
g7
I40
sg32
VC1840471
p16451
sg10
I3
sg11
VHSD
p16452
sg13
I1
sa(dp16453
g7
I33
sg32
VC2930923
p16454
sg10
I3
sg11
VNSD
p16455
sg13
I1
sa(dp16456
g7
I54
sg32
VC0020456
p16457
sg10
I13
sg11
Vhyperglycemia
p16458
sg13
I1
sasa(dp16459
g2
S'The objective of this study was to determine whether the management of type 2 diabetes (DM2) can be transferred from an internist to a nurse specialised in diabetes (NSD).\n'
p16460
sg4
(lp16461
sg29
(lp16462
(dp16463
g7
I135
sg32
VC2930923
p16464
sg10
I29
sg11
Vnurse specialised in diabetes
p16465
sg13
I4
sa(dp16466
g7
I71
sg32
VC0011860
p16467
sg10
I15
sg11
Vtype 2 diabetes
p16468
sg13
I3
sa(dp16469
g7
I166
sg32
VC2930923
p16470
sg10
I3
sg11
VNSD
p16471
sg13
I1
sa(dp16472
g7
I88
sg32
VC2931689
p16473
sg10
I3
sg11
VDM2
p16474
sg13
I1
sasa(dp16475
g2
S'There were highest incidences of leucopenia (42.2%), neutropenia (36.2%) and lowest incidence of thrombocytopenia (53.0%) in GP arm compared to NP arm (77.8%, 67.7%, 12.1%) or TP arm (71.0%, 57.0%, 13.0%) statistically (P&lt;0.01 for all).\n'
p16476
sg4
(lp16477
sg29
(lp16478
(dp16479
g7
I33
sg32
VC0023530
p16480
sg10
I10
sg11
Vleucopenia
p16481
sg13
I1
sasa(dp16482
g2
S'Notably, TBX2, TBX4, and TBX5 were downregulated and hypermethylated in lung CAFs, suggesting an association between epigenetic silencing of these factors and phenotypic alteration of lung fibroblasts in cancer.\n'
p16483
sg4
(lp16484
(dp16485
g7
I15
sg8
VP57082
p16486
sg10
I4
sg11
VTBX4
p16487
sg13
I1
sa(dp16488
g7
I25
sg8
g48
sg10
I4
sg11
VTBX5
p16489
sg13
I1
sa(dp16490
g7
I9
sg8
g48
sg10
I4
sg11
VTBX2
p16491
sg13
I1
sasg29
(lp16492
(dp16493
g7
I204
sg32
VC0006826
p16494
sg10
I6
sg11
Vcancer
p16495
sg13
I1
sa(dp16496
g7
I77
sg32
VC0795907
p16497
sg10
I4
sg11
VCAFs
p16498
sg13
I1
sasa(dp16499
g2
S'T-box transcription factor 5 (TBX5), a member of the conserved T-box transcription factor family that functions in organogenesis and embryogenesis, has recently been identified as a critical player in cancer development.\n'
p16500
sg4
(lp16501
(dp16502
g7
I63
sg8
g48
sg10
I33
sg11
VT-box transcription factor family
p16503
sg13
I4
sa(dp16504
g7
I30
sg8
g48
sg10
I4
sg11
VTBX5
p16505
sg13
I1
sa(dp16506
g7
I0
sg8
g48
sg10
I28
sg11
VT-box transcription factor 5
p16507
sg13
I4
sasg29
(lp16508
(dp16509
g7
I201
sg32
VC0006826
p16510
sg10
I6
sg11
Vcancer
p16511
sg13
I1
sasa(dp16512
g2
S'The aim of this study was to determine the role of TBX5 in non-small cell lung carcinoma (NSCLC).\n'
p16513
sg4
(lp16514
(dp16515
g7
I51
sg8
g48
sg10
I4
sg11
VTBX5
p16516
sg13
I1
sasg29
(lp16517
(dp16518
g7
I59
sg32
VC0007131
p16519
sg10
I29
sg11
Vnon-small cell lung carcinoma
p16520
sg13
I4
sa(dp16521
g7
I90
sg32
VC0007131
p16522
sg10
I5
sg11
VNSCLC
p16523
sg13
I1
sasa(dp16524
g2
S'Immunohistochemistry was used to detect the correlation between levels of TBX5 and clinicopathological features of NSCLC patients in tissue microarray.\n'
p16525
sg4
(lp16526
(dp16527
g7
I74
sg8
g48
sg10
I4
sg11
VTBX5
p16528
sg13
I1
sasg29
(lp16529
(dp16530
g7
I115
sg32
VC0007131
p16531
sg10
I5
sg11
VNSCLC
p16532
sg13
I1
sasa(dp16533
g2
S'Expression of TBX5 in NSCLC tissues and cell lines was evaluated by quantitative PCR and Western blot.\n'
p16534
sg4
(lp16535
(dp16536
g7
I14
sg8
g48
sg10
I4
sg11
VTBX5
p16537
sg13
I1
sasg29
(lp16538
(dp16539
g7
I22
sg32
VC0007131
p16540
sg10
I5
sg11
VNSCLC
p16541
sg13
I1
sasa(dp16542
g2
S'The role of TBX5 in regulating proliferation, colony formation, invasion, and apoptosis of NSCLC cells was evaluated in vitro.\n'
p16543
sg4
(lp16544
(dp16545
g7
I12
sg8
g48
sg10
I4
sg11
VTBX5
p16546
sg13
I1
sasg29
(lp16547
(dp16548
g7
I31
sg32
VC0334094
p16549
sg10
I13
sg11
Vproliferation
p16550
sg13
I1
sa(dp16551
g7
I64
sg32
VC2699153
p16552
sg10
I8
sg11
Vinvasion
p16553
sg13
I1
sa(dp16554
g7
I91
sg32
VC0007131
p16555
sg10
I5
sg11
VNSCLC
p16556
sg13
I1
sasa.